UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM N-CSR

CERTIFIED SHAREHOLDER REPORT OF REGISTERED MANAGEMENT

INVESTMENT COMPANIES

Investment Company Act file number: 811-22032

Name of Fund: BlackRock Enhanced International Dividend Trust (BGY)

Fund Address: 100 Bellevue Parkway, Wilmington, DE 19809

Name and address of agent for service: John M. Perlowski, Chief Executive Officer, BlackRock Enhanced International Dividend Trust, 50 Hudson Yards, New York, NY 10001

Registrant’s telephone number, including area code: (800) 882-0052, Option 4

Date of fiscal year end: 12/31/2023

Date of reporting period: 12/31/2023

Item 1 – Report to Stockholders

(a) The Report to Shareholders is attached herewith.

DECEMBER 31, 2023

2023 Annual Report

BlackRock Energy and Resources Trust (BGR)

BlackRock Enhanced Capital and Income Fund, Inc. (CII)

BlackRock Enhanced Equity Dividend Trust (BDJ)

BlackRock Enhanced Global Dividend Trust (BOE)

BlackRock Enhanced International Dividend Trust (BGY)

BlackRock Health Sciences Term Trust (BMEZ)

BlackRock Health Sciences Trust (BME)

BlackRock Innovation and Growth Term Trust (BIGZ)

BlackRock Resources & Commodities Strategy Trust (BCX)

BlackRock Science and Technology Term Trust (BSTZ)

BlackRock Science and Technology Trust (BST)

BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)

Not FDIC Insured • May Lose Value • No Bank Guarantee

 

 

Supplemental Information (unaudited)

 

Section 19(a) Notices

BlackRock Energy and Resources Trust’s (BGR), BlackRock Enhanced Capital and Income Fund, Inc.’s (CII), BlackRock Enhanced Equity Dividend Trust’s (BDJ), BlackRock Enhanced Global Dividend Trust’s (BOE), BlackRock Enhanced International Dividend Trust’s (BGY), BlackRock Health Sciences Term Trust’s (BMEZ), BlackRock Health Sciences Trust’s (BME), BlackRock Innovation and Growth Term Trust’s (BIGZ), BlackRock Resources & Commodities Strategy Trust’s (BCX), BlackRock Science and Technology Term Trust’s (BSTZ), BlackRock Science and Technology Trust’s (BST) and BlackRock Utilities, Infrastructure & Power Opportunities Trust’s (BUI) (collectively, the “Trusts” or individually, a “Trust”) amounts and sources of distributions reported are estimates and are being provided pursuant to regulatory requirements and are not being provided for tax reporting purposes. The actual amounts and sources for tax reporting purposes will depend upon each Trust’s investment experience during its fiscal year and may be subject to changes based on tax regulations. Each Trust will provide a Form 1099-DIV each calendar year that will tell you how to report these distributions for U.S. federal income tax purposes.

December 31, 2023

	Total Cumulative Distributions for the Fiscal Period											% Breakdown of the Total Cumulative Distributions for the Fiscal Period
Trust Name		Net Income		Net Realized Capital Gains Short-Term		Net Realized Capital Gains Long-Term		Return of Capital	(a)		Total Per Common Share		Net Income		Net Realized Capital Gains Short-Term		Net Realized Capital Gains Long-Term		Return of Capital		Total Per  Common  Share
BGR	$	0.386340	$	—	$	—	$	0.387660		$	0.774000		50	%	—	%	—	%	50	%	100%
CII		0.084620		—		1.109380		—			1.194000		7		—		93		—		100
BDJ		0.273080		0.049100		0.407220		—			0.729400		37		7		56		—		100
BOE		0.222930		—		—		0.533070			0.756000		29		—		—		71		100
BGY		0.088760		—		0.154160		0.162680			0.405600		22		—		38		40		100
BMEZ		—		—		—		1.582470			1.582470		—		—		—		100		100
BME		0.146200		—		1.586760		0.823040			2.556000		6		—		62		32		100
BIGZ		—		—		—		0.765770			0.765770		—		—		—		100		100
BCX		0.293280		—		—		0.328320			0.621600		47		—		—		53		100
BSTZ		—		—		0.167000		1.654710			1.821710		—		—		9		91		100
BST		—		—		—		3.000000			3.000000		—		—		—		100		100
BUI		0.360190		0.209850		0.606660		0.275300			1.452000		25		14		42		19		100

^(a)  Each Trust estimates that it has distributed more than its net income and net realized capital gains; therefore, a portion of the distribution may be a return of capital. A return of capital may occur, for example, when some or all of the shareholder’s investment in a Trust is returned to the shareholder. A return of capital does not necessarily reflect a Trust’s investment performance and should not be confused with “yield” or “income.” When distributions exceed total return performance, the difference will reduce a Trust’s net asset value per share.

Section 19(a) notices for the Trusts, as applicable, are available on the BlackRock website at blackrock.com.

Section 19(b) Disclosure

The Trusts, acting pursuant to a U.S. Securities and Exchange Commission (“SEC”) exemptive order and with the approval of each Trust’s Board of Trustees (the “Board”), each has adopted a managed distribution plan, consistent with its investment objectives and policies, to support a level distribution of income, capital gains and/or return of capital (the “Plan”). In accordance with the Plans, the Trusts currently distribute the following fixed amounts per share on a monthly basis:

Trust Name	Amount Per Common Share
BGR	$	0.065700
CII		0.099500
BDJ		0.056200
BOE		0.063000
BGY		0.033800
BMEZ		0.091600
BME		0.213000
BIGZ		0.044870
BCX		0.051800
BSTZ		0.102540
BST		0.250000
BUI		0.121000

The fixed amounts distributed per share are subject to change at the discretion of each Trust’s Board. Under its Plan, each Trust will distribute all available net income to its shareholders as required by the Internal Revenue Code of 1986, as amended (the “Code”). If sufficient income (inclusive of net income and short-term capital gains) is not earned on a monthly basis, the Trusts will distribute long-term capital gains and/or return of capital to shareholders in order to maintain a level distribution. Each monthly distribution to shareholders is expected to be at the fixed amount established by the Board; however, each Trust may make additional distributions from time to time, including additional capital gain distributions at the end of the taxable year, if required to meet requirements imposed by the Code and/or the Investment Company Act of 1940, as amended (the “1940 Act”).

Shareholders should not draw any conclusions about a Trust’s investment performance from the amount of these distributions or from the terms of the Plan. Each Trust’s total return performance is presented in its financial highlights table.

2 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Supplemental Information (unaudited) (continued)

 

The Board may amend, suspend or terminate a Trust’s Plan at any time without prior notice to the Trust’s shareholders if it deems such actions to be in the best interests of the Trust or its shareholders. The suspension or termination of the Plan could have the effect of creating a trading discount (if the Trust’s stock is trading at or above net asset value) or widening an existing trading discount. The Trusts are subject to risks that could have an adverse impact on their ability to maintain level distributions. Examples of potential risks include, but are not limited to, economic downturns impacting the markets, changes in interest rates, decreased market volatility, companies suspending or decreasing corporate dividend distributions and changes in the Code. Please refer to BDJ, BME, BST and BUI’s prospectuses for a more complete description of each Trust’s risks.

S U P P L E M E N T A L I N F O R M A T I O N 3

The Markets in Review

Dear Shareholder,

The combination of continued economic growth and cooling inflation provided a supportive backdrop for investors during the 12-month reporting period ended December 31, 2023. Significantly tighter monetary policy helped to rein in inflation, and the Consumer Price Index decelerated substantially in the first half of the year before stalling between 3% and 4% in the second half. A moderating labor market helped ease inflationary pressure, although wages continued to grow. Wage and job growth powered robust consumer spending, backstopping the economy. On October 7, 2023, Hamas launched a horrific attack on Israel. The ensuing war will have a significant humanitarian impact and could lead to heightened economic and market volatility. We see geopolitics as a structural market risk going forward. See our geopolitical risk dashboard at blackrock.com for more details.

Equity returns were robust during the period, as interest rates stabilized and the economy proved to be more resilient than many investors expected. The U.S. economy continued to show strength, and growth further accelerated in the third quarter of 2023. Large-capitalization U.S. stocks posted particularly substantial gains, supported by the performance of a few notable technology companies and small-capitalization U.S. stocks also advanced. Meanwhile, international developed market equities and emerging market stocks posted solid gains.

The 10-year U.S. Treasury yield ended 2023 where it began despite an eventful year that saw significant moves in bond markets. Overall, U.S. Treasuries gained as investors began to anticipate looser financial conditions. The corporate bond market benefited from improving economic sentiment, although high-yield corporate bond prices fared significantly better than investment-grade bonds as demand from yield-seeking investors remained strong.

The U.S. Federal Reserve (the “Fed”), attempting to manage persistent inflation, raised interest rates four times during the 12-month period, but paused its tightening in the second half of the period. The Fed also wound down its bond-buying programs and incrementally reduced its balance sheet by not replacing securities that reach maturity.

Supply constraints appear to have become an embedded feature of the new macroeconomic environment, making it difficult for developed economies to increase production without sparking higher inflation. Geopolitical fragmentation and an aging population risk further exacerbating these constraints, keeping the labor market tight and wage growth high. Although the Fed has stopped tightening for now, we believe that the new economic regime means that the Fed will need to maintain high rates for an extended period despite the market’s hopes for interest rate cuts, as reflected in the recent rally. In this new regime, we anticipate greater volatility and dispersion of returns, creating more opportunities for selective portfolio management.

We believe developed market equities have priced in an optimistic scenario for rate cuts, which we view as premature, so we prefer an underweight stance in the near term. Nevertheless, we are overweight on Japanese stocks as shareholder-friendly policies generate increased investor interest. We also believe that stocks with an AI tilt should benefit from an investment cycle that is set to support revenues and margins. In credit, there are selective opportunities in the near term despite tighter credit and financial conditions. For fixed income investing with a six- to twelve-month horizon, we see the most attractive investments in short-term U.S. Treasuries, U.S. mortgage-backed securities, and hard-currency emerging market bonds.

Overall, our view is that investors need to think globally, position themselves to be prepared for a decarbonizing economy, and be nimble as market conditions change. We encourage you to talk with your financial advisor and visit blackrock.com for further insight about investing in today’s markets.

Sincerely,

Rob Kapito

President, BlackRock Advisors, LLC

Rob Kapito

President, BlackRock Advisors, LLC

Total Returns as of December 31, 2023
	6-Month	12-Month
U.S. large cap equities (S&P 500® Index)	8.04%	26.29%
U.S. small cap equities (Russell 2000® Index)	8.18	16.93
International equities (MSCI Europe, Australasia, Far East Index)	5.88	18.24
Emerging market equities (MSCI Emerging Markets Index)	4.71	9.83
3-month Treasury bills (ICE BofA 3-Month U.S. Treasury Bill Index)	2.70	5.02
U.S. Treasury securities (ICE BofA 10-Year U.S. Treasury Index)	1.11	2.83
U.S. investment grade bonds (Bloomberg U.S. Aggregate Bond Index)	3.37	5.53
Tax-exempt municipal bonds (Bloomberg Municipal Bond Index)	3.63	6.40
U.S. high yield bonds (Bloomberg U.S. Corporate High Yield 2% Issuer Capped Index)	7.65	13.44
Past performance is not an indication of future results. Index performance is shown for illustrative purposes only. You cannot invest directly in an index.

4 T H I S  P A G E  I S  N O T  P A R T  O F  Y O U R  F U N D  R E P O R T

Table of Contents

	Page
Supplemental Information		2
The Markets in Review		4
Option Over-Writing Strategy		6
Derivative Financial Instruments		6
Annual Report:
Trust Summary		7
Financial Statements:
Schedules of Investments		44
Statements of Assets and Liabilities		133
Statements of Operations		136
Statements of Changes in Net Assets		139
Statements of Cash Flows		145
Financial Highlights		151
Notes to Financial Statements		163
Report of Independent Registered Public Accounting Firm		178
Important Tax Information		179
Investment Objectives, Policies and Risks		181
Shareholder Update		207
Automatic Dividend Reinvestment Plan		217
Trustee and Officer Information		218
Additional Information		222
Glossary of Terms Used in this Report		226

5

Option Over-Writing Strategy

 

Overview

In general, the goal of each of the Trusts is to provide total return through a combination of current income and realized and unrealized gains (capital appreciation). The Trusts seek to pursue these goals primarily by investing in a portfolio of equity securities and also by employing a strategy of writing (selling) call and put options in an effort to generate current gains from option premiums and to enhance each Trust’s risk-adjusted return. Each Trust’s objectives cannot be achieved in all market conditions.

Each Trust primarily writes single stock covered call options and may also from time to time write single stock put options. When writing (selling) a covered call option, a Trust holds an underlying equity security and enters into an option transaction which allows the counterparty to purchase the equity security at an agreed-upon price (“strike price”) within an agreed-upon time period. The Trust receives cash premiums from the counterparties upon writing (selling) the option, which along with net investment income and net realized gains, if any, are generally available to support current or future distributions paid by the Trust. During the option term, the counterparty may elect to exercise the option if the market value of the equity security rises above the strike price, and the Trust is obligated to sell the equity security to the counterparty at the strike price, realizing a gain or loss. Premiums received increase gains or reduce losses realized on the sale of the equity security. If the option remains unexercised upon its expiration, the Trust realizes gains equal to the premiums received. Alternatively, an option may be closed out by an offsetting purchase or sale of an option prior to expiration. The Trust realizes a capital gain from a closing purchase or sale transaction if the premium paid is less than the premium received from writing the option. The Trust realizes a capital loss from a closing purchase or sale transaction if the premium received is less than the premium paid to purchase the option.

Writing covered call options entails certain risks, which include, but are not limited to, the following: an increase in the value of the underlying equity security above the strike price can result in the exercise of a written option (sale by a Trust to the counterparty) when the Trust might not otherwise have sold the security; exercise of the option by the counterparty may result in a sale below the current market value and a gain or loss being realized by the Trust; and limiting the potential appreciation that could be realized on the underlying equity security to the extent of the strike price of the option. The premium that a Trust receives from writing a covered call option may not be sufficient to offset the potential appreciation on the underlying equity security above the strike price of the option that could have otherwise been realized by the Trust. As such, an option over-writing strategy may outperform the general equity market in flat or falling markets but underperform in rising markets.

Option Over-Writing Strategy Illustration

To illustrate these concepts, assume the following: (1) a common stock purchased at and currently trading at $37.15 per share; (2) a three-month call option is written by a Trust with a strike price of $40 (i.e., 7.7% higher than the current market price); and (3) the Trust receives $2.45, or 6.6% of the common stock’s value, as a premium. If the stock price remains unchanged, the option expires and there would be a 6.6% return for the three-month period. If the stock were to decline in price by 6.6% (i.e., decline to $34.70 per share), the option strategy would “break-even” from an economic perspective resulting in neither a gain nor a loss. If the stock were to climb to a price of $40 or above, the option would be exercised and the stock would return 7.7% coupled with the option premium received of 6.6% for a total return of 14.3%. Under this scenario, the Trust loses the benefit of any appreciation of the stock above $40, and thus is limited to a 14.3% total return. The premium from writing the call option serves to offset some of the unrealized loss on the stock in the event that the price of the stock declines, but if the stock were to decline more than 6.6% under this scenario, the Trust’s downside protection is eliminated and the stock could eventually become worthless.

Each Trust intends to write covered call and other options to varying degrees depending upon market conditions. Please refer to each Trust’s Schedule of Investments and the Notes to Financial Statements for details of written options.

Derivative Financial Instruments

The Trusts may invest in various derivative financial instruments. These instruments are used to obtain exposure to a security, commodity, index, market, and/or other assets without owning or taking physical custody of securities, commodities and/or other referenced assets or to manage market, equity, credit, interest rate, foreign currency exchange rate, commodity and/or other risks. Derivative financial instruments may give rise to a form of economic leverage and involve risks, including the imperfect correlation between the value of a derivative financial instrument and the underlying asset, possible default of the counterparty to the transaction or illiquidity of the instrument. Pursuant to Rule 18f-4 under the 1940 Act, among other things, the Trusts must either use derivative financial instruments with embedded leverage in a limited manner or comply with an outer limit on fund leverage risk based on value-at-risk. The Trusts’ successful use of a derivative financial instrument depends on the investment adviser’s ability to predict pertinent market movements accurately, which cannot be assured. The use of these instruments may result in losses greater than if they had not been used, may limit the amount of appreciation a Trust can realize on an investment and/or may result in lower distributions paid to shareholders. The Trusts’ investments in these instruments, if any, are discussed in detail in the Notes to Financial Statements.

6 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Trust Summary as of December 31, 2023   BlackRock Energy and Resources Trust (BGR)

Investment Objective

BlackRock Energy and Resources Trust’s (BGR) (the “Trust”) investment objective is to provide total return through a combination of current income and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of energy and natural resources companies and equity derivatives with exposure to the energy and natural resources industry. The Trust may invest directly in such securities or synthetically through the use of derivatives. The Trust seeks to pursue this goal primarily by investing in a portfolio of equity securities and also by employing a strategy of writing (selling) call and put options.

No assurance can be given that the Trust’s investment objective will be achieved.

Trust Information

Symbol on New York Stock Exchange	BGR
Initial Offering Date	December 29, 2004
Current Distribution Rate on Closing Market Price as of December 31, 2023 ($12.45)(a)	6.33%
Current Monthly Distribution per Common Share(b)	$0.065700
Current Annualized Distribution per Common Share(b)	$0.788400

^(a)  Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate may consist of income, net realized gains and/or a return of capital. Past performance is not an indication of future results.

^(b)  The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.

Market Price and Net Asset Value Per Share Summary

	12/31/23		12/31/22		Change			High		Low
Closing Market Price	$	12.45	$	12.53		(0.64	)%	$	13.36	$	11.23
Net Asset Value		14.13		14.21		(0.56	)		15.09		12.71

GROWTH OF $10,000 INVESTMENT

^(a)  Represents the Trust’s closing market price on the NYSE and reflects the reinvestment of dividends and/or distributions at actual reinvestment prices.

^(b)  An index that is designed to capture the large- and mid-cap segments across developed markets countries. All securities in the index are classified in the energy sector as per the Global Industry Classification Standard.

T R U S T S U M M A R Y 7

Trust Summary as of December 31, 2023 (continued)   BlackRock Energy and Resources Trust (BGR)

Performance

Returns for the period ended December 31, 2023 were as follows:

	Average Annual Total Returns
	1 Year			5 Years			10 Years
Trust at NAV(a)(b)		5.75	%		10.34	%		0.98	%
Trust at Market Price(a)(b)		5.66			10.57			0.78
MSCI World Energy Call Overwrite Index(c)		5.18			7.71			N/A
MSCI World Energy Index		2.54			9.88			2.03

^(a)  All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.

^(b)  The Trust’s discount to NAV widened during the period, which accounts for the difference between performance based on market price and performance based on NAV.

^(c)  An index that incorporates an option overlay component on the MSCI World Energy Index with a 33% overwrite level. The benchmark commenced on December 31, 2018 and therefore the benchmark does not have 10-year returns.

Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles. Past performance is not an indication of future results.

The Trust is presenting the performance of one or more indices for informational purposes only. The Trust is actively managed and does not seek to track or replicate the performance of any index. The index performance shown is not intended to be indicative of the Trust’s investment strategies, portfolio components or past or future performance.

More information about the Trust’s historical performance can be found in the “Closed End Funds” section of blackrock.com.

The following discussion relates to the Trust’s relative performance based on NAV:

What factors influenced performance?

Natural resources stocks posted gains as a group in 2023, but they lagged the broader equity market due largely to weakness in commodity prices.

The Trust’s overweight positions in Canadian Natural Resources Ltd. and Diamondback Energy, Inc., which rose on the strength of robust production and positive earnings results, contributed to performance. Zero weightings in Devon Energy Corp. and Occidental Petroleum Corp. also contributed. Devon reported weaker-than-expected profits, and Occidental’s share price fell following the announcement of a debt-trusted acquisition. The U.S. liquified natural gas exporter Cheniere Energy, Inc., which reported strong results and upgraded its earnings guidance throughout the year, was another noteworthy contributor.

On the negative side, an underweight in the oilfield services sub-sector detracted from performance. At the stock level, an overweight position in Patterson-UTI Energy Inc. detracted in the first half of the year. A zero weighting in Baker Hughes, Inc. hurt performance, as well. Elsewhere in the portfolio, zero weightings in Cameco Inc., Neste oyj, and Phillips 66 pressured results. A position in BP PLC also detracted. Although the company reported robust earnings, investors reacted negatively to the company’s decision to reduce its pace of share buybacks.

The Trust used an options overlay strategy in which calls were written on a portion of the portfolio’s holdings. This strategy contributed to results in the annual period.

The Trust’s practice of maintaining a specified level of monthly distributions to shareholders did not have a material impact on the Trust’s investment strategy. The distribution policy resulted in return of capital for the period. Refer to the financial highlights and income tax information sections in this report for further information about the distributions.

Describe recent portfolio activity.

The investment adviser added to the Trust’s weighting in the oilfield services subsector, and it modestly reduced the allocation to integrated oil companies. The investment adviser also reduced the Trust’s position in U.S. shale exploration and production companies, and it rotated its holdings in the integrated subsector in an effort to capitalize on differences in relative performance.

Describe portfolio positioning at period end.

The investment adviser actively manages the Trust’s positioning to focus on areas where it sees compelling return opportunities and attractive valuations. It believed valuations were favorable at the end of the reporting period given energy companies’ ability to generate profits and deliver high free cash flows. The Trust was overweight in European integrated producers, where the investment advisor saw the most compelling valuations. The Trust maintained selective exposure within the U.S. shale space.

As of December 31, 2023, the Trust had in place an option overwriting program whereby 29.8% of the underlying equities were overwritten with call options on individual stocks. These call options were typically written at prices above the prevailing market prices (estimated to be 3.9% out of the money) and for maturities averaging 48 days.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

8 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Trust Summary as of December 31, 2023 (continued)   BlackRock Energy and Resources Trust (BGR)

Overview of the Trust’s Total Investments

TEN LARGEST HOLDINGS

Security(a)	Percent of Total Investments
Exxon Mobil Corp.		16.3	%
Shell PLC		10.8
Chevron Corp.		8.8
TotalEnergies SE		8.2
ConocoPhillips		6.2
BP PLC		4.7
Canadian Natural Resources Ltd.		4.2
EOG Resources, Inc.		4.0
Williams Cos., Inc.		3.7
Cheniere Energy, Inc.		3.7

INDUSTRY ALLOCATION

Industry(a)(b)	Percentage of Total Investments
Oil, Gas & Consumable Fuels		93.6	%
Energy Equipment & Services		6.4

^(a)  Excludes short-term securities.

^(b)  For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

T R U S T S U M M A R Y 9

Trust Summary as of December 31, 2023    BlackRock Enhanced Capital and Income Fund, Inc. (CII)

Investment Objective

BlackRock Enhanced Capital and Income Fund, Inc.’s (CII) (the “Trust”) investment objective is to provide current income and capital appreciation. The Trust seeks to achieve its investment objective by investing in a portfolio of equity securities of U.S. and foreign issuers. The Trust may invest directly in such securities or synthetically through the use of derivatives. The Trust also seeks to achieve its investment objective by employing a strategy of writing (selling) call and put options.

No assurance can be given that the Trust’s investment objective will be achieved.

Trust Information

Symbol on New York Stock Exchange	CII
Initial Offering Date	April 30, 2004
Current Distribution Rate on Closing Market Price as of December 31, 2023 ($19.00)(a)	6.28%
Current Monthly Distribution per Common Share(b)	$0.099500
Current Annualized Distribution per Common Share(b)	$1.194000

^(a)  Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate may consist of income, net realized gains and/or a return of capital. Past performance is not an indication of future results.

^(b)  The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.

Market Price and Net Asset Value Per Share Summary

	12/31/23		12/31/22		Change			High		Low
Closing Market Price	$	19.00	$	17.12		10.98	%	$	19.32	$	16.82
Net Asset Value		19.81		17.55		12.88			19.84		17.42

GROWTH OF $10,000 INVESTMENT

^(a)  Represents the Trust’s closing market price on the NYSE and reflects the reinvestment of dividends and/or distributions at actual reinvestment prices.

^(b)  An index that measures the performance of the large-cap segment of the U.S. equity universe. It is a subset of the Russell 3000® Index and includes approximately 1,000 of the largest securities based on a combination of their market capitalization and current index membership. The Russell 1000® Index represents approximately 93% of the U.S. market.

10 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Trust Summary as of December 31, 2023 (continued)   BlackRock Enhanced Capital and Income Fund, Inc. (CII)

Performance

Returns for the period ended December 31, 2023 were as follows:

	Average Annual Total Returns
	1 Year			5 Years			10 Years
Trust at NAV(a)(b)		20.45	%		13.27	%		10.25	%
Trust at Market Price(a)(b)		18.43			14.18			11.27
MSCI USA Call Overwrite Index(c)		22.00			11.57			N/A
Russell 1000® Index		26.53			15.52			11.80

^(a)  All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.

^(b)  The Trust’s discount to NAV widened during the period, which accounts for the difference between performance based on market price and performance based on NAV.

^(c)  An index that incorporates an option overlay component on the MSCI USA Index with a 55% overwrite level. The benchmark commenced on December 31, 2018 and therefore the benchmark does not have 10-year returns.

Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles. Past performance is not an indication of future results.

The Trust is presenting the performance of one or more indices for informational purposes only. The Trust is actively managed and does not seek to track or replicate the performance of any index. The index performance shown is not intended to be indicative of the Trust’s investment strategies, portfolio components or past or future performance.

More information about the Trust’s historical performance can be found in the “Closed End Funds” section of blackrock.com.

The following discussion relates to the Trust’s relative performance based on NAV:

What factors influenced performance?

Stock selection within the healthcare sector was a leading contributor to relative performance, most notably within the pharmaceuticals industry. Investment decisions within communication services also proved additive, most notably an overweight allocation to the sector along with stock selection in interactive media and services. Finally, positioning within the energy sector and a lack of exposure to utilities was beneficial as well.

An underweight allocation to the information technology sector was the largest detractor during the period. Stock selection in materials also detracted, most notably an overweight allocation to and poor selection within the containers and packaging industry. Stock selection within consumer discretionary and industrials detracted as well.

The Trust utilized an options overlay strategy in which calls are written on a portion of the portfolio’s holdings. The Trust’s options overlay strategy detracted from relative performance for the 12-month period.

The Trust’s practice of maintaining a specified level of monthly distributions did not have a material impact on the Trust’s investment strategy. The distribution policy did not result in return of capital for the period. Refer to the financial highlights and income tax information sections in this report for further information about the distributions.

Describe recent portfolio activity.

During the reporting period, a combination of portfolio trading activity and market price changes resulted in the Trust adding exposure to the information technology and communication services sectors, while the Trust saw reduced exposure to industrials and materials.

Describe portfolio positioning at period end.

As of December 31, 2023, the Trust had an options overwriting program in place whereby 51% of the underlying equities were overwritten with call options. These call options were typically written at levels above prevailing market prices (estimated to be 6.0% out of the money) with an average time until expiration of 53 days.

At period end, the Trust’s largest absolute allocations were in IT, healthcare and financials. Relative to the benchmark, the Trust’s most significant overweight exposures were in communication services, health care and consumer discretionary. The Trust maintained its most significant relative underweight sector exposures to IT, real estate and utilities.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

T R U S T S U M M A R Y 11

Trust Summary as of December 31, 2023 (continued)   BlackRock Enhanced Capital and Income Fund, Inc. (CII)

Overview of the Trust’s Total Investments

TEN LARGEST HOLDINGS

Security(a)	Percent of Total Investments
Microsoft Corp.		8.7	%
Amazon.com, Inc.		5.5
Alphabet, Inc.		5.4
Apple, Inc.		4.4
Meta Platforms, Inc.		3.1
Berkshire Hathaway, Inc.		2.6
Advanced Micro Devices, Inc.		2.3
Comcast Corp.		2.3
Fortive Corp.		2.3
Sanofi SA		2.2

SECTOR ALLOCATION

Sector(a)(b)	Percent of Total Investments
Information Technology		25.2	%
Health Care		16.2
Financials		13.1
Communication Services		13.1
Consumer Discretionary		12.8
Industrials		6.9
Consumer Staples		5.5
Energy		4.2
Materials		3.0

^(a) Excludes short-term securities.

^(b)  For Trust compliance purposes, the Trust’s sector classifications refer to one or more of the sector sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such sector sub-classifications for reporting ease.

12 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Trust Summary as of December 31, 2023    BlackRock Enhanced Equity Dividend Trust (BDJ)

Investment Objective

BlackRock Enhanced Equity Dividend Trust’s (BDJ) (the “Trust”) primary investment objective is to provide current income and current gains, with a secondary investment objective of long-term capital appreciation. The Trust seeks to achieve its investment objectives by investing in common stocks that pay dividends and have the potential for capital appreciation and by utilizing an option writing strategy to enhance distributions to its shareholders. The Trust invests, under normal market conditions, at least 80% of its total assets in dividend paying equities and may invest up to 20% of its total assets in equity securities of issuers that do not pay dividends. The Trust may invest directly in such securities or synthetically through the use of derivatives.

No assurance can be given that the Trust’s investment objectives will be achieved.

Trust Information

Symbol on New York Stock Exchange	BDJ
Initial Offering Date	August 31, 2005
Current Distribution Rate on Closing Market Price as of December 31, 2023 ($7.69)(a)	8.77%
Current Monthly Distribution per Common Share(b)	$0.056200
Current Annualized Distribution per Common Share(b)	$0.674400

^(a)  Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate may consist of income, net realized gains and/or a return of capital. Past performance is not an indication of future results.

^(b)  The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.

Market Price and Net Asset Value Per Share Summary

	12/31/23		12/31/22		Change			High		Low
Closing Market Price	$	7.69	$	9.01		(14.65	)%	$	9.36	$	6.92
Net Asset Value		8.82		8.74		0.92			9.15		8.05

GROWTH OF $10,000 INVESTMENT

^(a) Represents the Trust’s closing market price on the NYSE and reflects the reinvestment of dividends and/or distributions at actual reinvestment prices.

^(b)  An index that measures the performance of the large-cap value segment of the U.S. equity universe. It includes those Russell 1000 companies with lower price-to-book ratios and lower expected growth values.

T R U S T S U M M A R Y 13

Trust Summary as of December 31, 2023 (continued)   BlackRock Enhanced Equity Dividend Trust (BDJ)

Performance

Returns for the period ended December 31, 2023 were as follows:

	Average Annual Total Returns
	1 Year			5 Years			10 Years
Trust at NAV(a)(b)		10.37	%		9.76	%		7.88	%
Trust at Market Price(a)(b)		(6.65	)		9.31			7.89
MSCI USA Value Call Overwrite Index(c)		5.33			7.12			N/A
Russell 1000® Value Index		11.46			10.91			8.40

^(a)  All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.

^(b)  The Trust moved from a premium to NAV to a discount during the period, which accounts for the difference between performance based on market price and performance based on NAV.

^(c)  An index that incorporates an option overlay component on the MSCI USA Value Index with a 55% overwrite level. The benchmark commenced on December 31, 2018 and therefore the benchmark does not have 10-year returns.

Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles. Past performance is not an indication of future results.

The Trust is presenting the performance of one or more indices for informational purposes only. The Trust is actively managed and does not seek to track or replicate the performance of any index. The index performance shown is not intended to be indicative of the Trust’s investment strategies, portfolio components or past or future performance.

More information about the Trust’s historical performance can be found in the “Closed End Funds” section of blackrock.com.

The following discussion relates to the Trust’s relative performance based on NAV:

What factors influenced performance?

The global equity markets produced robust returns in 2023 thanks to stronger-than-expected economic growth and a more favorable outlook for central bank policy. Dividend-paying stocks, while posting gains, lagged the broader market at a time in which investors displayed a preference for faster-growing companies.

Stock selection in the financial sector made the largest contribution to the Fund’s relative performance. Selection in health care also boosted results, mainly due to positioning in pharmaceuticals. Stock selection in energy was an additional contributor, led by the oil, gas, and consumable fuels industry group. Positioning in utilities contributed as well.

On the other hand, an underweight in the information technology sector detracted from performance. Stock selection in materials further weighed on results, with the weakest showing in the containers and packaging industry. Positioning in the consumer discretionary and consumer staples sectors also detracted.

The Trust used an options overlay strategy in which calls were written on a portion of the portfolio’s holdings. The options overlay strategy detracted from relative performance.

The Trust’s practice of maintaining a specified level of monthly distributions to shareholders did not have a material impact on the Trust’s investment strategy. The distribution policy did not result in return of capital for the period. Refer to the financial highlights and income tax information sections in this report for further information about the distributions.

Describe recent portfolio activity.

The Trust’s allocations to the financials and industrials sectors increased due to a combination of portfolio trading activity and market price changes. The Trust’s weightings in information technology and healthcare sectors decreased.

Describe portfolio positioning at period end.

As of December 31, 2023, the Trust had in place an option overwriting program whereby 50.8% of the underlying equities were overwritten with call options on individual stocks. These call options were typically written at prices above the prevailing market prices (estimated to be 5.0% out of the money) and for maturities averaging 55 days.

At period end, the Trust’s largest absolute allocations were in financials, healthcare, and industrials. Relative to the benchmark, the Trust’s most significant overweight exposures were in financials, communication services and health care. The Trust maintained its most significant relative underweight sector exposures to IT, real estate and materials.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

14 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Trust Summary as of December 31, 2023 (continued)   BlackRock Enhanced Equity Dividend Trust (BDJ)

Overview of the Trust’s Total Investments

TEN LARGEST HOLDINGS

Security(a)	Percent of Total Investments
Wells Fargo & Co.		3.2	%
Citigroup, Inc.		3.0
American International Group, Inc.		2.9
Shell PLC		2.6
Kraft Heinz Co.		2.4
Leidos Holdings, Inc.		2.3
L3Harris Technologies, Inc.		2.3
General Motors Co.		2.2
SS&C Technologies Holdings, Inc.		2.1
BP PLC		2.1

SECTOR ALLOCATION

Sector(a)(b)	Percent of Total Investments
Financials		26.9	%
Health Care		18.2
Industrials		11.5
Consumer Staples		8.8
Energy		8.5
Information Technology		7.3
Consumer Discretionary		6.3
Communication Services		5.5
Utilities		4.1
Materials		2.1
Real Estate		0.8

^(a)  Excludes short-term securities.

^(b)  For Trust compliance purposes, the Trust’s sector classifications refer to one or more of the sector sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such sector sub-classifications for reporting ease.

T R U S T S U M M A R Y 15

Trust Summary as of December 31, 2023     BlackRock Enhanced Global Dividend Trust (BOE)

Investment Objective

BlackRock Enhanced Global Dividend Trust’s (BOE) (the “Trust”) primary investment objective is to provide current income and current gains, with a secondary investment objective of long-term capital appreciation. The Trust seeks to achieve its investment objectives by investing primarily in equity securities issued by companies located in countries throughout the world and by employing a strategy of writing (selling) call and put options. Under normal circumstances, the Trust invests at least 80% of its net assets in dividend-paying equity securities and at least 40% of its assets outside of the U.S. (unless market conditions are not deemed favorable by Trust management, in which case the Trust would invest at least 30% of its assets outside of the U.S.). The Trust may invest in securities of companies of any market capitalization, but intends to invest primarily in securities of large capitalization companies. The Trust may invest directly in such securities or synthetically through the use of derivatives.

No assurance can be given that the Trust’s investment objectives will be achieved.

Trust Information

Symbol on New York Stock Exchange	BOE
Initial Offering Date	May 31, 2005
Current Distribution Rate on Closing Market Price as of December 31, 2023 ($ 9.92)(a)	7.62%
Current Monthly Distribution per Common Share(b)	$0.063000
Current Annualized Distribution per Common Share(b)	$0.756000

^(a)  Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate may consist of income, net realized gains and/or a return of capital. Past performance is not an indication of future results.

^(b) The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.

Market Price and Net Asset Value Per Share Summary

	12/31/23		12/31/22		Change			High		Low
Closing Market Price	$	9.92	$	9.56		3.77	%	$	10.59	$	8.87
Net Asset Value		11.81		10.97		7.66			11.81		10.56

GROWTH OF $10,000 INVESTMENT

^(a)  Represents the Trust’s closing market price on the NYSE and reflects the reinvestment of dividends and/or distributions at actual reinvestment prices.

^(b)  An index that captures large- and mid-cap representation across certain developed and emerging markets.

16 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Trust Summary as of December 31, 2023 (continued)   BlackRock Enhanced Global Dividend Trust (BOE)

Performance

Returns for the period ended December 31, 2023 were as follows:

	Average Annual Total Returns
	1 Year			5 Years			10 Years
Trust at NAV(a)(b)		16.16	%		8.89	%		5.14	%
Trust at Market Price(a)(b)		11.95			8.72			4.69
MSCI ACWI Call Overwrite Index(c)		18.00			8.97			N/A
MSCI ACWI		22.20			11.72			7.93

^(a) All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.

^(b) The Trust’s discount to NAV widened during the period, which accounts for the difference between performance based on market price and performance based on NAV.

^(c) An index that incorporates an option overlay component on the MSCI ACWI Index with a 45% overwrite level. The benchmark commenced on December 31, 2018 and therefore the benchmark does not have 10-year returns.

Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles. Past performance is not an indication of future results.

The Trust is presenting the performance of one or more indices for informational purposes only. The Trust is actively managed and does not seek to track or replicate the performance of any index. The index performance shown is not intended to be indicative of the Trust’s investment strategies, portfolio components or past or future performance.

More information about the Trust’s historical performance can be found in the “Closed End Funds” section of blackrock.com.

The following discussion relates to the Trust’s relative performance based on NAV:

What factors influenced performance?

At the individual stock level, a lack of exposure to Nvidia Corp. and Meta Platforms, Inc., along with an underweight position in Apple, Inc. were among the top detractors given the outsized gains posted by these stocks over the year. The Trust’s focus on investing in high quality companies with sustainable growing cash flows that pay a dividend limits its ability to invest in much of the universe of technology-related companies given that these companies typically pay very low dividends or have no dividend policies. The Trust’s position in International Flavors & Fragrances, Inc. also detracted from performance. The company missed earnings estimates and guided lower on full year 2023 growth given an uncertain market environment that led to weaker volumes and industry-wide consumer destocking in the United States. The Fund exited the position in the third quarter of 2023.

In terms of individual holdings, positive contributions were led by MediaTek, Inc. (“MediaTek”), a Taiwanese semiconductor company that supplies chips for smartphones in China. MediaTek shares benefited as expectations for central bank rate cuts supported growth-oriented areas of the market. In addition, the company continued to beat earnings estimates and saw significant improvements in inventory levels and expectations for the recovery in China’s smartphone market where the investment adviser believed it was positioned to continue to gain market share. Holdings of U.K. home construction company Taylor Wimpey PLC also contributed to performance. The shares were supported by expectations for lower U.K. mortgage rates and a more robust U.K. housing market in 2024. The company’s strong balance sheet and attractive land bank along with the structural imbalance between supply and demand in the U.K. housing market continued to make it an attractive holding in the view of the investment adviser. Finally, Spanish clothing retailer Industria de Diseno Textil SA, curator of brands such as Zara, reported strong profits over the year thanks to robust in-store and online sales. The company has been able to maintain pricing strength in markets outside the Eurozone, which has boosted profitability.

The Trust utilized an options overlay strategy in which calls are written on a portion of the portfolio’s holdings. The Trust’s options overlay strategy contributed positively to relative performance.

The Trust’s practice of maintaining a specified level of monthly distributions to shareholders did not have a material impact on the Trust’s investment strategy. The distribution policy resulted in return of capital for the period. Refer to the financial highlights and income tax information sections in this report for further information about the distributions.

Describe recent portfolio activity.

During the reporting period, the Trust added exposure to the industrials, information technology and energy sectors. The Trust reduced exposure to the consumer discretionary sector, particularly in relation to the luxury segment, as well as to healthcare and utilities.

Describe portfolio positioning at period end.

At period end, the Trust’s largest sector overweights were in industrials, healthcare and consumer staples, while consumer discretionary was the largest underweight. Regionally, the Trust was overweight Europe and underweight the United States.

As of December 31, 2023, the Trust had an options overwriting program in place whereby 44% of the underlying equities were overwritten with call options. These call options were typically written at levels above prevailing market prices (estimated to be 2.3% out of the money) with an average time until expiration of 57 days.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

T R U S T S U M M A R Y 17

Trust Summary as of December 31, 2023 (continued)   BlackRock Enhanced Global Dividend Trust (BOE)

Overview of the Trust’s Total Investments

TEN LARGEST HOLDINGS

Security(a)	Percent of Total Investments
Microsoft Corp.		4.8	%
Apple, Inc.		3.4
Nestle SA		3.0
Mondelez International, Inc.		2.9
Taiwan Semiconductor Manufacturing Co. Ltd.		2.8
AstraZeneca PLC		2.8
Union Pacific Corp.		2.7
AbbVie, Inc.		2.7
Accenture PLC		2.7
RELX PLC		2.6

GEOGRAPHIC ALLOCATION

Country/Geographic Region	Percentage of Total Investments
United States		50.9	%
United Kingdom		11.1
France		9.4
Switzerland		6.7
Taiwan		4.9
Netherlands		4.1
Ireland		4.1
Denmark		2.2
Mexico		2.1
Canada		2.0
Singapore		1.4
Indonesia		1.1
India		—	(b)

^(a) Excludes short-term securities.

^(b) Rounds to less than 0.1%.

18 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Trust Summary as of December 31, 2023    BlackRock Enhanced International Dividend Trust (BGY)

Investment Objective

BlackRock Enhanced International Dividend Trust’s (BGY) (the “Trust”) primary investment objective is to provide current income and current gains, with a secondary objective of long-term capital appreciation. The Trust seeks to achieve its investment objectives by investing primarily in equity securities issued by companies of any market capitalization located in countries throughout the world and by employing a strategy of writing (selling) call and put options. The Trust invests, under normal circumstances, at least 80% of its net assets in dividend-paying equity securities issued by non-U.S. companies of any market capitalization, but intends to invest primarily in securities of large capitalization companies. The Trust may invest directly in such securities or synthetically through the use of derivatives.

No assurance can be given that the Trust’s investment objectives will be achieved.

Trust Information

Symbol on New York Stock Exchange	BGY
Initial Offering Date	May 30, 2007
Current Distribution Rate on Closing Market Price as of December 31, 2023 ($ 5.27)(a)	7.70%
Current Monthly Distribution per Common Share(b)	$0.033800
Current Annualized Distribution per Common Share(b)	$0.405600

^(a)  Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate may consist of income, net realized gains and/or a return of capital. Past performance is not an indication of future results.

^(b) The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.

Market Price and Net Asset Value Per Share Summary

	12/31/23		12/31/22		Change			High		Low
Closing Market Price	$	5.27	$	5.02		4.98	%	$	5.64	$	4.68
Net Asset Value		6.21		5.78		7.44			6.40		5.54

GROWTH OF $10,000 INVESTMENT

^(a) Represents the Trust’s closing market price on the NYSE and reflects the reinvestment of dividends and/or distributions at actual reinvestment prices.

^(b)  An index that captures large- and mid-cap representation across certain developed markets countries (excluding the U.S.) and certain emerging markets countries.

T R U S T S U M M A R Y 19

Trust Summary as of December 31, 2023 (continued)   BlackRock Enhanced International Dividend Trust (BGY)

Performance

Returns for the period ended December 31, 2023 were as follows:

	Average Annual Total Returns
	1 Year			5 Years			10 Years
Trust at NAV(a)(b)		15.94	%		9.12	%		3.93	%
Trust at Market Price(a)(b)		13.29			8.82			3.49
MSCI ACWI ex USA Call Overwrite Index(c)		11.24			4.61			N/A
MSCI ACWI ex USA Index		15.62			7.08			3.83

^(a) All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.

^(b)  The Trust’s discount to NAV widened during the period, which accounts for the difference between performance based on market price and performance based on NAV.

^(c)  An index that incorporates an option overlay component on the MSCI ACWI ex USA Index with a 45% overwrite level. The benchmark commenced on December 31, 2018 and therefore the benchmark does not have 10-year returns.

Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles. Past performance is not an indication of future results.

The Trust is presenting the performance of one or more indices for informational purposes only. The Trust is actively managed and does not seek to track or replicate the performance of any index. The index performance shown is not intended to be indicative of the Trust’s investment strategies, portfolio components or past or future performance.

More information about the Trust’s historical performance can be found in the “Closed End Funds” section of blackrock.com.

The following discussion relates to the Trust’s relative performance based on NAV:

What factors influenced performance?

Stock selection within and an overweight to industrials led positive contributions to the Trust’s relative performance during the reporting period. Stock selection within and underweights to materials and consumer discretionary also contributed.

In terms of individual holdings, positive contributions were led by MediaTek Inc.(“MediaTek”), a Taiwanese semiconductor company that supplies chips for smartphones in China. MediaTek shares benefited as expectations for central bank rate cuts supported growth-oriented areas of the market. In addition, the company continued to beat earnings estimates and is seeing significant improvements in inventory levels and expectations for the recovery in China’s smartphone market where it is positioned to continue to gain market share. Spanish clothing retailer Industria de Diseno Textil SA, curator of brands such as Zara, reported strong profits during the period thanks to robust sales both in-store and online. The company has been able to maintain pricing strength in markets outside the eurozone, aiding profitability. Novo Nordisk A/S, the Danish multinational pharmaceutical company, also contributed to returns. The stock reacted positively as Novo Nordisk A/S reported that its latest trial resulted in a 20% decrease in cardiovascular events in obese patients using Wegovy, – the GLP-1 weight-loss drug manufactured by the company. This result was expected to help unlock reimbursement of the product in commercial plans and potentially lead to Medicare reimbursement, while differentiating Wegovy from competing products.

Stock selection in financials was the main detractor from relative performance during the period. Stock selection within and an overweight to consumer staples and stock selection within communication services also detracted.

Lonza Group AG, the Swiss pharmaceutical and biotech company and largest biologics contract manufacturer in the world, was the top detractor from relative performance over the period. Following the unexpected departure of the CEO in September 2023, the company held its Capital Markets Day in October 2023 and downgraded 2024 guidance. The reduced guidance was centered on Lonza Group AG’s Biologics business that management had previously indicated was “sold out for the foreseeable future”. The Trust subsequently exited the position. Prudential PLC, the U.K.-based multinational insurance company and leading provider of insurance products and services in Asia, also detracted during the period as the shares came under pressure due to weaker sentiment in China. The company posted strong new business profits for the first half of 2023 and the new CEO announced plans for a $1 billion organic investment program through 2025 to drive an increase in new business premiums growth. Finally, brewer Budweiser Brewing Co. APAC Ltd. had significant exposure to the on-premise and nightlife channels in China and saw its shares come under pressure due to increasing concerns over the strength of China’s post-pandemic reopening.

The Trust utilized an options overlay strategy in which calls are written on a portion of the portfolio’s holdings. The Trust’s options overlay strategy contributed to relative performance for the reporting period.

The Trust’s practice of maintaining a specified level of monthly distributions did not have a material impact on the Trust’s investment strategy. The distribution policy resulted in return of capital for the period. Refer to the financial highlights and income tax information sections in this report for further information about the distributions.

Describe recent portfolio activity.

During the reporting period, the Trust reduced its exposure to the materials, energy and information technology sectors, while adding to consumer staples, consumer discretionary and industrials.

Describe portfolio positioning at period end.

At period end, the Trust’s largest sector overweights were in industrials, healthcare and information technology. Regionally, the majority of portfolio assets comprised securities listed in Europe, with particularly significant exposure in Europe excluding the United Kingdom.

20 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Trust Summary as of December 31, 2023 (continued)   BlackRock Enhanced International Dividend Trust (BGY)

As of December 31, 2023, the Trust had an options overwriting program in place whereby 43% of the underlying equities were overwritten with call options. These call options were typically written at levels above prevailing market prices (estimated to be 2.3% out of the money) with an average time until expiration of 60 days.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

Overview of the Trust’s Total Investments

TEN LARGEST HOLDINGS

Security(a)	Percent of Total Investments
Taiwan Semiconductor Manufacturing Co. Ltd.		4.5	%
Novo Nordisk A/S		3.7
RELX PLC		3.6
Baker Hughes Co.		3.4
Keyence Corp.		3.3
ASML Holding NV		3.1
Atlas Copco AB		3.1
Air Liquide SA		3.0
FinecoBank Banca Fineco SpA		3.0
Shell PLC		3.0

GEOGRAPHIC ALLOCATION

Country/Geographic Region	Percentage of Total Investments
United Kingdom		13.4	%
Netherlands		11.9
France		10.5
United States		10.3
Japan		7.6
Taiwan		7.1
Sweden		5.7
Switzerland		4.5
Canada		4.4
Germany		4.3
Singapore		4.1
Denmark		3.7
Italy		3.0
Mexico		2.9
India		2.6
Indonesia		1.5
Brazil		1.4
China		1.1

^(a) Excludes short-term securities.

T R U S T S U M M A R Y 21

Trust Summary as of December 31, 2023   BlackRock Health Sciences Term Trust (BMEZ)

Investment Objective

BlackRock Health Sciences Term Trust’s (BMEZ) (the “Trust”) (formerly known as BlackRock Health Sciences Trust II) investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. Under normal market conditions, the Trust will invest at least 80% of its total assets in equity securities of companies principally engaged in the health sciences group of industries and equity derivatives with exposure to the health sciences group of industries. Equity derivatives in which the Trust invests include purchased and sold (written) call and put options on equity securities of companies in the health sciences group of industries.

On March 31, 2023 the Board approved a proposal to change the name of BlackRock Health Sciences Trust II, effective as of April 5, 2023, to BlackRock Health Sciences Term Trust. There were no changes to the Trust’s investment policies or strategies in conjunction with the name change.

No assurance can be given that the Trust’s investment objective will be achieved.

Trust Information

Symbol on New York Stock Exchange	BMEZ
Initial Offering Date	January 30, 2020
Current Distribution Rate on Closing Market Price as of December 31, 2023 ($14.65)(a)	7.50%
Current Monthly Distribution per Common Share(b)	$0.091600
Current Annualized Distribution per Common Share(b)	$1.099200

^(a)  Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate may consist of income, net realized gains and/or a return of capital. Past performance is not an indication of future results.

^(b)  The monthly distribution per Common Share, declared on February 1, 2024, was decreased to $0.090440 per share. The current distribution rate on closing market price, current monthly distribution per Common Share, and current annualized distribution per Common Share do not reflect the new distribution rate. The new distribution rate is not constant and is subject to change in the future. A portion of the distribution may be deemed a return of capital or net realized gain.

Market Price and Net Asset Value Per Share Summary

	12/31/23		12/31/22		Change			High		Low
Closing Market Price	$	14.65	$	15.43		(5.06	)%	$	16.99	$	13.02
Net Asset Value		17.91		18.76		(4.53	)		19.72		15.62

GROWTH OF $10,000 INVESTMENT

BMEZ commenced operations on January 30, 2020.

^(a)  Represents the Trust’s closing market price on the NYSE and reflects the reinvestment of dividends and/or distributions at actual reinvestment prices.

^(b) An index that captures large- and mid-cap representation across certain developed and emerging markets.

22 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Trust Summary as of December 31, 2023 (continued)   BlackRock Health Sciences Term Trust (BMEZ)

Performance

Returns for the period ended December 31, 2023 were as follows:

	Average Annual Total Returns
	1 Year			Since    Inception(a)
Trust at NAV(b)(c)		5.60	%		5.00%
Trust at Market Price(b)(c)		5.02			(0.24)
MSCI Custom ACWI SMID Growth HC Call Overwrite Index(d)		4.08			(6.87)
MSCI ACWI		22.20			8.44

^(a)  BMEZ commenced operations on January 30, 2020.

^(b)  All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.

^(c)  The Trust’s discount to NAV widened during the period, which accounts for the difference between performance based on market price and performance based on NAV.

^(d)  An index representing the Health Care sector stocks within the MSCI ACWI SMID Cap Growth Index and incorporating an option overlay component with a 25% overwrite level. The MSCI ACWI SMID Cap Growth Index captures mid- and small-cap securities exhibiting overall growth style characteristics across certain developed and emerging markets countries. The index commenced on March 31, 2022 and therefore the since inception return presented is for the period March 31, 2022 through the current reporting period.

Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles. Past performance is not an indication of future results.

The Trust is presenting the performance of one or more indices for informational purposes only. The Trust is actively managed and does not seek to track or replicate the performance of any index. The index performance shown is not intended to be indicative of the Trust’s investment strategies, portfolio components or past or future performance.

More information about the Trust’s historical performance can be found in the “Closed End Funds” section of blackrock.com.

The following discussion relates to the Trust’s relative performance based on NAV:

What factors influenced performance?

Selection in the biotechnology and pharmaceuticals sub-sectors contributed to the Fund’s relative performance in 2023.

At the individual security level, an out-of-benchmark position in Vertex Pharmaceuticals, Inc. was the largest contributor. The biotechnology company reported consistently strong earnings during the reporting period and released promising trial results for its non-opioid pain medicine. An overweight position in Reata Pharmaceuticals, Inc. (“Reata”) was another top contributor. The biotechnology giant Biogen, Inc. announced it would acquire the company for $7.3 billion to obtain Reata’s pipeline of rare disease treatments. An overweight in Blueprint Medicines also contributed positively. The precision therapy company reported increased sales of its hematological disorder treatment, Avyakit. Performance was further bolstered by a year-end rally in small- and mid-cap stocks after the Fed signaled it was likely to begin easing interest rates in 2024.

Security selection in the healthcare providers and services and medical devices and supplies sub-sectors detracted from relative performance.

An overweight in the oncology company Novocure, Ltd., which reported disappointing trial results for its ovarian cancer therapy, was the largest individual detractor from performance. Additionally, a separate trial caused market participants to question the commercial viability of the company’s experimental lung cancer treatment. An underweight in Align Technology, Inc. detracted, as well. The dental device company missed earnings expectations and provided negative future guidance, citing decreased orthodontic case starts and longer sales cycles for capital equipment purchases. An out-of-benchmark position in the Chinese medical devices company Adicon Holdings, Ltd., which declined due to the broader weakness in the nation’s stock market, also detracted.

The Trust used an options overlay strategy in which calls were written on a portion of the portfolio’s holdings. This strategy contributed to relative performance.

The Trust’s practice of maintaining a specified level of monthly distributions to shareholders did not have a material impact on the Trust’s investment strategy. The distribution policy resulted in return of capital for the period. Refer to the financial highlights and income tax information sections in this report for further information about the distributions.

Describe recent portfolio activity.

The Trust increased its allocations to the biotechnology, healthcare providers and services, and pharmaceuticals sub-sectors, while reducing its weighting in the medical devices and supplies sub-sector.

Describe portfolio positioning at period end.

At the end of the period, the Trust held 41% of net asset value in biotechnology, 36% in medical devices and supplies, 11% in healthcare providers and services, and 10% in pharmaceuticals. These industry weightings were the result of bottom-up stock selection.

As of December 31, 2023, the Trust had in place an option overwriting program whereby 25% of the underlying equities were overwritten with call options on individual stocks. These call options were typically written at prices above the prevailing market prices (estimated to be 6.8% out of the money) and for maturities averaging 57 days.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

T R U S T S U M M A R Y 23

Trust Summary as of December 31, 2023 (continued)   BlackRock Health Sciences Term Trust (BMEZ)

Overview of the Trust’s Total Investments

TEN LARGEST HOLDINGS

Security(a)	Percent of Total Investments
BioMarin Pharmaceutical, Inc.		2.1	%
Cencora, Inc.		2.1
Align Technology, Inc.		2.0
Amgen, Inc.		2.0
Cooper Cos., Inc.		2.0
Novo Nordisk A/S		1.9
STERIS PLC		1.8
Intuitive Surgical, Inc.		1.8
Bio-Techne Corp.		1.7
Blueprint Medicines Corp.		1.6

INDUSTRY ALLOCATION

Industry(a)(b)	Percentage of Total Investments
Biotechnology		41.3	%
Health Care Equipment & Supplies		20.9
Life Sciences Tools & Services		15.7
Health Care Providers & Services		10.6
Pharmaceuticals		9.6
Other*		1.9

^(a) Excludes short-term securities.

^(b)  For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

* Includes one or more investment categories that individually represents less than 1.0% of the Trust’s total investments. Please refer to the Schedule of Investments for details.

24 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Trust Summary as of December 31, 2023    BlackRock Health Sciences Trust (BME)

Investment Objective

BlackRock Health Sciences Trust’s (BME) (the “Trust”) investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives with exposure to the health sciences industry. The Trust seeks to pursue this goal primarily by investing in a portfolio of equity securities and by employing a strategy of writing (selling) call and put options.

No assurance can be given that the Trust’s investment objective will be achieved.

Trust Information

Symbol on New York Stock Exchange	BME
Initial Offering Date	March 31, 2005
Current Distribution Rate on Closing Market Price as of December 31, 2023 ($ 40.46)(a)	6.32%
Current Monthly Distribution per Common Share(b)	$0.213000
Current Annualized Distribution per Common Share(b)	$2.556000

^(a)  Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate may consist of income, net realized gains and/or a return of capital. Past performance is not an indication of future results.

^(b)  The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.

Market Price and Net Asset Value Per Share Summary

	12/31/23		12/31/22		Change			High		Low
Closing Market Price	$	40.46	$	43.58		(7.16	)%	$	43.68	$	35.53
Net Asset Value		42.18		43.30		(2.59	)		43.30		39.01

GROWTH OF $10,000 INVESTMENT

^(a)  Represents the Trust’s closing market price on the NYSE and reflects the reinvestment of dividends and/or distributions at actual reinvestment prices.

^(b) An unmanaged index that features companies involved in medical services or health care in the Russell 3000^® Index, which includes the largest 3,000 U.S. companies as determined by total market capitalization.

T R U S T S U M M A R Y 25

Trust Summary as of December 31, 2023 (continued)   BlackRock Health Sciences Trust (BME)

Performance

Returns for the period ended December 31, 2023 were as follows:

	Average Annual Total Returns
	1 Year			5 Years			10 Years
Trust at NAV(a)(b)		3.80	%		9.60	%		10.49	%
Trust at Market Price(a)(b)		(1.08	)		8.34			9.67
MSCI USA Investable Market Index Health Care Call Overwrite Index(c)		1.80			8.58			N/A
Russell 3000® Health Care Index		2.87			10.79			10.92

^(a)  All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.

^(b)  The Trust moved from a premium to NAV to a discount during the period, which accounts for the difference between performance based on market price and performance based on NAV.

^(c) An index that incorporates an option overlay component on the MSCI USA IMI Health Care Index with a 33% overwrite level. The benchmark commenced on December 31, 2018 and therefore the benchmark does not have 10-year returns.

Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles. Past performance is not an indication of future results.

The Trust is presenting the performance of one or more indices for informational purposes only. The Trust is actively managed and does not seek to track or replicate the performance of any index. The index performance shown is not intended to be indicative of the Trust’s investment strategies, portfolio components or past or future performance.

More information about the Trust’s historical performance can be found in the “Closed End Funds” section of blackrock.com.

The following discussion relates to the Trust’s relative performance based on NAV:

What factors influenced performance?

Security selection in the pharmaceuticals sub-sector contributed to the Trust’s performance in 2023, as did an overweight allocation to the biotechnology sub-sector.

At the individual security level, an underweight position in the pharmaceutical giant Pfizer, Inc. was the largest contributor to relative performance. The company experienced decreased demand for its COVID-19 products, and it provided negative guidance for 2024. Additionally, it reported negative trial results for its oral obesity and diabetes treatment program, adding to uncertainty about its ability to compete in the weight loss market. An underweight in Bristol-Myers Squibb Co. was another top contributor to relative returns. The drugmaker reported disappointing earnings as impending patent expirations put pricing pressure on the company’s offerings. An overweight position in Boston Scientific Corp. further helped results. The medical device company reported strong earnings as elective surgical procedure volume continued to normalize following the pandemic. The company also achieved positive trial results for its Farapulse pulsed-field ablation system, which offers a faster treatment for atrial fibrillation than the current procedure and potentially expands the company’s market share in this area.

On the negative side, an underweight allocation to the healthcare providers and services sub-sector and an overweight in the medical devices and supplies sub-sector detracted from relative performance.

An overweight position in the oncology company Novocure, Ltd., which reported disappointing trial results for its ovarian cancer therapy, was the largest detractor from performance. Additionally, a separate trial caused market participants to question the commercial viability of the company’s experimental lung cancer treatment. An overweight in Biogen, Inc. detracted on concerns about the company’s ability to commercialize its new Alzheimer’s treatment, Leqembi. Obstacles, including limited health insurance reimbursement and testing prerequisites for patients, contributed to the drug’s slow uptake. An underweight in Thermo Fisher Scientific, Inc., was another detractor of note. The Trust moved from an overweight in Thermo Fisher to an underweight in the third quarter 2023 due to a weak biotechnology funding market and uncertainty about China. However, a year-end rally in the biotechnology sector lifted the stock as market participants responded positively to signals of easing interest rates.

The Trust made use of options, principally writing call options on individual stocks, to seek enhanced income returns while continuing to participate in the performance of the underlying equities. The option overlay strategy contributed to results.

The Trust’s practice of maintaining a specified level of monthly distributions to shareholders did not have a material impact on the Trust’s investment strategy. The distribution policy resulted in return of capital for the period. Refer to the financial highlights and income tax information sections in this report for further information about the distributions.

Describe recent portfolio activity.

The Trust increased its allocations to the biotechnology and healthcare providers and services sub-sectors and reduced its weightings in the pharmaceuticals and medical devices and supplies sub-sectors.

The Trust held a 5.3% cash position at the end of the period, reflecting the investment adviser’s decision to take some profits on select positions in pharmaceutical and medical device companies. The elevated cash balance did not have a material impact on performance, and the Trust was not in a defensive investment position.

Describe portfolio positioning at period end.

At the end of the period, the Trust held 31% of net asset value in medical devices and supplies, 25% in biotechnology, 21% in healthcare providers and services, and 19% in pharmaceuticals. These industry weightings were the result of bottom-up stock selection.

26 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Trust Summary as of December 31, 2023 (continued)   BlackRock Health Sciences Trust (BME)

As of December 31, 2023, the Trust had in place an option overwriting program whereby 34% of the underlying equities were overwritten with call options on individual stocks. These call options were typically written at prices above the prevailing market prices (estimated to be 5.3% out of the money) and for maturities averaging 55 days.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

Overview of the Trust’s Total Investments

TEN LARGEST HOLDINGS

Security(a)	Percent of Total Investments
UnitedHealth Group, Inc.		9.5	%
Eli Lilly & Co.		8.4
AbbVie, Inc.		4.7
Boston Scientific Corp.		4.5
Merck & Co., Inc.		4.5
Amgen, Inc.		3.9
Abbott Laboratories		3.7
Danaher Corp.		3.2
Stryker Corp.		2.6
Gilead Sciences, Inc.		2.6

INDUSTRY ALLOCATION

Industry(a)(b)	Percentage of Total Investments
Biotechnology		25.7	%
Health Care Equipment & Supplies		23.4
Health Care Providers & Services		22.1
Pharmaceuticals		20.1
Life Sciences Tools & Services		8.6
Health Care Technology		0.1

^(a)  Excludes short-term securities.

^(b) For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

T R U S T S U M M A R Y 27

Trust Summary as of December 31, 2023    BlackRock Innovation and Growth Term Trust (BIGZ)

Investment Objective

BlackRock Innovation and Growth Term Trust’s (BIGZ) (the “Trust”) (formerly known as BlackRock Innovation and Growth Trust) investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust will invest primarily in equity securities issued by mid-and small-capitalization companies that the Trust’s adviser believes have above-average earnings growth potential. In selecting investments for the Trust, the Trust’s adviser focuses on mid- and small-capitalization growth companies that are “innovative.” These are companies that have introduced, or are seeking to introduce, a new product or service that potentially changes the marketplace. The Trust utilizes an option writing (selling) strategy in an effort to generate current gains from options premiums and to enhance the Trust’s risk-adjusted returns.

On March 31, 2023 the Board approved a proposal to change the name of BlackRock Innovation and Growth Trust, effective as of April 5, 2023, to BlackRock Innovation and Growth Term Trust. There were no changes to the Trust’s investment policies or strategies in conjunction with the name change.

No assurance can be given that the Trust’s investment objective will be achieved.

Trust Information

Symbol on New York Stock Exchange	BIGZ
Initial Offering Date	March 29, 2021
Current Distribution Rate on Closing Market Price as of December 31, 2023 ($7.33)(a)	7.35%
Current Monthly Distribution per Common Share(b)	$0.044870
Current Annualized Distribution per Common Share(b)	$0.538440

^(a) Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate may consist of income, net realized gains and/or a return of capital. Past performance is not an indication of future results.

^(b)  The monthly distribution per Common Share, declared on February 1, 2024, was decreased to $0.044660 per share. The current distribution rate on closing market price, current monthly distribution per Common Share, and current annualized distribution per Common Share do not reflect the new distribution rate. The new distribution rate is not constant and is subject to change in the future. A portion of the distribution may be deemed a return of capital or net realized gain.

Market Price and Net Asset Value Per Share Summary

	12/31/23		12/31/22		Change			High		Low
Closing Market Price	$	7.33	$	6.81		7.64	%	$	8.35	$	6.23
Net Asset Value		9.03		8.82		2.38			9.97		7.66

GROWTH OF $10,000 INVESTMENT

BIGZ commenced operations on March 29, 2021.

^(a) Represents the Trust’s closing market price on the NYSE and reflects the reinvestment of dividends and/or distributions at actual reinvestment prices.

^(b)  An index that measures the performance of the small to mid-cap growth segment of the U.S. equity universe. It includes those Russell 2500 companies with higher growth earning potential as defined by FTSE Russell’s leading style methodology.

28 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Trust Summary as of December 31, 2023 (continued)   BlackRock Innovation and Growth Term Trust (BIGZ)

Performance

Returns for the period ended December 31, 2023 were as follows:

	Average Annual Total Returns
		1 Year		Since Inception	(a)
Trust at NAV(b)(c)		13.28	%	(17.93	)%
Trust at Market Price(b)(c)		19.09		(23.90	)
MSCI USA SMID Growth Call Overwrite Index(d)		20.07		0.66
Russell 2500™ Growth Index		18.93		(2.58	)

^(a) BIGZ commenced operations on March 29, 2021.

^(b) All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.

^(c) The Trust’s discount to NAV narrowed during the period, which accounts for the difference between performance based on market price and performance based on NAV.

^(d) A custom benchmark that is made up of the MSCI USA SMID Growth Index, MSCI USA SMID Growth 25% Call Overwrite Cash and MSCI USA SMID Growth 25% Call Overwrite Option. The MSCI USA SMID Growth Index captures mid and small cap representations of securities exhibiting overall growth style characteristics in the U.S.

Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles. Past performance is not an indication of future results.

The Trust is presenting the performance of one or more indices for informational purposes only. The Trust is actively managed and does not seek to track or replicate the performance of any index. The index performance shown is not intended to be indicative of the Trust’s investment strategies, portfolio components or past or future performance.

More information about the Trust’s historical performance can be found in the “Closed End Funds” section of blackrock.com.

The following discussion relates to the Trust’s relative performance based on NAV:

What factors influenced performance?

Shares of smaller, innovative growth companies generally performed well in 2023, a time characterized by hearty investor risk appetites and outperformance for the growth style more broadly.

Stock selection in the industrials sector was the largest contributor to the Fund’s relative performance. An overweight position in Saia Inc., a U.S. trucking company that specializes in less-than-truckload (“LTL”) freight shipping methods, was a top contributor. Positioning in the aerospace and defense industry also added to relative performance, primarily as a result of an overweight in Axon Enterprise, Inc. Axon benefited from strong demand for its new products, as well as robust recurring revenues and positive customer retention metrics. In energy, the Fund’s zero weighting in the oil, gas and consumable fuels industry proved beneficial. Notably, the lack of a position in Texas Pacific Land Corp., a natural resource and real estate company, was a positive. Thirdly, avoidance of companies in the materials sector boosted relative return, including underweight allocations to the chemicals and containers and packaging industries.

Stock selection in the communication services sector was the largest detractor from relative performance, largely due to selection decisions among entertainment companies. Notably, an out-of-benchmark position in Under Canvas, Inc., an upscale camping experience provider, hurt results. In consumer discretionary, security selection in the hotels, restaurants and leisure industry proved costly. A key stock level detractor in the industry was the portfolio’s overweight position in Planet Fitness, Inc. Shares of the discount gym operator disappointed amid slowing new store growth, due in part to the impacts of higher interest rates on funding costs. Stock selection in the healthcare sector also dampened relative performance, with the largest adverse effect coming from an overweight in Phreesia, Inc., a software-as-a-service company in the healthcare technology sub-sector.

The Trust used an options overlay strategy in which calls were written on a portion of the portfolio’s holdings. The Trust’s options overlay strategy contributed to relative performance over the 12-month period.

The Trust’s practice of maintaining a specified level of monthly distributions to shareholders did not have a material impact on the Trust’s investment strategy. The distribution policy resulted in return of capital for the period. Refer to the financial highlights and income tax information sections in this report for further information about the distributions.

Describe recent portfolio activity.

Due to a combination of market changes and portfolio activity, the Trust’s allocations to information technology and real estate increased, while its weightings in communication services and consumer discretionary decreased. The Trust did not add any new private companies during the reporting period.

Describe portfolio positioning at period end.

On a sector basis, the portfolio’s largest overweight allocations were in the information technology and consumer discretionary sectors. The largest underweights were in industrials and energy.

As of December 31, 2023, the Trust had in place an option overwriting program whereby 13.04% of the underlying equities were overwritten with call options on individual stocks. These call options were typically written at prices above the prevailing market prices (estimated to be 6.2% out of the money) and for maturities averaging 60 days.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

T R U S T S U M M A R Y 29

Trust Summary as of December 31, 2023 (continued)   BlackRock Innovation and Growth Term Trust (BIGZ)

Overview of the Trust’s Total Investments

TEN LARGEST HOLDINGS
Security(a)	Percent of Total Investments
Axon Enterprise, Inc.		3.4	%
ANSYS, Inc.		2.8
Monolithic Power Systems, Inc.		2.8
CoStar Group, Inc.		2.7
HubSpot, Inc.		2.7
Saia, Inc.		2.6
Entegris, Inc.		2.6
Align Technology, Inc.		2.5
Planet Fitness, Inc.		2.4
West Pharmaceutical Services, Inc.		2.4

INDUSTRY ALLOCATION
Industry(a)(b)	Percentage of Total Investments
Software		23.6	%
Semiconductors & Semiconductor Equipment		11.6
Life Sciences Tools & Services		8.8
IT Services		8.0
Capital Markets		6.5
Aerospace & Defense		5.4
Health Care Equipment & Supplies		4.9
Hotels, Restaurants & Leisure		4.6
Automobile Components		3.3
Diversified Consumer Services		3.2
Real Estate Management & Development		2.7
Ground Transportation		2.6
Entertainment		2.2
Specialty Retail		2.0
Building Products		1.6
Machinery		1.3
Construction & Engineering		1.2
Wireless Telecommunication Services		1.1
Textiles, Apparel & Luxury Goods		1.0
Health Care Providers & Services		1.0
Other*		3.4

^(a)  Excludes short-term securities.

^(b) For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

* Includes one or more investment categories that individually represents less than 1.0% of the Trust’s total investments. Please refer to the Schedule of Investments for details.

30 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Trust Summary as of December 31, 2023   BlackRock Resources & Commodities Strategy Trust (BCX)

Investment Objective

BlackRock Resources & Commodities Strategy Trust’s (BCX) (the “Trust”) primary investment objective is to seek high current income and current gains, with a secondary objective of capital appreciation. The Trust will seek to achieve its investment objectives, under normal market conditions, by investing at least 80% of its total assets in equity securities issued by commodity or natural resources companies, derivatives with exposure to commodity or natural resources companies or investments in securities and derivatives linked to the underlying price movement of commodities or natural resources. While permitted, the Trust does not currently expect to invest in securities and derivatives linked to the underlying price movement of commodities or natural resources. The Trust seeks to pursue this goal primarily by investing in a portfolio of equity securities and also by employing a strategy of writing (selling) call and put options.

No assurance can be given that the Trust’s investment objectives will be achieved.

Trust Information

Symbol on New York Stock Exchange	BCX
Initial Offering Date	March 30, 2011
Current Distribution Rate on Closing Market Price as of December 31, 2023 ($ 8.88)(a)	7.00%
Current Monthly Distribution per Common Share(b)	$0.051800
Current Annualized Distribution per Common Share(b)	$0.621600

^(a)  Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate may consist of income, net realized gains and/or a return of capital. Past performance is not an indication of future results.

^(b) The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.

Market Price and Net Asset Value Per Share Summary

	12/31/23		12/31/22		Change			High		Low
Closing Market Price	$	8.88	$	9.97		(10.93	)%	$	10.56	$	8.43
Net Asset Value		10.57		11.23		(5.88	)		11.90		9.95

GROWTH OF $10,000 INVESTMENT

^(a)  Represents the Trust’s closing market price on the NYSE and reflects the reinvestment of dividends and/or distributions at actual reinvestment prices.

^(b)  An index that includes approximately 90 of the largest publicly-traded companies in the natural resources and commodities businesses that meet specific investability requirements across three primary commodity-related sectors: agribusiness, energy, and metals and mining.

T R U S T S U M M A R Y 31

Trust Summary as of December 31, 2023 (continued)   BlackRock Resources & Commodities Strategy Trust (BCX)

Performance

Returns for the period ended December 31, 2023 were as follows:

	Average Annual Total Returns
	1 Year			5 Years			10 Years
Trust at NAV(a)(b)		0.56	%		11.85	%		4.80	%
Trust at Market Price(a)(b)		(4.84	)		11.95			4.71
MSCI ACWI Select Liquidity Natural Resources Call Overwrite Index(c)		0.74			7.48			N/A
S&P Global Natural Resources Net Index		3.38			10.40			4.48

^(a)  All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.

^(b)  The Trust’s discount to NAV widened during the period, which accounts for the difference between performance based on market price and performance based on NAV.

^(c)  An index that incorporates an option overlay component on the MSCI ACWI Select Liquidity Natural Resources Index with a 33% overwrite level. The benchmark commenced on December 31, 2018 and therefore the benchmark does not have 10-year returns.

Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles. Past performance is not an indication of future results.

The Trust is presenting the performance of one or more indices for informational purposes only. The Trust is actively managed and does not seek to track or replicate the performance of any index. The index performance shown is not intended to be indicative of the Trust’s investment strategies, portfolio components or past or future performance.

More information about the Trust’s historical performance can be found in the “Closed End Funds” section of blackrock.com.

The following discussion relates to the Trust’s relative performance based on NAV:

What factors influenced performance?

Natural resources stocks posted gains as a group in 2023, but they trailed the broader equity market due largely to weakness in commodity prices.

The Trust’s underweight in Nutrien Ltd., which lagged due to a downturn in fertilizer prices, contributed to performance. An out-of-benchmark position in Cameco Corp. was also a strong contributor. Uranium prices rose on expectations for a revival in the nuclear energy industry, leading to a rally in the stock. The U.S. liquified natural gas exporter Cheniere Energy, Inc., which reported robust results and upgraded its earnings guidance throughout the year, was another noteworthy contributor.

First Quantum Minerals Ltd. (“First Quantum”) was a key detractor. In October 2023, the Panamanian government announced a referendum on whether to revoke the company’s mining license in the country. First Quantum’s Cobre Panama mine was subsequently closed in November 2023 after Panama’s Supreme Court ruled that the concession granted to the company was unconstitutional. Weakness in lithium prices impacted the Trust’s holdings in the industrial minerals sector, including Albemarle Corp. The agricultural chemical producer FMC Corp. was another key detractor. The stock came under pressure from the combination of weaker-than-expected earnings, reduced forward guidance, and a negative report from a short seller (an investor who expects the stock will fall).

The Trust used an options overlay strategy in which calls were written on a portion of the portfolio’s holdings. This strategy contributed to results in the annual period.

The Trust’s practice of maintaining a specified level of monthly distributions to shareholders did not have a material impact on the Trust’s investment strategy. The distribution policy resulted in return of capital for the period. Refer to the financial highlights and income tax information sections in this report for further information about the distributions.

Describe recent portfolio activity.

The investment adviser added to the energy sector in order to maintain an overweight position. It funded this move by reducing the Trust’s allocation to agricultural stocks. The investment adviser remained alert for investment ideas in undervalued energy stocks, companies that can benefit from the adoption of lower-carbon technologies, and longer-term growth opportunities in the nutrition area.

Describe portfolio positioning at period end.

At the end of the reporting period, 38.8% of the portfolio was invested in the energy sector, 38.5% in mining and 22.1% in agriculture. The remaining 0.6% was held in cash.

As of December 31, 2023, the Trust had in place an option overwriting program whereby 30.9% of the underlying equities were overwritten with call options on individual stocks. These call options were typically written at prices above the prevailing market prices (estimated to be 4.0% out of the money) and for maturities averaging 52 days.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

32 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Trust Summary as of December 31, 2023 (continued)   BlackRock Resources & Commodities Strategy Trust (BCX)

Overview of the Trust’s Total Investments

TEN LARGEST HOLDINGS
Security(a)	Percent of Total Investments
Shell PLC		7.7	%
TotalEnergies SE		6.4
Exxon Mobil Corp.		5.4
BHP Group Ltd.		4.9
Glencore PLC		4.8
Chevron Corp.		4.3
Vale SA		4.2
BP PLC		4.1
Wheaton Precious Metals Corp.		3.7
Freeport-McMoRan, Inc.		3.5

INDUSTRY ALLOCATION
Industry(a)(b)	Percentage of Total Investments
Metals & Mining		38.4	%
Oil, Gas & Consumable Fuels		37.6
Containers & Packaging		7.6
Chemicals		5.9
Food Products		4.9
Paper & Forest Products		2.3
Machinery		1.9
Energy Equipment & Services		1.4

^(a) Excludes short-term securities.

^(b) For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

T R U S T S U M M A R Y 33

Trust Summary as of December 31, 2023   BlackRock Science and Technology Term Trust (BSTZ)

Investment Objective

BlackRock Science and Technology Term Trust’s (BSTZ) (the “Trust”) (formerly known as BlackRock Science and Technology Trust II) investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities issued by U.S. and non-U.S. science and technology companies in any market capitalization range, selected for their rapid and sustainable growth potential from the development, advancement and use of science and/or technology. The Trust seeks to pursue this goal primarily by investing in a portfolio of equity securities and also by employing a strategy of writing (selling) call and put options.

On March 31, 2023 the Board approved a proposal to change the name of BlackRock Science and Technology Trust II, effective as of April 5, 2023, to BlackRock Science and Technology Term Trust. There were no changes to the Trust’s investment policies or strategies in conjunction with the name change.

No assurance can be given that the Trust’s investment objective will be achieved.

Trust Information

Symbol on New York Stock Exchange	BSTZ
Initial Offering Date	June 27, 2019
Current Distribution Rate on Closing Market Price as of December 31, 2023 ($ 16.71)(a)	7.36%
Current Monthly Distribution per Common Share(b)	$0.102540
Current Annualized Distribution per Common Share(b)	$1.230480

^(a)  Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate may consist of income, net realized gains and/or a return of capital. Past performance is not an indication of future results.

^(b)  The monthly distribution per Common Share, declared on February 1, 2024, was increased to $0.103260 per share. The current distribution rate on closing market price, current monthly distribution per Common Share, and current annualized distribution per Common Share do not reflect the new distribution rate. The new distribution rate is not constant and is subject to change in the future. A portion of the distribution may be deemed a return of capital or net realized gain.

Market Price and Net Asset Value Per Share Summary

	12/31/23		12/31/22		Change			High		Low
Closing Market Price	$	16.71	$	15.64		6.84	%	$	19.04	$	14.16
Net Asset Value		21.43		19.53		9.73			22.14		19.00

GROWTH OF $10,000 INVESTMENT

BSTZ commenced operations on June 27, 2019.

^(a) Represents the Trust’s closing market price on the NYSE and reflects the reinvestment of dividends and/or distributions at actual reinvestment prices.

^(b)  An index that captures large- and mid-cap representation across certain developed and emerging markets.

34 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Trust Summary as of December 31, 2023 (continued)   BlackRock Science and Technology Term Trust (BSTZ)

Performance

Returns for the period ended December 31, 2023 were as follows:

	Average Annual Total Returns
	1 Year		Since   Inception(a)
Trust at NAV(b)(c)(d)		21.74%		10.13%
Trust at Market Price(b)(c)(d)		18.54		4.22
MSCI Custom ACWI SMID Growth IT Call Overwrite Index(e)		31.60		2.34
MSCI ACWI		22.20		9.49

^(a)  BSTZ commenced operations on June 27, 2019.

^(b) All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.

^(c)  The Trust’s discount to NAV widened during the period, which accounts for the difference between performance based on market price and performance based on NAV.

^(d) For financial reporting purposes, the market value of certain investments were adjusted as of report date. Accordingly, the NAV per share and total return performance based on NAV presented herein are different than the information previously published on December 31, 2023.

^(e) An index representing the Information Technology sector stocks within the MSCI ACWI SMID Cap Growth Index and incorporating an option overlay component with a 25% overwrite level. An index that captures mid- and small-cap securities exhibiting overall growth style characteristics across certain developed and emerging markets. The index commenced on March 31, 2022 and therefore the since inception return presented is for the period March 31, 2022 through the current reporting period.

Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles. Past performance is not an indication of future results.

The Trust is presenting the performance of one or more indices for informational purposes only. The Trust is actively managed and does not seek to track or replicate the performance of any index. The index performance shown is not intended to be indicative of the Trust’s investment strategies, portfolio components or past or future performance.

More information about the Trust’s historical performance can be found in the “Closed End Funds” section of blackrock.com.

The following discussion relates to the Trust’s relative performance based on NAV:

What factors influenced performance?

Technology stocks produced strong returns in 2023, as investors gravitated toward companies seen as having the most attractive growth characteristics.

At the sector level, an overweight allocation to the semiconductors sub-sector contributed to the Fund’s relative performance. Security selection in the hardware sub-sector added value, as well. Among individual holdings, the Trust’s out-of-benchmark position in the semiconductor designer NVIDIA Corp. was the largest contributor to relative performance. The stock jumped on optimism around surging demand for the company’s graphics processing units that enable artificial intelligence (“AI”). An out-of-benchmark position in Tesla, Inc., was an additional noteworthy contributor. The stock rallied after the company reported stable revenues and revealed that demand growth for its electric vehicles continued to outpace supply. The firm’s tiered pricing also emerged as an effective tool for supporting sales. A zero weighting in SolarEdge Technologies, Inc. (“SolarEdge”), an Israeli solar inverter company that primarily services residential markets, also contributed. SolarEdge experienced price competition in key regions such as China and Europe.

At the sector level, security selection in the software and new industries sub-sectors detracted from relative performance. An out-of-benchmark position in Farmers Business Network, a private company, was a key detractor among the Trust’s individual holdings. The agriculture network company raised an additional funding round in the third calendar quarter 2023 after the near-failure of the business. At the same time, governance challenges led to fundamental weakness that dragged on the company’s private-market valuation. Similarly, an out-of-benchmark private position in ByteDance detracted from active returns. The parent company of the social media app TikTok experienced a decrease in valuation in tandem with those of its Chinese internet peers. An out-of-benchmark private position in Think & Learn was a further detractor of note. The private company’s valuation declined due to weakness across the educational technology industry. Idiosyncratic governance and execution challenges at the firm weighed on its valuation, as well.

The Trust used an options overlay strategy in which calls were written on a portion of the portfolio’s holdings. The Trust’s options overlay strategy contributed to relative performance for the 12-month period.

The Trust’s practice of maintaining a specified level of monthly distributions did not have a material impact on the Trust’s investment strategy. The distribution policy did not result in return of capital for the period. The distribution policy resulted in return of capital for the period. Refer to the financial highlights and income tax information sections in this report for further information about the distributions.

Describe recent portfolio activity.

Throughout the reporting period, the Trust added to semiconductor and hardware companies positioned to benefit from the growth of AI. On the other hand, it trimmed select internet holdings where advertising demand remained muted.

From a regional perspective, the Trust reduced its weighting in China due to concerns about the slow pace of the economic recovery in the region. On the other hand, it added to Japanese equities where it identified both attractive fundamentals and near-term catalysts. The Trust did not make any additional investments in private technology companies.

T R U S T S U M M A R Y 35

Trust Summary as of December 31, 2023 (continued)   BlackRock Science and Technology Term Trust (BSTZ)

Describe portfolio positioning at period end.

The Trust’s investment adviser continued to perform due diligence on multiple new opportunities, although at year-end exposure to private assets was above the 25% target. As of December 31, 2023, the Trust held 22 private investments, comprising 33% of total assets for a commitment of approximately $540 million. The investment adviser continued to seek opportunities to harvest the illiquidity premium by taking advantage of the Trust’s “closed” structure and adding holdings in private investments as the Trust’s capacity increased.

At the end of the period, the Trust held 32% of its net asset value in the semiconductor industry, 31% in software, 13% in hardware, 11% in internet, 9% in services, 3% in content and infrastructure, and 3% in new industries. These industry weightings were a result of bottom-up stock selection.

As of December 31, 2023, the Trust had in place an option overwriting program whereby 25.3% of the underlying equities were overwritten with call options on individual stocks. These call options were typically written at prices above the prevailing market prices (estimated to be 5.2% out of the money) and for maturities averaging 56 days.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

36 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Trust Summary as of December 31, 2023 (continued)   BlackRock Science and Technology Term Trust (BSTZ)

Overview of the Trust’s Total Investments

TEN LARGEST HOLDINGS
Security(a)	Percent of Total Investments
NVIDIA Corp.		4.9	%
Databricks, Inc.		4.3
Synopsys, Inc.		3.6
ByteDance Ltd.		3.1
PsiQuantum Corp.		2.9
SambaNova Systems, Inc.		2.5
GrubMarket, Inc.		2.4
Tesla, Inc.		2.0
SK Hynix, Inc.		1.9
Snyk Ltd.		1.8

INDUSTRY ALLOCATION
Industry(a)(b)	Percentage of Total Investments
Semiconductors & Semiconductor Equipment		31.8	%
Software		25.6
IT Services		7.0
Interactive Media & Services		5.0
Electronic Equipment, Instruments & Components		4.9
Entertainment		4.0
Technology Hardware, Storage & Peripherals		3.5
Professional Services		2.6
Consumer Staples Distribution & Retail		2.4
Communications Equipment		2.1
Automobiles		2.0
Financial Services		1.8
Diversified Consumer Services		1.7
Media		1.6
Broadline Retail		1.6
Other*		2.4

^(a)  Excludes short-term securities.

^(b)  For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

* Includes one or more investment categories that individually represents less than 1.0% of the Trust’s total investments. Please refer to the Consolidated Schedule of Investments for details.

T R U S T S U M M A R Y 37

Trust Summary as of December 31, 2023   BlackRock Science and Technology Trust (BST)

Investment Objective

BlackRock Science and Technology Trust’s (BST) (the “Trust”) investment objective is to provide income and total return through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of U.S. and non-U.S. science and technology companies in any market capitalization range, selected for their rapid and sustainable growth potential from the development, advancement and use of science and/or technology (high growth science and technology stocks), and/or potential to generate current income from advantageous dividend yields (cyclical science and technology stocks). The Trust seeks to pursue this goal primarily by investing in a portfolio of equity securities and also by employing a strategy of writing (selling) call and put options.

No assurance can be given that the Trust’s investment objective will be achieved.

Trust Information

Symbol on New York Stock Exchange	BST
Initial Offering Date	October 30, 2014
Current Distribution Rate on Closing Market Price as of December 31, 2023 ($33.66)(a)	8.91%
Current Monthly Distribution per Common Share(b)	$0.250000
Current Annualized Distribution per Common Share(b)	$3.000000

^(a)  Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate may consist of income, net realized gains and/or a return of capital. Past performance is not an indication of future results.

^(b)  The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.

Market Price and Net Asset Value Per Share Summary

	12/31/23		12/31/22		Change			High		Low
Closing Market Price	$	33.66	$	28.37		18.65	%	$	35.25	$	28.37
Net Asset Value		34.74		29.11		19.34			35.20		28.82

GROWTH OF $10,000 INVESTMENT

BST commenced operations on October 30, 2014.

^(a) Represents the Trust’s closing market price on the NYSE and reflects the reinvestment of dividends and/or distributions at actual reinvestment prices.

^(b) An index that includes large- and mid-cap securities across certain developed markets countries and certain emerging markets countries. All securities in the index are classified in the Information Technology sector as per the Global Industry Classification Standard.

38 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Trust Summary as of December 31, 2023 (continued)   BlackRock Science and Technology Trust (BST)

Performance

Returns for the period ended December 31, 2023 were as follows:

	Average Annual Total Returns
		1 Year		5 Years		Since Inception	(a)
Trust at NAV(b)(c)(d)		30.78	%	15.01	%	14.88	%
Trust at Market Price(b)(c)(d)		30.03		13.21		13.92
MSCI ACWI Information Technology Call Overwrite Index(e)		45.37		18.23		N/A
MSCI ACWI Information Technology Index		51.02		23.18		18.05

^(a) BST commenced operations on October 30, 2014.

^(b) All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.

^(c) The Trust’s discount to NAV widened during the period, which accounts for the difference between performance based on market price and performance based on NAV.

^(d) For financial reporting purposes, the market value of certain investments were adjusted as of report date. Accordingly, the NAV per share and total return performance based on NAV presented herein are different than the information previously published on December 31, 2023.

^(e) An index that incorporates an option overlay component on the MSCI ACWI IT Index with a 33% overwrite level. since inception.

Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles. Past performance is not an indication of future results.

The Trust is presenting the performance of one or more indices for informational purposes only. The Trust is actively managed and does not seek to track or replicate the performance of any index. The index performance shown is not intended to be indicative of the Trust’s investment strategies, portfolio components or past or future performance.

More information about the Trust’s historical performance can be found in the “Closed End Funds” section of blackrock.com.

The following discussion relates to the Trust’s relative performance based on NAV:

What factors influenced performance?

Technology stocks produced strong returns in 2023, as investors gravitated toward companies seen as having the most attractive growth characteristics.

At the sector level, the Trust’s underweight allocation to the hardware sub-sector contributed to relative performance. Among individual holdings, an out-of-benchmark position in Meta Platforms, Inc. (“Meta”) (formerly Facebook) was the leading contributor. Companies that demonstrated a commitment to cost discipline by reducing headcount expenses were generally rewarded by investors in 2023. In addition, Meta reported improvements in the use of artificial intelligence (“AI”) to increase monetization across its social media platforms. The Trust also benefited from a zero weighting in Cisco Systems, Inc., which lagged at a time of muted spending among its enterprise customers. An out-of-benchmark position in Tesla, Inc., was an additional contributor of note. The stock rallied after the company reported stable revenues and revealed that demand growth for its electric vehicles continued to outpace supply. The firm’s tiered pricing also emerged as an effective tool for supporting sales.

At the sector level, security selection in the semiconductors and software sub-sectors detracted from relative performance. An underweight position in the semiconductor designer NVIDIA Corp. was the most notable individual detractor. The stock jumped on optimism around surging demand for the company’s graphics processing units that enable generative AI. An out-of-benchmark position in Farmers Business Network, a private company, was an additional detractor. The agriculture network company raised an additional funding round in the third calendar quarter 2023 after the near-failure of the business. At the same time, governance challenges led to fundamental weakness that dragged on the company’s private-market valuation. A position in Bolt Financial, another private company, also detracted. The financial software company’s valuation fell along with those of its publicly traded peers in the financial technology space amid softer industry demand.

The Trust used an options overlay strategy in which calls were written on a portion of the portfolio’s holdings. The Trust’s options overlay strategy contributed to relative performance for the 12-month period.

The Trust’s practice of maintaining a specified level of monthly distributions to shareholders did not have a material impact on the Trust’s investment strategy. The distribution policy resulted in return of capital for the period. Refer to the financial highlights and income tax information sections in this report for further information about the distributions.

Describe recent portfolio activity.

The Trust increased its allocations to the semiconductors and software sub-sectors and reduced its weighting in the services sub-sector. Its allocations to the internet and hardware sub-sectors were relatively unchanged.

From a regional perspective, the Trust’s allocation to the United States increased. Its position in China and other emerging markets decreased.

Describe portfolio positioning at period end.

At the end of the period, the Trust held 32% of its net asset value in the software industry, 29% in semiconductors, 15% in internet, 12% in hardware, 10% in services, 2% in new industries, and 2% in content & infrastructure. These industry weightings were the result of bottom-up stock selection.

As of December 31, 2023, the Trust had in place an option overwriting program whereby 28% of the underlying equities were overwritten with call options on individual stocks. These call options were typically written at prices above the prevailing market prices (estimated to be 3.8% out of the money) and for maturities averaging 50 days.

T R U S T S U M M A R Y 39

Trust Summary as of December 31, 2023 (continued)   BlackRock Science and Technology Trust (BST)

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

Overview of the Trust’s Total Investments

TEN LARGEST HOLDINGS
Security(a)	Percent of Total Investments
Microsoft Corp.		9.2	%
Apple, Inc.		7.7
NVIDIA Corp.		7.1
Broadcom, Inc.		2.9
Cadence Design Systems, Inc.		2.8
ASML Holding NV		2.3
Mastercard, Inc.		2.3
Amazon.com, Inc.		2.2
Meta Platforms, Inc.		2.1
Alphabet, Inc.		1.9

INDUSTRY ALLOCATION
Industry(a)(b)	Percentage of Total Investments
Semiconductors & Semiconductor Equipment		28.2	%
Software		27.7
Technology Hardware, Storage & Peripherals		8.7
IT Services		7.9
Financial Services		5.4
Interactive Media & Services		5.2
Broadline Retail		3.7
Diversified Consumer Services		2.1
Entertainment		1.9
Automobiles		1.8
Professional Services		1.6
Consumer Staples Distribution & Retail		1.3
Communications Equipment		1.1
Ground Transportation		1.0
Other*		2.4

^(a) Excludes short-term securities.

^(b) For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

* Includes one or more investment categories that individually represents less than 1.0% of the Trust’s total investments. Please refer to the Consolidated Schedule of Investments for details.

40 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Trust Summary as of December 31, 2023   BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)

Investment Objective

BlackRock Utilities, Infrastructure & Power Opportunities Trust’s (BUI) (the “Trust”) investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities issued by companies that are engaged in the Utilities, Infrastructure and Power Opportunities business segments anywhere in the world and by employing a strategy of writing (selling) call and put options. The Trust considers the “Utilities” business segment to include products, technologies and services connected to the management, ownership, operation, construction, development or financing of facilities used to generate, transmit or distribute electricity, water, natural resources or telecommunications, the “Infrastructure” business segment to include companies that own or operate infrastructure assets or that are involved in the development, construction, distribution or financing of infrastructure assets and the “Power Opportunities” business segment to include companies with a significant involvement in, supporting, or necessary to renewable energy technology and development, alternative fuels, energy efficiency, automotive and sustainable mobility and technologies that enable or support the growth and adoption of new power and energy sources. Under normal circumstances, the Trust invests a substantial amount of its total assets in foreign issuers, issuers that primarily trade in a market located outside the United States or issuers that do a substantial amount of business outside the United States. The Trust may invest directly in such securities or synthetically through the use of derivatives.

No assurance can be given that the Trust’s investment objective will be achieved.

Trust Information

Symbol on New York Stock Exchange	BUI
Initial Offering Date	November 25, 2011
Current Distribution Rate on Closing Market Price as of December 31, 2023 ($ 21.82)(a)	6.65%
Current Monthly Distribution per Common Share(b)	$0.121000
Current Annualized Distribution per Common Share(b)	$1.452000

^(a)  Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate may consist of income, net realized gains and/or a return of capital. Past performance is not an indication of future results.

^(b)  The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.

Market Price and Net Asset Value Per Share Summary

	12/31/23		12/31/22		Change			High		Low
Closing Market Price	$	21.82	$	20.77		5.06	%	$	23.98	$	18.75
Net Asset Value		22.53		22.37		0.72			23.39		19.59

GROWTH OF $10,000 INVESTMENT

^(a) Represents the Trust’s closing market price on the NYSE and reflects the reinvestment of dividends and/or distributions at actual reinvestment prices.

^(b)  An index that captures large- and mid-cap representation across certain developed and emerging markets.

T R U S T S U M M A R Y 41

Trust Summary as of December 31, 2023 (continued)   BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)

Performance

Returns for the period ended December 31, 2023 were as follows:

	Average Annual Total Returns
	1 Year			5 Years			10 Years
Trust at NAV(a)(b)		7.66	%		10.73	%		8.15	%
Trust at Market Price(a)(b)		12.30			8.90			9.40
MSCI World Select Energy, Utilities and Industry Call Overwrite Index(c)		13.07			6.64			N/A
MSCI ACWI		22.20			11.72			7.93

^(a)  All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.

^(b)  The Trust’s discount to NAV narrowed during the period, which accounts for the difference between performance based on market price and performance based on NAV.

^(c)  An index that incorporates an option overlay component on the MSCI World Select Energy, Utilities and Industry Index with a 33% overwrite level. The benchmark commenced on December 31, 2018 and therefore the benchmark does not have 10-year returns.

Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles. Past performance is not an indication of future results.

The Trust is presenting the performance of one or more indices for informational purposes only. The Trust is actively managed and does not seek to track or replicate the performance of any index. The index performance shown is not intended to be indicative of the Trust’s investment strategies, portfolio components or past or future performance.

More information about the Trust’s historical performance can be found in the “Closed End Funds” section of blackrock.com.

The following discussion relates to the Trust’s relative performance based on NAV:

What factors influenced performance?

Infrastructure stocks, as a group, gained ground in 2023 but struggled relative to the broader equity market in the rising-rate environment.

Holdings in the industrial energy efficiency companies Ingersoll Rand, Inc., Air Liquide SA and Kingspan Group PLC were top contributors to the Trust’s performance during the reporting period. The companies benefited from strong demand, supported by a significant increase in U.S. clean-technology manufacturing following the passage of the Inflation Reduction Act. This trend was highlighted by growing investment in areas such as electric vehicle (“EV”) battery manufacturing, semiconductor fabrication plants and solar panel production. Eaton Corp. PLC, which makes products used in data centers, also performed well as the breakthrough in generative artificial intelligence was seen as driver for increased investment in this area.

On the other hand, positions in clean power utility companies detracted as bond yields rose. This resulted in a pronounced decline in valuations across the sector, weighing on shares of NextEra Energy, Inc. (“Nextera”) and EDP Renováveis SA. Nextera also experienced a change in management that further contributed to uncertainty. The investment adviser maintained the positions, as the companies consistently reported quarterly earnings in line with or ahead of consensus expectations. The EV battery producer LG Chem Ltd., which was pressured by concerns about slowing EV demand and greater price competition, also detracted.

The Trust used an options overlay strategy in which calls were written on a portion of the portfolio’s holdings. The Trust’s options overlay strategy contributed to relative performance in the 12-month period.

The Trust’s practice of maintaining a specified level of monthly distributions to shareholders did not have a material impact on the Trust’s investment strategy. The distribution policy resulted in return of capital for the period. Refer to the financial highlights and income tax information sections in this report for further information about the distributions.

Describe recent portfolio activity.

The investment adviser adjusted the portfolio throughout the reporting period in an effort to capitalize on market volatility. Most notably, the investment adviser moved positioning around in clean power utilities. It maintained a steady overall allocation to the broader utilities sector on the belief that earnings prospects remained favorable and rising rates had been fully discounted into prices.

Describe portfolio positioning at period end.

At the end of the reporting period, 48.4% of the portfolio was invested in the utilities sector, 32.8% in industrials and 9.4% in energy. The remainder was invested in other infrastructure- and power-related sectors.

As of December 31, 2023, the Trust had in place an option overwriting program whereby 33.5% of the underlying equities were overwritten with call options on individual stocks. These call options were typically written at prices above the prevailing market prices (estimated to be 2.6% out of the money) and for maturities averaging 58 days.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

42 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Trust Summary as of December 31, 2023 (continued)   BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)

Overview of the Trust’s Total Investments

TEN LARGEST HOLDINGS
Security(a)	Percent of Total Investments
NextEra Energy, Inc.		7.1	%
RWE AG		4.5
Enel SpA		4.3
Vinci SA		3.7
Vestas Wind Systems A/S		3.3
Atlas Copco AB		3.1
Sempra		2.9
Trane Technologies PLC		2.7
Duke Energy Corp.		2.7
PG&E Corp.		2.4

INDUSTRY ALLOCATION
Industry(a)(b)	Percentage of Total Investments
Electric Utilities		29.0	%
Multi-Utilities		10.6
Oil, Gas & Consumable Fuels		9.4
Independent Power and Renewable Electricity Producers		8.6
Building Products		8.0
Electrical Equipment		6.9
Machinery		6.2
Construction & Engineering		5.8
Semiconductors & Semiconductor Equipment		5.5
Commercial Services & Supplies		4.2
Chemicals		3.1
Electronic Equipment, Instruments & Components		1.5
Ground Transportation		1.2

^(a)  Excludes short-term securities.

^(b) For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

T R U S T S U M M A R Y 43

Schedule of Investments December 31, 2023   BlackRock Energy and Resources Trust (BGR) (Percentages shown are based on Net Assets)

Security	Shares		Value
Common Stocks
Energy Equipment & Services — 6.4%
NOV, Inc.		91,550	$	1,856,634
Patterson-UTI Energy, Inc.		106,500		1,150,200
Schlumberger NV		226,731		11,799,081
TechnipFMC PLC		222,150		4,474,101
Tenaris SA		205,600		3,576,035
Weatherford International PLC(a)		17,750		1,736,483
				24,592,534
Oil, Gas & Consumable Fuels — 93.0%
ARC Resources Ltd.		341,430		5,068,434
BP PLC		3,042,155		18,034,101
Canadian Natural Resources Ltd.		249,592		16,351,897
Cenovus Energy, Inc.		452,787		7,545,026
Cheniere Energy, Inc.		82,918		14,154,932
Chevron Corp.		228,590		34,096,484
ConocoPhillips(b)		205,819		23,889,367
Diamondback Energy, Inc.		60,351		9,359,233
EOG Resources, Inc.		128,616		15,556,105
Exxon Mobil Corp.(b)(c)		628,030		62,790,440
Galp Energia SGPS SA		199,093		2,929,390
Gazprom PJSC(a)(d)		879,200		99
Hess Corp.(b)		77,303		11,144,001
Kosmos Energy Ltd.(a)		308,034		2,066,908
Marathon Petroleum Corp.		94,745		14,056,368
Pembina Pipeline Corp.		256,800		8,841,339
Shell PLC, ADR(b)		634,410		41,744,178
TC Energy Corp.		299,300		11,691,459
TotalEnergies SE		462,811		31,470,674
Tourmaline Oil Corp.		130,433		5,865,818
Valero Energy Corp.		76,611		9,959,430
Williams Cos., Inc.		411,581		14,335,366
				360,951,049
Total Long-Term Investments — 99.4% (Cost: $261,065,835)				385,543,583

Security	Shares		Value
Short-Term Securities
Money Market Funds — 0.9%
BlackRock Liquidity Funds, T-Fund, Institutional Class, 5.26%(e)(f)		3,612,320	$	3,612,320
Total Short-Term Securities — 0.9% (Cost: $3,612,320)				3,612,320
Total Investments Before Options Written — 100.3% (Cost: $264,678,155)				389,155,903
Options Written — (0.4)% (Premiums Received: $(2,439,087))				(1,725,858	)
Total Investments, Net of Options Written — 99.9% (Cost: $262,239,068)				387,430,045
Other Assets Less Liabilities — 0.1%				551,812
Net Assets — 100.0%			$	387,981,857

^(a)  Non-income producing security.

^(b)  All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

^(c)  All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.

^(d)  Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.

^(e)  Affiliate of the Trust.

^(f)  Annualized 7-day yield as of period end.

For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

Affiliates

Investments in issuers considered to be affiliate(s) of the Trust during the year ended December 31, 2023 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

Affiliated Issuer	Value at 12/31/22		Purchases at Cost		Proceeds from Sale			Net Realized Gain (Loss)		Change in Unrealized Appreciation (Depreciation)		Value at 12/31/23		Shares Held at 12/31/23		Income		Capital Gain Distributions from Underlying Funds
BlackRock Liquidity Funds, T-Fund, Institutional Class	$	7,695,475	$	—	$	(4,083,155	)(a)	$	—	$	—	$	3,612,320		3,612,320	$	298,320	$	—

^(a) Represents net amount purchased (sold).

44 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Schedule of Investments (continued) December 31, 2023   BlackRock Energy and Resources Trust (BGR)

Derivative Financial Instruments Outstanding as of Period End

Exchange-Traded Options Written

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call
Diamondback Energy, Inc.		107		01/05/24		USD	160.00		USD	1,659	$	(4,280	)
Exxon Mobil Corp.		437		01/05/24		USD	107.00		USD	4,369		(1,311	)
Hess Corp.		88		01/05/24		USD	150.00		USD	1,269		(3,740	)
Schlumberger NV		168		01/05/24		USD	54.00		USD	874		(2,100	)
Valero Energy Corp.		138		01/05/24		USD	131.00		USD	1,794		(19,458	)
Williams Cos., Inc.		492		01/05/24		USD	37.00		USD	1,714		(2,460	)
Chevron Corp.		313		01/12/24		USD	155.00		USD	4,669		(17,372	)
ConocoPhillips		202		01/12/24		USD	119.00		USD	2,345		(18,887	)
EOG Resources, Inc.		220		01/12/24		USD	124.50		USD	2,661		(22,000	)
Exxon Mobil Corp.		437		01/12/24		USD	106.00		USD	4,369		(9,614	)
Hess Corp.		25		01/12/24		USD	145.00		USD	360		(7,750	)
Marathon Petroleum Corp.		134		01/12/24		USD	155.00		USD	1,988		(13,065	)
Schlumberger NV		230		01/12/24		USD	51.00		USD	1,197		(40,480	)
Shell PLC, ADR		549		01/12/24		USD	66.00		USD	3,612		(48,037	)
ARC Resources Ltd.		602		01/19/24		CAD	22.00		CAD	1,184		(1,817	)
Canadian Natural Resources Ltd.		120		01/19/24		CAD	94.00		CAD	1,042		(1,540	)
Chevron Corp.		314		01/19/24		USD	150.00		USD	4,684		(84,152	)
ConocoPhillips		190		01/19/24		USD	125.00		USD	2,205		(5,225	)
Diamondback Energy, Inc.		92		01/19/24		USD	160.00		USD	1,427		(15,640	)
Exxon Mobil Corp.		734		01/19/24		USD	100.00		USD	7,339		(161,113	)
Hess Corp.		110		01/19/24		USD	150.00		USD	1,586		(27,500	)
NOV, Inc.		261		01/19/24		USD	20.00		USD	529		(20,880	)
Patterson-UTI Energy, Inc.		117		01/19/24		USD	13.00		USD	126		(1,755	)
Schlumberger NV		144		01/19/24		USD	55.00		USD	749		(7,704	)
Shell PLC, ADR		374		01/19/24		USD	65.00		USD	2,461		(63,580	)
TechnipFMC PLC		666		01/19/24		USD	21.00		USD	1,341		(23,310	)
Tourmaline Oil Corp.		335		01/19/24		CAD	66.00		CAD	1,996		(1,264	)
Valero Energy Corp.		114		01/19/24		USD	130.00		USD	1,482		(42,465	)
Weatherford International PLC		51		01/19/24		USD	90.00		USD	499		(47,175	)
Williams Cos., Inc.		492		01/19/24		USD	37.00		USD	1,714		(4,920	)
Chevron Corp.		127		01/26/24		USD	145.00		USD	1,894		(81,597	)
ConocoPhillips		10		01/26/24		USD	116.00		USD	116		(3,225	)
EOG Resources, Inc.		204		01/26/24		USD	121.50		USD	2,467		(57,120	)
Exxon Mobil Corp.		464		01/26/24		USD	106.00		USD	4,639		(30,160	)
Hess Corp.		32		01/26/24		USD	140.00		USD	461		(27,520	)
Marathon Petroleum Corp.		178		01/26/24		USD	160.00		USD	2,641		(18,868	)
Schlumberger NV		206		01/26/24		USD	56.00		USD	1,072		(10,506	)
Shell PLC, ADR		434		01/26/24		USD	67.00		USD	2,856		(39,060	)
Williams Cos., Inc.		393		01/26/24		USD	36.00		USD	1,369		(11,790	)
ConocoPhillips		75		02/02/24		USD	121.00		USD	871		(13,125	)
ARC Resources Ltd.		524		02/16/24		CAD	21.00		CAD	1,031		(13,841	)
Canadian Natural Resources Ltd.		704		02/16/24		CAD	86.00		CAD	6,111		(205,879	)
Cenovus Energy, Inc.		150		02/16/24		CAD	24.00		CAD	331		(4,302	)
ConocoPhillips		202		02/16/24		USD	120.00		USD	2,345		(57,368	)
NOV, Inc.		41		02/16/24		USD	22.00		USD	83		(2,050	)
Patterson-UTI Energy, Inc.		234		02/16/24		USD	12.00		USD	253		(7,605	)
Shell PLC, ADR		736		02/16/24		USD	67.50		USD	4,843		(93,840	)
TechnipFMC PLC		67		02/16/24		USD	22.00		USD	135		(3,183	)
Tourmaline Oil Corp.		95		02/16/24		CAD	64.00		CAD	566		(3,692	)
Weatherford International PLC		7		02/16/24		USD	110.00		USD	68		(1,680	)
											$	(1,407,005	)

OTC Options Written

Description

Counterparty

Number of Contracts

Expiration Date

Exercise Price

Notional Amount (000)

Value

Call

Galp Energia SGPS SA

Goldman Sachs International

36,500

01/04/24

EUR

13.73

EUR

486

$

(1,148

)

TC Energy Corp.

Royal Bank of Canada

28,300

01/09/24

CAD

48.31

CAD

1,465

(76,401

)

S C H E D U L E O F I N V E S T M E N T S 45

Schedule of Investments (continued) December 31, 2023   BlackRock Energy and Resources Trust (BGR)

OTC Options Written (continued)

Description	Counterparty		Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
Tenaris SA		UBS AG		60,300		01/11/24		EUR	16.58		EUR	950	$	(2,813	)
TotalEnergies SE		Bank of America N.A.		124,900		01/18/24		EUR	62.70		EUR	7,693		(49,244	)
TC Energy Corp.		Royal Bank of Canada		35,200		01/29/24		CAD	52.43		CAD	1,822		(16,656	)
BP PLC		Morgan Stanley & Co. International PLC		562,900		01/30/24		GBP	4.87		GBP	2,618		(36,715	)
TotalEnergies SE		Morgan Stanley & Co. International PLC		4,700		01/30/24		EUR	63.63		EUR	290		(2,353	)
Galp Energia SGPS SA		Bank of America N.A.		35,400		02/01/24		EUR	13.66		EUR	472		(8,821	)
BP PLC		Bank of America N.A.		447,000		02/08/24		GBP	4.68		GBP	2,079		(82,485	)
TC Energy Corp.		Royal Bank of Canada		35,200		02/26/24		CAD	52.43		CAD	1,822		(32,425	)
Pembina Pipeline Corp.		Morgan Stanley & Co. International PLC		17,400		02/27/24		CAD	46.91		CAD	794		(9,792	)
													$	(318,853	)

Balances Reported in the Statements of Assets and Liabilities for Options Written

Description	Swap Premiums Paid		Swap Premiums Received		Unrealized Appreciation		Unrealized Depreciation			Value
Options Written	$	N/A	$	N/A	$	994,621	$	(281,392	)	$	(1,725,858)

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

	Commodity Contracts		Credit Contracts		Equity Contracts		Foreign Currency Exchange Contracts		Interest Rate Contracts		Other Contracts		Total
Liabilities — Derivative Financial Instruments
Options written
Options written at value	$	—	$	—	$	1,725,858	$	—	$	—	$	—	$	1,725,858

For the period ended December 31, 2023, the effect of derivative financial instruments in the Statements of Operations was as follows:

	Commodity Contracts		Credit Contracts		Equity Contracts			Foreign Currency Exchange Contracts		Interest Rate Contracts		Other Contracts		Total
Net Realized Gain (Loss) from:
Options purchased(a)	$	—	$	—	$	(734,586	)	$	—	$	—	$	—	$	(734,586	)
Options written		—		—		9,232,797			—		—		—		9,232,797
	$	—	$	—	$	8,498,211		$	—	$	—	$	—	$	8,498,211
Net Change in Unrealized Appreciation (Depreciation) on:
Options written	$	—	$	—	$	(1,712,020	)	$	—	$	—	$	—	$	(1,712,020	)

^(a)  Options purchased are included in net realized gain (loss) from investments — unaffiliated.

Average Quarterly Balances of Outstanding Derivative Financial Instruments

Options:
Average value of option contracts purchased	$	—	(a)
Average value of option contracts written	$	2,743,846

^(a)  Derivative financial instrument not held at any quarter-end. The risk exposure table serves as an indicator of activity during the period.

For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

46 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Schedule of Investments (continued) December 31, 2023   BlackRock Energy and Resources Trust (BGR)

Derivative Financial Instruments — Offsetting as of Period End

The Trust’s derivative assets and liabilities (by type) were as follows:

	Assets		Liabilities
Derivative Financial Instruments
Options	$	—	$	1,725,858
Total derivative assets and liabilities in the Statements of Assets and Liabilities		—		1,725,858
Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”)		—		(1,407,005	)
Total derivative assets and liabilities subject to an MNA	$	—	$	318,853

The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the Trust:

Counterparty		Derivative Liabilities Subject to an MNA by Counterparty		Derivatives Available for Offset		Non-Cash Collateral Pledged	(a)		Cash Collateral Pledged		Net Amount of Derivative Liabilities	(b)
Bank of America N.A.	$	140,550	$	—	$	—		$	—	$	140,550
Goldman Sachs International		1,148		—		—			—		1,148
Morgan Stanley & Co. International PLC		48,860		—		(48,860	)		—		—
Royal Bank of Canada		125,482		—		—			—		125,482
UBS AG		2,813		—		—			—		2,813
	$	318,853	$	—	$	(48,860	)	$	—	$	269,993

^(a)  Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes.

^(b)  Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation of financial instruments, refer to the Notes to Financial Statements.

The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s financial instruments into major categories is disclosed in the Schedule of Investments above.

	Level 1			Level 2			Level 3		Total
Assets
Investments
Long-Term Investments
Common Stocks
Energy Equipment & Services	$	21,016,499		$	3,576,035		$	—	$	24,592,534
Oil, Gas & Consumable Fuels		308,516,785			52,434,165			99		360,951,049
Short-Term Securities
Money Market Funds		3,612,320			—			—		3,612,320
	$	333,145,604		$	56,010,200		$	99	$	389,155,903
Derivative Financial Instruments(a)
Liabilities
Equity Contracts	$	(1,407,005	)	$	(318,853	)	$	—	$	(1,725,858	)

^(a)  Derivative financial instruments are options written. Options written are shown at value.

See notes to financial statements.

S C H E D U L E O F I N V E S T M E N T S 47

Schedule of Investments December 31, 2023   BlackRock Enhanced Capital and Income Fund, Inc. (CII) (Percentages shown are based on Net Assets)

Security	Shares		Value
Common Stocks
Automobile Components — 1.5%
Aptiv PLC(a)		147,551	$	13,238,276
Banks — 1.8%
JPMorgan Chase & Co.(b)		94,564		16,085,336
Beverages — 0.9%
Monster Beverage Corp.(a)		138,985		8,006,926
Broadline Retail — 5.5%
Amazon.com, Inc.(a)(b)		319,381		48,526,749
Building Products — 1.2%
Allegion PLC		80,992		10,260,877
Capital Markets — 3.4%
Intercontinental Exchange, Inc.(b)		151,536		19,461,768
LPL Financial Holdings, Inc.		45,624		10,384,935
				29,846,703
Chemicals — 3.1%
Axalta Coating Systems Ltd.(a)		355,562		12,078,441
Corteva, Inc.(b)		306,853		14,704,396
				26,782,837
Communications Equipment — 0.8%
Ciena Corp.(a)		155,832		7,013,998
Consumer Finance — 0.9%
American Express Co.		42,880		8,033,139
Consumer Staples Distribution & Retail(b) — 2.4%
Dollar General Corp.		76,260		10,367,547
Dollar Tree, Inc.(a)		72,274		10,266,522
				20,634,069
Diversified Telecommunication Services — 1.4%
Verizon Communications, Inc.		326,062		12,292,537
Electronic Equipment, Instruments & Components — 1.7%
Zebra Technologies Corp., Class A(a)		55,903		15,279,967
Entertainment — 1.0%
TKO Group Holdings, Inc., Class A(b)		107,011		8,729,957
Financial Services — 3.6%
Berkshire Hathaway, Inc., Class B(a)(b)		63,439		22,626,154
Voya Financial, Inc.		119,726		8,735,209
				31,361,363
Food Products — 1.2%
Mondelez International, Inc., Class A(b)		146,251		10,592,960
Health Care Equipment & Supplies — 1.8%
Medtronic PLC		193,236		15,918,782
Health Care Providers & Services — 6.5%
Elevance Health, Inc.		21,062		9,931,997
Humana, Inc.(b)		20,719		9,485,365
Laboratory Corp. of America Holdings(b)		37,688		8,566,106
Tenet Healthcare Corp.(a)		130,657		9,873,749
UnitedHealth Group, Inc.(b)		35,789		18,841,835
				56,699,052
Health Care Technology — 0.9%
Veeva Systems, Inc., Class A(a)(b)		39,050		7,517,906
Hotels, Restaurants & Leisure — 0.8%
Las Vegas Sands Corp.(b)		141,432		6,959,869

Security	Shares		Value
Household Durables — 2.2%
Sony Group Corp., ADR(c)		200,199	$	18,956,843
Insurance — 3.5%
Fidelity National Financial, Inc., Class A		228,435		11,654,754
Progressive Corp.		61,776		9,839,681
Reinsurance Group of America, Inc.(b)		53,822		8,707,323
				30,201,758
Interactive Media & Services(a) — 8.5%
Alphabet, Inc., Class A		337,582		47,156,830
Meta Platforms, Inc., Class A(b)		76,113		26,940,957
				74,097,787
IT Services — 2.0%
Cognizant Technology Solutions Corp., Class A		233,189		17,612,765
Life Sciences Tools & Services — 2.8%
Avantor, Inc.(a)		556,795		12,711,630
Fortrea Holdings, Inc.(a)(b)		187,843		6,555,720
Thermo Fisher Scientific, Inc.		10,253		5,442,190
				24,709,540
Machinery(b) — 4.6%
Caterpillar, Inc.		40,462		11,963,399
Fortive Corp.		269,413		19,836,879
Otis Worldwide Corp.		98,695		8,830,242
				40,630,520
Media — 2.3%
Comcast Corp., Class A(b)		459,529		20,150,347
Oil, Gas & Consumable Fuels — 4.3%
BP PLC, ADR(c)		316,478		11,203,321
ConocoPhillips(b)		130,814		15,183,581
Shell PLC		334,409		10,946,567
				37,333,469
Personal Care Products — 1.0%
Unilever PLC, ADR(b)		187,755		9,102,362
Pharmaceuticals — 4.3%
Novo Nordisk A/S, ADR(b)		170,760		17,665,122
Sanofi SA, ADR		396,772		19,731,472
				37,396,594
Professional Services — 1.1%
Dun & Bradstreet Holdings, Inc.		818,943		9,581,633
Semiconductors & Semiconductor Equipment — 7.7%
Advanced Micro Devices, Inc.(a)(d)		139,515		20,565,906
Applied Materials, Inc.(b)		105,417		17,084,933
Marvell Technology, Inc.		209,096		12,610,580
Micron Technology, Inc.		199,067		16,988,378
				67,249,797
Software — 8.8%
Microsoft Corp.(b)(d)		204,069		76,738,107
Specialty Retail — 1.8%
Ross Stores, Inc.(b)		113,388		15,691,765
Technology Hardware, Storage & Peripherals — 4.4%
Apple, Inc.(b)		198,730		38,261,487

48 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Schedule of Investments (continued) December 31, 2023   BlackRock Enhanced Capital and Income Fund, Inc. (CII) (Percentages shown are based on Net Assets)

Security	Shares		Value
Textiles, Apparel & Luxury Goods — 1.0%
Skechers USA, Inc., Class A(a)		142,987	$	8,913,810
Total Long-Term Investments — 100.7% (Cost: $554,276,107)				880,409,887
Short-Term Securities
Money Market Funds — 1.5%
BlackRock Liquidity Funds, T-Fund, Institutional Class, 5.26%(e)(f)		12,932,953		12,932,953
SL Liquidity Series, LLC, Money Market Series, 5.58%(e)(f)(g)		397,392		397,512
Total Short-Term Securities — 1.5% (Cost: $13,330,505)				13,330,465
Total Investments Before Options Written — 102.2% (Cost: $567,606,612)				893,740,352
Options Written — (2.1)% (Premiums Received: $(10,266,670))				(18,548,876	)
Total Investments, Net of Options Written — 100.1% (Cost: $557,339,942)				875,191,476
Liabilities in Excess of Other Assets — (0.1)%				(740,695	)
Net Assets — 100.0%			$	874,450,781

^(a)  Non-income producing security.

^(b)  All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

^(c)  All or a portion of this security is on loan.

^(d)  All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.

^(e)  Affiliate of the Trust.

^(f)  Annualized 7-day yield as of period end.

^(g)  All or a portion of this security was purchased with the cash collateral from loaned securities.

For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

Affiliates

Investments in issuers considered to be affiliate(s) of the Trust during the year ended December 31, 2023 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

Affiliated Issuer	Value at 12/31/22		Purchases at Cost			Proceeds from Sale			Net Realized Gain (Loss)			Change in Unrealized Appreciation (Depreciation)			Value at 12/31/23		Shares Held at 12/31/23		Income			Capital Gain Distributions from Underlying Funds
BlackRock Liquidity Funds, T-Fund, Institutional Class	$	14,661,156	$	—		$	(1,728,203	)(a)	$	—		$	—		$	12,932,953		12,932,953	$	617,975		$	—
SL Liquidity Series, LLC, Money Market Series		—		398,038	(a)		—			(486	)		(40	)		397,512		397,392		6,751	(b)		—
									$	(486	)	$	(40	)	$	13,330,465			$	624,726		$	—

^(a)  Represents net amount purchased (sold).

^(b)  All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.

Derivative Financial Instruments Outstanding as of Period End

Exchange-Traded Options Written

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call
Advanced Micro Devices, Inc.		135		01/05/24		USD	125.00		USD	1,990	$	(305,438	)
Amazon.com, Inc.		358		01/05/24		USD	152.50		USD	5,439		(54,237	)
Apple, Inc.		84		01/05/24		USD	195.00		USD	1,617		(5,670	)
Applied Materials, Inc.		346		01/05/24		USD	155.00		USD	5,608		(258,635	)
Elevance Health, Inc.		35		01/05/24		USD	485.00		USD	1,650		(1,838	)
JPMorgan Chase & Co.		150		01/05/24		USD	155.00		USD	2,552		(229,125	)
Meta Platforms, Inc., Class A		78		01/05/24		USD	340.00		USD	2,761		(117,390	)
Microsoft Corp.		260		01/05/24		USD	370.00		USD	9,777		(198,900	)

S C H E D U L E O F I N V E S T M E N T S 49

Schedule of Investments (continued) December 31, 2023   BlackRock Enhanced Capital and Income Fund, Inc. (CII)

Exchange-Traded Options Written (continued)

Description	Number of Contracts		Expiration Date		Exercise Price			Notional  Amount (000)			Value
Call (continued)
Mondelez International, Inc., Class A		109		01/05/24		USD	72.00		USD	789	$	(8,720	)
Ross Stores, Inc.		168		01/05/24		USD	132.00		USD	2,325		(113,400	)
UnitedHealth Group, Inc.		94		01/05/24		USD	550.00		USD	4,949		(658	)
Advanced Micro Devices, Inc.		50		01/12/24		USD	129.00		USD	737		(94,375	)
Alphabet, Inc., Class A		776		01/12/24		USD	141.00		USD	10,840		(136,964	)
Amazon.com, Inc.		332		01/12/24		USD	147.25		USD	5,044		(207,572	)
Apple, Inc.		416		01/12/24		USD	200.00		USD	8,009		(15,184	)
Applied Materials, Inc.		96		01/12/24		USD	150.00		USD	1,556		(121,440	)
Berkshire Hathaway, Inc., Class B		195		01/12/24		USD	355.00		USD	6,955		(97,500	)
Comcast Corp., Class A		345		01/12/24		USD	43.00		USD	1,513		(37,950	)
ConocoPhillips		89		01/12/24		USD	119.00		USD	1,033		(8,322	)
Dollar General Corp.		154		01/12/24		USD	139.00		USD	2,094		(28,105	)
Humana, Inc.		31		01/12/24		USD	495.00		USD	1,419		(2,170	)
JPMorgan Chase & Co.		149		01/12/24		USD	157.50		USD	2,534		(191,837	)
Las Vegas Sands Corp.		195		01/12/24		USD	48.00		USD	960		(36,563	)
Marvell Technology, Inc.		140		01/12/24		USD	55.00		USD	844		(77,000	)
Meta Platforms, Inc., Class A		80		01/12/24		USD	325.00		USD	2,832		(241,200	)
Microsoft Corp.		424		01/12/24		USD	375.00		USD	15,944		(263,940	)
Mondelez International, Inc., Class A		371		01/12/24		USD	72.00		USD	2,687		(43,592	)
Novo Nordisk A/S, ADR		360		01/12/24		USD	100.00		USD	3,724		(160,200	)
Ross Stores, Inc.		118		01/12/24		USD	131.00		USD	1,633		(89,680	)
Ross Stores, Inc.		199		01/12/24		USD	135.00		USD	2,754		(85,570	)
Thermo Fisher Scientific, Inc.		33		01/12/24		USD	500.00		USD	1,752		(110,055	)
Allegion PLC		195		01/19/24		USD	110.00		USD	2,470		(332,475	)
Alphabet, Inc., Class A		530		01/19/24		USD	137.00		USD	7,404		(249,100	)
Amazon.com, Inc.		295		01/19/24		USD	142.50		USD	4,482		(309,750	)
Apple, Inc.		296		01/19/24		USD	190.00		USD	5,699		(145,040	)
Applied Materials, Inc.		243		01/19/24		USD	165.00		USD	3,938		(75,937	)
Aptiv PLC		430		01/19/24		USD	82.50		USD	3,858		(337,550	)
Avantor, Inc.		940		01/19/24		USD	19.75		USD	2,146		(391,570	)
Axalta Coating Systems Ltd.		1,224		01/19/24		USD	31.00		USD	4,158		(400,860	)
Berkshire Hathaway, Inc., Class B		229		01/19/24		USD	360.00		USD	8,168		(67,440	)
BP PLC, ADR		345		01/19/24		USD	38.00		USD	1,221		(2,933	)
Caterpillar, Inc.		62		01/19/24		USD	250.00		USD	1,833		(290,625	)
Cognizant Technology Solutions Corp., Class A		214		01/19/24		USD	70.00		USD	1,616		(126,260	)
Cognizant Technology Solutions Corp., Class A		151		01/19/24		USD	72.50		USD	1,141		(53,605	)
Comcast Corp., Class A		133		01/19/24		USD	45.00		USD	583		(4,389	)
ConocoPhillips		107		01/19/24		USD	125.00		USD	1,242		(2,943	)
Corteva, Inc.		738		01/19/24		USD	48.25		USD	3,536		(72,866	)
Dollar General Corp.		156		01/19/24		USD	135.00		USD	2,121		(64,740	)
Dollar Tree, Inc.		139		01/19/24		USD	120.00		USD	1,974		(311,707	)
Elevance Health, Inc.		31		01/19/24		USD	480.00		USD	1,462		(17,360	)
Fortrea Holdings, Inc.		199		01/19/24		USD	35.00		USD	695		(35,820	)
Humana, Inc.		53		01/19/24		USD	505.00		USD	2,426		(3,578	)
Intercontinental Exchange, Inc.		331		01/19/24		USD	115.00		USD	4,251		(458,435	)
Intercontinental Exchange, Inc.		653		01/19/24		USD	120.00		USD	8,386		(561,580	)
JPMorgan Chase & Co.		176		01/19/24		USD	155.00		USD	2,994		(269,720	)
Laboratory Corp. of America Holdings		153		01/19/24		USD	213.22		USD	3,478		(231,562	)
Las Vegas Sands Corp.		85		01/19/24		USD	52.50		USD	418		(3,103	)
LPL Financial Holdings, Inc.		154		01/19/24		USD	240.00		USD	3,505		(26,565	)
Marvell Technology, Inc.		140		01/19/24		USD	55.00		USD	844		(80,850	)
Meta Platforms, Inc., Class A		81		01/19/24		USD	330.00		USD	2,867		(215,865	)
Micron Technology, Inc.		370		01/19/24		USD	80.00		USD	3,158		(224,775	)
Microsoft Corp.		316		01/19/24		USD	375.00		USD	11,883		(240,160	)
Mondelez International, Inc., Class A		38		01/19/24		USD	72.50		USD	275		(4,085	)
Monster Beverage Corp.		418		01/19/24		USD	57.50		USD	2,408		(51,205	)
Novo Nordisk A/S, ADR		247		01/19/24		USD	104.00		USD	2,555		(61,750	)
Otis Worldwide Corp.		196		01/19/24		USD	83.25		USD	1,754		(135,243	)
Progressive Corp.		195		01/19/24		USD	165.00		USD	3,106		(19,500	)
Reinsurance Group of America, Inc.		160		01/19/24		USD	165.00		USD	2,588		(30,400	)
Ross Stores, Inc.		314		01/19/24		USD	135.00		USD	4,345		(147,580	)
Sanofi SA, ADR		753		01/19/24		USD	47.60		USD	3,745		(216,792	)

50 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Schedule of Investments (continued) December 31, 2023   BlackRock Enhanced Capital and Income Fund, Inc. (CII)

Exchange-Traded Options Written (continued)

Description	Number of Contracts		Expiration Date		Exercise Price			Notional  Amount (000)			Value
Call (continued)
Skechers USA, Inc., Class A		120		01/19/24		USD	55.00		USD	748	$	(89,400	)
Sony Group Corp., ADR		500		01/19/24		USD	90.00		USD	4,735		(270,000	)
Tenet Healthcare Corp.		265		01/19/24		USD	80.00		USD	2,003		(24,513	)
Unilever PLC, ADR		389		01/19/24		USD	50.00		USD	1,886		(4,862	)
UnitedHealth Group, Inc.		94		01/19/24		USD	550.00		USD	4,949		(26,743	)
Verizon Communications, Inc.		882		01/19/24		USD	38.00		USD	3,325		(28,665	)
Zebra Technologies Corp., Class A		211		01/19/24		USD	250.00		USD	5,767		(547,545	)
Alphabet, Inc., Class A		566		01/26/24		USD	146.00		USD	7,906		(77,825	)
Amazon.com, Inc.		358		01/26/24		USD	150.00		USD	5,439		(194,215	)
Apple, Inc.		274		01/26/24		USD	200.00		USD	5,275		(29,044	)
BP PLC, ADR		920		01/26/24		USD	37.00		USD	3,257		(26,220	)
Caterpillar, Inc.		201		01/26/24		USD	295.00		USD	5,943		(151,252	)
Comcast Corp., Class A		1,564		01/26/24		USD	44.00		USD	6,858		(185,334	)
ConocoPhillips		137		01/26/24		USD	116.00		USD	1,590		(44,182	)
Dollar Tree, Inc.		122		01/26/24		USD	135.00		USD	1,733		(106,140	)
Fortive Corp.		427		01/26/24		USD	68.25		USD	3,144		(254,536	)
JPMorgan Chase & Co.		149		01/26/24		USD	165.00		USD	2,534		(97,967	)
Las Vegas Sands Corp.		285		01/26/24		USD	51.00		USD	1,402		(34,058	)
Marvell Technology, Inc.		139		01/26/24		USD	55.00		USD	838		(83,400	)
Medtronic PLC		35		01/26/24		USD	83.34		USD	288		(4,113	)
Meta Platforms, Inc., Class A		156		01/26/24		USD	340.00		USD	5,522		(311,610	)
Micron Technology, Inc.		119		01/26/24		USD	87.00		USD	1,016		(22,789	)
Microsoft Corp.		140		01/26/24		USD	385.00		USD	5,265		(94,150	)
Mondelez International, Inc., Class A		184		01/26/24		USD	71.00		USD	1,333		(44,160	)
Sony Group Corp., ADR		300		01/26/24		USD	92.00		USD	2,841		(121,500	)
Thermo Fisher Scientific, Inc.		33		01/26/24		USD	500.00		USD	1,752		(118,635	)
Amazon.com, Inc.		348		02/02/24		USD	157.40		USD	5,288		(110,260	)
Comcast Corp., Class A		9		02/02/24		USD	46.05		USD	39		(404	)
ConocoPhillips		101		02/02/24		USD	121.00		USD	1,172		(17,675	)
Medtronic PLC		64		02/02/24		USD	83.05		USD	527		(10,500	)
Micron Technology, Inc.		122		02/02/24		USD	87.00		USD	1,041		(29,097	)
Comcast Corp., Class A		154		02/09/24		USD	44.00		USD	675		(22,330	)
Medtronic PLC		111		02/09/24		USD	83.34		USD	914		(19,040	)
Micron Technology, Inc.		62		02/09/24		USD	87.00		USD	529		(17,205	)
Advanced Micro Devices, Inc.		94		02/16/24		USD	140.00		USD	1,386		(131,130	)
Alphabet, Inc., Class A		322		02/16/24		USD	145.00		USD	4,498		(123,970	)
Amazon.com, Inc.		384		02/16/24		USD	150.00		USD	5,834		(339,840	)
Apple, Inc.		221		02/16/24		USD	195.00		USD	4,255		(114,367	)
Aptiv PLC		351		02/16/24		USD	92.50		USD	3,149		(133,380	)
Avantor, Inc.		588		02/16/24		USD	21.00		USD	1,342		(142,590	)
Ciena Corp.		798		02/16/24		USD	45.10		USD	3,592		(150,145	)
Cognizant Technology Solutions Corp., Class A		101		02/16/24		USD	77.50		USD	763		(19,695	)
ConocoPhillips		89		02/16/24		USD	120.00		USD	1,033		(25,276	)
Dollar Tree, Inc.		208		02/16/24		USD	135.00		USD	2,955		(210,080	)
Fidelity National Financial, Inc., Class A		470		02/16/24		USD	47.79		USD	2,398		(189,389	)
Fortive Corp.		1,234		02/16/24		USD	69.93		USD	9,086		(638,829	)
Fortrea Holdings, Inc.		552		02/16/24		USD	32.50		USD	1,926		(201,480	)
Laboratory Corp. of America Holdings		96		02/16/24		USD	220.00		USD	2,182		(115,680	)
Medtronic PLC		111		02/16/24		USD	85.00		USD	914		(12,654	)
Micron Technology, Inc.		62		02/16/24		USD	77.50		USD	529		(58,125	)
Microsoft Corp.		186		02/16/24		USD	400.00		USD	6,994		(100,905	)
Progressive Corp.		206		02/16/24		USD	160.00		USD	3,281		(124,630	)
Reinsurance Group of America, Inc.		189		02/16/24		USD	165.00		USD	3,058		(75,127	)
Sanofi SA, ADR		771		02/16/24		USD	49.00		USD	3,834		(174,197	)
TKO Group Holdings, Inc., Class A		435		02/16/24		USD	80.00		USD	3,549		(224,025	)
Unilever PLC, ADR		514		02/16/24		USD	50.00		USD	2,492		(30,840	)
Voya Financial, Inc.		400		02/16/24		USD	77.50		USD	2,918		(34,000	)
Zebra Technologies Corp., Class A		57		02/16/24		USD	230.00		USD	1,558		(281,580	)
Fidelity National Financial, Inc., Class A		1,039		03/15/24		USD	47.31		USD	5,301		(614,376	)
Medtronic PLC		64		03/15/24		USD	85.00		USD	527		(12,992	)

S C H E D U L E  O F  I N V E S T M E N T S 51

Schedule of Investments (continued) December 31, 2023   BlackRock Enhanced Capital and Income Fund, Inc. (CII)

Exchange-Traded Options Written (continued)

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
Micron Technology, Inc.		62		03/15/24		USD	87.50		USD	529	$	(25,420	)
Otis Worldwide Corp.		271		03/15/24		USD	90.00		USD	2,425		(84,010	)
											$	(17,227,049	)

OTC Options Written

Description	Counterparty		Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call
Verizon Communications, Inc.		Citibank N.A.		35,500		01/03/24		USD	37.53		USD	1,338	$	(13,786	)
Otis Worldwide Corp.		UBS AG		18,500		01/04/24		USD	85.49		USD	1,655		(77,025	)
Verizon Communications, Inc.		Citibank N.A.		35,500		01/10/24		USD	37.53		USD	1,338		(8,812	)
Shell PLC		Goldman Sachs International		40,600		01/11/24		GBP	26.68		GBP	1,043		(2,830	)
Dun & Bradstreet Holdings, Inc.		Citibank N.A.		120,800		01/16/24		USD	9.82		USD	1,413		(265,220	)
Voya Financial, Inc.		JPMorgan Chase Bank N.A.		39,100		01/23/24		USD	71.55		USD	2,853		(98,306	)
Shell PLC		Goldman Sachs International		25,400		01/24/24		GBP	25.83		GBP	652		(15,746	)
Shell PLC		Morgan Stanley & Co. International PLC		70,000		01/30/24		GBP	26.54		GBP	1,798		(24,658	)
LPL Financial Holdings, Inc.		Citibank N.A.		14,300		01/31/24		USD	216.19		USD	3,255		(236,728	)
Meta Platforms, Inc., Class A		Citibank N.A.		9,900		01/31/24		USD	361.74		USD	3,504		(140,823	)
Skechers USA, Inc., Class A		Bank of America N.A.		21,400		01/31/24		USD	64.63		USD	1,334		(35,361	)
Dun & Bradstreet Holdings, Inc.		UBS AG		42,900		02/13/24		USD	11.84		USD	502		(33,852	)
Monster Beverage Corp.		Citibank N.A.		50,000		02/16/24		USD	56.12		USD	2,881		(141,506	)
Axalta Coating Systems Ltd.		Citibank N.A.		113,000		02/26/24		USD	33.10		USD	3,839		(227,174	)
													$	(1,321,827	)

Balances Reported in the Statements of Assets and Liabilities for Options Written

Description	Swap Premiums Paid		Swap Premiums Received		Unrealized Appreciation		Unrealized Depreciation		Value
Options Written	$	N/A	$	N/A	$	1,510,847	$	(9,793,053)	$	(18,548,876)

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

	Commodity Contracts		Credit Contracts		Equity Contracts		Foreign Currency Exchange Contracts		Interest Rate Contracts		Other Contracts		Total
Liabilities — Derivative Financial Instruments
Options written
Options written at value	$	—	$	—	$	18,548,876	$	—	$	—	$	—	$	18,548,876

For the period ended December 31, 2023, the effect of derivative financial instruments in the Statements of Operations was as follows:

	Commodity Contracts		Credit Contracts		Equity Contracts			Foreign Currency Exchange Contracts		Interest Rate Contracts		Other Contracts		Total
Net Realized Gain (Loss) from:
Options written	$	—	$	—	$	(10,946,814	)	$	—	$	—	$	—	$	(10,946,814	)
Net Change in Unrealized Appreciation (Depreciation) on:
Options written	$	—	$	—	$	(13,682,244	)	$	—	$	—	$	—	$	(13,682,244	)

52 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Schedule of Investments (continued) December 31, 2023   BlackRock Enhanced Capital and Income Fund, Inc. (CII)

Average Quarterly Balances of Outstanding Derivative Financial Instruments

Options:
Average value of option contracts written	$	14,431,983

For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

Derivative Financial Instruments — Offsetting as of Period End

The Trust’s derivative assets and liabilities (by type) were as follows:

	Assets		Liabilities
Derivative Financial Instruments
Options	$	—	$	18,548,876
Total derivative assets and liabilities in the Statements of Assets and Liabilities		—		18,548,876
Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”)		—		(17,227,049	)
Total derivative assets and liabilities subject to an MNA	$	—	$	1,321,827

The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the Trust:

Counterparty		Derivative Liabilities Subject to an MNA by Counterparty		Derivatives Available for Offset		Non-Cash Collateral Pledged	(a)		Cash Collateral Pledged		Net Amount of Derivative Liabilities	(b)
Bank of America N.A.	$	35,361	$	—	$	—		$	—	$	35,361
Citibank N.A.		1,034,049		—		(1,034,049	)		—		—
Goldman Sachs International		18,576		—		—			—		18,576
JPMorgan Chase Bank N.A.		98,306		—		—			—		98,306
Morgan Stanley & Co. International PLC		24,658		—		—			—		24,658
UBS AG		110,877		—		—			—		110,877
	$	1,321,827	$	—	$	(1,034,049	)	$	—	$	287,778

^(a)  Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes.

^(b)  Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation of financial instruments, refer to the Notes to Financial Statements.

The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s financial instruments into major categories is disclosed in the Schedule of Investments above.

	Level 1		Level 2		Level 3		Total
Assets
Investments
Long-Term Investments
Common Stocks
Automobile Components	$	13,238,276	$	—	$	—	$	13,238,276
Banks		16,085,336		—		—		16,085,336
Beverages		8,006,926		—		—		8,006,926
Broadline Retail		48,526,749		—		—		48,526,749
Building Products		10,260,877		—		—		10,260,877
Capital Markets		29,846,703		—		—		29,846,703
Chemicals		26,782,837		—		—		26,782,837
Communications Equipment		7,013,998		—		—		7,013,998
Consumer Finance		8,033,139		—		—		8,033,139
Consumer Staples Distribution & Retail		20,634,069		—		—		20,634,069
Diversified Telecommunication Services		12,292,537		—		—		12,292,537
Electronic Equipment, Instruments & Components		15,279,967		—		—		15,279,967
Entertainment		8,729,957		—		—		8,729,957

S C H E D U L E  O F  I N V E S T M E N T S 53

Schedule of Investments (continued) December 31, 2023   BlackRock Enhanced Capital and Income Fund, Inc. (CII)

Fair Value Hierarchy as of Period End (continued)

	Level 1			Level 2			Level 3		Total
Common Stocks (continued)
Financial Services	$	31,361,363		$	—		$	—	$	31,361,363
Food Products		10,592,960			—			—		10,592,960
Health Care Equipment & Supplies		15,918,782			—			—		15,918,782
Health Care Providers & Services		56,699,052			—			—		56,699,052
Health Care Technology		7,517,906			—			—		7,517,906
Hotels, Restaurants & Leisure		6,959,869			—			—		6,959,869
Household Durables		18,956,843			—			—		18,956,843
Insurance		30,201,758			—			—		30,201,758
Interactive Media & Services		74,097,787			—			—		74,097,787
IT Services		17,612,765			—			—		17,612,765
Life Sciences Tools & Services		24,709,540			—			—		24,709,540
Machinery		40,630,520			—			—		40,630,520
Media		20,150,347			—			—		20,150,347
Oil, Gas & Consumable Fuels		26,386,902			10,946,567			—		37,333,469
Personal Care Products		9,102,362			—			—		9,102,362
Pharmaceuticals		37,396,594			—			—		37,396,594
Professional Services		9,581,633			—			—		9,581,633
Semiconductors & Semiconductor Equipment		67,249,797			—			—		67,249,797
Software		76,738,107			—			—		76,738,107
Specialty Retail		15,691,765			—			—		15,691,765
Technology Hardware, Storage & Peripherals		38,261,487			—			—		38,261,487
Textiles, Apparel & Luxury Goods		8,913,810			—			—		8,913,810
Short-Term Securities
Money Market Funds		12,932,953			—			—		12,932,953
	$	882,396,273		$	10,946,567		$	—		893,342,840
Investments Valued at NAV(a)										397,512
									$	893,740,352
Derivative Financial Instruments(b)
Liabilities
Equity Contracts	$	(13,805,655	)	$	(4,743,221	)	$	—	$	(18,548,876	)

^(a)  Certain investments of the Trust were fair valued using NAV as a practical expedient as no quoted market value is available and therefore have been excluded from the fair value hierarchy.

^(b)  Derivative financial instruments are options written. Options written are shown at value.

See notes to financial statements.

54 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Consolidated Schedule of Investments December 31, 2023   BlackRock Enhanced Equity Dividend Trust (BDJ) (Percentages shown are based on Net Assets)

Security	Shares		Value
Common Stocks
Aerospace & Defense(a) — 3.7%
L3Harris Technologies, Inc.(b)		180,535	$	38,024,282
RTX Corp.		269,046		22,637,530
				60,661,812
Automobile Components — 0.4%
Lear Corp.		47,800		6,749,838
Automobiles — 2.2%
General Motors Co.(a)(b)		1,018,667		36,590,519
Banks — 11.0%
Bank of America Corp.		314,801		10,599,350
Citigroup, Inc.(a)		970,830		49,939,495
Citizens Financial Group, Inc.		352,124		11,669,389
First Citizens BancShares, Inc., Class A		23,527		33,384,107
JPMorgan Chase & Co.(a)		122,378		20,816,498
Wells Fargo & Co.(a)		1,098,968		54,091,205
				180,500,044
Beverages — 0.9%
Constellation Brands, Inc., Class A(a)		42,599		10,298,308
Keurig Dr. Pepper, Inc.		123,060		4,100,359
				14,398,667
Building Products — 0.8%
Allegion PLC		104,660		13,259,375
Capital Markets — 4.1%
Carlyle Group, Inc.		414,230		16,855,019
Goldman Sachs Group, Inc.		33,980		13,108,465
Intercontinental Exchange, Inc.		84,950		10,910,128
Raymond James Financial, Inc.		146,399		16,323,488
UBS Group AG, Registered Shares		319,280		9,917,335
				67,114,435
Chemicals — 0.6%
International Flavors & Fragrances, Inc.		127,520		10,325,294
Communications Equipment — 2.0%
Cisco Systems, Inc.(a)		632,570		31,957,436
Consumer Finance — 0.5%
American Express Co.		47,010		8,806,853
Consumer Staples Distribution & Retail — 2.0%
Dollar General Corp.		237,476		32,284,862
Containers & Packaging — 1.5%
Sealed Air Corp.(b)		688,332		25,137,885
Diversified Telecommunication Services — 2.4%
AT&T, Inc.		827,562		13,886,490
Verizon Communications, Inc.(b)		657,980		24,805,846
				38,692,336
Electric Utilities — 2.8%
American Electric Power Co., Inc.		224,679		18,248,428
Exelon Corp.		256,819		9,219,802
NextEra Energy, Inc.		80,460		4,887,141
PG&E Corp.(c)		763,531		13,766,464
				46,121,835
Entertainment — 0.1%
Walt Disney Co.(c)		19,020		1,717,316

Security	Shares		Value
Financial Services — 5.1%
AP Arsenal Co. Invest LP(c)(d)		15,830,106	$	15,830,106
Equitable Holdings, Inc.		227,446		7,573,952
Fidelity National Information Services, Inc.(b)		575,110		34,546,858
Visa, Inc., Class A		96,229		25,053,220
				83,004,136
Food Products — 2.4%
Kraft Heinz Co.(a)(b)		1,079,834		39,932,261
Ground Transportation — 0.6%
Union Pacific Corp.		37,481		9,206,083
Health Care Equipment & Supplies — 5.0%
Baxter International, Inc.(a)		830,532		32,108,367
Koninklijke Philips NV(c)		830,415		19,433,561
Medtronic PLC		374,970		30,890,029
				82,431,957
Health Care Providers & Services — 8.0%
Cardinal Health, Inc.		262,089		26,418,571
Cencora, Inc.		44,126		9,062,598
Cigna Group		74,674		22,361,129
CVS Health Corp.		63,370		5,003,695
Elevance Health, Inc.(a)		62,056		29,263,128
Humana, Inc.		19,428		8,894,333
Laboratory Corp. of America Holdings(a)		135,817		30,869,846
				131,873,300
Household Durables — 2.1%
Newell Brands, Inc.		747,674		6,489,810
Panasonic Holdings Corp.		1,179,300		11,613,243
Sony Group Corp.		179,600		16,996,060
				35,099,113
Industrial Conglomerates — 0.4%
Siemens AG, Registered Shares		36,162		6,784,327
Insurance — 6.7%
American International Group, Inc.(a)		703,484		47,661,041
Fidelity National Financial, Inc., Class A		496,525		25,332,706
First American Financial Corp.		29,750		1,917,090
Prudential PLC		576,635		6,505,990
Willis Towers Watson PLC		118,625		28,612,350
				110,029,177
IT Services — 1.3%
Cognizant Technology Solutions Corp., Class A(a)		282,568		21,342,361
Leisure Products — 0.3%
Hasbro, Inc.		102,660		5,241,820
Life Sciences Tools & Services — 0.7%
Fortrea Holdings, Inc.(c)		206,687		7,213,377
Thermo Fisher Scientific, Inc.		8,080		4,288,783
				11,502,160
Machinery — 1.3%
CNH Industrial NV		814,300		9,918,174
Fortive Corp.		74,754		5,504,137
Komatsu Ltd.		220,700		5,743,351
				21,165,662

S C H E D U L E  O F I N V E S T M E N T S 55

Consolidated Schedule of Investments (continued) December 31, 2023   BlackRock Enhanced Equity Dividend Trust (BDJ) (Percentages shown are based on Net Assets)

Security	Shares			Value
Media — 2.7%
Comcast Corp., Class A(a)	751,887			$   32,970,245
Fox Corp., Class A		380,307			11,283,709
					44,253,954
Multi-Utilities — 1.4%
Public Service Enterprise Group, Inc.		115,778			7,079,825
Sempra		212,882			15,908,672
					22,988,497
Oil, Gas & Consumable Fuels — 8.6%
BP PLC		5,837,860			34,607,229
Chevron Corp.		64,390			9,604,413
Enterprise Products Partners LP(a)		1,007,778			26,554,950
Formentera Partners Fund II LP(d)(e)		—	(f)		10,716,626
Shell PLC		1,316,592			43,097,409
Suncor Energy, Inc.		521,730			16,716,229
					141,296,856
Personal Care Products — 1.8%
Unilever PLC, ADR(a)		610,738			29,608,578
Pharmaceuticals — 4.8%
AstraZeneca PLC		95,155			12,835,443
Bayer AG, Registered Shares		384,584			14,269,567
Eli Lilly & Co.		18,167			10,589,908
Novo Nordisk A/S, ADR		78,264			8,096,411
Pfizer, Inc.		140,670			4,049,889
Sanofi SA		286,792			28,499,317
					78,340,535
Professional Services — 4.9%
Leidos Holdings, Inc.(a)		361,660			39,146,079
Robert Half, Inc.		65,910			5,794,807
SS&C Technologies Holdings, Inc.		584,940			35,745,683
					80,686,569
Semiconductors & Semiconductor Equipment — 2.9%
Intel Corp.		122,570			6,159,142
Micron Technology, Inc.(b)		373,400			31,865,956
Taiwan Semiconductor Manufacturing Co. Ltd., ADR		92,084			9,576,736
					47,601,834
Software — 1.3%
Microsoft Corp.		57,206			21,511,744
Specialized REITs — 0.9%
American Tower Corp.		22,100			4,770,948
Crown Castle, Inc.		81,370			9,373,010
					14,143,958
Specialty Retail — 0.8%
Ross Stores, Inc.		88,225			12,209,458
Textiles, Apparel & Luxury Goods — 0.6%
Ralph Lauren Corp., Class A		52,173			7,523,347
Tapestry, Inc.		47,920			1,763,935
					9,287,282

Security	Shares		Value
Tobacco — 1.4%
British American Tobacco PLC, ADR		783,226	$	22,940,690
Wireless Telecommunication Services — 0.4%
Rogers Communications, Inc., Class B		152,562		7,141,935
Total Common Stocks — 101.4% (Cost: $1,412,065,198)				1,663,942,754
Preferred Securities
Preferred Stocks — 0.5%
Household Products — 0.5%
Henkel AG & Co. KGaA		106,570		8,572,705
				8,572,705
Total Preferred Securities — 0.5% (Cost: $8,384,952)				8,572,705
Total Long-Term Investments — 101.9% (Cost: $1,420,450,150)				1,672,515,459
Short-Term Securities
Money Market Funds — 0.3%
BlackRock Liquidity Funds, T-Fund, Institutional Class, 5.26%(g)(h)		5,204,534		5,204,534
Total Short-Term Securities — 0.3% (Cost: $5,204,534)				5,204,534
Total Investments Before Options Written — 102.2% (Cost: $1,425,654,684)				1,677,719,993
Options Written — (2.2)% (Premiums Received: $(20,613,526))				(36,487,628	)
Total Investments, Net of Options Written — 100.0% (Cost: $1,405,041,158)				1,641,232,365
Other Assets Less Liabilities — 0.0%				368,758
Net Assets — 100.0%			$	1,641,601,123

^(a)  All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

^(b)  All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.

^(c)  Non-income producing security.

^(d)  Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.

^(e)  All or a portion of the security is held by a wholly-owned subsidiary. See Note 1 of the Notes to Consolidated Financial Statements for details on the wholly-owned subsidiary.

^(f)  Investment does not issue shares.

^(g)  Affiliate of the Trust.

^(h)  Annualized 7-day yield as of period end.

For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

56 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Consolidated Schedule of Investments (continued) December 31, 2023 BlackRock Enhanced Equity Dividend Trust (BDJ)

Affiliates

Investments in issuers considered to be affiliate(s) of the Trust during the year ended December 31, 2023 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

Affiliated Issuer	Value at 12/31/22		Purchases at Cost			Proceeds from Sale			Net Realized Gain (Loss)			Change in Unrealized Appreciation (Depreciation)		Value at 12/31/23		Shares Held at 12/31/23		Income			Capital Gain Distributions from Underlying Funds
BlackRock Liquidity Funds, T-Fund, Institutional Class	$	76,042,437	$	—		$	(70,837,903	)(a)	$	—		$	—	$	5,204,534		5,204,534	$	2,734,658		$	—
SL Liquidity Series, LLC, Money Market Series(b)		—		331	(a)		—			(331	)		—		—		—		1,130	(c)		—
									$	(331	)	$	—	$	5,204,534			$	2,735,788		$	—

^(a)  Represents net amount purchased (sold).

^(b)  As of period end, the entity is no longer held.

^(c)  All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.

Derivative Financial Instruments Outstanding as of Period End

Exchange-Traded Options Written

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call
American International Group, Inc.		733		01/05/24		USD	67.00		USD	4,966	$	(67,802	)
AT&T, Inc.		968		01/05/24		USD	16.50		USD	1,624		(38,720	)
Baxter International, Inc.		1,458		01/05/24		USD	37.00		USD	5,637		(247,860	)
Cardinal Health, Inc.		503		01/05/24		USD	106.00		USD	5,070		(5,030	)
Cigna Group		216		01/05/24		USD	285.00		USD	6,468		(329,400	)
Cisco Systems, Inc.		1,277		01/05/24		USD	49.00		USD	6,451		(201,766	)
Elevance Health, Inc.		119		01/05/24		USD	485.00		USD	5,612		(6,248	)
Goldman Sachs Group, Inc.		68		01/05/24		USD	340.00		USD	2,623		(314,500	)
JPMorgan Chase & Co.		164		01/05/24		USD	155.00		USD	2,790		(250,510	)
Kraft Heinz Co.		1,823		01/05/24		USD	35.00		USD	6,741		(370,980	)
Ross Stores, Inc.		80		01/05/24		USD	132.00		USD	1,107		(54,000	)
RTX Corp.		715		01/05/24		USD	85.00		USD	6,016		(31,103	)
Taiwan Semiconductor Manufacturing Co. Ltd.		384		01/05/24		USD	98.00		USD	3,994		(236,160	)
AT&T, Inc.		986		01/12/24		USD	17.50		USD	1,655		(6,409	)
Chevron Corp.		188		01/12/24		USD	155.00		USD	2,804		(10,434	)
Cigna Group		16		01/12/24		USD	265.00		USD	479		(56,560	)
Cisco Systems, Inc.		1,126		01/12/24		USD	49.00		USD	5,689		(173,967	)
Citigroup, Inc.		733		01/12/24		USD	48.00		USD	3,771		(267,545	)
Comcast Corp., Class A		1,264		01/12/24		USD	43.00		USD	5,543		(139,040	)
Constellation Brands, Inc., Class A		143		01/12/24		USD	240.00		USD	3,457		(95,095	)
CVS Health Corp.		150		01/12/24		USD	76.00		USD	1,184		(51,000	)
Dollar General Corp.		374		01/12/24		USD	139.00		USD	5,085		(68,255	)
Eli Lilly & Co.		39		01/12/24		USD	615.00		USD	2,273		(9,867	)
Fox Corp., Class A		414		01/12/24		USD	30.00		USD	1,228		(16,560	)
Humana, Inc.		43		01/12/24		USD	495.00		USD	1,969		(3,010	)
Intel Corp.		224		01/12/24		USD	44.00		USD	1,126		(141,120	)
JPMorgan Chase & Co.		240		01/12/24		USD	157.50		USD	4,082		(309,000	)
Microsoft Corp.		9		01/12/24		USD	375.00		USD	338		(5,603	)
Novo Nordisk A/S, ADR		177		01/12/24		USD	100.00		USD	1,831		(78,765	)
PG&E Corp.		1,076		01/12/24		USD	17.50		USD	1,940		(78,548	)
Ross Stores, Inc.		135		01/12/24		USD	131.00		USD	1,868		(102,600	)
Ross Stores, Inc.		67		01/12/24		USD	135.00		USD	927		(28,810	)
RTX Corp.		764		01/12/24		USD	83.00		USD	6,428		(149,362	)
Suncor Energy, Inc.		772		01/12/24		USD	35.00		USD	2,473		(3,860	)
Union Pacific Corp.		26		01/12/24		USD	235.00		USD	639		(30,030	)
Union Pacific Corp.		52		01/12/24		USD	240.00		USD	1,277		(37,960	)
Verizon Communications, Inc.		509		01/12/24		USD	39.00		USD	1,919		(4,327	)
Visa, Inc., Class A		89		01/12/24		USD	260.00		USD	2,317		(29,593	)
Allegion PLC		365		01/19/24		USD	110.00		USD	4,624		(622,325	)

S C H E D U L E  O F  I N V E S T M E N T S 57

Consolidated Schedule of Investments (continued) December 31, 2023 BlackRock Enhanced Equity Dividend Trust (BDJ)

Exchange-Traded Options Written (continued)

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
American Electric Power Co., Inc.		442		01/19/24		USD	80.00		USD	3,590	$	(100,555	)
American International Group, Inc.		775		01/19/24		USD	66.00		USD	5,251		(179,107	)
American Tower Corp.		121		01/19/24		USD	220.00		USD	2,612		(33,880	)
AT&T, Inc.		1,290		01/19/24		USD	16.00		USD	2,165		(110,295	)
Bank of America Corp.		741		01/19/24		USD	28.00		USD	2,495		(429,780	)
Bank of America Corp.		112		01/19/24		USD	31.00		USD	377		(32,424	)
Cardinal Health, Inc.		436		01/19/24		USD	105.00		USD	4,395		(19,620	)
Carlyle Group, Inc.		1,068		01/19/24		USD	31.10		USD	4,346		(1,051,982	)
Chevron Corp.		83		01/19/24		USD	145.00		USD	1,238		(48,555	)
Citigroup, Inc.		1,062		01/19/24		USD	42.50		USD	5,463		(969,075	)
Citizens Financial Group, Inc.		1,004		01/19/24		USD	30.00		USD	3,327		(331,320	)
Cognizant Technology Solutions Corp., Class A		959		01/19/24		USD	70.00		USD	7,243		(565,810	)
Comcast Corp., Class A		611		01/19/24		USD	45.00		USD	2,679		(20,163	)
Constellation Brands, Inc., Class A		91		01/19/24		USD	250.00		USD	2,200		(26,163	)
Crown Castle, Inc.		133		01/19/24		USD	120.00		USD	1,532		(9,643	)
Dollar General Corp.		375		01/19/24		USD	135.00		USD	5,098		(155,625	)
Elevance Health, Inc.		109		01/19/24		USD	480.00		USD	5,140		(61,040	)
Eli Lilly & Co.		29		01/19/24		USD	640.00		USD	1,690		(3,886	)
Enterprise Products Partners LP		1,269		01/19/24		USD	27.51		USD	3,344		(2,661	)
Exelon Corp.		556		01/19/24		USD	41.00		USD	1,996		(2,780	)
Fidelity National Information Services, Inc.		855		01/19/24		USD	57.50		USD	5,136		(273,600	)
First American Financial Corp.		81		01/19/24		USD	58.01		USD	522		(55,166	)
First Citizens BancShares, Inc., Class A		39		01/19/24		USD	1,520.00		USD	5,534		(25,545	)
First Citizens BancShares, Inc., Class A		90		01/19/24		USD	1,480.00		USD	12,771		(118,350	)
Fortrea Holdings, Inc.		567		01/19/24		USD	35.00		USD	1,979		(102,060	)
Fox Corp., Class A		413		01/19/24		USD	30.00		USD	1,225		(20,650	)
General Motors Co.		1,815		01/19/24		USD	30.00		USD	6,519		(1,102,612	)
Goldman Sachs Group, Inc.		118		01/19/24		USD	340.00		USD	4,552		(563,155	)
Intercontinental Exchange, Inc.		132		01/19/24		USD	115.00		USD	1,695		(182,820	)
Intercontinental Exchange, Inc.		335		01/19/24		USD	120.00		USD	4,302		(288,100	)
JPMorgan Chase & Co.		29		01/19/24		USD	155.00		USD	493		(44,443	)
Kraft Heinz Co.		2,294		01/19/24		USD	35.00		USD	8,483		(495,504	)
L3Harris Technologies, Inc.		466		01/19/24		USD	190.00		USD	9,815		(1,001,900	)
Laboratory Corp. of America Holdings		556		01/19/24		USD	213.22		USD	12,637		(841,494	)
Lear Corp.		174		01/19/24		USD	140.00		USD	2,457		(72,210	)
Leidos Holdings, Inc.		958		01/19/24		USD	105.00		USD	10,369		(373,620	)
Micron Technology, Inc.		410		01/19/24		USD	80.00		USD	3,499		(249,075	)
Microsoft Corp.		182		01/19/24		USD	375.00		USD	6,844		(138,320	)
Newell Brands, Inc.		777		01/19/24		USD	8.00		USD	674		(66,045	)
Novo Nordisk A/S, ADR		84		01/19/24		USD	104.00		USD	869		(21,000	)
PG&E Corp.		1,563		01/19/24		USD	17.00		USD	2,818		(195,375	)
Raymond James Financial, Inc.		318		01/19/24		USD	110.00		USD	3,546		(101,760	)
Robert Half, Inc.		181		01/19/24		USD	77.41		USD	1,591		(195,750	)
Ross Stores, Inc.		202		01/19/24		USD	135.00		USD	2,795		(94,940	)
Sealed Air Corp.		593		01/19/24		USD	35.00		USD	2,166		(124,530	)
Sempra		584		01/19/24		USD	75.00		USD	4,364		(64,240	)
SS&C Technologies Holdings, Inc.		1,562		01/19/24		USD	56.13		USD	9,545		(818,799	)
Taiwan Semiconductor Manufacturing Co. Ltd.		122		01/19/24		USD	105.00		USD	1,269		(33,367	)
Unilever PLC, ADR		1,854		01/19/24		USD	50.00		USD	8,988		(23,175	)
Union Pacific Corp.		102		01/19/24		USD	220.00		USD	2,505		(267,750	)
Union Pacific Corp.		26		01/19/24		USD	235.00		USD	639		(31,850	)
Verizon Communications, Inc.		1,731		01/19/24		USD	36.00		USD	6,526		(307,252	)
Visa, Inc., Class A		335		01/19/24		USD	255.00		USD	8,722		(261,300	)
Wells Fargo & Co.		2,281		01/19/24		USD	42.50		USD	11,227		(1,585,295	)
Willis Towers Watson PLC		182		01/19/24		USD	250.00		USD	4,390		(17,745	)
Cencora, Inc.		129		01/25/24		USD	204.00		USD	2,649		(59,040	)
American International Group, Inc.		732		01/26/24		USD	66.00		USD	4,959		(192,150	)
American International Group, Inc.		459		01/26/24		USD	68.00		USD	3,110		(60,817	)
AT&T, Inc.		1,307		01/26/24		USD	17.00		USD	2,193		(41,824	)
Baxter International, Inc.		678		01/26/24		USD	39.00		USD	2,621		(62,715	)
Cardinal Health, Inc.		502		01/26/24		USD	108.00		USD	5,060		(11,295	)
Chevron Corp.		83		01/26/24		USD	145.00		USD	1,238		(53,328	)

58 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Consolidated Schedule of Investments (continued) December 31, 2023 BlackRock Enhanced Equity Dividend Trust (BDJ)

Exchange-Traded Options Written (continued)

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
Cigna Group		89		01/26/24		USD	310.00		USD	2,665	$	(32,040	)
Cisco Systems, Inc.		1,076		01/26/24		USD	51.00		USD	5,436		(51,648	)
Citigroup, Inc.		897		01/26/24		USD	45.75		USD	4,614		(532,578	)
Comcast Corp., Class A		637		01/26/24		USD	44.00		USD	2,793		(75,484	)
Eli Lilly & Co.		31		01/26/24		USD	595.00		USD	1,807		(36,580	)
Enterprise Products Partners LP		1,268		01/26/24		USD	26.27		USD	3,341		(63,955	)
Fortive Corp.		56		01/26/24		USD	68.25		USD	412		(33,382	)
Fox Corp., Class A		1,264		01/26/24		USD	31.00		USD	3,750		(31,600	)
Intel Corp.		225		01/26/24		USD	49.00		USD	1,131		(67,837	)
JPMorgan Chase & Co.		240		01/26/24		USD	165.00		USD	4,082		(157,800	)
Medtronic PLC		284		01/26/24		USD	85.00		USD	2,340		(16,330	)
Medtronic PLC		99		01/26/24		USD	83.34		USD	816		(11,633	)
Micron Technology, Inc.		548		01/26/24		USD	87.00		USD	4,677		(104,942	)
Microsoft Corp.		16		01/26/24		USD	385.00		USD	602		(10,760	)
PG&E Corp.		755		01/26/24		USD	17.50		USD	1,361		(64,930	)
Suncor Energy, Inc.		634		01/26/24		USD	32.00		USD	2,031		(63,400	)
Visa, Inc., Class A		92		01/26/24		USD	260.00		USD	2,395		(54,280	)
Walt Disney Co.		104		01/26/24		USD	96.00		USD	939		(6,136	)
Newell Brands, Inc.		1,107		01/31/24		USD	9.50		USD	961		(25,995	)
Comcast Corp., Class A		1,249		02/02/24		USD	46.05		USD	5,477		(56,063	)
Intel Corp.		225		02/02/24		USD	51.00		USD	1,131		(52,313	)
Kraft Heinz Co.		1,822		02/02/24		USD	37.00		USD	6,738		(152,137	)
Medtronic PLC		522		02/02/24		USD	83.05		USD	4,300		(85,638	)
Micron Technology, Inc.		547		02/02/24		USD	87.00		USD	4,668		(130,459	)
PG&E Corp.		805		02/02/24		USD	18.00		USD	1,451		(45,885	)
Visa, Inc., Class A		13		02/02/24		USD	260.68		USD	338		(8,345	)
Newell Brands, Inc.		1,106		02/07/24		USD	9.75		USD	960		(25,147	)
Comcast Corp., Class A		374		02/09/24		USD	44.00		USD	1,640		(54,230	)
Medtronic PLC		317		02/09/24		USD	83.34		USD	2,611		(54,376	)
Micron Technology, Inc.		274		02/09/24		USD	87.00		USD	2,338		(76,035	)
American Electric Power Co., Inc.		793		02/16/24		USD	82.50		USD	6,441		(136,792	)
American International Group, Inc.		1,169		02/16/24		USD	67.50		USD	7,920		(289,327	)
Bank of America Corp.		878		02/16/24		USD	34.00		USD	2,956		(100,092	)
Baxter International, Inc.		1,186		02/16/24		USD	40.00		USD	4,585		(148,250	)
British American Tobacco PLC, ADR		1,031		02/16/24		USD	29.44		USD	3,020		(91,141	)
Carlyle Group, Inc.		1,210		02/16/24		USD	35.50		USD	4,923		(830,445	)
Cencora, Inc.		39		02/16/24		USD	204.00		USD	801		(26,005	)
Citigroup, Inc.		518		02/16/24		USD	48.00		USD	2,665		(213,675	)
Cognizant Technology Solutions Corp., Class A		595		02/16/24		USD	77.50		USD	4,494		(116,025	)
CVS Health Corp.		195		02/16/24		USD	75.00		USD	1,540		(100,912	)
Dollar General Corp.		260		02/16/24		USD	130.00		USD	3,535		(256,100	)
Enterprise Products Partners LP		1,887		02/16/24		USD	26.14		USD	4,972		(86,525	)
Exelon Corp.		300		02/16/24		USD	40.50		USD	1,077		(3,070	)
Exelon Corp.		558		02/16/24		USD	37.00		USD	2,003		(39,060	)
Fidelity National Financial, Inc., Class A		1,777		02/16/24		USD	47.79		USD	9,066		(716,053	)
Fidelity National Information Services, Inc.		1,446		02/16/24		USD	62.50		USD	8,686		(278,355	)
First American Financial Corp.		82		02/16/24		USD	65.00		USD	528		(19,065	)
Fortive Corp.		355		02/16/24		USD	69.93		USD	2,614		(183,780	)
Fortrea Holdings, Inc.		569		02/16/24		USD	32.50		USD	1,986		(207,685	)
General Motors Co.		605		02/16/24		USD	34.00		USD	2,173		(178,475	)
Humana, Inc.		63		02/16/24		USD	505.00		USD	2,884		(27,405	)
International Flavors & Fragrances, Inc.		702		02/16/24		USD	82.50		USD	5,684		(221,130	)
L3Harris Technologies, Inc.		526		02/16/24		USD	200.00		USD	11,079		(762,700	)
Laboratory Corp. of America Holdings		190		02/16/24		USD	220.00		USD	4,319		(228,950	)
Leidos Holdings, Inc.		1,031		02/16/24		USD	110.00		USD	11,160		(306,722	)
Medtronic PLC		317		02/16/24		USD	85.00		USD	2,611		(36,138	)
Microsoft Corp.		107		02/16/24		USD	400.00		USD	4,024		(58,048	)
Ralph Lauren Corp., Class A		99		02/16/24		USD	150.00		USD	1,428		(40,095	)
Raymond James Financial, Inc.		487		02/16/24		USD	110.00		USD	5,430		(248,370	)
Robert Half, Inc.		181		02/16/24		USD	84.25		USD	1,591		(111,588	)
Rogers Communications, Inc., Class B		459		02/16/24		CAD	64.00		CAD	2,847		(37,931	)
Sempra		586		02/16/24		USD	76.48		USD	4,379		(80,387	)

S C H E D U L E  O F  I N V E S T M E N T S 59

Consolidated Schedule of Investments (continued) December 31, 2023 BlackRock Enhanced Equity Dividend Trust (BDJ)

Exchange-Traded Options Written (continued)

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
SS&C Technologies Holdings, Inc.		1,655		02/16/24		USD	58.00		USD	10,114	$	(702,874	)
Suncor Energy, Inc.		648		02/16/24		USD	34.00		USD	2,076		(42,120	)
Unilever PLC, ADR		1,505		02/16/24		USD	50.00		USD	7,296		(90,300	)
Wells Fargo & Co.		2,114		02/16/24		USD	45.00		USD	10,405		(1,009,435	)
Ralph Lauren Corp., Class A		187		02/26/24		USD	136.00		USD	2,697		(235,492	)
Equitable Holdings, Inc.		626		02/28/24		USD	32.90		USD	2,085		(111,455	)
British American Tobacco PLC, ADR		1,032		03/15/24		USD	30.00		USD	3,023		(87,720	)
Citigroup, Inc.		673		03/15/24		USD	52.50		USD	3,462		(126,860	)
Enterprise Products Partners LP		1,115		03/15/24		USD	27.00		USD	2,938		(30,105	)
Fidelity National Financial, Inc., Class A		953		03/15/24		USD	47.31		USD	4,862		(563,523	)
General Motors Co.		1,654		03/15/24		USD	36.00		USD	5,941		(337,416	)
Medtronic PLC		522		03/15/24		USD	85.00		USD	4,300		(105,966	)
Micron Technology, Inc.		274		03/15/24		USD	87.50		USD	2,338		(112,340	)
Rogers Communications, Inc., Class B		380		03/15/24		CAD	64.00		CAD	2,357		(43,304	)
											$	(31,429,198	)

OTC Options Written

Description	Counterparty	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call
Verizon Communications, Inc.	Citibank N.A.		66,500		01/03/24		USD	37.53		USD	2,507	$	(25,826	)
Citizens Financial Group, Inc.	Citibank N.A.		33,200		01/04/24		USD	28.31		USD	1,100		(161,538	)
Prudential PLC	Bank of America N.A.		96,800		01/09/24		GBP	9.14		GBP	857		(8,277	)
Bayer AG, Registered Shares	Morgan Stanley & Co. International PLC		135,700		01/10/24		EUR	42.74		EUR	4,561		(84	)
Citizens Financial Group, Inc.	Citibank N.A.		33,700		01/10/24		USD	29.03		USD	1,117		(140,281	)
Koninklijke Philips NV	Morgan Stanley & Co. International PLC		130,500		01/10/24		EUR	19.04		EUR	2,766		(300,018	)
Panasonic Holdings Corp.	BNP Paribas SA		217,100		01/10/24		JPY	1,479.86		JPY	301,445		(15,583	)
Verizon Communications, Inc.	Citibank N.A.		66,600		01/10/24		USD	37.53		USD	2,511		(16,532	)
BP PLC	UBS AG		2,182,700		01/11/24		GBP	4.92		GBP	10,151		(22,424	)
Henkel AG & Co. KGaA, Preference Shares	Morgan Stanley & Co. International PLC		13,900		01/11/24		EUR	72.36		EUR	1,013		(15,743	)
Komatsu Ltd.	Societe Generale		18,400		01/11/24		JPY	3,785.05		JPY	67,515		(4,089	)
Komatsu Ltd.	UBS AG		42,300		01/11/24		JPY	3,861.20		JPY	155,211		(5,987	)
NextEra Energy, Inc.	Barclays Bank PLC		22,100		01/11/24		USD	57.37		USD	1,342		(82,938	)
Komatsu Ltd.	UBS AG		60,700		01/17/24		JPY	3,880.13		JPY	222,726		(11,837	)
Shell PLC	Goldman Sachs International		276,700		01/17/24		GBP	26.49		GBP	7,106		(49,681	)
Henkel AG & Co. KGaA, Preference Shares	Morgan Stanley & Co. International PLC		13,900		01/18/24		EUR	72.35		EUR	1,013		(18,704	)
Sanofi SA	Morgan Stanley & Co. International PLC		99,900		01/18/24		EUR	87.55		EUR	8,993		(316,286	)
Sony Group Corp.	Bank of America N.A.		24,300		01/18/24		JPY	13,535.12		JPY	324,241		(46,206	)
Public Service Enterprise Group, Inc.	JPMorgan Chase Bank N.A.		5,900		01/22/24		USD	64.49		USD	361		(1,086	)
AstraZeneca PLC	Goldman Sachs International		52,300		01/23/24		GBP	103.39		GBP	5,535		(269,602	)
Koninklijke Philips NV	Goldman Sachs International		217,800		01/23/24		EUR	19.22		EUR	4,617		(484,300	)
Panasonic Holdings Corp.	Bank of America N.A.		261,500		01/23/24		JPY	1,596.90		JPY	363,095		(11,921	)
Sanofi SA	Morgan Stanley & Co. International PLC		57,900		01/23/24		EUR	89.72		EUR	5,212		(107,975	)
Siemens AG, Registered Shares	UBS AG		19,900		01/23/24		EUR	163.50		EUR	3,382		(177,910	)
Shell PLC	Goldman Sachs International		356,700		01/24/24		GBP	25.83		GBP	9,160		(221,123	)
Prudential PLC	Goldman Sachs International		96,800		01/25/24		GBP	9.12		GBP	857		(20,415	)
UBS Group AG, Registered Shares	Goldman Sachs International		87,800		01/26/24		CHF	25.58		CHF	2,294		(99,424	)
BP PLC	Morgan Stanley & Co. International PLC		732,200		01/30/24		GBP	4.87		GBP	3,405		(47,757	)
Equitable Holdings, Inc.	Bank of America N.A.		62,400		01/30/24		USD	30.15		USD	2,078		(215,838	)
Prudential PLC	Morgan Stanley & Co. International PLC		222,200		01/30/24		GBP	9.04		GBP	1,967		(64,732	)
Shell PLC	Morgan Stanley & Co. International PLC		90,800		01/30/24		GBP	26.54		GBP	2,332		(31,982	)
Sony Group Corp.	Bank of America N.A.		44,200		01/30/24		JPY	13,438.59		JPY	589,771		(123,148	)
Cencora, Inc.	Citibank N.A.		7,400		01/31/24		USD	201.54		USD	1,520		(51,186	)
Public Service Enterprise Group, Inc.	JPMorgan Chase Bank N.A.		57,700		01/31/24		USD	63.86		USD	3,528		(21,632	)
Willis Towers Watson PLC	Morgan Stanley & Co. International PLC		47,000		01/31/24		USD	243.57		USD	11,336		(301,828	)
Bayer AG, Registered Shares	Goldman Sachs International		75,900		02/01/24		EUR	33.49		EUR	2,551		(101,774	)
Koninklijke Philips NV	Goldman Sachs International		108,500		02/01/24		EUR	18.88		EUR	2,300		(288,155	)
Panasonic Holdings Corp.	BNP Paribas SA		116,200		02/01/24		JPY	1,496.41		JPY	161,345		(16,747	)
Panasonic Holdings Corp.	Societe Generale		53,800		02/01/24		JPY	1,432.55		JPY	74,702		(14,370	)
NextEra Energy, Inc.	Barclays Bank PLC		22,100		02/02/24		USD	57.94		USD	1,342		(90,525	)

60 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Consolidated Schedule of Investments (continued) December 31, 2023 BlackRock Enhanced Equity Dividend Trust (BDJ)

OTC Options Written (continued)

Description	Counterparty	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
Sealed Air Corp.	Goldman Sachs International		61,300		02/02/24		USD	34.98		USD	2,239	$	(161,831	)
Crown Castle, Inc.	JPMorgan Chase Bank N.A.		19,800		02/05/24		USD	117.74		USD	2,281		(52,882	)
BP PLC	Bank of America N.A.		296,000		02/08/24		GBP	4.68		GBP	1,377		(54,621	)
Sealed Air Corp.	Citibank N.A.		92,500		02/13/24		USD	35.44		USD	3,378		(253,970	)
Sealed Air Corp.	UBS AG		62,200		02/20/24		USD	33.27		USD	2,272		(275,394	)
Crown Castle, Inc.	JPMorgan Chase Bank N.A.		11,600		02/26/24		USD	113.50		USD	1,336		(69,161	)
Citizens Financial Group, Inc.	Citibank N.A.		26,500		02/27/24		USD	33.33		USD	878		(45,383	)
UBS Group AG, Registered Shares	Goldman Sachs International		87,800		02/27/24		CHF	25.70		CHF	2,294		(139,724	)
												$	(5,058,430	)

Balances Reported in the Consolidated Statements of Assets and Liabilities for Options Written

Description	Swap Premiums Paid		Swap Premiums Received		Unrealized Appreciation		Unrealized Depreciation			Value
Options Written	$	N/A	$	N/A	$	3,457,080	$	(19,331,182	)	$	(36,487,628	)

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Consolidated Statements of Assets and Liabilities were as follows:

	Commodity Contracts		Credit Contracts		Equity Contracts		Foreign Currency Exchange Contracts		Interest Rate Contracts		Other Contracts		Total
Liabilities — Derivative Financial Instruments
Options written
Options written at value	$	—	$	—	$	36,487,628	$	—	$	—	$	—	$	36,487,628

For the period ended December 31, 2023, the effect of derivative financial instruments in the Consolidated Statements of Operations was as follows:

	Commodity Contracts		Credit Contracts		Equity Contracts			Foreign Currency Exchange Contracts		Interest Rate Contracts		Other Contracts		Total
Net Realized Gain (Loss) from:
Options purchased(a)	$	—	$	—	$	(8,293,785	)	$	—	$	—	$	—	$	(8,293,785	)
Options written		—		—		(6,887,226	)		—		—		—		(6,887,226	)
	$	—	$	—	$	(15,181,011	)	$	—	$	—	$	—	$	(15,181,011	)
Net Change in Unrealized Appreciation (Depreciation) on:
Options written	$	—	$	—	$	(23,815,466	)	$	—	$	—	$	—	$	(23,815,466	)

^(a)  Options purchased are included in net realized gain (loss) from investments — unaffiliated.

Average Quarterly Balances of Outstanding Derivative Financial Instruments

Options:
Average value of option contracts purchased	$	—	(a)
Average value of option contracts written	$	24,853,085

^(a)  Derivative financial instrument not held at any quarter-end. The risk exposure table serves as an indicator of activity during the period.

For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Consolidated Financial Statements.

S C H E D U L E  O F  I N V E S T M E N T S 61

Consolidated Schedule of Investments (continued) December 31, 2023 BlackRock Enhanced Equity Dividend Trust (BDJ)

Derivative Financial Instruments — Offsetting as of Period End

The Trust’s derivative assets and liabilities (by type) were as follows:

	Assets		Liabilities
Derivative Financial Instruments
Options	$	—	$	36,487,628
Total derivative assets and liabilities in the Consolidated Statements of Assets and Liabilities		—		36,487,628
Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”)		—		(31,429,198	)
Total derivative assets and liabilities subject to an MNA	$	—	$	5,058,430

The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the Trust:

Counterparty		Derivative Liabilities Subject to an MNA by  Counterparty		Derivatives Available for Offset		Non-Cash Collateral Pledged	(a)		Cash    Collateral Pledged		Net Amount of Derivative Liabilities	(b)
Bank of America N.A.	$	460,011	$	—	$	(460,011	)	$	—	$	—
Barclays Bank PLC		173,463		—		(170,839	)		—		2,624
BNP Paribas SA		32,330		—		(32,330	)		—		—
Citibank N.A.		694,716		—		(694,716	)		—		—
Goldman Sachs International		1,836,029		—		(1,836,029	)		—		—
JPMorgan Chase Bank N.A.		144,761		—		(144,761	)		—		—
Morgan Stanley & Co. International PLC		1,205,109		—		(1,205,109	)		—		—
Societe Generale		18,459		—		(18,459	)		—		—
UBS AG		493,552		—		(493,552	)		—		—
	$	5,058,430	$	—	$	(5,055,806	)	$	—	$	2,624

^(a)  Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes.

^(b)  Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Consolidated Statements of Assets and Liabilities.

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation of financial instruments, refer to the Notes to Consolidated Financial Statements.

The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s financial instruments into major categories is disclosed in the Consolidated Schedule of Investments above.

	Level 1			Level 2			Level 3			Total
Assets
Investments
Long-Term Investments
Common Stocks
Aerospace & Defense	$	60,661,812		$	—		$	—		$	60,661,812
Automobile Components		6,749,838			—			—			6,749,838
Automobiles		36,590,519			—			—			36,590,519
Banks		180,500,044			—			—			180,500,044
Beverages		14,398,667			—			—			14,398,667
Building Products		13,259,375			—			—			13,259,375
Capital Markets		57,197,100			9,917,335			—			67,114,435
Chemicals		10,325,294			—			—			10,325,294
Communications Equipment		31,957,436			—			—			31,957,436
Consumer Finance		8,806,853			—			—			8,806,853
Consumer Staples Distribution & Retail		32,284,862			—			—			32,284,862
Containers & Packaging		25,137,885			—			—			25,137,885
Diversified Telecommunication Services		38,692,336			—			—			38,692,336
Electric Utilities		46,121,835			—			—			46,121,835
Entertainment		1,717,316			—			—			1,717,316
Financial Services		67,174,030			—			15,830,106			83,004,136
Food Products		39,932,261			—			—			39,932,261

62 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Consolidated Schedule of Investments (continued) December 31, 2023 BlackRock Enhanced Equity Dividend Trust (BDJ)

Fair Value Hierarchy as of Period End (continued)

	Level 1				Level 2				Level 3			Total
Common Stocks (continued)
Ground Transportation	$	9,206,083			$	—			$	—		$	9,206,083
Health Care Equipment & Supplies		62,998,396				19,433,561				—			82,431,957
Health Care Providers & Services		131,873,300				—				—			131,873,300
Household Durables		6,489,810				28,609,303				—			35,099,113
Industrial Conglomerates		—				6,784,327				—			6,784,327
Insurance		103,523,187				6,505,990				—			110,029,177
IT Services		21,342,361				—				—			21,342,361
Leisure Products		5,241,820				—				—			5,241,820
Life Sciences Tools & Services		11,502,160				—				—			11,502,160
Machinery		15,422,311				5,743,351				—			21,165,662
Media		44,253,954				—				—			44,253,954
Multi-Utilities		22,988,497				—				—			22,988,497
Oil, Gas & Consumable Fuels		52,875,592				77,704,638				10,716,626			141,296,856
Personal Care Products		29,608,578				—				—			29,608,578
Pharmaceuticals		22,736,208				55,604,327				—			78,340,535
Professional Services		80,686,569				—				—			80,686,569
Semiconductors & Semiconductor Equipment		47,601,834				—				—			47,601,834
Software		21,511,744				—				—			21,511,744
Specialized REITs		14,143,958				—				—			14,143,958
Specialty Retail		12,209,458				—				—			12,209,458
Textiles, Apparel & Luxury Goods		9,287,282				—				—			9,287,282
Tobacco		22,940,690				—				—			22,940,690
Wireless Telecommunication Services		7,141,935				—				—			7,141,935
Preferred Securities
Preferred Stocks		—				8,572,705				—			8,572,705
Short-Term Securities
Money Market Funds		5,204,534				—				—			5,204,534
	$	1,432,297,724			$	218,875,537			$	26,546,732		$	1,677,719,993
Derivative Financial Instruments(a)
Liabilities
Equity Contracts	$	(23,585,749	)		$	(12,901,879	)		$	—		$	(36,487,628	)

^(a)  Derivative financial instruments are options written. Options written are shown at value.

A reconciliation of Level 3 financial instruments is presented when the Trust had a significant amount of Level 3 investments and derivative financial instruments at the beginning and/or end of the year in relation to net assets. The following table is a reconciliation of Level 3 investments for which significant unobservable inputs were used in determining fair value:

	Common Stocks
Assets
Opening balance, as of December 31, 2022	$	11,435,463
Transfers into Level 3		—
Transfers out of Level 3		—
Accrued discounts/premiums		—
Net realized gain (loss)		(106,982	)
Net change in unrealized appreciation (depreciation)(a)(b)		(813,619	)
Purchases		21,332,655
Sales		(5,300,785	)
Closing balance, as of December 31, 2023	$	26,546,732
Net change in unrealized appreciation (depreciation) on investments still held at December 31, 2023(b)	$	(813,619	)

^(a)  Included in the related net change in unrealized appreciation (depreciation) in the Consolidated Statements of Operations.

^(b)  Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized appreciation (depreciation) on investments still held at December 31, 2023 is generally due to investments no longer held or categorized as Level 3 at period end.

S C H E D U L E  O F  I N V E S T M E N T S 63

Consolidated Schedule of Investments (continued) December 31, 2023 BlackRock Enhanced Equity Dividend Trust (BDJ)

The following table summarizes the valuation approaches used and unobservable inputs utilized by the BlackRock Valuation Committee (the “Valuation Committee”) to determine the value of certain of the Trust’s Level 3 financial instruments as of period end.

		Value	Valuation Approach	Unobservable Inputs	Range of Unobservable Inputs Utilized	(a)	Weighted Average of Unobservable Inputs Based on Fair Value
Assets
Common Stocks	$	26,546,732	Income	Discount Rate	11%		—
			Market	EBITDA Multiple	7.71x		—
	$	26,546,732

^(a)  A significant change in unobservable input would have resulted in a correlated (inverse) significant change to value.

See notes to financial statements.

64 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Schedule of Investments  December 31, 2023   BlackRock Enhanced Global Dividend Trust (BOE) (Percentages shown are based on Net Assets)

Security	Shares		Value
Common Stocks
Canada — 2.0%
TELUS Corp.		820,022	$	14,592,747
Denmark — 2.2%
Novo Nordisk A/S, Class B		152,408		15,794,217
France — 9.6%
Air Liquide SA		89,151		17,357,292
EssilorLuxottica SA		93,763		18,827,490
LVMH Moet Hennessy Louis Vuitton SE		18,418		14,965,304
Sanofi SA		183,527		18,237,587
				69,387,673
India — 0.0%
AceVector Limited, Series I, (Acquired 08/31/18, Cost: $2,637,143)(a)(b)(c)		566,400		284,447
Indonesia — 1.1%
Bank Rakyat Indonesia Persero Tbk PT		22,422,100		8,333,569
Ireland — 4.1%
Allegion PLC		121,238		15,359,642
Medtronic PLC(d)		175,741		14,477,544
				29,837,186
Mexico — 2.1%
Wal-Mart de Mexico SAB de CV		3,624,607		15,276,669
Netherlands — 4.2%
Koninklijke KPN NV		4,200,135		14,470,004
Shell PLC		477,667		15,716,808
				30,186,812
Singapore — 1.4%
DBS Group Holdings Ltd.		405,168		10,246,220
Switzerland — 6.8%
Nestle SA, Registered Shares		190,916		22,130,956
TE Connectivity Ltd.		76,977		10,815,268
Zurich Insurance Group AG, Class N		31,721		16,584,591
				49,530,815
Taiwan — 5.0%
MediaTek, Inc.		477,000		15,750,493
Taiwan Semiconductor Manufacturing Co. Ltd.		1,076,000		20,628,575
				36,379,068
United Kingdom — 11.3%
AstraZeneca PLC		152,719		20,600,242
BAE Systems PLC		1,044,412		14,783,641
Prudential PLC		1,065,116		12,017,369
RELX PLC		487,507		19,315,727
Taylor Wimpey PLC, Series L		8,107,080		15,175,769
				81,892,748
United States — 51.2%
AbbVie, Inc.(e)		126,869		19,660,889
Accenture PLC, Class A		55,699		19,545,336
American Express Co.		58,216		10,906,197

Security	Shares		Value
United States (continued)
Apple, Inc.(d)(e)		128,400	$	24,720,852
Assurant, Inc.(d)		63,722		10,736,520
Baker Hughes Co., Class A(d)(e)		442,901		15,138,356
Carrier Global Corp.		236,117		13,564,922
Citizens Financial Group, Inc.(e)		429,755		14,242,081
Intercontinental Exchange, Inc.(d)		145,616		18,701,463
M&T Bank Corp.		80,031		10,970,649
Microsoft Corp.(d)		93,741		35,250,366
Mondelez International, Inc., Class A(d)		294,985		21,365,764
Oracle Corp.(e)		153,421		16,175,176
Otis Worldwide Corp.(e)		211,801		18,949,835
Paychex, Inc.(e)		148,004		17,628,756
Philip Morris International, Inc.(d)(e)		194,950		18,340,896
Republic Services, Inc.(e)		87,104		14,364,321
Synchrony Financial		225,639		8,617,153
Union Pacific Corp.		80,294		19,721,812
United Parcel Service, Inc., Class B(d)		96,388		15,155,085
UnitedHealth Group, Inc.(d)		34,608		18,220,074
Williams Cos., Inc.(d)		290,496		10,117,976
				372,094,479
Total Long-Term Investments — 101.0% (Cost: $605,816,932)			733,836,650
Short-Term Securities
Money Market Funds — 0.4%
BlackRock Liquidity Funds, T-Fund, Institutional Class, 5.26%(f)(g)		2,668,223		2,668,223
Total Short-Term Securities — 0.4% (Cost: $2,668,223)				2,668,223
Total Investments Before Options Written — 101.4% (Cost: $608,485,155)				736,504,873
Options Written — (1.5)% (Premiums Received: $(6,679,071))				(10,846,451	)
Total Investments, Net of Options Written — 99.9% (Cost: $601,806,084)				725,658,422
Other Assets Less Liabilities — 0.1%				830,765
Net Assets — 100.0%			$	726,489,187

^(a)  Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.

^(b)  Non-income producing security.

^(c) Restricted security as to resale, excluding 144A securities. The Trust held restricted securities with a current value of $284,447, representing less than 0.05% of its net assets as of period end, and an original cost of $2,637,143.

^(d)  All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

^(e) All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.

^(f)  Affiliate of the Trust.

^(g)  Annualized 7-day yield as of period end.

S C H E D U L E O F I N V E S T M E N T S 65

Schedule of Investments (continued) December 31, 2023   BlackRock Enhanced Global Dividend Trust (BOE)

Affiliates

Investments in issuers considered to be affiliate(s) of the Trust during the year ended December 31, 2023 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

Affiliated Issuer	Value at 12/31/22		Purchases at Cost		Proceeds from Sale			Net Realized Gain (Loss)		Change in Unrealized Appreciation (Depreciation)		Value at 12/31/23		Shares Held at 12/31/23		Income			Capital Gain Distributions from Underlying Funds
BlackRock Liquidity Funds, T-Fund, Institutional Class	$	6,643,752	$	—	$	(3,975,529	)(a)	$	—	$	—	$	2,668,223		2,668,223	$	436,584		$	—
SL Liquidity Series, LLC, Money Market Series(b)		—		—		(1,183	)(a)		1,183		—		—		—		2,641	(c)		—
								$	1,183	$	—	$	2,668,223			$	439,225		$	—

^(a)  Represents net amount purchased (sold).

^(b)  As of period end, the entity is no longer held.

^(c)  All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.

Derivative Financial Instruments Outstanding as of Period End

Exchange-Traded Options Written

Description	Number of Contracts		Expiration Date		Exercise Price			Notional  Amount (000)			Value
Call
American Express Co.		134		01/05/24		USD	167.50		USD	2,510	$	(266,995	)
Microsoft Corp.		209		01/05/24		USD	370.00		USD	7,859		(159,885	)
Mondelez International, Inc., Class A		468		01/05/24		USD	72.00		USD	3,390		(37,440	)
UnitedHealth Group, Inc.		47		01/05/24		USD	550.00		USD	2,474		(329	)
Williams Cos., Inc.		280		01/05/24		USD	37.00		USD	975		(1,400	)
AbbVie, Inc.		364		01/12/24		USD	146.00		USD	5,641		(346,710	)
American Express Co.		181		01/12/24		USD	172.50		USD	3,391		(270,595	)
Apple, Inc.		260		01/12/24		USD	200.00		USD	5,006		(9,490	)
M&T Bank Corp.		196		01/12/24		USD	126.50		USD	2,687		(220,808	)
Mondelez International, Inc., Class A		368		01/12/24		USD	72.00		USD	2,665		(43,240	)
Philip Morris International, Inc.		292		01/12/24		USD	94.00		USD	2,747		(35,770	)
Union Pacific Corp.		100		01/12/24		USD	235.00		USD	2,456		(115,500	)
Union Pacific Corp.		160		01/12/24		USD	240.00		USD	3,930		(116,800	)
United Parcel Service, Inc., Class B		167		01/12/24		USD	160.00		USD	2,626		(22,545	)
AbbVie, Inc.		112		01/19/24		USD	145.00		USD	1,736		(119,000	)
Accenture PLC, Class A		147		01/19/24		USD	347.50		USD	5,158		(107,310	)
Allegion PLC		272		01/19/24		USD	125.00		USD	3,446		(94,520	)
Apple, Inc.		129		01/19/24		USD	190.00		USD	2,484		(63,210	)
Assurant, Inc.		168		01/19/24		USD	163.50		USD	2,831		(117,263	)
Baker Hughes Co., Class A		336		01/19/24		USD	36.00		USD	1,148		(7,560	)
Carrier Global Corp.		176		01/19/24		USD	57.50		USD	1,011		(24,640	)
Carrier Global Corp.		355		01/19/24		USD	60.00		USD	2,039		(17,750	)
Citizens Financial Group, Inc.		781		01/19/24		USD	30.00		USD	2,588		(257,730	)
Intercontinental Exchange, Inc.		690		01/19/24		USD	115.00		USD	8,862		(955,650	)
Intercontinental Exchange, Inc.		33		01/19/24		USD	120.00		USD	424		(28,380	)
Microsoft Corp.		123		01/19/24		USD	375.00		USD	4,625		(93,480	)
Mondelez International, Inc., Class A		468		01/19/24		USD	72.50		USD	3,390		(50,310	)
Otis Worldwide Corp.		311		01/19/24		USD	83.25		USD	2,783		(214,595	)
Paychex, Inc.		282		01/19/24		USD	120.00		USD	3,359		(41,595	)
Republic Services, Inc.		37		01/19/24		USD	160.00		USD	610		(21,645	)
Republic Services, Inc.		270		01/19/24		USD	165.00		USD	4,453		(62,100	)
Synchrony Financial		499		01/19/24		USD	31.00		USD	1,906		(366,765	)
TE Connectivity Ltd.		186		01/19/24		USD	135.00		USD	2,613		(120,900	)
Union Pacific Corp.		100		01/19/24		USD	235.00		USD	2,456		(122,500	)
UnitedHealth Group, Inc.		47		01/19/24		USD	550.00		USD	2,474		(13,372	)
Williams Cos., Inc.		280		01/19/24		USD	37.00		USD	975		(2,800	)
Baker Hughes Co., Class A		224		01/25/24		USD	32.30		USD	766		(51,788	)
AbbVie, Inc.		94		01/26/24		USD	152.50		USD	1,457		(37,130	)
Accenture PLC, Class A		103		01/26/24		USD	345.00		USD	3,614		(107,120	)
Apple, Inc.		129		01/26/24		USD	200.00		USD	2,484		(13,674	)

66 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Schedule of Investments (continued) December 31, 2023   BlackRock Enhanced Global Dividend Trust (BOE)

Exchange-Traded Options Written  (continued)

Description	Number of Contracts		Expiration Date		Exercise Price			Notional  Amount (000)			Value
Call (continued)
Medtronic PLC		48		01/26/24		USD	85.00		USD	395	$	(2,760	)
Medtronic PLC		69		01/26/24		USD	83.34		USD	568		(8,108	)
Microsoft Corp.		110		01/26/24		USD	385.00		USD	4,136		(73,975	)
Mondelez International, Inc., Class A		23		01/26/24		USD	71.00		USD	167		(5,520	)
Oracle Corp.		345		01/26/24		USD	104.00		USD	3,637		(111,262	)
Philip Morris International, Inc.		315		01/26/24		USD	97.00		USD	2,964		(17,325	)
United Parcel Service, Inc., Class B		170		01/26/24		USD	165.00		USD	2,673		(15,555	)
Williams Cos., Inc.		456		01/26/24		USD	36.00		USD	1,588		(13,680	)
Medtronic PLC		83		02/02/24		USD	83.05		USD	684		(13,617	)
Medtronic PLC		221		02/09/24		USD	83.34		USD	1,821		(37,909	)
Oracle Corp.		345		02/09/24		USD	110.00		USD	3,637		(45,712	)
Baker Hughes Co., Class A		165		02/12/24		USD	34.75		USD	564		(18,087	)
Allegion PLC		272		02/16/24		USD	125.00		USD	3,446		(148,240	)
Apple, Inc.		59		02/16/24		USD	195.00		USD	1,136		(30,533	)
Assurant, Inc.		120		02/16/24		USD	164.90		USD	2,022		(105,099	)
Carrier Global Corp.		531		02/16/24		USD	60.00		USD	3,051		(79,650	)
Citizens Financial Group, Inc.		782		02/16/24		USD	30.99		USD	2,592		(227,698	)
M&T Bank Corp.		164		02/16/24		USD	145.00		USD	2,248		(54,940	)
Medtronic PLC		221		02/16/24		USD	85.00		USD	1,821		(25,194	)
Microsoft Corp.		73		02/16/24		USD	400.00		USD	2,745		(39,603	)
Otis Worldwide Corp.		105		02/16/24		USD	85.10		USD	939		(61,323	)
Paychex, Inc.		384		02/16/24		USD	130.00		USD	4,574		(8,640	)
Philip Morris International, Inc.		270		02/16/24		USD	95.00		USD	2,540		(61,425	)
Republic Services, Inc.		84		02/16/24		USD	164.96		USD	1,385		(37,278	)
Synchrony Financial		516		02/16/24		USD	35.60		USD	1,971		(177,661	)
TE Connectivity Ltd.		160		02/16/24		USD	140.00		USD	2,248		(79,200	)
TELUS Corp.		1,534		02/16/24		CAD	26.00		CAD	3,617		(6,946	)
Baker Hughes Co., Class A		224		02/22/24		USD	32.30		USD	766		(61,073	)
Baker Hughes Co., Class A		376		02/26/24		USD	36.10		USD	1,285		(30,762	)
Baker Hughes Co., Class A		224		03/07/24		USD	32.30		USD	766		(65,494	)
Medtronic PLC		148		03/15/24		USD	85.00		USD	1,219		(30,044	)
Otis Worldwide Corp.		269		03/15/24		USD	90.00		USD	2,407		(83,390	)
TELUS Corp.		602		03/15/24		CAD	26.00		CAD	1,420		(3,180	)
TELUS Corp.		602		04/19/24		CAD	26.00		CAD	1,420		(5,906	)
											$	(6,547,083	)

OTC Options Written

Description	Counterparty	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call
Citizens Financial Group, Inc.	Citibank N.A.		25,800		01/04/24		USD	28.31		USD	855	$	(125,532	)
Otis Worldwide Corp.	UBS AG		30,300		01/04/24		USD	85.49		USD	2,711		(126,155	)
Taiwan Semiconductor Manufacturing Co. Ltd.	JPMorgan Chase Bank N.A.		90,000		01/04/24		TWD	576.08		TWD	52,955		(51,441	)
MediaTek, Inc.	Morgan Stanley & Co. International PLC		119,700		01/09/24		TWD	936.85		TWD	121,304		(210,705	)
Novo Nordisk A/S, Class B	Morgan Stanley & Co. International PLC		7,500		01/09/24		DKK	703.28		DKK	5,248		(12,207	)
Prudential PLC	Bank of America N.A.		152,100		01/09/24		GBP	9.14		GBP	1,346		(13,005	)
Air Liquide SA	Morgan Stanley & Co. International PLC		40,100		01/10/24		EUR	168.61		EUR	7,072		(357,536	)
AstraZeneca PLC	Morgan Stanley & Co. International PLC		23,100		01/10/24		GBP	107.35		GBP	2,445		(27,724	)
Citizens Financial Group, Inc.	Citibank N.A.		26,200		01/10/24		USD	29.03		USD	868		(109,061	)
DBS Group Holdings Ltd.	UBS AG		110,800		01/10/24		SGD	33.42		SGD	3,698		(31,255	)
LVMH Moet Hennessy Louis Vuitton SE	Morgan Stanley & Co. International PLC		8,200		01/10/24		EUR	731.07		EUR	6,035		(131,271	)
Taiwan Semiconductor Manufacturing Co. Ltd.	JPMorgan Chase Bank N.A.		114,000		01/10/24		TWD	568.14		TWD	67,076		(95,802	)
Taylor Wimpey PLC	UBS AG		535,500		01/10/24		GBP	1.21		GBP	786		(178,507	)
Nestle SA, Registered Shares	UBS AG		26,700		01/11/24		CHF	100.25		CHF	2,603		(3,767	)
EssilorLuxottica SA	Goldman Sachs International		12,500		01/12/24		EUR	177.75		EUR	2,274		(71,555	)
Koninklijke KPN NV	Morgan Stanley & Co. International PLC		533,000		01/12/24		EUR	3.17		EUR	1,663		(11,186	)
RELX PLC	Goldman Sachs International		44,900		01/12/24		EUR	35.81		EUR	1,611		(23,135	)
DBS Group Holdings Ltd.	JPMorgan Chase Bank N.A.		71,500		01/17/24		SGD	32.18		SGD	2,386		(75,090	)
MediaTek, Inc.	JPMorgan Chase Bank N.A.		77,000		01/17/24		TWD	927.62		TWD	78,032		(159,859	)
Wal-Mart de Mexico SAB de CV	Citibank N.A.		415,700		01/17/24		MXN	68.08		MXN	29,752		(100,851	)

S C H E D U L E  O F  I N V E S T M E N T S 67

Schedule of Investments (continued) December 31, 2023   BlackRock Enhanced Global Dividend Trust (BOE)

OTC Options Written (continued)

Description	Counterparty	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
Koninklijke KPN NV	UBS AG		394,550		01/18/24		EUR	3.19		EUR	1,231	$	(10,676	)
Novo Nordisk A/S, Class B	Morgan Stanley & Co. International PLC		7,500		01/18/24		DKK	703.28		DKK	5,248		(17,509	)
RELX PLC	Goldman Sachs International		33,750		01/18/24		EUR	34.28		EUR	1,211		(65,178	)
Sanofi SA	Morgan Stanley & Co. International PLC		29,000		01/18/24		EUR	87.55		EUR	2,610		(91,815	)
Taiwan Semiconductor Manufacturing Co. Ltd.	Goldman Sachs International		82,000		01/18/24		TWD	594.66		TWD	48,247		(21,691	)
Taylor Wimpey PLC	UBS AG		535,500		01/18/24		GBP	1.23		GBP	786		(169,149	)
Zurich Insurance Group AG, Class N	Morgan Stanley & Co. International PLC		6,700		01/18/24		CHF	432.35		CHF	2,946		(79,358	)
AstraZeneca PLC	Goldman Sachs International		60,200		01/23/24		GBP	103.39		GBP	6,371		(310,326	)
BAE Systems PLC	UBS AG		121,700		01/23/24		GBP	10.62		GBP	1,351		(85,851	)
Novo Nordisk A/S, Class B	Goldman Sachs International		6,600		01/23/24		DKK	711.62		DKK	4,619		(14,469	)
Prudential PLC	UBS AG		83,200		01/23/24		GBP	8.74		GBP	736		(36,433	)
RELX PLC	Goldman Sachs International		44,900		01/23/24		EUR	35.81		EUR	1,611		(31,977	)
Sanofi SA	Morgan Stanley & Co. International PLC		35,100		01/23/24		EUR	89.72		EUR	3,160		(65,456	)
Taylor Wimpey PLC	Bank of America N.A.		881,700		01/23/24		GBP	1.40		GBP	1,295		(99,922	)
Wal-Mart de Mexico SAB de CV	JPMorgan Chase Bank N.A.		799,700		01/23/24		MXN	68.95		MXN	57,235		(174,601	)
Koninklijke KPN NV	Goldman Sachs International		532,600		01/24/24		EUR	3.17		EUR	1,662		(18,250	)
Koninklijke KPN NV	Goldman Sachs International		394,550		01/24/24		EUR	3.18		EUR	1,231		(13,311	)
Prudential PLC	Goldman Sachs International		83,300		01/25/24		GBP	9.12		GBP	737		(17,568	)
Nestle SA, Registered Shares	Morgan Stanley & Co. International PLC		56,900		01/30/24		CHF	101.82		CHF	5,547		(18,390	)
Prudential PLC	Morgan Stanley & Co. International PLC		92,200		01/30/24		GBP	9.04		GBP	816		(26,860	)
Taylor Wimpey PLC, Series L	UBS AG		81,200		01/30/24		GBP	1.32		GBP	119		(16,306	)
Zurich Insurance Group AG, Class N	Morgan Stanley & Co. International PLC		7,600		01/30/24		CHF	444.21		CHF	3,342		(32,249	)
EssilorLuxottica SA	UBS AG		29,600		01/31/24		EUR	183.98		EUR	5,384		(88,937	)
RELX PLC	Morgan Stanley & Co. International PLC		52,000		02/01/24		EUR	36.80		EUR	1,866		(22,850	)
Shell PLC	Bank of America N.A.		105,100		02/01/24		EUR	30.26		EUR	3,133		(53,843	)
Wal-Mart de Mexico SAB de CV	Citibank N.A.		415,600		02/01/24		MXN	68.03		MXN	29,744		(117,632	)
Taiwan Semiconductor Manufacturing Co. Ltd.	JPMorgan Chase Bank N.A.		198,000		02/05/24		TWD	585.66		TWD	116,500		(106,966	)
BAE Systems PLC	UBS AG		172,400		02/06/24		GBP	10.80		GBP	1,915		(103,623	)
Prudential PLC	Goldman Sachs International		68,500		02/07/24		GBP	8.84		GBP	606		(31,808	)
RELX PLC	Morgan Stanley & Co. International PLC		43,900		02/07/24		EUR	36.02		EUR	1,576		(38,026	)
Shell PLC	Morgan Stanley & Co. International PLC		62,000		02/07/24		EUR	30.46		EUR	1,848		(32,745	)
Taylor Wimpey PLC	Goldman Sachs International		766,000		02/08/24		GBP	1.40		GBP	1,125		(89,856	)
BAE Systems PLC	Goldman Sachs International		172,400		02/13/24		GBP	10.88		GBP	1,915		(100,160	)
Novo Nordisk A/S, Class B	Goldman Sachs International		31,800		02/13/24		DKK	720.40		DKK	22,253		(103,318	)
Taylor Wimpey PLC	Goldman Sachs International		476,300		02/14/24		GBP	1.47		GBP	699		(31,746	)
Citizens Financial Group, Inc.	Citibank N.A.		26,200		02/27/24		USD	33.33		USD	868		(44,869	)
												$	(4,299,368	)

Balances Reported in the Statements of Assets and Liabilities for Options Written

Description	Swap Premiums Paid		Swap Premiums Received		Unrealized Appreciation		Unrealized Depreciation			Value
Options Written	$	N/A	$	N/A	$	1,243,098	$	(5,410,478	)	$	(10,846,451	)

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

	Commodity Contracts		Credit Contracts		Equity Contracts		Foreign Currency Exchange Contracts		Interest Rate Contracts		Other Contracts		Total
Liabilities — Derivative Financial Instruments
Options written
Options written at value	$	—	$	—	$	10,846,451	$	—	$	—	$	—	$	10,846,451

68 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Schedule of Investments (continued) December 31, 2023   BlackRock Enhanced Global Dividend Trust (BOE)

For the period ended December 31, 2023, the effect of derivative financial instruments in the Statements of Operations was as follows:

	Commodity Contracts		Credit Contracts		Equity Contracts			Foreign Currency Exchange Contracts		Interest Rate Contracts		Other Contracts		Total
Net Realized Gain (Loss) from:
Options purchased(a)	$	—	$	—	$	(7,590,517	)	$	—	$	—	$	—	$	(7,590,517	)
Options written		—		—		4,801,919			—		—		—		4,801,919
	$	—	$	—	$	(2,788,598	)	$	—	$	—	$	—	$	(2,788,598	)
Net Change in Unrealized Appreciation (Depreciation) on:
Options written	$	—	$	—	$	(7,553,097	)	$	—	$	—	$	—	$	(7,553,097	)

^(a)  Options purchased are included in net realized gain (loss) from investments — unaffiliated.

Average Quarterly Balances of Outstanding Derivative Financial Instruments

Options:
Average value of option contracts purchased	$	—(a)
Average value of option contracts written	$	7,695,249

^(a)  Derivative financial instrument not held at any quarter-end. The risk exposure table serves as an indicator of activity during the period.

For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

Derivative Financial Instruments — Offsetting as of Period End

The Trust’s derivative assets and liabilities (by type) were as follows:

	Assets		Liabilities
Derivative Financial Instruments
Options	$	—	$	10,846,451
Total derivative assets and liabilities in the Statements of Assets and Liabilities		—		10,846,451
Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”)		—		(6,547,083	)
Total derivative assets and liabilities subject to an MNA	$	—	$	4,299,368

The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the Trust:

Counterparty		Derivative Liabilities Subject to an MNA by Counterparty		Derivatives Available for Offset		Non-Cash Collateral Pledged	(a)		Cash Collateral Pledged			Net Amount of Derivative Liabilities
Bank of America N.A.	$	166,770	$	—	$	(166,770	)	$	—		$	—
Citibank N.A.		497,945		—		(497,945	)		—			—
Goldman Sachs International		944,348		—		(414,348	)		(530,000	)		—
JPMorgan Chase Bank N.A.		663,759		—		(663,759	)		—			—
Morgan Stanley & Co. International PLC		1,175,887		—		(1,175,887	)		—			—
UBS AG		850,659		—		(850,659	)		—			—
	$	4,299,368	$	—	$	(3,769,368)		$	(530,000	)	$	—

^(a)  Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes.

S C H E D U L E  O F  I N V E S T M E N T S 69

Schedule of Investments (continued) December 31, 2023   BlackRock Enhanced Global Dividend Trust (BOE)

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation of financial instruments, refer to the Notes to Financial Statements.

The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s financial instruments into major categories is disclosed in the Schedule of Investments above.

	Level 1				Level 2				Level 3			Total
Assets
Investments
Long-Term Investments
Common Stocks
Canada	$	14,592,747			$	—			$	—		$	14,592,747
Denmark		—				15,794,217				—			15,794,217
France		—				69,387,673				—			69,387,673
India		—				—				284,447			284,447
Indonesia		—				8,333,569				—			8,333,569
Ireland		29,837,186				—				—			29,837,186
Mexico		15,276,669				—				—			15,276,669
Netherlands		—				30,186,812				—			30,186,812
Singapore		—				10,246,220				—			10,246,220
Switzerland		10,815,268				38,715,547				—			49,530,815
Taiwan		—				36,379,068				—			36,379,068
United Kingdom		14,783,641				67,109,107				—			81,892,748
United States		372,094,479				—				—			372,094,479
Short-Term Securities
Money Market Funds		2,668,223				—				—			2,668,223
	$	460,068,213			$	276,152,213			$	284,447		$	736,504,873
Derivative Financial Instruments(a)
Liabilities
Equity Contracts	$	(5,098,520	)		$	(5,747,931	)		$	—		$	(10,846,451	)

^(a)  Derivative financial instruments are options written. Options written are shown at value.

See notes to financial statements.

70 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Schedule of Investments  December 31, 2023 BlackRock Enhanced International Dividend Trust (BGY) (Percentages shown are based on Net Assets)

Security	Shares		Value
Common Stocks
Brazil — 1.5%
B3 SA - Brasil Bolsa Balcao		3,072,226	$	9,192,006
Canada — 4.5%
Canadian National Railway Co.		129,475		16,274,149
TELUS Corp.		661,770		11,776,564
				28,050,713
China — 1.1%
Yum China Holdings, Inc. (a)		159,098		6,750,528
Denmark — 3.7%
Novo Nordisk A/S, Class B		223,426		23,153,894
France — 10.7%
Air Liquide SA		97,316		18,946,980
EssilorLuxottica SA		65,768		13,206,130
LVMH Moet Hennessy Louis Vuitton SE		19,763		16,058,166
Sanofi SA		186,010		18,484,330
				66,695,606
Germany — 4.4%
MTU Aero Engines AG, Class N		59,338		12,784,112
Symrise AG, Class A		130,733		14,366,970
				27,151,082
India — 2.6%
AceVector Limited, Series I, (Acquired 01/25/22, Cost: $3,948,600) (b)(c)(d)		848,000		425,866
HDFC Bank Ltd.		782,464		16,021,748
				16,447,614
Indonesia — 1.6%
Bank Rakyat Indonesia Persero Tbk PT		26,413,700		9,817,118
Italy — 3.0%
FinecoBank Banca Fineco SpA		1,247,909		18,773,747
Japan — 7.7%
KDDI Corp.		321,100		10,184,811
Keyence Corp.		47,600		20,913,358
Sony Group Corp.		177,900		16,835,183
				47,933,352
Mexico — 2.9%
Wal-Mart de Mexico SAB de CV		4,298,658		18,117,599
Netherlands — 12.1%
ASML Holding NV		26,026		19,646,702
Heineken NV		183,267		18,619,833
Koninklijke KPN NV		5,283,115		18,201,008
Shell PLC		567,699		18,679,156
				75,146,699
Singapore — 4.2%
DBS Group Holdings Ltd.		477,400		12,072,882
United Overseas Bank Ltd.		653,100		14,095,986
				26,168,868
Sweden — 5.9%
Assa Abloy AB, Class B		599,526		17,277,842
Atlas Copco AB, A Shares		1,108,482		19,100,375
				36,378,217

Security	Shares		Value
Switzerland — 4.6%
Nestle SA, Registered Shares		129,067	$	14,961,428
Zurich Insurance Group AG, Class N		25,565		13,366,069
				28,327,497
Taiwan — 7.2%
MediaTek, Inc.		513,000		16,939,210
Taiwan Semiconductor Manufacturing Co. Ltd.		1,468,000		28,143,818
				45,083,028
United Kingdom — 13.6%
AstraZeneca PLC		132,185		17,830,414
BAE Systems PLC		891,229		12,615,337
Prudential PLC		1,363,945		15,388,963
RELX PLC		571,799		22,655,497
Smith & Nephew PLC		492,926		6,771,357
Taylor Wimpey PLC, Series L		5,105,774		9,557,577
				84,819,145
United States(a) — 9.1%
Baker Hughes Co., Class A (e)		628,896		21,495,665
Freeport-McMoRan, Inc.		145,401		6,189,721
Otis Worldwide Corp. (e)		142,255		12,727,555
Visa, Inc., Class A (e)		62,660		16,313,531
				56,726,472
Total Long-Term Investments — 100.4% (Cost: $516,484,782)				624,733,185
Short-Term Securities
Money Market Funds — 1.3%
BlackRock Liquidity Funds, T-Fund, Institutional Class, 5.26%(f)(g)		8,260,103		8,260,103
Total Short-Term Securities — 1.3% (Cost: $8,260,103)				8,260,103
Total Investments Before Options Written — 101.7% (Cost: $524,744,885)				632,993,288
Options Written — (1.7)% (Premiums Received: $(6,047,973))				(10,496,177	)
Total Investments, Net of Options Written — 100.0% (Cost: $518,696,912)				622,497,111
Liabilities in Excess of Other Assets — 0.0%				(15,261	)
Net Assets — 100.0%			$622,481,850

^(a)  All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

^(b)  Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.

^(c)  Non-income producing security.

^(d)  Restricted security as to resale, excluding 144A securities. The Trust held restricted securities with a current value of $425,866, representing 0.1% of its net assets as of period end, and an original cost of $3,948,600.

^(e)  All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.

^(f)  Affiliate of the Trust.

^(g)  Annualized 7-day yield as of period end.

S C H E D U L E  O F  I N V E S T M E N T S 71

Schedule of Investments (continued) December 31, 2023   BlackRock Enhanced International Dividend Trust (BGY)

Affiliates

Investments in issuers considered to be affiliate(s) of the Trust during the year ended December 31, 2023 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

Affiliated Issuer	Value at 12/31/22		Purchases at Cost			Proceeds from Sale		Net Realized Gain (Loss)		Change in Unrealized Appreciation (Depreciation)		Value at 12/31/23		Shares Held at 12/31/23		Income		Capital Gain Distributions from Underlying Funds
BlackRock Liquidity Funds, T-Fund, Institutional Class	$	5,622,321	$	2,637,782	(a)	$	—	$	—	$	—	$	8,260,103		8,260,103	$	518,836	$	—

^(a)  Represents net amount purchased (sold).

Derivative Financial Instruments Outstanding as of Period End

Exchange-Traded Options Written

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call
Freeport-McMoRan, Inc.		370		01/05/24		USD	38.00		USD	1,575	$	(170,200	)
Visa, Inc., Class A		37		01/12/24		USD	260.00		USD	963		(12,302	)
Baker Hughes Co., Class A		268		01/19/24		USD	36.00		USD	916		(6,030	)
Canadian National Railway Co.		241		01/19/24		CAD	155.00		CAD	4,014		(221,439	)
Otis Worldwide Corp.		100		01/19/24		USD	83.25		USD	895		(69,001	)
Visa, Inc., Class A		50		01/19/24		USD	255.00		USD	1,302		(39,000	)
Yum China Holdings, Inc.		358		01/19/24		USD	47.50		USD	1,519		(3,580	)
Baker Hughes Co., Class A		381		01/25/24		USD	32.30		USD	1,302		(88,085	)
Visa, Inc., Class A		223		01/26/24		USD	260.00		USD	5,806		(131,570	)
Visa, Inc., Class A		34		02/02/24		USD	260.68		USD	885		(21,826	)
Baker Hughes Co., Class A		395		02/12/24		USD	34.75		USD	1,350		(43,299	)
Canadian National Railway Co.		341		02/16/24		CAD	160.00		CAD	5,679		(234,831	)
Freeport-McMoRan, Inc.		370		02/16/24		USD	39.00		USD	1,575		(164,650	)
Otis Worldwide Corp.		437		02/16/24		USD	85.10		USD	3,910		(255,221	)
TELUS Corp.		346		02/16/24		CAD	26.00		CAD	816		(1,567	)
Baker Hughes Co., Class A		381		02/22/24		USD	32.30		USD	1,302		(103,879	)
Baker Hughes Co., Class A		394		02/26/24		USD	36.10		USD	1,347		(32,235	)
Baker Hughes Co., Class A		381		03/07/24		USD	32.30		USD	1,302		(111,399	)
Otis Worldwide Corp.		103		03/15/24		USD	90.00		USD	922		(31,930	)
TELUS Corp.		985		03/15/24		CAD	26.00		CAD	2,323		(5,204	)
TELUS Corp.		985		04/19/24		CAD	26.00		CAD	2,323		(9,664	)
											$	(1,756,912	)

OTC Options Written

Description	Counterparty	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call
Taiwan Semiconductor Manufacturing Co. Ltd.	JPMorgan Chase Bank N.A.		96,000		01/04/24		TWD	576.08		TWD	56,485	$	(54,871	)
MediaTek, Inc.	Morgan Stanley & Co. International PLC		57,900		01/09/24		TWD	936.85		TWD	58,676		(101,921	)
MTU Aero Engines AG, Class N	Bank of America N.A.		6,900		01/09/24		EUR	187.87		EUR	1,347		(58,421	)
Prudential PLC	Bank of America N.A.		183,300		01/09/24		GBP	9.14		GBP	1,622		(15,673	)
Sony Group Corp.	Societe Generale		37,400		01/09/24		JPY	13,611.90		JPY	499,037		(41,163	)
Symrise AG, Class A	Bank of America N.A.		36,100		01/09/24		EUR	97.33		EUR	3,594		(108,824	)
Air Liquide SA	Morgan Stanley & Co. International PLC		57,800		01/10/24		EUR	168.61		EUR	10,194		(515,351	)
ASML Holding NV	Morgan Stanley & Co. International PLC		4,500		01/10/24		EUR	630.76		EUR	3,077		(261,902	)
DBS Group Holdings Ltd.	UBS AG		95,400		01/10/24		SGD	33.42		SGD	3,184		(26,911	)
FinecoBank Banca Fineco SpA	Morgan Stanley & Co. International PLC		210,400		01/10/24		EUR	12.13		EUR	2,867		(342,762	)
Heineken NV	Goldman Sachs International		34,300		01/10/24		EUR	87.82		EUR	3,157		(164,427	)
Keyence Corp.	Societe Generale		8,300		01/10/24		JPY	62,553.70		JPY	514,179		(64,191	)
LVMH Moet Hennessy Louis Vuitton SE	Morgan Stanley & Co. International PLC		7,000		01/10/24		EUR	731.07		EUR	5,152		(112,060	)
Taiwan Semiconductor Manufacturing Co. Ltd.	JPMorgan Chase Bank N.A.		172,000		01/10/24		TWD	568.14		TWD	101,202		(144,544	)
Taylor Wimpey PLC, Series L	UBS AG		1,290,000		01/10/24		GBP	1.32		GBP	1,894		(249,226	)
Atlas Copco AB, A Shares	Goldman Sachs International		68,800		01/11/24		SEK	159.29		SEK	11,957		(99,868	)

72 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Schedule of Investments (continued) December 31, 2023   BlackRock Enhanced International Dividend Trust (BGY)

OTC Options Written (continued)

Description	Counterparty	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
Nestle SA, Registered Shares	UBS AG		35,050		01/11/24		CHF	100.25		CHF	3,417	$	(4,945	)
Shell PLC	Goldman Sachs International		64,600		01/11/24		EUR	30.62		EUR	1,925		(6,438	)
Assa Abloy AB, Class B	Goldman Sachs International		170,000		01/12/24		SEK	272.41		SEK	49,414		(320,530	)
Koninklijke KPN NV	Morgan Stanley & Co. International PLC		534,000		01/12/24		EUR	3.17		EUR	1,666		(11,207	)
RELX PLC	Goldman Sachs International		69,000		01/12/24		EUR	35.81		EUR	2,476		(35,553	)
Atlas Copco AB, A Shares	Bank of America N.A.		202,000		01/17/24		SEK	163.50		SEK	35,106		(218,692	)
DBS Group Holdings Ltd.	JPMorgan Chase Bank N.A.		119,400		01/17/24		SGD	32.18		SGD	3,985		(125,395	)
KDDI Corp.	BNP Paribas SA		88,300		01/17/24		JPY	4,666.97		JPY	394,905		(13,135	)
MediaTek, Inc.	JPMorgan Chase Bank N.A.		171,000		01/17/24		TWD	927.62		TWD	173,291		(355,011	)
MTU Aero Engines AG, Class N	Bank of America N.A.		23,700		01/17/24		EUR	188.90		EUR	4,625		(202,863	)
United Overseas Bank Ltd.	JPMorgan Chase Bank N.A.		156,600		01/17/24		SGD	27.46		SGD	4,461		(142,313	)
Wal-Mart de Mexico SAB de CV	Citibank N.A.		734,000		01/17/24		MXN	68.08		MXN	52,532		(178,072	)
FinecoBank Banca Fineco SpA	Morgan Stanley & Co. International PLC		210,400		01/18/24		EUR	12.70		EUR	2,867		(225,714	)
Koninklijke KPN NV	UBS AG		468,550		01/18/24		EUR	3.19		EUR	1,462		(12,678	)
Sanofi SA	Morgan Stanley & Co. International PLC		3,400		01/18/24		EUR	87.55		EUR	306		(10,764	)
Taiwan Semiconductor Manufacturing Co. Ltd.	Goldman Sachs International		198,000		01/18/24		TWD	594.66		TWD	116,500		(52,375	)
Taylor Wimpey PLC, Series L	UBS AG		1,290,000		01/18/24		GBP	1.32		GBP	1,894		(252,910	)
Zurich Insurance Group AG, Class N	Morgan Stanley & Co. International PLC		5,300		01/18/24		CHF	432.35		CHF	2,331		(62,776	)
Assa Abloy AB, Class B	UBS AG		170,000		01/23/24		SEK	272.46		SEK	49,414		(342,265	)
AstraZeneca PLC	Goldman Sachs International		72,800		01/23/24		GBP	103.39		GBP	7,704		(375,278	)
BAE Systems PLC	UBS AG		52,400		01/23/24		GBP	10.62		GBP	582		(36,965	)
FinecoBank Banca Fineco SpA	Goldman Sachs International		158,900		01/23/24		EUR	12.88		EUR	2,165		(148,972	)
Keyence Corp.	Citibank N.A.		13,100		01/23/24		JPY	64,933.75		JPY	811,535		(83,098	)
Novo Nordisk A/S, Class B	Goldman Sachs International		78,200		01/23/24		DKK	711.62		DKK	54,724		(171,439	)
Prudential PLC	UBS AG		90,300		01/23/24		GBP	8.74		GBP	799		(39,542	)
RELX PLC	Goldman Sachs International		69,000		01/23/24		EUR	35.81		EUR	2,476		(49,141	)
Sanofi SA	Morgan Stanley & Co. International PLC		61,800		01/23/24		EUR	89.72		EUR	5,563		(115,248	)
Smith & Nephew PLC	Goldman Sachs International		126,400		01/23/24		GBP	10.56		GBP	1,362		(63,009	)
Sony Group Corp.	Bank of America N.A.		42,700		01/23/24		JPY	12,954.17		JPY	569,756		(200,286	)
Symrise AG, Class A	Bank of America N.A.		30,200		01/23/24		EUR	105.31		EUR	3,006		(11,530	)
Wal-Mart de Mexico SAB de CV	JPMorgan Chase Bank N.A.		466,300		01/23/24		MXN	68.95		MXN	33,373		(101,809	)
Koninklijke KPN NV	Goldman Sachs International		533,400		01/24/24		EUR	3.17		EUR	1,665		(18,278	)
Koninklijke KPN NV	Goldman Sachs International		468,550		01/24/24		EUR	3.18		EUR	1,462		(15,807	)
United Overseas Bank Ltd.	UBS AG		63,000		01/24/24		SGD	27.74		SGD	1,795		(47,617	)
ASML Holding NV	Bank of America N.A.		9,000		01/25/24		EUR	650.68		EUR	6,154		(394,599	)
Prudential PLC	Goldman Sachs International		90,400		01/25/24		GBP	9.12		GBP	800		(19,066	)
Nestle SA, Registered Shares	Morgan Stanley & Co. International PLC		23,000		01/30/24		CHF	101.82		CHF	2,242		(7,433	)
Prudential PLC	Morgan Stanley & Co. International PLC		95,600		01/30/24		GBP	9.04		GBP	846		(27,850	)
Taylor Wimpey PLC, Series L	UBS AG		1,290,000		01/30/24		GBP	1.32		GBP	1,894		(259,043	)
Zurich Insurance Group AG, Class N	Morgan Stanley & Co. International PLC		6,300		01/30/24		CHF	444.21		CHF	2,770		(26,733	)
EssilorLuxottica SA	UBS AG		29,600		01/31/24		EUR	183.98		EUR	5,384		(88,937	)
B3 SA - Brasil Bolsa Balcao	Citibank N.A.		768,100		02/01/24		BRL	13.96		BRL	11,163		(151,254	)
KDDI Corp.	BNP Paribas SA		88,300		02/01/24		JPY	4,703.22		JPY	394,905		(19,408	)
RELX PLC	Morgan Stanley & Co. International PLC		29,400		02/01/24		EUR	36.80		EUR	1,055		(12,919	)
Shell PLC	Bank of America N.A.		82,500		02/01/24		EUR	30.26		EUR	2,459		(42,265	)
Wal-Mart de Mexico SAB de CV	Citibank N.A.		734,100		02/01/24		MXN	68.03		MXN	52,540		(207,781	)
Taiwan Semiconductor Manufacturing Co. Ltd.	JPMorgan Chase Bank N.A.		48,000		02/05/24		TWD	585.65		TWD	28,242		(25,931	)
BAE Systems PLC	UBS AG		246,300		02/06/24		GBP	10.80		GBP	2,735		(148,041	)
Koninklijke KPN NV	Morgan Stanley & Co. International PLC		372,900		02/06/24		EUR	3.20		EUR	1,164		(15,470	)
Smith & Nephew PLC	Morgan Stanley & Co. International PLC		95,400		02/06/24		GBP	10.97		GBP	1,028		(33,417	)
United Overseas Bank Ltd.	Citibank N.A.		74,200		02/06/24		SGD	28.52		SGD	2,114		(30,727	)
B3 SA - Brasil Bolsa Balcao	Citibank N.A.		768,100		02/07/24		BRL	13.69		BRL	11,163		(190,988	)
Prudential PLC	Goldman Sachs International		154,100		02/07/24		GBP	8.84		GBP	1,364		(71,557	)
RELX PLC	Morgan Stanley & Co. International PLC		90,000		02/07/24		EUR	36.02		EUR	3,230		(77,957	)
Shell PLC	Morgan Stanley & Co. International PLC		51,600		02/07/24		EUR	30.46		EUR	1,538		(27,252	)
Atlas Copco AB, A Shares	Bank of America N.A.		228,000		02/08/24		SEK	168.64		SEK	39,625		(190,187	)
Heineken NV	Morgan Stanley & Co. International PLC		37,000		02/08/24		EUR	90.09		EUR	3,405		(148,691	)
BAE Systems PLC	Goldman Sachs International		102,400		02/13/24		GBP	10.88		GBP	1,137		(59,492	)
Yum China Holdings, Inc.	Morgan Stanley & Co. International PLC		35,700		02/26/24		USD	45.19		USD	1,515		(48,497	)
												$	(8,739,265	)

S C H E D U L E  O F  I N V E S T M E N T S 73

Schedule of Investments (continued) December 31, 2023   BlackRock Enhanced International Dividend Trust (BGY)

Balances Reported in the Statements of Assets and Liabilities for Options Written

Description

Swap Premiums Paid

Swap Premiums Received

Unrealized Appreciation

Unrealized Depreciation

Value

Options Written

$  N/A

$  N/A

$ 823,460

$ (5,271,664

)

$ (10,496,177

)

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

	Commodity Contracts		Credit Contracts		Equity Contracts		Foreign Currency Exchange Contracts		Interest Rate Contracts		Other Contracts		Total
Liabilities — Derivative Financial Instruments
Options written
Options written at value	$	—	$	—	$	10,496,177	$	—	$	—	$	—	$	10,496,177

For the period ended December 31, 2023, the effect of derivative financial instruments in the Statements of Operations was as follows:

	Commodity Contracts		Credit Contracts		Equity Contracts			Foreign Currency Exchange Contracts		Interest Rate Contracts		Other Contracts		Total
Net Realized Gain (Loss) from:
Options purchased(a)	$	—	$	—	$	(11,196,135	)	$	—	$	—	$	—	$	(11,196,135	)
Options written		—		—		13,525,844			—		—		—		13,525,844
	$	—	$	—	$	2,329,709		$	—	$	—	$	—	$	2,329,709
Net Change in Unrealized Appreciation (Depreciation) on:
Options written	$	—	$	—	$	(5,754,650	)	$	—	$	—	$	—	$	(5,754,650	)

^(a)  Options purchased are included in net realized gain (loss) from investments — unaffiliated.

Average Quarterly Balances of Outstanding Derivative Financial Instruments

Options:
Average value of option contracts purchased	$	—	(a)
Average value of option contracts written	$	6,703,347

^(a)  Derivative financial instrument not held at any quarter-end. The risk exposure table serves as an indicator of activity during the period.

For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

Derivative Financial Instruments — Offsetting as of Period End

The Trust’s derivative assets and liabilities (by type) were as follows:

	Assets		Liabilities
Derivative Financial Instruments Options	$	—	$	10,496,177
Total derivative assets and liabilities in the Statements of Assets and Liabilities		—		10,496,177
Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”)		—		(1,756,912	)
Total derivative assets and liabilities subject to an MNA	$	—	$	8,739,265

74 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Schedule of Investments (continued) December 31, 2023   BlackRock Enhanced International Dividend Trust (BGY)

The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the Trust:

Counterparty		Derivative Liabilities Subject to an MNA by Counterparty		Derivatives Available for Offset		Non-Cash Collateral Pledged	(a)		Cash Collateral Pledged		Net Amount of Derivative Liabilities	(b)
Bank of America N.A.	$	1,443,340	$	—	$	(1,443,340	)	$	—	$	—
BNP Paribas SA		32,543		—		—			—		32,543
Citibank N.A.		841,920		—		(841,920	)		—		—
Goldman Sachs International		1,671,230		—		(1,671,230	)		—		—
JPMorgan Chase Bank N.A.		949,874		—		(949,874	)		—		—
Morgan Stanley & Co. International PLC		2,185,924		—		(2,185,924	)		—		—
Societe Generale		105,354		—		—			—		105,354
UBS AG		1,509,080		—		(1,509,080	)		—		—
	$	8,739,265	$	—	$	(8,601,368	)	$	—	$	137,897

^(a)  Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes.

^(b)  Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation of financial instruments, refer to the Notes to Financial Statements.

The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s financial instruments into major categories is disclosed in the Schedule of Investments above.

	Level 1			Level 2			Level 3		Total
Assets
Investments
Long-Term Investments
Common Stocks
Brazil	$	—		$	9,192,006		$	—	$	9,192,006
Canada		28,050,713			—			—		28,050,713
China		6,750,528			—			—		6,750,528
Denmark		—			23,153,894			—		23,153,894
France		—			66,695,606			—		66,695,606
Germany		—			27,151,082			—		27,151,082
India		—			16,021,748			425,866		16,447,614
Indonesia		—			9,817,118			—		9,817,118
Italy		—			18,773,747			—		18,773,747
Japan		—			47,933,352			—		47,933,352
Mexico		18,117,599			—			—		18,117,599
Netherlands		—			75,146,699			—		75,146,699
Singapore		—			26,168,868			—		26,168,868
Sweden		—			36,378,217			—		36,378,217
Switzerland		—			28,327,497			—		28,327,497
Taiwan		—			45,083,028			—		45,083,028
United Kingdom		12,615,337			72,203,808			—		84,819,145
United States		56,726,472			—			—		56,726,472
Short-Term Securities
Money Market Funds		8,260,103			—			—		8,260,103
	$	130,520,752		$	502,046,670		$	425,866	$	632,993,288
Derivative Financial Instruments(a)
Liabilities
Equity Contracts	$	(1,031,967	)	$	(9,464,210	)	$	—	$	(10,496,177	)

^(a)  Derivative financial instruments are options written. Options written are shown at value.

See notes to financial statements.

S C H E D U L E  O F  I N V E S T M E N T S 75

Schedule of Investments  December 31, 2023 BlackRock Health Sciences Term Trust (BMEZ) (Percentages shown are based on Net Assets)

Security	Shares		Value
Common Stocks
Biotechnology — 37.6%
4D Molecular Therapeutics, Inc.(a)		95,330	$	1,931,386
Abbisko Cayman Ltd.		10,378,250		4,844,022
AbbVie, Inc.		149,565		23,178,088
AC Immune SA(a)		752,390		3,761,950
Alkermes PLC(a)		183,485		5,089,874
Allakos, Inc.(a)		136,405		372,386
Alnylam Pharmaceuticals, Inc.(a)(b)		102,967		19,708,913
Amgen, Inc.(b)(c)		132,690		38,217,374
Annexon, Inc.(a)		237,835		1,079,771
Antengene Corp. Ltd.(a)		5,019,274		1,285,592
Apellis Pharmaceuticals, Inc.(a)(d)		51,390		3,076,205
Arcturus Therapeutics Holdings, Inc.(a)		103,675		3,268,873
Arcus Biosciences, Inc.(a)		169,790		3,242,989
Argenx SE, ADR(a)		69,867		26,579,503
Arrowhead Pharmaceuticals, Inc.(a)		81,025		2,479,365
Autolus Therapeutics PLC, ADR(a)		462,111		2,975,995
BeiGene Ltd., ADR(a)		68,555		12,364,580
Bicycle Therapeutics PLC, ADR(a)(d)		278,270		5,031,122
Biogen, Inc.(a)		99,215		25,673,866
Biohaven Ltd.(a)		99,155		4,243,834
BioMarin Pharmaceutical, Inc.(a)(c)		420,758		40,569,486
Biomea Fusion, Inc.(a)		146,215		2,123,042
Black Diamond Therapeutics, Inc.(a)(d)		833,550		2,342,276
Blueprint Medicines Corp.(a)		322,440		29,741,866
Bridgebio Pharma, Inc.(a)		66,595		2,688,440
Cabaletta Bio, Inc.(a)		506,395		11,495,166
Cerevel Therapeutics Holdings, Inc.(a)		221,156		9,377,014
Connect Biopharma Holdings Ltd., ADR(a)		1,040,067		1,227,279
CureVac NV(a)(d)		320,123		1,347,718
Everest Medicines Ltd.		3,113,667		8,343,091
Exact Sciences Corp.(a)		83,290		6,161,794
Exelixis, Inc.(a)		599,320		14,377,687
Galapagos NV, ADR(a)		74,410		3,024,767
Genmab A/S(a)		34,827		11,104,694
Genmab A/S, ADR(a)(d)		114,086		3,632,498
Gilead Sciences, Inc.		168,195		13,625,477
Halozyme Therapeutics, Inc.(a)		158,300		5,850,768
Immuneering Corp., Class A(a)		335,561		2,466,373
Immunocore Holdings PLC, ADR(a)		59,868		4,090,182
Immunocore Holdings PLC, Series C, ADR(a)		321,900		21,992,208
ImmunoGen, Inc.(a)		207,169		6,142,561
Incyte Corp.(a)		227,420		14,279,702
Ionis Pharmaceuticals, Inc.(a)		405,860		20,532,457
Iovance Biotherapeutics, Inc.(a)		168,215		1,367,588
Karuna Therapeutics, Inc.(a)		21,350		6,757,489
Keros Therapeutics, Inc.(a)		124,317		4,942,844
Kinnate Biopharma, Inc.(a)		196,773		466,352
Legend Biotech Corp., ADR(a)(d)		316,032		19,015,645
LianBio, Series A, ADR(a)		615,188		2,749,890
MacroGenics, Inc.(a)		190,555		1,833,139
Merus NV(a)(d)		411,972		11,329,230
Mirati Therapeutics, Inc.(a)		180,175		10,585,281
Monte Rosa Therapeutics, Inc.(a)		266,168		1,503,849
MoonLake Immunotherapeutics, Class A(a)(d)		114,141		6,892,975
Morphic Holding, Inc.(a)		75,190		2,171,487
Neurocrine Biosciences, Inc.(a)		204,955		27,004,871
Neurogene, Inc.		372,050		7,210,329
Nuvalent, Inc., Class A(a)(d)		241,500		17,771,985
Prime Medicine, Inc.(a)(d)		412,139		3,651,552
Protagonist Therapeutics, Inc.(a)		421,725		9,670,154

Security	Shares		Value
Biotechnology (continued)
PTC Therapeutics, Inc.(a)		225,815	$	6,223,461
REVOLUTION Medicines, Inc.(a)		181,447		5,203,900
Rhythm Pharmaceuticals, Inc.(a)(d)		580,575		26,689,033
Rocket Pharmaceuticals, Inc.(a)		252,097		7,555,347
Roivant Sciences Ltd.(a)		607,105		6,817,789
Sarepta Therapeutics, Inc.(a)(b)		237,759		22,927,100
Tenaya Therapeutics, Inc.(a)		165,729		536,962
TScan Therapeutics, Inc.(a)		1,045,767		6,096,822
Twist Bioscience Corp.(a)		130,265		4,801,568
Ultragenyx Pharmaceutical, Inc.(a)		118,142		5,649,550
United Therapeutics Corp.(a)(b)		55,704		12,248,753
Vaxcyte, Inc.(a)		277,670		17,437,676
Vertex Pharmaceuticals, Inc.(a)		25,510		10,379,764
Viking Therapeutics, Inc.(a)		235,245		4,377,909
Voyager Therapeutics, Inc.(a)(d)		164,865		1,391,461
Xenon Pharmaceuticals, Inc.(a)		420,084		19,349,069
				717,553,058
Electronic Equipment, Instruments & Components — 0.2%
908 Devices, Inc.(a)		274,084		3,075,222
Health Care Equipment & Supplies — 20.0%
Abbott Laboratories		127,770		14,063,644
Alcon, Inc.		174,349		13,620,144
Align Technology, Inc.(a)(c)		139,485		38,218,890
Becton Dickinson & Co.		84,050		20,493,911
Boston Scientific Corp.(a)		455,830		26,351,532
CONMED Corp.		98,215		10,755,525
ConvaTec Group PLC(e)		4,411,215		13,727,210
Cooper Cos., Inc.		99,160		37,526,110
Dexcom, Inc.(a)		76,385		9,478,615
Hologic, Inc.(a)(b)		194,620		13,905,599
Inspire Medical Systems, Inc.(a)(d)		89,190		18,143,922
Intuitive Surgical, Inc.(a)(b)		100,308		33,839,907
Masimo Corp.(a)(d)		145,470		17,050,539
Novocure Ltd.(a)		213,335		3,185,092
Nyxoah SA(a)		648,041		3,006,910
Orchestra BioMed Holdings, Inc.(a)		233,344		2,130,431
Penumbra, Inc.(a)(d)		59,993		15,090,639
Pulmonx Corp.(a)		335,566		4,278,467
Shockwave Medical, Inc.(a)		63,915		12,179,642
SI-BONE, Inc.(a)		204,910		4,301,061
STERIS PLC		158,575		34,862,714
Stryker Corp.		44,605		13,357,413
Tandem Diabetes Care, Inc.(a)		129,700		3,836,526
Zimmer Biomet Holdings, Inc.		154,445		18,795,956
				382,200,399
Health Care Providers & Services — 9.6%
Adicon Holdings Ltd., (Acquired 07/19/23, Cost: $17,840,000)(f)		10,696,226		17,862,430
Cencora, Inc.(b)(c)		193,355		39,711,250
Centene Corp.(a)(d)		179,980		13,356,316
Chemed Corp.		10,662		6,234,604
Elevance Health, Inc.		28,805		13,583,286
Encompass Health Corp.(b)		82,323		5,492,591
Guardant Health, Inc.(a)		196,470		5,314,513
Humana, Inc.		18,270		8,364,189
Kindstar Globalgene Technology, Inc.(a)(e)		4,092,500		880,502
McKesson Corp.		38,905		18,012,237
Molina Healthcare, Inc.(a)		70,995		25,651,203
UnitedHealth Group, Inc.(b)		52,210		27,486,999
				181,950,120

76 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Schedule of Investments (continued) December 31, 2023 BlackRock Health Sciences Term Trust (BMEZ) (Percentages shown are based on Net Assets)

Security	Shares		Value
Health Care Technology — 0.1%
Sophia Genetics SA(a)(d)		291,485	$	1,372,894
Life Sciences Tools & Services — 14.7%
10X Genomics, Inc., Class A(a)		231,935		12,979,083
Avantor, Inc.(a)(b)(d)		664,444		15,169,257
Bio-Rad Laboratories, Inc., Class A(a)		20,190		6,519,149
Bio-Techne Corp.		415,455		32,056,508
Bruker Corp.		185,257		13,612,684
Charles River Laboratories International, Inc.(a)		102,105		24,137,622
Danaher Corp.		82,550		19,097,117
Gerresheimer AG		243,305		25,312,387
Lonza Group AG, Registered Shares		23,365		9,850,361
Mettler-Toledo International, Inc.(a)		15,590		18,910,046
QIAGEN NV(a)		663,980		28,836,652
Rapid Micro Biosystems, Inc., Class A(a)		549,778		406,836
Repligen Corp.(a)(d)		95,255		17,126,849
Waters Corp.(a)		90,145		29,678,438
West Pharmaceutical Services, Inc.(b)(c)		77,325		27,227,679
				280,920,668
Pharmaceuticals — 8.6%
Arvinas, Inc.(a)		232,960		9,588,634
Axsome Therapeutics, Inc.(a)		38,160		3,037,154
Catalent, Inc.(a)		347,125		15,596,326
Elanco Animal Health, Inc.(a)		1,234,695		18,396,956
Eli Lilly & Co.(b)		43,825		25,546,469
Merck & Co., Inc.		200,730		21,883,585
Novo Nordisk A/S, Class B		339,190		35,150,651
Nuvation Bio, Inc., Class A(a)		200,496		302,749
Sanofi SA, ADR		496,860		24,708,848
Structure Therapeutics, Inc., ADR(a)(d)		258,475		10,535,441
				164,746,813
Total Common Stocks — 90.8% (Cost: $1,647,249,899)				1,731,819,174
	Benefical Interest (000)
Other Interests
Biotechnology(f)(g)(h) — 0.2%
Affinivax, Inc., (Acquired 08/18/22, Cost: $ —)	$	183		2,458,061
Amunix Pharmaceuticals, Inc., (Acquired 02/08/22, Cost: $ —)		5,657		2,206,257
Total Other Interests — 0.2% (Cost: $ — )				4,664,318
	Shares
Preferred Securities
Preferred Stocks — 8.5%
Biotechnology(a)(g) — 3.2%
ABCURO, Series B		1,092,954		6,011,247
Bright Peak Therapeutics, Inc., Series B, (Acquired 05/14/21, Cost: $8,000,004)(f)		2,048,132		3,236,049
Cellarity, Inc., Series B, (Acquired 01/15/21, Cost: $14,584,998)(f)		2,430,833		8,070,365

Security	Shares		Value
Biotechnology (continued)
Genesis Therapeutics, Series B, (Acquired 08/10/23, Cost: $6,999,996)(f)		1,370,506	$	7,003,286
Goldfinch Bio, Inc., Series B, (Acquired 06/26/20, Cost: $4,543,847)(f)		3,850,718		1,309,244
Kartos Therapeutics, Series C, (Acquired 08/22/23, Cost: $7,539,875)(f)		1,333,783		7,562,550
Laronde, Inc., Series B, (Acquired 07/28/21, Cost: $13,498,156)(f)		482,077		13,498,156
Mirvie, Inc., Series B, (Acquired 10/15/21, Cost: $6,250,000)(f)		2,793,833		5,000,961
NiKang Therapeutics, Inc., Series C, (Acquired 05/20/21, Cost: $7,999,996)(f)		1,394,189		4,252,276
OnKure, Inc., Series C, (Acquired 03/24/23, Cost: $7,022,595)(f)		2,541,380		5,540,208
				61,484,342
Health Care Equipment & Supplies(a)(f)(g) — 0.8%
Exo Imaging, Inc., Series C, (Acquired 06/24/21, Cost: $13,225,003)		2,257,597		5,960,056
Nucleix Ltd., Series AA, (Acquired 03/25/21, Cost: $6,929,998)		2,379,480		6,448,391
Swift Health Systems, Inc., Series D, (Acquired 08/27/21, Cost: $6,441,930)		2,078,042		1,745,555
				14,154,002
Health Care Providers & Services(a)(f)(g) — 1.0%
Everly Well, Inc., Series D, (Acquired 11/25/20, Cost: $9,999,986)		382,775		3,789,473
Numab Therapeutics AG, Series C, (Acquired 05/07/21, Cost: $7,770,441)		815,851		7,508,099
Quanta Dialysis Technologies Ltd., Series D, (Acquired 06/18/21, Cost: $14,071,890)		115,766,240		7,820,757
				19,118,329
Health Care Technology — 0.8%
Carbon Health Technologies, Inc., Series D2, (Acquired 02/02/23, Cost: $17,100,000)(a)(f)(g)		1,694,781		14,931,020
Life Sciences Tools & Services — 0.9%
Sartorius AG		47,930		17,600,893
Pharmaceuticals(a)(f)(g) — 0.9%
Adarx Pharamaceuticals, Series C, (Acquired 08/02/23, Cost: $7,160,001)		860,577		7,168,607
Insitro, Inc.
Series B, (Acquired 05/21/20, Cost: $5,000,000)		802,478		8,377,870
Series C, (Acquired 03/10/21, Cost: $3,600,018)		196,818		2,054,780
				17,601,257
Semiconductors & Semiconductor Equipment — 0.9%
PsiQuantum Corp., Series D, (Acquired 05/21/21, Cost: $14,999,996)(a)(f)(g)		571,947		16,254,734
				161,144,577
Total Preferred Securities — 8.5% (Cost: $206,096,023)				161,144,577
Rights
Biotechnology — 0.0%
Korro Bio, Inc., CVR		231,775		3,152

S C H E D U L E  O F  I N V E S T M E N T S 77

Schedule of Investments (continued) December 31, 2023 BlackRock Health Sciences Term Trust (BMEZ) (Percentages shown are based on Net Assets)

Security	Shares		Value
Health Care Equipment & Supplies — 0.0%
Abiomed, Inc., CVR(g)		98,636	$	268,290
Total Rights — 0.0% (Cost: $100,609)				271,442
Warrants
Health Care Providers & Services — 0.0%
CareMax, Inc., (Issued/Exercisable 09/15/20, 1 Share for 1 Warrant, Expires 08/06/26, Strike Price USD 11.50)(a)		63,808		478
Pharmaceuticals — 0.0%
Nuvation Bio, Inc., (Issued/Exercisable 08/17/20, 1 Share for 1 Warrant, Expires 07/07/27, Strike Price USD 11.50)(a)		68,880		4,133
Total Warrants — 0.0% (Cost: $227,724)				4,611
Total Long-Term Investments — 99.5% (Cost: $1,853,674,255)				1,897,904,122
Short-Term Securities
Money Market Funds — 2.8%
BlackRock Liquidity Funds, T-Fund, Institutional Class, 5.26%(i)(j)		40,473,813		40,473,813
SL Liquidity Series, LLC, Money Market Series, 5.58%(i)(j)(k)		12,304,554		12,308,246
Total Short-Term Securities — 2.8% (Cost: $52,782,639)				52,782,059
Total Investments Before Options Written — 102.3% (Cost: $1,906,456,894)				1,950,686,181
Options Written — (1.7)% (Premiums Received: $(14,726,316))				(31,431,446	)
Total Investments, Net of Options Written — 100.6% (Cost: $1,891,730,578)				1,919,254,735
Liabilities in Excess of Other Assets — (0.6)%				(11,883,803	)
Net Assets — 100.0%			$	1,907,370,932

^(a)  Non-income producing security.

^(b)  All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

^(c)  All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.

^(d)  All or a portion of this security is on loan.

^(e)  Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may be resold in transactions exempt from registration to qualified institutional investors.

^(f)  Restricted security as to resale, excluding 144A securities. The Trust held restricted securities with a current value of $160,059,185, representing 8.4% of its net assets as of period end, and an original cost of $200,578,730.

^(g)  Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.

^(h)  Other interests represent beneficial interests in liquidation trusts and other reorganization or private entities.

⁽ⁱ⁾  Affiliate of the Trust.

^(j)  Annualized 7-day yield as of period end.

^(k)  All or a portion of this security was purchased with the cash collateral from loaned securities.

For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

78 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Schedule of Investments (continued) December 31, 2023 BlackRock Health Sciences Term Trust (BMEZ)

Affiliates

Investments in issuers considered to be affiliate(s) of the Trust during the year ended December 31, 2023 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

	Affiliated Issuer	Value at 12/31/22		Purchases at Cost			Proceeds from Sale			Net Realized Gain (Loss)		Change in Unrealized Appreciation (Depreciation)			Value at 12/31/23		Shares Held at 12/31/23		Income			Capital Gain Distributions from Underlying Funds
	BlackRock Liquidity Funds, T-Fund, Institutional Class	$	83,001,707	$	—		$	(42,527,894	)(a)	$	—	$	—		$	40,473,813		40,473,813	$	2,845,610		$	—
	DA32 Life Science Tech Acquisition Corp., Class A(b)		14,818,508		—			(15,444,684	)		476,495		149,681			N/A		N/A		—			—
	SL Liquidity Series, LLC, Money Market Series		1,828,050		10,470,673	(a)		—			10,301		(778	)		12,308,246		12,304,554		458,690	(c)		—
										$	486,796	$	148,903		$	52,782,059			$	3,304,300		$	—

^(a)  Represents net amount purchased (sold).

^(b)  As of period end, the entity is no longer held.

^(c)  All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.

Derivative Financial Instruments Outstanding as of Period End

Forward Foreign Currency Exchange Contracts

	Currency Purchased		Currency Sold			Counterparty	Settlement Date			Unrealized Appreciation (Depreciation)
	JPY	1,030,785,200		USD	7,206,933	Barclays Bank PLC		03/14/24		$	182,850
	JPY	7,025,754,800		USD	49,121,960	Morgan Stanley & Co. International PLC		03/14/24			1,246,245
										$	1,429,095

Exchange-Traded Options Written

	Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
	Call
	Amgen, Inc.		60		01/05/24		USD	275.00		USD	1,728	$	(80,250	)
	Centene Corp.		78		01/05/24		USD	75.00		USD	579		(3,705	)
	Danaher Corp.		91		01/05/24		USD	230.00		USD	2,105		(30,940	)
	Dexcom, Inc.		265		01/05/24		USD	121.00		USD	3,288		(106,000	)
	Elevance Health, Inc.		92		01/05/24		USD	485.00		USD	4,338		(4,830	)
	McKesson Corp.		60		01/05/24		USD	470.00		USD	2,778		(9,600	)
	UnitedHealth Group, Inc.		56		01/05/24		USD	550.00		USD	2,948		(392	)
	Alcon, Inc.		797		01/09/24		USD	76.00		USD	6,226		(206,442	)
	AbbVie, Inc.		151		01/12/24		USD	146.00		USD	2,340		(143,827	)
	Biogen, Inc.		93		01/12/24		USD	245.00		USD	2,407		(134,385	)
	Centene Corp.		194		01/12/24		USD	75.00		USD	1,440		(21,340	)
	Eli Lilly & Co.		48		01/12/24		USD	615.00		USD	2,798		(12,144	)
	Gilead Sciences, Inc.		204		01/12/24		USD	80.00		USD	1,653		(38,046	)
	Humana, Inc.		29		01/12/24		USD	495.00		USD	1,328		(2,030	)
	Intuitive Surgical, Inc.		75		01/12/24		USD	320.00		USD	2,530		(157,500	)
	McKesson Corp.		4		01/12/24		USD	460.00		USD	185		(3,900	)
	Merck & Co., Inc.		321		01/12/24		USD	102.01		USD	3,500		(237,250	)
	10X Genomics, Inc., Class A		396		01/19/24		USD	45.00		USD	2,216		(457,380	)
	AbbVie, Inc.		151		01/19/24		USD	150.00		USD	2,340		(89,090	)
	Align Technology, Inc.		133		01/19/24		USD	240.00		USD	3,644		(501,410	)
	Alnylam Pharmaceuticals, Inc.		329		01/19/24		USD	200.00		USD	6,297		(133,245	)
	Amgen, Inc.		60		01/19/24		USD	285.00		USD	1,728		(44,700	)
	Apellis Pharmaceuticals, Inc.		164		01/19/24		USD	62.00		USD	982		(96,760	)
	Arcturus Therapeutics Holdings, Inc.		331		01/19/24		USD	30.00		USD	1,044		(96,817	)
	Argenx SE, ADR		71		01/19/24		USD	520.00		USD	2,701		(33,370	)
	Arrowhead Pharmaceuticals, Inc.		129		01/19/24		USD	30.00		USD	395		(24,833	)
	Avantor, Inc.		830		01/19/24		USD	19.75		USD	1,895		(345,748	)

S C H E D U L E  O F  I N V E S T M E N T S 79

Schedule of Investments (continued) December 31, 2023 BlackRock Health Sciences Term Trust (BMEZ)

Exchange-Traded Options Written (continued)

	Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
	Call (continued)
	Becton Dickinson & Co.		78		01/19/24		USD	245.00		USD	1,902	$	(28,080	)
	BeiGene Ltd., ADR		219		01/19/24		USD	200.00		USD	3,950		(61,867	)
	Biogen, Inc.		115		01/19/24		USD	245.00		USD	2,976		(191,475	)
	BioMarin Pharmaceutical, Inc.		586		01/19/24		USD	90.00		USD	5,650		(421,920	)
	Bio-Techne Corp.		517		01/19/24		USD	65.00		USD	3,989		(612,645	)
	Blueprint Medicines Corp.		540		01/19/24		USD	65.00		USD	4,981		(1,495,800	)
	Blueprint Medicines Corp.		491		01/19/24		USD	85.00		USD	4,529		(491,000	)
	Bridgebio Pharma, Inc.		213		01/19/24		USD	35.00		USD	860		(130,995	)
	Bruker Corp.		296		01/19/24		USD	70.00		USD	2,175		(146,520	)
	Cabaletta Bio, Inc.		960		01/19/24		USD	22.50		USD	2,179		(172,800	)
	Catalent, Inc.		277		01/19/24		USD	40.00		USD	1,245		(149,580	)
	Cencora, Inc.		148		01/19/24		USD	200.00		USD	3,040		(105,820	)
	Centene Corp.		109		01/19/24		USD	77.50		USD	809		(5,995	)
	Cerevel Therapeutics Holdings, Inc.		398		01/19/24		USD	25.00		USD	1,688		(698,490	)
	Charles River Laboratories International, Inc.		108		01/19/24		USD	230.00		USD	2,553		(111,780	)
	Chemed Corp.		29		01/19/24		USD	590.00		USD	1,696		(19,285	)
	CONMED Corp.		157		01/19/24		USD	115.00		USD	1,719		(20,410	)
	Cooper Cos., Inc.		159		01/19/24		USD	360.00		USD	6,017		(333,105	)
	Danaher Corp.		90		01/19/24		USD	230.00		USD	2,082		(58,500	)
	Dexcom, Inc.		265		01/19/24		USD	122.50		USD	3,288		(153,700	)
	Elanco Animal Health, Inc.		1,482		01/19/24		USD	12.00		USD	2,208		(448,305	)
	Encompass Health Corp.		83		01/19/24		USD	65.00		USD	554		(20,543	)
	Encompass Health Corp.		49		01/19/24		USD	68.80		USD	327		(2,442	)
	Exact Sciences Corp.		81		01/19/24		USD	80.00		USD	599		(13,973	)
	Exelixis, Inc.		959		01/19/24		USD	22.00		USD	2,301		(239,750	)
	Galapagos NV, ADR		119		01/19/24		USD	37.50		USD	484		(37,187	)
	Gilead Sciences, Inc.		407		01/19/24		USD	82.50		USD	3,297		(35,206	)
	Guardant Health, Inc.		467		01/19/24		USD	25.00		USD	1,263		(122,587	)
	Halozyme Therapeutics, Inc.		128		01/19/24		USD	43.50		USD	473		(8,506	)
	Hologic, Inc.		311		01/19/24		USD	75.00		USD	2,222		(10,108	)
	Humana, Inc.		29		01/19/24		USD	505.00		USD	1,328		(1,958	)
	Immunocore Holdings PLC, ADR		95		01/19/24		USD	50.00		USD	649		(176,700	)
	Incyte Corp.		411		01/19/24		USD	57.50		USD	2,581		(242,490	)
	Inspire Medical Systems, Inc.		155		01/19/24		USD	165.00		USD	3,153		(616,125	)
	Intuitive Surgical, Inc.		79		01/19/24		USD	340.00		USD	2,665		(69,125	)
	Ionis Pharmaceuticals, Inc.		750		01/19/24		USD	52.50		USD	3,794		(95,625	)
	Karuna Therapeutics, Inc.		31		01/19/24		USD	230.00		USD	981		(270,320	)
	Keros Therapeutics, Inc.		198		01/19/24		USD	40.00		USD	787		(63,360	)
	Keros Therapeutics, Inc.		199		01/19/24		USD	35.00		USD	791		(119,400	)
	Legend Biotech Corp., ADR		496		01/19/24		USD	75.00		USD	2,984		(9,920	)
	Masimo Corp.		295		01/19/24		USD	120.00		USD	3,458		(116,525	)
	Merck & Co., Inc.		160		01/19/24		USD	110.00		USD	1,744		(21,280	)
	Mettler-Toledo International, Inc.		49		01/19/24		USD	1,240.00		USD	5,944		(103,390	)
	Molina Healthcare, Inc.		113		01/19/24		USD	380.00		USD	4,083		(29,380	)
	MoonLake Immunotherapeutics, Class A		365		01/19/24		USD	80.00		USD	2,204		(68,437	)
	Neurocrine Biosciences, Inc.		320		01/19/24		USD	115.00		USD	4,216		(555,200	)
	Neurocrine Biosciences, Inc.		335		01/19/24		USD	125.00		USD	4,414		(284,750	)
	Nuvalent, Inc., Class A		386		01/19/24		USD	70.00		USD	2,841		(241,250	)
	Repligen Corp.		82		01/19/24		USD	160.00		USD	1,474		(174,660	)
	REVOLUTION Medicines, Inc.		286		01/19/24		USD	22.50		USD	820		(184,470	)
	Rhythm Pharmaceuticals, Inc.		1,206		01/19/24		USD	32.10		USD	5,544		(1,740,315	)
	Rocket Pharmaceuticals, Inc.		403		01/19/24		USD	25.00		USD	1,208		(207,545	)
	Sanofi SA, ADR		586		01/19/24		USD	47.60		USD	2,914		(168,712	)
	Seagen, Inc.		78		01/19/24		USD	215.00		USD	1,784		(109,980	)
	Shockwave Medical, Inc.		20		01/19/24		USD	185.00		USD	381		(21,300	)
	STERIS PLC		252		01/19/24		USD	219.50		USD	5,540		(138,934	)
	Structure Therapeutics, Inc., ADR		262		01/19/24		USD	70.00		USD	1,068		(6,550	)
	Stryker Corp.		69		01/19/24		USD	300.00		USD	2,066		(38,295	)
	Tandem Diabetes Care, Inc.		207		01/19/24		USD	32.50		USD	612		(15,525	)
	Twist Bioscience Corp.		208		01/19/24		USD	35.00		USD	767		(101,920	)
	Ultragenyx Pharmaceutical, Inc.		159		01/19/24		USD	40.00		USD	760		(124,815	)
	UnitedHealth Group, Inc.		56		01/19/24		USD	550.00		USD	2,948		(15,932	)

80 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Schedule of Investments (continued) December 31, 2023 BlackRock Health Sciences Term Trust (BMEZ)

Exchange-Traded Options Written (continued)

	Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
	Call (continued)
	Vaxcyte, Inc.		325		01/19/24		USD	55.00		USD	2,041	$	(284,375	)
	Vertex Pharmaceuticals, Inc.		67		01/19/24		USD	370.00		USD	2,726		(261,300	)
	Viking Therapeutics, Inc.		376		01/19/24		USD	14.00		USD	700		(182,360	)
	Waters Corp.		90		01/19/24		USD	320.00		USD	2,963		(134,100	)
	West Pharmaceutical Services, Inc.		348		01/19/24		USD	380.00		USD	12,254		(33,930	)
	Xenon Pharmaceuticals, Inc.		672		01/19/24		USD	45.00		USD	3,095		(285,600	)
	Zimmer Biomet Holdings, Inc.		247		01/19/24		USD	120.00		USD	3,006		(91,390	)
	Cencora, Inc.		80		01/25/24		USD	204.00		USD	1,643		(36,614	)
	Abbott Laboratories		204		01/26/24		USD	109.00		USD	2,245		(61,812	)
	Align Technology, Inc.		313		01/26/24		USD	280.00		USD	8,576		(342,735	)
	Amgen, Inc.		304		01/26/24		USD	285.00		USD	8,756		(258,400	)
	Biogen, Inc.		109		01/26/24		USD	265.00		USD	2,821		(54,500	)
	Danaher Corp.		83		01/26/24		USD	235.00		USD	1,920		(39,840	)
	Intuitive Surgical, Inc.		166		01/26/24		USD	330.00		USD	5,600		(307,930	)
	Merck & Co., Inc.		161		01/26/24		USD	107.00		USD	1,755		(56,350	)
	Vertex Pharmaceuticals, Inc.		14		01/26/24		USD	405.00		USD	570		(17,360	)
	Bio-Techne Corp.		812		01/31/24		USD	77.00		USD	6,265		(596,475	)
	McKesson Corp.		60		02/09/24		USD	475.00		USD	2,778		(64,500	)
	10X Genomics, Inc., Class A		188		02/16/24		USD	50.00		USD	1,052		(141,000	)
	10X Genomics, Inc., Class A		158		02/16/24		USD	55.00		USD	884		(75,840	)
	Abbott Laboratories		204		02/16/24		USD	110.00		USD	2,245		(67,320	)
	AbbVie, Inc.		170		02/16/24		USD	160.00		USD	2,634		(37,485	)
	Argenx SE, ADR		54		02/16/24		USD	500.00		USD	2,054		(27,000	)
	Arrowhead Pharmaceuticals, Inc.		130		02/16/24		USD	35.00		USD	398		(15,925	)
	Avantor, Inc.		457		02/16/24		USD	21.00		USD	1,043		(110,822	)
	Becton Dickinson & Co.		190		02/16/24		USD	240.00		USD	4,633		(196,650	)
	Biohaven Ltd.		317		02/16/24		USD	40.00		USD	1,357		(163,255	)
	BioMarin Pharmaceutical, Inc.		760		02/16/24		USD	100.00		USD	7,328		(207,100	)
	Bio-Rad Laboratories, Inc., Class A		64		02/16/24		USD	350.00		USD	2,066		(48,640	)
	Boston Scientific Corp.		1,458		02/16/24		USD	57.50		USD	8,429		(335,340	)
	Cabaletta Bio, Inc.		660		02/16/24		USD	30.00		USD	1,498		(46,200	)
	Cencora, Inc.		275		02/16/24		USD	204.00		USD	5,648		(183,369	)
	Centene Corp.		194		02/16/24		USD	77.50		USD	1,440		(31,040	)
	Charles River Laboratories International, Inc.		109		02/16/24		USD	240.00		USD	2,577		(100,825	)
	CONMED Corp.		157		02/16/24		USD	120.00		USD	1,719		(20,018	)
	Cooper Cos., Inc.		158		02/16/24		USD	350.00		USD	5,979		(533,250	)
	Elanco Animal Health, Inc.		1,481		02/16/24		USD	13.00		USD	2,207		(333,225	)
	Eli Lilly & Co.		92		02/16/24		USD	620.00		USD	5,363		(147,660	)
	Encompass Health Corp.		131		02/16/24		USD	68.80		USD	874		(18,935	)
	Exact Sciences Corp.		185		02/16/24		USD	75.00		USD	1,369		(94,350	)
	Exelixis, Inc.		958		02/16/24		USD	23.00		USD	2,298		(210,760	)
	Galapagos NV, ADR		119		02/16/24		USD	42.50		USD	484		(10,710	)
	Gilead Sciences, Inc.		204		02/16/24		USD	77.50		USD	1,653		(110,670	)
	Halozyme Therapeutics, Inc.		378		02/16/24		USD	45.00		USD	1,397		(9,450	)
	Hologic, Inc.		311		02/16/24		USD	75.00		USD	2,222		(36,542	)
	Immunocore Holdings PLC, ADR		96		02/16/24		USD	65.00		USD	656		(63,360	)
	Inspire Medical Systems, Inc.		130		02/16/24		USD	175.00		USD	2,645		(456,950	)
	Ionis Pharmaceuticals, Inc.		548		02/16/24		USD	55.00		USD	2,772		(80,830	)
	Karuna Therapeutics, Inc.		35		02/16/24		USD	240.00		USD	1,108		(275,275	)
	Legend Biotech Corp., ADR		515		02/16/24		USD	70.00		USD	3,099		(77,250	)
	Molina Healthcare, Inc.		114		02/16/24		USD	400.00		USD	4,119		(49,020	)
	Nuvalent, Inc., Class A		386		02/16/24		USD	80.00		USD	2,841		(133,170	)
	Penumbra, Inc.		191		02/16/24		USD	260.00		USD	4,804		(207,235	)
	PTC Therapeutics, Inc.		722		02/16/24		USD	31.00		USD	1,990		(149,815	)
	Repligen Corp.		222		02/16/24		USD	185.00		USD	3,992		(179,820	)
	REVOLUTION Medicines, Inc.		294		02/16/24		USD	28.00		USD	843		(80,850	)
	Rhythm Pharmaceuticals, Inc.		651		02/16/24		USD	40.41		USD	2,993		(479,126	)
	Rocket Pharmaceuticals, Inc.		403		02/16/24		USD	27.12		USD	1,208		(165,105	)
	Sanofi SA, ADR		1,003		02/16/24		USD	49.00		USD	4,988		(226,614	)
	Shockwave Medical, Inc.		184		02/16/24		USD	184.95		USD	3,506		(335,382	)
	STERIS PLC		255		02/16/24		USD	202.97		USD	5,606		(521,776	)
	Structure Therapeutics, Inc., ADR		262		02/16/24		USD	85.00		USD	1,068		(19,650	)

S C H E D U L E  O F  I N V E S T M E N T S 81

Schedule of Investments (continued) December 31, 2023 BlackRock Health Sciences Term Trust (BMEZ)

Exchange-Traded Options Written (continued)

	Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
	Call (continued)
	Stryker Corp.		73		02/16/24		USD	310.00		USD	2,186	$	(50,370	)
	Tandem Diabetes Care, Inc.		208		02/16/24		USD	32.50		USD	615		(35,880	)
	Twist Bioscience Corp.		208		02/16/24		USD	35.00		USD	767		(130,000	)
	Ultragenyx Pharmaceutical, Inc.		219		02/16/24		USD	45.00		USD	1,047		(97,455	)
	United Therapeutics Corp.		94		02/16/24		USD	260.00		USD	2,067		(3,995	)
	Vaxcyte, Inc.		564		02/16/24		USD	60.00		USD	3,542		(301,740	)
	Viking Therapeutics, Inc.		376		02/16/24		USD	18.00		USD	700		(99,640	)
	Xenon Pharmaceuticals, Inc.		672		02/16/24		USD	47.50		USD	3,095		(233,520	)
	Bruker Corp.		296		03/15/24		USD	72.50		USD	2,175		(143,560	)
	Incyte Corp.		316		03/15/24		USD	65.00		USD	1,984		(84,530	)
												$	(26,603,366	)

OTC Options Written

	Description	Counterparty	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
	Call
	QIAGEN NV	Morgan Stanley & Co. International PLC		106,200		01/04/24		USD	39.91		USD	4,612	$	(381,140	)
	United Therapeutics Corp.	BNP Paribas SA		8,400		01/04/24		USD	235.69		USD	1,847		(487	)
	Waters Corp.	Morgan Stanley & Co. International PLC		19,800		01/04/24		USD	273.35		USD	6,519		(1,111,401	)
	Elanco Animal Health, Inc.	Goldman Sachs International		98,800		01/08/24		USD	9.64		USD	1,472		(521,540	)
	Gerresheimer AG	Morgan Stanley & Co. International PLC		14,900		01/09/24		EUR	97.55		EUR	1,404		(15,936	)
	Masimo Corp.	BNP Paribas SA		17,000		01/09/24		USD	86.94		USD	1,993		(517,067	)
	Novo Nordisk A/S, Class B	Goldman Sachs International		19,700		01/09/24		DKK	736.76		DKK	13,786		(6,431	)
	ConvaTec Group PLC	Morgan Stanley & Co. International PLC		510,000		01/10/24		GBP	2.17		GBP	1,245		(178,081	)
	Zimmer Biomet Holdings, Inc.	Barclays Bank PLC		24,700		01/10/24		USD	117.91		USD	3,006		(114,276	)
	ConvaTec Group PLC	UBS AG		411,500		01/17/24		GBP	2.30		GBP	1,005		(79,270	)
	Gerresheimer AG	Morgan Stanley & Co. International PLC		28,000		01/17/24		EUR	99.47		EUR	2,639		(31,259	)
	Genmab A/S	Morgan Stanley & Co. International PLC		9,200		01/18/24		DKK	2,308.53		DKK	19,809		(11,257	)
	Novo Nordisk A/S, Class B	Morgan Stanley & Co. International PLC		19,600		01/18/24		DKK	703.28		DKK	13,716		(45,757	)
	ConvaTec Group PLC	UBS AG		490,000		01/23/24		GBP	2.30		GBP	1,196		(98,652	)
	Genmab A/S	Morgan Stanley & Co. International PLC		1,900		01/23/24		DKK	2,284.88		DKK	4,091		(5,012	)
	Gerresheimer AG	UBS AG		20,000		01/23/24		EUR	88.70		EUR	1,885		(160,745	)
	QIAGEN NV	Morgan Stanley & Co. International PLC		106,200		01/23/24		USD	40.29		USD	4,612		(388,600	)
	Cencora, Inc.	Citibank N.A.		11,500		01/31/24		USD	201.54		USD	2,362		(79,546	)
	Gerresheimer AG	UBS AG		14,900		02/01/24		EUR	88.60		EUR	1,404		(130,320	)
	Sartorius AG	Bank of America N.A.		15,300		02/01/24		EUR	306.80		EUR	5,089		(607,225	)
	Novo Nordisk A/S, Class B	Morgan Stanley & Co. International PLC		69,200		02/06/24		DKK	735.42		DKK	48,425		(141,574	)
	Genmab A/S	Citibank N.A.		36,500		02/26/24		USD	32.28		USD	1,162		(66,022	)
	Lonza Group AG, Registered Shares	Goldman Sachs International		7,400		02/27/24		CHF	359.38		CHF	2,624		(136,482	)
													$	(4,828,080	)

Balances Reported in the Statements of Assets and Liabilities for Options Written

	Description	Swap Premiums Paid		Swap Premiums Received		Unrealized Appreciation		Unrealized Depreciation			Value
	Options Written	$	N/A	$	N/A	$	2,395,662	$	(19,100,792	)	$	(31,431,446)

82 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Schedule of Investments (continued) December 31, 2023   BlackRock Health Sciences Term Trust (BMEZ)

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

	Commodity Contracts		Credit Contracts		Equity Contracts		Foreign Currency Exchange Contracts		Interest Rate Contracts		Other Contracts		Total
Assets — Derivative Financial Instruments
Forward foreign currency exchange contracts
Unrealized appreciation on forward foreign currency exchange contracts	$	—	$	—	$	—	$	1,429,095	$	—	$	—	$	1,429,095
Liabilities — Derivative Financial Instruments
Options written
Options written at value	$	—	$	—	$	31,431,446	$	—	$	—	$	—	$	31,431,446

For the period ended December 31, 2023, the effect of derivative financial instruments in the Statements of Operations was as follows:

	Commodity Contracts		Credit Contracts		Equity Contracts			Foreign Currency Exchange Contracts			Interest Rate Contracts		Other Contracts		Total
Net Realized Gain (Loss) from:
Forward foreign currency exchange contracts	$	—	$	—	$	—		$	(57,158	)	$	—	$	—	$	(57,158	)
Options purchased(a)		—		—		(2,939,621	)		—			—		—		(2,939,621	)
Options written		—		—		24,415,306			—			—		—		24,415,306
	$	—	$	—	$	21,475,685		$	(57,158	)	$	—	$	—	$	21,418,527
Net Change in Unrealized Appreciation (Depreciation) on:
Forward foreign currency exchange contracts	$	—	$	—	$	—		$	(3,535,460	)	$	—	$	—	$	(3,535,460	)
Options written		—		—		(19,080,793	)		—			—		—		(19,080,793	)
	$	—	$	—	$	(19,080,793	)	$	(3,535,460	)	$	—	$	—	$	(22,616,253	)

^(a)  Options purchased are included in net realized gain (loss) from investments — unaffiliated.

Average Quarterly Balances of Outstanding Derivative Financial Instruments

Forward foreign currency exchange contracts:
Average amounts purchased — in USD	$	1,628,769
Average amounts sold — in USD	$	88,273,543
Options:
Average value of option contracts purchased	$	38
Average value of option contracts written	$	19,905,286

For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

Derivative Financial Instruments — Offsetting as of Period End

The Trust’s derivative assets and liabilities (by type) were as follows:

	Assets		Liabilities
Derivative Financial Instruments
Forward foreign currency exchange contracts	$	1,429,095	$	—
Options		—		31,431,446
Total derivative assets and liabilities in the Statements of Assets and Liabilities		1,429,095		31,431,446
Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”)		—		(26,603,366	)
Total derivative assets and liabilities subject to an MNA	$	1,429,095	$	4,828,080

S C H E D U L E  O F  I N V E S T M E N T S 83

Schedule of Investments (continued) December 31, 2023   BlackRock Health Sciences Term Trust (BMEZ)

The following table presents the Trust’s derivative assets and liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral received and pledged by the Trust:

Counterparty		Derivative Assets Subject to an MNA by Counterparty		Derivatives Available for Offset	(a)		Non-Cash Collateral Received			Cash Collateral Received		Net Amount of Derivative Assets	(b)(c)
Barclays Bank PLC	$	182,850	$	(114,276	)	$	—		$	—	$	68,574
Morgan Stanley & Co. International PLC		1,246,245		(1,246,245	)		—			—		—
	$	1,429,095	$	(1,360,521	)	$	—		$	—	$	68,574

Counterparty		Derivative Liabilities Subject to an MNA by Counterparty		Derivatives Available for Offset	(a)		Non-Cash Collateral Pledged	(d)		Cash Collateral Pledged			Net Amount of Derivative Liabilities	(e)
Bank of America N.A.	$	607,225	$	—		$	(607,225	)	$	—		$	—
Barclays Bank PLC		114,276		(114,276	)		—			—			—
BNP Paribas SA		517,554		—			—			(440,000	)		77,554
Citibank N.A.		145,568		—			—			—			145,568
Goldman Sachs International		664,453		—			(664,453	)		—			—
Morgan Stanley & Co. International PLC		2,310,017		(1,246,245	)		(1,047,772	)		(16,000	)		—
UBS AG		468,987		—			(468,987	)		—			—
	$	4,828,080	$	(1,360,521	)	$	(2,788,437	)	$	(456,000	)	$	223,122

^(a)  The amount of derivatives available for offset is limited to the amount of derivative asset and/or liabilities that are subject to an MNA.

^(b)  Net amount may also include forward foreign currency exchange contracts that are not required to be collateralized.

^(c)  Net amount represents the net amount receivable from the counterparty in the event of default.

^(d)  Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes.

^(e)  Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation of financial instruments, refer to the Notes to Financial Statements.

The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s financial instruments into major categories is disclosed in the Schedule of Investments above.

	Level 1		Level 2		Level 3		Total
Assets
Investments
Long-Term Investments
Common Stocks
Biotechnology	$	686,050,922	$	31,502,136	$	—	$	717,553,058
Electronic Equipment, Instruments & Components		3,075,222		—		—		3,075,222
Health Care Equipment & Supplies		368,473,189		13,727,210		—		382,200,399
Health Care Providers & Services		164,087,690		17,862,430		—		181,950,120
Health Care Technology		1,372,894		—		—		1,372,894
Life Sciences Tools & Services		245,757,920		35,162,748		—		280,920,668
Pharmaceuticals		129,596,162		35,150,651		—		164,746,813
Other Interests		—		—		4,664,318		4,664,318
Preferred Securities
Preferred Stocks		—		17,600,893		143,543,684		161,144,577
Rights		—		3,152		268,290		271,442
Warrants		4,611		—		—		4,611

84 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Schedule of Investments (continued) December 31, 2023   BlackRock Health Sciences Term Trust (BMEZ)

Fair Value Hierarchy as of Period End (continued)

	Level 1			Level 2			Level 3		Total
Short-Term Securities
Money Market Funds	$	40,473,813		$	—		$	—	$	40,473,813
	$	1,638,892,423		$	151,009,220		$	148,476,292		1,938,377,935
Investments Valued at NAV(a)										12,308,246
									$	1,950,686,181
Derivative Financial Instruments(b)
Assets
Foreign Currency Exchange Contracts	$	—		$	1,429,095		$	—	$	1,429,095
Liabilities
Equity Contracts		(21,191,621	)		(10,239,825	)		—		(31,431,446	)
	$	(21,191,621	)	$	(8,810,730	)	$	—	$	(30,002,351	)

^(a)  Certain investments of the Trust were fair valued using NAV as a practical expedient as no quoted market value is available and therefore have been excluded from the fair value hierarchy.

^(b)  Derivative financial instruments are forward foreign currency exchange contracts and options written. Forward foreign currency exchange contracts are valued at the unrealized appreciation (depreciation) on the instrument and options written are shown at value.

A reconciliation of Level 3 financial instruments is presented when the Trust had a significant amount of Level 3 investments and derivative financial instruments at the beginning and/or end of the year in relation to net assets. The following table is a reconciliation of Level 3 investments for which significant unobservable inputs were used in determining fair value:

	Common Stocks			Other Interests			Preferred Stocks			Rights		Total
Assets
Opening balance, as of December 31, 2022	$	12,093,187		$	4,076,191		$	158,791,702		$	—	$	174,961,080
Transfers into Level 3		—			—			—			—		—
Transfers out of Level 3		—			—			—			—		—
Other(a)		(12,093,187	)		5,987,002			6,005,576			100,609		—
Accrued discounts/premiums		—			—			—			—		—
Net realized gain (loss)		—			1,973,468			—			—		1,973,468
Net change in unrealized appreciation (depreciation)(b)(c)		—			(5,398,876	)		(24,086,134	)		167,681		(29,317,329	)
Purchases		—			—			51,822,457			—		51,822,457
Sales		—			(1,973,467	)		(48,989,917	)		—		(50,963,384	)
Closing balance, as of December 31, 2023	$	—		$	4,664,318		$	143,543,684		$	268,290	$	148,476,292
Net change in unrealized appreciation (depreciation) on investments still held at December 31, 2023(c)	$	—		$	(1,322,685	)	$	(18,668,933	)	$	167,681	$	(19,823,937	)

^(a)  Certain Level 3 investments were re-classified between Common Stocks, Preferred Stocks and Rights.

^(b)  Included in the related net change in unrealized appreciation (depreciation) in the Statements of Operations.

^(c)  Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized appreciation (depreciation) on investments still held at December 31, 2023 is generally due to investments no longer held or categorized as Level 3 at period end.

The following table summarizes the valuation approaches used and unobservable inputs utilized by the BlackRock Valuation Committee (the “Valuation Committee”) to determine the value of certain of the Trust’s Level 3 financial instruments as of period end.

	Value	Valuation Approach	Unobservable Inputs	Range of Unobservable Inputs Utilized	(a)	Weighted Average of Unobservable Inputs Based on Fair Value
Assets
Preferred Stocks(b)	143,543,684	Market	Revenue Multiple	2.25x - 5.75x		3.51x
			Volatility	50% - 100%		74%
			Time to Exit	1.5 - 4.0 years		2.5 years
			Market Adjustment Multiple	0.60x - 1.20x		0.91x
		Income	Discount Rate	6%		—
Other Interests	4,664,318	Income	Discount Rate	5% - 6%		6%

S C H E D U L E  O F  I N V E S T M E N T S 85

Schedule of Investments (continued) December 31, 2023   BlackRock Health Sciences Term Trust (BMEZ)

		Value	Valuation Approach	Unobservable Inputs	Range of Unobservable Inputs Utilized	(a)	Weighted Average of Unobservable Inputs Based on Fair Value
Rights		268,290	Income	Discount Rate	5%		—
	$	148,476,292

^(a)  A significant change in unobservable input would have resulted in a correlated (inverse) significant change to value.

^(b)  For the period end December 31, 2023, the valuation technique for investments classified as Preferred Stocks amounting to $1,309,244 changed to a Discounted Cash Flow approach. The investments were previously valued utilizing a Option Pricing Model. The change was due to consideration of the information that was available at the time the investments were valued.

See notes to financial statements.

86 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Schedule of Investments  December 31, 2023   BlackRock Health Sciences Trust (BME) (Percentages shown are based on Net Assets)

Security	Shares		Value
Common Stocks
Biotechnology — 24.3%
AbbVie, Inc.		171,601	$	26,593,007
AC Immune SA(a)		78,180		390,900
Alnylam Pharmaceuticals, Inc.(a)		13,010		2,490,244
Amgen, Inc.(b)		75,441		21,728,517
Argenx SE, ADR(a)		16,353		6,221,172
BeiGene Ltd., ADR(a)		6,675		1,203,903
Biogen, Inc.(a)		42,571		11,016,098
BioMarin Pharmaceutical, Inc.(a)		45,161		4,354,424
Biomea Fusion, Inc.(a)		9,387		136,299
Blueprint Medicines Corp.(a)		26,672		2,460,225
Cabaletta Bio, Inc.(a)		29,605		672,033
Cerevel Therapeutics Holdings, Inc.(a)		16,659		706,342
CureVac NV(a)		29,850		125,668
Exact Sciences Corp.(a)		14,991		1,109,034
Genmab A/S(a)		2,927		933,283
Genmab A/S, ADR(a)		19,943		634,985
Gilead Sciences, Inc.		178,480		14,458,665
Immuneering Corp., Class A(a)		14,456		106,252
Immunocore Holdings PLC, ADR(a)		12,497		853,795
Incyte Corp.(a)		27,851		1,748,764
Ionis Pharmaceuticals, Inc.(a)		25,805		1,305,475
Karuna Therapeutics, Inc.(a)		2,227		704,868
Legend Biotech Corp., ADR(a)		32,098		1,931,337
Merus NV(a)		23,470		645,425
Mirati Therapeutics, Inc.(a)		15,747		925,136
Moderna, Inc.(a)		33,556		3,337,144
MoonLake Immunotherapeutics, Class A(a)		10,337		624,251
Morphic Holding, Inc.(a)		7,827		226,044
Neurocrine Biosciences, Inc.(a)		9,808		1,292,302
Neurogene, Inc.		19,342		374,848
Nuvalent, Inc., Class A(a)		13,886		1,021,871
Prime Medicine, Inc.(a)		22,929		203,151
Protagonist Therapeutics, Inc.(a)		27,836		638,279
PTC Therapeutics, Inc.(a)		19,817		546,156
Regeneron Pharmaceuticals, Inc.(a)		9,307		8,174,245
REVOLUTION Medicines, Inc.(a)		18,339		525,963
Rhythm Pharmaceuticals, Inc.(a)		49,466		2,273,952
Rocket Pharmaceuticals, Inc.(a)		18,343		549,740
Roivant Sciences Ltd.(a)		53,725		603,332
Sarepta Therapeutics, Inc.(a)		36,858		3,554,217
Tenaya Therapeutics, Inc.(a)		25,502		82,626
Ultragenyx Pharmaceutical, Inc.(a)		14,268		682,296
Vaxcyte, Inc.(a)		28,905		1,815,234
Vertex Pharmaceuticals, Inc.(a)		27,779		11,302,997
Viking Therapeutics, Inc.(a)		17,352		322,921
Xenon Pharmaceuticals, Inc.(a)		32,241		1,485,020
				143,092,440
Health Care Equipment & Supplies — 22.1%
Abbott Laboratories(b)		190,037		20,917,373
Alcon, Inc.		91,365		7,137,434
Align Technology, Inc.(a)		11,220		3,074,280
Baxter International, Inc.		60,439		2,336,572
Becton Dickinson & Co.		39,171		9,551,065
Boston Scientific Corp.(a)		441,434		25,519,300
Cooper Cos., Inc.		13,642		5,162,678
Dexcom, Inc.(a)		28,333		3,515,842
Envista Holdings Corp.(a)		22,246		535,239
GE HealthCare, Inc.(a)		42,353		3,274,734
IDEXX Laboratories, Inc.(a)		7,516		4,171,756
Inspire Medical Systems, Inc.(a)		5,782		1,176,232

Security	Shares		Value
Health Care Equipment & Supplies (continued)
Intuitive Surgical, Inc.(a)		42,340	$	14,283,822
Masimo Corp.(a)		15,144		1,775,028
Medtronic PLC		79,846		6,577,713
Novocure Ltd.(a)		29,303		437,494
Orchestra BioMed Holdings, Inc.(a)		18,076		165,034
Penumbra, Inc.(a)		12,105		3,044,892
Shockwave Medical, Inc.(a)		3,150		600,264
STERIS PLC		9,997		2,197,840
Stryker Corp.		49,207		14,735,528
				130,190,120
Health Care Providers & Services — 21.1%
Cencora, Inc.		62,148		12,763,956
Centene Corp.(a)		77,624		5,760,477
Cigna Group		31,736		9,503,345
Elevance Health, Inc.(b)		28,967		13,659,678
Guardant Health, Inc.(a)		15,095		408,320
HCA Healthcare, Inc.		21,723		5,879,982
Humana, Inc.		15,630		7,155,570
Laboratory Corp. of America Holdings		6,745		1,533,071
McKesson Corp.		25,848		11,967,107
Quest Diagnostics, Inc.		11,479		1,582,725
UnitedHealth Group, Inc.(b)		102,008		53,704,152
				123,918,383
Life Sciences Tools & Services — 8.3%
10X Genomics, Inc., Class A(a)		15,123		846,283
Agilent Technologies, Inc.		23,561		3,275,686
Avantor, Inc.(a)		88,349		2,017,008
Bio-Techne Corp.		16,718		1,289,961
Danaher Corp.		78,006		18,045,908
IQVIA Holdings, Inc.(a)		9,048		2,093,526
Mettler-Toledo International, Inc.(a)		1,010		1,225,090
Nautilus Biotechnology, Inc.(a)		16,560		49,515
QIAGEN NV(a)		36,163		1,570,559
Rapid Micro Biosystems, Inc., Class A(a)		20,561		15,215
Repligen Corp.(a)		8,125		1,460,875
Thermo Fisher Scientific, Inc.		24,009		12,743,737
West Pharmaceutical Services, Inc.		11,152		3,926,842
				48,560,205
Pharmaceuticals — 19.1%
AstraZeneca PLC		17,449		2,353,693
Catalent, Inc.(a)		20,853		936,925
Daiichi Sankyo Co. Ltd.		34,800		952,710
Elanco Animal Health, Inc.(a)		97,264		1,449,233
Eli Lilly & Co.		81,287		47,383,818
Johnson & Johnson(b)		70,368		11,029,480
Merck & Co., Inc.(b)		230,007		25,075,363
Novo Nordisk A/S, Class B		68,574		7,106,403
Pfizer, Inc.(b)		282,816		8,142,273
Sanofi SA		26,788		2,661,998
Structure Therapeutics, Inc., ADR(a)		26,914		1,097,015
Zoetis, Inc., Class A		20,979		4,140,625
				112,329,536
Total Common Stocks — 94.9% (Cost: $376,066,296)				558,090,684

S C H E D U L E  O F  I N V E S T M E N T S 87

Schedule of Investments (continued) December 31, 2023 BlackRock Health Sciences Trust (BME) (Percentages shown are based on Net Assets)

Security	Benefical Interest (000)		Value
Other Interests
Biotechnology — 0.0%
Affinivax, Inc., (Acquired 08/18/22, Cost: $ —)(c)(d)(e)	$	6	$	84,962
Health Care Providers & Services — 0.0%
Afferent Pharmaceuticals, Inc., (Acquired 09/30/15, Cost: $ —)(c)(d)(e)		190		26,622
Total Other Interests — 0.0% (Cost: $ — )				111,584
	Shares
Preferred Securities
Preferred Stocks — 0.8%(a)(c)(e)
Biotechnology — 0.3%
Cellarity, Inc., Series B, (Acquired 01/15/21, Cost: $265,002)		44,167		146,635
Genesis Therapeutics, Series B, (Acquired 08/10/23, Cost: $292,001)		57,170		292,139
Goldfinch Bio, Inc., Series B, (Acquired 06/26/20, Cost: $224,200)		190,000		64,600
Kartos Therapeutics, Series C, (Acquired 08/22/23, Cost: $485,124)		85,817		486,582
Laronde, Inc., Series B, (Acquired 07/28/21, Cost: $590,800)		21,100		590,800
				1,580,756
Health Care Equipment & Supplies — 0.2%
Exo Imaging, Inc., Series C, (Acquired 06/24/21, Cost: $595,999)		101,741		268,596
Nucleix Ltd., Series AA, (Acquired 03/25/21, Cost: $1,070,001)		367,395		995,641
Swift Health Systems, Inc., Series D, (Acquired 08/27/21, Cost: $286,998)		92,580		77,767
				1,342,004
Health Care Providers & Services — 0.1%
Quanta Dialysis Technologies Ltd., Series D, (Acquired 06/18/21, Cost: $515,759)		4,243,029		286,644
Health Care Technology — 0.1%
Carbon Health Technologies, Inc., Series D2, (Acquired 02/02/23, Cost: $907,000)		89,892		791,948
Pharmaceuticals — 0.1%
Adarx Pharamaceuticals, Series C, (Acquired 08/02/23, Cost: $440,003)		52,885		440,532
Insitro, Inc., Series C, (Acquired 03/10/21, Cost: $560,000)		30,616		319,631
				760,163
				4,761,515
Total Preferred Securities — 0.8% (Cost: $6,232,887)				4,761,515

Security	Shares		Value
Rights
Biotechnology — 0.0%
Korro Bio, Inc., CVR		28,060	$	382
Health Care Equipment & Supplies — 0.0%
Abiomed, Inc., CVR(c)		14,359		39,056
Total Rights — 0.0% (Cost: $14,646)				39,438
Warrants
Health Care Providers & Services — 0.0%
CareMax, Inc., (Issued/Exercisable 09/15/20, 1 Share for 1 Warrant, Expires 08/06/26, Strike Price USD 11.50)(a)		4,201		32
Pharmaceuticals — 0.0%
Nuvation Bio, Inc., (Issued/Exercisable 08/17/20, 1 Share for 1 Warrant, Expires 07/07/27, Strike Price USD 11.50)(a)		4,050		243
Total Warrants — 0.0% (Cost: $14,031)				275
Total Long-Term Investments — 95.7% (Cost: $382,327,860)				563,003,496
Short-Term Securities
Money Market Funds — 5.3%
BlackRock Liquidity Funds, T-Fund, Institutional Class, 5.26%(f)(g)		31,396,977		31,396,977
Total Short-Term Securities — 5.3% (Cost: $31,396,977)				31,396,977
Total Investments Before Options Written — 101.0% (Cost: $413,724,837)				594,400,473
Options Written — (1.2)% (Premiums Received: $(4,793,338))				(7,272,745	)
Total Investments, Net of Options Written — 99.8% (Cost: $408,931,499)				587,127,728
Other Assets Less Liabilities — 0.2%			1,007,702
Net Assets — 100.0%			$	588,135,430

^(a)  Non-income producing security.

^(b)  All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

^(c)  Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.

^(d)  Other interests represent beneficial interests in liquidation trusts and other reorganization or private entities.

^(e)  Restricted security as to resale, excluding 144A securities. The Trust held restricted securities with a current value of $4,873,099, representing 0.8% of its net assets as of period end, and an original cost of $6,232,887.

^(f)  Affiliate of the Trust.

^(g)  Annualized 7-day yield as of period end.

For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

88 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Schedule of Investments (continued) December 31, 2023   BlackRock Health Sciences Trust (BME)

Affiliates

Investments in issuers considered to be affiliate(s) of the Trust during the year ended December 31, 2023 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

Affiliated Issuer	Value at 12/31/22		Purchases at Cost			Proceeds from Sale			Net Realized Gain (Loss)		Change in Unrealized Appreciation (Depreciation)			Value at 12/31/23		Shares Held at 12/31/23		Income			Capital Gain Distributions from Underlying Funds
BlackRock Liquidity Funds, T-Fund, Institutional Class	$	23,195,315	$	8,201,662	(a)	$	—		$	—	$	—		$	31,396,977		31,396,977	$	1,268,777		$	—
SL Liquidity Series, LLC, Money Market Series(b)		675,980		—			(676,809	)(a)		1,094		(265	)		—		—		25,650	(c)		—
									$	1,094	$	(265	)	$	31,396,977			$	1,294,427		$	—

^(a)  Represents net amount purchased (sold).

^(b)  As of period end, the entity is no longer held.

^(c)  All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.

Derivative Financial Instruments Outstanding as of Period End

Exchange-Traded Options Written

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call
Abbott Laboratories		410		01/05/24		USD	105.00		USD	4,513	$	(214,225	)
Amgen, Inc.		110		01/05/24		USD	275.00		USD	3,168		(147,125	)
Centene Corp.		62		01/05/24		USD	75.00		USD	460		(2,945	)
Cigna Group		70		01/05/24		USD	285.00		USD	2,096		(106,750	)
Danaher Corp.		76		01/05/24		USD	230.00		USD	1,758		(25,840	)
Elevance Health, Inc.		24		01/05/24		USD	485.00		USD	1,132		(1,260	)
McKesson Corp.		17		01/05/24		USD	470.00		USD	787		(2,720	)
Pfizer, Inc.		154		01/05/24		USD	31.00		USD	443		(308	)
Thermo Fisher Scientific, Inc.		36		01/05/24		USD	500.00		USD	1,911		(114,120	)
UnitedHealth Group, Inc.		153		01/05/24		USD	550.00		USD	8,055		(1,071	)
Alcon, Inc.		135		01/09/24		USD	76.00		USD	1,055		(34,968	)
AbbVie, Inc.		165		01/12/24		USD	146.00		USD	2,557		(157,162	)
Biogen, Inc.		67		01/12/24		USD	245.00		USD	1,734		(96,815	)
Centene Corp.		95		01/12/24		USD	75.00		USD	705		(10,450	)
Cigna Group		36		01/12/24		USD	265.00		USD	1,078		(127,260	)
Danaher Corp.		63		01/12/24		USD	225.00		USD	1,457		(57,960	)
Eli Lilly & Co.		126		01/12/24		USD	615.00		USD	7,345		(31,878	)
Gilead Sciences, Inc.		226		01/12/24		USD	80.00		USD	1,831		(42,149	)
Humana, Inc.		21		01/12/24		USD	495.00		USD	961		(1,470	)
Intuitive Surgical, Inc.		58		01/12/24		USD	320.00		USD	1,957		(121,800	)
Johnson & Johnson		61		01/12/24		USD	160.00		USD	956		(4,057	)
Johnson & Johnson		60		01/12/24		USD	155.00		USD	940		(19,320	)
McKesson Corp.		43		01/12/24		USD	460.00		USD	1,991		(41,925	)
Merck & Co., Inc.		318		01/12/24		USD	102.01		USD	3,467		(235,033	)
Moderna, Inc.		31		01/12/24		USD	85.00		USD	308		(45,957	)
Regeneron Pharmaceuticals, Inc.		10		01/12/24		USD	860.00		USD	878		(30,550	)
10X Genomics, Inc., Class A		30		01/19/24		USD	45.00		USD	168		(34,650	)
AbbVie, Inc.		118		01/19/24		USD	145.00		USD	1,829		(125,375	)
Alcon, Inc.		69		01/19/24		USD	72.50		USD	539		(41,745	)
Align Technology, Inc.		10		01/19/24		USD	240.00		USD	274		(37,700	)
Alnylam Pharmaceuticals, Inc.		49		01/19/24		USD	200.00		USD	938		(19,845	)
Amgen, Inc.		166		01/19/24		USD	285.00		USD	4,781		(123,670	)
Argenx SE, ADR		31		01/19/24		USD	520.00		USD	1,179		(14,570	)
Avantor, Inc.		130		01/19/24		USD	19.75		USD	297		(54,153	)
Becton Dickinson & Co.		48		01/19/24		USD	245.00		USD	1,170		(17,280	)
BeiGene Ltd., ADR		25		01/19/24		USD	200.00		USD	451		(7,063	)
Biogen, Inc.		23		01/19/24		USD	245.00		USD	595		(38,295	)
BioMarin Pharmaceutical, Inc.		41		01/19/24		USD	90.00		USD	395		(29,520	)
Bio-Techne Corp.		23		01/19/24		USD	65.00		USD	177		(27,255	)

S C H E D U L E  O F  I N V E S T M E N T S 89

Schedule of Investments (continued) December 31, 2023   BlackRock Health Sciences Trust (BME)

Exchange-Traded Options Written (continued)

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
Blueprint Medicines Corp.		60		01/19/24		USD	65.00		USD	553	$	(166,200	)
Blueprint Medicines Corp.		41		01/19/24		USD	85.00		USD	378		(41,000	)
Cabaletta Bio, Inc.		50		01/19/24		USD	22.50		USD	114		(9,000	)
Catalent, Inc.		31		01/19/24		USD	40.00		USD	139		(16,740	)
Cencora, Inc.		97		01/19/24		USD	200.00		USD	1,992		(69,355	)
Centene Corp.		41		01/19/24		USD	77.50		USD	304		(2,255	)
Cerevel Therapeutics Holdings, Inc.		32		01/19/24		USD	25.00		USD	136		(56,160	)
Cooper Cos., Inc.		26		01/19/24		USD	360.00		USD	984		(54,470	)
Danaher Corp.		77		01/19/24		USD	230.00		USD	1,781		(50,050	)
Elanco Animal Health, Inc.		138		01/19/24		USD	12.00		USD	206		(41,745	)
Elevance Health, Inc.		10		01/19/24		USD	480.00		USD	472		(5,600	)
Eli Lilly & Co.		74		01/19/24		USD	640.00		USD	4,314		(9,916	)
Exact Sciences Corp.		37		01/19/24		USD	80.00		USD	274		(6,383	)
GE HealthCare, Inc.		160		01/19/24		USD	75.00		USD	1,237		(52,000	)
Gilead Sciences, Inc.		141		01/19/24		USD	82.50		USD	1,142		(12,197	)
Guardant Health, Inc.		43		01/19/24		USD	25.00		USD	116		(11,288	)
HCA Healthcare, Inc.		50		01/19/24		USD	245.00		USD	1,353		(136,500	)
HCA Healthcare, Inc.		32		01/19/24		USD	265.00		USD	866		(30,880	)
Humana, Inc.		7		01/19/24		USD	505.00		USD	320		(473	)
IDEXX Laboratories, Inc.		28		01/19/24		USD	570.00		USD	1,554		(20,020	)
Immunocore Holdings PLC, ADR		18		01/19/24		USD	50.00		USD	123		(33,480	)
Incyte Corp.		61		01/19/24		USD	57.50		USD	383		(35,990	)
Inspire Medical Systems, Inc.		21		01/19/24		USD	165.00		USD	427		(83,475	)
Intuitive Surgical, Inc.		48		01/19/24		USD	340.00		USD	1,619		(42,000	)
Ionis Pharmaceuticals, Inc.		79		01/19/24		USD	52.50		USD	400		(10,073	)
IQVIA Holdings, Inc.		34		01/19/24		USD	240.00		USD	787		(5,950	)
Johnson & Johnson		146		01/19/24		USD	160.00		USD	2,288		(13,067	)
Karuna Therapeutics, Inc.		1		01/19/24		USD	230.00		USD	32		(8,720	)
Legend Biotech Corp., ADR		54		01/19/24		USD	75.00		USD	325		(1,080	)
Masimo Corp.		41		01/19/24		USD	120.00		USD	481		(16,195	)
Merck & Co., Inc.		278		01/19/24		USD	110.00		USD	3,031		(36,974	)
Mettler-Toledo International, Inc.		3		01/19/24		USD	1,240.00		USD	364		(6,330	)
Moderna, Inc.		75		01/19/24		USD	80.00		USD	746		(150,375	)
MoonLake Immunotherapeutics, Class A		39		01/19/24		USD	80.00		USD	236		(7,313	)
Neurocrine Biosciences, Inc.		15		01/19/24		USD	115.00		USD	198		(26,025	)
Neurocrine Biosciences, Inc.		22		01/19/24		USD	125.00		USD	290		(18,700	)
Nuvalent, Inc., Class A		26		01/19/24		USD	70.00		USD	191		(16,250	)
Pfizer, Inc.		340		01/19/24		USD	31.00		USD	979		(3,740	)
Quest Diagnostics, Inc.		12		01/19/24		USD	135.00		USD	165		(4,800	)
Quest Diagnostics, Inc.		32		01/19/24		USD	140.00		USD	441		(4,160	)
Regeneron Pharmaceuticals, Inc.		25		01/19/24		USD	885.00		USD	2,196		(46,375	)
REVOLUTION Medicines, Inc.		34		01/19/24		USD	22.50		USD	98		(21,930	)
Rhythm Pharmaceuticals, Inc.		98		01/19/24		USD	32.10		USD	451		(141,419	)
Rocket Pharmaceuticals, Inc.		32		01/19/24		USD	25.00		USD	96		(16,480	)
Shockwave Medical, Inc.		6		01/19/24		USD	185.00		USD	114		(6,390	)
STERIS PLC		18		01/19/24		USD	219.50		USD	396		(9,924	)
Structure Therapeutics, Inc., ADR		32		01/19/24		USD	70.00		USD	130		(800	)
Stryker Corp.		126		01/19/24		USD	300.00		USD	3,773		(69,930	)
Ultragenyx Pharmaceutical, Inc.		12		01/19/24		USD	40.00		USD	57		(9,420	)
UnitedHealth Group, Inc.		153		01/19/24		USD	550.00		USD	8,055		(43,528	)
Vaxcyte, Inc.		23		01/19/24		USD	55.00		USD	144		(20,125	)
Vertex Pharmaceuticals, Inc.		53		01/19/24		USD	370.00		USD	2,157		(206,700	)
Viking Therapeutics, Inc.		33		01/19/24		USD	14.00		USD	61		(16,005	)
West Pharmaceutical Services, Inc.		48		01/19/24		USD	380.00		USD	1,690		(4,680	)
Xenon Pharmaceuticals, Inc.		61		01/19/24		USD	45.00		USD	281		(25,925	)
Zoetis, Inc., Class A		79		01/19/24		USD	200.00		USD	1,559		(20,737	)
Cencora, Inc.		23		01/25/24		USD	204.00		USD	472		(10,527	)
Abbott Laboratories		156		01/26/24		USD	109.00		USD	1,717		(47,268	)
AbbVie, Inc.		166		01/26/24		USD	152.50		USD	2,573		(65,570	)
Align Technology, Inc.		32		01/26/24		USD	280.00		USD	877		(35,040	)
Amgen, Inc.		10		01/26/24		USD	285.00		USD	288		(8,500	)
Baxter International, Inc.		202		01/26/24		USD	39.00		USD	781		(18,685	)

90 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Schedule of Investments (continued) December 31, 2023   BlackRock Health Sciences Trust (BME)

Exchange-Traded Options Written (continued)

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
Biogen, Inc.		71		01/26/24		USD	265.00		USD	1,837	$	(35,500	)
Cigna Group		7		01/26/24		USD	310.00		USD	210		(2,520	)
Danaher Corp.		80		01/26/24		USD	235.00		USD	1,851		(38,400	)
Eli Lilly & Co.		141		01/26/24		USD	595.00		USD	8,219		(166,380	)
Intuitive Surgical, Inc.		54		01/26/24		USD	330.00		USD	1,822		(100,170	)
Medtronic PLC		26		01/26/24		USD	85.00		USD	214		(1,495	)
Medtronic PLC		23		01/26/24		USD	83.34		USD	189		(2,703	)
Merck & Co., Inc.		278		01/26/24		USD	107.00		USD	3,031		(97,300	)
Moderna, Inc.		21		01/26/24		USD	94.00		USD	209		(19,320	)
Vertex Pharmaceuticals, Inc.		55		01/26/24		USD	405.00		USD	2,238		(68,200	)
Bio-Techne Corp.		40		01/31/24		USD	77.00		USD	309		(29,383	)
Medtronic PLC		59		02/02/24		USD	83.05		USD	486		(9,679	)
McKesson Corp.		38		02/09/24		USD	475.00		USD	1,759		(40,850	)
Medtronic PLC		68		02/09/24		USD	83.34		USD	560		(11,664	)
10X Genomics, Inc., Class A		18		02/16/24		USD	50.00		USD	101		(13,500	)
10X Genomics, Inc., Class A		9		02/16/24		USD	55.00		USD	50		(4,320	)
Abbott Laboratories		156		02/16/24		USD	110.00		USD	1,717		(51,480	)
AbbVie, Inc.		40		02/16/24		USD	160.00		USD	620		(8,820	)
AbbVie, Inc.		163		02/16/24		USD	155.00		USD	2,526		(69,275	)
Agilent Technologies, Inc.		90		02/16/24		USD	140.00		USD	1,251		(43,650	)
Alcon, Inc.		143		02/16/24		USD	77.50		USD	1,117		(41,470	)
Argenx SE, ADR		9		02/16/24		USD	500.00		USD	342		(4,500	)
Avantor, Inc.		75		02/16/24		USD	21.00		USD	171		(18,187	)
Baxter International, Inc.		27		02/16/24		USD	40.00		USD	104		(3,375	)
Becton Dickinson & Co.		100		02/16/24		USD	240.00		USD	2,438		(103,500	)
BioMarin Pharmaceutical, Inc.		130		02/16/24		USD	100.00		USD	1,253		(35,425	)
Boston Scientific Corp.		1,677		02/16/24		USD	57.50		USD	9,695		(385,710	)
Cabaletta Bio, Inc.		60		02/16/24		USD	30.00		USD	136		(4,200	)
Cencora, Inc.		64		02/16/24		USD	204.00		USD	1,314		(42,675	)
Centene Corp.		96		02/16/24		USD	77.50		USD	712		(15,360	)
Cooper Cos., Inc.		25		02/16/24		USD	350.00		USD	946		(84,375	)
Dexcom, Inc.		132		02/16/24		USD	120.00		USD	1,638		(141,900	)
Elanco Animal Health, Inc.		139		02/16/24		USD	13.00		USD	207		(31,275	)
Exact Sciences Corp.		19		02/16/24		USD	75.00		USD	141		(9,690	)
Gilead Sciences, Inc.		358		02/16/24		USD	77.50		USD	2,900		(194,215	)
Humana, Inc.		31		02/16/24		USD	505.00		USD	1,419		(13,485	)
Immunocore Holdings PLC, ADR		29		02/16/24		USD	65.00		USD	198		(19,140	)
Ionis Pharmaceuticals, Inc.		19		02/16/24		USD	55.00		USD	96		(2,803	)
Karuna Therapeutics, Inc.		4		02/16/24		USD	240.00		USD	127		(31,460	)
Laboratory Corp. of America Holdings		25		02/16/24		USD	220.00		USD	568		(30,125	)
Legend Biotech Corp., ADR		67		02/16/24		USD	70.00		USD	403		(10,050	)
Medtronic PLC		68		02/16/24		USD	85.00		USD	560		(7,752	)
Nuvalent, Inc., Class A		26		02/16/24		USD	80.00		USD	191		(8,970	)
Penumbra, Inc.		45		02/16/24		USD	260.00		USD	1,132		(48,825	)
PTC Therapeutics, Inc.		75		02/16/24		USD	31.00		USD	207		(15,562	)
Repligen Corp.		30		02/16/24		USD	185.00		USD	539		(24,300	)
REVOLUTION Medicines, Inc.		35		02/16/24		USD	28.00		USD	100		(9,625	)
Rhythm Pharmaceuticals, Inc.		89		02/16/24		USD	40.41		USD	409		(65,503	)
Rocket Pharmaceuticals, Inc.		37		02/16/24		USD	27.12		USD	111		(15,158	)
Shockwave Medical, Inc.		6		02/16/24		USD	184.95		USD	114		(10,936	)
STERIS PLC		19		02/16/24		USD	202.97		USD	418		(38,877	)
Structure Therapeutics, Inc., ADR		25		02/16/24		USD	85.00		USD	102		(1,875	)
Stryker Corp.		60		02/16/24		USD	310.00		USD	1,797		(41,400	)
Thermo Fisher Scientific, Inc.		36		02/16/24		USD	530.00		USD	1,911		(81,360	)
Ultragenyx Pharmaceutical, Inc.		42		02/16/24		USD	45.00		USD	201		(18,690	)
Vaxcyte, Inc.		86		02/16/24		USD	60.00		USD	540		(46,010	)
Viking Therapeutics, Inc.		32		02/16/24		USD	18.00		USD	60		(8,480	)
West Pharmaceutical Services, Inc.		6		02/16/24		USD	342.92		USD	211		(13,076	)
Xenon Pharmaceuticals, Inc.		61		02/16/24		USD	47.50		USD	281		(21,197	)
Envista Holdings Corp.		84		03/15/24		USD	25.00		USD	202		(10,920	)

S C H E D U L E  O F  I N V E S T M E N T S 91

Schedule of Investments (continued) December 31, 2023   BlackRock Health Sciences Trust (BME)

Exchange-Traded Options Written (continued)

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
Incyte Corp.		44		03/15/24		USD	65.00		USD	276	$	(11,770	)
Medtronic PLC		59		03/15/24		USD	85.00		USD	486		(11,977	)
											$	(6,958,918	)

OTC Options Written

Description	Counterparty	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call
QIAGEN NV	Morgan Stanley & Co. International PLC		6,800		01/04/24		USD	39.91		USD	295	$	(24,404	)
Elanco Animal Health, Inc.	Goldman Sachs International		9,200		01/08/24		USD	9.64		USD	137		(48,565	)
Masimo Corp.	BNP Paribas SA		1,600		01/09/24		USD	86.94		USD	188		(48,665	)
Novo Nordisk A/S, Class B	Goldman Sachs International		1,900		01/09/24		DKK	736.76		DKK	1,330		(620	)
Daiichi Sankyo Co. Ltd.	BNP Paribas SA		13,200		01/17/24		JPY	4,310.70		JPY	50,954		(2,682	)
Genmab A/S	Morgan Stanley & Co. International PLC		1,100		01/18/24		DKK	2,308.53		DKK	2,368		(1,346	)
Novo Nordisk A/S, Class B	Morgan Stanley & Co. International PLC		1,100		01/18/24		DKK	703.28		DKK	770		(2,568	)
Sanofi SA	Morgan Stanley & Co. International PLC		5,400		01/18/24		EUR	87.55		EUR	486		(17,097	)
AstraZeneca PLC	Goldman Sachs International		6,700		01/23/24		GBP	103.39		GBP	709		(34,538	)
Novo Nordisk A/S, Class B	Goldman Sachs International		21,200		01/23/24		DKK	711.62		DKK	14,836		(46,477	)
QIAGEN NV	Morgan Stanley & Co. International PLC		6,800		01/23/24		USD	40.29		USD	295		(24,882	)
Sanofi SA	Morgan Stanley & Co. International PLC		4,700		01/23/24		EUR	89.72		EUR	423		(8,765	)
Cencora, Inc.	Citibank N.A.		5,200		01/31/24		USD	201.53		USD	1,068		(35,969	)
Novo Nordisk A/S, Class B	Morgan Stanley & Co. International PLC		1,800		02/06/24		DKK	735.42		DKK	1,260		(3,683	)
Genmab A/S	Citibank N.A.		7,500		02/26/24		USD	32.28		USD	239		(13,566	)
												$	(313,827	)

Balances Reported in the Statements of Assets and Liabilities for Options Written

Description	Swap Premiums Paid		Swap Premiums Received		Unrealized Appreciation		Unrealized Depreciation			Value
Options Written	$	N/A	$	N/A	$	1,134,305	$	(3,613,712	)	$	(7,272,745	)

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

	Commodity Contracts		Credit Contracts		Equity Contracts		Foreign Currency Exchange Contracts		Interest Rate Contracts		Other Contracts		Total
Liabilities — Derivative Financial Instruments
Options written
Options written at value	$	—	$	—	$	7,272,745	$	—	$	—	$	—	$	7,272,745

92 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Schedule of Investments (continued) December 31, 2023   BlackRock Health Sciences Trust (BME)

For the period ended December 31, 2023, the effect of derivative financial instruments in the Statements of Operations was as follows:

	Commodity Contracts		Credit Contracts		Equity Contracts			Foreign Currency Exchange Contracts		Interest Rate Contracts		Other Contracts		Total
Net Realized Gain (Loss) from:
Options purchased(a)	$	—	$	—	$	(209,469	)	$	—	$	—	$	—	$	(209,469	)
Options written		—		—		5,205,429			—		—		—		5,205,429
	$	—	$	—	$	4,995,960		$	—	$	—	$	—	$	4,995,960
Net Change in Unrealized Appreciation (Depreciation) on:
Options written	$	—	$	—	$	(4,658,396	)	$	—	$	—	$	—	$	(4,658,396	)

^(a)  Options purchased are included in net realized gain (loss) from investments — unaffiliated.

Average Quarterly Balances of Outstanding Derivative Financial Instruments

Options:
Average value of option contracts purchased	$	—	(a)
Average value of option contracts written	$	5,600,802

^(a)  Derivative financial instrument not held at any quarter-end. The risk exposure table serves as an indicator of activity during the period.

For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

Derivative Financial Instruments — Offsetting as of Period End

The Trust’s derivative assets and liabilities (by type) were as follows:

	Assets		Liabilities
Derivative Financial Instruments
Options	$	—	$	7,272,745
Total derivative assets and liabilities in the Statements of Assets and Liabilities		—		7,272,745
Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”)		—		(6,958,918	)
Total derivative assets and liabilities subject to an MNA	$	—	$	313,827

The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the Trust:

Counterparty		Derivative Liabilities Subject to an MNA by Counterparty		Derivatives Available for Offset		Non-Cash Collateral Pledged		Cash Collateral Pledged		Net Amount of Derivative Liabilities	(a)
BNP Paribas SA	$	51,347	$	—	$	—	$	—	$	51,347
Citibank N.A.		49,535		—		—		—		49,535
Goldman Sachs International		130,200		—		—		—		130,200
Morgan Stanley & Co. International PLC		82,745		—		—		—		82,745
	$	313,827	$	—	$	—	$	—	$	313,827

^(a)  Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

S C H E D U L E  O F  I N V E S T M E N T S 93

Schedule of Investments (continued) December 31, 2023   BlackRock Health Sciences Trust (BME)

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation of financial instruments, refer to the Notes to Financial Statements.

The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s financial instruments into major categories is disclosed in the Schedule of Investments above.

	Level 1			Level 2			Level 3		Total
Assets
Investments
Long-Term Investments
Common Stocks
Biotechnology	$	141,784,309		$	1,308,131		$	—	$	143,092,440
Health Care Equipment & Supplies		130,190,120			—			—		130,190,120
Health Care Providers & Services		123,918,383			—			—		123,918,383
Life Sciences Tools & Services		48,560,205			—			—		48,560,205
Pharmaceuticals		99,254,732			13,074,804			—		112,329,536
Other Interests		—			—			111,584		111,584
Preferred Securities
Preferred Stocks		—			—			4,761,515		4,761,515
Rights		—			382			39,056		39,438
Warrants		275			—			—		275
Short-Term Securities
Money Market Funds		31,396,977			—			—		31,396,977
	$	575,105,001		$	14,383,317		$	4,912,155	$	594,400,473
Derivative Financial Instruments(a)
Liabilities
Equity Contracts	$	(6,233,240	)	$	(1,039,505	)	$	—	$	(7,272,745	)

^(a)  Derivative financial instruments are options written. Options written are shown at value.

See notes to financial statements.

94 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Schedule of Investments  December 31, 2023   BlackRock Innovation and Growth Term Trust (BIGZ) (Percentages shown are based on Net Assets)

Security	Shares		Value
Common Stocks
Aerospace & Defense — 5.4%
Axon Enterprise, Inc.(a)(b)		269,406	$	69,595,652
HEICO Corp.		222,346		39,771,029
				109,366,681
Air Freight & Logistics — 0.8%
GXO Logistics, Inc.(b)		273,731		16,741,388
Automobile Components — 1.2%
Fox Factory Holding Corp.(b)(c)		363,790		24,548,549
Biotechnology — 0.8%
Halozyme Therapeutics, Inc.(b)(c)		410,430		15,169,493
Building Products — 1.6%
AZEK Co., Inc., Class A(b)		830,411		31,763,221
Capital Markets — 4.2%
TPG, Inc., Class A		911,268		39,339,439
Tradeweb Markets, Inc., Class A(d)		496,893		45,157,636
				84,497,075
Construction & Engineering — 1.2%
Comfort Systems USA, Inc.		119,706		24,619,933
Diversified Consumer Services(b) — 2.9%
Duolingo, Inc., Class A		111,847		25,372,492
Grammarly, Inc., (Acquired 11/17/21, Cost: $26,250,012)(e)(f)		1,001,454		17,174,936
Ideal Image, Class A, (Acquired 05/05/21, Cost: $50,000,000)(e)(f)		6,224		16,239,254
				58,786,682
Entertainment — 1.3%
Liberty Media Corp.-Liberty Formula One, Class C(b)		409,685		25,863,414
Food Products — 0.3%
Freshpet, Inc.(b)		62,788		5,447,487
Ground Transportation — 2.6%
Saia, Inc.(b)(c)		122,155		53,530,764
Health Care Equipment & Supplies(b) — 5.0%
Align Technology, Inc.		187,295		51,318,830
IDEXX Laboratories, Inc.		69,304		38,467,185
Inmode Ltd.		70,065		1,558,246
Inspire Medical Systems, Inc.		44,833		9,120,377
				100,464,638
Health Care Providers & Services — 1.0%
Surgery Partners, Inc.(b)		651,580		20,844,044
Hotels, Restaurants & Leisure — 3.5%
Planet Fitness, Inc., Class A(b)(d)		675,050		49,278,650
Vail Resorts, Inc.		97,604		20,835,526
				70,114,176
Industrial REITs — 0.1%
Innovative Industrial Properties, Inc.		13,416		1,352,601
Rexford Industrial Realty, Inc.		13,893		779,397
				2,131,998
IT Services(b) — 5.7%
DigitalOcean Holdings, Inc.		333,354		12,230,758
Globant SA		165,042		39,276,695

Security	Shares		Value
IT Services (continued)
MongoDB, Inc., Class A(c)		117,109	$	47,880,015
Patreon, Inc., (Acquired 08/19/21, Cost: $11,732,736)(e)(f)		208,333		5,874,991
Teya Services Ltd., (Acquired 11/16/21, Cost: $49,999,974)(e)(f)		25,742		11,115,138
			116,377,597
Life Sciences Tools & Services — 8.8%
Azenta, Inc.(b)(c)		86,715		5,648,615
Bio-Techne Corp		615,651		47,503,631
Charles River Laboratories International, Inc.(b)		137,183		32,430,061
Repligen Corp.(b)		247,772		44,549,406
West Pharmaceutical Services, Inc.		139,329		49,060,528
				179,192,241
Machinery — 1.3%
AutoStore Holdings Ltd.(b)(c)(g)		13,757,639		27,030,178
Professional Services(b) — 0.3%
Fiverr International Ltd.		195,955		5,333,895
Paylocity Holding Corp.		6,588		1,086,032
				6,419,927
Real Estate Management & Development — 2.8%
CoStar Group, Inc.(b)		636,962		55,664,109
Semiconductors & Semiconductor Equipment — 9.2%
ASM International NV		81,580		42,460,310
Entegris, Inc.(d)		436,574		52,310,297
Lattice Semiconductor Corp.(b)		501,878		34,624,563
Monolithic Power Systems, Inc.(a)(d)		90,663		57,188,407
				186,583,577
Software — 16.7%
ANSYS, Inc.(b)		159,716		57,957,742
Aspen Technology, Inc.(b)(c)		164,760		36,271,914
Bentley Systems, Inc., Class B		798,964		41,689,941
Confluent, Inc., Class A(b)		1,444,548		33,802,423
HubSpot, Inc.(b)		94,841		55,058,994
JFrog Ltd.(b)		601,511		20,818,296
PagerDuty, Inc.(b)(c)		333,419		7,718,650
SiteMinder Ltd.(b)		5,400,709		18,874,399
Snorkel AI, Inc., (Acquired 06/30/21, Cost: $2,999,997)(b)(e)(f)		199,738		1,737,721
Snyk Ltd., Ordinary Shares, (Acquired 09/02/21, Cost: $25,961,537)(b)(e)(f)		1,809,860		19,763,671
Zscaler, Inc.(b)		204,319		45,268,918
				338,962,669
Specialty Retail — 1.4%
Floor & Decor Holdings, Inc., Class A(b)(c)		262,151		29,245,566
Textiles, Apparel & Luxury Goods — 1.1%
On Holding AG, Class A(b)		793,857		21,410,323
Total Common Stocks — 79.2% (Cost: $1,457,618,260)			1,604,775,730

S C H E D U L E  O F  I N V E S T M E N T S 95

Schedule of Investments (continued) December 31, 2023   BlackRock Innovation and Growth Term Trust (BIGZ) (Percentages shown are based on Net Assets)

Security	Shares		Value
Preferred Securities
Preferred Stocks — 21.8%(b)(e)
Aerospace & Defense — 0.1%
SkySafe, Inc., Series B, (Acquired 12/02/21, Cost: $4,999,999)(f)		909,438	$	1,045,854
Automobile Components — 2.2%
Relativity Space, Inc., Series E, (Acquired 05/27/21, Cost: $50,000,009)(f)		2,189,612		43,836,032
Capital Markets(f) — 2.4%
Anchor Labs, Inc., Series D, (Acquired 11/24/21, Cost: $9,999,995)		428,785		2,752,800
The Production Board LLC, Series A3, (Acquired 06/04/21, Cost: $50,000,001)		16,666,667		30,500,000
Varo Money, Inc., Series E, (Acquired 08/27/21, Cost: $40,000,001)		4,316,904		14,720,643
				47,973,443
Diversified Consumer Services — 0.3%
Grammarly, Inc., Series 3, (Acquired 11/17/21, Cost: $8,750,004)(f)		333,818		5,898,564
Diversified Telecommunication Services — 0.6%
Discord, Inc., Series I, (Acquired 09/13/21, Cost: $17,999,912)(f)		32,690		12,802,058
Entertainment — 0.9%
Under Canvas, Inc., Class A, (Acquired 08/19/21, Cost: $49,999,983)(f)		2,172,486		18,683,380
Food Products — 0.6%
Motif Food Works, Inc., Series B, (Acquired 06/08/21, Cost: $39,999,986)(f)		1,972,240		12,444,834
Hotels, Restaurants & Leisure(f) — 1.2%
Dapper Labs, Inc., Series 7, (Acquired 07/20/21, Cost: $29,999,946)		191,067		3,330,298
Underdog Sports, Inc., Series B, (Acquired 01/11/22, Cost: $14,999,974)		291,061		21,477,391
				24,807,689
IT Services(f) — 2.3%
Patreon, Inc., Series D, (Acquired 07/14/21, Cost: $23,333,352)		416,667		11,750,009
Via Transportation, Inc., Series G, (Acquired 11/05/21, Cost: $24,999,974)		549,357		30,335,493
Wagestream Holdings Ltd., Series C, (Acquired 02/11/22, Cost: $10,024,684)		762,746		5,259,788
				47,345,290
Semiconductors & Semiconductor Equipment — 2.5%
PsiQuantum Corp., Series D, (Acquired 05/21/21, Cost: $39,999,990)(f)		1,525,192		43,345,957
Rivos, Inc., Series A1		2,997,684		6,534,951
				49,880,908
Software(f) — 7.1%
AnyRoad, Inc., Series B, (Acquired 12/07/21, Cost: $14,999,995)		2,745,894		11,917,180
Bolt Financial, Inc., Series E, (Acquired 01/18/22, Cost: $44,999,983)		898,024		19,145,872
Deepgram, Inc., Series B, (Acquired 10/22/21, Cost: $11,999,997)		2,165,400		13,273,902
Dragos, Inc., Series D, (Acquired 09/28/21, Cost: $39,999,959)		900,760		34,670,252
Genesys Cloud Services, Inc., (Acquired 11/24/21, Cost: $30,000,101)		4,651,163		16,883,722

Security	Shares		Value
Software (continued)
Open Space Labs, Inc., Series D, (Acquired 01/31/22, Cost: $15,000,003)		1,687,916	$	13,739,636
Snorkel AI, Inc., Series C, (Acquired 06/30/21, Cost: $10,999,993)		732,373		6,371,645
Snyk Ltd., Series F, (Acquired 09/02/21, Cost: $24,038,470)		1,685,092		18,401,205
Validere Technologies, Inc., Series B, (Acquired 10/21/21, Cost: $10,000,000)		4,684,060		8,431,308
				142,834,722
Specialty Retail — 0.5%
Super73, Inc., Series C-1, (Acquired 10/25/22, Cost: $12,000,000)(f)		1,400,669		10,799,158
Wireless Telecommunication Services — 1.1%
Loft Orbital Solutions, Inc., Series B, (Acquired 10/14/21, Cost: $24,999,992)(f)		1,365,305		22,855,206
				441,207,138
Total Preferred Securities — 21.8% (Cost: $662,142,595)				441,207,138
Total Long-Term Investments — 101.0% (Cost: $2,119,760,855)				2,045,982,868
Short-Term Securities
Money Market Funds — 1.0%
BlackRock Liquidity Funds, T-Fund, Institutional Class, 5.26%(h)(i)		326,227		326,227
SL Liquidity Series, LLC, Money Market Series, 5.58%(h)(i)(j)		20,498,856		20,505,005
Total Short-Term Securities — 1.0% (Cost: $20,830,071)				20,831,232
Total Investments Before Options Written — 102.0% (Cost: $2,140,590,926)				2,066,814,100
Options Written — (0.8)%
(Premiums Received: $(8,337,243))				(16,978,313	)
Total Investments, Net of Options Written — 101.2% (Cost: $2,132,253,683)				2,049,835,787
Liabilities in Excess of Other Assets — (1.2)%				(23,365,949	)
Net Assets — 100.0%			$	2,026,469,838

^(a)  All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.

^(b)  Non-income producing security.

^(c)  All or a portion of this security is on loan.

^(d)  All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

^(e)  Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.

^(f)  Restricted security as to resale, excluding 144A securities. The Trust held restricted securities with a current value of $506,577,898, representing 25.0% of its net assets as of period end, and an original cost of $821,090,559.

^(g)  Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may be resold in transactions exempt from registration to qualified institutional investors.

^(h)  Affiliate of the Trust.

⁽ⁱ⁾  Annualized 7-day yield as of period end.

^(j)  All or a portion of this security was purchased with the cash collateral from loaned securities.

96 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Schedule of Investments (continued) December 31, 2023   BlackRock Innovation and Growth Term Trust (BIGZ)

For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

Affiliates

Investments in issuers considered to be affiliate(s) of the Trust during the year ended December 31, 2023 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

Affiliated Issuer	Value at 12/31/22		Purchases at Cost			Proceeds from Sale			Net Realized Gain (Loss)			Change in Unrealized Appreciation (Depreciation)		Value at 12/31/23		Shares Held at 12/31/23		Income			Capital Gain Distributions from Underlying Funds
BlackRock Liquidity Funds, T-Fund, Institutional Class	$	20,778,628	$	—		$	(20,452,401	)(a)	$	—		$	—	$	326,227		326,227	$	445,542		$	—
SL Liquidity Series, LLC, Money Market Series		184,600		20,319,860	(a)		—			(616	)		1,161		20,505,005		20,498,856		63,099	(b)		—
									$	(616	)	$	1,161	$	20,831,232			$	508,641		$	—

^(a)  Represents net amount purchased (sold).

^(b)  All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.

Derivative Financial Instruments Outstanding as of Period End

Exchange-Traded Options Written

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call
MongoDB, Inc., Class A		87		01/12/24		USD	430.00		USD	3,557	$	(39,150	)
On Holding AG, Class A		252		01/12/24		USD	31.00		USD	680		(3,150	)
Rexford Industrial Realty, Inc.		70		01/12/24		USD	47.00		USD	393		(64,347	)
Zscaler, Inc.		161		01/12/24		USD	200.00		USD	3,567		(356,615	)
Align Technology, Inc.		37		01/19/24		USD	240.00		USD	1,014		(139,490	)
ANSYS, Inc.		75		01/19/24		USD	310.00		USD	2,722		(415,125	)
Aspen Technology, Inc.		174		01/19/24		USD	220.00		USD	3,831		(89,610	)
Axon Enterprise, Inc.		180		01/19/24		USD	230.00		USD	4,650		(531,000	)
AZEK Co., Inc., Class A		617		01/19/24		USD	34.00		USD	2,360		(280,874	)
Azenta, Inc.		140		01/19/24		USD	60.00		USD	912		(90,300	)
Bio-Techne Corp.		360		01/19/24		USD	65.00		USD	2,778		(426,600	)
Charles River Laboratories International, Inc.		117		01/19/24		USD	230.00		USD	2,766		(121,095	)
Comfort Systems USA, Inc.		112		01/19/24		USD	200.00		USD	2,304		(111,440	)
Confluent, Inc., Class A		835		01/19/24		USD	21.00		USD	1,954		(231,712	)
Confluent, Inc., Class A		1,476		01/19/24		USD	25.00		USD	3,454		(92,250	)
CoStar Group, Inc.		417		01/19/24		USD	85.00		USD	3,644		(148,035	)
DigitalOcean Holdings, Inc.		109		01/19/24		USD	30.00		USD	400		(75,210	)
Duolingo, Inc., Class A		67		01/19/24		USD	240.00		USD	1,520		(33,500	)
Entegris, Inc.		280		01/19/24		USD	105.00		USD	3,355		(453,600	)
Fiverr International Ltd.		313		01/19/24		USD	30.00		USD	852		(14,085	)
Floor & Decor Holdings, Inc., Class A		293		01/19/24		USD	95.00		USD	3,269		(506,890	)
Fox Factory Holding Corp.		270		01/19/24		USD	70.00		USD	1,822		(47,925	)
Freshpet, Inc.		72		01/19/24		USD	75.00		USD	625		(91,080	)
Freshpet, Inc.		30		01/19/24		USD	77.50		USD	260		(30,300	)
Globant SA		170		01/19/24		USD	230.00		USD	4,046		(205,700	)
GXO Logistics, Inc.		187		01/19/24		USD	60.00		USD	1,144		(42,075	)
Halozyme Therapeutics, Inc.		292		01/19/24		USD	43.50		USD	1,079		(19,404	)
HEICO Corp.		177		01/19/24		USD	190.00		USD	3,166		(6,637	)
HubSpot, Inc.		77		01/19/24		USD	480.00		USD	4,470		(787,710	)
IDEXX Laboratories, Inc.		110		01/19/24		USD	570.00		USD	6,106		(78,650	)
Inmode Ltd.		119		01/19/24		USD	25.00		USD	265		(4,760	)
Inspire Medical Systems, Inc.		79		01/19/24		USD	165.00		USD	1,607		(314,025	)
JFrog Ltd.		263		01/19/24		USD	26.00		USD	910		(231,743	)
MongoDB, Inc., Class A		40		01/19/24		USD	410.00		USD	1,635		(57,000	)
On Holding AG, Class A		296		01/19/24		USD	30.00		USD	798		(9,620	)

S C H E D U L E  O F  I N V E S T M E N T S 97

Schedule of Investments (continued) December 31, 2023   BlackRock Innovation and Growth Term Trust (BIGZ)

Exchange-Traded Options Written (continued)

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
PagerDuty, Inc.		533		01/19/24		USD	25.00		USD	1,234	$	(10,660	)
Paylocity Holding Corp.		29		01/19/24		USD	165.00		USD	478		(15,225	)
Planet Fitness, Inc., Class A		540		01/19/24		USD	65.00		USD	3,942		(437,400	)
Repligen Corp.		357		01/19/24		USD	160.00		USD	6,419		(760,410	)
Saia, Inc.		115		01/19/24		USD	430.00		USD	5,040		(235,750	)
Surgery Partners, Inc.		534		01/19/24		USD	35.00		USD	1,708		(25,365	)
Tradeweb Markets, Inc., Class A		795		01/19/24		USD	95.00		USD	7,225		(39,750	)
Vail Resorts, Inc.		92		01/19/24		USD	240.00		USD	1,964		(2,760	)
West Pharmaceutical Services, Inc.		104		01/19/24		USD	380.00		USD	3,662		(10,140	)
Align Technology, Inc.		262		01/26/24		USD	280.00		USD	7,179		(286,890	)
MongoDB, Inc., Class A		18		01/26/24		USD	400.00		USD	736		(41,625	)
On Holding AG, Class A		547		01/26/24		USD	29.00		USD	1,475		(35,555	)
Bio-Techne Corp.		667		01/31/24		USD	77.00		USD	5,147		(489,962	)
ANSYS, Inc.		180		02/16/24		USD	310.00		USD	6,532		(1,054,800	)
AZEK Co., Inc., Class A		711		02/16/24		USD	35.25		USD	2,720		(297,269	)
Bentley Systems, Inc., Class B		500		02/16/24		USD	55.00		USD	2,609		(48,750	)
Charles River Laboratories International, Inc.		117		02/16/24		USD	240.00		USD	2,766		(108,225	)
Comfort Systems USA, Inc.		79		02/16/24		USD	210.00		USD	1,625		(60,435	)
CoStar Group, Inc.		600		02/16/24		USD	90.00		USD	5,243		(127,500	)
DigitalOcean Holdings, Inc.		424		02/16/24		USD	32.50		USD	1,556		(243,800	)
Floor & Decor Holdings, Inc., Class A		126		02/16/24		USD	115.00		USD	1,406		(58,590	)
Fox Factory Holding Corp.		312		02/16/24		USD	70.00		USD	2,105		(84,240	)
Globant SA		110		02/16/24		USD	230.00		USD	2,618		(199,100	)
GXO Logistics, Inc.		250		02/16/24		USD	60.00		USD	1,529		(91,250	)
Halozyme Therapeutics, Inc.		364		02/16/24		USD	45.00		USD	1,345		(9,100	)
HEICO Corp.		178		02/16/24		USD	195.00		USD	3,184		(16,020	)
Innovative Industrial Properties, Inc.		21		02/16/24		USD	105.00		USD	212		(6,720	)
MongoDB, Inc., Class A		42		02/16/24		USD	480.00		USD	1,717		(21,525	)
Monolithic Power Systems, Inc.		62		02/16/24		USD	630.00		USD	3,911		(256,060	)
On Holding AG, Class A		175		02/16/24		USD	32.50		USD	472		(6,125	)
Planet Fitness, Inc., Class A		540		02/16/24		USD	75.00		USD	3,942		(122,850	)
Repligen Corp.		78		02/16/24		USD	185.00		USD	1,402		(63,180	)
Saia, Inc.		80		02/16/24		USD	470.00		USD	3,506		(126,000	)
Surgery Partners, Inc.		604		02/16/24		USD	36.20		USD	1,932		(54,962	)
TPG, Inc., Class A		1,058		02/16/24		USD	35.00		USD	4,567		(973,360	)
Vail Resorts, Inc.		64		02/16/24		USD	240.00		USD	1,366		(5,600	)
West Pharmaceutical Services, Inc.		118		02/16/24		USD	342.92		USD	4,155		(257,168	)
Zscaler, Inc.		180		02/16/24		USD	220.00		USD	3,988		(240,300	)
JFrog Ltd.		230		02/23/24		USD	30.20		USD	796		(125,027	)
Monolithic Power Systems, Inc.		93		03/15/24		USD	640.00		USD	5,866		(418,035	)
											$	(13,618,190	)

OTC Options Written

Description	Counterparty	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call
SiteMinder Ltd.	Goldman Sachs International		41,400		01/04/24		AUD	4.61		AUD	212	$	(14,666	)
Lattice Semiconductor Corp.	JPMorgan Chase Bank N.A.		5,100		01/08/24		USD	79.66		USD	352		(167	)
AutoStore Holdings Ltd.	Goldman Sachs International		250,000		01/09/24		NOK	14.69		NOK	4,990		(130,804	)
SiteMinder Ltd.	UBS AG		39,300		01/09/24		AUD	4.81		AUD	202		(8,936	)
ASM International NV	Morgan Stanley & Co. International PLC		8,000		01/11/24		EUR	472.18		EUR	3,772		(86,654	)
AutoStore Holdings Ltd.	Goldman Sachs International		259,700		01/11/24		NOK	17.90		NOK	5,184		(56,480	)
Aspen Technology, Inc.	Morgan Stanley & Co. International PLC		8,900		01/12/24		USD	190.81		USD	1,959		(265,906	)
SiteMinder Ltd.	UBS AG		67,000		01/12/24		AUD	5.14		AUD	344		(5,394	)
AutoStore Holdings Ltd.	Barclays Bank PLC		250,900		01/17/24		NOK	15.90		NOK	5,008		(102,504	)
AutoStore Holdings Ltd.	Goldman Sachs International		259,700		01/18/24		NOK	17.90		NOK	5,184		(59,271	)
ASM International NV	Bank of America N.A.		5,100		01/23/24		EUR	461.39		EUR	2,404		(114,729	)
AutoStore Holdings Ltd.	Goldman Sachs International		250,000		01/23/24		NOK	18.09		NOK	4,990		(55,883	)
Lattice Semiconductor Corp.	Citibank N.A.		56,000		01/23/24		USD	62.43		USD	3,863		(424,202	)
SiteMinder Ltd.	UBS AG		67,000		01/23/24		AUD	5.24		AUD	344		(5,357	)

98 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Schedule of Investments (continued) December 31, 2023   BlackRock Innovation and Growth Term Trust (BIGZ)

OTC Options Written (continued)

Description	Counterparty	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
AutoStore Holdings Ltd.	Goldman Sachs International		125,000		01/24/24		NOK	18.91		NOK	2,495	$	(20,783	)
SiteMinder Ltd.	UBS AG		55,000		01/24/24		AUD	4.98		AUD	282		(9,483	)
Bentley Systems, Inc., Class B	JPMorgan Chase Bank N.A.		78,000		01/26/24		USD	53.50		USD	4,070		(62,156	)
Duolingo, Inc., Class A	Barclays Bank PLC		11,100		01/26/24		USD	222.00		USD	2,518		(163,016	)
JFrog Ltd.	Citibank N.A.		47,000		01/26/24		USD	27.98		USD	1,627		(327,147	)
TPG, Inc., Class A	UBS AG		40,000		01/29/24		USD	32.25		USD	1,727		(452,433	)
AutoStore Holdings Ltd.	Goldman Sachs International		267,000		01/30/24		NOK	18.38		NOK	5,330		(58,407	)
Axon Enterprise, Inc.	Bank of America N.A.		25,100		01/31/24		USD	254.10		USD	6,484		(268,677	)
Entegris, Inc.	UBS AG		44,500		01/31/24		USD	122.47		USD	5,332		(165,740	)
HubSpot, Inc.	Barclays Bank PLC		7,400		01/31/24		USD	569.59		USD	4,296		(256,072	)
AutoStore Holdings Ltd.	Morgan Stanley & Co. International PLC		260,000		02/06/24		NOK	19.74		NOK	5,190		(39,966	)
Lattice Semiconductor Corp.	Goldman Sachs International		10,700		02/06/24		USD	62.25		USD	738		(92,315	)
SiteMinder Ltd.	Goldman Sachs International		32,500		02/08/24		AUD	5.05		AUD	167		(5,631	)
AutoStore Holdings Ltd.	Morgan Stanley & Co. International PLC		260,000		02/13/24		NOK	19.74		NOK	5,190		(45,355	)
SiteMinder Ltd.	Goldman Sachs International		32,500		02/13/24		AUD	5.05		AUD	167		(5,924	)
AutoStore Holdings Ltd.	Morgan Stanley & Co. International PLC		260,000		02/21/24		NOK	19.74		NOK	5,190		(49,699	)
SiteMinder Ltd.	JPMorgan Chase Bank N.A.		32,500		02/21/24		AUD	5.05		AUD	167		(6,366	)
												$	(3,360,123	)

Balances Reported in the Statements of Assets and Liabilities for Options Written

Description	Swap Premiums Paid		Swap Premiums Received		Unrealized Appreciation		Unrealized Depreciation			Value
Options Written	$	N/A	$	N/A	$	1,369,510	$	(10,010,580	)	$	(16,978,313	)

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

	Commodity Contracts		Credit Contracts		Equity Contracts		Foreign Currency Exchange Contracts		Interest Rate Contracts		Other Contracts		Total
Liabilities — Derivative Financial Instruments
Options written
Options written at value	$	—	$	—	$	16,978,313	$	—	$	—	$	—	$	16,978,313

For the period ended December 31, 2023, the effect of derivative financial instruments in the Statements of Operations was as follows:

	Commodity Contracts		Credit  Contracts		Equity Contracts			Foreign Currency Exchange Contracts		Interest Rate Contracts		Other Contracts		Total
Net Realized Gain (Loss) from:
Options purchased(a)	$	—	$	—	$	(1,549,151	)	$	—	$	—	$	—	$	(1,549,151	)
Options written		—		—		(1,695,478	)		—		—		—		(1,695,478	)
	$	—	$	—	$	(3,244,629	)	$	—	$	—	$	—	$	(3,244,629	)
Net Change in Unrealized Appreciation (Depreciation) on:
Options written	$	—	$	—	$	(14,212,806	)	$	—	$	—	$	—	$	(14,212,806	)

^(a) Options purchased are included in net realized gain (loss) from investments — unaffiliated.

S C H E D U L E  O F  I N V E S T M E N T S 99

Schedule of Investments (continued) December 31, 2023   BlackRock Innovation and Growth Term Trust (BIGZ)

Average Quarterly Balances of Outstanding Derivative Financial Instruments

Options:
Average value of option contracts purchased	$	—	(a)
Average value of option contracts written	$	12,587,699

^(a)  Derivative financial instrument not held at any quarter-end. The risk exposure table serves as an indicator of activity during the period.

For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

Derivative Financial Instruments — Offsetting as of Period End

The Trust’s derivative assets and liabilities (by type) were as follows:

	Assets		Liabilities
Derivative Financial Instruments
Options	$	—	$	16,978,313
Total derivative assets and liabilities in the Statements of Assets and Liabilities		—		16,978,313
Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”)		—		(13,618,190	)
Total derivative assets and liabilities subject to an MNA	$	—	$	3,360,123

The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the Trust:

Counterparty		Derivative Liabilities Subject to an MNA by Counterparty		Derivatives Available for Offset		Non-Cash Collateral Pledged	(a)		Cash Collateral Pledged		Net Amount of Derivative Liabilities
Bank of America N.A.	$	383,406	$	—	$	(383,406	)	$	—	$	—
Barclays Bank PLC		521,592		—		(521,592	)		—		—
Citibank N.A.		751,349		—		(751,349	)		—		—
Goldman Sachs International		500,164		—		(500,164	)		—		—
JPMorgan Chase Bank N.A.		68,689		—		(68,689	)		—		—
Morgan Stanley & Co. International PLC		487,580		—		(487,580	)		—		—
UBS AG		647,343		—		(647,343	)		—		—
	$	3,360,123	$	—	$	(3,360,123	)	$	—	$	—

^(a)  Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes.

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation of financial instruments, refer to the Notes to Financial Statements.

The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s financial instruments into major categories is disclosed in the Schedule of Investments above.

	Level 1		Level 2		Level 3		Total
Assets
Investments
Long-Term Investments
Common Stocks
Aerospace & Defense	$	109,366,681	$	—	$	—	$	109,366,681
Air Freight & Logistics		16,741,388		—		—		16,741,388
Automobile Components		24,548,549		—		—		24,548,549
Biotechnology		15,169,493		—		—		15,169,493
Building Products		31,763,221		—		—		31,763,221
Capital Markets		84,497,075		—		—		84,497,075
Construction & Engineering		24,619,933		—		—		24,619,933
Diversified Consumer Services		25,372,492		—		33,414,190		58,786,682
Entertainment		25,863,414		—		—		25,863,414
Food Products		5,447,487		—		—		5,447,487
Ground Transportation		53,530,764		—		—		53,530,764

100 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Schedule of Investments (continued) December 31, 2023   BlackRock Innovation and Growth Term Trust (BIGZ)

Fair Value Hierarchy as of Period End (continued)

	Level 1			Level 2			Level 3		Total
Common Stocks (continued)
Health Care Equipment & Supplies	$	100,464,638		$	—		$	—	$	100,464,638
Health Care Providers & Services		20,844,044			—			—		20,844,044
Hotels, Restaurants & Leisure		70,114,176			—			—		70,114,176
Industrial REITs		2,131,998			—			—		2,131,998
IT Services		99,387,468			—			16,990,129		116,377,597
Life Sciences Tools & Services		179,192,241			—			—		179,192,241
Machinery		—			27,030,178			—		27,030,178
Professional Services		6,419,927			—			—		6,419,927
Real Estate Management & Development		55,664,109			—			—		55,664,109
Semiconductors & Semiconductor Equipment		144,123,267			42,460,310			—		186,583,577
Software		298,586,878			18,874,399			21,501,392		338,962,669
Specialty Retail		29,245,566			—			—		29,245,566
Textiles, Apparel & Luxury Goods		21,410,323			—			—		21,410,323
Preferred Securities
Preferred Stocks		—			—			441,207,138		441,207,138
Short-Term Securities
Money Market Funds		326,227			—			—		326,227
	$	1,444,831,359		$	88,364,887		$	513,112,849		2,046,309,095
Investments Valued at NAV(a)										20,505,005
									$	2,066,814,100
Derivative Financial Instruments(b)
Liabilities
Equity Contracts	$	(11,797,434	)	$	(5,180,879	)	$	—	$	(16,978,313	)

^(a)  Certain investments of the Trust were fair valued using NAV as a practical expedient as no quoted market value is available and therefore have been excluded from the fair value hierarchy.

^(b)  Derivative financial instruments are options written. Options written are shown at value.

A reconciliation of Level 3 financial instruments is presented when the Trust had a significant amount of Level 3 investments and derivative financial instruments at the beginning and/or end of the year in relation to net assets. The following table is a reconciliation of Level 3 investments for which significant unobservable inputs were used in determining fair value:

	Common Stocks			Preferred Stocks			Total
Assets
Opening balance, as of December 31, 2022	$	102,169,910		$	471,282,347		$	573,452,257
Transfers into Level 3		—			—			—
Transfers out of Level 3		—			—			—
Accrued discounts/premiums		—			—			—
Net realized gain (loss)		—			—			—
Net change in unrealized appreciation (depreciation)(a)(b)		(30,264,199	)		(30,075,209	)		(60,339,408	)
Purchases		—			—			—
Sales		—			—			—
Closing balance, as of December 31, 2023	$	71,905,711		$	441,207,138		$	513,112,849
Net change in unrealized appreciation (depreciation) on investments still held at December 31, 2023(b)	$	(30,264,199	)	$	(30,075,209	)	$	(60,339,408	)

^(a)  Included in the related net change in unrealized appreciation (depreciation) in the Statements of Operations.

^(b)  Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized appreciation (depreciation) on investments still held at December 31, 2023 is generally due to investments no longer held or categorized as Level 3 at period end.

The following table summarizes the valuation approaches used and unobservable inputs utilized by the BlackRock Valuation Committee (the “Valuation Committee”) to determine the value of certain of the Trust’s Level 3 financial instruments as of period end.

		Value	Valuation Approach	Unobservable Inputs	Range of   Unobservable Inputs Utilized	(a)	Weighted Average of Unobservable Inputs Based on Fair Value
Assets
Common Stocks	$	71,905,711	Market	Revenue Multiple	1.30x - 22.00x		12.41x

S C H E D U L E  O F  I N V E S T M E N T S 101

Schedule of Investments (continued) December 31, 2023 BlackRock Innovation and Growth Term Trust (BIGZ)

	Value		Valuation Approach		Unobservable Inputs	Range of Unobservable Inputs Utilized(a)		Weighted Average of Unobservable Inputs Based on Fair Value
					Time to Exit		2.0 years		—
					Volatility		90%		—
					Gross Profit Multiple		15.00x		—
Preferred Stocks	$	441,207,138		Market	Revenue Multiple		1.90x - 24.00x		9.85x
					Time to Exit		1.0 - 5.0 years		3.2 years
					Volatility		40% - 100%		70%
					Market Adjustment Multiple		0.55x - 1.20x		0.93x
	$	513,112,849

^(a) A significant change in unobservable input would have resulted in a correlated (inverse) significant change to value.

See notes to financial statements.

102 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Schedule of Investments  December 31, 2023 BlackRock Resources & Commodities Strategy Trust (BCX) (Percentages shown are based on Net Assets)

Security	Shares		Value
Common Stocks
Chemicals — 5.8%
Albemarle Corp.		19,588	$	2,830,074
CF Industries Holdings, Inc.(a)		383,868		30,517,506
Nutrien Ltd.		330,969		18,643,484
				51,991,064
Containers & Packaging — 7.5%
Avery Dennison Corp.		70,747		14,302,214
Graphic Packaging Holding Co.		371,023		9,145,717
Packaging Corp. of America(a)		102,319		16,668,788
Smurfit Kappa Group PLC		680,511		26,975,801
				67,092,520
Energy Equipment & Services — 1.4%
Schlumberger NV		233,156		12,133,438
Food Products — 4.9%
Archer-Daniels-Midland Co.		261,696		18,899,693
Bunge Global SA		168,237		16,983,525
Hofseth International, (Acquired 05/26/21, Cost: $10,198,056)(b)(c)(d)		18,993,283		7,776,854
				43,660,072
Machinery — 1.9%
AGCO Corp.(e)		139,452		16,930,869
Metals & Mining — 37.5%
Alcoa Corp.		212,525		7,225,850
Anglo American PLC		282,853		7,078,877
ArcelorMittal SA, ADR(f)		579,793		16,460,323
Barrick Gold Corp.		761,298		13,771,881
BHP Group Ltd., Series L, ADR(a)		637,814		43,569,074
Filo Corp.(c)		109,223		1,740,083
Filo Corp. Legend(c)		175,560		2,796,930
First Quantum Minerals Ltd.		488,526		4,000,232
Franco-Nevada Corp.		64,021		7,094,167
Freeport-McMoRan, Inc.(a)(e)		727,912		30,987,214
Glencore PLC		7,075,731		42,532,536
Newmont Corp.		374,569		15,503,411
Norsk Hydro ASA		3,371,460		22,661,622
Polyus PJSC(b)(c)		104,732		12
Rio Tinto PLC		370,896		27,587,639
Stelco Holdings, Inc.		399,098		15,116,961
Teck Resources Ltd., Class B(f)		137,086		5,794,625
Vale SA, ADR		2,325,042		36,875,166
Wheaton Precious Metals Corp.		666,054		32,863,104
				333,659,707
Oil, Gas & Consumable Fuels — 37.4%
BP PLC		6,065,163		35,954,697
Cameco Corp.		273,333		11,780,652
Canadian Natural Resources Ltd.		290,681		19,043,823
Cheniere Energy, Inc.(e)		86,708		14,801,923
Chevron Corp.(a)(e)		255,423		38,098,895
ConocoPhillips(a)		211,898		24,595,001
EOG Resources, Inc.(a)		82,977		10,036,068
Exxon Mobil Corp.(a)		480,000		47,990,400
Galp Energia SGPS SA		434,726		6,396,417
Gazprom PJSC(b)(c)		5,430,000		608
Shell PLC, ADR(a)		1,040,175		68,443,515
TotalEnergies SE		828,786		56,356,600
				333,498,599

Security	Shares		Value
Paper & Forest Products — 2.3%
Precious Woods Holding AG, Registered Shares(c)		20,000	$	142,679
UPM-Kymmene OYJ		540,993		20,406,621
				20,549,300
Total Common Stocks — 98.7% (Cost: $756,600,468)				879,515,569
	Par (000)
Corporate Bonds
Metals & Mining — 0.8%
Allied Gold Corp., 8.75%, 09/07/28	$	7,200		7,200,000
Total Corporate Bonds — 0.8% (Cost: $7,200,000)				7,200,000
Total Long-Term Investments — 99.5% (Cost: $763,800,468)				886,715,569
	Shares
Short-Term Securities
Money Market Funds — 2.3%
BlackRock Liquidity Funds, T-Fund, Institutional Class, 5.26%(g)(h)		14,160,077		14,160,077
SL Liquidity Series, LLC, Money Market Series, 5.58%(g)(h)(i)		6,148,624		6,150,469
Total Short-Term Securities — 2.3% (Cost: $20,311,045)				20,310,546
Total Investments Before Options Written — 101.8% (Cost: $784,111,513)				907,026,115
Options Written — (1.2)% (Premiums Received: $(6,777,331))				(10,021,060	)
Total Investments, Net of Options Written — 100.6% (Cost: $777,334,182)				897,005,055
Liabilities in Excess of Other Assets — (0.6)%				(5,666,563	)
Net Assets — 100.0%			$	891,338,492

^(a)  All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

^(b)  Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.

^(c)  Non-income producing security.

^(d)  Restricted security as to resale, excluding 144A securities. The Trust held restricted securities with a current value of $7,776,854, representing 0.9% of its net assets as of period end, and an original cost of $10,198,056.

^(e)  All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.

^(f)  All or a portion of this security is on loan.

^(g)  Affiliate of the Trust.

^(h)  Annualized 7-day yield as of period end.

⁽ⁱ⁾  All or a portion of this security was purchased with the cash collateral from loaned securities.

For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

S C H E D U L E  O F  I N V E S T M E N T S 103

Schedule of Investments (continued) December 31, 2023   BlackRock Resources & Commodities Strategy Trust (BCX)

Affiliates

Investments in issuers considered to be affiliate(s) of the Trust during the year ended December 31, 2023 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

Affiliated Issuer	Value at 12/31/22		Purchases at Cost			Proceeds from Sale			Net Realized Gain (Loss)		Change in Unrealized Appreciation (Depreciation)			Value at 12/31/23		Shares Held at 12/31/23		Income			Capital Gain Distributions from Underlying Funds
BlackRock Liquidity Funds, T-Fund, Institutional Class	$	19,404,102	$	—		$	(5,244,025	)(a)	$	—	$	—		$	14,160,077		14,160,077	$	1,252,534		$	—
SL Liquidity Series, LLC, Money Market Series		—		6,146,031	(a)		—			4,937		(499	)		6,150,469		6,148,624		17,994	(b)		—
									$	4,937	$	(499	)	$	20,310,546			$	1,270,528		$	—

^(a)  Represents net amount purchased (sold).

^(b)  All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.

Derivative Financial Instruments Outstanding as of Period End

Exchange-Traded Options Written

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call
Archer-Daniels-Midland Co.		272		01/05/24		USD	75.00		USD	1,964	$	(2,040	)
Barrick Gold Corp.		945		01/05/24		USD	18.50		USD	1,710		(10,395	)
Exxon Mobil Corp.		291		01/05/24		USD	107.00		USD	2,909		(873	)
Freeport-McMoRan, Inc.		930		01/05/24		USD	38.00		USD	3,959		(427,800	)
Newmont Corp.		328		01/05/24		USD	40.00		USD	1,358		(51,332	)
Newmont Corp.		22		01/05/24		USD	41.00		USD	91		(1,782	)
Schlumberger NV		237		01/05/24		USD	54.00		USD	1,233		(2,963	)
Albemarle Corp.		36		01/12/24		USD	130.00		USD	520		(57,060	)
Alcoa Corp.		192		01/12/24		USD	28.00		USD	653		(117,600	)
ArcelorMittal SA, ADR		1,100		01/12/24		USD	26.00		USD	3,123		(283,250	)
Archer-Daniels-Midland Co.		269		01/12/24		USD	75.00		USD	1,943		(6,725	)
Cameco Corp.		511		01/12/24		USD	49.00		USD	2,202		(3,833	)
Chevron Corp.		296		01/12/24		USD	155.00		USD	4,415		(16,428	)
ConocoPhillips		171		01/12/24		USD	119.00		USD	1,985		(15,989	)
EOG Resources, Inc.		134		01/12/24		USD	124.50		USD	1,621		(13,400	)
Exxon Mobil Corp.		319		01/12/24		USD	106.00		USD	3,189		(7,018	)
Newmont Corp.		350		01/12/24		USD	40.36		USD	1,449		(55,298	)
Nutrien Ltd.		874		01/12/24		USD	57.00		USD	4,923		(87,400	)
Schlumberger NV		250		01/12/24		USD	51.00		USD	1,301		(44,000	)
Shell PLC, ADR		932		01/12/24		USD	66.00		USD	6,133		(81,550	)
AGCO Corp.		280		01/19/24		USD	125.00		USD	3,399		(37,100	)
AGCO Corp.		80		01/19/24		USD	120.00		USD	971		(29,600	)
Albemarle Corp.		37		01/19/24		USD	135.00		USD	535		(47,360	)
Alcoa Corp.		281		01/19/24		USD	30.00		USD	955		(123,640	)
ArcelorMittal SA, ADR		1,067		01/19/24		USD	26.00		USD	3,029		(277,420	)
Archer-Daniels-Midland Co.		211		01/19/24		USD	77.50		USD	1,524		(2,638	)
Avery Dennison Corp.		132		01/19/24		USD	200.00		USD	2,669		(64,020	)
Barrick Gold Corp.		700		01/19/24		USD	16.00		USD	1,266		(157,150	)
BHP Group Ltd., ADR		755		01/19/24		USD	62.50		USD	5,157		(468,100	)
Bunge Global SA		333		01/19/24		USD	111.00		USD	3,362		(2,487	)
Cameco Corp.		510		01/19/24		USD	48.00		USD	2,198		(12,495	)
Canadian Natural Resources Ltd.		884		01/19/24		CAD	94.00		CAD	7,674		(11,341	)
Chevron Corp.		306		01/19/24		USD	150.00		USD	4,564		(82,008	)
ConocoPhillips		332		01/19/24		USD	125.00		USD	3,854		(9,130	)
Exxon Mobil Corp.		897		01/19/24		USD	100.00		USD	8,968		(196,891	)
Filo Corp.		400		01/19/24		CAD	19.50		CAD	844		(60,375	)
Franco-Nevada Corp.		239		01/19/24		USD	120.00		USD	2,648		(14,340	)
Freeport-McMoRan, Inc.		575		01/19/24		USD	36.00		USD	2,448		(383,812	)
Newmont Corp.		207		01/19/24		USD	37.50		USD	857		(86,940	)
Newmont Corp.		143		01/19/24		USD	42.50		USD	592		(10,225	)

104 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Schedule of Investments (continued) December 31, 2023   BlackRock Resources & Commodities Strategy Trust (BCX)

Exchange-Traded Options Written (continued)

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
Packaging Corp. of America		200		01/19/24		USD	165.00		USD	3,258	$	(44,000	)
Schlumberger NV		110		01/19/24		USD	52.50		USD	572		(15,070	)
Schlumberger NV		112		01/19/24		USD	55.00		USD	583		(5,992	)
Shell PLC, ADR		658		01/19/24		USD	65.00		USD	4,330		(111,860	)
Stelco Holdings, Inc.		780		01/19/24		CAD	44.00		CAD	3,915		(394,400	)
Stelco Holdings, Inc.		159		01/19/24		CAD	41.00		CAD	798		(113,996	)
Teck Resources Ltd., Class B		512		01/19/24		USD	40.00		USD	2,164		(143,616	)
Vale SA, ADR		1,576		01/19/24		USD	16.00		USD	2,500		(54,372	)
Alcoa Corp.		178		01/26/24		USD	27.00		USD	605		(128,605	)
Barrick Gold Corp.		600		01/26/24		USD	17.00		USD	1,085		(81,300	)
Chevron Corp.		343		01/26/24		USD	145.00		USD	5,116		(220,377	)
ConocoPhillips		23		01/26/24		USD	116.00		USD	267		(7,418	)
EOG Resources, Inc.		176		01/26/24		USD	121.50		USD	2,129		(49,280	)
Exxon Mobil Corp.		287		01/26/24		USD	106.00		USD	2,869		(18,655	)
Freeport-McMoRan, Inc.		871		01/26/24		USD	42.00		USD	3,708		(160,699	)
Newmont Corp.		328		01/26/24		USD	45.00		USD	1,358		(11,152	)
Nutrien Ltd.		350		01/26/24		USD	58.00		USD	1,972		(42,875	)
Schlumberger NV		162		01/26/24		USD	56.00		USD	843		(8,262	)
Shell PLC, ADR		1,105		01/26/24		USD	67.00		USD	7,271		(99,450	)
ConocoPhillips		87		02/02/24		USD	121.00		USD	1,010		(15,225	)
Newmont Corp.		7		02/02/24		USD	44.00		USD	29		(459	)
Vale SA, ADR		2,390		02/05/24		USD	15.90		USD	3,791		(141,851	)
Bunge Global SA		295		02/07/24		USD	105.01		USD	2,978		(52,643	)
AGCO Corp.		161		02/16/24		USD	120.00		USD	1,955		(114,310	)
Alcoa Corp.		143		02/16/24		USD	30.00		USD	486		(74,002	)
Archer-Daniels-Midland Co.		226		02/16/24		USD	77.50		USD	1,632		(15,820	)
Avery Dennison Corp.		132		02/16/24		USD	201.00		USD	2,669		(107,099	)
Barrick Gold Corp.		600		02/16/24		USD	19.00		USD	1,085		(28,500	)
BHP Group Ltd., ADR		956		02/16/24		USD	62.50		USD	6,530		(664,420	)
Canadian Natural Resources Ltd.		202		02/16/24		CAD	86.00		CAD	1,754		(59,073	)
ConocoPhillips		171		02/16/24		USD	120.00		USD	1,985		(48,564	)
Freeport-McMoRan, Inc.		344		02/16/24		USD	39.00		USD	1,464		(153,080	)
Packaging Corp. of America		182		02/16/24		USD	170.00		USD	2,965		(60,970	)
Shell PLC, ADR		1,153		02/16/24		USD	67.50		USD	7,587		(147,007	)
Stelco Holdings, Inc.		560		02/16/24		CAD	46.00		CAD	2,811		(258,858	)
Vale SA, ADR		2,390		02/16/24		USD	16.00		USD	3,791		(152,960	)
Vale SA, ADR		2,334		02/27/24		USD	15.87		USD	3,702		(181,529	)
											$	(7,351,557	)

OTC Options Written

Description	Counterparty	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call
BHP Group Ltd., ADR	JPMorgan Chase Bank N.A.		67,200		01/04/24		USD	63.08		USD	4,590	$	(356,206	)
Galp Energia SGPS SA	Goldman Sachs International		87,100		01/04/24		EUR	13.73		EUR	1,161		(2,739	)
Rio Tinto PLC	Goldman Sachs International		48,300		01/05/24		GBP	56.22		GBP	2,819		(145,938	)
UPM-Kymmene OYJ	Bank of America N.A.		95,400		01/10/24		EUR	33.52		EUR	3,260		(89,024	)
Anglo American PLC	Morgan Stanley & Co. International PLC		105,700		01/11/24		GBP	21.58		GBP	2,075		(4,861	)
Glencore PLC	Morgan Stanley & Co. International PLC		955,400		01/11/24		GBP	4.55		GBP	4,505		(240,540	)
Smurfit Kappa Group PLC	Bank of America N.A.		78,700		01/11/24		EUR	32.70		EUR	2,826		(282,159	)
UPM-Kymmene OYJ	UBS AG		69,500		01/17/24		EUR	33.08		EUR	2,375		(100,152	)
UPM-Kymmene OYJ	UBS AG		37,300		01/17/24		EUR	33.34		EUR	1,274		(45,422	)
Glencore PLC	Bank of America N.A.		1,689,257		01/23/24		GBP	4.55		GBP	7,966		(486,045	)
Graphic Packaging Holding Co.	Bank of America N.A.		69,300		01/25/24		USD	23.67		USD	1,708		(88,904	)
Rio Tinto PLC	Goldman Sachs International		48,300		01/25/24		GBP	56.76		GBP	2,819		(160,446	)
BP PLC	Morgan Stanley & Co. International PLC		1,612,500		01/30/24		GBP	4.87		GBP	7,499		(105,174	)
Smurfit Kappa Group PLC	Goldman Sachs International		99,200		01/30/24		EUR	34.87		EUR	3,562		(195,104	)
TotalEnergies SE	Morgan Stanley & Co. International PLC		258,800		01/30/24		EUR	63.63		EUR	15,941		(129,583	)
Galp Energia SGPS SA	Bank of America N.A.		75,400		02/01/24		EUR	13.66		EUR	1,005		(18,789	)

S C H E D U L E  O F  I N V E S T M E N T S 105

Schedule of Investments (continued) December 31, 2023   BlackRock Resources & Commodities Strategy Trust (BCX)

OTC Options Written (continued)

Description	Counterparty	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
BP PLC	Bank of America N.A.		654,400		02/08/24		GBP	4.68		GBP	3,043	$	(120,757	)
Graphic Packaging Holding Co.	Bank of America N.A.		69,300		02/14/24		USD	23.78		USD	1,708		(97,660	)
												$	(2,669,503	)

Balances Reported in the Statements of Assets and Liabilities for Options Written

Description	Swap Premiums Paid		Swap Premiums Received		Unrealized Appreciation		Unrealized Depreciation			Value
Options Written	$	N/A	$	N/A	$	1,600,359	$	(4,844,088	)	$	(10,021,060	)

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

	Commodity Contracts		Credit Contracts		Equity Contracts		Foreign Currency  Exchange Contracts		Interest Rate  Contracts		Other  Contracts		Total
Liabilities — Derivative Financial Instruments
Options written
Options written at value	$	—	$	—	$	10,021,060	$	—	$	—	$	—	$	10,021,060

For the period ended December 31, 2023, the effect of derivative financial instruments in the Statements of Operations was as follows:

	Commodity Contracts		Credit  Contracts		Equity Contracts			Foreign Currency  Exchange Contracts		Interest Rate  Contracts		Other  Contracts		Total
Net Realized Gain (Loss) from:
Options purchased(a)	$	—	$	—	$	(1,777,915	)	$	—	$	—	$	—	$	(1,777,915	)
Options written		—		—		21,043,307			—		—		—		21,043,307
	$	—	$	—	$	19,265,392		$	—	$	—	$	—	$	19,265,392
Net Change in Unrealized Appreciation (Depreciation) on:
Options written	$	—	$	—	$	(6,718,319	)	$	—	$	—	$	—	$	(6,718,319	)

^(a) Options purchased are included in net realized gain (loss) from investments — unaffiliated.

Average Quarterly Balances of Outstanding Derivative Financial Instruments

Options:
Average value of option contracts purchased	$	—	(a)
Average value of option contracts written	$	7,632,191

^(a) Derivative financial instrument not held at any quarter-end. The risk exposure table serves as an indicator of activity during the period.

For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

106 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Schedule of Investments (continued) December 31, 2023   BlackRock Resources & Commodities Strategy Trust (BCX)

Derivative Financial Instruments — Offsetting as of Period End

The Trust’s derivative assets and liabilities (by type) were as follows:

	Assets		Liabilities
Derivative Financial Instruments
Options	$	—	$	10,021,060
Total derivative assets and liabilities in the Statements of Assets and Liabilities		—		10,021,060
Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”)		—		(7,351,557	)
Total derivative assets and liabilities subject to an MNA	$	—	$	2,669,503

The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the Trust:

Counterparty		Derivative Liabilities Subject to an MNA by Counterparty		Derivatives Available for Offset		Non-Cash Collateral Pledged	(a)		Cash  Collateral Pledged		Net Amount of Derivative Liabilities	(b)
Bank of America N.A.	$	1,183,338	$	—	$	(1,183,338	)	$	—	$	—
Goldman Sachs International		504,227		—		(504,227	)		—		—
JPMorgan Chase Bank N.A.		356,206		—		(356,206	)		—		—
Morgan Stanley & Co. International PLC		480,158		—		(480,158	)		—		—
UBS AG		145,574		—		—			—		145,574
	$	2,669,503	$	—	$	(2,523,929	)	$	—	$	145,574

^(a)  Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes.

^(b)  Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation of financial instruments, refer to the Notes to Financial Statements.

The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s financial instruments into major categories is disclosed in the Schedule of Investments above.

	Level 1		Level 2		Level 3		Total
Assets
Investments
Long-Term Investments
Common Stocks
Chemicals	$	51,991,064	$	—	$	—	$	51,991,064
Containers & Packaging		40,116,719		26,975,801		—		67,092,520
Energy Equipment & Services		12,133,438		—		—		12,133,438
Food Products		35,883,218		—		7,776,854		43,660,072
Machinery		16,930,869		—		—		16,930,869
Metals & Mining		231,002,091		102,657,604		12		333,659,707
Oil, Gas & Consumable Fuels		234,790,277		98,707,714		608		333,498,599
Paper & Forest Products		—		20,549,300		—		20,549,300
Corporate Bonds		—		7,200,000		—		7,200,000
Short-Term Securities
Money Market Funds		14,160,077		—		—		14,160,077
	$	637,007,753	$	256,090,419	$	7,777,474		900,875,646
Investments Valued at NAV(a)								6,150,469
							$	907,026,115

S C H E D U L E  O F  I N V E S T M E N T S 107

Schedule of Investments (continued) December 31, 2023   BlackRock Resources & Commodities Strategy Trust (BCX)

Fair Value Hierarchy as of Period End (continued)

	Level 1			Level 2			Level 3		Total
Derivative Financial Instruments(b)
Liabilities
Equity Contracts	$	(6,810,650	)	$	(3,210,410	)	$	—	$	(10,021,060	)

^(a)  Certain investments of the Trust were fair valued using NAV as a practical expedient as no quoted market value is available and therefore have been excluded from the fair value hierarchy.

^(b)  Derivative financial instruments are options written. Options written are shown at value.

A reconciliation of Level 3 financial instruments is presented when the Trust had a significant amount of Level 3 investments and derivative financial instruments at the beginning and/or end of the year in relation to net assets. The following table is a reconciliation of Level 3 investments for which significant unobservable inputs were used in determining fair value:

	Common Stocks
Assets
Opening balance, as of December 31, 2022	$	9,267,847
Transfers into Level 3		—
Transfers out of Level 3		—
Accrued discounts/premiums		—
Net realized gain (loss)		—
Net change in unrealized appreciation (depreciation)(a)(b)		(1,490,373	)
Purchases		—
Sales		—
Closing balance, as of December 31, 2023	$	7,777,474
Net change in unrealized appreciation (depreciation) on investments still held at December 31, 2023(b)	$	(1,490,373	)

^(a)  Included in the related net change in unrealized appreciation (depreciation) in the Statements of Operations.

^(b)  Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized appreciation (depreciation) on investments still held at December 31, 2023 is generally due to investments no longer held or categorized as Level 3 at period end.

The Trust’s financial instruments that are categorized as Level 3 were valued utilizing third-party pricing information without adjustment. Such valuations are based on unobservable inputs. A significant change in third-party information could result in a significantly lower or higher value of such Level 3 financial instruments.

See notes to financial statements.

108 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Consolidated Schedule of Investments  December 31, 2023   BlackRock Science and Technology Term Trust (BSTZ) (Percentages shown are based on Net Assets)

Security	Shares		Value
Common Stocks
Automobiles — 2.0%
Tesla, Inc.(a)(b)		129,453	$	32,166,482
Broadline Retail — 1.6%
MercadoLibre, Inc.(b)		16,617		26,114,280
Communications Equipment — 1.2%
Accton Technology Corp.		1,151,000		19,563,294
Consumer Finance — 0.9%
Kaspi.KZ JSC, GDR, Registered Shares		166,340		15,303,280
Diversified Consumer Services — 0.1%
Think & Learn Private Ltd., (Acquired 09/30/20, Cost: $7,113,729)(b)(c)(d)		4,651		975,251
Electronic Equipment, Instruments & Components — 4.9%
Coherent Corp.(b)		154,995		6,746,931
Ibiden Co. Ltd.		209,800		11,573,763
Jabil, Inc.		222,958		28,404,849
Lotes Co. Ltd.		243,000		8,449,942
Sunny Optical Technology Group Co. Ltd.		749,900		6,817,254
TDK Corp.		156,500		7,421,912
Yageo Corp.		571,000		11,087,355
				80,502,006
Entertainment — 3.6%
Nexon Co. Ltd.		195,500		3,555,967
Nintendo Co. Ltd.		186,900		9,725,130
Roku, Inc., Class A(b)		79,125		7,252,598
Spotify Technology SA(b)		82,970		15,590,893
Take-Two Interactive Software, Inc.(b)		142,462		22,929,259
				59,053,847
Financial Services — 0.5%
Wise PLC, Class A(b)		763,574		8,492,073
Hotels, Restaurants & Leisure — 0.4%
Expedia Group, Inc.(b)		39,542		6,002,080
Interactive Media & Services — 2.0%
Kakao Corp.		187,210		7,853,398
NAVER Corp.(b)		70,822		12,253,638
Pinterest, Inc., Class A(b)		325,200		12,045,408
				32,152,444
IT Services — 5.6%
Automattic, Inc., Series E, (Acquired 02/03/21, Cost: $34,000,000)(b)(c)(d)		400,000		17,944,000
Cloudflare, Inc., Class A(b)		103,807		8,642,971
CNEX Labs, Inc., (Acquired 12/ 14/21, Cost: $5,699,998)(b)(c)(d)		1,161,804		2,358,462
Farmer’s Business Network, Inc.(b)(c)		361,834		1,418,389
Klarna Holdings AB, Ordinary Shares, (Acquired 08/07/19, Cost: $23,354,997)(b)(c)(d)		86,839		24,620,016
MongoDB, Inc., Class A(b)(e)(f)		69,850		28,558,173
NEC Corp.		123,500		7,297,138
				90,839,149
Machinery — 0.4%
Harmonic Drive Systems, Inc.		236,600		6,961,217
Media — 1.6%
Informa PLC		2,631,592		26,174,876

Security	Shares		Value
Professional Services — 1.9%
Legalzoom.com, Inc.(b)		635,469	$	7,180,800
Wolters Kluwer NV, Class C		164,326		23,378,574
				30,559,374
Real Estate Management & Development — 0.7%
Zillow Group, Inc., Class C(b)		204,329		11,822,476
Semiconductors & Semiconductor Equipment — 25.1%
AIXTRON SE		191,444		8,151,211
Alchip Technologies Ltd.		162,000		17,213,846
Alphawave IP Group PLC(b)		4,742,583		7,784,301
Amkor Technology, Inc.		217,640		7,240,883
ARM Holdings PLC, ADR(b)(f)		173,541		13,040,738
ASM International NV		51,003		26,545,761
BE Semiconductor Industries NV		161,788		24,426,095
Credo Technology Group Holding Ltd.(b)		1,402,517		27,307,006
eMemory Technology, Inc.		100,000		7,951,434
King Yuan Electronics Co. Ltd.		2,316,000		6,392,516
Lasertec Corp.		72,400		19,006,914
Lattice Semiconductor Corp.(b)		278,514		19,214,681
Marvell Technology, Inc.(e)		273,265		16,480,612
Monolithic Power Systems, Inc.(e)		38,890		24,531,034
Mythic AI, Inc., Series C, (Acquired 01/26/21, Cost: $7,000,000)(b)(c)(d)		10,189		—
NVIDIA Corp.(a)		163,273		80,856,055
Phison Electronics Corp.		480,000		8,113,364
Rambus, Inc.(b)		325,023		22,182,820
SK Hynix, Inc.		286,367		31,253,502
SOITEC(b)		145,996		26,125,167
Wolfspeed, Inc.(b)(e)		335,547		14,599,650
				408,417,590
Software — 17.4%
Altium Ltd.		750,551		23,925,740
Appier Group, Inc.(b)		488,100		6,373,877
Databricks, Inc., (Acquired 07/24/20, Cost: $5,501,686)(b)(c)(d)		343,659		26,551,094
Datadog, Inc., Class A(b)		93,787		11,383,866
DataRobot, Inc., (Acquired 03/01/21, Cost: $1,384,813)(b)(c)(d)		92,093		424,549
Freee KK(b)		416,300		8,984,394
HashiCorp, Inc., Class A(b)		338,505		8,002,258
Kinaxis, Inc.(b)		84,207		9,450,529
Klaviyo, Inc., Series A(b)		543,117		15,087,790
Manhattan Associates, Inc.(b)		36,367		7,830,542
Palo Alto Networks, Inc.(b)(f)		96,500		28,455,920
Samsara, Inc., Class A(b)		429,023		14,320,788
SentinelOne, Inc., Class A(b)		392,516		10,770,639
SiteMinder Ltd.(b)		3,068,245		10,722,903
Snorkel AI, Inc., (Acquired 10/13/20, Cost: $2,017,593)(b)(c)(d)		500,250		4,352,175
Snyk Ltd., Ordinary Shares, (Acquired 11/02/20, Cost: $9,287,400)(b)(c)(d)		1,267,643		13,842,662
Synopsys, Inc.(b)(e)		115,666		59,557,580
Unity Software, Inc.(b)		223,386		9,134,254
Xero Ltd.(b)		185,993		14,189,133
				283,360,693
Technology Hardware, Storage & Peripherals — 3.5%
Pure Storage, Inc., Class A(b)		655,052		23,359,154
Super Micro Computer, Inc.(b)		26,070		7,410,658
Western Digital Corp.(b)		205,636		10,769,157

C O N S O L I D A T E D  S C H E D U L E  O F  I N V E S T M E N T S 109

Consolidated Schedule of Investments (continued) December 31, 2023 BlackRock Science and Technology Term Trust (BSTZ) (Percentages shown are based on Net Assets)

Security	Shares		Value
Technology Hardware, Storage & Peripherals (continued)
Wistron Corp.		1,842,000	$	5,892,734
Wiwynn Corp.		174,000		10,302,628
				57,734,331
Total Common Stocks — 73.4% (Cost: $814,553,709)				1,196,194,743
Preferred Securities
Preferred Stocks — 27.5%(b)(c)(d)
Communications Equipment — 1.0%
Astranis Space Technologies Corp., Series C, (Acquired 03/19/21, Cost: $17,000,010)		775,515		15,456,014
Consumer Staples Distribution & Retail — 2.4%
GrubMarket, Inc., Series D, (Acquired 07/23/20, Cost: $8,000,001)		1,762,969		39,843,099
Diversified Consumer Services — 1.6%
FlixMobility GmbH, Series F, (Acquired 07/26/19, Cost: $16,947,253)		850		25,413,540
Think & Learn Private Ltd., Series F, (Acquired 09/30/20, Cost: $14,251,080)		4,920		1,031,657
				26,445,197
Entertainment — 0.4%
ResearchGate GmbH, Series D, (Acquired 09/24/20, Cost: $6,999,988)		424,688		6,493,479
Financial Services(g) — 1.3%
Trumid Holdings LLC
Class J-A, (Acquired 07/24/20, Cost: $9,999,857)		20,154		10,782,390
Class J-B, (Acquired 07/24/20, Cost: $5,999,914)		20,154		10,782,390
				21,564,780
Interactive Media & Services — 3.1%
ByteDance Ltd., Series E-1, (Acquired 11/11/20, Cost: $33,777,337)		308,260		50,306,991
IT Services — 1.5%
Deep Instinct Ltd., Series D-2, (Acquired 03/19/21, Cost: $12,000,008)		1,974,374		10,859,057
TRAX Ltd.
(Acquired 09/12/19, Cost: $10,999,988)		293,333		7,978,658
(Acquired 02/18/21, Cost: $9,999,998)		191,806		5,217,123
				24,054,838
Professional Services — 0.8%
Rapyd Financial Network Ltd., Series E, (Acquired 03/31/21, Cost: $13,999,978)		190,705		13,034,687
Semiconductors & Semiconductor Equipment — 7.0%
PsiQuantum Corp.
Series C, (Acquired 09/09/19, Cost: $9,101,310)		1,962,335		47,056,793
Series D, (Acquired 05/21/21, Cost: $19,999,969)		762,595		21,672,950
SambaNova Systems, Inc.
Series C, (Acquired 02/20/20, Cost: $33,904,162)		636,800		40,678,784
Series D, (Acquired 04/09/21, Cost: $6,999,979)		73,670		4,706,040
				114,114,567
Software — 8.4%
Databricks, Inc.
Series F, (Acquired 10/22/19, Cost: $13,200,019)		922,038		71,236,656

Security	Shares		Value
Software (continued)
Databricks, Inc. (continued)
Series G, (Acquired 02/01/21, Cost: $18,500,004)		312,909	$	24,175,349
DataRobot, Inc., Series F, (Acquired 10/27/20, Cost: $11,499,999)		875,059		5,022,839
Snorkel AI, Inc., Series B, (Acquired 10/13/20, Cost: $999,996)		247,943		2,157,104
Snyk Ltd., Seed Preferred, (Acquired 11/02/20, Cost: $13,212,590)		2,663,936		29,090,181
Unqork, Inc.
Series B, (Acquired 09/19/19, Cost: $6,801,016)		597,680		3,711,593
Series C, (Acquired 09/18/20, Cost: $7,994,787)		292,000		2,271,760
				137,665,482
				448,979,134
Total Preferred Securities — 27.5% (Cost: $302,189,243)				448,979,134
Total Long-Term Investments — 100.9% (Cost: $1,116,742,952)				1,645,173,877
Short-Term Securities
Money Market Funds — 0.3%
BlackRock Liquidity Funds, T-Fund, Institutional Class, 5.26%(h)(i)		1,471,804		1,471,804
SL Liquidity Series, LLC, Money Market Series, 5.58%(h)(i)(j)		2,877,856		2,878,719
Total Short-Term Securities — 0.3% (Cost: $4,349,961)				4,350,523
Total Investments Before Options Written — 101.2% (Cost: $1,121,092,913)				1,649,524,400
Options Written — (1.2)% (Premiums Received: $(14,635,894))				(18,907,082	)
Total Investments, Net of Options Written — 100.0% (Cost: $1,106,457,019)				1,630,617,318
Liabilities in Excess of Other Assets — 0.0%				(793,089	)
Net Assets — 100.0%			$	1,629,824,229

^(a)  All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.

^(b)  Non-income producing security.

^(c)  Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.

^(d)  Restricted security as to resale, excluding 144A securities. The Trust held restricted securities with a current value of $540,047,343, representing 33.1% of its net assets as of period end, and an original cost of $397,549,459.

^(e)  All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

^(f)  All or a portion of this security is on loan.

^(g)  All or a portion of the security is held by a wholly-owned subsidiary. See Note 1 of the Notes to Consolidated Financial Statements for details on the wholly-owned subsidiary.

^(h)  Affiliate of the Trust.

⁽ⁱ⁾  Annualized 7-day yield as of period end.

^(j)  All or a portion of this security was purchased with the cash collateral from loaned securities.

For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

110 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Consolidated Schedule of Investments (continued) December 31, 2023   BlackRock Science and Technology Term Trust (BSTZ)

Affiliates

Investments in issuers considered to be affiliate(s) of the Trust during the year ended December 31, 2023 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

Affiliated Issuer	Value at 12/31/22		Purchases at Cost			Proceeds from Sale			Net Realized Gain (Loss)		Change in Unrealized Appreciation (Depreciation)		Value at 12/31/23		Shares Held at 12/31/23		Income			Capital Gain Distributions from Underlying Funds
BlackRock Liquidity Funds, T-Fund, Institutional Class	$	20,683,361	$	—		$	(19,211,557	)(a)	$	—	$	—	$	1,471,804		1,471,804	$	395,145		$	—
SL Liquidity Series, LLC, Money Market Series		—		2,865,526	(a)		—			12,631		562		2,878,719		2,877,856		78,328	(b)		—
									$	12,631	$	562	$	4,350,523			$	473,473		$	—

^(a)  Represents net amount purchased (sold).

^(b)  All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.

Derivative Financial Instruments Outstanding as of Period End

Exchange-Traded Options Written

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call
Credo Technology Group Holding Ltd.		787		01/04/24		USD	19.75		USD	1,532	$	(24,289	)
MercadoLibre, Inc.		16		01/05/24		USD	1,600.00		USD	2,514		(15,680	)
NVIDIA Corp.		84		01/05/24		USD	490.00		USD	4,160		(85,680	)
Pinterest, Inc., Class A		423		01/05/24		USD	33.00		USD	1,567		(173,430	)
SentinelOne, Inc., Class A		378		01/05/24		USD	24.00		USD	1,037		(160,650	)
Super Micro Computer, Inc.		42		01/05/24		USD	290.00		USD	1,194		(21,840	)
Tesla, Inc.		80		01/05/24		USD	255.00		USD	1,988		(30,200	)
Wolfspeed, Inc.		356		01/05/24		USD	45.00		USD	1,549		(30,260	)
ARM Holdings PLC, ADR		346		01/12/24		USD	75.00		USD	2,600		(99,302	)
Cloudflare, Inc., Class A		217		01/12/24		USD	80.00		USD	1,807		(100,363	)
Credo Technology Group Holding Ltd.		720		01/12/24		USD	16.75		USD	1,402		(201,691	)
Datadog, Inc., Class A		178		01/12/24		USD	125.00		USD	2,161		(26,522	)
Expedia Group, Inc.		98		01/12/24		USD	145.00		USD	1,488		(78,645	)
Marvell Technology, Inc.		284		01/12/24		USD	56.00		USD	1,713		(131,350	)
MercadoLibre, Inc.		3		01/12/24		USD	1,620.00		USD	471		(4,650	)
MongoDB, Inc., Class A		44		01/12/24		USD	430.00		USD	1,799		(19,800	)
NVIDIA Corp.		96		01/12/24		USD	475.00		USD	4,754		(245,520	)
NVIDIA Corp.		96		01/12/24		USD	485.00		USD	4,754		(177,120	)
Palo Alto Networks, Inc.		246		01/12/24		USD	305.00		USD	7,254		(70,479	)
Roku, Inc., Class A		166		01/12/24		USD	112.00		USD	1,522		(2,656	)
SentinelOne, Inc., Class A		340		01/12/24		USD	21.50		USD	933		(214,200	)
Spotify Technology SA		109		01/12/24		USD	210.00		USD	2,048		(2,725	)
Take-Two Interactive Software, Inc.		203		01/12/24		USD	162.50		USD	3,267		(42,427	)
Tesla, Inc.		217		01/12/24		USD	255.00		USD	5,392		(133,997	)
Unity Software, Inc.		343		01/12/24		USD	33.00		USD	1,403		(261,537	)
Wolfspeed, Inc.		645		01/12/24		USD	40.00		USD	2,806		(280,575	)
ARM Holdings PLC, ADR		338		01/19/24		USD	55.00		USD	2,540		(687,830	)
Cloudflare, Inc., Class A		394		01/19/24		USD	85.00		USD	3,280		(97,909	)
Credo Technology Group Holding Ltd.		2,176		01/19/24		USD	20.00		USD	4,237		(125,120	)
Datadog, Inc., Class A		165		01/19/24		USD	125.00		USD	2,003		(36,548	)
Expedia Group, Inc.		61		01/19/24		USD	120.00		USD	926		(197,182	)
Jabil, Inc.		446		01/19/24		USD	130.00		USD	5,682		(86,970	)
Kinaxis, Inc.		166		01/19/24		CAD	155.00		CAD	2,469		(23,490	)
Klaviyo, Inc., Series A		555		01/19/24		USD	35.00		USD	1,542		(22,200	)
Klaviyo, Inc., Series A		555		01/19/24		USD	32.50		USD	1,542		(8,325	)
Legalzoom.com, Inc.		1,474		01/19/24		USD	12.50		USD	1,666		(14,740	)
Manhattan Associates, Inc.		80		01/19/24		USD	230.00		USD	1,723		(7,200	)
Marvell Technology, Inc.		295		01/19/24		USD	52.50		USD	1,779		(236,000	)
Marvell Technology, Inc.		106		01/19/24		USD	61.00		USD	639		(16,748	)
MercadoLibre, Inc.		22		01/19/24		USD	1,600.00		USD	3,457		(66,110	)
MongoDB, Inc., Class A		55		01/19/24		USD	410.00		USD	2,249		(78,375	)

C O N S O L I D A T E D  S C H E D U L E  O F  I N V E S T M E N T S 111

Consolidated Schedule of Investments (continued) December 31, 2023   BlackRock Science and Technology Term Trust (BSTZ)

Exchange-Traded Options Written (continued)

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
NVIDIA Corp.		113		01/19/24		USD	490.00		USD	5,596	$	(207,920	)
Palo Alto Networks, Inc.		88		01/19/24		USD	286.67		USD	2,595		(117,700	)
Pinterest, Inc., Class A		284		01/19/24		USD	35.00		USD	1,052		(68,586	)
Rambus, Inc.		630		01/19/24		USD	70.00		USD	4,300		(129,150	)
Roku, Inc., Class A		150		01/19/24		USD	105.00		USD	1,375		(12,450	)
Samsara, Inc., Class A		550		01/19/24		USD	30.00		USD	1,836		(214,500	)
Samsara, Inc., Class A		123		01/19/24		USD	40.00		USD	411		(2,460	)
SentinelOne, Inc., Class A		378		01/19/24		USD	24.00		USD	1,037		(139,860	)
Spotify Technology SA		125		01/19/24		USD	185.00		USD	2,349		(90,625	)
Super Micro Computer, Inc.		30		01/19/24		USD	330.00		USD	853		(9,225	)
Synopsys, Inc.		157		01/19/24		USD	540.00		USD	8,084		(57,305	)
Take-Two Interactive Software, Inc.		190		01/19/24		USD	155.00		USD	3,058		(143,449	)
Tesla, Inc.		179		01/19/24		USD	246.67		USD	4,448		(211,667	)
Unity Software, Inc.		408		01/19/24		USD	35.00		USD	1,668		(251,940	)
Wolfspeed, Inc.		356		01/19/24		USD	47.50		USD	1,549		(48,060	)
Zillow Group, Inc., Class C		230		01/19/24		USD	45.00		USD	1,331		(300,150	)
Marvell Technology, Inc.		408		01/26/24		USD	55.00		USD	2,461		(244,800	)
MercadoLibre, Inc.		25		01/26/24		USD	1,625.00		USD	3,929		(71,625	)
MongoDB, Inc., Class A		101		01/26/24		USD	400.00		USD	4,129		(233,562	)
NVIDIA Corp.		122		01/26/24		USD	495.00		USD	6,042		(227,530	)
Pinterest, Inc., Class A		190		01/26/24		USD	36.00		USD	704		(36,385	)
Spotify Technology SA		97		01/26/24		USD	200.00		USD	1,823		(24,493	)
Super Micro Computer, Inc.		32		01/26/24		USD	320.00		USD	910		(24,160	)
Tesla, Inc.		169		01/26/24		USD	270.00		USD	4,199		(104,358	)
Western Digital Corp.		199		01/26/24		USD	53.00		USD	1,042		(31,641	)
NVIDIA Corp.		143		02/02/24		USD	505.00		USD	7,082		(244,172	)
Tesla, Inc.		143		02/02/24		USD	279.65		USD	3,553		(77,350	)
Western Digital Corp.		622		02/09/24		USD	53.00		USD	3,257		(154,878	)
Credo Technology Group Holding Ltd.		2,060		02/16/24		USD	20.00		USD	4,011		(216,300	)
Kinaxis, Inc.		170		02/16/24		CAD	160.00		CAD	2,528		(43,942	)
MongoDB, Inc., Class A		79		02/16/24		USD	480.00		USD	3,230		(40,488	)
Monolithic Power Systems, Inc.		99		02/16/24		USD	630.00		USD	6,245		(408,870	)
Pinterest, Inc., Class A		403		02/16/24		USD	35.00		USD	1,493		(151,125	)
Rambus, Inc.		670		02/16/24		USD	70.00		USD	4,573		(278,050	)
Samsara, Inc., Class A		673		02/16/24		USD	36.09		USD	2,246		(131,839	)
Take-Two Interactive Software, Inc.		192		02/16/24		USD	165.00		USD	3,090		(105,600	)
Unity Software, Inc.		589		02/16/24		USD	39.00		USD	2,408		(276,830	)
Datadog, Inc., Class A		32		03/15/24		USD	140.00		USD	388		(11,280	)
Monolithic Power Systems, Inc.		70		03/15/24		USD	640.00		USD	4,415		(314,650	)
Samsara, Inc., Class A		760		03/15/24		USD	40.00		USD	2,537		(125,400	)
SentinelOne, Inc., Class A		474		03/15/24		USD	32.00		USD	1,301		(46,215	)
Zillow Group, Inc., Class C		460		03/15/24		USD	60.00		USD	2,662		(186,300	)
											$	(10,157,225	)

OTC Options Written

Description	Counterparty	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call
Kaspi.KZ JSC, GDR, Registered Shares	Bank of America N.A.		2,300		01/04/24		USD	93.03		USD	212	$	(2,331	)
Palo Alto Networks, Inc.	Citibank N.A.		8,700		01/04/24		USD	256.59		USD	2,565		(335,177	)
SiteMinder Ltd.	Goldman Sachs International		43,200		01/04/24		AUD	4.61		AUD	222		(15,304	)
SK Hynix, Inc.	JPMorgan Chase Bank N.A.		6,800		01/04/24		KRW	138,107.44		KRW	955,799		(23,105	)
Lattice Semiconductor Corp.	JPMorgan Chase Bank N.A.		39,900		01/08/24		USD	79.66		USD	2,753		(1,309	)
Altium Ltd.	UBS AG		56,900		01/09/24		AUD	44.26		AUD	2,662		(105,046	)
BE Semiconductor Industries NV	Bank of America N.A.		12,800		01/09/24		EUR	115.92		EUR	1,751		(292,773	)
SiteMinder Ltd.	UBS AG		46,400		01/09/24		AUD	4.82		AUD	238		(10,550	)
SOITEC	Bank of America N.A.		4,400		01/09/24		EUR	167.27		EUR	713		(5,552	)
Yageo Corp.	Morgan Stanley & Co. International PLC		116,000		01/09/24		TWD	559.98		TWD	69,128		(125,134	)
Alphawave IP Group PLC	Barclays Bank PLC		100,000		01/10/24		GBP	1.15		GBP	129		(18,046	)
Informa PLC	Bank of America N.A.		72,600		01/10/24		GBP	7.34		GBP	567		(45,121	)

112 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Consolidated Schedule of Investments (continued) December 31, 2023   BlackRock Science and Technology Term Trust (BSTZ)

OTC Options Written (continued)

Description	Counterparty	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
Synopsys, Inc.	UBS AG		16,000		01/10/24		USD	539.69		USD	8,239	$	(31,870	)
Kaspi.KZ JSC, GDR, Registered Shares	Bank of America N.A.		3,000		01/11/24		USD	94.55		USD	276		(3,476	)
Wise PLC, Class A	Bank of America N.A.		95,000		01/11/24		GBP	7.59		GBP	829		(143,867	)
AIXTRON SE	UBS AG		76,500		01/12/24		EUR	34.41		EUR	2,950		(366,695	)
Alphawave IP Group PLC	UBS AG		150,000		01/12/24		GBP	1.21		GBP	193		(18,254	)
Freee KK	Citibank N.A.		87,400		01/12/24		JPY	3,664.75		JPY	265,958		(5,273	)
Kaspi.KZ JSC, GDR, Registered Shares	Morgan Stanley & Co. International PLC		8,000		01/12/24		USD	98.58		USD	736		(2,899	)
Pure Storage, Inc., Class A	JPMorgan Chase Bank N.A.		160,000		01/12/24		USD	36.98		USD	5,706		(53,494	)
SiteMinder Ltd.	UBS AG		67,000		01/12/24		AUD	5.14		AUD	344		(5,394	)
SK Hynix, Inc.	JPMorgan Chase Bank N.A.		33,000		01/12/24		KRW	124,206.67		KRW	4,638,438		(447,461	)
Altium Ltd.	Goldman Sachs International		34,500		01/17/24		AUD	44.43		AUD	1,614		(63,802	)
Kaspi.KZ JSC, GDR, Registered Shares	Bank of America N.A.		3,000		01/17/24		USD	94.45		USD	276		(4,824	)
Yageo Corp.	Morgan Stanley & Co. International PLC		116,000		01/17/24		TWD	555.90		TWD	69,128		(145,184	)
Alphawave IP Group PLC	Morgan Stanley & Co. International PLC		80,000		01/18/24		GBP	1.15		GBP	103		(15,271	)
BE Semiconductor Industries NV	Morgan Stanley & Co. International PLC		40,100		01/18/24		EUR	126.33		EUR	5,484		(506,213	)
Ibiden Co. Ltd.	Societe Generale		80,600		01/18/24		JPY	8,027.85		JPY	626,936		(122,574	)
SiteMinder Ltd.	Goldman Sachs International		92,500		01/18/24		AUD	4.78		AUD	474		(24,339	)
SOITEC	Morgan Stanley & Co. International PLC		7,100		01/18/24		EUR	169.69		EUR	1,151		(11,330	)
Wolters Kluwer NV, Class C	Goldman Sachs International		65,700		01/18/24		EUR	124.95		EUR	8,467		(336,324	)
Alphawave IP Group PLC	UBS AG		150,000		01/23/24		GBP	1.22		GBP	193		(19,305	)
Altium Ltd.	UBS AG		54,400		01/23/24		AUD	45.84		AUD	2,545		(65,238	)
Altium Ltd.	UBS AG		37,100		01/23/24		AUD	45.77		AUD	1,736		(45,830	)
ASM International NV	Bank of America N.A.		22,200		01/23/24		EUR	461.39		EUR	10,467		(499,410	)
BE Semiconductor Industries NV	Bank of America N.A.		15,200		01/23/24		EUR	132.60		EUR	2,079		(117,506	)
Informa PLC	Goldman Sachs International		329,500		01/23/24		GBP	7.74		GBP	2,571		(71,849	)
Kaspi.KZ JSC, GDR, Registered Shares	Morgan Stanley & Co. International PLC		3,000		01/23/24		USD	104.55		USD	276		(586	)
Lattice Semiconductor Corp.	Citibank N.A.		3,000		01/23/24		USD	62.43		USD	207		(22,725	)
Lotes Co. Ltd.	Morgan Stanley & Co. International PLC		28,000		01/23/24		TWD	916.70		TWD	29,882		(142,709	)
SiteMinder Ltd.	UBS AG		67,000		01/23/24		AUD	5.24		AUD	344		(5,357	)
Wise PLC, Class A	UBS AG		90,000		01/23/24		GBP	8.32		GBP	785		(76,094	)
Wise PLC, Class A	UBS AG		10,900		01/23/24		GBP	8.44		GBP	95		(8,138	)
Xero Ltd.	Goldman Sachs International		40,300		01/23/24		AUD	105.92		AUD	4,512		(231,619	)
Alphawave IP Group PLC	UBS AG		80,000		01/24/24		GBP	1.18		GBP	103		(13,624	)
SiteMinder Ltd.	UBS AG		50,000		01/24/24		AUD	4.98		AUD	256		(8,621	)
Accton Technology Corp.	JPMorgan Chase Bank N.A.		111,600		01/25/24		TWD	584.60		TWD	58,215		(18,870	)
NEC Corp.	Citibank N.A.		24,700		01/25/24		JPY	8,391.41		JPY	205,779		(33,021	)
SOITEC	Morgan Stanley & Co. International PLC		7,100		01/25/24		EUR	169.69		EUR	1,151		(17,793	)
Xero Ltd.	Goldman Sachs International		42,300		01/25/24		AUD	105.71		AUD	4,735		(251,864	)
Alphawave IP Group PLC	Goldman Sachs International		80,000		01/30/24		GBP	1.24		GBP	103		(10,102	)
Kaspi.KZ JSC, GDR, Registered Shares	Morgan Stanley & Co. International PLC		3,000		01/30/24		USD	104.55		USD	276		(994	)
NAVER Corp.	JPMorgan Chase Bank N.A.		28,300		01/30/24		KRW	219,950.00		KRW	6,306,166		(220,304	)
SiteMinder Ltd.	Goldman Sachs International		50,000		01/30/24		AUD	4.99		AUD	256		(9,088	)
Legalzoom.com, Inc.	Morgan Stanley & Co. International PLC		118,400		01/31/24		USD	11.56		USD	1,338		(45,204	)
Manhattan Associates, Inc.	UBS AG		6,500		01/31/24		USD	220.21		USD	1,400		(46,499	)
Synopsys, Inc.	Citibank N.A.		16,100		01/31/24		USD	582.67		USD	8,290		(26,113	)
Wise PLC, Class A	Goldman Sachs International		30,000		01/31/24		GBP	9.42		GBP	262		(7,626	)
Alphawave IP Group PLC	UBS AG		150,000		02/01/24		GBP	1.21		GBP	193		(23,139	)
Altium Ltd.	UBS AG		60,400		02/01/24		AUD	46.58		AUD	2,825		(63,634	)
Freee KK	Societe Generale		94,600		02/01/24		JPY	3,141.60		JPY	287,868		(119,557	)
Informa PLC	UBS AG		343,500		02/01/24		GBP	7.79		GBP	2,680		(73,212	)
Kaspi.KZ JSC, GDR, Registered Shares	Bank of America N.A.		8,000		02/01/24		USD	99.70		USD	736		(8,380	)
Lasertec Corp.	Societe Generale		37,300		02/01/24		JPY	36,077.60		JPY	1,380,705		(637,500	)
Lotes Co. Ltd.	Bank of America N.A.		12,000		02/01/24		TWD	968.20		TWD	12,807		(45,087	)
SOITEC	Morgan Stanley & Co. International PLC		7,100		02/01/24		EUR	169.69		EUR	1,151		(24,575	)
Accton Technology Corp.	JPMorgan Chase Bank N.A.		349,000		02/05/24		TWD	552.44		TWD	182,052		(183,410	)
Alchip Technologies Ltd.	JPMorgan Chase Bank N.A.		65,000		02/05/24		TWD	3,942.00		TWD	211,973		(74,722	)
eMemory Technology, Inc.	JPMorgan Chase Bank N.A.		60,000		02/05/24		TWD	2,819.50		TWD	146,420		(86,536	)
Lotes Co. Ltd.	JPMorgan Chase Bank N.A.		57,000		02/05/24		TWD	1,009.40		TWD	60,831		(162,588	)
Wiwynn Corp.	JPMorgan Chase Bank N.A.		70,000		02/05/24		TWD	1,799.20		TWD	127,204		(301,629	)
Kaspi.KZ JSC, GDR, Registered Shares	Morgan Stanley & Co. International PLC		3,000		02/06/24		USD	104.55		USD	276		(1,543	)
Lattice Semiconductor Corp.	Goldman Sachs International		27,800		02/06/24		USD	62.25		USD	1,918		(239,848	)
Nintendo Co., Ltd.	BNP Paribas SA		72,800		02/06/24		JPY	7,099.15		JPY	534,117		(196,929	)

C O N S O L I D A T E D  S C H E D U L E  O F  I N V E S T M E N T S 113

Consolidated Schedule of Investments (continued) December 31, 2023 BlackRock Science and Technology Term Trust (BSTZ)

 

OTC Options Written (continued)

Description	Counterparty	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
Samsara, Inc., Class A	Bank of America N.A.		41,000		02/06/24		USD	27.90		USD	1,369	$	(247,799	)
SK Hynix, Inc.	Morgan Stanley & Co. International PLC		19,000		02/06/24		KRW	139,072.00		KRW	2,670,616		(100,531	)
Alphawave IP Group PLC	UBS AG		150,000		02/07/24		GBP	1.23		GBP	193		(21,456	)
Altium Ltd.	UBS AG		57,000		02/07/24		AUD	47.48		AUD	2,666		(47,928	)
Informa PLC	Goldman Sachs International		307,100		02/07/24		GBP	7.90		GBP	2,396		(49,052	)
NEC Corp.	Societe Generale		24,700		02/07/24		JPY	8,391.41		JPY	205,779		(41,357	)
SOITEC	UBS AG		7,000		02/07/24		EUR	167.99		EUR	1,135		(33,933	)
Appier Group, Inc.	Citibank N.A.		195,300		02/08/24		JPY	1,629.72		JPY	359,597		(374,989	)
SiteMinder Ltd.	Goldman Sachs International		92,000		02/08/24		AUD	5.05		AUD	472		(15,939	)
Wise PLC, Class A	UBS AG		79,600		02/08/24		GBP	8.72		GBP	695		(52,171	)
Kaspi.KZ JSC, GDR, Registered Shares	Morgan Stanley & Co. International PLC		3,000		02/13/24		USD	104.55		USD	276		(2,054	)
SiteMinder Ltd.	Goldman Sachs International		92,000		02/13/24		AUD	5.05		AUD	472		(16,770	)
SOITEC	Bank of America N.A.		8,300		02/13/24		EUR	171.44		EUR	1,345		(37,707	)
Alphawave IP Group PLC	Barclays Bank PLC		100,000		02/14/24		GBP	1.30		GBP	129		(10,457	)
Kaspi.KZ JSC, GDR, Registered Shares	Morgan Stanley & Co. International PLC		3,000		02/21/24		USD	104.55		USD	276		(2,601	)
SiteMinder Ltd.	JPMorgan Chase Bank N.A.		92,000		02/21/24		AUD	5.05		AUD	472		(18,020	)
SOITEC	Bank of America N.A.		8,200		02/21/24		EUR	171.44		EUR	1,329		(43,893	)
Kaspi.KZ JSC, GDR, Registered Shares	Morgan Stanley & Co. International PLC		3,000		02/28/24		USD	104.55		USD	276		(3,252	)
SOITEC	Barclays Bank PLC		9,100		02/28/24		EUR	168.35		EUR	1,475		(64,870	)
Kaspi.KZ JSC, GDR, Registered Shares	Morgan Stanley & Co. International PLC		3,000		03/05/24		USD	104.55		USD	276		(3,791	)
Kaspi.KZ JSC, GDR, Registered Shares	Morgan Stanley & Co. International PLC		3,000		03/12/24		USD	104.55		USD	276		(4,396	)
Kaspi.KZ JSC, GDR, Registered Shares	Morgan Stanley & Co. International PLC		3,000		03/19/24		USD	104.55		USD	276		(4,979	)
Kaspi.KZ JSC, GDR, Registered Shares	Morgan Stanley & Co. International PLC		3,000		03/26/24		USD	104.55		USD	276		(5,542	)
												$	(8,749,857	)

Balances Reported in the Consolidated Statements of Assets and Liabilities for Options Written

Description	Swap Premiums Paid		Swap Premiums Received		Unrealized Appreciation		Unrealized Depreciation			Value
Options Written	$	N/A	$	N/A	$	3,605,089	$	(7,876,277	)	$	(18,907,082	)

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Consolidated Statements of Assets and Liabilities were as follows:

	Commodity Contracts		Credit  Contracts		Equity Contracts		Foreign Currency  Exchange Contracts		Interest Rate  Contracts		Other  Contracts		Total
Liabilities — Derivative Financial Instruments
Options written
Options written at value	$	—	$	—	$	18,907,082	$	—	$	—	$	—	$	18,907,082

For the period ended December 31, 2023, the effect of derivative financial instruments in the Consolidated Statements of Operations was as follows:

	Commodity Contracts		Credit  Contracts		Equity  Contracts			Foreign Currency  Exchange Contracts		Interest Rate  Contracts		Other  Contracts		Total
Net Realized Gain (Loss) from:
Options purchased(a)	$	—	$	—	$	(4,070,240	)	$	—	$	—	$	—	$	(4,070,240	)
Options written		—		—		(25,763,522	)		—		—		—		(25,763,522	)
	$	—	$	—	$	(29,833,762	)	$	—	$	—	$	—	$	(29,833,762	)
Net Change in Unrealized Appreciation (Depreciation) on:
Options written	$	—	$	—	$	(13,974,383	)	$	—	$	—	$	—	$	(13,974,383	)

^(a)  Options purchased are included in net realized gain (loss) from investments — unaffiliated.

114 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Consolidated Schedule of Investments (continued) December 31, 2023 BlackRock Science and Technology Term Trust (BSTZ)

 

Average Quarterly Balances of Outstanding Derivative Financial Instruments

Options:
Average value of option contracts purchased	$	—	(a)
Average value of option contracts written	$	20,879,531

^(a) Derivative financial instrument not held at any quarter-end. The risk exposure table serves as an indicator of activity during the period.

For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Consolidated Financial Statements.

Derivative Financial Instruments — Offsetting as of Period End

The Trust’s derivative assets and liabilities (by type) were as follows:

	Assets		Liabilities
Derivative Financial Instruments
Options	$	—	$	18,907,082
Total derivative assets and liabilities in the Consolidated Statements of Assets and Liabilities		—		18,907,082
Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”)		—		(10,157,225	)
Total derivative assets and liabilities subject to an MNA	$	—	$	8,749,857

The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the Trust:

Counterparty		Derivative Liabilities Subject to an MNA by Counterparty		Derivatives Available for Offset		Non-Cash Collateral Pledged	(a)		Cash Collateral Pledged	(a)		Net Amount of Derivative Liabilities	(b)
Bank of America N.A.	$	1,497,726	$	—	$	—		$	(1,497,726	)	$	—
Barclays Bank PLC		93,373		—		—			—			93,373
BNP Paribas SA		196,929		—		(167,880	)		—			29,049
Citibank N.A.		797,298		—		—			(797,298	)		—
Goldman Sachs International		1,343,526		—		(1,343,526	)		—			—
JPMorgan Chase Bank N.A.		1,591,448		—		(1,591,448	)		—			—
Morgan Stanley & Co. International PLC		1,166,581		—		(1,166,581	)		—			—
Societe Generale		920,988		—		(920,988	)		—			—
UBS AG		1,141,988		—		(1,141,988	)		—			—
	$	8,749,857	$	—	$	(6,332,411	)	$	(2,295,024	)	$	122,422

^(a)  Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes.

^(b)  Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Consolidated Statements of Assets and Liabilities.

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation of financial instruments, refer to the Notes to Consolidated Financial Statements.

The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s financial instruments into major categories is disclosed in the Consolidated Schedule of Investments above.

	Level 1		Level 2		Level 3		Total
Assets
Investments
Long-Term Investments
Common Stocks
Automobiles	$	32,166,482	$	—	$	—	$	32,166,482
Broadline Retail		26,114,280		—		—		26,114,280
Communications Equipment		—		19,563,294		—		19,563,294
Consumer Finance		15,303,280		—		—		15,303,280
Diversified Consumer Services		—		—		975,251		975,251
Electronic Equipment, Instruments & Components		35,151,780		45,350,226		—		80,502,006
Entertainment		45,772,750		13,281,097		—		59,053,847

C O N S O L I D A T E D  S C H E D U L E  O F  I N V E S T M E N T S 115

Consolidated Schedule of Investments (continued) December 31, 2023 BlackRock Science and Technology Term Trust (BSTZ)

 

Fair Value Hierarchy as of Period End (continued)

	Level 1			Level 2			Level 3		Total
Common Stocks (continued)
Financial Services	$	—		$	8,492,073		$	—	$	8,492,073
Hotels, Restaurants & Leisure		6,002,080			—			—		6,002,080
Interactive Media & Services		12,045,408			20,107,036			—		32,152,444
IT Services		37,201,144			7,297,138			46,340,867		90,839,149
Machinery		—			6,961,217			—		6,961,217
Media		—			26,174,876			—		26,174,876
Professional Services		7,180,800			23,378,574			—		30,559,374
Real Estate Management & Development		11,822,476			—			—		11,822,476
Semiconductors & Semiconductor Equipment		225,453,479			182,964,111			—		408,417,590
Software		173,994,166			64,196,047			45,170,480		283,360,693
Technology Hardware, Storage & Peripherals		41,538,969			16,195,362			—		57,734,331
Preferred Securities
Preferred Stocks		—			—			448,979,134		448,979,134
Short-Term Securities
Money Market Funds		1,471,804			—			—		1,471,804
	$	671,218,898		$	433,961,051		$	541,465,732		1,646,645,681
Investments Valued at NAV(a)										2,878,719
									$	1,649,524,400
Derivative Financial Instruments(b)
Liabilities
Equity Contracts	$	(9,722,056	)	$	(9,185,026	)	$	—	$	(18,907,082	)

^(a)  Certain investments of the Trust were fair valued using NAV as a practical expedient as no quoted market value is available and therefore have been excluded from the fair value hierarchy.

^(b)  Derivative financial instruments are options written. Options written are shown at value.

A reconciliation of Level 3 financial instruments is presented when the Trust had a significant amount of Level 3 investments and derivative financial instruments at the beginning and/or end of the year in relation to net assets. The following table is a reconciliation of Level 3 investments for which significant unobservable inputs were used in determining fair value:

	Common Stocks			Preferred Stocks			Warrants			Total
Assets
Opening balance, as of December 31, 2022	$	94,490,236		$	413,908,201		$	44,581		$	508,443,018
Transfers into Level 3		—			—			—			—
Transfers out of Level 3		—			—			—			—
Other(a)		(11,996,492	)		11,996,492			—			—
Accrued discounts/premiums		—			—			—			—
Net realized gain (loss)		—			—			—			—
Net change in unrealized appreciation (depreciation)(b)(c)		(1,968,145	)		35,035,442			(44,581	)		33,022,716
Purchases		11,960,999			—			—			11,960,999
Sales		—			(11,961,001	)		—			(11,961,001	)
Closing balance, as of December 31, 2023	$	92,486,598		$	448,979,134		$	—		$	541,465,732
Net change in unrealized appreciation (depreciation) on investments still held at December 31, 2023(c)	$	(1,968,145	)	$	39,939,523		$	—		$	37,971,378

^(a)  Certain Level 3 investments were re-classified between Common Stocks and Preferred Stocks.

^(b)  Included in the related net change in unrealized appreciation (depreciation) in the Consolidated Statements of Operations.

^(c)  Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized appreciation (depreciation) on investments still held at December 31, 2023 is generally due to investments no longer held or categorized as Level 3 at period end.

The following table summarizes the valuation approaches used and unobservable inputs utilized by the BlackRock Valuation Committee (the “Valuation Committee”) to determine the value of certain of the Trust’s Level 3 financial instruments as of period end.

		Value	Valuation Approach	Unobservable Inputs	Range of   Unobservable Inputs Utilized	(a)	Weighted Average of Unobservable Inputs Based on Fair Value
Assets
Common Stocks	$	92,486,598	Market	Revenue Multiple	1.00x - 29.00x		14.58x

116 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Consolidated Schedule of Investments (continued) December 31, 2023 BlackRock Science and Technology Term Trust (BSTZ)

		Value	Valuation Approach	Unobservable Inputs	Range of Unobservable Inputs Utilized	(a)	Weighted Average of Unobservable Inputs Based on Fair Value
				Volatility	60% - 70%		62%
				Time to Exit	1.0 - 3.0 years		1.3 years
Preferred Stocks(b)		448,979,134	Market	Revenue Multiple	1.00x - 31.00x		16.88x
				Time to Exit	2.0 - 4.0 years		3.6 years
				Volatility	39% - 80%		57%
				Market Adjustment Multiple	1.20x - 1.20x		1.20x
				Gross Profit Multiple	6.50x		—
	$	541,465,732

^(a)  A significant change in unobservable input would have resulted in a correlated (inverse) significant change to value.

^(b)  For the period end December 31, 2023, the valuation technique for certain investments classified as Preferred Stocks used recent prior transaction prices as inputs within the model used for the approximation of fair value.

See notes to financial statements.

C O N S O L I D A T E D  S C H E D U L E  O F  I N V E S T M E N T S 117

Consolidated Schedule of Investments December 31, 2023   BlackRock Science and Technology Trust (BST) (Percentages shown are based on Net Assets)

Security	Shares		Value
Common Stocks
Automobiles — 1.8%
Tesla, Inc.(a)(b)		88,868	$	22,081,921
Broadline Retail(b) — 3.7%
Amazon.com, Inc.		173,939		26,428,291
MercadoLibre, Inc.(a)		11,498		18,069,567
				44,497,858
Capital Markets — 0.7%
S&P Global, Inc.		19,255		8,482,213
Communications Equipment — 1.2%
Arista Networks, Inc.(b)		36,016		8,482,128
Motorola Solutions, Inc.		16,945		5,305,310
				13,787,438
Diversified Consumer Services(b)(c)(d) — 1.0%
Grammarly, Inc., (Acquired 11/17/21, Cost: $18,749,975)		715,323		12,267,790
Think & Learn Private Ltd., (Acquired 09/30/20, Cost: $1,524,948)		997		209,057
				12,476,847
Entertainment — 2.0%
Nintendo Co. Ltd.		130,100		6,769,606
Spotify Technology SA(b)		49,956		9,387,232
Take-Two Interactive Software, Inc.(b)		47,267		7,607,624
				23,764,462
Financial Services — 4.5%
Mastercard, Inc., Class A		64,052		27,318,818
Visa, Inc., Class A		79,203		20,620,501
Wise PLC, Class A(b)		499,198		5,551,821
				53,491,140
Ground Transportation — 1.0%
Uber Technologies, Inc.(b)		191,091		11,765,473
Household Durables — 0.5%
Sony Group Corp.		63,100		5,971,333
Interactive Media & Services(b) — 4.0%
Alphabet, Inc., Class A		165,332		23,095,227
Meta Platforms, Inc., Class A		71,332		25,248,675
				48,343,902
IT Services — 4.5%
Automattic, Inc., Series E, (Acquired 02/03/21, Cost: $7,999,945)(b)(c)(d)		94,117		4,222,089
Farmer’s Business Network, Inc.(b)(c)		203,366		797,195
Fujitsu Ltd.		34,700		5,222,128
Klarna Holdings AB, Ordinary Shares, (Acquired 08/07/19, Cost: $7,971,978)(b)(c)(d)		26,430		7,493,258
MongoDB, Inc., Class A(b)(e)		37,832		15,467,613
Patreon, Inc., (Acquired 08/19/21, Cost: $3,352,226)(b)(c)(d)		59,524		1,678,577
Shopify, Inc., Class A(b)(e)		98,199		7,649,702
Snowflake, Inc., Class A(b)		25,853		5,144,747
Teya Services Ltd., (Acquired 12/17/21, Cost: $24,999,987)(b)(c)(d)		12,871		5,557,569
				53,232,878

Security	Shares		Value
Professional Services — 1.6%
Ant Group Co., Ltd., Series C(b)(c)		1,703,548	$	4,480,331
Equifax, Inc.		20,539		5,079,089
RELX PLC		239,670		9,508,622
				19,068,042
Semiconductors & Semiconductor Equipment — 24.7%
Advanced Micro Devices, Inc.(b)(f)		152,642		22,500,957
ARM Holdings PLC, ADR(b)(e)		122,687		9,219,315
ASM International NV		25,186		13,108,672
ASML Holding NV(b)		37,127		28,026,708
Broadcom, Inc.(a)		31,215		34,843,744
Credo Technology Group Holding Ltd.(b)		505,651		9,845,025
Lam Research Corp.		18,864		14,775,417
Marvell Technology, Inc.		129,364		7,801,943
Micron Technology, Inc.		214,444		18,300,651
Monolithic Power Systems, Inc.(a)		15,577		9,825,660
NVIDIA Corp.(f)		174,497		86,414,404
QUALCOMM, Inc.		41,834		6,050,451
SOITEC(b)		68,927		12,334,100
STMicroelectronics NV		111,740		5,604,762
Taiwan Semiconductor Manufacturing Co. Ltd., ADR		76,372		7,942,688
Wolfspeed, Inc.(a)(b)		208,349		9,065,265
				295,659,762
Software — 23.6%
Adobe, Inc.(b)		15,654		9,339,177
ANSYS, Inc.(b)		22,559		8,186,210
Autodesk, Inc.(b)		28,054		6,830,588
Cadence Design Systems, Inc.(a)(b)		123,246		33,568,513
Constellation Software, Inc./Canada		3,971		9,845,521
Crowdstrike Holdings, Inc., Class A(b)		42,478		10,845,483
Databricks, Inc., (Acquired 07/24/20, Cost: $960,476)(b)(c)(d)		59,997		4,635,368
Datadog, Inc., Class A(b)		40,806		4,953,032
DataRobot, Inc., (Acquired 03/01/21, Cost: $583,275)(b)(c)(d)		38,789		178,817
Intuit, Inc.		25,968		16,230,779
Microsoft Corp.(a)(f)		297,098		111,720,732
Oracle Corp.(a)		120,170		12,669,523
Palo Alto Networks, Inc.(b)		28,947		8,535,891
Salesforce, Inc.(b)		64,706		17,026,737
ServiceNow, Inc.(b)		19,645		13,878,996
SiteMinder Ltd.(b)		951,492		3,325,275
Snorkel AI, Inc., (Acquired 06/30/21, Cost: $997,636)(b)(c)(d)		66,422		577,871
Snyk Ltd., Ordinary Shares, (Acquired 09/02/21, Cost: $5,192,307)(b)(c)(d)		361,972		3,952,734
Xero Ltd.(b)		77,120		5,883,372
				282,184,619
Specialty Retail — 0.0%
AceVector Limited, Series I, (Acquired 08/31/18, Cost: $1,998,435)(b)(c)(d)		168,640		84,691
Technology Hardware, Storage & Peripherals — 8.8%
Apple, Inc.(a)		487,116		93,784,443

118 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Consolidated Schedule of Investments (continued) December 31, 2023   BlackRock Science and Technology Trust (BST) (Percentages shown are based on Net Assets)

Security	Shares		Value
Technology Hardware, Storage & Peripherals (continued)
Quanta Computer, Inc.		762,000	$	5,547,679
Western Digital Corp.(b)		112,683		5,901,209
				105,233,331
Total Common Stocks — 83.6% (Cost: $553,064,487)				1,000,125,910
	Par (000)
Convertible Notes
Financial Services — 0.0%
Wyre, Inc., (Acquired: 12/14/21, Cost: $8,000,000), 6.00%, 12/08/24(c)(d)	$	80		1
Total Convertible Notes — 0.0% (Cost: $8,000,000)				1
	Shares
Preferred Securities
Preferred Stocks — 17.7%(b)(c)
Chemicals — 0.8%
Solugen, Inc., Series C, (Acquired 09/02/21, Cost: $9,999,977)(d)		269,284		9,290,298
Consumer Staples Distribution & Retail — 1.3%
Grubmarket, Inc., Series E, (Acquired 10/18/21, Cost: $6,999,994)(d)		709,724		16,039,762
Diversified Consumer Services(d) — 1.1%
FlixMobility GmbH, Series F, (Acquired 07/26/19, Cost: $5,482,937)		275		8,222,028
Grammarly, Inc., Series 3, (Acquired 11/17/21, Cost: $6,249,992)		238,441		4,213,252
Think & Learn Private Ltd., Series F, (Acquired 09/30/20, Cost: $3,052,975)		1,054		221,009
				12,656,289
Diversified Telecommunication Services — 0.4%
Discord, Inc., Series I, (Acquired 09/13/21, Cost: $7,000,088)(d)		12,713		4,978,665
Financial Services(d)(g) — 1.0%
Trumid Holdings LLC
Class J-A, (Acquired 07/24/20, Cost: $2,499,716)		5,038		2,695,330
Class J-B, (Acquired 07/24/20, Cost: $1,499,830)		5,038		2,695,330
Class L, (Acquired 09/15/21, Cost: $9,999,695)		11,420		6,109,700
				11,500,360
Interactive Media & Services — 1.2%
ByteDance Ltd., Series E-1, (Acquired 11/11/20, Cost: $9,650,746)(d)		88,075		14,373,542
IT Services(d) — 3.5%
Deep Instinct Ltd., Series D-2, (Acquired 03/19/21, Cost: $2,999,391)		493,493		2,714,212

Security	Shares		Value
IT Services (continued)
MNTN Digital, Inc., Series D, (Acquired 11/05/21, Cost: $24,999,980)		1,088,598	$	13,770,765
Patreon, Inc., Series D, (Acquired 07/14/21, Cost: $6,666,632)		119,047		3,357,125
TRAX Ltd.
(Acquired 09/12/19, Cost: $4,000,013)		106,667		2,901,342
(Acquired 02/18/21, Cost: $1,999,989)		38,361		1,043,419
Voltron Data, Inc.
Series A, (Acquired 01/18/22, Cost: $10,000,000)		6,201,935		8,992,806
Series SEED, (Acquired 07/14/21, Cost: $5,000,000)		9,090,909		9,727,273
				42,506,942
Semiconductors & Semiconductor Equipment — 3.9%
PsiQuantum Corp.(d)
Series C, (Acquired 09/09/19, Cost: $3,200,234)		690,003		16,546,272
Series D, (Acquired 05/21/21, Cost: $5,000,025)		190,650		5,418,273
Rivos, Inc.
Series A1		2,700,557		5,887,214
Series A2		2,464,862		4,831,130
Series A3		1,027,026		2,012,971
SambaNova Systems, Inc., Series C, (Acquired 02/20/20, Cost: $9,972,125)(d)		187,300		11,964,724
				46,660,584
Software(d) — 4.5%
Bolt Financial, Inc., Series E, (Acquired 01/18/22, Cost: $29,999,955)		598,682		12,763,900
Databricks, Inc.
Series F, (Acquired 10/22/19, Cost: $3,999,999)		279,405		21,586,830
Series G, (Acquired 02/01/21, Cost: $4,500,001)		76,113		5,880,491
DataRobot, Inc., Series F, (Acquired 10/27/20, Cost: $2,999,996)		228,276		1,310,304
Prosimo, Inc., Series B, (Acquired 11/04/21, Cost: $4,999,998)		2,515,811		3,874,349
Snorkel AI, Inc., Series C, (Acquired 06/30/21, Cost: $4,999,985)		332,896		2,896,195
Snyk Ltd., Series F, (Acquired 09/02/21, Cost: $4,807,688)		337,018		3,680,237
Unqork, Inc.
Series B, (Acquired 09/19/19, Cost: $3,198,416)		281,080		1,745,507
Series C, (Acquired 09/18/20, Cost: $1,303,260)		47,600		370,328
				54,108,141
				212,114,583
Total Preferred Securities — 17.7% (Cost: $211,087,341)				212,114,583

C O N S O L I D A T E D  S C H E D U L E  O F  I N V E S T M E N T S 119

Consolidated Schedule of Investments (continued) December 31, 2023   BlackRock Science and Technology Trust (BST)  (Percentages shown are based on Net Assets)

Security	Shares		Value
Warrants
Software — 0.0%
Constellation Software, Inc., (Issued 08/29/23, 1 Share for 1 Warrant, Expires 03/31/40, Strike Price CAD 11.50)(b)(c)		3,923	$	—
Total Warrants — 0.0% (Cost: $ — )				—
Total Long-Term Investments — 101.3% (Cost: $772,151,828)				1,212,240,494
Short-Term Securities
Money Market Funds — 0.5%
BlackRock Liquidity Funds, T-Fund, Institutional Class, 5.26%(h)(i)		365,499		365,499
SL Liquidity Series, LLC, Money Market Series, 5.58%(h)(i)(j)		5,859,120		5,860,878
Total Short-Term Securities — 0.5% (Cost: $6,226,872)				6,226,377
Total Investments Before Options Written — 101.8% (Cost: $778,378,700)				1,218,466,871
Options Written — (1.3)% (Premiums Received: $(10,495,969))				(15,464,670	)
Total Investments, Net of Options Written — 100.5% (Cost: $767,882,731)				1,203,002,201
Liabilities in Excess of Other Assets — (0.5)%				(6,577,575	)
Net Assets — 100.0%			$	1,196,424,626

^(a)  All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

^(b)  Non-income producing security.

^(c)  Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.

^(d)  Restricted security as to resale, excluding 144A securities. The Trust held restricted securities with a current value of $240,241,090, representing 20.1% of its net assets as of period end, and an original cost of $279,414,825.

^(e)  All or a portion of this security is on loan.

^(f)  All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.

^(g)  All or a portion of the security is held by a wholly-owned subsidiary. See Note 1 of the Notes to Consolidated Financial Statements for details on the wholly-owned subsidiary.

^(h)  Affiliate of the Trust.

⁽ⁱ⁾  Annualized 7-day yield as of period end.

^(j)  All or a portion of this security was purchased with the cash collateral from loaned securities.

For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

Affiliates

Investments in issuers considered to be affiliate(s) of the Trust during the year ended December 31, 2023 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

Affiliated Issuer	Value at 12/31/22		Purchases at Cost			Proceeds from Sale			Net Realized Gain (Loss)		Change in Unrealized Appreciation (Depreciation)			Value at 12/31/23		Shares Held at 12/31/23		Income			Capital Gain Distributions from Underlying Funds
BlackRock Liquidity Funds, T-Fund, Institutional Class	$	5,779,501	$	—		$	(5,414,002	)(a)	$	—	$	—		$	365,499		365,499	$	354,864		$	—
SL Liquidity Series, LLC, Money Market Series		825,025		5,035,416	(a)		—			1,012		(575	)		5,860,878		5,859,120		16,851	(b)		—
									$	1,012	$	(575	)	$	6,226,377			$	371,715		$	—

^(a)  Represents net amount purchased (sold).

^(b)  All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.

Derivative Financial Instruments Outstanding as of Period End

Exchange-Traded Options Written

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call
Credo Technology Group Holding Ltd.		306		01/04/24		USD	19.75		USD	596	$	(9,444	)
Adobe, Inc.		32		01/05/24		USD	625.00		USD	1,909		(2,048	)

120 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Consolidated Schedule of Investments (continued) December 31, 2023   BlackRock Science and Technology Trust (BST)

Exchange-Traded Options Written (continued)

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
Advanced Micro Devices, Inc.		212		01/05/24		USD	125.00		USD	3,125	$	(479,650	)
Amazon.com, Inc.		173		01/05/24		USD	152.50		USD	2,629		(26,210	)
Crowdstrike Holdings, Inc., Class A		81		01/05/24		USD	240.00		USD	2,068		(126,157	)
Lam Research Corp.		45		01/05/24		USD	725.00		USD	3,525		(267,075	)
MercadoLibre, Inc.		14		01/05/24		USD	1,600.00		USD	2,200		(13,720	)
Meta Platforms, Inc., Class A		55		01/05/24		USD	340.00		USD	1,947		(82,775	)
NVIDIA Corp.		122		01/05/24		USD	490.00		USD	6,042		(124,441	)
S&P Global, Inc.		32		01/05/24		USD	415.00		USD	1,410		(84,160	)
ServiceNow, Inc.		21		01/05/24		USD	710.00		USD	1,484		(15,330	)
Shopify, Inc., Class A		233		01/05/24		USD	70.00		USD	1,815		(185,235	)
Taiwan Semiconductor Manufacturing Co. Ltd.		61		01/05/24		USD	98.00		USD	634		(37,515	)
Tesla, Inc.		50		01/05/24		USD	255.00		USD	1,242		(18,875	)
Uber Technologies, Inc.		516		01/05/24		USD	56.00		USD	3,177		(287,670	)
Wolfspeed, Inc.		246		01/05/24		USD	45.00		USD	1,070		(20,910	)
Advanced Micro Devices, Inc.		32		01/12/24		USD	129.00		USD	472		(60,400	)
Alphabet, Inc., Class A		194		01/12/24		USD	141.00		USD	2,710		(34,241	)
Amazon.com, Inc.		60		01/12/24		USD	147.25		USD	912		(37,513	)
ARM Holdings PLC, ADR		268		01/12/24		USD	75.00		USD	2,014		(76,916	)
Autodesk, Inc.		65		01/12/24		USD	230.00		USD	1,583		(94,900	)
Credo Technology Group Holding Ltd.		310		01/12/24		USD	16.75		USD	604		(86,839	)
Intuit, Inc.		59		01/12/24		USD	590.00		USD	3,688		(226,855	)
Marvell Technology, Inc.		186		01/12/24		USD	56.00		USD	1,122		(86,025)
Mastercard, Inc., Class A		127		01/12/24		USD	415.00		USD	5,417		(169,545	)
MercadoLibre, Inc.		6		01/12/24		USD	1,620.00		USD	943		(9,300	)
Meta Platforms, Inc., Class A		77		01/12/24		USD	325.00		USD	2,725		(232,155	)
MongoDB, Inc., Class A		19		01/12/24		USD	430.00		USD	777		(8,550	)
NVIDIA Corp.		104		01/12/24		USD	475.00		USD	5,150		(265,980	)
NVIDIA Corp.		104		01/12/24		USD	485.00		USD	5,150		(191,880	)
Palo Alto Networks, Inc.		10		01/12/24		USD	305.00		USD	295		(2,865	)
QUALCOMM, Inc.		80		01/12/24		USD	134.00		USD	1,157		(88,600	)
Salesforce, Inc.		182		01/12/24		USD	250.00		USD	4,789		(255,710	)
ServiceNow, Inc.		40		01/12/24		USD	705.00		USD	2,826		(57,400	)
Snowflake, Inc., Class A		48		01/12/24		USD	200.00		USD	955		(22,680	)
Spotify Technology SA		51		01/12/24		USD	210.00		USD	958		(1,275	)
Take-Two Interactive Software, Inc.		94		01/12/24		USD	162.50		USD	1,513		(19,646	)
Tesla, Inc.		161		01/12/24		USD	255.00		USD	4,001		(99,417	)
Visa, Inc., Class A		8		01/12/24		USD	260.00		USD	208		(2,660	)
Wolfspeed, Inc.		445		01/12/24		USD	40.00		USD	1,936		(193,575	)
Adobe, Inc.		38		01/19/24		USD	610.00		USD	2,267		(31,635	)
Advanced Micro Devices, Inc.		240		01/19/24		USD	145.00		USD	3,538		(153,600	)
Alphabet, Inc., Class A		268		01/19/24		USD	137.00		USD	3,744		(125,960	)
Amazon.com, Inc.		61		01/19/24		USD	142.50		USD	927		(64,050	)
ANSYS, Inc.		73		01/19/24		USD	310.00		USD	2,649		(404,055)
Arista Networks, Inc.		50		01/19/24		USD	220.00		USD	1,178		(85,750	)
ARM Holdings PLC, ADR		268		01/19/24		USD	55.00		USD	2,014		(545,380	)
Cadence Design Systems, Inc.		260		01/19/24		USD	270.00		USD	7,082		(202,800	)
Credo Technology Group Holding Ltd.		829		01/19/24		USD	20.00		USD	1,614		(47,668	)
Crowdstrike Holdings, Inc., Class A		110		01/19/24		USD	275.00		USD	2,809		(18,370	)
Lam Research Corp.		39		01/19/24		USD	740.00		USD	3,055		(197,730	)
Marvell Technology, Inc.		185		01/19/24		USD	52.50		USD	1,116		(148,000	)
Marvell Technology, Inc.		42		01/19/24		USD	61.00		USD	253		(6,636	)
MercadoLibre, Inc.		15		01/19/24		USD	1,600.00		USD	2,357		(45,075	)
Meta Platforms, Inc., Class A		78		01/19/24		USD	330.00		USD	2,761		(207,870	)
MongoDB, Inc., Class A		47		01/19/24		USD	410.00		USD	1,922		(66,975	)
Motorola Solutions, Inc.		87		01/19/24		USD	320.00		USD	2,724		(14,790	)
NVIDIA Corp.		127		01/19/24		USD	490.00		USD	6,289		(233,680	)
Palo Alto Networks, Inc.		84		01/19/24		USD	286.67		USD	2,477		(112,350	)
QUALCOMM, Inc.		83		01/19/24		USD	140.00		USD	1,200		(52,083	)
S&P Global, Inc.		32		01/19/24		USD	420.00		USD	1,410		(74,560	)
Salesforce, Inc.		80		01/19/24		USD	260.00		USD	2,105		(57,600	)
Snowflake, Inc., Class A		38		01/19/24		USD	170.00		USD	756		(113,620	)
Spotify Technology SA		105		01/19/24		USD	185.00		USD	1,973		(76,125	)

C O N S O L I D A T E D  S C H E D U L E  O F  I N V E S T M E N T S 121

Consolidated Schedule of Investments (continued) December 31, 2023   BlackRock Science and Technology Trust (BST)

Exchange-Traded Options Written (continued)

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
Taiwan Semiconductor Manufacturing Co. Ltd.		129		01/19/24		USD	105.00		USD	1,342	$	(35,282)
Take-Two Interactive Software, Inc.		104		01/19/24		USD	155.00		USD	1,674		(78,520	)
Tesla, Inc.		146		01/19/24		USD	246.67		USD	3,628		(172,645	)
Visa, Inc., Class A		124		01/19/24		USD	255.00		USD	3,228		(96,720	)
Wolfspeed, Inc.		246		01/19/24		USD	47.50		USD	1,070		(33,210	)
Alphabet, Inc., Class A		102		01/26/24		USD	146.00		USD	1,425		(14,025	)
Amazon.com, Inc.		190		01/26/24		USD	150.00		USD	2,887		(103,075	)
Arista Networks, Inc.		114		01/26/24		USD	250.00		USD	2,685		(26,220	)
Autodesk, Inc.		61		01/26/24		USD	245.00		USD	1,485		(35,380	)
Broadcom, Inc.		10		01/26/24		USD	1,150.00		USD	1,116		(17,550	)
Broadcom, Inc.		68		01/26/24		USD	1,135.00		USD	7,591		(161,500	)
Intuit, Inc.		57		01/26/24		USD	630.00		USD	3,563		(76,950	)
Marvell Technology, Inc.		169		01/26/24		USD	55.00		USD	1,019		(101,400	)
Mastercard, Inc., Class A		177		01/26/24		USD	420.00		USD	7,549		(230,985	)
MercadoLibre, Inc.		16		01/26/24		USD	1,625.00		USD	2,514		(45,840	)
Meta Platforms, Inc., Class A		84		01/26/24		USD	340.00		USD	2,973		(167,790	)
Micron Technology, Inc.		131		01/26/24		USD	87.00		USD	1,118		(25,087	)
MongoDB, Inc., Class A		67		01/26/24		USD	400.00		USD	2,739		(154,937	)
NVIDIA Corp.		181		01/26/24		USD	495.00		USD	8,963		(337,565	)
Oracle Corp.		187		01/26/24		USD	104.00		USD	1,972		(60,308	)
ServiceNow, Inc.		27		01/26/24		USD	700.00		USD	1,908		(81,405	)
Shopify, Inc., Class A		208		01/26/24		USD	73.00		USD	1,620		(134,680)
Spotify Technology SA		168		01/26/24		USD	200.00		USD	3,157		(42,420	)
Tesla, Inc.		119		01/26/24		USD	270.00		USD	2,957		(73,482	)
Visa, Inc., Class A		130		01/26/24		USD	260.00		USD	3,385		(76,700	)
Western Digital Corp.		119		01/26/24		USD	53.00		USD	623		(18,921	)
Amazon.com, Inc.		249		02/02/24		USD	157.40		USD	3,783		(78,893	)
Micron Technology, Inc.		132		02/02/24		USD	87.00		USD	1,126		(31,482	)
NVIDIA Corp.		147		02/02/24		USD	505.00		USD	7,280		(251,002	)
Tesla, Inc.		110		02/02/24		USD	279.65		USD	2,733		(59,500	)
Visa, Inc., Class A		104		02/02/24		USD	260.68		USD	2,708		(66,761	)
Micron Technology, Inc.		259		02/09/24		USD	87.00		USD	2,210		(71,872	)
Oracle Corp.		363		02/09/24		USD	110.00		USD	3,827		(48,098	)
Western Digital Corp.		388		02/09/24		USD	53.00		USD	2,032		(96,612	)
Advanced Micro Devices, Inc.		202		02/16/24		USD	140.00		USD	2,978		(281,790	)
Alphabet, Inc., Class A		179		02/16/24		USD	145.00		USD	2,500		(68,915	)
Amazon.com, Inc.		49		02/16/24		USD	150.00		USD	745		(43,365	)
ANSYS, Inc.		34		02/16/24		USD	310.00		USD	1,234		(199,240	)
Cadence Design Systems, Inc.		300		02/16/24		USD	280.00		USD	8,171		(252,000	)
Credo Technology Group Holding Ltd.		1,960		02/16/24		USD	20.00		USD	3,816		(205,800	)
Micron Technology, Inc.		188		02/16/24		USD	77.50		USD	1,604		(176,250	)
MongoDB, Inc., Class A		37		02/16/24		USD	480.00		USD	1,513		(18,963	)
Monolithic Power Systems, Inc.		59		02/16/24		USD	630.00		USD	3,722		(243,670)
QUALCOMM, Inc.		25		02/16/24		USD	150.00		USD	362		(10,875	)
Snowflake, Inc., Class A		30		02/16/24		USD	190.00		USD	597		(49,725	)
Take-Two Interactive Software, Inc.		18		02/16/24		USD	165.00		USD	290		(9,900	)
Uber Technologies, Inc.		479		02/16/24		USD	60.00		USD	2,949		(220,340	)
Datadog, Inc., Class A		183		03/15/24		USD	140.00		USD	2,221		(64,507	)
Micron Technology, Inc.		254		03/15/24		USD	87.50		USD	2,168		(104,140	)
Monolithic Power Systems, Inc.		15		03/15/24		USD	640.00		USD	946		(67,425	)
Salesforce, Inc.		29		03/15/24		USD	290.00		USD	763		(13,050	)
Uber Technologies, Inc.		247		03/15/24		USD	70.00		USD	1,521		(37,421	)
											$	(12,366,697	)

OTC Options Written

Description

Counterparty

Number of Contracts

Expiration Date

Exercise Price

Notional Amount (000)

Value

Call

Palo Alto Networks, Inc.

Citibank N.A.

3,600

01/04/24

USD

256.59

USD

1,062

$

(138,694

)

SiteMinder Ltd.

Goldman Sachs International

12,900

01/04/24

AUD

4.61

AUD

66

(4,570

)

122 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Consolidated Schedule of Investments (continued) December 31, 2023   BlackRock Science and Technology Trust (BST)

OTC Options Written (continued)

Description	Counterparty	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
ASML Holding NV	Goldman Sachs International		17,400		01/09/24		EUR	615.00		EUR	11,898	$	(1,302,964	)
RELX PLC	Goldman Sachs International		102,300		01/09/24		GBP	29.57		GBP	3,184		(209,634	)
SiteMinder Ltd.	UBS AG		14,100		01/09/24		AUD	4.82		AUD	72		(3,206	)
SOITEC	Bank of America N.A.		2,000		01/09/24		EUR	167.27		EUR	324		(2,524	)
Sony Group Corp.	Societe Generale		14,000		01/09/24		JPY	13,611.90		JPY	186,805		(15,409	)
Wise PLC, Class A	Bank of America N.A.		70,000		01/11/24		GBP	7.59		GBP	611		(106,007	)
SiteMinder Ltd.	UBS AG		22,000		01/12/24		AUD	5.14		AUD	113		(1,771	)
SiteMinder Ltd.	Goldman Sachs International		25,500		01/18/24		AUD	4.78		AUD	131		(6,710	)
SOITEC	Morgan Stanley & Co. International PLC		4,400		01/18/24		EUR	169.69		EUR	713		(7,021	)
Sony Group Corp.	Societe Generale		12,300		01/18/24		JPY	12,904.75		JPY	164,122		(58,269	)
ASM International NV	Bank of America N.A.		12,200		01/23/24		EUR	461.39		EUR	5,752		(274,450	)
SiteMinder Ltd.	UBS AG		22,000		01/23/24		AUD	5.24		AUD	113		(1,759	)
STMicroelectronics NV	Goldman Sachs International		52,500		01/23/24		EUR	45.81		EUR	2,385		(64,479	)
Wise PLC, Class A	UBS AG		61,800		01/23/24		GBP	8.32		GBP	539		(52,251	)
Wise PLC, Class A	UBS AG		13,300		01/23/24		GBP	8.44		GBP	116		(9,929	)
Xero Ltd.	Goldman Sachs International		18,200		01/23/24		AUD	105.92		AUD	2,037		(104,602	)
SiteMinder Ltd.	UBS AG		15,000		01/24/24		AUD	4.98		AUD	77		(2,586	)
Fujitsu, Ltd.	Citibank N.A.		8,000		01/25/24		JPY	21,335.37		JPY	169,757		(28,386	)
SOITEC	Morgan Stanley & Co. International PLC		4,400		01/25/24		EUR	169.69		EUR	713		(11,026	)
Xero Ltd.	Goldman Sachs International		18,700		01/25/24		AUD	105.71		AUD	2,093		(111,344	)
SiteMinder Ltd.	Goldman Sachs International		15,000		01/30/24		AUD	4.99		AUD	77		(2,726	)
Meta Platforms, Inc., Class A	Citibank N.A.		2,600		01/31/24		USD	361.74		USD	920		(36,984	)
Wise PLC, Class A	Goldman Sachs International		18,500		01/31/24		GBP	9.42		GBP	161		(4,703	)
Fujitsu, Ltd.	BNP Paribas SA		8,000		02/01/24		JPY	21,335.38		JPY	169,757		(32,304	)
Quanta Computer, Inc.	JPMorgan Chase Bank N.A.		382,000		02/01/24		TWD	210.08		TWD	85,354		(197,822	)
SOITEC	Morgan Stanley & Co. International PLC		4,400		02/01/24		EUR	169.69		EUR	713		(15,229	)
Nintendo Co., Ltd.	BNP Paribas SA		56,300		02/06/24		JPY	7,099.15		JPY	413,060		(152,295	)
SOITEC	UBS AG		5,000		02/07/24		EUR	167.99		EUR	810		(24,238	)
SiteMinder Ltd.	Goldman Sachs International		31,000		02/08/24		AUD	5.05		AUD	159		(5,371	)
Wise PLC, Class A	UBS AG		61,100		02/08/24		GBP	8.72		GBP	533		(40,046	)
SiteMinder Ltd.	Goldman Sachs International		31,000		02/13/24		AUD	5.05		AUD	159		(5,651	)
SOITEC	Bank of America N.A.		5,700		02/13/24		EUR	171.44		EUR	924		(25,895	)
SiteMinder Ltd.	JPMorgan Chase Bank N.A.		31,000		02/21/24		AUD	5.05		AUD	159		(6,072	)
SOITEC	Bank of America N.A.		5,800		02/21/24		EUR	171.44		EUR	940		(31,046	)
												$	(3,097,973	)

Balances Reported in the Consolidated Statements of Assets and Liabilities for Options Written

Description

Swap Premiums Paid

Swap Premiums Received

Unrealized Appreciation

Unrealized Depreciation

Value

Options Written

$  N/A

$   N/A

$ 1,565,851

$ (6,534,552

)

$ (15,464,670

)

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Consolidated Statements of Assets and Liabilities were as follows:

	Commodity Contracts		Credit Contracts		Equity Contracts		Foreign Currency Exchange Contracts		Interest Rate Contracts		Other Contracts		Total
Liabilities — Derivative Financial Instruments
Options written Options written at value	$	—	$	—	$	15,464,670	$	—	$	—	$	—	$	15,464,670

C O N S O L I D A T E D  S C H E D U L E  O F  I N V E S T M E N T S 123

Consolidated Schedule of Investments (continued) December 31, 2023   BlackRock Science and Technology Trust (BST)

For the period ended December 31, 2023, the effect of derivative financial instruments in the Consolidated Statements of Operations was as follows:

	Commodity Contracts		Credit Contracts		Equity Contracts			Foreign Currency Exchange Contracts		Interest Rate Contracts		Other Contracts		Total
Net Realized Gain (Loss) from:
Options purchased(a)	$	—	$	—	$	(2,858,012	)	$	—	$	—	$	—	$	(2,858,012	)
Options written		—		—		(31,419,636	)		—		—		—		(31,419,636	)
	$	—	$	—	$	(34,277,648	)	$	—	$	—	$	—	$	(34,277,648	)
Net Change in Unrealized Appreciation (Depreciation) on:
Options written	$	—	$	—	$	(12,373,937	)	$	—	$	—	$	—	$	(12,373,937	)

^(a) Options purchased are included in net realized gain (loss) from investments — unaffiliated.

Average Quarterly Balances of Outstanding Derivative Financial Instruments

Options:
Average value of option contracts purchased	$	—	(a)
Average value of option contracts written	$	13,976,316

^(a) Derivative financial instrument not held at any quarter-end. The risk exposure table serves as an indicator of activity during the period.

For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Consolidated Financial Statements.

Derivative Financial Instruments — Offsetting as of Period End

The Trust’s derivative assets and liabilities (by type) were as follows:

	Assets				Liabilities
Derivative Financial Instruments Options			$	—	$	15,464,670
Total derivative assets and liabilities in the Consolidated Statements of Assets and Liabilities				—		15,464,670
Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”)				—		(12,366,697	)
Total derivative assets and liabilities subject to an MNA			$	—	$	3,097,973

The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the Trust:

Counterparty		Derivative Liabilities Subject to an MNA by Counterparty		Derivatives Available for Offset		Non-Cash Collateral Pledged	(a)		Cash Collateral Pledged	(a)		Net Amount of Derivative Liabilities	(b)
Bank of America N.A.	$	439,922	$	—	$	—		$	(439,922	)	$	—
BNP Paribas SA		184,599		—		—			—			184,599
Citibank N.A.		204,064		—		—			(10,000	)		194,064
Goldman Sachs International		1,822,754		—		(1,822,754	)		—			—
JPMorgan Chase Bank N.A.		203,894		—		—			—			203,894
Morgan Stanley & Co. International PLC		33,276		—		(33,276	)		—			—
Societe Generale		73,678		—		—			—			73,678
UBS AG		135,786		—		(135,786	)		—			—
	$	3,097,973	$	—	$	(1,991,816	)	$	(449,922	)	$	656,235

^(a)  Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes.

^(b)  Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Consolidated Statements of Assets and Liabilities.

124 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Consolidated Schedule of Investments (continued) December 31, 2023   BlackRock Science and Technology Trust (BST)

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation of financial instruments, refer to the Notes to Consolidated Financial Statements.

The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s financial instruments into major categories is disclosed in the Consolidated Schedule of Investments above.

	Level 1			Level 2			Level 3		Total
Assets
Investments
Long-Term Investments
Common Stocks
Automobiles	$	22,081,921		$	—		$	—	$	22,081,921
Broadline Retail		44,497,858			—			—		44,497,858
Capital Markets		8,482,213			—			—		8,482,213
Communications Equipment		13,787,438			—			—		13,787,438
Diversified Consumer Services		—			—			12,476,847		12,476,847
Entertainment		16,994,856			6,769,606			—		23,764,462
Financial Services		47,939,319			5,551,821			—		53,491,140
Ground Transportation		11,765,473			—			—		11,765,473
Household Durables		—			5,971,333			—		5,971,333
Interactive Media & Services		48,343,902			—			—		48,343,902
IT Services		28,262,062			5,222,128			19,748,688		53,232,878
Professional Services		5,079,089			9,508,622			4,480,331		19,068,042
Semiconductors & Semiconductor Equipment		236,585,520			59,074,242			—		295,659,762
Software		263,631,182			9,208,647			9,344,790		282,184,619
Specialty Retail		—			—			84,691		84,691
Technology Hardware, Storage & Peripherals		99,685,652			5,547,679			—		105,233,331
Convertible Notes		—			—			1		1
Preferred Securities
Preferred Stocks		—			—			212,114,583		212,114,583
Warrants		—			—			—		—
Short-Term Securities
Money Market Funds		365,499			—			—		365,499
	$	847,501,984		$	106,854,078		$	258,249,931		1,212,605,993
Investments Valued at NAV(a)										5,860,878
									$	1,218,466,871
Derivative Financial Instruments(b)
Liabilities
Equity Contracts	$	(12,027,747	)	$	(3,436,923	)	$	—	$	(15,464,670	)

^(a)  Certain investments of the Trust were fair valued using NAV as a practical expedient as no quoted market value is available and therefore have been excluded from the fair value hierarchy.

^(b)  Derivative financial instruments are options written. Options written are shown at value.

A reconciliation of Level 3 financial instruments is presented when the Trust had a significant amount of Level 3 investments and derivative financial instruments at the beginning and/or end of the year in relation to net assets. The following table is a reconciliation of Level 3 investments for which significant unobservable inputs were used in determining fair value:

	Common Stocks			Convertible Notes			Preferred Stocks		Warrants			Total
Assets
Opening balance, as of December 31, 2022	$	60,069,300		$	1,920,000		$	195,967,596	$	16,212		$	257,973,108
Transfers into Level 3		—			—			—		—			—
Transfers out of Level 3		—			—			—		—			—
Other(a)		(11,157,597	)		—			11,157,597		—			—
Accrued discounts/premiums		—			—			—		—			—
Net realized gain (loss)		—			—			—		—			—
Net change in unrealized appreciation (depreciation)(b)(c)		(12,776,204	)		(1,919,999	)		12,989,241		(16,212	)		(1,723,174	)

C O N S O L I D A T E D   S C H E D U L E  O F  I N V E S T M E N T S 125

Consolidated Schedule of Investments (continued) December 31, 2023   BlackRock Science and Technology Trust (BST)

	Common Stocks			Convertible Notes			Preferred Stocks			Warrants			Total
Purchases	$	9,999,848		$	—		$	6,799,994		$	—		$	16,799,842
Sales		—			—			(14,799,845	)		—			(14,799,845	)
Closing balance, as of December 31, 2023	$	46,135,347		$	1		$	212,114,583		$	—	(d)	$	258,249,931
Net change in unrealized appreciation (depreciation) on investments still held at December 31, 2023(c)	$	(12,776,204	)	$	(1,919,999	)	$	12,468,281		$	—	(d)	$	(2,227,922	)

^(a)  Certain Level 3 investments were re-classified between Common Stocks and Preferred Stocks.

^(b)  Included in the related net change in unrealized appreciation (depreciation) in the Consolidated Statements of Operations.

^(c)  Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized appreciation (depreciation) on investments still held at December 31, 2023 is generally due to investments no longer held or categorized as Level 3 at period end.

^(d)  Rounds to less than $1.

The following table summarizes the valuation approaches used and unobservable inputs utilized by the BlackRock Valuation Committee (the “Valuation Committee”) to determine the value of certain of the Trust’s Level 3 financial instruments as of period end. The table does not include Level 3 financial instruments with values based upon unadjusted third-party pricing information in the amount of $1. A significant change in third party information could result in a significantly lower or higher value of such Level 3 financial instruments.

		Value	Valuation Approach	Unobservable Inputs	Range of Unobservable Inputs Utilized	(a)	Weighted Average of Unobservable Inputs Based on Fair Value
Assets
Common Stocks	$	46,135,347	Market	Revenue Multiple	1.00x - 29.00x		12.50x
				Volatility	70%		—
				Time to Exit	2.6 - 3.0 years		2.6 years
				Gross Profit Multiple	15.00x		—
				Terminal Growth Rate	5%		—
			Income	Discount	12%		—
Preferred Stocks(b)		212,114,583	Market	Revenue Multiple	1.00x - 31.00x		15.54x
				Volatility	50% - 75%		64%
				Time to Exit	2.0 - 5.0 years		4.0 years
				Market Adjustment Multiple	1.20x - 1.20x		1.20x
				Gross Profit Multiple	6.50x		—
	$	258,249,930

^(a)  A significant change in unobservable input would have resulted in a correlated (inverse) significant change to value.

^(b)  For the period end December 31, 2023, the valuation technique for certain investments classified as Preferred Stocks used recent prior transaction prices as inputs within the model used for the approximation of fair value.

See notes to financial statements.

126 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Schedule of Investments December 31, 2023   BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI) (Percentages shown are based on Net Assets)

Security	Shares		Value
Common Stocks
Building Products — 8.1%
Cie de Saint-Gobain SA		124,450	$	9,177,853
Johnson Controls International PLC		187,209		10,790,727
Kingspan Group PLC		82,065		7,092,494
Trane Technologies PLC		56,900		13,877,910
				40,938,984
Chemicals — 3.1%
Air Liquide SA		40,768		7,937,343
Linde PLC		18,778		7,712,313
				15,649,656
Commercial Services & Supplies — 4.2%
Republic Services, Inc.		63,250		10,430,557
Waste Management, Inc.		60,250		10,790,775
				21,221,332
Construction & Engineering — 5.8%
Quanta Services, Inc.		49,260		10,630,308
Vinci SA		148,150		18,643,971
				29,274,279
Electric Utilities — 29.1%
American Electric Power Co., Inc.(a)		75,350		6,119,929
Duke Energy Corp.(a)		140,018		13,587,347
EDP - Energias de Portugal SA		2,285,000		11,500,401
Enel SpA		2,922,775		21,744,882
Exelon Corp.(a)		275,958		9,906,892
Neoenergia SA		902,200		3,962,332
NextEra Energy, Inc.(a)(b)		598,330		36,342,564
Orsted A/S(c)		74,600		4,135,567
PG&E Corp.(d)		682,650		12,308,179
Southern Co.		160,250		11,236,730
SSE PLC		481,500		11,366,279
Xcel Energy, Inc.		82,590		5,113,147
				147,324,249
Electrical Equipment — 6.9%
Eaton Corp. PLC		16,090		3,874,794
Prysmian SpA		100,900		4,599,533
Schneider Electric SE		34,332		6,911,244
Sunrun, Inc.(d)		140,600		2,759,978
Vestas Wind Systems A/S(d)		528,921		16,735,963
				34,881,512
Electronic Equipment, Instruments & Components(d) — 1.5%
Rogers Corp.		27,250		3,598,908
Samsung SDI Co. Ltd.		10,750		3,913,973
				7,512,881
Ground Transportation — 1.2%
Union Pacific Corp.		25,800		6,336,996
Independent Power and Renewable Electricity Producers — 8.7%
AES Corp.		239,890		4,617,882
China Longyuan Power Group Corp. Ltd., Class H		3,620,000		2,748,970
EDP Renovaveis SA		537,080		10,994,731
Orron Energy AB(d)		3,401,100		2,690,207
RWE AG		502,645		22,876,832
				43,928,622
Machinery — 6.2%
Atlas Copco AB, B Shares		1,064,300		15,790,098
Ingersoll Rand, Inc.		131,700		10,185,678
Spirax-Sarco Engineering PLC		40,950		5,478,933
				31,454,709

Security	Shares		Value
Multi-Utilities — 10.6%
CenterPoint Energy, Inc.		179,000	$	5,114,030
CMS Energy Corp.(a)		169,260		9,828,927
Dominion Energy, Inc.(a)		122,898		5,776,206
National Grid PLC		552,524		7,443,225
Public Service Enterprise Group, Inc.		184,792		11,300,031
Sempra(b)		194,200		14,512,566
				53,974,985
Oil, Gas & Consumable Fuels — 9.4%
Cheniere Energy, Inc.(b)		70,350		12,009,449
Enterprise Products Partners LP		137,063		3,611,610
Hess Midstream LP, Class A		113,800		3,599,494
Pembina Pipeline Corp.		191,600		6,596,575
TC Energy Corp.		247,700		9,675,825
Williams Cos., Inc.(b)		352,805		12,288,198
				47,781,151
Semiconductors & Semiconductor Equipment — 5.5%
Analog Devices, Inc.		27,174		5,395,669
ASML Holding NV		7,750		5,850,378
Canadian Solar, Inc.(d)(e)		88,290		2,315,847
First Solar, Inc.(d)(e)		20,234		3,485,914
Infineon Technologies AG, Class N		116,050		4,846,551
STMicroelectronics NV		118,700		5,953,868
				27,848,227
Total Long-Term Investments — 100.3% (Cost: $353,774,571)				508,127,583
Short-Term Securities
Money Market Funds — 1.3%
BlackRock Liquidity Funds, T-Fund, Institutional Class, 5.26%(f)(g)		5,318,307		5,318,307
SL Liquidity Series, LLC, Money Market Series, 5.58%(f)(g)(h)		1,297,588		1,297,977
Total Short-Term Securities — 1.3% (Cost: $6,616,280)				6,616,284
Total Investments Before Options Written — 101.6% (Cost: $360,390,851)				514,743,867
Options Written — (1.5)% (Premiums Received: $(3,994,666))				(7,790,856	)
Total Investments, Net of Options Written — 100.1% (Cost: $356,396,185)				506,953,011
Liabilities in Excess of Other Assets — (0.1)%				(491,081	)
Net Assets — 100.0%			$	506,461,930

^(a)  All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

^(b)  All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.

^(c)  Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may be resold in transactions exempt from registration to qualified institutional investors.

^(d)  Non-income producing security.

^(e)  All or a portion of this security is on loan.

^(f)  Affiliate of the Trust.

^(g)  Annualized 7-day yield as of period end.

^(h)  All or a portion of this security was purchased with the cash collateral from loaned securities.

S C H E D U L E  O F  I N V E S T M E N T S 127

Schedule of Investments (continued) December 31, 2023   BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)

For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

Affiliates

Investments in issuers considered to be affiliate(s) of the Trust during the year ended December 31, 2023 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

Affiliated Issuer	Value at 12/31/22		Purchases at Cost			Proceeds from Sale			Net Realized Gain (Loss)		Change in Unrealized Appreciation (Depreciation)			Value at 12/31/23		Shares Held at 12/31/23		Income			Capital Gain Distributions from Underlying Funds
BlackRock Liquidity Funds, T-Fund, Institutional Class	$	11,042,199	$	—		$	(5,723,892	)(a)	$	—	$	—		$	5,318,307		5,318,307	$	525,353		$	—
SL Liquidity Series, LLC, Money Market Series		225,179		1,071,499	(a)		—			1,417		(118	)		1,297,977		1,297,588		10,772	(b)		—
									$	1,417	$	(118	)	$	6,616,284			$	536,125		$	—

^(a)  Represents net amount purchased (sold).

^(b)  All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.

Derivative Financial Instruments Outstanding as of Period End

Exchange-Traded Options Written

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call
Analog Devices, Inc.		51		01/05/24		USD	190.00		USD	1,013	$	(43,860	)
Analog Devices, Inc.		44		01/05/24		USD	185.00		USD	874		(60,280	)
Linde PLC		32		01/05/24		USD	415.00		USD	1,314		(4,640	)
Southern Co.		280		01/05/24		USD	72.00		USD	1,963		(1,400	)
Waste Management, Inc.		51		01/05/24		USD	172.52		USD	913		(35,141	)
Williams Cos., Inc.		603		01/05/24		USD	37.00		USD	2,100		(3,015	)
CMS Energy Corp.		241		01/10/24		USD	59.00		USD	1,399		(8,491	)
First Solar, Inc.		35		01/12/24		USD	160.00		USD	603		(50,050	)
PG&E Corp.		649		01/12/24		USD	17.50		USD	1,170		(47,377	)
Union Pacific Corp.		22		01/12/24		USD	235.00		USD	540		(25,410	)
Union Pacific Corp.		45		01/12/24		USD	240.00		USD	1,105		(32,850	)
AES Corp.		780		01/19/24		USD	17.00		USD	1,502		(187,200	)
American Electric Power Co., Inc.		128		01/19/24		USD	80.00		USD	1,040		(29,120	)
CMS Energy Corp.		351		01/19/24		USD	60.00		USD	2,038		(7,897	)
Dominion Energy, Inc.		312		01/19/24		USD	47.50		USD	1,466		(26,520	)
Duke Energy Corp.		295		01/19/24		USD	92.50		USD	2,863		(144,550	)
Eaton Corp. PLC		56		01/19/24		USD	240.00		USD	1,349		(28,560	)
Enterprise Products Partners LP		101		01/19/24		USD	27.51		USD	266		(212	)
Exelon Corp.		170		01/19/24		USD	41.00		USD	610		(850	)
Hess Midstream LP, Class A		200		01/19/24		USD	33.00		USD	633		(5,000	)
Ingersoll Rand, Inc.		150		01/19/24		USD	70.00		USD	1,160		(116,250	)
Ingersoll Rand, Inc.		310		01/19/24		USD	75.00		USD	2,398		(116,250	)
Johnson Controls International PLC		229		01/19/24		USD	55.00		USD	1,320		(70,990	)
Linde PLC		33		01/19/24		USD	415.00		USD	1,355		(13,860	)
PG&E Corp.		889		01/19/24		USD	17.00		USD	1,603		(111,126	)
Republic Services, Inc.		100		01/19/24		USD	160.00		USD	1,649		(58,500	)
Sempra		366		01/19/24		USD	75.00		USD	2,735		(40,260	)
Southern Co.		280		01/19/24		USD	72.50		USD	1,963		(6,300	)
Trane Technologies PLC		199		01/19/24		USD	230.00		USD	4,854		(294,520	)
Union Pacific Corp.		22		01/19/24		USD	235.00		USD	540		(26,950	)
Waste Management, Inc.		159		01/19/24		USD	170.32		USD	2,848		(164,349	)
Williams Cos., Inc.		603		01/19/24		USD	37.00		USD	2,100		(6,030	)
Enterprise Products Partners LP		100		01/26/24		USD	26.27		USD	264		(5,044	)
First Solar, Inc.		35		01/26/24		USD	190.00		USD	603		(9,625	)
PG&E Corp.		136		01/26/24		USD	17.50		USD	245		(11,696	)
Williams Cos., Inc.		28		01/26/24		USD	36.00		USD	98		(840	)

128 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Schedule of Investments (continued) December 31, 2023   BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)

Exchange-Traded Options Written (continued)

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
Xcel Energy, Inc.		146		02/01/24		USD	62.75		USD	904	$	(16,522	)
PG&E Corp.		715		02/02/24		USD	18.00		USD	1,289		(40,755	)
AES Corp.		60		02/16/24		USD	20.00		USD	116		(3,300	)
American Electric Power Co., Inc.		136		02/16/24		USD	82.50		USD	1,105		(23,460	)
CenterPoint Energy, Inc.		313		02/16/24		USD	30.00		USD	894		(7,825	)
Dominion Energy, Inc.		127		02/16/24		USD	50.00		USD	597		(8,255	)
Duke Energy Corp.		195		02/16/24		USD	98.35		USD	1,892		(31,876	)
Enterprise Products Partners LP		193		02/16/24		USD	26.14		USD	509		(8,850	)
Exelon Corp.		757		02/16/24		USD	40.50		USD	2,718		(7,746	)
Exelon Corp.		38		02/16/24		USD	37.00		USD	136		(2,660	)
Hess Midstream LP, Class A		200		02/16/24		USD	33.00		USD	633		(16,000	)
Quanta Services, Inc.		74		02/16/24		USD	210.00		USD	1,597		(89,170	)
Republic Services, Inc.		121		02/16/24		USD	164.96		USD	1,995		(53,698	)
Sempra		316		02/16/24		USD	76.48		USD	2,361		(43,349	)
Enterprise Products Partners LP		85		03/15/24		USD	27.00		USD	224		(2,295	)
Quanta Services, Inc.		98		03/15/24		USD	216.50		USD	2,115		(107,325	)
											$	(2,258,099	)

OTC Options Written

Description	Counterparty		Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call
Atlas Copco AB, B Shares		UBS AG		106,600		01/04/24		SEK	130.52		SEK	15,951	$	(200,506	)
ASML Holding NV		Goldman Sachs International		2,700		01/09/24		EUR	615.00		EUR	1,846		(202,184	)
TC Energy Corp.		Royal Bank of Canada		27,900		01/09/24		CAD	48.31		CAD	1,444		(75,321	)
Air Liquide SA		Morgan Stanley & Co. International PLC		14,300		01/10/24		EUR	168.61		EUR	2,522		(127,500	)
China Longyuan Power Group Corp. Ltd., Class H		Goldman Sachs International		597,000		01/10/24		HKD	6.90		HKD	3,540		(138	)
Kingspan Group PLC		Bank of America N.A.		14,400		01/10/24		EUR	67.66		EUR	1,127		(172,411	)
Prysmian SpA		Morgan Stanley & Co. International PLC		12,600		01/10/24		EUR	36.02		EUR	520		(72,424	)
Vinci SA		Bank of America N.A.		51,800		01/10/24		EUR	107.53		EUR	5,905		(365,008	)
EDP - Energias de Portugal SA		Bank of America N.A.		169,200		01/11/24		EUR	4.32		EUR	771		(47,726	)
NextEra Energy, Inc.		Barclays Bank PLC		107,500		01/11/24		USD	57.37		USD	6,530		(403,429	)
Orron Energy AB		Morgan Stanley & Co. International PLC		236,000		01/11/24		SEK	7.50		SEK	1,883		(12,940	)
Schneider Electric SE		Goldman Sachs International		5,900		01/11/24		EUR	168.08		EUR	1,076		(91,759	)
Neoenergia SA		Morgan Stanley & Co. International PLC		118,400		01/12/24		BRL	19.85		BRL	2,526		(32,113	)
China Longyuan Power Group Corp. Ltd., Class H		Bank of America N.A.		670,000		01/17/24		HKD	6.91		HKD	3,973		(668	)
EDP - Energias de Portugal SA		Bank of America N.A.		386,000		01/17/24		EUR	4.32		EUR	1,760		(110,903	)
Kingspan Group PLC		Morgan Stanley & Co. International PLC		14,400		01/17/24		EUR	70.94		EUR	1,127		(123,949	)
Orron Energy AB		Morgan Stanley & Co. International PLC		400,000		01/17/24		SEK	7.59		SEK	3,191		(20,840	)
EDP Renovaveis SA		Morgan Stanley & Co. International PLC		39,000		01/18/24		EUR	16.91		EUR	723		(76,070	)
Enel SpA		Morgan Stanley & Co. International PLC		519,400		01/18/24		EUR	6.40		EUR	3,500		(207,533	)
Infineon Technologies AG, Class N		Goldman Sachs International		19,200		01/18/24		EUR	37.84		EUR	726		(18,891	)
Infineon Technologies AG, Class N		UBS AG		400		01/18/24		EUR	35.66		EUR	15		(1,108	)
National Grid PLC		Morgan Stanley & Co. International PLC		125,200		01/18/24		GBP	10.15		GBP	1,323		(76,437	)
Orsted A/S		Bank of America N.A.		19,200		01/18/24		DKK	323.67		DKK	7,187		(153,224	)
Public Service Enterprise Group, Inc.		JPMorgan Chase Bank N.A.		23,200		01/22/24		USD	64.49		USD	1,419		(4,272	)
EDP Renovaveis SA		Bank of America N.A.		60,900		01/23/24		EUR	17.44		EUR	1,129		(94,878	)
Neoenergia SA		Morgan Stanley & Co. International PLC		118,400		01/23/24		BRL	19.85		BRL	2,526		(37,004	)
Neoenergia SA		Morgan Stanley & Co. International PLC		79,000		01/23/24		BRL	21.25		BRL	1,685		(5,780	)
Prysmian SpA		Goldman Sachs International		22,800		01/23/24		EUR	37.79		EUR	941		(91,145	)
RWE AG		Bank of America N.A.		159,300		01/23/24		EUR	40.96		EUR	6,568		(161,200	)
SSE PLC		Morgan Stanley & Co. International PLC		147,500		01/23/24		GBP	19.07		GBP	2,732		(17,494	)
STMicroelectronics NV		Goldman Sachs International		41,500		01/23/24		EUR	45.81		EUR	1,886		(50,969	)
Compagnie de Saint-Gobain S.A.		UBS AG		21,800		01/25/24		EUR	61.66		EUR	1,456		(131,333	)
RWE AG		UBS AG		16,700		01/25/24		EUR	40.75		EUR	688		(20,012	)
Spirax-Sarco Engineering PLC		Morgan Stanley & Co. International PLC		14,300		01/25/24		GBP	93.90		GBP	1,501		(213,320	)
TC Energy Corp.		Royal Bank of Canada		29,400		01/29/24		CAD	52.43		CAD	1,522		(13,911	)
Atlas Copco AB, B Shares		Goldman Sachs International		250,000		01/30/24		SEK	145.58		SEK	37,410		(152,791	)
EDP Renovaveis SA		Morgan Stanley & Co. International PLC		4,700		01/30/24		EUR	17.33		EUR	87		(8,192	)
Enel SpA		Bank of America N.A.		503,600		01/30/24		EUR	6.56		EUR	3,394		(64,746	)

S C H E D U L E  O F  I N V E S T M E N T S 129

Schedule of Investments (continued) December 31, 2023   BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)

OTC Options Written (continued)

Description	Counterparty		Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
Johnson Controls International PLC		JPMorgan Chase Bank N.A.		42,600		01/30/24		USD	55.64		USD	2,455	$	(135,681	)
Orron Energy AB		Morgan Stanley & Co. International PLC		550,000		01/30/24		SEK	7.60		SEK	4,388		(30,966	)
Orsted A/S		Morgan Stanley & Co. International PLC		6,900		01/30/24		DKK	338.22		DKK	2,583		(47,695	)
Schneider Electric SE		Bank of America N.A.		6,100		01/30/24		EUR	172.21		EUR	1,112		(76,860	)
Vestas Wind Systems A/S		UBS AG		103,000		01/30/24		DKK	193.49		DKK	22,008		(370,846	)
Public Service Enterprise Group, Inc.		JPMorgan Chase Bank N.A.		20,700		01/31/24		USD	63.86		USD	1,266		(7,760	)
EDP - Energias de Portugal SA		Bank of America N.A.		178,000		02/01/24		EUR	4.64		EUR	812		(19,338	)
SSE PLC		Morgan Stanley & Co. International PLC		147,500		02/01/24		GBP	19.07		GBP	2,732		(26,261	)
NextEra Energy, Inc.		Barclays Bank PLC		107,500		02/02/24		USD	57.94		USD	6,530		(440,336	)
Vestas Wind Systems A/S		UBS AG		82,100		02/06/24		DKK	196.73		DKK	17,542		(277,447	)
EDP - Energias de Portugal SA		Morgan Stanley & Co. International PLC		66,500		02/08/24		EUR	4.54		EUR	303		(11,604	)
EDP Renovaveis SA		Bank of America N.A.		83,400		02/08/24		EUR	17.70		EUR	1,547		(130,704	)
Infineon Technologies AG, Class N		Morgan Stanley & Co. International PLC		21,100		02/08/24		EUR	38.15		EUR	798		(31,107	)
Public Service Enterprise Group, Inc.		JPMorgan Chase Bank N.A.		20,700		02/12/24		USD	61.90		USD	1,266		(25,837	)
National Grid PLC		Goldman Sachs International		68,200		02/13/24		GBP	10.56		GBP	721		(25,696	)
Compagnie de Saint-Gobain S.A.		UBS AG		21,800		02/14/24		EUR	61.96		EUR	1,456		(135,610	)
Atlas Copco AB, B Shares		Morgan Stanley & Co. International PLC		16,000		02/21/24		SEK	144.79		SEK	2,394		(12,491	)
Xcel Energy, Inc.		Goldman Sachs International		14,300		02/21/24		USD	61.55		USD	885		(31,653	)
TC Energy Corp.		Royal Bank of Canada		29,400		02/26/24		CAD	52.43		CAD	1,522		(27,082	)
Pembina Pipeline Corp.		Morgan Stanley & Co. International PLC		13,600		02/27/24		CAD	46.91		CAD	620		(7,654	)
													$	(5,532,757	)

Balances Reported in the Statements of Assets and Liabilities for Options Written

Description	Swap Premiums Paid		Swap Premiums Received		Unrealized Appreciation		Unrealized Depreciation			Value
Options Written	$	N/A	$	N/A	$	511,521	$	(4,307,711	)	$	(7,790,856	)

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

	Commodity Contracts		Credit Contracts		Equity Contracts		Foreign Currency Exchange Contracts		Interest Rate Contracts		Other Contracts		Total
Liabilities — Derivative Financial Instruments
Options written
Options written at value	$	—	$	—	$	7,790,856	$	—	$	—	$	—	$	7,790,856

For the period ended December 31, 2023, the effect of derivative financial instruments in the Statements of Operations was as follows:

	Commodity Contracts		Credit Contracts		Equity Contracts			Foreign Currency Exchange Contracts		Interest Rate Contracts		Other Contracts		Total
Net Realized Gain (Loss) from:
Options purchased(a)	$	—	$	—	$	(2,511,082	)	$	—	$	—	$	—	$	(2,511,082	)
Options written		—		—		7,412,060			—		—		—		7,412,060
	$	—	$	—	$	4,900,978		$	—	$	—	$	—	$	4,900,978
Net Change in Unrealized Appreciation (Depreciation) on:
Options written	$	—	$	—	$	(5,317,561	)	$	—	$	—	$	—	$	(5,317,561	)

^(a)  Options purchased are included in net realized gain (loss) from investments — unaffiliated.

130 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Schedule of Investments (continued) December 31, 2023   BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)

Average Quarterly Balances of Outstanding Derivative Financial Instruments

Options:
Average value of option contracts purchased	$	—	(a)
Average value of option contracts written	$	4,659,318

^(a) Derivative financial instrument not held at any quarter-end. The risk exposure table serves as an indicator of activity during the period.

For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

Derivative Financial Instruments — Offsetting as of Period End

The Trust’s derivative assets and liabilities (by type) were as follows:

	Assets		Liabilities
Derivative Financial Instruments
Options	$	—	$	7,790,856
Total derivative assets and liabilities in the Statements of Assets and Liabilities		—		7,790,856
Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”)		—		(2,258,099	)
Total derivative assets and liabilities subject to an MNA	$	—	$	5,532,757

The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the Trust:

Counterparty	Derivative Liabilities Subject to an MNA by Counterparty		Derivatives Available for Offset		Non-Cash Collateral Pledged(a)			Cash Collateral Pledged		Net Amount of Derivative Liabilities(b)
Bank of America N.A.	$	1,397,666	$	—	$	(1,397,666	)	$	—	$	—
Barclays Bank PLC		843,765		—		(843,765	)		—		—
Goldman Sachs International		665,226		—		(665,226	)		—		—
JPMorgan Chase Bank N.A.		173,550		—		(75,257	)		—		98,293
Morgan Stanley & Co. International PLC		1,199,374		—		(1,199,374	)		—		—
Royal Bank of Canada		116,314		—		—			—		116,314
UBS AG		1,136,862		—		(1,136,862	)		—		—
	$	5,532,757	$	—	$	(5,318,150	)	$	—	$	214,607

^(a) Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes.

^(b) Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation of financial instruments, refer to the Notes to Financial Statements.

The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s financial instruments into major categories is disclosed in the Schedule of Investments above.

	Level 1		Level 2		Level 3		Total
Assets
Investments
Long-Term Investments
Common Stocks
Building Products	$	24,668,637	$	16,270,347	$	—	$	40,938,984
Chemicals		7,712,313		7,937,343		—		15,649,656
Commercial Services & Supplies		21,221,332		—		—		21,221,332
Construction & Engineering		10,630,308		18,643,971		—		29,274,279
Electric Utilities		94,614,788		52,709,461		—		147,324,249
Electrical Equipment		6,634,772		28,246,740		—		34,881,512
Electronic Equipment, Instruments & Components		3,598,908		3,913,973		—		7,512,881
Ground Transportation		6,336,996		—		—		6,336,996
Independent Power and Renewable Electricity Producers		4,617,882		39,310,740		—		43,928,622

S C H E D U L E  O F  I N V E S T M E N T S 131

Schedule of Investments (continued) December 31, 2023   BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)

Fair Value Hierarchy as of Period End (continued)

	Level 1			Level 2			Level 3		Total
Common Stocks (continued)
Machinery	$	10,185,678		$	21,269,031		$	—	$	31,454,709
Multi-Utilities		46,531,760			7,443,225			—		53,974,985
Oil, Gas & Consumable Fuels		47,781,151			—			—		47,781,151
Semiconductors & Semiconductor Equipment		11,197,430			16,650,797			—		27,848,227
Short-Term Securities
Money Market Funds		5,318,307			—			—		5,318,307
	$	301,050,262		$	212,395,628		$	—		513,445,890
Investments Valued at NAV(a)										1,297,977
									$	514,743,867
Derivative Financial Instruments(b)
Liabilities
Equity Contracts	$	(1,775,496	)	$	(6,015,360	)	$	—	$	(7,790,856	)

^(a) Certain investments of the Trust were fair valued using NAV as a practical expedient as no quoted market value is available and therefore have been excluded from the fair value hierarchy.

^(b) Derivative financial instruments are options written. Options written are shown at value.

See notes to financial statements.

132 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Statements of Assets and Liabilities

December 31, 2023

	BGR			CII		BDJ(a)		BOE
ASSETS
Investments, at value — unaffiliated(b)(c)	$	385,543,583		$	880,409,887	$	1,672,515,459	$	733,836,650
Investments, at value — affiliated(d)		3,612,320			13,330,465		5,204,534		2,668,223
Cash		—			—		272,377		—
Cash pledged as collateral for OTC derivatives		—			—		—		530,000
Foreign currency, at value(e)		163,667			—		882		24
Receivables:
Investments sold		484,023			—		—		306,893
Options written		108,187			124,997		111,675		40,637
Securities lending income — affiliated		—			315		—		—
Dividends — unaffiliated		601,043			513,627		2,060,255		1,826,743
Dividends — affiliated		21,673			39,772		89,084		16,407
Deferred offering costs		—			—		208,889		—
Prepaid expenses		3,815			6,042		14,631		6,414
Total assets		390,538,311			894,425,105		1,680,477,786		739,231,991
LIABILITIES
Due to broker		—			—		—		530,000
Collateral on securities loaned		—			397,585		—		—
Options written, at value(f)		1,725,858			18,548,876		36,487,628		10,846,451
Payables:
Investments purchased		—			—		—		117
Accounting services fees		10,983			11,774		22,979		14,255
Custodian fees		8,435			7,886		32,245		26,592
Investment advisory fees		321,437			618,507		1,099,961		500,730
Trustees’ and Officer’s fees		421,043			254,806		1,019,525		676,190
Options written		—			43,370		49,358		11,852
Other accrued expenses		9,083			3,046		8,368		14,212
Professional fees		46,669			71,873		119,829		104,414
Transfer agent fees		12,946			16,601		36,770		17,991
Total liabilities		2,556,454			19,974,324		38,876,663		12,742,804
Commitments and contingent liabilities
NET ASSETS	$	387,981,857		$	874,450,781	$	1,641,601,123	$	726,489,187
NET ASSETS CONSIST OF
Paid-in capital(g)(h)(i)	$	507,480,248		$	561,832,951	$	1,310,873,538	$	650,889,396
Accumulated earnings (loss)		(119,498,391	)		312,617,830		330,727,585		75,599,791
NET ASSETS	$	387,981,857		$	874,450,781	$	1,641,601,123	$	726,489,187
Net asset value	$	14.13		$	19.81	$	8.82	$	11.81
(a) Consolidated Statement of Assets and Liabilities.
(b) Investments, at cost — unaffiliated	$	261,065,835		$	554,276,107	$	1,420,450,150	$	605,816,932
(c)  Securities loaned, at value	$	—		$	389,928	$	—	$	—
(d) Investments, at cost — affiliated	$	3,612,320		$	13,330,505	$	5,204,534	$	2,668,223
(e) Foreign currency, at cost	$	164,468		$	—	$	1,015	$	29
(f)  Premiums received	$	2,439,087		$	10,266,670	$	20,613,526	$	6,679,071
(g) Shares outstanding		27,464,975			44,146,919		186,135,109		61,525,804
(h) Shares authorized		Unlimited			200 million		Unlimited		Unlimited
(i)  Par value	$	0.001		$	0.10	$	0.001	$	0.001

See notes to financial statements.

F I N A N C I A L  S T A T E M E N T S 133

Statements of Assets and Liabilities (continued)

December 31, 2023

	BGY		BMEZ			BME		BIGZ
ASSETS
Investments, at value — unaffiliated(a)(b)	$	624,733,185	$	1,897,904,122		$	563,003,496	$	2,045,982,868
Investments, at value — affiliated(c)		8,260,103		52,782,059			31,396,977		20,831,232
Cash pledged as collateral for OTC derivatives		—		456,000			—		—
Foreign currency, at value(d)		71,830		1,168			534		367
Receivables:
Investments sold		114,555		68,999			958,057		—
Options written		—		60,590			38,374		—
Securities lending income — affiliated		—		10,797			146		4,367
Dividends — unaffiliated		1,006,356		1,032,893			473,056		321,424
Dividends — affiliated		32,178		310,218			145,414		7,085
Unrealized appreciation on forward foreign currency exchange contracts		—		1,429,095			—		—
Deferred offering costs		—		—			82,600		—
Prepaid expenses		5,495		16,160			5,292		16,620
Total assets		634,223,702		1,954,072,101			596,103,946		2,067,163,963
LIABILITIES
Bank overdraft		—		291,881			60,686		—
Collateral on securities loaned		—		12,300,667			—		20,504,459
Options written, at value(e)		10,496,177		31,431,446			7,272,745		16,978,313
Payables:
Accounting services fees		11,774		73,720			6,786		77,172
Custodian fees		30,184		70,982			14,995		25,318
Deferred foreign capital gain tax		4,475		—			—		—
Investment advisory fees		515,908		1,954,724			489,107		2,101,647
Trustees’ and Officer’s fees		566,973		220,367			35,975		190,437
Options written		—		637			181		—
Other accrued expenses		15,681		69,110			13,695		225,454
Professional fees		82,978		170,562			60,267		241,684
Proxy fees		—		88,733			—		309,518
Transfer agent fees		17,702		28,340			14,079		40,123
Total liabilities		11,741,852		46,701,169			7,968,516		40,694,125
Commitments and contingent liabilities
NET ASSETS	$	622,481,850	$	1,907,370,932		$	588,135,430	$	2,026,469,838
NET ASSETS CONSIST OF
Paid-in capital(f)(g)(h)	$	540,011,552	$	1,951,060,860		$	417,617,800	$	4,022,207,780
Accumulated earnings (loss)		82,470,298		(43,689,928	)		170,517,630		(1,995,737,942	)
NET ASSETS	$	622,481,850	$	1,907,370,932		$	588,135,430	$	2,026,469,838
Net asset value	$	6.21	$	17.91		$	42.18	$	9.03
(a) Investments, at cost — unaffiliated	$	516,484,782	$	1,853,674,255		$	382,327,860	$	2,119,760,855
(b) Securities loaned, at value	$	—	$	11,862,741		$	—	$	19,672,989
(c)  Investments, at cost — affiliated	$	8,260,103	$	52,782,639		$	31,396,977	$	20,830,071
(d) Foreign currency, at cost	$	72,034	$	1,152		$	531	$	365
(e) Premiums received	$	6,047,973	$	14,726,316		$	4,793,338	$	8,337,243
(f)  Shares outstanding		100,271,847		106,514,258			13,943,973		224,418,826
(g) Shares authorized		Unlimited		Unlimited			Unlimited		Unlimited
(h) Par value	$	0.001	$	0.001		$	0.001	$	0.001

See notes to financial statements.

134 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Statements of Assets and Liabilities (continued)

December 31, 2023

	BCX			BSTZ(a)		BST(a)		BUI
ASSETS
Investments, at value — unaffiliated(b)(c)	$	886,715,569		$	1,645,173,877	$	1,212,240,494	$	508,127,583
Investments, at value — affiliated(d)		20,310,546			4,350,523		6,226,377		6,616,284
Cash		11,212			—		—		118,852
Cash pledged as collateral for OTC derivatives		—			2,810,000		480,000		—
Foreign currency, at value(e)		32			—		3,106		311,516
Receivables:
Investments sold		—			5,008,596		1,911,624		—
Options written		144,623			73,559		64,797		5,666
Securities lending income — affiliated		1,145			2,549		3,275		390
Dividends — unaffiliated		1,303,716			249,242		165,225		766,502
Dividends — affiliated		59,141			16,169		5,862		39,225
Interest — unaffiliated		159,250			—		—		—
Deferred offering costs		—			—		190,226		104,426
Prepaid expenses		—			12,591		10,113		—
Total assets		908,705,234			1,657,697,106		1,221,301,099		516,090,444
LIABILITIES
Bank overdraft		—			343,159		506,784		—
Foreign bank overdraft(f)		—			4,202		—		—
Due to broker		—			680,000		—		—
Collateral on securities loaned		6,147,790			2,865,527		5,861,189		1,296,550
Options written, at value(g)		10,021,060			18,907,082		15,464,670		7,790,856
Payables:
Investments purchased		—			984,914		1,560,753		—
Accounting services fees		14,708			63,912		12,205		12,205
Custodian fees		16,921			69,972		22,959		16,734
Deferred capital gain tax		—			1,502,552		—		—
Investment advisory fees		744,129			1,706,024		1,000,816		421,840
Offering costs		—			—		122,160		—
Trustees’ and Officer’s fees		270,533			207,525		18,503		8,241
Options written		—			10,649		—		—
Other accrued expenses		31,460			115,292		81,798		28,508
Professional fees		95,437			381,996		196,191		39,716
Transfer agent fees		24,704			30,071		28,445		13,864
Total liabilities		17,366,742			27,872,877		24,876,473		9,628,514
Commitments and contingent liabilities
NET ASSETS	$	891,338,492		$	1,629,824,229	$	1,196,424,626	$	506,461,930
NET ASSETS CONSIST OF
Paid-in capital(h)(i)(j)	$	1,017,257,473		$	1,204,518,485	$	778,585,324	$	376,938,330
Accumulated earnings (loss)		(125,918,981	)		425,305,744		417,839,302		129,523,600
NET ASSETS	$	891,338,492		$	1,629,824,229	$	1,196,424,626	$	506,461,930
Net asset value	$	10.57		$	21.43	$	34.74	$	22.53
(a) Consolidated Statement of Assets and Liabilities.
(b) Investments, at cost — unaffiliated	$	763,800,468		$	1,116,742,952	$	772,151,828	$	353,774,571
(c)  Securities loaned, at value	$	5,956,421		$	2,734,659	$	5,574,481	$	1,261,058
(d) Investments, at cost — affiliated	$	20,311,045		$	4,349,961	$	6,226,872	$	6,616,280
(e) Foreign currency, at cost	$	31		$	—	$	3,199	$	311,331
(f)  Foreign bank overdraft, at cost	$	—		$	4,244	$	—	$	—
(g) Premiums received	$	6,777,331		$	14,635,894	$	10,495,969	$	3,994,666
(h) Shares outstanding		84,363,295			76,070,675		34,439,660		22,475,026
(i)  Shares authorized		Unlimited			Unlimited		Unlimited		Unlimited
(j)  Par value	$	0.001		$	0.001	$	0.001	$	0.001

See notes to financial statements.

F I N A N C I A L  S T A T E M E N T S 135

Statements of Operations

Year Ended December 31, 2023

	BGR			CII			BDJ(a)			BOE
INVESTMENT INCOME
Dividends — unaffiliated	$	14,969,795		$	9,850,246		$	45,971,564		$	20,734,128
Dividends — affiliated		298,320			617,975			2,734,658			436,584
Securities lending income — affiliated — net		—			6,751			1,130			2,641
Other income — unaffiliated		—			—			—			1,660
Foreign taxes withheld		(677,148	)		(229,698	)		(669,939	)		(1,152,741	)
Foreign withholding tax claims		—			—			—			92,863
Total investment income		14,590,967			10,245,274			48,037,413			20,115,135
EXPENSES
Investment advisory		4,701,620			7,010,587			12,943,290			7,083,506
Trustees and Officer		68,275			68,931			223,235			107,935
Professional		67,273			63,469			83,302			85,609
Transfer agent		61,481			83,739			166,466			92,586
Accounting services		44,026			50,619			95,592			60,591
Custodian		38,393			30,538			121,839			101,549
Printing and postage		12,806			12,250			12,155			13,049
Registration		9,635			15,141			63,956			21,543
Miscellaneous		43,350			45,572			122,140			111,703
Total expenses excluding interest expense		5,046,859			7,380,846			13,831,975			7,678,071
Interest expense		1,981			25			1,285			12,510
Total expenses		5,048,840			7,380,871			13,833,260			7,690,581
Less:
Fees waived and/or reimbursed by the Manager		(866,525	)		(9,345	)		(42,031	)		(1,246,244	)
Total expenses after fees waived and/or reimbursed		4,182,315			7,371,526			13,791,229			6,444,337
Net investment income		10,408,652			2,873,748			34,246,184			13,670,798
REALIZED AND UNREALIZED GAIN (LOSS)
Net realized gain (loss) from:
Investments — unaffiliated		13,956,583			38,254,751			109,803,621			(8,384,018	)
Investments — affiliated		—			(486	)		(331	)		1,183
Foreign currency transactions		(19,792	)		5,820			(29,970	)		49,737
Options written		9,232,797			(10,946,814	)		(6,887,226	)		4,801,919
		23,169,588			27,313,271			102,886,094			(3,531,179	)
Net change in unrealized appreciation (depreciation) on:
Investments — unaffiliated		(13,465,014	)		135,702,696			36,602,051			94,322,957
Investments — affiliated		—			(40	)		—			—
Foreign currency translations		7,464			—			56,565			70,714
Options written		(1,712,020	)		(13,682,244	)		(23,815,466	)		(7,553,097	)
		(15,169,570	)		122,020,412			12,843,150			86,840,574
Net realized and unrealized gain		8,000,018			149,333,683			115,729,244			83,309,395
NET INCREASE IN NET ASSETS RESULTING FROM OPERATIONS	$	18,408,670		$	152,207,431		$	149,975,428		$	96,980,193

^(a) Consolidated Statement of Operations.

See notes to financial statements.

136 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Statements of Operations (continued)

Year Ended December 31, 2023

	BGY			BMEZ			BME			BIGZ
INVESTMENT INCOME
Dividends — unaffiliated	$	16,468,093		$	10,039,140		$	6,937,337		$	4,032,845
Dividends — affiliated		518,836			2,845,610			1,268,777			445,542
Securities lending income — affiliated — net		—			458,690			25,650			63,099
Foreign taxes withheld		(1,573,063	)		(197,616	)		(38,198	)		(103,355	)
Total investment income		15,413,866			13,145,824			8,193,566			4,438,131
EXPENSES
Investment advisory		6,151,366			24,524,202			5,832,589			25,361,872
Custodian		134,274			122,197			51,615			76,364
Professional		106,618			132,875			98,133			189,064
Trustees and Officer		90,917			131,469			37,651			130,669
Transfer agent		84,967			112,265			75,539			113,140
Accounting services		50,619			210,489			30,592			211,126
Registration		35,250			77,430			6,969			118,823
Printing and postage		13,432			7,656			12,150			51,776
Proxy		—			384,226			—			2,215,984
Miscellaneous		119,953			311,104			61,916			810,404
Total expenses excluding interest expense		6,787,396			26,013,913			6,207,154			29,279,222
Interest expense		11,998			2,572			55			1,499
Total expenses		6,799,394			26,016,485			6,207,209			29,280,721
Less:
Fees waived and/or reimbursed by the Manager		(7,794	)		(42,748	)		(19,166	)		(6,701	)
Total expenses after fees waived and/or reimbursed		6,791,600			25,973,737			6,188,043			29,274,020
Net investment income (loss)		8,622,266			(12,827,913	)		2,005,523			(24,835,889	)
REALIZED AND UNREALIZED GAIN (LOSS)
Net realized gain (loss) from:
Investments — unaffiliated		11,484,884	(a)		(24,744,005	)		21,495,636			(393,354,886	)
Investments — affiliated		—			486,796			1,094			(616	)
Forward foreign currency exchange contracts		—			(57,158	)		—			—
Foreign currency transactions		92,350			(226,545	)		(16,353	)		14,472
Options written		13,525,844			24,415,306			5,205,429			(1,695,478	)
		25,103,078			(125,606	)		26,685,806			(395,036,508	)
Net change in unrealized appreciation (depreciation) on:
Investments — unaffiliated		55,264,286	(b)		105,248,841			(4,024,478	)		645,656,803
Investments — affiliated		—			148,903			(265	)		1,161
Forward foreign currency exchange contracts		—			(3,535,460	)		—			—
Foreign currency translations		76,633			30,590			8,828			(3,742	)
Options written		(5,754,650	)		(19,080,793	)		(4,658,396	)		(14,212,806	)
		49,586,269			82,812,081			(8,674,311	)		631,441,416
Net realized and unrealized gain		74,689,347			82,686,475			18,011,495			236,404,908
NET INCREASE IN NET ASSETS RESULTING FROM OPERATIONS	$	83,311,613		$	69,858,562		$	20,017,018		$	211,569,019
(a) Net of foreign capital gain tax and capital gain tax refund, if applicable of	$	5,424		$	—		$	—		$	—
(b) Net of reduction in deferred foreign capital gain tax of	$	68,252		$	—		$	—		$	—

See notes to financial statements.

F I N A N C I A L  S T A T E M E N T S 137

Statements of Operations (continued)

Year Ended December 31, 2023

	BCX			BSTZ(a)			BST(a)			BUI
INVESTMENT INCOME
Dividends — unaffiliated	$	34,681,757		$	6,443,460		$	4,090,208		$	13,347,378
Dividends — affiliated		1,252,534			395,145			354,864			525,353
Securities lending income — affiliated — net		17,994			78,328			16,851			10,772
Foreign taxes withheld		(1,719,124	)		(763,345	)		(125,252	)		(689,625	)
Foreign withholding tax claims		—			—			—			25,957
Total investment income		34,233,161			6,153,588			4,336,671			13,219,835
EXPENSES
Investment advisory		9,268,898			19,807,795			10,967,904			4,969,829
Transfer agent		119,977			151,677			147,249			72,110
Custodian		84,957			202,787			102,677			64,294
Trustees and Officer		81,038			106,732			61,745			29,277
Professional		72,375			185,694			191,977			76,063
Accounting services		59,025			173,820			49,023			49,023
Registration		30,063			26,861			14,365			12,685
Printing and postage		12,892			11,562			15,566			12,845
Miscellaneous		116,687			627,205			432,022			97,398
Total expenses excluding interest expense		9,845,912			21,294,133			11,982,528			5,383,524
Interest expense		2,847			21,132			14,556			2,654
Total expenses		9,848,759			21,315,265			11,997,084			5,386,178
Less:
Fees waived and/or reimbursed by the Manager		(18,912	)		(5,929	)		(5,407	)		(8,011	)
Total expenses after fees waived and/or reimbursed		9,829,847			21,309,336			11,991,677			5,378,167
Net investment income (loss)		24,403,314			(15,155,748	)		(7,655,006	)		7,841,668
REALIZED AND UNREALIZED GAIN (LOSS)
Net realized gain (loss) from:
Investments — unaffiliated		12,875,880			(14,848,604	)		81,791,251			11,729,367
Investments — affiliated		4,937			12,631			1,012			1,417
Foreign currency transactions		25,265			(425,111	)		(6,781	)		49,491
Options written		21,043,307			(25,763,522	)		(31,419,636	)		7,412,060
Payment by affiliate		—			127,092			—			—
		33,949,389			(40,897,514	)		50,365,846			19,192,335
Net change in unrealized appreciation (depreciation) on:
Investments — unaffiliated		(60,295,894	)		349,981,389	(b)		259,808,753	(b)		14,349,399
Investments — affiliated		(499	)		562			(575	)		(118	)
Foreign currency translations		24,073			6,975			150			18,026
Options written		(6,718,319	)		(13,974,383	)		(12,373,937	)		(5,317,561	)
		(66,990,639	)		336,014,543			247,434,391			9,049,746
Net realized and unrealized gain (loss)		(33,041,250	)		295,117,029			297,800,237			28,242,081
NET INCREASE (DECREASE) IN NET ASSETS RESULTING FROM OPERATIONS	$	(8,637,936	)	$	279,961,281		$	290,145,231		$	36,083,749
(a) Consolidated Statement of Operations.
(b) Net of reduction in deferred capital gain tax of	$	—		$	1,956,748		$	113,475		$	—

See notes to financial statements.

138 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Statements of Changes in Net Assets

 

	BGR						CII
	Year Ended 12/31/23			Year Ended 12/31/22			Year Ended 12/31/23			Year Ended 12/31/22
INCREASE (DECREASE) IN NET ASSETS
OPERATIONS
Net investment income	$	10,408,652		$	12,071,039		$	2,873,748		$	2,696,846
Net realized gain		23,169,588			34,809,940			27,313,271			100,213,617
Net change in unrealized appreciation (depreciation)		(15,169,570	)		66,906,553			122,020,412			(211,028,139	)
Net increase (decrease) in net assets resulting from operations		18,408,670			113,787,532			152,207,431			(108,117,676	)
DISTRIBUTIONS TO SHAREHOLDERS(a)
From net investment income and net realized gain		(10,396,825	)		(11,890,970	)		(52,698,168	)		(92,693,757	)
Return of capital		(11,108,880	)		(4,610,793	)		—			—
Decrease in net assets resulting from distributions to shareholders		(21,505,705	)		(16,501,763	)		(52,698,168	)		(92,693,757	)
CAPITAL SHARE TRANSACTIONS
Reinvestment of distributions		—			—			274,446			—
Redemption of shares resulting from share repurchase program (including transaction costs)		(7,413,692	)		(12,296,655	)		—			—
Net increase (decrease) in net assets derived from capital share transactions		(7,413,692	)		(12,296,655	)		274,446			—
NET ASSETS
Total increase (decrease) in net assets		(10,510,727	)		84,989,114			99,783,709			(200,811,433	)
Beginning of year		398,492,584			313,503,470			774,667,072			975,478,505
End of year	$	387,981,857		$	398,492,584		$	874,450,781		$	774,667,072

^(a) Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

See notes to financial statements.

F I N A N C I A L  S T A T E M E N T S 139

Statements of Changes in Net Assets (continued)

 

	BDJ(a)						BOE
	Year Ended 12/31/23			Year Ended 12/31/22			Year Ended 12/31/23			Year Ended 12/31/22
INCREASE (DECREASE) IN NET ASSETS
OPERATIONS
Net investment income	$	34,246,184		$	30,038,016		$	13,670,798		$	12,760,469
Net realized gain (loss)		102,886,094			147,475,079			(3,531,179	)		15,653,551
Net change in unrealized appreciation (depreciation)		12,843,150			(250,207,024	)		86,840,574			(137,096,032	)
Net increase (decrease) in net assets resulting from operations		149,975,428			(72,693,929	)		96,980,193			(108,682,012	)
DISTRIBUTIONS TO SHAREHOLDERS(b)
From net investment income and net realized gain		(135,982,780	)		(204,152,869	)		(13,739,848	)		(38,142,002	)
Return of capital		—			—			(33,325,380	)		(9,962,064	)
Decrease in net assets resulting from distributions to shareholders		(135,982,780	)		(204,152,869	)		(47,065,228	)		(48,104,066	)
CAPITAL SHARE TRANSACTIONS
Reinvestment of distributions		702,786			3,650,249			—			—
Redemption of shares resulting from share repurchase program (including transaction costs)		(2,735,878	)		—			(11,889,663	)		(12,470,648	)
Net increase (decrease) in net assets derived from capital share transactions		(2,033,092	)		3,650,249			(11,889,663	)		(12,470,648	)
NET ASSETS
Total increase (decrease) in net assets		11,959,556			(273,196,549	)		38,025,302			(169,256,726	)
Beginning of year		1,629,641,567			1,902,838,116			688,463,885			857,720,611
End of year	$	1,641,601,123		$	1,629,641,567		$	726,489,187		$	688,463,885

^(a)  Consolidated Statement of Changes in Net Assets.

^(b)  Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

See notes to financial statements.

140 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Statements of Changes in Net Assets (continued)

 

	BGY						BMEZ
	Year Ended 12/31/23			Year Ended 12/31/22			Year Ended 12/31/23			Year Ended 12/31/22
INCREASE (DECREASE) IN NET ASSETS
OPERATIONS
Net investment income (loss)	$	8,622,266		$	10,518,833		$	(12,827,913	)	$	(20,420,947	)
Net realized gain (loss)		25,103,078			14,980,788			(125,606	)		(26,244,107	)
Net change in unrealized appreciation (depreciation)		49,586,269			(92,154,694	)		82,812,081			(636,053,199	)
Net increase (decrease) in net assets resulting from operations		83,311,613			(66,655,073	)		69,858,562			(682,718,253	)
DISTRIBUTIONS TO SHAREHOLDERS(a)
From net investment income and net realized gain		(17,300,662	)		(20,170,266	)		—			(183,050,144	)
Return of capital		(23,857,237	)		(21,930,456	)		(170,987,587	)		(11,869,565	)
Decrease in net assets resulting from distributions to shareholders		(41,157,899	)		(42,100,722	)		(170,987,587	)		(194,919,709	)
CAPITAL SHARE TRANSACTIONS
Redemption of shares resulting from share repurchase program (including transaction costs)		(13,143,239	)		(7,282,700	)		(47,918,763	)		(47,829,587	)
NET ASSETS
Total increase (decrease) in net assets		29,010,475			(116,038,495	)		(149,047,788	)		(925,467,549	)
Beginning of year		593,471,375			709,509,870			2,056,418,720			2,981,886,269
End of year	$	622,481,850		$	593,471,375		$	1,907,370,932		$	2,056,418,720

^(a) Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

See notes to financial statements.

F I N A N C I A L  S T A T E M E N T S 141

Statements of Changes in Net Assets (continued)

 

	BME						BIGZ
	Year Ended 12/31/23			Year Ended 12/31/22			Year Ended 12/31/23			Year Ended 12/31/22
INCREASE (DECREASE) IN NET ASSETS
OPERATIONS
Net investment income (loss)	$	2,005,523		$	1,539,556		$	(24,835,889	)	$	(31,271,483	)
Net realized gain (loss)		26,685,806			13,676,395			(395,036,508	)		(1,316,372,963	)
Net change in unrealized appreciation (depreciation)		(8,674,311	)		(41,687,030	)		631,441,416			(308,670,678	)
Net increase (decrease) in net assets resulting from operations		20,017,018			(26,471,079	)		211,569,019			(1,656,315,124	)
DISTRIBUTIONS TO SHAREHOLDERS(a)
From net investment income and net realized gain		(25,396,234	)		(32,998,527	)		—			—
Return of capital		(10,214,453	)		(1,403,564	)		(173,714,456	)		(233,929,900	)
Decrease in net assets resulting from distributions to shareholders		(35,610,687	)		(34,402,091	)		(173,714,456	)		(233,929,900	)
CAPITAL SHARE TRANSACTIONS
Net proceeds from the issuance of shares		3,020,683			33,618,939			—			—
Reinvestment of distributions		511,503			1,676,333			—			—
Redemption of shares resulting from share repurchase program (including transaction costs)		—			—			(37,872,639	)		(64,919,571	)
Net increase (decrease) in net assets derived from capital share transactions		3,532,186			35,295,272			(37,872,639	)		(64,919,571	)
NET ASSETS
Total decrease in net assets		(12,061,483	)		(25,577,898	)		(18,076	)		(1,955,164,595	)
Beginning of year		600,196,913			625,774,811			2,026,487,914			3,981,652,509
End of year	$	588,135,430		$	600,196,913		$	2,026,469,838		$	2,026,487,914

^(a) Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

See notes to financial statements.

142 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Statements of Changes in Net Assets (continued)

 

	BCX						BSTZ(a)
	Year Ended 12/31/23			Year Ended 12/31/22			Year Ended 12/31/23			Year Ended 12/31/22
INCREASE (DECREASE) IN NET ASSETS
OPERATIONS
Net investment income (loss)	$	24,403,314		$	26,122,375		$	(15,155,748	)	$	(23,377,483	)
Net realized gain (loss)		33,949,389			164,961,884			(40,897,514	)		116,813,048
Net change in unrealized appreciation (depreciation)		(66,990,639	)		(53,573,504	)		336,014,543			(1,429,494,278	)
Net increase (decrease) in net assets resulting from operations		(8,637,936	)		137,510,755			279,961,281			(1,336,058,713	)
DISTRIBUTIONS TO SHAREHOLDERS(b)
From net investment income and net realized gain		(24,357,046	)		(26,024,883	)		—			(70,402,537	)
Return of capital		(29,035,558	)		(22,531,891	)		(140,469,092	)		(110,549,120	)
Decrease in net assets resulting from distributions to shareholders		(53,392,604	)		(48,556,774	)		(140,469,092	)		(180,951,657	)
CAPITAL SHARE TRANSACTIONS
Redemption of shares resulting from share repurchase program (including transaction costs)		(29,812,008	)		(7,554,830	)		(34,325,597	)		(7,293,625	)
NET ASSETS
Total increase (decrease) in net assets		(91,842,548	)		81,399,151			105,166,592			(1,524,303,995	)
Beginning of year		983,181,040			901,781,889			1,524,657,637			3,048,961,632
End of year	$	891,338,492		$	983,181,040		$	1,629,824,229		$	1,524,657,637

^(a)  Consolidated Statement of Changes in Net Assets.

^(b)  Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

See notes to financial statements.

F I N A N C I A L  S T A T E M E N T S 143

Statements of Changes in Net Assets (continued)

 

	BST(a)						BUI
	Year Ended 12/31/23			Year Ended 12/31/22			Year Ended 12/31/23			Year Ended 12/31/22
INCREASE (DECREASE) IN NET ASSETS
OPERATIONS
Net investment income (loss)	$	(7,655,006	)	$	(9,272,089	)	$	7,841,668		$	7,295,744
Net realized gain		50,365,846			51,379,805			19,192,335			7,425,254
Net change in unrealized appreciation (depreciation)		247,434,391			(696,878,029	)		9,049,746			(59,248,817	)
Net increase (decrease) in net assets resulting from operations		290,145,231			(654,770,313	)		36,083,749			(44,527,819	)
DISTRIBUTIONS TO SHAREHOLDERS(b)
From net investment income and net realized gain		(50,091,649	)		(69,684,200	)		(21,447,319	)		(18,983,124	)
Return of capital		(51,595,440	)		(27,306,002	)		(11,077,670	)		(13,135,583	)
Decrease in net assets resulting from distributions to shareholders		(101,687,089	)		(96,990,202	)		(32,524,989	)		(32,118,707	)
CAPITAL SHARE TRANSACTIONS
Net proceeds from the issuance of shares		41,619,188			28,525,537			3,779,817			14,467,890
Reinvestment of distributions		5,644,095			2,771,741			730,387			766,909
Net increase in net assets derived from capital share transactions		47,263,283			31,297,278			4,510,204			15,234,799
NET ASSETS
Total increase (decrease) in net assets		235,721,425			(720,463,237	)		8,068,964			(61,411,727	)
Beginning of year		960,703,201			1,681,166,438			498,392,966			559,804,693
End of year	$	1,196,424,626		$	960,703,201		$	506,461,930		$	498,392,966

^(a)  Consolidated Statement of Changes in Net Assets.

^(b)  Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

See notes to financial statements.

144 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Statements of Cash Flows

Year Ended December 31, 2023

	BGR			CII			BDJ(a)			BOE
CASH PROVIDED BY (USED FOR) OPERATING ACTIVITIES
Net increase in net assets resulting from operations	$	18,408,670		$	152,207,431		$	149,975,428		$	96,980,193
Adjustments to reconcile net increase in net assets resulting from operations to net cash provided by operating activities:
Proceeds from sales of long-term investments and principal paydowns/payups		155,259,253			299,421,903			738,966,890			363,701,155
Purchases of long-term investments		(147,272,203	)		(235,741,075	)		(698,110,301	)		(330,769,604	)
Net proceeds from sales of short-term securities		4,083,155			1,330,166			70,837,572			3,976,712
Premiums paid on closing options written		(21,610,723	)		(113,646,798	)		(165,872,491	)		(50,374,267	)
Premiums received from options written		28,273,392			99,822,466			158,385,773			54,159,601
Net realized (gain) loss on investments and options written		(22,920,725	)		(27,280,542	)		(102,827,132	)		3,739,905
Net unrealized (appreciation) depreciation on investments, options written and foreign currency translations		15,177,844			(122,020,412	)		(12,786,583	)		(86,769,860	)
(Increase) Decrease in Assets
Receivables
Dividends — affiliated		2,178			46,761			233,670			10,292
Dividends — unaffiliated		119,573			43,195			309,576			(145,719	)
Securities lending income — affiliated		—			(315	)		—			—
Prepaid expenses		(3,815	)		(6,042	)		(14,631	)		(6,414	)
Deferred offering costs		—			—			(208,889	)		—
Increase (Decrease) in Liabilities
Due to broker		—			—			—			530,000
Collateral on securities loaned		—			397,585			—			—
Payables
Accounting services fees		(3,703	)		(3,884	)		(7,699	)		(4,754	)
Custodian fees		(7,606	)		(68	)		(20,442	)		(14,517	)
Investment advisory fees		(6,328	)		39,963			(34,244	)		12,621
Trustees’ and Officer’s fees		14,268			26,371			108,558			29,364
Other accrued expenses		(19,397	)		(48,293	)		(32,354	)		(14,595	)
Professional fees		(24,123	)		(30,540	)		(52,758	)		(27,087	)
Transfer agent fees		(9,570	)		(10,588	)		(23,655	)		(13,244	)
Other liabilities		—			—			(666,808	)		—
Net cash provided by operating activities		29,460,140			54,547,284			138,159,480			54,999,782
CASH PROVIDED BY (USED FOR) FINANCING ACTIVITIES
Cash dividends paid to shareholders		(21,597,278	)		(54,523,046	)		(135,279,994	)		(47,201,093	)
Net payments on redemption of capital shares		(7,673,529	)		—			(2,735,878	)		(12,222,062	)
Decrease in bank overdraft		(83,281	)		(24,238	)		—			—
Net cash used for financing activities		(29,354,088	)		(54,547,284	)		(138,015,872	)		(59,423,155	)
CASH IMPACT FROM FOREIGN EXCHANGE FLUCTUATIONS
Cash impact from foreign exchange fluctuations		(810	)		—			(2	)		(155	)
CASH AND FOREIGN CURRENCY
Net increase (decrease) in restricted and unrestricted cash and foreign currency		105,242			—			143,606			(4,423,528	)
Restricted and unrestricted cash and foreign currency at beginning of year		58,425			—			129,653			4,953,552
Restricted and unrestricted cash and foreign currency at end of year	$	163,667		$	—		$	273,259		$	530,024
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid during the year for interest expense	$	1,981		$	25		$	1,285		$	12,510
NON-CASH FINANCING ACTIVITIES
Reinvestment of distributions	$	—		$	274,446		$	702,786		$	—

F I N A N C I A L  S T A T E M E N T S 145

Statements of Cash Flows (continued)

Year Ended December 31, 2023

	BGR		CII		BDJ(a)		BOE
RECONCILIATION OF RESTRICTED AND UNRESTRICTED CASH AND FOREIGN CURRENCY AT THE END OF YEAR TO THE STATEMENTS OF ASSETS AND LIABILITIES
Cash	$	—	$	—	$	272,377	$	—
Cash pledged
Collateral — OTC derivatives		—		—		—		530,000
Foreign currency at value		163,667		—		882		24
	$	163,667	$	—	$	273,259	$	530,024

^(a) Consolidated Statement of Cash Flows.

See notes to financial statements.

146 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Statements of Cash Flows (continued)

Year Ended December 31, 2023

	BGY			BMEZ			BME			BIGZ
CASH PROVIDED BY (USED FOR) OPERATING ACTIVITIES
Net increase in net assets resulting from operations	$	83,311,613		$	69,858,562		$	20,017,018		$	211,569,019
Adjustments to reconcile net increase in net assets resulting from operations to net cash provided by operating activities:
Proceeds from sales of long-term investments		378,012,871			1,388,198,381			276,514,413			1,004,863,164
Purchases of long-term investments		(350,204,293	)		(1,212,826,357	)		(241,735,506	)		(779,071,516	)
Net proceeds from sales (purchases) of short-term securities		(2,637,782	)		32,057,220			(7,524,854	)		132,541
Premiums paid on closing options written		(29,738,122	)		(100,995,609	)		(38,654,231	)		(71,188,435	)
Premiums received from options written		43,528,696			119,727,132			42,173,622			66,060,586
Net realized (gain) loss on investments and options written		(24,861,160	)		1,723,983			(26,689,552	)		395,265,926
Net unrealized (appreciation) depreciation on investments, options written and foreign currency translations		(49,439,379	)		(82,781,507	)		8,683,167			(631,426,944	)
(Increase) Decrease in Assets
Receivables
Dividends — affiliated		(16,306	)		(137,063	)		(73,363	)		10,476
Dividends — unaffiliated		281,025			(237,570	)		51,234			(113,427	)
Securities lending income — affiliated		—			31,029			4,310			3,221
Prepaid expenses		(5,495	)		(16,160	)		(5,292	)		(16,620	)
Deferred offering costs		—			—			(4,426	)		—
Increase (Decrease) in Liabilities
Collateral on securities loaned		—			10,470,673			(675,895	)		20,319,859
Payables
Accounting services fees		(3,884	)		(1,418	)		(2,228	)		(2,428	)
Custodian fees		(12,737	)		(47,364	)		(1,746	)		(2,794	)
Deferred foreign capital gain tax		(68,252	)		—			—			—
Investment advisory fees		7,499			(256,219	)		(22,241	)		(106,788	)
Trustees’ and Officer’s fees		18,863			77,726			12,638			78,419
Other accrued expenses		(13,184	)		(126,201	)		(24,844	)		(109,246	)
Professional fees		(21,108	)		3,689			(15,408	)		36,486
Proxy fees		—			88,733			—			309,518
Transfer agent fees		(10,140	)		(24,185	)		(8,140	)		(38,665	)
Net cash provided by operating activities		48,128,725			224,787,475			32,018,676			216,572,352
CASH PROVIDED BY (USED FOR) FINANCING ACTIVITIES
Cash dividends paid to shareholders		(41,320,547	)		(173,524,946	)		(35,099,184	)		(176,112,694	)
Payments for offering costs		—			—			(497	)		—
Net payments on redemption of capital shares		(13,143,239	)		(51,038,060	)		—			(40,459,636	)
Increase in bank overdraft		—			196,568			57,766			—
Proceeds from issuance of capital shares		—			—			3,020,683			—
Net cash used for financing activities		(54,463,786	)		(224,366,438	)		(32,021,232	)		(216,572,330	)
CASH IMPACT FROM FOREIGN EXCHANGE FLUCTUATIONS
Cash impact from foreign exchange fluctuations		(2,005	)		16			(28	)		10
CASH AND FOREIGN CURRENCY
Net increase (decrease) in restricted and unrestricted cash and foreign currency		(6,337,066	)		421,053			(2,584	)		32
Restricted and unrestricted cash and foreign currency at beginning of year		6,408,896			36,115			3,118			335
Restricted and unrestricted cash and foreign currency at end of year	$	71,830		$	457,168		$	534		$	367
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid during the year for interest expense	$	11,998		$	2,572		$	55		$	1,499
NON-CASH FINANCING ACTIVITIES
Reinvestment of distributions	$	—		$	—		$	511,503		$	—

F I N A N C I A L  S T A T E M E N T S 147

Statements of Cash Flows (continued)

Year Ended December 31, 2023

	BGY		BMEZ		BME		BIGZ
RECONCILIATION OF RESTRICTED AND UNRESTRICTED CASH AND FOREIGN CURRENCY AT THE END OF YEAR TO THE STATEMENTS OF ASSETS AND LIABILITIES
Cash pledged
Collateral — OTC derivatives	$	—	$	456,000	$	—	$	—
Foreign currency at value		71,830		1,168		534		367
	$	71,830	$	457,168	$	534	$	367

See notes to financial statements.

148 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Statements of Cash Flows (continued)

Year Ended December 31, 2023

	BCX			BSTZ(a)			BST(a)			BUI
CASH PROVIDED BY (USED FOR) OPERATING ACTIVITIES
Net increase (decrease) in net assets resulting from operations	$	(8,637,936	)	$	279,961,281		$	290,145,231		$	36,083,749
Adjustments to reconcile net increase (decrease) in net assets resulting from operations to net cash provided by operating activities:
Proceeds from sales of long-term investments and principal paydowns/payups		454,061,490			814,156,277			436,821,798			163,826,356
Purchases of long-term investments		(417,686,429	)		(617,172,687	)		(350,433,270	)		(156,804,674	)
Net proceeds from sales (purchases) of short-term securities		(902,005	)		16,346,031			378,587			4,652,393
Premiums paid on closing options written		(48,050,251	)		(155,845,035	)		(131,697,471	)		(23,113,180	)
Premiums received from options written		65,847,566			126,407,741			99,092,517			29,917,467
Net realized (gain) loss on investments and options written		(33,581,296	)		41,324,283			(49,817,838	)		(18,317,996	)
Net unrealized (appreciation) depreciation on investments, options written and foreign currency translations		67,014,722			(334,050,748	)		(247,319,836	)		(9,031,905	)
(Increase) Decrease in Assets
Receivables
Dividends — affiliated		18,603			42,344			28,000			(470	)
Dividends — unaffiliated		298,258			(3,314	)		208,491			240,077
Interest — unaffiliated		(159,250	)		—			—			—
Securities lending income — affiliated		(1,145	)		(2,549	)		(2,001	)		1,742
Prepaid expenses		—			(12,591	)		(10,113	)		—
Other assets		—			680,607			—			—
Deferred offering costs		—			—			15,149			(1,089	)
Increase (Decrease) in Liabilities
Due to broker		—			680,000			—			—
Collateral on securities loaned		6,147,790			2,865,527			5,036,333			1,071,499
Payables
Accounting services fees		(4,977	)		(3,794	)		(4,128	)		(4,128	)
Custodian fees		(9,391	)		7,468			(14,492	)		(9,453	)
Deferred capital gain tax		—			(1,956,748	)		(113,475	)		—
Investment advisory fees		(93,556	)		23,937			154,885			(6,370	)
Trustees’ and Officer’s fees		17,514			61,976			15,517			7,795
Other accrued expenses		(87,879	)		(68,059	)		(68,655	)		(81,981	)
Professional fees		(37,767	)		6,639			20,994			(23,282	)
Transfer agent fees		(17,661	)		(24,601	)		(18,683	)		(7,601	)
Net cash provided by operating activities		84,136,400			173,423,985			52,417,540			28,398,949
CASH PROVIDED BY (USED FOR) FINANCING ACTIVITIES
Cash dividends paid to shareholders		(53,560,583	)		(142,794,066	)		(96,618,820	)		(31,944,926	)
Payments for offering costs		—			—			(7,750	)		—
Net payments on redemption of capital shares		(30,516,383	)		(36,266,037	)		—			—
Increase (decrease) in bank overdraft		(117,583	)		347,361			418,700			—
Proceeds from issuance of capital shares		—			—			41,619,188			3,779,817
Net cash used for financing activities		(84,194,549	)		(178,712,742	)		(54,588,682	)		(28,165,109	)
CASH IMPACT FROM FOREIGN EXCHANGE FLUCTUATIONS
Cash impact from foreign exchange fluctuations		(10	)		(72	)		(930	)		185
CASH AND FOREIGN CURRENCY
Net increase (decrease) in restricted and unrestricted cash and foreign currency		(58,159	)		(5,288,829	)		(2,172,072	)		234,025
Restricted and unrestricted cash and foreign currency at beginning of year		69,403			8,098,829			2,655,178			196,343
Restricted and unrestricted cash and foreign currency at end of year	$	11,244		$	2,810,000		$	483,106		$	430,368
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid during the year for interest expense	$	2,847		$	21,132		$	14,556		$	2,654
NON-CASH FINANCING ACTIVITIES
Reinvestment of distributions	$	—		$	—		$	5,644,095		$	730,387

F I N A N C I A L  S T A T E M E N T S 149

Statements of Cash Flows (continued)

Year Ended December 31, 2023

	BCX		BSTZ(a)		BST(a)		BUI
RECONCILIATION OF RESTRICTED AND UNRESTRICTED CASH AND FOREIGN CURRENCY AT THE END OF YEAR TO THE STATEMENTS OF ASSETS AND LIABILITIES
Cash	$	11,212	$	—	$	—	$	118,852
Cash pledged
Collateral — OTC derivatives		—		2,810,000		480,000		—
Foreign currency at value		32		—		3,106		311,516
	$	11,244	$	2,810,000	$	483,106	$	430,368

^(a) Consolidated Statement of Cash Flows.

See notes to financial statements.

150 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Financial Highlights

(For a share outstanding throughout each period)

	BGR
	Year Ended 12/31/23			Year Ended 12/31/22			Year Ended 12/31/21			Year Ended 12/31/20			Year Ended 12/31/19
Net asset value, beginning of year	$	14.21		$	10.77		$	8.17		$	12.57		$	11.98
Net investment income(a)		0.37			0.42			0.28			0.32			0.34
Net realized and unrealized gain (loss)		0.32			3.60			2.77			(4.06	)		1.18
Net increase (decrease) from investment operations		0.69			4.02			3.05			(3.74	)		1.52
Distributions(b)
From net investment income		(0.37	)		(0.42	)		(0.28	)		(0.32	)		(0.34	)
Return of capital		(0.40	)		(0.16	)		(0.17	)		(0.34	)		(0.59	)
Total distributions		(0.77	)		(0.58	)		(0.45	)		(0.66	)		(0.93	)
Net asset value, end of year	$	14.13		$	14.21		$	10.77		$	8.17		$	12.57
Market price, end of year	$	12.45		$	12.53		$	9.48		$	7.10		$	11.88
Total Return(c)
Based on net asset value		5.75	%		38.51	%		38.36	%(d)		(29.03	)%		13.74	%
Based on market price		5.66	%		38.76	%		40.14	%		(34.74	)%		23.23	%
Ratios to Average Net Assets(e)
Total expenses		1.29	%		1.26	%		1.33	%		1.37	%		1.35	%
Total expenses after fees waived and/or reimbursed		1.07	%		1.04	%		1.11	%		1.15	%		1.16	%
Net investment income		2.66	%		3.21	%		2.88	%		3.77	%		2.67	%
Supplemental Data
Net assets, end of year (000)	$	387,982		$	398,493		$	313,503		$	237,868		$	374,896
Portfolio turnover rate		38	%		76	%		61	%		62	%		24	%

^(a)  Based on average shares outstanding.

^(b)  Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

^(c)  Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.

^(d)  Includes payment from an affiliate, which had no impact on the Trust’s total return.

^(e)  Excludes fees and expenses incurred indirectly as a result of investments in underlying funds.

See notes to financial statements.

F I N A N C I A L  H I G H L I G H T S 151

Financial Highlights (continued)

(For a share outstanding throughout each period)

	CII
	Year Ended 12/31/23			Year Ended 12/31/22			Year Ended 12/31/21			Year Ended 12/31/20			Year Ended 12/31/19
Net asset value, beginning of year	$	17.55		$	22.10		$	19.12		$	17.96		$	15.28
Net investment income(a)		0.07			0.06			0.04			0.13			0.18
Net realized and unrealized gain (loss)		3.38			(2.51	)		4.04			2.08			3.50
Net increase (decrease) from investment operations		3.45			(2.45	)		4.08			2.21			3.68
Distributions(b)
From net investment income		(0.07	)		(0.04	)		(0.04	)		(0.13	)		(0.19	)
From net realized gain		(1.12	)		(2.06	)		(1.06	)		(0.92	)		(0.44	)
Return of capital		—			—			—			—			(0.37	)
Total distributions		(1.19	)		(2.10	)		(1.10	)		(1.05	)		(1.00	)
Net asset value, end of year	$	19.81		$	17.55		$	22.10		$	19.12		$	17.96
Market price, end of year	$	19.00		$	17.12		$	22.12		$	17.40		$	17.25
Total Return(c)
Based on net asset value		20.45	%		(10.95	)%		21.97	%		13.94	%		25.08	%
Based on market price		18.43	%		(13.21	)%		34.15	%		7.97	%		30.38	%
Ratios to Average Net Assets(d)
Total expenses		0.89	%		0.89	%		0.90	%		0.91	%		0.91	%
Total expenses after fees waived and/or reimbursed		0.89	%		0.89	%		0.90	%		0.91	%		0.91	%
Net investment income		0.35	%		0.31	%		0.21	%		0.78	%		1.08	%
Supplemental Data
Net assets, end of year (000)	$	874,451		$	774,667		$	975,479		$	843,673		$	792,638
Portfolio turnover rate		28	%		32	%		27	%		46	%		32	%

^(a)  Based on average shares outstanding.

^(b)  Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

^(c)  Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.

^(d)  Excludes fees and expenses incurred indirectly as a result of investments in underlying funds.

See notes to financial statements.

152 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Financial Highlights (continued)

(For a share outstanding throughout each period)

	BDJ
		Year Ended 12/31/23	(a)		Year Ended 12/31/22	(a)		Year Ended 12/31/21			Year Ended 12/31/20			Year Ended 12/31/19
Net asset value, beginning of year	$	8.74		$	10.23		$	9.35		$	10.03		$	8.74
Net investment income(b)		0.18			0.16			0.15			0.18			0.18
Net realized and unrealized gain (loss)		0.63			(0.56	)		1.60			(0.26	)		1.86
Net increase (decrease) from investment operations		0.81			(0.40	)		1.75			(0.08	)		2.04
Distributions(c)
From net investment income		(0.13	)		(0.04	)		(0.28	)		(0.15	)		(0.08	)
From net realized gain		(0.60	)		(1.05	)		(0.59	)		(0.45	)		(0.67	)
Total distributions		(0.73	)		(1.09	)		(0.87	)		(0.60	)		(0.75	)
Net asset value, end of year	$	8.82		$	8.74		$	10.23		$	9.35		$	10.03
Market price, end of year	$	7.69		$	9.01		$	10.08		$	8.47		$	9.92
Total Return(d)
Based on net asset value		10.37	%		(3.71	)%(e)		19.33	%		0.77	%		24.52	%
Based on market price		(6.65	)%		0.74	%		29.80	%		(7.70	)%		38.53	%
Ratios to Average Net Assets(f)
Total expenses		0.86	%		0.84	%		0.85	%		0.86	%		0.87	%
Total expenses after fees waived and/or reimbursed		0.86	%		0.84	%		0.85	%		0.86	%		0.87	%
Net investment income		2.12	%		1.69	%		1.44	%		2.15	%		1.99	%
Supplemental Data
Net assets, end of year (000)	$	1,641,601		$	1,629,642		$	1,902,838		$	1,739,122		$	1,881,675
Portfolio turnover rate		43	%		81	%		40	%		48	%		40	%

^(a)  Consolidated Financial Highlights.

^(b)  Based on average shares outstanding.

^(c)  Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

^(d)  Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.

^(e)  Includes payment from an affiliate, which had no impact on the Trust’s total return.

^(f)  Excludes fees and expenses incurred indirectly as a result of investments in underlying funds.

See notes to financial statements.

F I N A N C I A L  H I G H L I G H T S 153

Financial Highlights (continued)

(For a share outstanding throughout each period)

	BOE
	Year Ended 12/31/23			Year Ended 12/31/22			Year Ended 12/31/21			Year Ended 12/31/20			Year Ended 12/31/19
Net asset value, beginning of year	$	10.97		$	13.40		$	12.28		$	12.32		$	11.07
Net investment income(a)		0.22			0.20			0.19			0.26			0.30
Net realized and unrealized gain (loss)		1.38			(1.87	)		1.69			0.46			1.71
Net increase (decrease) from investment operations		1.60			(1.67	)		1.88			0.72			2.01
Distributions(b)
From net investment income		(0.22	)		(0.19	)		(0.19	)		(0.26	)		(0.31	)
From net realized gain		—			(0.41	)		(0.57	)		—			—
Return of capital		(0.54	)		(0.16	)		—			(0.50	)		(0.45	)
Total distributions		(0.76	)		(0.76	)		(0.76	)		(0.76	)		(0.76	)
Net asset value, end of year	$	11.81		$	10.97		$	13.40		$	12.28		$	12.32
Market price, end of year	$	9.92		$	9.56		$	12.18		$	10.91		$	10.99
Total Return(c)
Based on net asset value		16.16	%		(11.87	)%		16.21	%		7.65	%		19.54	%
Based on market price		11.95	%		(15.51	)%		18.89	%		7.22	%		25.98	%
Ratios to Average Net Assets(d)
Total expenses		1.09	%		1.06	%		1.07	%		1.09	%		1.12	%
Total expenses after fees waived and/or reimbursed		0.91	%		0.89	%		0.90	%		0.92	%		0.94	%
Total expenses after fees waived and/or reimbursed and excluding professional fees for foreign withholding taxes		0.91	%		0.88	%		0.90	%		0.92	%		0.94	%
Net investment income		1.93	%		1.72	%		1.46	%		2.33	%		2.62	%
Supplemental Data
Net assets, end of year (000)	$	726,489		$	688,464		$	857,721		$	786,230		$	807,712
Portfolio turnover rate		46	%		44	%		65	%		61	%		26	%

^(a)  Based on average shares outstanding.

^(b)  Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

^(c)  Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.

^(d)  Excludes fees and expenses incurred indirectly as a result of investments in underlying funds.

See notes to financial statements.

154 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Financial Highlights (continued)

(For a share outstanding throughout each period)

	BGY
	Year Ended 12/31/23			Year Ended 12/31/22			Year Ended 12/31/21			Year Ended 12/31/20			Year Ended 12/31/19
Net asset value, beginning of year	$	5.78		$	6.81		$	6.49		$	6.47		$	5.79
Net investment income(a)		0.09			0.10			0.09			0.12			0.16
Net realized and unrealized gain (loss)		0.75			(0.72	)		0.64			0.31			0.93
Net increase (decrease) from investment operations		0.84			(0.62	)		0.73			0.43			1.09
Distributions(b)
From net investment income		(0.08	)		(0.10	)		(0.14	)		(0.13	)		(0.16	)
From net realized gain		(0.09	)		(0.10	)		(0.15	)		—			(0.19	)
Return of capital		(0.24	)		(0.21	)		(0.12	)		(0.28	)		(0.06	)
Total distributions		(0.41	)		(0.41	)		(0.41	)		(0.41	)		(0.41	)
Net asset value, end of year	$	6.21		$	5.78		$	6.81		$	6.49		$	6.47
Market price, end of year	$	5.27		$	5.02		$	6.28		$	5.87		$	5.89
Total Return(c)
Based on net asset value		15.94	%		(8.33	)%		11.92	%		8.18	%		20.20	%
Based on market price		13.29	%		(13.67	)%		14.11	%		7.49	%		27.22	%
Ratios to Average Net Assets(d)
Total expenses		1.10	%		1.08	%		1.09	%		1.10	%		1.13	%
Total expenses after fees waived and/or reimbursed		1.10	%		1.03	%		0.99	%		1.00	%		1.03	%
Total expenses after fees waived and/or reimbursed and excluding professional fees for foreign withholding taxes		1.10	%		1.02	%		0.99	%		1.00	%		1.03	%
Net investment income		1.40	%		1.71	%		1.34	%		1.99	%		2.57	%
Supplemental Data
Net assets, end of year (000)	$	622,482		$	593,471		$	709,510		$	676,949		$	683,247
Portfolio turnover rate		55	%		41	%		71	%		60	%		28	%

^(a)  Based on average shares outstanding.

^(b)  Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

^(c)  Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.

^(d)  Excludes fees and expenses incurred indirectly as a result of investments in underlying funds.

See notes to financial statements.

F I N A N C I A L  H I G H L I G H T S 155

Financial Highlights (continued)

(For a share outstanding throughout each period)

	BMEZ
		Year Ended 12/31/23			Year Ended 12/31/22			Year Ended 12/31/21			Period from 01/30/20 to 12/31/20	(a)
Net asset value, beginning of period	$	18.76		$	26.47		$	30.73		$	20.00
Net investment loss(b)		(0.12	)		(0.18	)		(0.32	)		(0.22	)
Net realized and unrealized gain (loss)		0.85			(5.79	)		(2.23	)		11.85
Net increase (decrease) from investment operations		0.73			(5.97	)		(2.55	)		11.63
Distributions(c)
From net realized gain		—			(1.63	)		(1.71	)		(0.90	)
Return of capital		(1.58	)		(0.11	)		—			—
Total distributions		(1.58	)		(1.74	)		(1.71	)		(0.90	)
Net asset value, end of period	$	17.91		$	18.76		$	26.47		$	30.73
Market price, end of period	$	14.65		$	15.43		$	25.36		$	28.65
Total Return(d)
Based on net asset value		5.60	%		(21.66	)%		(8.31	)%		59.62	%(e)(f)
Based on market price		5.02	%		(32.75	)%		(5.76	)%		48.82	%(f)
Ratios to Average Net Assets(g)
Total expenses		1.33	%(h)		1.32	%		1.30	%		1.29	%(i)
Total expenses after fees waived and/or reimbursed		1.32	%(h)		1.32	%		1.30	%		1.28	%(i)
Net investment loss		(0.65	)%		(0.91	)%		(1.10	)%		(1.00	)%(i)
Supplemental Data
Net assets, end of period (000)	$	1,907,371		$	2,056,419		$	2,981,886		$	3,462,638
Portfolio turnover rate		63	%		63	%		44	%		43	%

^(a)  Commencement of operations.

^(b)  Based on average shares outstanding.

^(c)  Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

^(d)  Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.

^(e)  Includes payment from an affiliate, which had no impact on the Trust’s total return.

^(f)  Not annualized.

^(g)  Excludes fees and expenses incurred indirectly as a result of investments in underlying funds.

^(h)  Includes non-recurring expenses of proxy costs. Without these costs, total expenses, total expenses after fees waived and/or reimbursed would have been 1.31% and 1.30%, respectively.

⁽ⁱ⁾  Annualized.

See notes to financial statements.

156 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Financial Highlights (continued)

(For a share outstanding throughout each period)

	BME
	Year Ended 12/31/23			Year Ended 12/31/22			Year Ended 12/31/21			Year Ended 12/31/20			Year Ended 12/31/19
Net asset value, beginning of year	$	43.30		$	47.96		$	45.66		$	41.19		$	35.87
Net investment income(a)		0.14			0.11			—			0.01			0.06
Net realized and unrealized gain (loss)		1.30			(2.21	)		4.74			6.86			7.66
Net increase (decrease) from investment operations		1.44			(2.10	)		4.74			6.87			7.72
Distributions(b)
From net investment income		(0.17	)		(0.12	)		(0.00	)(c)		(0.05	)		(0.12	)
From net realized gain		(1.66	)		(2.34	)		(2.44	)		(2.35	)		(2.28	)
Return of capital		(0.73	)		(0.10	)		—			—			—
Total distributions		(2.56	)		(2.56	)		(2.44	)		(2.40	)		(2.40	)
Net asset value, end of year	$	42.18		$	43.30		$	47.96		$	45.66		$	41.19
Market price, end of year	$	40.46		$	43.58		$	48.50		$	47.59		$	42.50
Total Return(d)
Based on net asset value		3.80	%		(4.19	)%		10.66	%(e)		17.50	%		22.26	%
Based on market price		(1.08	)%		(4.64	)%		7.37	%		18.69	%		24.15	%
Ratios to Average Net Assets(f)
Total expenses		1.06	%		1.08	%		1.08	%		1.10	%		1.09	%
Total expenses after fees waived and/or reimbursed		1.06	%		1.07	%		1.08	%		1.10	%		1.09	%
Net investment income		0.34	%		0.27	%		0.01	%		0.01	%		0.16	%
Supplemental Data
Net assets, end of year (000)	$	588,135		$	600,197		$	625,775		$	545,936		$	446,773
Portfolio turnover rate		43	%		41	%		49	%		28	%		47	%

^(a)  Based on average shares outstanding.

^(b)  Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

^(c)  Amount is greater than $(0.005) per share.

^(d)  Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.

^(e)  Includes payment from an affiliate, which had no impact on the Trust’s total return.

^(f)  Excludes fees and expenses incurred indirectly as a result of investments in underlying funds.

See notes to financial statements.

F I N A N C I A L  H I G H L I G H T S 157

Financial Highlights (continued)

(For a share outstanding throughout each period)

	BIGZ
	Year Ended 12/31/23			Year Ended 12/31/22			Period from 03/29/21(a) to 12/31/21
Net asset value, beginning of period	$	8.82		$	16.72		$	20.00
Net investment loss(b)		(0.11	)		(0.13	)		(0.15	)
Net realized and unrealized gain (loss)		1.09			(6.78	)		(2.43	)
Net increase (decrease) from investment operations		0.98			(6.91	)		(2.58	)
Distribution from return of capital(c)		(0.77	)		(0.99	)		(0.70	)
Net asset value, end of period	$	9.03		$	8.82		$	16.72
Market price, end of period	$	7.33		$	6.81		$	14.54
Total Return(d)
Based on net asset value		13.28	%		(41.14	)%(e)		(13.03	)%(f)
Based on market price		19.09	%		(47.74	)%		(24.37	)%(f)
Ratios to Average Net Assets(g)
Total expenses		1.44	%(h)		1.36	%		1.29	%(i)
Total expenses after fees waived and/or reimbursed		1.44	%(h)		1.36	%		1.28	%(i)
Net investment loss		(1.22	)%		(1.22	)%		(1.02	)%(i)
Supplemental Data
Net assets, end of period (000)	$	2,026,470		$	2,026,488		$	3,981,653
Portfolio turnover rate		37	%		41	%		55	%

^(a)  Commencement of operations.

^(b)  Based on average shares outstanding.

^(c)  Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

^(d)  Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.

^(e)  Includes payment from an affiliate, which had no impact on the Trust’s total return.

^(f)  Not annualized.

^(g)  Excludes fees and expenses incurred indirectly as a result of investments in underlying funds.

^(h)  Includes non-recurring expenses of proxy costs. Without these costs, total expenses, total expenses after fees waived and/or reimbursed would have been 1.33% and 1.33%, respectively.

⁽ⁱ⁾  Annualized.

See notes to financial statements.

158 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Financial Highlights (continued)

(For a share outstanding throughout each period)

	BCX
	Year Ended 12/31/23			Year Ended 12/31/22			Year Ended 12/31/21			Year Ended 12/31/20			Year Ended 12/31/19
Net asset value, beginning of year	$	11.23		$	10.21		$	8.45		$	9.04		$	8.44
Net investment income(a)		0.29			0.30			0.29			0.20			0.23
Net realized and unrealized gain (loss)		(0.33	)		1.27			1.95			(0.26	)		0.99
Net increase (decrease) from investment operations		(0.04	)		1.57			2.24			(0.06	)		1.22
Distributions(b)
From net investment income		(0.28	)		(0.29	)		(0.38	)		(0.23	)		(0.23	)
Return of capital		(0.34	)		(0.26	)		(0.10	)		(0.30	)		(0.39	)
Total distributions		(0.62	)		(0.55	)		(0.48	)		(0.53	)		(0.62	)
Net asset value, end of year	$	10.57		$	11.23		$	10.21		$	8.45		$	9.04
Market price, end of year	$	8.88		$	9.97		$	9.35		$	7.41		$	8.07
Total Return(c)
Based on net asset value		0.56	%		16.31	%		27.20	%		1.56	%		15.88	%
Based on market price		(4.84	)%		12.76	%		32.83	%		(0.23	)%		23.67	%
Ratios to Average Net Assets(d)
Total expenses		1.06	%		1.05	%		1.07	%		1.09	%		1.11	%
Total expenses after fees waived and/or reimbursed		1.06	%		1.05	%		1.07	%		1.09	%		1.11	%
Total expenses after fees waived and/or reimbursed and excluding professional fees for foreign withholding taxes		1.06	%		1.05	%		1.07	%		1.09	%		1.11	%
Net investment income		2.63	%		2.73	%		3.05	%		2.62	%		2.56	%
Supplemental Data
Net assets, end of year (000)	$	891,338		$	983,181		$	901,782		$	746,615		$	822,754
Portfolio turnover rate		46	%		92	%		66	%		78	%		69	%

^(a)  Based on average shares outstanding.

^(b)  Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

^(c)  Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.

^(d)  Excludes fees and expenses incurred indirectly as a result of investments in underlying funds.

See notes to financial statements.

F I N A N C I A L  H I G H L I G H T S 159

Financial Highlights (continued)

(For a share outstanding throughout each period)

	BSTZ
	Year Ended 12/31/23(a)			Year Ended 12/31/22(a)			Year Ended 12/31/21(a)			Year Ended 12/31/20(a)			Period from 06/27/19(b) to 12/31/19
Net asset value, beginning of period	$	19.53		$	38.82		$	38.72		$	20.95		$	20.00
Net investment loss(c)		(0.20	)		(0.30	)		(0.51	)		(0.30	)		(0.05	)
Net realized and unrealized gain (loss)		3.92			(16.69	)		3.69			19.32			1.50
Net increase (decrease) from investment operations		3.72			(16.99	)		3.18			19.02			1.45
Distributions(d)
From net realized gain		—			(0.89	)		(3.08	)		(1.10	)		—
Return of capital		(1.82	)		(1.41	)		—			(0.15	)		(0.50	)
Total distributions		(1.82	)		(2.30	)		(3.08	)		(1.25	)		(0.50	)
Net asset value, end of period	$	21.43		$	19.53		$	38.82		$	38.72		$	20.95
Market price, end of period	$	16.71		$	15.64		$	38.94		$	36.38		$	20.50
Total Return(e)
Based on net asset value		21.74	%(f)		(43.98	)%		8.41	%		94.60	%(f)		7.40	%(g)
Based on market price		18.54	%		(55.27	)%		15.75	%		86.85	%		5.10	%(g)
Ratios to Average Net Assets(h)
Total expenses		1.35	%		1.33	%		1.31	%		1.33	%		1.32	%(i)
Total expenses after fees waived and/or reimbursed		1.34	%		1.33	%		1.31	%		1.33	%		1.30	%(i)
Net investment loss		(0.96	)%		(1.16	)%		(1.25	)%		(1.16	)%		(0.48	)%(i)
Supplemental Data
Net assets, end of period (000)	$	1,629,824		$	1,524,658		$	3,048,962		$	3,023,744		$	1,635,966
Portfolio turnover rate		38	%		47	%		18	%		45	%		16	%

^(a)  Consolidated Financial Highlights.

^(b)  Commencement of operations.

^(c)  Based on average shares outstanding.

^(d)  Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

^(e)  Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.

^(f)  Includes payment from an affiliate, which impacted the Fund’s total return. Excluding the payment from an affiliate, the Fund’s total return would have been 21.68%.

^(g)  Not annualized.

^(h)  Excludes fees and expenses incurred indirectly as a result of investments in underlying funds.

⁽ⁱ⁾  Annualized.

See notes to financial statements.

160 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Financial Highlights (continued)

(For a share outstanding throughout each period)

	BST
	Year Ended 12/31/23(a)			Year Ended 12/31/22(a)			Year Ended 12/31/21(a)			Year Ended 12/31/20(a)			Year Ended 12/31/19
Net asset value, beginning of year	$	29.11		$	52.40		$	51.94		$	32.45		$	26.21
Net investment loss(b)		(0.23	)		(0.29	)		(0.43	)		(0.28	)		(0.17	)
Net realized and unrealized gain (loss)		8.86			(20.00	)		5.84			21.82			9.92
Net increase (decrease) from investment operations		8.63			(20.29	)		5.41			21.54			9.75
Distributions(c)
From net realized gain		(1.48	)		(2.16	)		(4.27	)		(2.05	)		(3.51	)
Return of capital		(1.52	)		(0.84	)		—			—			—
Total distributions		(3.00	)		(3.00	)		(4.27	)		(2.05	)		(3.51	)
Dilutive effect of rights offer (Note 10)		—			—			(0.68	)		—			—
Net asset value, end of year	$	34.74		$	29.11		$	52.40		$	51.94		$	32.45
Market price, end of year	$	33.66		$	28.37		$	49.97		$	53.30		$	33.27
Total Return(d)
Based on net asset value		30.78	%		(39.56	)%(e)		9.44	%		68.76	%(f)		37.82	%
Based on market price		30.03	%		(38.23	)%		1.70	%		68.92	%		34.77	%
Ratios to Average Net Assets(g)
Total expenses		1.09	%		1.11	%		1.05	%		1.09	%		1.08	%
Total expenses after fees waived and/or reimbursed		1.09	%		1.11	%		1.00	%		0.99	%		0.92	%
Total expenses after fees waived and/or reimbursed and excluding dividend expense		1.09	%		1.10	%		1.00	%		0.99	%		0.92	%
Net investment loss		(0.70	)%		(0.77	)%		(0.78	)%		(0.73	)%		(0.52	)%
Supplemental Data
Net assets, end of year (000)	$	1,196,425		$	960,703		$	1,681,166		$	1,297,344		$	742,672
Portfolio turnover rate		32	%		38	%		31	%		20	%		32	%

^(a)  Consolidated Financial Highlights.

^(b)  Based on average shares outstanding.

^(c)  Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

^(d)  Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.

^(e)  Includes payment from an affiliate, which had no impact on the Trust’s total return.

^(f)  For financial reporting purposes, the market value of a certain investment was adjusted as of the report date. Accordingly, the net asset value (NAV) per share and total return performance based on NAV presented herein are different than the information previously published as of December 31, 2020.

^(g)  Excludes fees and expenses incurred indirectly as a result of investments in underlying funds.

See notes to financial statements.

F I N A N C I A L  H I G H L I G H T S 161

Financial Highlights (continued)

(For a share outstanding throughout each period)

	BUI
	Year Ended 12/31/23			Year Ended 12/31/22			Year Ended 12/31/21			Year Ended 12/31/20			Year Ended 12/31/19
Net asset value, beginning of year	$	22.37		$	25.86		$	23.80		$	22.02		$	18.77
Net investment income(a)		0.35			0.33			0.24			0.33			0.37
Net realized and unrealized gain (loss)		1.26			(2.37	)		3.27			2.90			4.33
Net increase (decrease) from investment operations		1.61			(2.04	)		3.51			3.23			4.70
Distributions(b)
From net investment income		(0.37	)		(0.30	)		(0.24	)		(0.20	)		(0.24	)
From net realized gain		(0.59	)		(0.56	)		(0.76	)		(1.08	)		(1.06	)
Return of capital		(0.49	)		(0.59	)		(0.45	)		(0.17	)		(0.15	)
Total distributions		(1.45	)		(1.45	)		(1.45	)		(1.45	)		(1.45	)
Net asset value, end of year	$	22.53		$	22.37		$	25.86		$	23.80		$	22.02
Market price, end of year	$	21.82		$	20.77		$	26.62		$	25.04		$	22.31
Total Return(c)
Based on net asset value		7.66	%		(7.73	)%		15.13	%		15.87	%		25.63	%
Based on market price		12.30	%		(16.78	)%		12.65	%		20.32	%		20.91	%
Ratios to Average Net Assets(d)
Total expenses		1.08	%		1.08	%		1.08	%		1.13	%		1.12	%
Total expenses after fees waived and/or reimbursed		1.08	%		1.08	%		1.07	%		1.10	%		1.10	%
Net investment income		1.58	%		1.44	%		0.97	%		1.58	%		1.78	%
Supplemental Data
Net assets, end of year (000)	$	506,462		$	498,393		$	559,805		$	444,526		$	383,337
Portfolio turnover rate		31	%		36	%		20	%		39	%		39	%

^(a)  Based on average shares outstanding.

^(b)  Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

^(c)  Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.

^(d)  Excludes fees and expenses incurred indirectly as a result of investments in underlying funds.

See notes to financial statements.

162 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Notes to Financial Statements

1. ORGANIZATION

The following are registered under the Investment Company Act of 1940, as amended (the “1940 Act”), as closed-end management investment companies and are referred to herein collectively as the “Trusts”, or individually as a “Trust”:

Trust Name	Herein Referred To As	Organized	Diversification Classification
BlackRock Energy and Resources Trust	BGR	Delaware	Non-diversified
BlackRock Enhanced Capital and Income Fund, Inc.	CII	Maryland	Diversified
BlackRock Enhanced Equity Dividend Trust	BDJ	Delaware	Diversified
BlackRock Enhanced Global Dividend Trust	BOE	Delaware	Diversified
BlackRock Enhanced International Dividend Trust	BGY	Delaware	Diversified
BlackRock Health Sciences Term Trust	BMEZ	Maryland	Non-diversified
BlackRock Health Sciences Trust	BME	Delaware	Diversified
BlackRock Innovation and Growth Term Trust	BIGZ	Maryland	Non-diversified
BlackRock Resources & Commodities Strategy Trust	BCX	Delaware	Non-diversified
BlackRock Science and Technology Term Trust	BSTZ	Delaware	Diversified*
BlackRock Science and Technology Trust	BST	Delaware	Diversified
BlackRock Utilities, Infrastructure & Power Opportunities Trust	BUI	Delaware	Diversified

* The Trust’s classification changed from non-diversified to diversified during the reporting period.

The Boards of Directors and Boards of Trustees of the Trusts are collectively referred to throughout this report as the “Board,” and the trustees thereof are collectively referred to throughout this report as “Trustees”. The Trusts determine and make available for publication the net asset values (“NAVs”) of their Common Shares on a daily basis.

On March 31, 2023, the Board approved a proposal to change the name of BlackRock Innovation and Growth Trust, BlackRock Health Sciences Trust II and BlackRock Science and Technology Trust II , effective as of April 5, 2023, to BlackRock Innovation and Growth Term Trust, BlackRock Health Sciences Term Trust and BlackRock Science and Technology Term Trust, respectively. There were no changes to the Trusts’ investment policies or strategies in conjunction with the name changes.

The Trusts, together with certain other registered investment companies advised by BlackRock Advisors, LLC (the “Manager”) or its affiliates, are included in a complex of funds referred to as the BlackRock Fixed-Income Complex.

Basis of Consolidation: The accompanying consolidated financial statements of BDJ include the accounts of BDJ Subsidiary, LLC (the “BDJ Taxable Subsidiary”), which is a wholly-owned taxable subsidiary of BDJ. The BDJ Taxable Subsidiary enables BDJ to hold certain pass-through investments and satisfy regulated investment company tax requirements. Income earned and gains realized on the investment held by the BDJ Taxable Subsidiary are taxable to such subsidiary. A tax provision for income, if any, is shown as income tax in the Consolidated Statement of Operations for BDJ. A tax provision for realized and unrealized gains, if any, is included as a reduction of realized and/or unrealized gain (loss) in the Consolidated Statement of Operations for BDJ. Taxes payable or deferred as of December 31, 2023, if any, are disclosed in the Consolidated Statements of Assets and Liabilities. BDJ may invest up to 25% of its total assets in the BDJ Taxable Subsidiary. The net assets of the BDJ Taxable Subsidiary as of period end were $10,716,626, which is 0.6% of BDJ’s consolidated net assets. Intercompany accounts and transactions, if any, have been eliminated. The BDJ Taxable Subsidiary is subject to the same investment policies and restrictions that apply to BDJ.

The accompanying consolidated financial statements of BSTZ include the accounts of BSTZ Subsidiary, LLC (the “BSTZ Taxable Subsidiary”), which is a wholly-owned taxable subsidiary of BSTZ. The BSTZ Taxable Subsidiary enables BSTZ to hold certain pass-through investments and satisfy regulated investment company tax requirements. Income earned and gains realized on the investment held by the BSTZ Taxable Subsidiary are taxable to such subsidiary. A tax provision for income, if any, is shown as income tax in the Consolidated Statement of Operations for BSTZ. A tax provision for realized and unrealized gains, if any, is included as a reduction of realized and/or unrealized gain (loss) in the Consolidated Statement of Operations for BSTZ. Taxes payable or deferred as of December 31, 2023, if any, are disclosed in the Consolidated Statements of Assets and Liabilities. BSTZ may invest up to 25% of its total assets in the BSTZ Taxable Subsidiary. The net assets of the BSTZ Taxable Subsidiary as of period end were $21,564,780, which is 1.3% of BSTZ’s consolidated net assets. Intercompany accounts and transactions, if any, have been eliminated. The BSTZ Taxable Subsidiary is subject to the same investment policies and restrictions that apply to BSTZ.

The accompanying consolidated financial statements of BST include the accounts of BST Subsidiary, LLC (the “BST Taxable Subsidiary”), which is a wholly-owned taxable subsidiary of BST. The BST Taxable Subsidiary enables BST to hold certain pass-through investments and satisfy regulated investment company tax requirements. Income earned and gains realized on the investment held by the BST Taxable Subsidiary are taxable to such subsidiary. A tax provision for income, if any, is shown as income tax in the Consolidated Statement of Operations for BST. A tax provision for realized and unrealized gains, if any, is included as a reduction of realized and/or unrealized gain (loss) in the Consolidated Statement of Operations for BST. Taxes payable or deferred as of December 31, 2023, if any, are disclosed in the Consolidated Statements of Assets and Liabilities. BST may invest up to 25% of its total assets in the BST Taxable Subsidiary. The net assets of the BST Taxable Subsidiary as of period end were $11,500,360, which is 0.9% of BST’s consolidated net assets. Intercompany accounts and transactions, if any, have been eliminated. The BST Taxable Subsidiary is subject to the same investment policies and restrictions that apply to BST.

2. SIGNIFICANT ACCOUNTING POLICIES

The financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), which may require management to make estimates and assumptions that affect the reported amounts of assets and liabilities in the financial statements, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of increases and decreases in net assets from operations during the reporting period. Actual results

N O T E S  T O  F I N A N C I A L  S T A T E M E N T S 163

Notes to Financial Statements (continued)

could differ from those estimates. Each Trust is considered an investment company under U.S. GAAP and follows the accounting and reporting guidance applicable to investment companies. Below is a summary of significant accounting policies:

Investment Transactions and Income Recognition: For financial reporting purposes, investment transactions are recorded on the dates the transactions are executed. Realized gains and losses on investment transactions are determined using the specific identification method. Dividend income and capital gain distributions, if any, are recorded on the ex-dividend dates. Non-cash dividends, if any, are recorded on the ex-dividend dates at fair value. Dividends from foreign securities where the ex-dividend dates may have passed are subsequently recorded when the Trusts are informed of the ex-dividend dates. Under the applicable foreign tax laws, a withholding tax at various rates may be imposed on capital gains, dividends and interest. Upon notification from issuers, a portion of the dividend income received from a real estate investment trust may be redesignated as a reduction of cost of the related investment and/or realized gain. Interest income, including amortization and accretion of premiums and discounts on debt securities, is recognized daily on an accrual basis.

Foreign Currency Translation: Each Trust’s books and records are maintained in U.S. dollars. Securities and other assets and liabilities denominated in foreign currencies are translated into U.S. dollars using exchange rates determined as of the close of trading on the New York Stock Exchange (“NYSE”). Purchases and sales of investments are recorded at the rates of exchange prevailing on the respective dates of such transactions. Generally, when the U.S. dollar rises in value against a foreign currency, the investments denominated in that currency will lose value; the opposite effect occurs if the U.S. dollar falls in relative value.

Each Trust does not isolate the effect of fluctuations in foreign exchange rates from the effect of fluctuations in the market prices of investments for financial reporting purposes. Accordingly, the effects of changes in exchange rates on investments are not segregated in the Statements of Operations from the effects of changes in market prices of those investments, but are included as a component of net realized and unrealized gain (loss) from investments. Each Trust reports realized currency gains (losses) on foreign currency related transactions as components of net realized gain (loss) for financial reporting purposes, whereas such components are generally treated as ordinary income for U.S. federal income tax purposes.

ForeignTaxes: The Trusts may be subject to foreign taxes (a portion of which may be reclaimable) on income, stock dividends, capital gains on investments, or certain foreign currency transactions. All foreign taxes are recorded in accordance with the applicable foreign tax regulations and rates that exist in the foreign jurisdictions in which each Trust invests. These foreign taxes, if any, are paid by each Trust and are reflected in its Statements of Operations as follows: foreign taxes withheld at source are presented as a reduction of income, foreign taxes on securities lending income are presented as a reduction of securities lending income, foreign taxes on stock dividends are presented as “Foreign taxes withheld”, and foreign taxes on capital gains from sales of investments and foreign taxes on foreign currency transactions are included in their respective net realized gain (loss) categories. Foreign taxes payable or deferred as of December 31, 2023, if any, are disclosed in the Statements of Assets and Liabilities.

The Trusts file withholding tax reclaims in certain jurisdictions to recover a portion of amounts previously withheld. The Trusts may record a reclaim receivable based on collectability, which includes factors such as the jurisdiction’s applicable laws, payment history and market convention. The Statements of Operations include tax reclaims recorded as well as professional and other fees, if any, associated with recovery of foreign withholding taxes.

Bank Overdraft: The Trusts had outstanding cash disbursements exceeding deposited cash amounts at the custodian during the reporting period and as of the report date. The Trusts are obligated to repay the custodian for any overdraft, including any related costs or expenses, where applicable. For financial reporting purposes, overdraft fees, if any, are included in interest expense in the Statements of Operations.

Collateralization: If required by an exchange or counterparty agreement, the Trusts may be required to deliver/deposit cash and/or securities to/with an exchange, or broker-dealer or custodian as collateral for certain investments.

Distributions: Distributions paid by the Trusts are recorded on the ex-dividend dates. Subject to the Trusts’ managed distribution plan, the Trusts intend to make monthly cash distributions to shareholders, which may consist of net investment income, and net realized and unrealized gains on investments and/or return of capital.

The character of distributions is determined in accordance with U.S. federal income tax regulations, which may differ from U.S. GAAP. The portion of distributions that exceeds a Trust’s current and accumulated earnings and profits, which are measured on a tax basis, will constitute a non-taxable return of capital. See Income Tax Information note for the tax character of each Trust’s distributions paid during the year.

Deferred Compensation Plan: Under the Deferred Compensation Plan (the “Plan”) approved by each Trust’s Board, the trustees who are not “interested persons” of the Trusts, as defined in the 1940 Act (“Independent Trustees”), may defer a portion of their annual complex-wide compensation. Deferred amounts earn an approximate return as though equivalent dollar amounts had been invested in common shares of certain funds in the BlackRock Fixed-Income Complex selected by the Independent Trustees. This has the same economic effect for the Independent Trustees as if the Independent Trustees had invested the deferred amounts directly in certain funds in the BlackRock Fixed-Income Complex.

The Plan is not funded and obligations thereunder represent general unsecured claims against the general assets of each Trust, as applicable. Deferred compensation liabilities, if any, are included in the Trustees’ and Officer’s fees payable in the Statements of Assets and Liabilities and will remain as a liability of the Trusts until such amounts are distributed in accordance with the Plan. Net appreciation (depreciation) in the value of participants’ deferral accounts is allocated among the participating funds in the BlackRock Fixed-Income Complex and reflected as Trustees and Officer expense on the Statements of Operations. The Trustees and Officer expense may be negative as a result of a decrease in value of the deferred accounts.

Indemnifications: In the normal course of business, a Trust enters into contracts that contain a variety of representations that provide general indemnification. A Trust’s maximum exposure under these arrangements is unknown because it involves future potential claims against a Trust, which cannot be predicted with any certainty.

Other: Expenses directly related to a Trust are charged to that Trust. Other operating expenses shared by several funds, including other funds managed by the Manager, are prorated among those funds on the basis of relative net assets or other appropriate methods.

164 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Notes to Financial Statements (continued)

3. INVESTMENT VALUATION AND FAIR VALUE MEASUREMENTS

Investment Valuation Policies: Each Trust’s investments are valued at fair value (also referred to as “market value” within the financial statements) each day that the Trust is open for business and, for financial reporting purposes, as of the report date. U.S. GAAP defines fair value as the price a fund would receive to sell an asset or pay to transfer a liability in an orderly transaction between market participants at the measurement date. The Board has approved the designation of each Trust’s Manager as the valuation designee for each Trust. Each Trust determines the fair values of its financial instruments using various independent dealers or pricing services under the Manager’s policies. If a security’s market price is not readily available or does not otherwise accurately represent the fair value of the security, the security will be valued in accordance with the Manager’s policies and procedures as reflecting fair value. The Manager has formed a committee (the “Valuation Committee”) to develop pricing policies and procedures and to oversee the pricing function for all financial instruments, with assistance from other BlackRock pricing committees.

Fair Value Inputs and Methodologies: The following methods and inputs are used to establish the fair value of each Trust’s assets and liabilities:

• Equity investments traded on a recognized securities exchange are valued at that day’s official closing price, as applicable, on the exchange where the stock is primarily traded. Equity investments traded on a recognized exchange for which there were no sales on that day may be valued at the last available bid (long positions) or ask (short positions) price.

• Fixed-income investments for which market quotations are readily available are generally valued using the last available bid price or current market quotations provided by independent dealers or third-party pricing services. Pricing services generally value fixed-income securities assuming orderly transactions of an institutional round lot size, but a fund may hold or transact in such securities in smaller, odd lot sizes. Odd lots may trade at lower prices than institutional round lots. The pricing services may use matrix pricing or valuation models that utilize certain inputs and assumptions to derive values, including transaction data (e.g., recent representative bids and offers), market data, credit quality information, perceived market movements, news, and other relevant information. Certain fixed-income securities, including asset-backed and mortgage related securities may be valued based on valuation models that consider the estimated cash flows of each tranche of the entity, establish a benchmark yield and develop an estimated tranche specific spread to the benchmark yield based on the unique attributes of the tranche. The amortized cost method of valuation may be used with respect to debt obligations with sixty days or less remaining to maturity unless the Manager determines such method does not represent fair value.

• Investments in open-end U.S. mutual funds (including money market funds) are valued at that day’s published NAV.

• The Trusts value their investment in SL Liquidity Series, LLC, Money Market Series (the “Money Market Series”) at fair value, which is ordinarily based upon their pro rata ownership in the underlying fund’s net assets.

• Forward foreign currency exchange contracts are valued at the mean between the bid and ask prices and are determined as of the close of trading on the NYSE based on that day’s prevailing forward exchange rate for the underlying currencies.

• Exchange-traded options are valued at the mean between the last bid and ask prices at the close of the options market in which the options trade. An exchange-traded option for which there is no mean price is valued at the last bid (long positions) or ask (short positions) price. If no bid or ask price is available, the prior day’s price will be used, unless it is determined that the prior day’s price no longer reflects the fair value of the option. Over-the-counter (“OTC”) options and options on swaps (“swaptions”) are valued by an independent pricing service using a mathematical model, which incorporates a number of market data factors, such as the trades and prices of the underlying instruments.

Generally, trading in foreign instruments is substantially completed each day at various times prior to the close of trading on the NYSE. Each business day, the Trusts use current market factors supplied by independent pricing services to value certain foreign instruments (“Systematic Fair Value Price”). The Systematic Fair Value Price is designed to value such foreign securities at fair value as of the close of trading on the NYSE, which follows the close of the local markets.

If events (e.g., market volatility, company announcement or a natural disaster) occur that are expected to materially affect the value of such investment, or in the event that application of these methods of valuation results in a price for an investment that is deemed not to be representative of the market value of such investment, or if a price is not available, the investment will be valued by the Valuation Committee in accordance with the Manager’s policies and procedures as reflecting fair value (“Fair Valued Investments”). The fair valuation approaches that may be used by the Valuation Committee include market approach, income approach and cost approach. Valuation techniques such as discounted cash flow, use of market comparables and matrix pricing are types of valuation approaches and are typically used in determining fair value. When determining the price for Fair Valued Investments, the Valuation Committee seeks to determine the price that each Trust might reasonably expect to receive or pay from the current sale or purchase of that asset or liability in an arm’s-length transaction. Fair value determinations shall be based upon all available factors that the Valuation Committee deems relevant and consistent with the principles of fair value measurement.

For investments in equity or debt issued by privately held companies or funds (“Private Company” or collectively, the “Private Companies”) and other Fair Valued Investments, the fair valuation approaches that are used by the Valuation Committee and third-party pricing services utilized by the Valuation Committee include one or a combination of, but not limited to, the following inputs.

	Standard Inputs Generally Considered By The Valuation Committee And Third-Party Pricing Services
Market approach	(i)  recent market transactions, including subsequent rounds of financing, in the underlying investment or comparable issuers; (ii) recapitalizations and other transactions across the capital structure; and (iii)   market multiples of comparable issuers.
Income approach	(i)  future cash flows discounted to present and adjusted as appropriate for liquidity, credit, and/or market risks; (ii) quoted prices for similar investments or assets in active markets; and

N O T E S  T O  F I N A N C I A L  S T A T E M E N T S 165

Notes to Financial Statements (continued)

	Standard Inputs Generally Considered By The Valuation Committee And Third-Party Pricing Services
	(iii)   other risk factors, such as interest rates, yield curves, volatilities, prepayment speeds, loss severities, credit risks, recovery rates, liquidation amounts and/or default rates.
Cost approach	(i)  audited or unaudited financial statements, investor communications and financial or operational metrics issued by the Private Company; (ii) changes in the valuation of relevant indices or publicly traded companies comparable to the Private Company; (iii)   relevant news and other public sources; and (iv)   known secondary market transactions in the Private Company’s interests and merger or acquisition activity in companies comparable to the Private Company.

Investments in series of preferred stock issued by Private Companies are typically valued utilizing market approach in determining the enterprise value of the company. Such investments often contain rights and preferences that differ from other series of preferred and common stock of the same issuer. Enterprise valuation techniques such as an option pricing model (“OPM”), a probability weighted expected return model (“PWERM”), current value method or a hybrid of those techniques are used as deemed appropriate under the circumstances. The use of these valuation techniques involves a determination of the exit scenarios of the investment in order to appropriately allocate the enterprise value of the company among the various parts of its capital structure.

The Private Companies are not subject to the public company disclosure, timing, and reporting standards applicable to other investments held by a Trust. Typically, the most recently available information by a Private Company is as of a date that is earlier than the date a Trust is calculating its NAV. This factor may result in a difference between the value of the investment and the price a Trust could receive upon the sale of the investment.

Fair Value Hierarchy: Various inputs are used in determining the fair value of financial instruments. These inputs to valuation techniques are categorized into a fair value hierarchy consisting of three broad levels for financial reporting purposes as follows:

• Level 1 – Unadjusted price quotations in active markets/exchanges for identical assets or liabilities that each Trust has the ability to access;

• Level 2 – Other observable inputs (including, but not limited to, quoted prices for similar assets or liabilities in markets that are active, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the assets or liabilities (such as interest rates, yield curves, volatilities, prepayment speeds, loss severities, credit risks and default rates) or other market–corroborated inputs); and

• Level 3 – Unobservable inputs based on the best information available in the circumstances, to the extent observable inputs are not available (including the Valuation Committee’s assumptions used in determining the fair value of financial instruments).

The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). Accordingly, the degree of judgment exercised in determining fair value is greatest for instruments categorized in Level 3. The inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the fair value hierarchy classification is determined based on the lowest level input that is significant to the fair value measurement in its entirety. Investments classified within Level 3 have significant unobservable inputs used by the Valuation Committee in determining the price for Fair Valued Investments. Level 3 investments include equity or debt issued by Private Companies that may not have a secondary market and/or may have a limited number of investors. The categorization of a value determined for financial instruments is based on the pricing transparency of the financial instruments and is not necessarily an indication of the risks associated with investing in those securities.

As of December 31, 2023, certain investments of CII, BMEZ, BIGZ, BCX, BSTZ, BST and BUI were fair valued using NAV as a practical expedient as no quoted market value is available and therefore have been excluded from the fair value hierarchy.

4. SECURITIES AND OTHER INVESTMENTS

Preferred Stocks: Preferred stock has a preference over common stock in liquidation (and generally in receiving dividends as well), but is subordinated to the liabilities of the issuer in all respects. As a general rule, the market value of preferred stock with a fixed dividend rate and no conversion element varies inversely with interest rates and perceived credit risk, while the market price of convertible preferred stock generally also reflects some element of conversion value. Because preferred stock is junior to debt securities and other obligations of the issuer, deterioration in the credit quality of the issuer will cause greater changes in the value of a preferred stock than in a more senior debt security with similar stated yield characteristics. Unlike interest payments on debt securities, preferred stock dividends are payable only if declared by the issuer’s board of directors. Preferred stock also may be subject to optional or mandatory redemption provisions.

Warrants: Warrants entitle a fund to purchase a specified number of shares of common stock and are non-income producing. The purchase price and number of shares are subject to adjustment under certain conditions until the expiration date of the warrants, if any. If the price of the underlying stock does not rise above the strike price before the warrant expires, the warrant generally expires without any value and a fund will lose any amount it paid for the warrant. Thus, investments in warrants may involve more risk than investments in common stock. Warrants may trade in the same markets as their underlying stock; however, the price of the warrant does not necessarily move with the price of the underlying stock.

Commitments: Commitments are agreements to acquire an investment at a future date (subject to conditions) in connection with a potential public or non-public offering. Such agreements may obligate a fund to make future cash payments. As of December 31, 2023, BDJ had outstanding commitments of $7,443,073. These commitments are not included in the net assets of BDJ as of December 31, 2023.

Securities Lending: Certain Trusts may lend their securities to approved borrowers, such as brokers, dealers and other financial institutions. The borrower pledges and maintains with the Trusts collateral consisting of cash, an irrevocable letter of credit issued by a bank, or securities issued or guaranteed by the U.S. Government. The initial

166 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Notes to Financial Statements (continued)

collateral received by each Trust is required to have a value of at least 102% of the current value of the loaned securities for securities traded on U.S. exchanges and a value of at least 105% for all other securities. The collateral is maintained thereafter at a value equal to at least 100% of the current market value of the securities on loan. The market value of the loaned securities is determined at the close of each business day of the Trust and any additional required collateral is delivered to the Trust, or excess collateral returned by the Trust, on the next business day. During the term of the loan, the Trusts are entitled to all distributions made on or in respect of the loaned securities, but do not receive interest income on securities received as collateral. Loans of securities are terminable at any time and the borrower, after notice, is required to return borrowed securities within the standard time period for settlement of securities transactions.

As of period end, any securities on loan were collateralized by cash and/or U.S. Government obligations. Cash collateral invested by the securities lending agent, BlackRock Investment Management, LLC (“BIM”), if any, is disclosed in the Schedules of Investments. Any non-cash collateral received cannot be sold, re-invested or pledged by the Trust, except in the event of borrower default. The securities on loan, if any, are disclosed in the Trusts’ Schedules of Investments. The market value of any securities on loan and the value of related collateral, if any, are shown separately in the Statements of Assets and Liabilities as a component of investments at value – unaffiliated and collateral on securities loaned, respectively.

Securities lending transactions are entered into by the Trusts under Master Securities Lending Agreements (each, an “MSLA”), which provide the right, in the event of default (including bankruptcy or insolvency), for the non-defaulting party to liquidate the collateral and calculate a net exposure to the defaulting party or request additional collateral. In the event that a borrower defaults, the Trusts, as lender, would offset the market value of the collateral received against the market value of the securities loaned. When the value of the collateral is greater than that of the market value of the securities loaned, the lender is left with a net amount payable to the defaulting party. However, bankruptcy or insolvency laws of a particular jurisdiction may impose restrictions on or prohibitions against such a right of offset in the event of an MSLA counterparty’s bankruptcy or insolvency. Under the MSLA, absent an event of default, the borrower can resell or re-pledge the loaned securities, and the Trusts can reinvest cash collateral received in connection with loaned securities. Upon an event of default, the parties’ obligations to return the securities or collateral to the other party are extinguished, and the parties can resell or re-pledge the loaned securities or the collateral received in connection with the loaned securities in order to satisfy the defaulting party’s net payment obligation for all transactions under the MSLA. The defaulting party remains liable for any deficiency.

As of period end, the following table is a summary of the Trusts’ securities on loan by counterparty which are subject to offset under an MSLA:

Trust Name/Counterparty		Securities Loaned at Value		Cash Collateral Received	(a)		Non-Cash Collateral Received, at Fair Value	(a)		Net Amount
CII
Citigroup Global Markets, Inc.	$	388,229	$	(388,229	)	$	—		$	—
Credit Suisse Securities (USA) LLC		1,699		(1,699	)		—			—
	$	389,928	$	(389,928	)	$	—		$	—
BMEZ
Barclays Capital, Inc.	$	229,896	$	(229,896	)	$	—		$	—
BofA Securities, Inc.		16,500		(16,500	)		—			—
Citigroup Global Markets, Inc.		6,461,660		(6,461,660	)		—			—
Goldman Sachs & Co. LLC		2,252,539		(2,252,539	)		—			—
Morgan Stanley		2,115,151		(2,115,151	)		—			—
National Financial Services LLC		785,307		(785,307	)		—			—
Toronto-Dominion Bank		1,688		(1,688	)		—			—
	$	11,862,741	$	(11,862,741	)	$	—		$	—
BIGZ
Barclays Capital, Inc.	$	3,929,480	$	(3,929,480	)	$	—		$	—
J.P. Morgan Securities LLC		1,959,182		(1,959,182	)		—			—
Morgan Stanley		1,518,708		(1,518,708	)		—			—
State Street Bank & Trust Co.		9,985,344		(9,985,344	)		—			—
Toronto-Dominion Bank		2,280,275		(2,280,275	)		—			—
	$	19,672,989	$	(19,672,989	)	$	—		$	—
BCX
Citigroup Global Markets, Inc.	$	3,633,437	$	(3,633,437	)	$	—		$	—
Credit Suisse Securities (USA) LLC		312,291		(312,291	)		—			—
J.P. Morgan Securities LLC		1,854,548		(1,854,548	)		—			—
Morgan Stanley		156,145		(156,145	)		—			—
	$	5,956,421	$	(5,956,421	)	$	—		$	—
BSTZ
Goldman Sachs & Co. LLC	$	825,664	$	(825,664	)	$	—		$	—
J.P. Morgan Securities LLC		69,960		(69,960	)		—			—
Morgan Stanley		1,743,364		(1,743,364	)		—			—
State Street Bank & Trust Co.		95,671		(95,671	)		—			—
	$	2,734,659	$	(2,734,659	)	$	—		$	—
BST
Citigroup Global Markets, Inc.	$	1,022,125	$	(1,022,125	)	$	—		$	—

N O T E S  T O  F I N A N C I A L  S T A T E M E N T S 167

Notes to Financial Statements (continued)

Trust Name/Counterparty		Securities Loaned at Value		Cash Collateral Received	(a)		Non-Cash Collateral Received, at Fair Value	(a)		Net Amount
BST (continued)
J.P. Morgan Securities LLC	$	3,687,666	$	(3,687,666	)	$	—		$	—
Toronto-Dominion Bank		864,690		(864,690	)		—			—
	$	5,574,481	$	(5,574,481	)	$	—		$	—
BUI
Barclays Capital, Inc.	$	1,040,726	$	(1,040,726	)	$	—		$	—
Goldman Sachs & Co. LLC		23,607		(23,607	)		—			—
Morgan Stanley		196,725		(196,725	)		—			—
	$	1,261,058	$	(1,261,058	)	$	—		$	—

^(a)  Collateral received, if any, in excess of the market value of securities on loan is not presented in this table. The total cash collateral received by each Trust is disclosed in the Trust’s Statements of Assets and Liabilities.

The risks of securities lending include the risk that the borrower may not provide additional collateral when required or may not return the securities when due. To mitigate these risks, the Trusts benefit from a borrower default indemnity provided by BIM. BIM’s indemnity allows for full replacement of the securities loaned to the extent the collateral received does not cover the value on the securities loaned in the event of borrower default. Each Trust could incur a loss if the value of an investment purchased with cash collateral falls below the market value of loaned securities or if the value of an investment purchased with cash collateral falls below the value of the original cash collateral received. Such losses are borne entirely by the Trusts.

5. DERIVATIVE FINANCIAL INSTRUMENTS

The Trusts engage in various portfolio investment strategies using derivative contracts both to increase the returns of the Trusts and/or to manage their exposure to certain risks such as credit risk, equity risk, interest rate risk, foreign currency exchange rate risk, commodity price risk or other risks (e.g., inflation risk). Derivative financial instruments categorized by risk exposure are included in the Schedules of Investments. These contracts may be transacted on an exchange or OTC.

Forward Foreign Currency Exchange Contracts: Forward foreign currency exchange contracts are entered into to gain or reduce exposure to foreign currencies (foreign currency exchange rate risk).

A forward foreign currency exchange contract is an agreement between two parties to buy and sell a currency at a set exchange rate on a specified date. These contracts help to manage the overall exposure to the currencies in which some of the investments held by the Trusts are denominated and in some cases, may be used to obtain exposure to a particular market. The contracts are traded OTC and not on an organized exchange.

The contract is marked-to-market daily and the change in market value is recorded as unrealized appreciation (depreciation) in the Statements of Assets and Liabilities. When a contract is closed, a realized gain or loss is recorded in the Statements of Operations equal to the difference between the value at the time it was opened and the value at the time it was closed. Non-deliverable forward foreign currency exchange contracts are settled with the counterparty in cash without the delivery of foreign currency. The use of forward foreign currency exchange contracts involves the risk that the value of a forward foreign currency exchange contract changes unfavorably due to movements in the value of the referenced foreign currencies, and such value may exceed the amount(s) reflected in the Statements of Assets and Liabilities. Cash amounts pledged for forward foreign currency exchange contracts are considered restricted and are included in cash pledged as collateral for OTC derivatives in the Statements of Assets and Liabilities. The Trust’s risk of loss from counterparty credit risk on OTC derivatives is generally limited to the aggregate unrealized gain netted against any collateral held by the Trust.

Options: The Trusts may purchase and write call and put options to increase or decrease their exposure to the risks of underlying instruments, including equity risk, interest rate risk and/or commodity price risk and/or, in the case of options written, to generate gains from options premiums.

A call option gives the purchaser (holder) of the option the right (but not the obligation) to buy, and obligates the seller (writer) to sell (when the option is exercised) the underlying instrument at the exercise or strike price at any time or at a specified time during the option period. A put option gives the holder the right to sell and obligates the writer to buy the underlying instrument at the exercise or strike price at any time or at a specified time during the option period.

Premiums paid on options purchased and premiums received on options written, as well as the daily fluctuation in market value, are included in investments at value – unaffiliated and options written at value, respectively, in the Statements of Assets and Liabilities. When an instrument is purchased or sold through the exercise of an option, the premium is offset against the cost or proceeds of the underlying instrument. When an option expires, a realized gain or loss is recorded in the Statements of Operations to the extent of the premiums received or paid. When an option is closed or sold, a gain or loss is recorded in the Statements of Operations to the extent the cost of the closing transaction exceeds the premiums received or paid. When the Trusts write a call option, such option is typically “covered,” meaning that they hold the underlying instrument subject to being called by the option counterparty. When the Trusts write a put option, cash is segregated in an amount sufficient to cover the obligation. These amounts, which are considered restricted, are included in cash pledged as collateral for options written in the Statements of Assets and Liabilities.

In purchasing and writing options, the Trusts bear the risk of an unfavorable change in the value of the underlying instrument or the risk that they may not be able to enter into a closing transaction due to an illiquid market. Exercise of a written option could result in the Trusts purchasing or selling a security when they otherwise would not, or at a price different from the current market value.

Master Netting Arrangements: In order to define its contractual rights and to secure rights that will help it mitigate its counterparty risk, a Trust may enter into an International Swaps and Derivatives Association, Inc. Master Agreement (“ISDA Master Agreement”) or similar agreement with its derivative contract counterparties. An ISDA Master Agreement is a bilateral agreement between a Trust and a counterparty that governs certain OTC derivatives and typically contains, among other things, collateral posting

168 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Notes to Financial Statements (continued)

terms and netting provisions in the event of a default and/or termination event. Under an ISDA Master Agreement, a Trust may, under certain circumstances, offset with the counterparty certain derivative financial instruments’ payables and/or receivables with collateral held and/or posted and create one single net payment. The provisions of the ISDA Master Agreement typically permit a single net payment in the event of default including the bankruptcy or insolvency of the counterparty. However, bankruptcy or insolvency laws of a particular jurisdiction may impose restrictions on or prohibitions against the right of offset in bankruptcy, insolvency or other events.

Collateral Requirements: For derivatives traded under an ISDA Master Agreement, the collateral requirements are typically calculated by netting the mark-to-market amount for each transaction under such agreement and comparing that amount to the value of any collateral currently pledged by the Trusts and the counterparty.

Cash collateral that has been pledged to cover obligations of the Trusts and cash collateral received from the counterparty, if any, is reported separately in the Statements of Assets and Liabilities as cash pledged as collateral and cash received as collateral, respectively. Non-cash collateral pledged by the Trusts, if any, is noted in the Schedules of Investments. Generally, the amount of collateral due from or to a counterparty is subject to a certain minimum transfer amount threshold before a transfer is required, which is determined at the close of business of the Trusts. Any additional required collateral is delivered to/pledged by the Trusts on the next business day. Typically, the counterparty is not permitted to sell, re-pledge or use cash and non-cash collateral it receives. A Trust generally agrees not to use non-cash collateral that it receives but may, absent default or certain other circumstances defined in the underlying ISDA Master Agreement, be permitted to use cash collateral received. In such cases, interest may be paid pursuant to the collateral arrangement with the counterparty. To the extent amounts due to the Trusts from the counterparties are not fully collateralized, each Trust bears the risk of loss from counterparty non-performance. Likewise, to the extent the Trusts have delivered collateral to a counterparty and stand ready to perform under the terms of their agreement with such counterparty, each Trust bears the risk of loss from a counterparty in the amount of the value of the collateral in the event the counterparty fails to return such collateral. Based on the terms of agreements, collateral may not be required for all derivative contracts.

For financial reporting purposes, the Trusts do not offset derivative assets and derivative liabilities that are subject to netting arrangements, if any, in the Statements of Assets and Liabilities.

6. INVESTMENT ADVISORY AGREEMENT AND OTHER TRANSACTIONS WITH AFFILIATES

Investment Advisory: Each Trust entered into an Investment Advisory Agreement with the Manager, the Trusts’ investment adviser and an indirect, wholly-owned subsidiary of BlackRock, Inc. (“BlackRock”), to provide investment advisory and administrative services. The Manager is responsible for the management of each Trust’s portfolio and provides the personnel, facilities, equipment and certain other services necessary to the operations of each Trust.

For such services, each Trust, except BCX, pays the Manager a monthly fee at the following annual rates:

Average weekly value of each Trust’s net assets:

	BGR			BDJ			BOE			BME
Investment advisory fees		1.20	%		0.80	%		1.00	%		1.00	%

Average daily value of each Trust’s net assets, plus the proceeds of any outstanding debt securities or borrowings for leverage:

	CII
Investment advisory fees		0.85	%

Average daily value of each Trust’s net assets:

	BGY			BUI
Investment advisory fees		1.00	%		1.00	%

Average daily value of each Trust’s managed assets:

	BMEZ			BIGZ			BSTZ			BST
Investment advisory fees		1.25	%		1.25	%		1.25	%		1.00	%

For such services, BCX pays the Manager a monthly fee at an annual rate equal to 1.00% of the sum of the average daily value of the net assets of the Trust (excluding the value of the Trust’s interest in the BCX Subsidiary, LLC (the “BCX Taxable Subsidiary”), which is a wholly-owned taxable subsidiary of BCX) and the average daily value of the net assets of its subsidiary, which fee is allocated pro rata between the Trust and the BCX Taxable Subsidiary based on the average daily value of their respective net assets (excluding, in the case of the Trust, the value of the Trust’s interest in the BCX Taxable Subsidiary). The BCX Taxable Subsidiary had no net assets or activity during the period ended December 31, 2023.

For purposes of calculating these fees, “net assets” mean the total assets of BGR, CII, BDJ, BOE, BGY, BME, BCX and BUI minus the sum of its accrued liabilities.

For purposes of calculating these fees, “managed assets” are determined as total assets of BMEZ, BIGZ, BSTZ and BST (including any assets attributable to money borrowed for investment purposes) less the sum of its accrued liabilities (other than money borrowed for investment purposes).

The Manager provides investment management and other services to BDJ Taxable Subsidiary, BSTZ Taxable Subsidiary and BST Taxable Subsidiary. The Manager does not receive separate compensation from the BDJ Taxable Subsidiary, BSTZ Taxable Subsidiary or BST Taxable Subsidiary for providing investment management or administrative services. However, BDJ pays the Manager based on the Trust’s net assets, which includes the assets of the BDJ Taxable Subsidiary, and BSTZ and BST pay the Manager based on the Trust’s managed assets, which includes the assets of the BSTZ Taxable Subsidiary and BST Taxable Subsidiary, respectively.

N O T E S  T O  F I N A N C I A L  S T A T E M E N T S 169

Notes to Financial Statements (continued)

With respect to BGR, BOE, BGY, BCX and BUI, the Manager entered into separate sub-advisory agreements with BlackRock International Limited (“BIL”), an affiliate of the Manager. The Manager pays BIL for services it provides for that portion of each Trust for which BIL acts as sub-adviser, a monthly fee that is equal to a percentage of the investment advisory fees paid by each Trust to the Manager.

Distribution Fees: BDJ, BME, BST and BUI have each entered into Distribution Agreements with BlackRock Investments, LLC (“BRIL”), an affiliate of the Manager, to provide for distribution of BDJ’s, BME’s, BST’s and BUI’s common shares on a reasonable best efforts basis through an equity shelf offering (a “Shelf Offering”) (the “Distribution Agreement”). Pursuant to the Distribution Agreement, BRIL will receive commissions with respect to sales of common shares at a commission rate of 1.00% of the gross proceeds of the sale of BDJ’s, BME’s, BST’s and BUI’s common shares and a portion of such commission is re-allowed to broker-dealers engaged by BRIL. The commissions retained by BRIL during the year ended December 31, 2023 amounted to $0, $6,106, $84,111 and $7,641 for each of BDJ, BME, BST and BUI, respectively.

Expense Limitations, Waivers and Reimbursements: The Manager voluntarily agreed to waive a portion of the investment advisory fees on the following Trusts as a percentage of their average weekly net assets, as follows:

BGR			BOE
	0.220	%		0.175	%

These voluntary waivers may be reduced or discontinued at any time without notice.

For the year ended December 31, 2023, the investment advisory fees waived, which are included in fees waived and/or reimbursed by the Manager in the Statements of Operations, were as follows:

Trust Name	Fees Waived and/or Reimbursed by the Manager
BGR	$	861,964
BOE		1,239,614

With respect to each Trust, the Manager contractually agreed to waive its investment advisory fees by the amount of investment advisory fees each Trust pays to the Manager indirectly through its investment in affiliated money market funds (the “affiliated money market fund waiver”) through June 30, 2025. The contractual agreement may be terminated upon 90 days’ notice by a majority of the Independent trustees, or by a vote of a majority of the outstanding voting securities of a Trust. These amounts are included in fees waived and/or reimbursed by the Manager in the Statements of Operations. For the year ended December 31, 2023, the amounts waived were as follows:

Trust Name	Fees Waived and/or Reimbursed by the Manager
BGR	$	4,561
CII		9,345
BDJ		42,031
BOE		6,630
BGY		7,794
BMEZ		42,748
BME		19,166
BIGZ		6,701
BCX		18,912
BSTZ		5,929
BST		5,407
BUI		8,011

The Manager contractually agreed to waive its investment advisory fee with respect to any portion of each Trust’s assets invested in affiliated equity and fixed-income mutual funds and affiliated exchange-traded funds that have a contractual management fee through June 30, 2025. The agreement can be renewed for annual periods thereafter, and may be terminated on 90 days’ notice, each subject to approval by a majority of the Trusts’ Independent Trustees. For the year ended December 31, 2023, there were no fees waived by the Manager pursuant to this arrangement.

Securities Lending: The U.S. Securities and Exchange Commission (“SEC”) has issued an exemptive order which permits BIM, an affiliate of the Manager, to serve as securities lending agent for the Trusts, subject to applicable conditions. As securities lending agent, BIM bears all operational costs directly related to securities lending. The Trusts are responsible for expenses in connection with the investment of cash collateral received for securities on loan (the “collateral investment expenses”). The cash collateral is invested in a private investment company, Money Market Series, managed by the Manager or its affiliates. However, BIM has agreed to cap the collateral investment expenses of the Money Market Series to an annual rate of 0.04%. The investment adviser to the Money Market Series will not charge any advisory fees with respect to shares purchased by the Trusts. The Money Market Series may impose a discretionary liquidity fee of up to 2% of the value withdrawn, if such fee is determined to be in the best interests of the Money Market Series. The Money Market Series seeks current income consistent with maintaining liquidity and preserving capital. Although the Money Market Series is not registered under the 1940 Act, its investments may follow the parameters of investments by a money market fund that is subject to Rule 2a-7 under the 1940 Act.

Securities lending income is equal to the total of income earned from the reinvestment of cash collateral, net of fees and other payments to and from borrowers of securities, and less the collateral investment expenses. Each Trust retains a portion of securities lending income and remits a remaining portion to BIM as compensation for its services as securities lending agent.

170 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Notes to Financial Statements (continued)

Pursuant to the current securities lending agreement, each of CII, BDJ, BMEZ, BME, BIGZ and BST retains 81% of securities lending income (which excludes collateral investment expenses), and this amount retained can never be less than 70% of the total of securities lending income plus the collateral investment expenses.

In addition, commencing the business day following the date that the aggregate securities lending income earned across the BlackRock Fixed-Income Complex in a calendar year exceeds a specified threshold, each of CII, BDJ, BMEZ, BME, BIGZ and BST, pursuant to the securities lending agreement, will retain for the remainder of that calendar year securities lending income in an amount equal to 81% of securities lending income (which excludes collateral investment expenses), and this amount retained can never be less than 70% of the total of securities lending income plus the collateral investment expenses.

Pursuant to the current securities lending agreement, each of BGR, BOE, BGY, BCX, BSTZ and BUI retains 82% of securities lending income (which excludes collateral investment expenses), and this amount retained can never be less than 70% of the total of securities lending income plus the collateral investment expenses.

In addition, commencing the business day following the date that the aggregate securities lending income earned across the BlackRock Fixed-Income Complex in a calendar year exceeds a specified threshold, each of BGR, BOE, BGY, BCX, BSTZ and BUI, pursuant to the securities lending agreement, will retain for the remainder of that calendar year securities lending income in an amount equal to 85% of securities lending income (which excludes collateral investment expenses), and this amount retained can never be less than 70% of the total of securities lending income plus the collateral investment expenses.

Prior to January 1, 2023, BIM was permitted to lend each Trust’s securities only when the difference between the borrower rebate rate (i.e., a negotiated interest rate payment for cash collateral pledged in connection with a securities lending transaction) and the risk free rate exceeded a certain level (such securities, the “specials only securities”). Effective January 1, 2023, this limitation no longer applies.

The share of securities lending income earned by each Trust is shown as securities lending income — affiliated — net in the Statements of Operations. For the year ended December 31, 2023, each Trust paid BIM the following amounts for securities lending agent services:

Trust Name	Amounts
CII	$	1,530
BDJ		230
BOE		566
BMEZ		107,504
BME		5,993
BIGZ		14,292
BCX		3,731
BSTZ		15,199
BST		3,859
BUI		2,253

Trustees and Officers: Certain trustees and/or officers of the Trusts are directors and/or officers of BlackRock or its affiliates. The Trusts reimburse the Manager for a portion of the compensation paid to the Trusts’ Chief Compliance Officer, which is included in Trustees and Officer in the Statements of Operations.

Other Transactions: During the period ended December 31, 2023, BSTZ received a reimbursement of $127,092, from an affiliate, which is included in payment by affiliate in the Statements of Operations, related to an operating event.

The Trusts may purchase securities from, or sell securities to, an affiliated fund provided the affiliation is due solely to having a common investment adviser, common officers, or common trustees. For the year ended December 31, 2023, the purchase and sale transactions and any net realized gains (losses) with affiliated funds in compliance with Rule 17a-7 under the 1940 Act were as follows:

Trust Name	Purchases		Sales		Net Realized Gain (Loss)
BOE	$	—	$	1,624,132	$	48,460
BGY		2,972,174		—		—
BUI		261,340		—		—

7. PURCHASES AND SALES

For the year ended December 31, 2023, purchases and sales of investments, excluding short-term securities, were as follows:

Trust Name	Purchases		Sales
BGR	$	146,537,617	$	155,743,276
CII		235,741,075		299,421,903
BDJ		689,480,343		734,197,999
BOE		322,976,129		363,804,994
BGY		337,874,205		378,018,464
BMEZ		1,209,309,621		1,388,053,476
BME		241,292,839		275,704,754
BIGZ		761,816,098		1,000,525,033
BCX		415,902,973		448,984,371
BSTZ		607,642,765		812,220,813

N O T E S  T O  F I N A N C I A L  S T A T E M E N T S 171

Notes to Financial Statements (continued)

Trust Name	Purchases		Sales
BST	$	348,579,186	$	437,668,495
BUI		154,271,528		163,843,293

8. INCOME TAX INFORMATION

It is each Trust’s policy to comply with the requirements of the Internal Revenue Code of 1986, as amended, applicable to regulated investment companies, and to distribute substantially all of its taxable income to its shareholders. Therefore, no U.S. federal income tax provision is required.

Each Trust files U.S. federal and various state and local tax returns. No income tax returns are currently under examination. The statute of limitations on each Trust’s U.S. federal tax returns generally remains open for a period of three years after they are filed. The statutes of limitations on each Trust’s state and local tax returns may remain open for an additional year depending upon the jurisdiction.

Management has analyzed tax laws and regulations and their application to the Trusts as of December 31, 2023, inclusive of the open tax return years, and does not believe that there are any uncertain tax positions that require recognition of a tax liability in the Trusts’ financial statements.

U.S. GAAP requires that certain components of net assets be adjusted to reflect permanent differences between financial and tax reporting. These reclassifications have no effect on net assets or NAVs per share. As of period end, permanent differences attributable to timing and recognition of partnership income, non-deductible expenses, the realization for tax purposes of unrealized gains on investments in passive foreign investment companies and net operating losses were reclassified to the following accounts:

Trust Name	Paid-in Capital			Accumulated Earnings (Loss)
BGR	$	558,373		$	(558,373	)
BDJ		(5,192	)		5,192
BMEZ		(7,775,158	)		7,775,158
BIGZ		(17,277,154	)		17,277,154
BSTZ		6,950,700			(6,950,700	)
BST		(6,831,334	)		6,831,334
BUI		(828	)		828

The tax character of distributions paid was as follows:

Trust Name	Year Ended 12/31/23		Year Ended 12/31/22
BGR
Ordinary income	$	10,396,825	$	11,890,970
Return of capital		11,108,880		4,610,793
	$	21,505,705	$	16,501,763
CII
Ordinary income	$	11,634,813	$	21,905,388
Long-term capital gains		41,063,355		70,788,369
	$	52,698,168	$	92,693,757
BDJ
Ordinary income	$	33,363,489	$	25,303,490
Long-term capital gains		102,619,291		178,849,379
	$	135,982,780	$	204,152,869
BOE
Ordinary income	$	13,739,848	$	16,041,931
Long-term capital gains		—		22,100,071
Return of capital		33,325,380		9,962,064
	$	47,065,228	$	48,104,066
BGY
Ordinary income	$	9,930,219	$	13,622,966
Long-term capital gains		7,370,443		6,547,300
Return of capital		23,857,237		21,930,456
	$	41,157,899	$	42,100,722
BMEZ
Ordinary income	$	—	$	82,094,690
Long-term capital gains		—		100,955,454
Return of capital		170,987,587		11,869,565
	$	170,987,587	$	194,919,709

172 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Notes to Financial Statements (continued)

Trust Name	Year Ended 12/31/23		Year Ended 12/31/22
BME
Ordinary income	$	2,244,293	$	1,635,849
Long-term capital gains		23,151,941		31,362,678
Return of capital		10,214,453		1,403,564
	$	35,610,687	$	34,402,091
BIGZ
Return of capital	$	173,714,456	$	233,929,900
BCX
Ordinary income	$	24,357,046	$	26,024,883
Return of capital		29,035,558		22,531,891
	$	53,392,604	$	48,556,774
BSTZ
Long-term capital gains	$	—	$	70,402,537
Return of capital		140,469,092		110,549,120
	$	140,469,092	$	180,951,657
BST
Long-term capital gains	$	50,091,649	$	69,684,200
Return of capital		51,595,440		27,306,002
	$	101,687,089	$	96,990,202
BUI
Ordinary income	$	19,423,039	$	6,721,779
Long-term capital gains		2,024,280		12,261,345
Return of capital		11,077,670		13,135,583
	$	32,524,989	$	32,118,707

As of December 31, 2023, the tax components of accumulated earnings (loss) were as follows:

Trust Name	Undistributed Ordinary Income		Undistributed Long-Term Capital Gains		Non-Expiring Capital Loss Carryforwards(a)			Net Unrealized Gains (Losses)(b)			Qualified Late-Year Capital Losses(c)			Qualified Late-Year Ordinary Losses(c)			Total
BGR	$	—	$	—	$	(216,932,775	)	$	97,434,384		$	—		$	—		$	(119,498,391	)
CII		760,791		6,838,242		—			305,018,797			—			—			312,617,830
BDJ		48,047,312		59,596,798		—			223,083,475			—			—			330,727,585
BOE		—		—		(25,380,164	)		100,988,008			—			(8,053	)		75,599,791
BGY		—		—		—			82,521,124			—			(50,826	)		82,470,298
BMEZ		—		—		(42,780,406	)		(909,522	)		—			—			(43,689,928	)
BME		—		—		—			170,517,630			—			—			170,517,630
BIGZ		—		—		(1,900,736,865	)		(95,001,077	)		—			—			(1,995,737,942	)
BCX		—		—		(226,104,461	)		100,185,480			—			—			(125,918,981	)
BSTZ		—		—		(42,767,288	)		468,073,032			—			—			425,305,744
BST		—		—		—			417,844,294			—			(4,992	)		417,839,302
BUI		—		—		—			130,638,968			(1,112,144	)		(3,224	)		129,523,600

^(a)  Amounts available to offset future realized capital gains.

^(b)  The difference between book-basis and tax-basis net unrealized gains (losses) was attributable primarily to the tax deferral of losses on wash sales and straddles, the realization for tax purposes of unrealized gains (losses) on certain futures and foreign currency exchange contracts, the realization for tax purposes of unrealized gains on investments in passive foreign investment companies, the timing and recognition of partnership income, the characterization of corporate actions and the deferral of compensation to Trustees.

^(c)  The Trust has elected to defer these qualified late-year losses and recognize such losses in the next taxable year.

During the year ended December 31, 2023, the Trusts listed below utilized the following amounts of their respective capital loss carryforwards:

Trust Name	Amounts
BGR	$	23,500,872
BCX		32,537,780

As of December 31, 2023, gross unrealized appreciation and depreciation based on cost of investments (including short positions and derivatives, if any) for U.S. federal income tax purposes were as follows:

Trust Name	Tax Cost		Gross Unrealized Appreciation		Gross Unrealized Depreciation			Net Unrealized Appreciation (Depreciation)
BGR	$	281,286,449	$	114,088,294	$	(5,505,611	)	$	108,582,683

N O T E S  T O  F I N A N C I A L  S T A T E M E N T S 173

Notes to Financial Statements (continued)

Trust Name	Tax Cost		Gross Unrealized Appreciation		Gross Unrealized Depreciation			Net Unrealized Appreciation (Depreciation)
CII	$	570,272,743	$	335,884,367	$	(20,698,964	)	$	315,185,403
BDJ		1,420,599,223		319,272,656		(78,025,988	)		241,246,668
BOE		611,807,574		144,094,769		(23,564,850	)		120,529,919
BGY		526,743,102		123,625,084		(21,823,102	)		101,801,982
BMEZ		1,928,270,758		282,639,045		(276,928,752	)		5,710,293
BME		415,025,903		194,342,100		(17,446,937	)		176,895,163
BIGZ		2,148,876,232		331,360,334		(422,063,536	)		(90,703,202	)
BCX		795,748,271		167,473,973		(59,439,858	)		108,034,115
BSTZ		1,146,622,280		608,585,224		(109,954,292	)		498,630,932
BST		780,348,418		555,341,869		(122,192,117	)		433,149,752
BUI		359,156,640		161,999,603		(10,208,566	)		151,791,037

9. PRINCIPAL RISKS

In the normal course of business, the Trusts invest in securities or other instruments and may enter into certain transactions, and such activities subject each Trust to various risks, including among others, fluctuations in the market (market risk) or failure of an issuer to meet all of its obligations. The value of securities or other instruments may also be affected by various factors, including, without limitation: (i) the general economy; (ii) the overall market as well as local, regional or global political and/or social instability; (iii) regulation, taxation or international tax treaties between various countries; or (iv) currency, interest rate and price fluctuations. Local, regional or global events such as war, acts of terrorism, the spread of infectious illness or other public health issues, recessions, or other events could have a significant impact on the Trusts and their investments. BDJ’s, BME’s, BST’s and BUI’s prospectuses provide details of the risks to which each Trust is subject.

The Trusts may be exposed to additional risks when reinvesting cash collateral in money market funds that do not seek to maintain a stable NAV per share of $1.00, which may be subject to discretionary liquidity fees under certain circumstances.

Illiquidity Risk: Each Trust may invest without limitation in illiquid or less liquid investments or investments in which no secondary market is readily available or which are otherwise illiquid, including private placement securities. A Trust may not be able to readily dispose of such investments at prices that approximate those at which a Trust could sell such investments if they were more widely traded and, as a result of such illiquidity, a Trust may have to sell other investments or engage in borrowing transactions if necessary to raise funds to meet its obligations. Limited liquidity can also affect the market price of investments, thereby adversely affecting a Trust’s NAV and ability to make dividend distributions. Privately issued debt securities are often of below investment grade quality, frequently are unrated and present many of the same risks as investing in below investment grade public debt securities.

Valuation Risk: The market values of equities, such as common stocks and preferred securities or equity related investments, such as futures and options, may decline due to general market conditions which are not specifically related to a particular company. They may also decline due to factors which affect a particular industry or industries. A Trust may invest in illiquid investments. An illiquid investment is any investment that a Trust reasonably expects cannot be sold or disposed of in current market conditions in seven calendar days or less without the sale or disposition significantly changing the market value of the investment. A Trust may experience difficulty in selling illiquid investments in a timely manner at the price that it believes the investments are worth. Prices may fluctuate widely over short or extended periods in response to company, market or economic news. Markets also tend to move in cycles, with periods of rising and falling prices. This volatility may cause each Trust’s NAV to experience significant increases or decreases over short periods of time. If there is a general decline in the securities and other markets, the NAV of a Trust may lose value, regardless of the individual results of the securities and other instruments in which a Trust invests.

The price a Trust could receive upon the sale of any particular portfolio investment may differ from a Trust’s valuation of the investment, particularly for securities that trade in thin or volatile markets or that are valued using a fair valuation technique or a price provided by an independent pricing service. Changes to significant unobservable inputs and assumptions (i.e., publicly traded company multiples, growth rate, time to exit) due to the lack of observable inputs may significantly impact the resulting fair value and therefore a Trust’s results of operations. As a result, the price received upon the sale of an investment may be less than the value ascribed by a Trust, and a Trust could realize a greater than expected loss or lesser than expected gain upon the sale of the investment. A Trust’s ability to value its investments may also be impacted by technological issues and/or errors by pricing services or other third-party service providers.

Counterparty Credit Risk: The Trusts may be exposed to counterparty credit risk, or the risk that an entity may fail to or be unable to perform on its commitments related to unsettled or open transactions, including making timely interest and/or principal payments or otherwise honoring its obligations. The Trusts manage counterparty credit risk by entering into transactions only with counterparties that the Manager believes have the financial resources to honor their obligations and by monitoring the financial stability of those counterparties. Financial assets, which potentially expose the Trusts to market, issuer and counterparty credit risks, consist principally of financial instruments and receivables due from counterparties. The extent of the Trusts’ exposure to market, issuer and counterparty credit risks with respect to these financial assets is approximately their value recorded in the Statements of Assets and Liabilities, less any collateral held by the Trusts.

A derivative contract may suffer a mark-to-market loss if the value of the contract decreases due to an unfavorable change in the market rates or values of the underlying instrument. Losses can also occur if the counterparty does not perform under the contract.

For OTC options purchased, each Trust bears the risk of loss in the amount of the premiums paid plus the positive change in market values net of any collateral held by the Trusts should the counterparty fail to perform under the contracts. Options written by the Trusts do not typically give rise to counterparty credit risk, as options written generally obligate the Trusts, and not the counterparty, to perform. The Trusts may be exposed to counterparty credit risk with respect to options written to the extent each Trust deposits collateral with its counterparty to a written option.

174 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Notes to Financial Statements (continued)

With exchange-traded options purchased, there is less counterparty credit risk to the Trusts since the exchange or clearinghouse, as counterparty to such instruments, guarantees against a possible default. The clearinghouse stands between the buyer and the seller of the contract; therefore, credit risk is limited to failure of the clearinghouse. While offset rights may exist under applicable law, a Trust does not have a contractual right of offset against a clearing broker or clearinghouse in the event of a default (including the bankruptcy or insolvency).

Geographic/Asset Class Risk: A diversified portfolio, where this is appropriate and consistent with a fund’s objectives, minimizes the risk that a price change of a particular investment will have a material impact on the NAV of a fund. The investment concentrations within each Trust’s portfolio are disclosed in its Schedule of Investments.

As of period end, the Trusts listed below invested a significant portion of their assets in securities in the following sectors:

Sectors	Trust Name
Energy		BGR, BCX
Financials		BDJ
Health Care		BMEZ, BME
Information Technology		CII, BSTZ, BST, BIGZ
Materials		BCX
Utilities		BUI

Changes in economic conditions affecting such sectors would have a greater impact on the Trusts and could affect the value, income and/or liquidity of positions in such securities.

Certain Trusts invest a significant portion of their assets in securities within a single or limited number of market sectors. When a fund concentrates its investments in this manner, it assumes the risk that economic, regulatory, political and social conditions affecting such sectors may have a significant impact on the Trust and could affect the income from, or the value or liquidity of, the Trust’s portfolio. Investment percentages in specific sectors are presented in the Schedules of Investments.

Certain Trusts invest a substantial amount of their assets in issuers located in a single country or a limited number of countries. When a fund concentrates its investments in this manner, it assumes the risk that economic, regulatory, political and social conditions in those countries may have a significant impact on their investment performance and could affect the income from, or the value or liquidity of, the Trust’s portfolio. Unanticipated or sudden political or social developments may cause uncertainty in the markets and as a result adversely affect the Trust’s investments. Foreign issuers may not be subject to the same uniform accounting, auditing and financial reporting standards and practices as used in the United States. Foreign securities markets may also be more volatile and less liquid than U.S. securities and may be less subject to governmental supervision not typically associated with investing in U.S. securities. Investment percentages in specific countries are presented in the Schedules of Investments.

Certain Trusts invest a significant portion of their assets in securities of issuers located in the United States. A decrease in imports or exports, changes in trade regulations, inflation and/or an economic recession in the United States may have a material adverse effect on the U.S. economy and the securities listed on U.S. exchanges. Proposed and adopted policy and legislative changes in the United States may also have a significant effect on U.S. markets generally, as well as on the value of certain securities. Governmental agencies project that the United States will continue to maintain elevated public debt levels for the foreseeable future which may constrain future economic growth. Circumstances could arise that could prevent the timely payment of interest or principal on U.S. government debt, such as reaching the legislative “debt ceiling.” Such non-payment would result in substantial negative consequences for the U.S. economy and the global financial system. If U.S. relations with certain countries deteriorate, it could adversely affect issuers that rely on the United States for trade. The United States has also experienced increased internal unrest and discord. If these trends were to continue, they may have an adverse impact on the U.S. economy and the issuers in which the Trusts invest.

Certain Trusts invest a significant portion of their assets in securities of issuers located in Europe or with significant exposure to European issuers or countries. The European financial markets have recently experienced volatility and adverse trends due to concerns about economic downturns in, or rising government debt levels of, several European countries as well as acts of war in the region. These events may spread to other countries in Europe and may affect the value and liquidity of certain of the Trusts’ investments.

Responses to the financial problems by European governments, central banks and others, including austerity measures and reforms, may not work, may result in social unrest and may limit future growth and economic recovery or have other unintended consequences. Further defaults or restructurings by governments and others of their debt could have additional adverse effects on economies, financial markets and asset valuations around the world. The United Kingdom has withdrawn from the European Union, and one or more other countries may withdraw from the European Union and/or abandon the Euro, the common currency of the European Union. These events and actions have adversely affected, and may in the future adversely affect, the value and exchange rate of the Euro and may continue to significantly affect the economies of every country in Europe, including countries that do not use the Euro and non-European Union member states. The impact of these actions, especially if they occur in a disorderly fashion, is not clear but could be significant and far reaching. In addition, Russia launched a large-scale invasion of Ukraine on February 24, 2022. The extent and duration of the military action, resulting sanctions and resulting future market disruptions in the region are impossible to predict, but have been, and may continue to be, significant and have a severe adverse effect on the region, including significant negative impacts on the economy and the markets for certain securities and commodities, such as oil and natural gas, as well as other sectors.

10. CAPITAL SHARE TRANSACTIONS

Each Trust is authorized to issue an unlimited number of shares, with the exception of CII, all of which were initially classified as Common Shares. CII is authorized to issue 200 million Common Shares. The par value for each Trust’s Common Shares is $0.001, except for CII, which is $0.10. The Board is authorized, however, to reclassify any unissued Common Shares to Preferred Shares without the approval of Common Shareholders.

BDJ, BME, BST and BUI have each filed a prospectus with the SEC allowing them to issue an additional 40,000,000, 4,000,000, 18,000,000 and 8,000,000 Common Shares, respectively, through an equity Shelf Offering. Under the Shelf Offerings, BDJ, BME, BST and BUI, subject to market conditions, may raise additional equity capital from time to time in varying amounts and utilizing various offering methods at a net price at or above each Trust’s NAV per Common Share (calculated within 48 hours of pricing). As of

N O T E S  T O  F I N A N C I A L  S T A T E M E N T S 175

Notes to Financial Statements (continued)

period end, 40,000,000, 3,332,695, 15,898,551 and 7,658,406 Common Shares, respectively, remain available for issuance under the Shelf Offerings. During the year ended December 31, 2023, BDJ, BME, BST and BUI issued 0, 71,333, 1,266,090 and 167,658 shares, respectively, under the Trust’s respective current Shelf Offering and the Trust’s prior Shelf Offering. See Additional Information — Shelf Offering Program for additional information.

Initial costs incurred by each of BDJ, BME, BST and BUI in connection with their Shelf Offerings are recorded as “Deferred offering costs” in the Statements of Assets and Liabilities. As shares are sold, a portion of the costs attributable to the shares sold will be charged against paid-in-capital. Any remaining deferred charges at the end of the Shelf Offering period will be charged to expense.

For the periods shown, shares issued and outstanding increased by the following amounts as a result of shares issued through the Shelf Offering:

	Year Ended
Trust Name	12/31/23		12/31/22
BME		71,333		774,304
BST		1,266,090		835,359
BUI		167,658		590,894

For the periods shown, shares issued and outstanding increased by the following amounts as a result of dividend reinvestment:

	Year Ended
Trust Name	12/31/23		12/31/22
CII		14,818		—
BDJ		78,103		412,658
BME		12,112		38,955
BST		173,563		81,277
BUI		31,913		32,898

The Trusts participate in an open market share repurchase program (the “Repurchase Program”). From December 1, 2022 through November 30, 2023, each Trust may repurchase up to 5% of its outstanding common shares under the Repurchase Program, based on common shares outstanding as of the close of business on November 30, 2022, subject to certain conditions. From December 1, 2023 through November 30, 2024, each Trust may repurchase up to 5% of its outstanding common shares under the Repurchase Program, based on common shares outstanding as of the close of business on November 30, 2023, subject to certain conditions. The Repurchase Program has an accretive effect as shares are purchased at a discount to the Trust’s NAV. There is no assurance that the Trusts will purchase shares in any particular amounts. For the year ended December 31, 2023, CII, BME, BST and BUI did not repurchase any shares.

The total cost of the shares repurchased is reflected in the Trusts’ Statements of Changes in Net Assets. For the periods shown, shares repurchased and cost, including transaction costs, were as follows:

	BGR
	Shares		Amounts
Year Ended December 31, 2023		587,768	$	7,413,692
Year Ended December 31, 2022		1,055,728		12,296,655
	BDJ
	Shares		Amounts
Year Ended December 31, 2023		359,086	$	2,735,878
	BOE
	Shares		Amounts
Year Ended December 31, 2023		1,214,010	$	11,889,663
Year Ended December 31, 2022		1,285,502		12,470,648
	BGY
	Shares		Amounts
Year Ended December 31, 2023		2,473,793	$	13,143,239
Year Ended December 31, 2022		1,492,331		7,282,700
	BMEZ
	Shares		Amounts
Year Ended December 31, 2023		3,082,831	$	47,918,763
Year Ended December 31, 2022		3,072,736		47,829,587
	BIGZ
	Shares		Amounts
Year Ended December 31, 2023		5,247,265	$	37,872,639
Year Ended December 31, 2022		8,519,618		64,919,571

176 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Notes to Financial Statements (continued)

	BCX
	Shares		Amounts
Year Ended December 31, 2023		3,155,189	$	29,812,008
Year Ended December 31, 2022		797,510		7,554,830
	BSTZ
	Shares		Amounts
Year Ended December 31, 2023		2,006,073	$	34,325,597
Year Ended December 31, 2022		461,288		7,293,625

For the year ended December 31, 2022, shares issued and outstanding remained constant for CII.

As of December 31, 2023, BlackRock Financial Management, Inc., an affiliate of the Trust, owned 5,000 Shares of BIGZ.

11. FOREIGN WITHHOLDINGS TAX CLAIMS

The Internal Revenue Service (“IRS”) has issued guidance to address U.S. income tax liabilities attributable to fund shareholders resulting from the recovery of foreign taxes withheld in prior calendar years. These withheld foreign taxes were passed through to shareholders in the form of foreign tax credits in the year the taxes were withheld. Assuming there are sufficient foreign taxes paid which BOE and BUI is able to pass through to shareholders as a foreign tax credit in the current year, BOE and BUI will be able to offset the prior years’ withholding taxes recovered against the foreign taxes paid in the current year. Accordingly, no federal income tax liability is recorded by the BOE and BUI.

12. SUBSEQUENT EVENTS

Management’s evaluation of the impact of all subsequent events on the Trusts’ financial statements was completed through the date the financial statements were issued and the following item was noted:

The Trusts declared and paid or will pay distributions to Common Shareholders as follows:

Trust Name	Declaration Date		Record Date		Payable/ Paid Date		Dividend Per Common Share
BGR		01/02/24		01/12/24		01/31/24	$	0.065700
		02/01/24		02/15/24		02/29/24		0.065700
CII		01/02/24		01/12/24		01/31/24		0.099500
		02/01/24		02/15/24		02/29/24		0.099500
BDJ		01/02/24		01/12/24		01/31/24		0.056200
		02/01/24		02/15/24		02/29/24		0.056200
BOE		01/02/24		01/12/24		01/31/24		0.063000
		02/01/24		02/15/24		02/29/24		0.063000
BGY		01/02/24		01/12/24		01/31/24		0.033800
		02/01/24		02/15/24		02/29/24		0.033800
BMEZ		01/02/24		01/12/24		01/31/24		0.090910
		02/01/24		02/15/24		02/29/24		0.090440
BME		01/02/24		01/12/24		01/31/24		0.213000
		02/01/24		02/15/24		02/29/24		0.213000
BIGZ		01/02/24		01/12/24		01/31/24		0.044720
		02/01/24		02/15/24		02/29/24		0.044660
BCX		01/02/24		01/12/24		01/31/24		0.051800
		02/01/24		02/15/24		02/29/24		0.051800
BSTZ		01/02/24		01/12/24		01/31/24		0.102710
		02/01/24		02/15/24		02/29/24		0.103260
BST		01/02/24		01/12/24		01/31/24		0.250000
		02/01/24		02/15/24		02/29/24		0.250000
BUI		01/02/24		01/12/24		01/31/24		0.121000
		02/01/24		02/15/24		02/29/24		0.121000

N O T E S  T O  F I N A N C I A L  S T A T E M E N T S 177

Report of Independent Registered Public Accounting Firm

To the Shareholders and the Board of Trustees/Directors of BlackRock Energy and Resources Trust, BlackRock Enhanced Capital and Income Fund, Inc., BlackRock Enhanced Equity Dividend Trust, BlackRock Enhanced Global Dividend Trust, BlackRock Enhanced International Dividend Trust, BlackRock Health Sciences Term Trust, BlackRock Health Sciences Trust, BlackRock Innovation and Growth Term Trust, BlackRock Resources & Commodities Strategy Trust, BlackRock Science and Technology Term Trust, BlackRock Science and Technology Trust and BlackRock Utilities, Infrastructure & Power Opportunities Trust:

Opinion on the Financial Statements and Financial Highlights

We have audited the accompanying statements of assets and liabilities of BlackRock Energy and Resources Trust, BlackRock Enhanced Capital and Income Fund, Inc., BlackRock Enhanced Equity Dividend Trust, BlackRock Enhanced Global Dividend Trust, BlackRock Enhanced International Dividend Trust, BlackRock Health Sciences Term Trust (formerly, BlackRock Health Sciences Trust II), BlackRock Health Sciences Trust, BlackRock Innovation and Growth Term Trust (formerly, BlackRock Innovation and Growth Trust), BlackRock Resources & Commodities Strategy Trust, BlackRock Science and Technology Term Trust (formerly, BlackRock Science and Technology Trust II), BlackRock Science and Technology Trust and BlackRock Utilities, Infrastructure & Power Opportunities Trust (the “Funds”), including the schedules of investments, as of December 31, 2023, the related statements of operations and cash flows for the year then ended, the statements of changes in net assets for each of the two years in the period then ended, and the financial highlights for the periods indicated in the table below, and the related notes. Such financial statements and financial highlights of BlackRock Science and Technology Trust and BlackRock Science and Technology Term Trust are consolidated as of and for the four years in the period ended December 31, 2023. Such financial statements and financial highlights of BlackRock Enhanced Equity Dividend Trust are consolidated as of and for the two years in the period ended December 31, 2023. In our opinion, the financial statements and financial highlights present fairly, in all material respects, the financial position of the Funds as of December 31, 2023, and the results of their operations and their cash flows for the year then ended, the statements of changes in their net assets for each of the two years in the period then ended, and the financial highlights for the periods indicated in the table below, in conformity with accounting principles generally accepted in the United States of America.

Fund	Financial Highlights
BlackRock Energy and Resources Trust, BlackRock Enhanced Capital and Income Fund, Inc., BlackRock Enhanced Equity Dividend Trust, BlackRock Enhanced Global Dividend Trust, BlackRock Enhanced International Dividend Trust, BlackRock Health Sciences Trust, BlackRock Resources & Commodities Strategy Trust, BlackRock Science and Technology Trust and BlackRock Utilities, Infrastructure & Power Opportunities Trust	For each of the five years in the period ended December 31, 2023
BlackRock Science and Technology Term Trust	For each of the four years in the period ended December 31, 2023 and for the period from June 27, 2019 (commencement of operations) through December 31, 2019
BlackRock Health Sciences Term Trust	For each of the three years in the period ended December 31, 2023 and for the period from January 30, 2020 (commencement of operations) through December 31, 2020
BlackRock Innovation and Growth Term Trust	For each of the two years in the period ended December 31, 2023 and for the period from March 29, 2021 (commencement of operations) through December 31, 2021

Basis for Opinion

These financial statements and financial highlights are the responsibility of the Funds’ management. Our responsibility is to express an opinion on the Funds’ financial statements and financial highlights based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Funds in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements and financial highlights are free of material misstatement, whether due to error or fraud. The Funds are not required to have, nor were we engaged to perform, an audit of their internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Funds’ internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements and financial highlights, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements and financial highlights. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements and financial highlights. Our procedures included confirmation of securities owned as of December 31, 2023, by correspondence with custodians or counterparties; when replies were not received, we performed other auditing procedures. We believe that our audits provide a reasonable basis for our opinion.

Deloitte & Touche LLP

Boston, Massachusetts

February 23, 2024

We have served as the auditor of one or more BlackRock investment companies since 1992.

178 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Important Tax Information (unaudited)

The following amounts, or maximum amounts allowable by law, are hereby designated as qualified dividend income for individuals for the fiscal year ended December 31, 2023:

Trust Name	Qualified Dividend Income
BGR	$	13,529,966
CII		9,319,392
BDJ		37,581,659
BOE		15,057,065
BGY		8,994,577
BME		6,649,650
BCX		32,387,805
BUI		11,804,459

The Trusts hereby designate the following amounts, or maximum amounts allowable by law, as capital gain dividends, subject to a long-term capital gains tax rate as noted below, for the fiscal year ended December 31, 2023:

Trust Name	20% Rate Long-Term Capital Gain Dividends
CII	$	41,063,355
BDJ		102,619,291
BGY		7,370,443
BME		23,151,941
BST		50,091,649
BUI		2,024,280

The Trusts intend to pass through to their shareholders the following amounts, or maximum amounts allowable by law, of foreign source income earned and foreign taxes paid for the fiscal year ended December 31, 2023:

Trust Name	Foreign Source Income Earned		Foreign Taxes Paid
BOE	$	8,597,159	$	1,044,144
BGY		9,311,402		1,554,067
BCX		18,451,675		1,746,843
BUI		4,035,929		669,585

The Funds hereby designate the following amounts, or maximum amounts allowable by law, of distributions from direct federal obligation interest for the fiscal year ended December 31, 2023:

Trust Name	Federal Obligation Interest
BGR	$	31,845
CII		26,735
BDJ		305,744
BOE		45,218
BGY		47,256
BME		52,698
BCX		136,130
BUI		48,902

The law varies in each state as to whether and what percent of ordinary income dividends attributable to federal obligations is exempt from state income tax. Shareholders are advised to check with their tax advisers to determine if any portion of the dividends received is exempt from state income tax.

The following percentages, or maximum percentages allowable by law, of ordinary income distributions paid during the fiscal year ended December 31, 2023 qualified for the dividends-received deduction for corporate shareholders:

Trust Name	Dividends-Received   Deduction
BGR		73.52%
CII		39.13
BDJ		67.24
BOE		51.50
BGY		8.09
BME		100.00
BCX		31.07
BUI		33.61

I M P O R T A N T  T A X  I N F O R M A T I O N 179

Important Tax Information (unaudited) (continued)

The Funds hereby designate the following amounts, or maximum amounts allowable by law, as interest income eligible to be treated as a Section 163(j) interest dividend for the fiscal year ended December 31, 2023:

Trust Name	Interest Dividends
BGR	$	203,142
CII		170,587
BDJ		1,950,371
BOE		288,451
BGY		307,117
BME		336,323
BCX		868,386
BUI		312,452

The Trusts hereby designate the following amounts, or maximum amounts allowable by law, as interest-related dividends and qualified short-term capital gains eligible for exemption from U.S. withholding tax for nonresident aliens and foreign corporations for the fiscal year ended December 31, 2023:

Trust Name	Interest- Related Dividends		Qualified Short-Term Capital Gains
BGR	$	203,142	$	—
CII		170,587		8,705,798
BDJ		1,950,371		9,829,694
BOE		288,451		—
BGY		301,449		1,289,033
BME		336,323		—
BCX		868,386		—
BUI		311,874		11,232,021

180 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Investment Objectives, Policies and Risks

Recent Changes

The following information is a summary of certain changes since December 31, 2022.This information may not reflect all of the changes that have occurred since you purchased the relevant Trust.

Effective August 28, 2023, BlackRock Science and Technology Term Trust (BSTZ) began operating as a diversified fund.

Except as noted above, during each Trust’s most recent fiscal year, there were no material changes in the Trust’s investment objectives or policies that have not been approved by shareholders or in the principal risk factors associated with investment in the Trust.

Investment Objectives and Policies

BlackRock Energy and Resources Trust (BGR)

The Trust’s investment objective is to provide total return through a combination of current income and capital appreciation. The Trust seeks to achieve this objective by investing primarily in equity securities of companies engaged in the energy and natural resources business and equity derivatives with exposure to the energy and natural resources industry.

Under normal market conditions, the Trust invests at least 80% of its total assets in equity securities of energy and natural resources companies and equity derivatives with exposure to the energy and natural resources industry. The Trust may invest directly in securities or synthetically through the use of derivatives. The Trust will not invest, under normal market conditions, less than 25% of its total assets in securities of energy and natural resources companies and equity derivatives with exposure to the energy and natural resources industry without shareholder approval. Companies in the energy and natural resources industry include those companies involved in the exploration, production or distribution of energy or natural resources, such as gas, oil, metals and minerals as well as related transportation companies and equipment manufacturers. These equity securities may include common stocks, preferred shares, convertible securities, warrants, depositary receipts, equity interests in Canadian Royalty Trusts and equity interests in master limited partnerships (“MLPs”). The Trust will not invest more than 25% of its total assets in MLPs. The Trust may invest in companies located anywhere in the world. The Trust expects to invest primarily in companies located in developed countries, but may invest in companies located in emerging markets. Under normal market conditions, the Trust will invest at least 30% of its total assets in at least two countries other than the United States. The Trust may invest in companies of any market capitalization, including small capitalization and mid-capitalization companies. The Trust does not intend to invest directly in commodities.

As part of its strategy, the Trust currently intends to employ an option strategy of writing (selling) covered call options on common stocks. The Trust seeks to produce current income and gains generated from option writing premiums. In addition to its covered call strategy the Trust may, to a lesser extent, pursue an option strategy that includes the sale (writing) of both put options and call options on certain of the common stocks in the Trust’s portfolio.

The Trust may invest up to 20% of its total assets in other U.S. and other non-U.S. investments. These investments may include equity and debt securities of companies not engaged in the energy and natural resources industry. The Trust reserves the right to invest up to 10% of its total assets in non-investment grade debt securities, commonly known as “junk bonds.”

In addition to the option strategies discussed above, the Trust may engage in transactions such as options, futures, swaps, foreign currency transactions including forward foreign currency contracts, currency swaps or options on currency and currency futures and other derivatives transactions for hedging purposes or to enhance total return. The Trust may also engage in short sales of securities.

The percentage limitations applicable to the Trust’s portfolio described herein apply only at the time of investment and the Trust will not be required to sell securities due to subsequent changes in the value of securities it owns.

Application of the Trust’s investment philosophy, from time to time, may cause the Trust to invest a significant portion of its assets in a particular country or region of the world. The Trust anticipates that its investment strategy will cause it to invest in a number of countries throughout the world, but the actual number of countries represented in the Trust’s portfolio will vary over time. The Trust anticipates that application of its investment philosophy currently would cause it to invest in issuers located in 10 countries globally, including the United States. Under normal market conditions, the Trust will invest in the equity securities of issuers in at least three different countries, including the United States, and will invest at least 30% of its total assets at the time of investment in the equity securities of non-United States issuers. However, the Trust may invest in the securities of non-United States issuers without limit.

Leverage: The Trust may, but does not currently intend to, incur indebtedness or issue preferred shares for investment purposes.

The Trust may enter into derivative transactions that have leverage embedded in them.

BlackRock Enhanced Capital and Income Fund, Inc. (CII)

The Trust’s investment objective is to provide current income and capital appreciation. The Trust’s investment objective is a fundamental policy and may not be changed without the approval of a majority of the outstanding voting securities of the Trust (as defined in the Investment Company Act of 1940, as amended (the “Investment Company Act”)).

The Trust seeks to achieve its investment objective by investing in a portfolio of equity securities of U.S. and foreign issuers. The Trust may invest directly in securities or synthetically through the use of derivatives. BlackRock Advisors, LLC (the “Manager”) from time to time may vary the percentage of the Trust’s assets invested in any particular type of equity security based on such factors as market and economic conditions, fiscal and monetary policy and the relative security valuation of the various equity asset classes.

I N V E S T M E N T  O B J E C T I V E S ,  P O L I C I E S  A N D  R I S K S 181

Investment Objectives, Policies and Risks (continued)

Investment Objectives and Policies (continued)

The Trust also seeks to achieve its investment objective by employing a strategy of writing (selling) call and put options on indices of securities and sectors of securities. In addition to its option strategy on indices, the Trust may pursue a strategy that includes the writing (selling) of both call and put options on individual common stocks. These option strategies are intended to generate current gains from option premiums as a means to enhance distributions payable to the Trust’s stockholders. As the Trust writes calls and puts over more of its portfolio, its ability to benefit from capital appreciation becomes more limited.

To the extent the Trust invests in dividend-paying common stocks, the Manager currently intends to emphasize those securities that: (i) are eligible to pay “qualified dividend” income and/or (ii) make payments that are eligible for the dividends received deduction allowed to corporate taxpayers (“Dividends Received Deduction”) pursuant to Section 243 of the Internal Revenue Code of 1986, as amended (the “Code”). Long-term capital gains and qualified dividend income are currently eligible for reduced U.S. federal income tax rates for individuals. Long-term capital gains and qualified dividend income included in distributions of a regulated investment company (a “RIC”) to its individual stockholders are generally passed through to such stockholders and taxed at such reduced rates. Pursuant to Section 243 of the Code, corporations generally may deduct a portion of the dividend income they receive from domestic corporations. Corporate stockholders of a RIC generally are permitted to claim a deduction with respect to that portion of their dividend distributions attributable to amounts that the RIC designates as qualifying for the Dividends Received Deduction. Although the Trust has the ability to borrow money for investment purposes, it has no current intention to do so. If, however, the Trust did use leverage, the use of leverage through borrowings may reduce the amount of dividends it can designate as qualifying for the Dividends Received Deduction which will, in turn, limit the tax benefit to a corporate stockholder of investing in the Trust. Corporate stockholders should consider whether an investment in the Trust is appropriate in light of the Trust’s ability to borrow. No assurance can be given as to what percentage of the dividends paid on the Trust’s common stock will be eligible for: (i) the reduced U.S. federal income tax rate for qualified dividend income and long-term capital gains for individuals or (ii) the Dividends Received Deduction for corporate stockholders of the Trust.

Investment in the Trust’s common stock offers the individual investor several potential benefits. The Trust offers investors the opportunity to invest in a professionally managed portfolio which contains common stocks and preferred securities of U.S. and foreign issuers. The Manager provides professional management, which includes the extensive securities and credit analysis needed to invest in common stocks, preferred securities and foreign securities. The Trust also relieves the investor of the burdensome administrative details involved in managing a portfolio of such investments. These benefits are at least partially offset by the expenses involved in running an investment company. Such expenses primarily consist of advisory fees and operational costs. The use of leverage also involves certain expenses and risk considerations.

The Trust may engage in various portfolio strategies to seek to increase its return or to hedge its portfolio against movements in interest rates, in currency rates and in the securities markets through the use of derivatives, such as indexed and inverse securities, options, futures, options on futures, total return swaps, short selling and foreign exchange transactions. No assurance can be given that the Trust will employ these strategies or that, if employed, they will be effective.

The Trust may vary its investment objective and policies for temporary defensive purposes during periods in which the Manager believes that conditions in the securities markets or other economic, financial or political conditions warrant and in order to keep the Trust’s cash fully invested, including during the periods which the net proceeds of the offering are being invested. Under such conditions, the Trust may invest up to 100% of its total assets in securities issued or guaranteed by the United States government or its instrumentalities or agencies, certificates of deposit, bankers’ acceptances and other bank obligations, commercial paper rated in the highest category by an established rating service, or other debt securities deemed by the Manager to be consistent with a defensive posture, or may hold its assets in cash.

Leverage: The Trust does not currently intend to, but may, leverage its portfolio through borrowings, the issuance of debt securities, the issuance of preferred stock or a combination thereof.

The Trust may enter into derivative transactions that have leverage embedded in them.

BlackRock Enhanced Equity Dividend Trust (BDJ)

The Trust’s primary investment objective is to provide current income and current gains, with a secondary objective of long-term capital appreciation. The Trust’s investment objectives are not fundamental and may be changed by the Board of Trustees without shareholder approval.

The Trust seeks to achieve its investment objectives by investing in common stocks that pay dividends and have the potential for capital appreciation and by utilizing an option writing strategy to enhance distributions to its shareholders. The Trust uses an option strategy that writes options on approximately 50-60% of its total assets.

Under normal market conditions, the Trust invests at least 80% of its total assets in dividend-paying equities and may invest up to 20% of its total assets in equity securities of issuers that do not pay dividends. The Trust may invest directly in securities or synthetically through the use of derivatives.

To the extent the Trust invests in dividend-paying common stocks, BlackRock Advisors, LLC (the “Manager”) may emphasize those securities that: (i) are eligible to pay “qualified dividend” income, and/or (ii) make payments that are eligible for the dividends received deduction allowed to corporate taxpayers pursuant to Section 243 of the Internal Revenue Code of 1986, as amended (the “Code”). Long-term capital gains and qualified dividend income are currently eligible for reduced U.S. federal income tax rates for individuals. Long-term capital gains and qualified dividend income properly reported as being included in distributions of a regulated investment company (a “RIC”) to its individual shareholders are generally passed through to such shareholders and taxed at such reduced rates. Pursuant to Section 243 of the Code, corporations generally may deduct a portion of the dividend income they receive from domestic corporations. Corporate shareholders of a RIC generally are permitted to claim a deduction with respect to that portion of their dividend distributions attributable to amounts that the RIC reports as qualifying for the dividends received deduction. Although the Trust has the ability to borrow money for investment purposes, it has no current intention to do so. If, however, the Trust did use leverage, the use of leverage through borrowings may reduce the amount of dividends it can designate as qualifying for the dividends received deduction which will, in turn, limit the tax benefit to a corporate shareholder of investing in the Trust. Corporate shareholders should consider whether an investment in the Trust is appropriate in light of the Trust’s ability to borrow. No assurance can be given as to what percentage of the dividends paid on the Trust’s common stock will be eligible for: (i) the reduced U.S. federal income tax rate for qualified dividend income and long-term capital gains for individuals, or (ii) the dividends received deduction for corporate shareholders of the Trust.

The Trust may invest up to 20% of its total assets in preferred securities.

182 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Investment Objectives, Policies and Risks (continued)

Investment Objectives and Policies (continued)

The Trust may invest up to 10% of its total assets in privately placed or restricted securities (including in Rule 144A securities, which are privately placed securities purchased by qualified institutional buyers), illiquid securities and securities in which no secondary market is readily available, including those of private companies.

The Trust may invest in shares of real estate investment trusts.

The Trust may invest up to 20% of its total assets in non-U.S. securities, which may include securities denominated in U.S. dollars or in foreign currencies or multinational currency units. The Trust may invest in foreign securities of emerging market issuers, but investments in such securities will not comprise more than 10% of its total assets. The Trust will consider a company a U.S. company and not a foreign company if it meets one or more of the following tests: (i) such company was organized in the United States; (ii) such company’s primary business office is in the United States; (iii) the principal trading market for such company’s assets are located in the United States; (iv) 50% or more of such company’s assets are located in the United States; or (v) 50% or more of such issuer’s revenues are derived from the United States.

The Trust may enter into forward currency contracts to purchase or sell foreign currencies for a fixed amount of U.S. dollars or another foreign currency.

The Trust may enter into are interest rate swaps and the purchase or sale of interest rate caps and floors. The Trust expects to enter into these transactions primarily to preserve a return or spread on a particular investment or portion of its portfolio as a duration management technique or to protect against any increase in the price of securities the Trust anticipates purchasing at a later date. The Trust intends to use these transactions for hedging and risk management purposes and not as a speculative investment. The Trust will not sell interest rate caps or floors that it does not own. The Trust will only enter into interest rate swap, cap or floor transactions with counterparties the Investment Advisor believes to be creditworthy at the time they enter into such transactions.

The Trust will not make a short sale if, after giving effect to such sale, the market value of all securities sold short exceeds 25% of the value of the Trust’s total assets or the Trust’s aggregate short sales of a particular class of securities exceeds 25% of the outstanding securities of that class. The Trust may also make short sales “against the box” without respect to such limitations.

Leverage: The Trust may borrow funds for investment purposes and/or issue debt securities or preferred shares to purchase additional securities. These practices are known as “leverage.” The Trust may borrow from banks and other financial institutions and may also borrow additional funds using such investment techniques as the Manager may from time to time determine. The Trust may borrow in an amount up to 5% of its total assets for temporary or emergency purposes.

The Trust currently does not intend to incur indebtedness or issue preferred shares for investment purposes, except in connection with derivative instruments such as exchange listed and over-the-counter put and call options on securities, financial futures, equity indices, and other financial instruments, purchase and sell futures contracts and options thereon, swaps, forward foreign currency contracts and various interest rate transactions, short sales, repurchase agreements, reverse repurchase agreements, when issued or forward commitment transactions and similar investment strategies.

The Trust may enter into derivative transactions that have leverage embedded in them.

BlackRock Enhanced Global Dividend Trust (BOE)

The Trust’s investment objective is primarily to seek current income and current gains, with a secondary objective of long-term capital appreciation. The Trust’s investment objective is not a fundamental policy and may be changed without prior shareholder approval.

The Trust seeks to achieve its investment objective by investing primarily in equity securities issued by companies located in countries throughout the world and by utilizing an option writing strategy to enhance current gains. BlackRock Advisors, LLC (the “Manager”) or BlackRock International Limited (“BIL” and together with the Manager, the “Advisors”), the Trust’s sub-advisor, from time to time may vary the percentage of the Trust’s assets invested in any particular type of equity security, based on factors such as market and economic conditions, fiscal and monetary policy and the relative security valuation of the various equity asset classes.

The Trust also seeks to achieve its investment objective by employing a strategy of writing (selling) call and put options on indices of securities and sectors of securities. The Trust intends to write covered put and call options with respect to approximately 30% to 45% of its total assets, although this percentage may vary from time to time with market conditions. In addition to its option strategy on indices, the Trust may pursue a strategy that includes the writing (selling) of both call and put options on individual common stocks. These option strategies are intended to generate current gains from option premiums as a means to enhance distributions payable to the Trust’s shareholders. As the Trust writes calls and puts over more of its portfolio, its ability to benefit from capital appreciation becomes more limited.

Under normal market conditions, the Trust is required to invest at least 80% of its net assets in dividend-paying equity securities and at least 40% of its assets outside of the U.S. (unless market conditions are not deemed favorable by Trust management, in which case the Trust would invest at least 30% of its assets outside of the U.S.). The Trust may invest directly in securities or synthetically through the use of derivatives. Equity securities in which the Trust invests include common stocks, preferred stocks, convertible securities, warrants, depositary receipts and equity interests in real estate investment trusts. The Trust may invest in companies located anywhere in the world. The Trust may invest in companies of any size market capitalization, but intends to invest primarily in the securities of large capitalization companies. The Trust may invest in companies conducting initial public offerings. The Trust may invest up to 25% of its total assets in equity securities of issuers in emerging countries. The Trust may invest up to 20% of its total assets in debt securities, including debt securities issued by companies located in emerging markets. The Trust may invest up to 10% of its total assets in non-investment grade debt securities, commonly known as “junk bonds.”

Application of the Trust’s investment philosophy, from time to time, may cause the Trust to invest a significant portion of its assets in a particular country or region of the world. The Trust’s investment strategy causes it to invest in issuers located in a number of countries throughout the world, but the actual number of countries represented in the Trust’s portfolio will vary over time. Under normal market conditions, the Trust invests in the equity securities of issuers in at least three different countries, including the United States. However, the Trust may invest in the securities of non-U.S. issuers without limit.

I N V E S T M E N T  O B J E C T I V E S ,  P O L I C I E S  A N D  R I S K S 183

Investment Objectives, Policies and Risks (continued)

Investment Objectives and Policies (continued)

The Trust may engage in various portfolio strategies to seek to increase its return or to hedge its portfolio against movements in interest rates, in currency rates and in the securities markets through the use of derivatives, such as indexed and inverse securities, options, futures, options on futures, interest rate transactions, including interest rate swaps, total return swaps and credit default swaps and short selling and foreign exchange transactions. Each of these portfolio strategies is described below. No assurance can be given that the Trust will employ these strategies or that, if employed, they will be effective.

The percentage limitations applicable to the Trust’s portfolio described herein apply only at the time of investment, and the Trust will not be required to sell securities due to subsequent changes in the value of securities it owns.

To the extent the Trust invests in dividend-paying common stocks, the Advisors currently intend to emphasize those securities that: (i) are eligible to pay “qualified dividend” income and/or (ii) make payments that are eligible for the dividends received deduction allowed to corporate taxpayers pursuant to Section 243 of the Internal Revenue Code of 1986, as amended (the “Code”). Long-term capital gains and qualified dividend income are currently eligible for reduced U.S. federal income tax rates for individuals. Long-term capital gains and qualified dividend income included in distributions of a regulated investment company (a “RIC”) to its individual shareholders are generally passed through to such shareholders and taxed at such reduced rates. Pursuant to Section 243 of the Code, corporations generally may deduct a portion of the dividend income they receive from domestic corporations. Corporate shareholders of a RIC generally are permitted to claim a deduction with respect to that portion of their dividend distributions attributable to amounts that the RIC designates as qualifying for the Dividends Received Deduction. Although the Trust has the ability to borrow money for investment purposes, it has no current intention to do so. If, however, the Trust did use leverage, the use of leverage through borrowings may reduce the amount of dividends it can designate as qualifying for the Dividends Received Deduction which will, in turn, limit the tax benefit to a corporate shareholder of investing in the Trust. Corporate shareholders should consider whether an investment in the Trust is appropriate in light of the Trust’s ability to borrow. No assurance can be given as to what percentage of the dividends paid on the Trust’s common stock will be eligible for: (i) the reduced U.S. federal income tax rate for qualified dividend income and long-term capital gains for individuals or (ii) the Dividends Received Deduction for corporate shareholders of the Trust.

In selecting investments for the Trust, the Advisors combine fundamental research with a top-down strategy, analyzing 70 sub-industry groups on an ongoing basis. The Advisors seek to identify companies that it believes have the potential to outperform the market. The Advisors’ investment techniques for the Trust include assessing industry structure and dynamics, evaluating growth catalysts on an industry and individual company basis and assessing a company’s valuation relative to the broad market and its respective industry group. The Advisors seek to invest in companies that it believes have sizeable market opportunities, global, regional or local competitive advantages, sound business models and financial strength, proven management teams and compelling relative and absolute valuations.

Leverage: The Trust may, but does not currently intend to, incur indebtedness or issue preferred shares for investment purposes.

The Trust may enter into derivative transactions that have leverage embedded in them

BlackRock Enhanced International Dividend Trust (BGY)

The Trust’s primary investment objective is to seek current income and current gains, with a secondary objective of long-term capital appreciation. “Current gains” means gains realized from the Trust’s option strategy (described below) pursuant to which the Trust seeks to enhance monthly distributions to investors. The Trust’s investment objectives may be changed without shareholder approval.

The Trust seeks to achieve its objectives by investing primarily in equity securities issued by companies of any market capitalization located in countries throughout the world and utilizing an option writing (selling) strategy to enhance current gains. Under normal circumstances, the Trust invests at least 80% of its net assets in dividend-paying equity securities issued by non-U.S. companies of any market capitalization, but intends to invest primarily in securities of large capitalization companies. The Trust may invest directly in securities or synthetically through the use of derivatives. The Trust may invest up to 20% of its total assets in equity securities of issuers located in the United States. The Trust may invest up to 50% of its total assets in equity securities of issuers located in emerging market countries. Emerging market countries generally include every nation in the world except the United States, Canada, Japan, Australia, New Zealand and most countries in Western Europe. Equity securities in which the Trust anticipates investing include common stocks, preferred stocks, convertible securities, warrants, depositary receipts and equity interests in real estate investment trusts.

Under normal circumstances, the Trust anticipates it will allocate a substantial amount (approximately 40% or more — unless market conditions are not deemed favorable by BlackRock Advisors, LLC (the “Manager”) or BlackRock International Limited (“BIL” and together with the Manager, the “Advisors”), the Trust’s sub-advisor, in which case the Trust would invest at least 30%) — of its total assets in securities of (i) foreign government issuers, (ii) issuers organized or located outside the U.S., (iii) issuers which primarily trade in a market located outside the U.S., or (iv) issuers doing a substantial amount of business outside the U.S., which the Trust considers to be companies that derive at least 50% of their revenue or profits from business outside the U.S. or have at least 50% of their sales or assets outside the U.S. The Trust will allocate its assets among various regions and countries, including the United States (but in no less than three different countries). For temporary defensive purposes, the Trust may deviate very substantially from the allocation described above.

The Trust seeks to generate current dividends and income by investing in equity securities that pay dividends. The Trust will seek income a portion of which is classified as “qualified dividend income,” which is dividend income that is eligible to be taxed at a maximum U.S. federal income tax rate of generally 20%. The lower U.S. federal tax rates generally apply to dividend income from taxable domestic corporations and certain qualified foreign corporations, provided that holding period and other requirements are met by both the Trust and the shareholder.

As part of its investment strategy, the Trust intends to write (sell) covered call and put options on individual common stocks, stock indices and stock sectors. The Trust may utilize over-the-counter options to a significant extent in order to employ its option strategy. This option strategy is intended to generate current gains from option premiums as a means to enhance distributions payable to the Trust’s shareholders. As the Trust writes covered calls over more of its portfolio, its ability to benefit from capital appreciation becomes more limited.

184 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Investment Objectives, Policies and Risks (continued)

Investment Objectives and Policies (continued)

A call option written by the Trust on a security is “covered” if the Trust owns the security underlying the call or has an absolute and immediate right to acquire that security without additional cash consideration (or, if additional cash consideration is required, the Trust’s custodian segregates sufficient cash or other assets determined to be liquid by the Advisors (in accordance with procedures established by the Board of Trustees (the “Board”))) upon conversion or exchange of other securities held by the Trust. A call option is also covered if the Trust holds a call on the same security as the call written where the exercise price of the call held is (i) equal to or less than the exercise price of the call written or (ii) greater than the exercise price of the call written, provided the difference is maintained by the Trust in segregated assets determined to be liquid by the Advisors as described above.

A put option written by the Trust on a security is “covered” if the Trust segregates assets determined to be liquid by the Advisors (in accordance with procedures established by the Board) equal to the exercise price. A put option is also covered if the Trust holds a put on the same security as the put written where the exercise price of the put held is (i) equal to or greater than the exercise price of the put written or (ii) less than the exercise price of the put written, provided the difference is maintained by the Trust in segregated assets determined to be liquid by the Advisors as described above.

An index- or sector-oriented option is considered “covered” if the Trust maintains with its custodian assets determined to be liquid in an amount equal to the contract value of the applicable basket of securities. An index or sector call option also is covered if the Trust holds a call on the same basket of securities as the call written where the exercise price of the call held is (i) equal to or less than the exercise price of the call written or (ii) greater than the exercise price of the call written, provided the difference is maintained by the Trust in segregated assets determined to be liquid. An index or sector put option also is covered if the Trust holds a put on the same basket of securities as the put written where the exercise price of the put held is (i) equal to or more than the exercise price of the put written or (ii) less than the exercise price of the put written, provided the difference is maintained by the Trust in segregated assets determined to be liquid. Because index and sector options both refer to options on baskets of securities and generally have similar characteristics, we refer to these types of options collectively as “index options.”

The Trust generally intends to write covered put and call options with respect to approximately 30% to 45% of its total assets, although this percentage may vary from time to time with market conditions. As the Trust writes covered calls over more of its portfolio, its ability to benefit from capital appreciation becomes more limited.

The Trust may hold or have exposure to equity securities of issuers of any size, including small and medium capitalization companies, and to issuers in any industry or sector. The Trust will not invest 25% or more of its total assets in securities of issuers in any single industry.

The Trust may invest in the securities of smaller, less seasoned companies. The Trust also may engage in short sales of securities and may lend its portfolio securities to banks or dealers which meet the creditworthiness standards established by the Board.

Although not intended to be a significant element in the Trust’s investment strategy, from time to time the Trust may purchase and sell derivative instruments such as exchange-listed and over-the-counter put and call options on securities, financial futures, equity indices and other financial instruments, purchase and sell financial futures contracts and options thereon, engage in swaps and purchase derivative instruments that combine features of these instruments for hedging and risk management purposes or to enhance total return. The percentage limitations set herein apply at the time of investment, and the Trust will not be required to sell securities because of subsequent changes in market values.

Leverage: Although the Agreement and Declaration of Trust of the Trust provides that the Board of the Trust may authorize the Trust to issue preferred shares or incur indebtedness, the Trust currently does not intend to issue preferred shares or incur indebtedness for investment purposes.

The Trust may enter into derivative transactions that have leverage embedded in them.

BlackRock Health Sciences Trust (BME)

The Trust’s investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives with exposure to the health sciences industry. Equity derivatives in which the Trust invests as part of this non-fundamental investment policy include purchased and sold (written) call and put options on equity securities of companies in the health sciences and related industries.

The Trust’s investment objective may be changed by the Board of Trustees without prior shareholder approval; however, the Trust will not change its policy of investing, under normal market conditions, at least 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives with exposure to the health sciences industry unless it provides shareholders with notice at least 60 days prior to changing this non-fundamental policy, or unless such change was previously approved by shareholders.

Companies in the health sciences industry include health care providers as well as businesses involved in researching, developing, producing, distributing or delivering medical, dental, optical, pharmaceutical or biotechnology products, supplies, equipment or services or that provide support services to these companies. These companies also include those that own or operate health facilities and hospitals or provide related administrative, management or financial support. Other health sciences industries in which the Trust may invest include: clinical testing laboratories; diagnostics; hospital, laboratory or physician ancillary products and support services; rehabilitation services; employer health insurance management services; and vendors of goods and services specifically to companies engaged in the health sciences. BlackRock Advisors, LLC (the “Manager”) determines, in its discretion, whether a company is engaged in the health sciences and related industries.

While the Trust will invest primarily in companies providing products and services for human health, it may also invest in companies whose products or services relate to the growth or survival of animals and plants. Non-human health sciences industries include companies engaged in the development, production or distribution of products or services that: increase crop, animal and animal product yields by enhancing growth or increasing disease resistance, improve agricultural product characteristics, such as taste, appearance, nutritional content and shelf life; reduce the cost of producing agricultural products; or improve pet health.

I N V E S T M E N T  O B J E C T I V E S ,  P O L I C I E S  A N D  R I S K S 185

Investment Objectives, Policies and Risks (continued)

Investment Objectives and Policies (continued)

The Trust will consider a company to be principally engaged in a health sciences or related industry if 50% or more of its revenues are derived from, or 50% or more of its assets are related to, its health sciences business. Although the Trust generally will invest in companies included in the Russell 3000^® Index, the Trust may invest in equity securities of health sciences companies with any size market capitalization, including small and mid-cap health sciences companies and companies that are not included in the Russell 3000^® Index.

As part of its investment strategy, the Trust employs an option strategy of writing (selling) covered call options on common stocks in its portfolio, writing other call and put options on individual common stocks and, to a lesser extent, writing call and put options on indices of health sciences securities. The Trust seeks to generate current gains from options premiums and to enhance the Trust’s risk-adjusted returns. The Trust generally intends to write call and put options with respect to approximately 30% to 50% of its total assets, although this percentage may vary from time to time with market conditions.

The Trust invests primarily in equity securities, including common stocks, preferred stocks, convertible securities, warrants and depositary receipts, of issuers engaged in the health sciences or related industries and equity interests in real estate investment trusts (“REITs”) that own hospitals. The Trust may invest in companies of any size market capitalization.

The Trust may invest in preferred securities, including preferred securities that may be converted into common stock or other securities of the same or a different issuer. The types of preferred securities in which the Trust may invest include trust preferred securities.

The Trust may invest in convertible securities. A convertible security is a bond, debenture, note, preferred security or other security that may be converted into or exchanged for a prescribed amount of common stock or other equity security of the same or a different issuer within a particular period of time at a specified price or formula.

The Trust may purchase warrants, which are privileges issued by corporations enabling the owners to subscribe to and purchase a specified number of shares of the corporation at a specified price during a specified period of time.

The Trust may invest in sponsored and unsponsored American Depositary Receipts (“ADRs”), European Depositary Receipts (“EDRs”), Global Depositary Receipts (“GDRs”) and other similar global instruments.

The Trust may invest in equity interests of REITs. REITs possess certain risks which differ from an investment in common stocks. REITs are financial vehicles that pool investor’s capital to purchase or finance real estate. REITs may concentrate their investments in specific geographic areas or in specific property types (i.e., hotels, shopping malls, residential complexes and office buildings).

The Trust may invest without limitation in securities of U.S. issuers and non-U.S. issuers located in countries throughout the world, including in developed and emerging markets. Foreign securities in which the Trust may invest may be U.S. dollar-denominated or non-U.S. dollar-denominated. For purposes of the Trust, a company is deemed to be a non-U.S. company if it meets the following tests: (i) such company was not organized in the United States; (ii) such company’s primary business office is not in the United States; (iii) the principal trading market for such company’s securities is not located in the United States; (iv) less than 50% of such company’s assets are located in the United States; or (v) 50% or more of such issuer’s revenues are derived from outside the United States.

The Trust may invest up to 20% of its total assets in other investments. These investments may include equity and debt securities of companies not engaged in the health sciences industry. Fixed-income securities in which the Trust may invest include bonds or other debt securities issued by U.S. or foreign (non-U.S.) corporations or other business entities and U.S. Government and agency securities. The Trust has no set policy regarding portfolio maturity or duration of the fixed-income securities it may hold, and such securities may be of any maturity.

The Trust reserves the right to invest up to 10% of its total assets in securities rated, at the time of investment, below investment grade quality, such as those rated “Ba” or below by Moody’s Investors Service, Inc. and “BB” or below by S&P Global Ratings, or securities comparably rated by other rating agencies or in securities determined by the Manager to be of comparable quality. Such securities commonly are referred to as “high yield” or “junk” bonds.

The Trust may invest in registered investment companies in accordance with the Investment Company Act of 1940, as amended (the “Investment Company Act”). The Investment Company Act generally prohibits the Trust from investing more than 5% of its assets in any one other investment company or more than 10% of its assets in all other investment companies.

In addition to the option strategies discussed above, the Trust may engage in strategic transactions to facilitate portfolio management, mitigate risks and generate total return. The Trust may use a variety of other investment management techniques and instruments. The Trust may purchase and sell futures contracts, enter into various interest rate transactions such as swaps, caps, floors or collars, currency transactions such as currency forward contracts, currency futures contracts, currency swaps or options on currency or currency futures and swap contracts (including, but not limited to, credit default swaps) and may purchase and sell exchange-listed and over-the-counter put and call options on securities and swap contracts, financial indices and futures contracts and use other derivative instruments or management techniques. The Trust also may purchase derivative instruments that combine features of these instruments.

In connection with its hedging and other risk management strategies, the Trust may also enter into contracts for the purchase or sale for future delivery (“future contracts”) of securities, aggregates of securities, financial indices, and U.S. Government debt securities or options on the foregoing to hedge the value of its portfolio securities that might result from a change in interest rates or market movements. The Trust may engage in such transactions for bona fide hedging, risk management and other appropriate portfolio management purposes.

The Trust may enter into such transactions without limit for bona fide strategic purposes, including risk management and duration management and other portfolio strategies. The Trust may also engage in transactions in futures contracts or related options for non-strategic purposes to enhance income or gain provided that the Trust will not enter into a futures contract or related option (except for closing transactions) for purposes other than bona fide strategic purposes, or risk management including duration management unless it does so consistent with the rules of the Commodities Futures Trading Commission (the “CFTC”).

186 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Investment Objectives, Policies and Risks (continued)

Investment Objectives and Policies (continued)

The Trust may engage in options and futures transactions on exchanges and options in the over-the-counter (“OTC”) markets.

The Trust intends to enter into options and futures transactions only with banks or dealers the Manager believes to be creditworthy at the time they enter into such transactions.

The CFTC subjects advisers to registered investment companies to regulation by the CFTC if a fund that is advised by the investment adviser either (i) invests, directly or indirectly, more than a prescribed level of its liquidation value in CFTC-regulated futures, options and swaps (“CFTC Derivatives”), or (ii) markets itself as providing investment exposure to such instruments. To the extent the Trust uses CFTC Derivatives, it intends to do so below such prescribed levels and will not market itself as a “commodity pool” or a vehicle for trading such instruments. Accordingly, the Manager has claimed an exclusion from the definition of the term “commodity pool operator” under the Commodity Exchange Act (“CEA”) pursuant to Rule 4.5 under the CEA. The Manager is not, therefore, subject to registration or regulation as a “commodity pool operator” under the CEA in respect of the Trust.

In order to enhance income or reduce fluctuations in net asset value, the Trust may sell or purchase call options on securities and indices based upon the prices of futures contracts and debt or equity securities that are traded on U.S. and non-U.S. securities exchanges and on the over-the-counter markets.

As with calls, the Trust may purchase put options on securities (whether or not it holds such securities in its portfolio), indices or future contracts. For the same purposes, the Trust may also sell puts on securities, indices or futures contracts on such securities if the Trust’s contingent obligations on such puts are secured by designating cash or liquid assets on its books and records having a value not less than the exercise price. The Trust will not sell puts if, as a result, more than 50% of the Trust’s assets would be required to be segregated on its books to cover its potential obligation under its hedging and other investment transactions.

The Trust may enter into interest rate swaps and the purchase or sale of interest rate caps and floors. The Trust expects to enter into these transactions primarily to preserve a return or spread on a particular investment or portion of its portfolio as a duration management technique or to protect against any increase in the price of securities the Trust anticipates purchasing at a later date. The Trust may enter into interest rate swaps, caps and floors on either an asset-based or liability-based basis.

The Trust intends to use these transactions for risk management purposes and not as a speculative investment. The Trust will not sell interest rate caps or floors that it does not own. The Trust will only enter into interest rate swap, cap or floor transactions with counterparties the Manager believes to be creditworthy at the time they enter into such transactions.

The Trust may engage in credit derivative transactions. There are two broad categories of credit derivatives: default price risk derivatives and market spread derivatives. Default price risk derivatives are linked to the price of reference securities or loans after a default by the issuer or borrower, respectively. Market spread derivatives are based on the risk that changes in market factors, such as credit spreads, can cause a decline in the value of a security, loan or index. There are three basic transactional forms for credit derivatives: swaps, options and structured instruments.

The Trust may enter into forward currency contracts to purchase or sell foreign currencies for a fixed amount of U.S. dollars or another foreign currency. A forward currency contract involves an obligation to purchase or sell a specific currency at a future date, which may be any fixed number of days (term) from the date of the forward currency contract agreed upon by the parties, at a price set at the time the forward currency contract is entered into. Forward currency contracts are traded directly between currency traders (usually large commercial banks) and their customers.

The Trust may make short sales of securities for risk management, in order to maintain portfolio flexibility or to enhance income or gain. The Trust will not make a short sale if, after giving effect to such sale, the market value of all securities sold short exceeds 25% of the value of its total assets or the Trust’s aggregate short sales of a particular class of securities exceeds 25% of the outstanding securities of that class. The Trust may also make short sales “against the box” without respect to such limitations. In this type of short sale, at the time of the sale, the Trust owns or has the immediate and unconditional right to acquire at no additional cost the identical security.

The Trust may invest in illiquid investments. Illiquid investments are subject to legal or contractual restrictions on disposition or lack an established secondary market. The sale of restricted and illiquid investments often requires more time and results in higher brokerage charges or dealer discounts and other selling expenses than does the sale of investments eligible for trading on national securities exchanges or in the over-the-counter markets. Restricted investments may sell at a price lower than similar investments that are not subject to restrictions on resale.

The Trust may purchase securities on a “when-issued” basis and may purchase or sell securities on a “forward commitment” basis in order to acquire the security or to hedge against anticipated changes in interest rates and prices. When-issued securities and forward commitments may be sold prior to the settlement date, but the Trust will enter into when-issued and forward commitments only with the intention of actually receiving or delivering the securities, as the case may be.

The Trust may lend securities with a value up to 33 1/3% of its total assets (including such loans) to banks, brokers and other financial institutions.

As temporary investments, the Trust may invest in repurchase agreements. The Trust will only enter into repurchase agreements with registered securities dealers or domestic banks that, in the opinion of the Manager, present minimal credit risk.

The Trust may deviate from its investment strategy and invest all or any portion of its assets in cash, cash equivalents or short-term debt securities when the Manager determines that it is temporarily unable to follow the Trust’s investment strategy or that it is impractical to do so or pending re-investment of proceeds received in connection with the sale of a security. The Trust may not achieve its investment objective when it does so. The Manager’s determination that it is temporarily unable to follow the Trust’s investment strategy or that it is impractical to do so will generally occur only in situations in which a market disruption event has occurred and where trading in the securities selected through application of the Trust’s investment strategy is extremely limited or absent. Short-term debt investments include U.S. Government securities, including bills, notes and bonds differing as to maturity and rates of interest that are either issued or guaranteed by the U.S. Treasury or by U.S. Government agencies or instrumentalities, certificates of deposit issued against funds deposited in a bank or a savings and loan association, repurchase agreements, which involve purchases of debt securities, and commercial paper, which consists of short-term unsecured promissory notes, including variable rate master demand notes issued by corporations to finance their current

I N V E S T M E N T  O B J E C T I V E S ,  P O L I C I E S  A N D  R I S K S 187

Investment Objectives, Policies and Risks (continued)

Investment Objectives and Policies (continued)

operations. Investments in commercial paper will be limited to commercial paper rated in the highest categories by a major rating agency and which mature within one year of the date of purchase or carry a variable or floating rate of interest.

Leverage: The Trust does not currently borrow money for investment purposes or have preferred shares outstanding, and has no present intention of borrowing money for investment purposes or issuing preferred shares in the future.

The Trust may enter into derivative transactions that have leverage embedded in them.

The Trust may enter into reverse repurchase agreements and “dollar roll” transactions.

BlackRock Health Sciences Term Trust (BMEZ)

The Trust’s investment objectives are to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust’s investment objectives may be changed by the Board of Trustees of the Trust (the “Board”) without prior shareholder approval.

BlackRock Advisors, LLC (the “Manager”) believes that the knowledge and experience of its Health Sciences Team enable it to evaluate the macro environment and assess its impact on health sciences companies and the various sub-industries within the health sciences group of industries. Within this framework, the Manager identifies stocks with attractive characteristics, evaluates the use of options and provides ongoing portfolio risk management.

The top-down or macro component of the investment process is designed to assess the various interrelated macro variables affecting the health sciences group of industries as a whole. The Manager evaluates health sciences sub-industries (i.e., pharmaceuticals, biotechnology, medical devices, healthcare services, etc.). Selection of sub-industries within the health sciences group of industries is a result of both the Manager’s sub-industry analysis, as well as the Manager’s bottom-up fundamental company analysis. Risk/reward analysis is a key component of both top-down and bottom-up analysis.

Bottom-up security selection is focused on identifying companies with the most attractive characteristics within each sub-industry of the health sciences group of industries. The Manager seeks to identify companies with strong product potential, solid earnings growth and/or earnings power which are under appreciated by investors, a quality management team and compelling relative and absolute valuation. The Manager believes that the knowledge and experience of its Health Sciences Team enables it to identify attractive health sciences securities.

The Manager intends to utilize option strategies that consist of writing (selling) call options on a portion of the common stocks in the Trust’s portfolio, as well as other option strategies such as writing other calls and puts or using options to manage risk. The portfolio management team will work closely to determine which option strategies to pursue to seek to generate current gains from options premiums and to enhance the Trust’s risk-adjusted returns.

Under normal market conditions, the Trust will invest at least 80% of its total assets in equity securities of companies principally engaged in the health sciences group of industries and equity derivatives with exposure to the health sciences group of industries. Equity derivatives in which the Trust invests as part of this non-fundamental investment policy include purchased and sold (written) call and put options on equity securities of companies in the health sciences group of industries.

The Trust will consider a company to be principally engaged in the health sciences group of industries if (i) it is classified in an industry within the health sciences group of industries by a third-party industry classification system or (ii) it is not classified in any industry by such third-party industry classification system and the Manager determines that the company is principally engaged in the health sciences group of industries.

Companies in the health sciences group of industries include health care providers as well as businesses involved in researching, developing, producing, distributing or delivering medical, dental, optical, pharmaceutical or biotechnology products, supplies, equipment or services or that provide support services to these companies. These companies also include those that own or operate health facilities and hospitals or provide related administrative, management or financial support. Other companies in the health sciences group of industries in which the Trust may invest include: clinical testing laboratories; diagnostics; hospital, laboratory or physician ancillary products and support services; rehabilitation services; employer health insurance management services; and vendors of goods and services specifically to companies engaged in the health sciences. The Trust will concentrate its investments in the health sciences group of industries.

While the Trust will invest primarily in companies providing products and services for human health, it may also invest in companies whose products or services relate to the growth or survival of animals and plants. Non-human health sciences companies include those engaged in the development, production or distribution of products or services that: increase crop, animal and animal product yields by enhancing growth or increasing disease resistance; improve agricultural product characteristics, such as taste, appearance, nutritional content and shelf life; reduce the cost of producing agricultural products; or improve pet health.

The Trust may invest in companies of any market capitalization located anywhere in the world, including companies located in emerging markets. The Trust will focus its investments in mid- and small-capitalization companies. Foreign securities in which the Trust may invest may be U.S. dollar-denominated or non-U.S. dollar-denominated.

The Trust invests primarily in equity securities, including common stocks, preferred stocks, convertible securities, warrants and depositary receipts, of health sciences companies and limited partnership interests in REITs that own hospitals.

The Trust may invest in shares of companies through IPOs. The Trust may also invest, without limit, in privately placed or restricted securities (including in Rule 144A securities, which are privately placed securities purchased by qualified institutional buyers), illiquid securities and securities in which no secondary market is readily available, including those of private companies. Issuers of these securities may not have a class of securities registered, and may not be subject to periodic reporting, pursuant to the Securities Exchange Act of 1934, as amended. The Trust intends to invest up to 25% of its total assets, measured at the time of investment, in illiquid privately placed or restricted securities. The Trust expects certain of such investments to be in “late-stage private securities,” which are securities of private companies that have demonstrated sustainable

188 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Investment Objectives, Policies and Risks (continued)

Investment Objectives and Policies (continued)

business operations and generally have a well-known product or service with a strong market presence. Late-stage private companies have generally had large cash flows from their core business operations and are expanding into new markets with their products or services. Late-stage private companies may also be referred to as “pre-IPO companies.”

The Trust may invest up to 20% of its total assets in other investments, including equity securities issued by companies that are not principally engaged in the health sciences group of industries and debt securities issued by any issuer, including non-investment grade debt securities. The Trust’s investments in non-investment grade securities and those deemed to be of similar quality are considered speculative with respect to the issuer’s capacity to pay interest and repay principal and are commonly referred to as “junk” or “high yield” securities. The Trust has no set policy regarding portfolio maturity or duration of the fixed-income securities it may hold, and such securities may be of any maturity.

As part of its investment strategy, the Trust intends to employ a strategy of writing (selling) covered call options on a portion of the common stocks in its portfolio, writing (selling) other call and put options on individual common stocks, and, to a lesser extent, writing (selling) call and put index options. This options writing strategy is intended to generate current gains from options premiums and to enhance the Trust’s risk-adjusted returns. A substantial portion of the options written by the Trust may be over-the-counter (“OTC”) options.

During temporary defensive periods (i.e., in response to adverse market, economic or political conditions), the Trust may invest up to 100% of its total assets in liquid, short-term investments, including high quality, short-term securities. The Trust may not achieve its investment objectives under these circumstances. The Manager’s determination that it is temporarily unable to follow the Trust’s investment strategy or that it is impractical to do so will generally occur only in situations in which a market disruption event has occurred and where trading in the securities selected through application of the Trust’s investment strategy is extremely limited or absent.

The Trust may purchase and sell futures contracts, enter into various interest rate transactions such as swaps, caps, floors or collars, currency transactions such as currency forward contracts, currency futures contracts, currency swaps or options on currency or currency futures and swap contracts (including, but not limited to, credit default swaps) and may purchase and sell exchange-listed and OTC put and call options on securities and swap contracts, financial indices and futures contracts and use other derivative instruments or management techniques for duration management and other risk management purposes, including to attempt to protect against possible changes in the market value of the Trust’s portfolio resulting from trends in the securities markets and changes in interest rates or to protect the Trust’s unrealized gains in the value of its portfolio securities, to facilitate the sale of portfolio securities for investment purposes, to establish a position in the securities markets as a temporary substitute for purchasing particular securities or to enhance income or gain.

The Trust may also invest in securities of other open- or closed-end investment companies, including exchange-traded funds and business development companies, subject to applicable regulatory limits, that invest primarily in securities of the types in which the Trust may invest directly. The Trust classifies its investments in such investment companies as “equity securities” for purposes of its investment policies based upon such investment companies’ stated investment objectives, policies and restrictions.

The Trust may lend securities with a value of up to 33 1/3% of its total assets (including such loans) to financial institutions that provide cash or securities issued or guaranteed by the U.S. Government as collateral.

The Trust may also engage in short sales of securities. The Trust will not make a short sale if, after giving effect to such sale, the market value of all securities sold short exceeds 25% of the value of its Managed Assets or the Trust’s aggregate short sales of a particular class of securities exceeds 25% of the outstanding securities of that class. The Trust may make short sales “against the box” without respect to such limitations. In this type of short sale, at the time of the sale the Trust owns or has the immediate and unconditional right to acquire at no additional cost the identical security. “Managed Assets” means the total assets of the Trust (including any assets attributable to money borrowed for investment purposes) minus the sum of the Trust’s accrued liabilities (other than money borrowed for investment purposes).

Unless otherwise stated herein, the Trust’s investment policies are non-fundamental policies and may be changed by the Board without prior shareholder approval. The percentage limitations applicable to the Trust’s portfolio described herein apply only at the time of initial investment and the Trust will not be required to sell investments due to subsequent changes in the value of investments that it owns. The Trust’s investment objectives may be changed by the Board without prior shareholder approval; however, the Trust will not change its policy of investing, under normal market conditions, at least 80% of its total assets in equity securities of companies principally engaged in the health sciences group of industries and equity derivatives with exposure to the health sciences group of industries unless it provides shareholders at least 60 days’ written notice before implementation of the change in compliance with rules of the Securities and Exchange Commission.

Leverage: The Trust currently does not intend to borrow money or issue debt securities or preferred shares. Although it has no present intention to do so, the Trust reserves the right to borrow money from banks or other financial institutions, or issue debt securities or preferred shares, in the future if it believes that market conditions would be conducive to the successful implementation of a leveraging strategy through borrowing money or issuing debt securities or preferred shares. Any such leveraging will not be fully achieved until the proceeds resulting from the use of leverage have been invested in accordance with the Trust’s investment objectives and policies.

The Trust may enter into reverse repurchase agreements with respect to its portfolio investments subject to certain investment restrictions.

The Trust may enter into “dollar roll” transactions.

The Trust may enter into derivative transactions that have leverage embedded in them.

The Trust may also borrow money as a temporary measure for extraordinary or emergency purposes, including the payment of dividends and the settlement of securities transactions which otherwise might require untimely dispositions of Trust securities.

I N V E S T M E N T  O B J E C T I V E S ,  P O L I C I E S  A N D  R I S K S 189

Investment Objectives, Policies and Risks (continued)

Investment Objectives and Policies (continued)

BlackRock Innovation and Growth Term Trust (BIGZ)

The Trust’s investment objectives are to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust is not intended as, and you should not construe it to be, a complete investment program. There can be no assurance that the Trust’s investment objectives will be achieved or that the Trust’s investment program will be successful. The Trust’s investment objectives may be changed by the Board of Trustees of the Trust (the “Board”) without prior shareholder approval.

In selecting investments for the Trust, BlackRock Advisors, LLC (the “Manager”) focuses on equity securities of mid- and small-capitalization growth companies that are “innovative.” These are companies that have introduced, or are seeking to introduce, a new product or service that potentially changes the marketplace. In evaluating innovative companies, the Manager seeks to identify, using its own internal research and analysis, companies capitalizing on innovation or that are enabling the further development of the theme of innovation in the markets in which they operate.

Among other things, common criteria for innovative companies across industries may include developing new products, selling in new markets or channels, applying a new or superior technology to legacy industries, refining existing processes for efficiency, changing or pivoting business model, or creating tools that empower new breakthroughs.

In addition, the Trust seeks to invest in companies where, in the opinion of the Manager, free cash flow is likely to grow for a sustained period. Factors considered in the Manager’s analysis of a company may include 1) a large and underpenetrated addressable market, 2) a technology or service model that creates recurring demand for product, and 3) a competitive landscape that allows for stable or expanding margins. The Manager’s outlook for a company based upon these and other factors is then compared to the outlook of the company implied in the current share price of the company. The Manager looks to invest in companies where its view of future cash flows is more favorable than that which it believes is reflected by the current price.

The Manager will identify trends that have ramifications for individual companies or entire industries. Risk/reward analysis is a key component of both top-down and bottom-up analysis.

Bottom-up security selection is focused on identifying innovative companies with the most attractive growth characteristics. The Manager seeks to identify companies with strong product potential, solid earnings growth and/or earnings power which are under appreciated by investors, a quality management team and compelling relative and absolute valuation. The Manager believes that the knowledge and experience of its investment team enables it to identify attractive innovative companies.

The Trust intends to utilize option strategies that consist of writing (selling) call options on a portion of the common stocks in its portfolio, as well as other option strategies such as writing other calls and puts or using options to manage risk. The portfolio management team will work closely to determine which option strategies to pursue to seek to generate current gains from options premiums and to enhance the Trust’s risk-adjusted returns.

The Trust will invest primarily in equity securities issued by mid- and small-capitalization companies that the Manager believes have above-average earnings growth potential.

Equity securities include common stocks, preferred stocks, convertible securities, warrants and depositary receipts, though the Trust seeks to buy primarily common stock. Although universal definitions of mid-capitalization companies and small-capitalization companies do not exist, the Trust generally defines mid-capitalization and small-capitalization companies as those companies with market capitalizations, at the time of the Trust’s investment, comparable in size to the companies in the Russell 2500™ Growth Index (between $20.75 million and $20.98 billion as of December 31, 2023). In the future, the Trust may define mid- and small-capitalization companies using a different index or classification system.

The Trust may invest in shares of companies through IPOs. The Trust may also invest, without limit, in privately placed or restricted securities (including in Rule 144A securities, which are privately placed securities purchased by qualified institutional buyers), illiquid securities and securities in which no secondary market is readily available, including those of private companies. Issuers of these securities may not have a class of securities registered, and may not be subject to periodic reporting, pursuant to the Exchange Act. Under normal market conditions, the Trust currently intends to invest up to 25% of its total assets, measured at the time of investment, in illiquid privately placed or restricted securities. The Trust expects certain of such investments to be in “late-stage private securities,” which are securities of private companies that have demonstrated sustainable business operations and generally have a well-known product or service with a strong market presence. Late-stage private companies have generally had large cash flows from their core business operations and are expanding into new markets with their products or services. Late-stage private companies may also be referred to as “pre-IPO companies.”

The Trust may invest up to 25% of its assets in securities of foreign companies, including companies located in emerging markets. Foreign securities in which the Trust may invest may be U.S. dollar-denominated or non-U.S. dollar-denominated.

The Trust may also invest in securities of other open- or closed-end investment companies, including exchange-traded funds and business development companies, subject to applicable regulatory limits, that invest primarily in securities of the types in which the Trust may invest directly. The Trust classifies its investments in such investment companies as “equity securities” for purposes of its investment policies based upon such investment companies’ stated investment objectives, policies and restrictions.

As part of its investment strategy, the Trust intends to employ a strategy of writing (selling) covered call options on a portion of the common stocks in its portfolio, writing (selling) other call and put options on individual common stocks, including uncovered call and put options, and, to a lesser extent, writing (selling) covered and uncovered call and put index options. This options writing strategy is intended to generate current gains from options premiums and to enhance the Trust’s risk-adjusted returns. A substantial portion of the options written by the Trust may be over-the-counter options.

The Trust may also purchase and sell futures contracts, enter into various interest rate transactions such as swaps, caps, floors or collars, currency transactions such as currency forward contracts, currency futures contracts, currency swaps or options on currency or currency futures and swap contracts (including, but not limited to, credit default swaps) and may purchase and sell exchange-listed and over-the-counter (“OTC”) put and call options on securities and swap contracts, financial indices and futures contracts and use other derivative instruments or management techniques for duration management and other risk management purposes, including to attempt to protect

190 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Investment Objectives, Policies and Risks (continued)

Investment Objectives and Policies (continued)

against possible changes in the market value of the Trust’s portfolio resulting from trends in the securities markets and changes in interest rates or to protect the Trust’s unrealized gains in the value of its portfolio securities, to facilitate the sale of portfolio securities for investment purposes, to establish a position in the securities markets as a temporary substitute for purchasing particular securities or to enhance income or gain.

During temporary defensive periods (i.e., in response to adverse market, economic or political conditions), the Trust may invest up to 100% of its total assets in liquid, short-term investments, including high quality, short-term securities. The Trust may not achieve its investment objectives under these circumstances. The Manager’s determination that it is temporarily unable to follow the Trust’s investment strategy or that it is impractical to do so will generally occur only in situations in which a market disruption event has occurred and where trading in the securities selected through application of the Trust’s investment strategy is extremely limited or absent.

The Trust may lend securities with a value of up to 33 1/3% of its total assets (including such loans) to financial institutions that provide cash or securities issued or guaranteed by the U.S. Government as collateral.

The Trust may engage in active and frequent trading of portfolio securities to achieve its investment objectives.

Unless otherwise stated herein, the Trust’s investment policies are non-fundamental policies and may be changed by the Board without prior shareholder approval. The percentage limitations applicable to the Trust’s portfolio described in this prospectus apply only at the time of initial investment and the Trust will not be required to sell investments due to subsequent changes in the value of investments that it owns. The Trust’s investment objectives may be changed by the Board without prior shareholder approval.

Leverage: The Trust currently does not intend to borrow money or issue debt securities or preferred shares. The Trust is, however, permitted to borrow money or issue debt securities in an amount up to 33 1/3% of its Managed Assets (50% of its net assets), and issue preferred shares in an amount up to 50% of its Managed Assets (100% of its net assets). “Managed Assets” means the total assets of the Trust (including any assets attributable to money borrowed for investment purposes) minus the sum of the Trust’s accrued liabilities (other than money borrowed for investment purposes). Although it has no present intention to do so, the Trust reserves the right to borrow money from banks or other financial institutions, or issue debt securities or preferred shares, in the future if it believes that market conditions would be conducive to the successful implementation of a leveraging strategy through borrowing money or issuing debt securities or preferred shares.

The Trust is permitted to leverage its portfolio by entering into one or more credit facilities.

The Trust may enter into reverse repurchase agreements with respect to its portfolio investments subject to the Trust’s investment restrictions.

The Trust may enter into “dollar roll” transactions.

The Trust may enter into derivative transactions that have leverage embedded in them.

The Trust may also borrow money as a temporary measure for extraordinary or emergency purposes, including the payment of dividends and the settlement of securities transactions which otherwise might require untimely dispositions of Trust securities.

BlackRock Resources & Commodities Strategy Trust (BCX)

The Trust’s primary investment objective is to seek high current income and current gains, with a secondary objective of capital appreciation. The Trust will seek to achieve its objectives by investing substantially all of its assets in equity securities issued by commodity or natural resources companies, derivatives with exposure to commodity or natural resources companies or investments in securities and derivatives linked to the underlying price movement of commodities or natural resources, including commodity-linked derivatives such as commodity-linked notes, commodity futures, forward contracts and swaps and other similar derivative instruments and investment vehicles that invest in commodities, natural resources or commodity-linked derivatives. The Trust’s investment objectives are not fundamental and may be changed by the Board of Trustees of the Trust (the “Board”).

The Trust will seek to achieve its investment objectives, under normal market conditions, by investing at least 80% of its total assets in equity securities issued by commodity or natural resources companies, derivatives with exposure to commodity or natural resources companies or investments in securities and derivatives linked to the underlying price movement of commodities or natural resources, including commodity-linked derivatives such as commodity-linked notes, commodity futures, forward contracts and swaps and other similar derivative instruments and investment vehicles that invest in commodities, natural resources or commodity-linked derivatives. Commodities and natural resources include, without limitation, minerals, metals (including precious, industrial and rare metals), steel, agricultural products and commodities, livestock, environmental commodities, wool, ethanol, chemicals, forest products (including wood, pulp and paper), plastic, rubber, sugar, cotton, cocoa, coffee, basic materials, building materials, water, oil, gas, consumable fuel, energy and other natural resources. Commodity and natural resources companies, include, but are not limited to, companies in commodities, natural resources and energy businesses and in associated businesses and companies that provide services or have exposure to such businesses (collectively, the “Commodities and Natural Resources Sector”). These companies include, without limitation, companies engaged in the exploration, ownership, production, refinement, processing, transportation, distribution or marketing of commodities or natural resources, companies that use commodities and natural resources extensively in their products, including companies that are engaged in businesses such as integrated oil, oil and gas exploration and production, gold, metals and minerals, steel and iron ore production, aluminum and related products, energy services, and technology, metal production, forest products, including timber and related wood and paper products, chemicals, fertilizer and agricultural chemicals, building materials, coal and other consumable fuel, alternative energy sources, environmental services and agricultural products (including crop growers, owners of plantations, and companies that produce and process foods), as well as related transportation companies and equipment manufacturers. The Trust will consider a company to be a commodity or natural resources company if: (i) at least 50% of the company’s assets, income, sales or profits are committed to or derived from the Commodities and Natural Resources Sector; or (ii) a third party classification (such as (a) Standard Industry Classifications and the North American Industry Classification

I N V E S T M E N T  O B J E C T I V E S ,  P O L I C I E S  A N D  R I S K S 191

Investment Objectives, Policies and Risks (continued)

Investment Objectives and Policies (continued)

System, each of which is published by the Executive Office of the President, Office of Management and Budget and (b) classifications used by third party data providers including, without limitation, FactSet Research Systems Inc. and MSCI Barra), has given the company an industry or sector classification consistent with the Commodities and Natural Resources Sector.

Equity securities held by the Trust may include common stocks, preferred stocks, convertible securities, warrants, depositary receipts, equity interests in Canadian Royalty Trusts, and equity interests in master limited partnerships (“MLPs”). The Trust will not invest more than 25% of the value of its total assets in MLPs. The Trust’s economic exposure to securities and derivatives linked to the underlying price movements of commodities or natural resources, including commodity-linked derivatives such as commodity-linked notes, commodity futures, forward contracts and swaps and other similar derivative instruments and investment vehicles that invest in commodities, natural resources or commodity-linked derivatives (“Commodity-Related Instruments”) will not exceed 20% of its total assets. Commodity-Related Instruments may include, but will not be limited to, investments in structured notes, partnership interests, exchange-traded funds that make commodity-related or natural resources-related investments, mutual funds and strategic transactions, including futures contracts on commodities and natural resources, forward contracts on commodities and natural resources and swap contracts on commodities and natural resources.

The Trust may invest in such Commodity-Related Instruments either directly or indirectly through the BlackRock Cayman Resources & Commodities Strategy Fund, Ltd., a wholly-owned subsidiary of the Trust formed in the Cayman Islands (the “Subsidiary”). Investments in the Subsidiary are intended to provide the Trust with exposure to commodities market returns within the limitations of the federal tax requirements that apply to the Trust. The Trust may gain exposure to certain Commodity-Related Instruments and certain other commodity-related and natural resources-related investments that, if the Trust invested in such investments directly, would not produce qualifying income for purposes of the income tests applicable to regulated investment companies under the Internal Revenue Code of 1986, as amended, by investing in the Subsidiary. The Manager is the manager of the Subsidiary. The Subsidiary (unlike the Trust) may invest without limitation in commodity-related instruments.

The Subsidiary will be managed pursuant to compliance policies and procedures that are the same, in all material respects, as the policies and procedures adopted by the Trust. As a result, the Manager, in managing the Subsidiary’s portfolio, will be subject to the same investment policies and restrictions that apply to the management of the Trust, and, in particular, to the requirements relating to portfolio leverage, liquidity, brokerage, and the timing and method of the valuation of the Subsidiary’s portfolio investments and shares of the Subsidiary. The Trust’s Chief Compliance Officer will oversee implementation of the Subsidiary’s policies and procedures, and make periodic reports to the Board regarding the Subsidiary’s compliance with its policies and procedures. The Trust and Subsidiary will test for compliance with certain investment restrictions on a consolidated basis, except that with respect to the Subsidiary’s investments in certain securities that may involve leverage, the Subsidiary will comply with asset segregation requirements to the same extent as the Trust.

The Manager will provide investment management and other services to the Subsidiary pursuant to the investment management agreement among the Manager, the Trust and the Subsidiary. The Trust and the Subsidiary will pay the Manager based on the Trust’s assets (excluding the value of the Trust’s interest in the Subsidiary) and the Subsidiary’s assets, respectively. The Subsidiary has also entered into separate contracts for the provision of custody and audit services with the same or with affiliates of the same service providers that provide those services to the Trust. The financial statements of the Subsidiary are consolidated with the Trust’s financial statements in the Trust’s annul and semi-annual reports.

Although the Trust is permitted to invest up to 20% of its total assets in Commodity-Related Instruments, the Trust is not required to invest in Commodity-Related Instruments and does not currently expect to invest in securities and derivatives linked to the underlying price movement of commodities or natural resources. The Trust may invest in Commodity-Related Instruments (either directly or through the Subsidiary) when BlackRock Advisors, LLC (the “Manager”) or BlackRock International Limited (“BIL” and together with the Manager, the “Advisors”), the Trust’s sub-advisor, believes it is advantageous for the Trust to do so.

While permitted, the Trust does not currently expect to invest in securities and derivatives linked to the underlying price movement of commodities or natural resources; therefore, the Trust does not currently intend to invest any assets in the Subsidiary.

The Commodity Futures Trading Commission (the “CFTC”) subjects advisers to registered investment companies to regulation by the CFTC if a fund that is advised by the investment adviser either (i) invests directly or indirectly more than a prescribed level of its liquidation value in CFTC-regulated futures, options and swaps (“CFTC Derivatives”), or (ii) markets itself as providing investment exposure to such instruments. To the extent the Trust uses CFTC Derivatives, it intends to do so below such prescribed levels and will not market itself as a “commodity pool” or a vehicle for trading such instruments. Accordingly, the Manager has claimed an exclusion from the definition of the term “commodity pool operator” under the Commodity Exchange Act (“CEA”) pursuant to Rule 4.5 under the CEA. The Manager is not, therefore, subject to registration or regulation as a “commodity pool operator” under the CEA in respect of the Trust.

The Trust may invest in companies of any market capitalization located anywhere in the world. The Trust expects to invest primarily in companies located in developed countries, but may invest in companies located in emerging markets.

The Trust may invest up to 20% of its total assets in debt securities issued by companies in the Commodities and Natural Resources Sector or any type of securities issued by companies that are not in the Commodities and Natural Resources Sector.

As part of its investment strategy, the Trust may employ a strategy of writing (selling) covered call options on a portion of the common stocks in its portfolio, writing (selling) covered put options and, to a lesser extent, writing (selling) covered call and put options on indices of securities and sectors of securities. This option strategy is intended to generate current gains from option premiums as a means to enhance distributions payable to the Trust’s shareholders.

In addition to the option strategies discussed above, the Trust may engage in strategic transactions for hedging purposes or to enhance total return. The Trust may also engage in short sales of securities.

The Trust may lend securities with a value up to 33 1/3% of its total assets (including such loans) to financial institutions that provide cash or securities issued or guaranteed by the U.S. Government as collateral.

192 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Investment Objectives, Policies and Risks (continued)

Investment Objectives and Policies (continued)

The Trust may implement various temporary “defensive” strategies at times when the Advisors determine that conditions in the markets make pursuing the Trust’s basic investment strategy inconsistent with the best interests of its shareholders. These strategies may include investing all or a portion of the Trust’s assets in U.S. Government obligations and short-term debt securities that may be either tax-exempt or taxable.

Under current market conditions, the Trust currently does not intend to engage in short sales or incur indebtedness or issue preferred shares for investment purposes, except the Trust may engage for hedging purposes, risk management, or to enhance total return, including engaging in transactions, such as options, futures, swaps, foreign currency transactions, such as forward foreign currency contracts, currency swaps or options on currency and currency futures and other derivatives transactions , repurchase agreements, reverse repurchase agreements, when issued or forward commitment transactions and similar investment strategies, which may give rise to a form of leverage.

Unless otherwise stated herein, the Trust’s investment objectives and investment policies are non-fundamental policies and may be changed by the Board. In addition, the percentage limitations applicable to the Trust’s portfolio described herein apply only at the time of investment, and the Trust will not be required to sell investments due to subsequent changes in the value of investments that it owns.

BlackRock Science and Technology Trust (BST)

The Trust’s investment objectives are to provide income and total return through a combination of current income, current gains and long-term capital appreciation. The Trust’s investment objectives may be changed by the Board of Trustees (the “Board”) without prior shareholder approval.

BlackRock Advisors, LLC (the “Manager”) may consider a variety of factors when choosing investments for the Trust, such as:

• selecting companies with the potential for rapid and sustainable growth from the development, advancement and use of science and/or technology (high growth science and technology stocks); and

• identifying companies that have above-average return potential based on factors such as revenue and earnings growth, profitability, valuation and dividend yield (cyclical science and technology stocks.

In addition, a variety of countries, including emerging market countries, and industries are likely to be represented in the Trust’s portfolio.

The Trust generally will sell a stock when, in the Manager’s opinion, the stock is fully valued, there is a need to rebalance the portfolio or there is a better opportunity elsewhere.

The Trust may engage in active and frequent trading of portfolio securities to seek to achieve its investment objectives.

Under normal market conditions, the Trust invests at least 80% of its total assets in equity securities issued by U.S. and non-U.S. science and technology companies in any market capitalization range, selected for their rapid and sustainable growth potential from the development, advancement and use of science and/or technology (high growth science and technology stocks), and/or potential to generate current income from advantageous dividend yields (cyclical science and technology stocks).

Science and technology companies are companies whose products, processes or services, in the Manager’s view, are being, or are expected to be, significantly benefited by the use or commercial application of scientific or technological developments or discoveries. These companies include companies that, in the Manager’s view, derive a competitive advantage by the application of scientific or technological developments or discoveries to grow their business or increase their competitive advantage, as well as companies that utilize science and/or technology as an agent of change to significantly enhance their business opportunities.

Science, technology and science- or technology-related companies may include companies operating in any industry, including, but not limited to software, internet software & services, IT services, hardware, communications equipment, semiconductors and semiconductor equipment, media, internet retail, consumer finance, life sciences tools & services, biotechnology, pharmaceuticals, energy, defense/aerospace, diversified telecom services and wireless telecom services. Examples of potential high growth companies include those operating in IT services, the internet, software and sciences; examples of potential cyclical companies include those operating in hardware, telecom, semiconductors and components. The Manager determines, in its discretion, whether a company is a science, technology or science- or technology-related company.

The Trust may invest in companies of any market capitalization located anywhere in the world, including companies located in emerging markets. Equity securities in which the Trust may invest include common stocks, preferred stocks, convertible securities, warrants, depositary receipts, exchange-traded funds and equity interests in real estate investment trusts and master limited partnerships. From time to time, the Trust may invest in shares of companies through initial public offerings. The Trust may also invest, without limit, in privately placed or restricted securities (including in Rule 144A securities, which are privately placed securities purchased by qualified institutional buyers), illiquid securities and securities in which no secondary market is readily available, including those of private companies. Issuers of these securities may not have a class of securities registered, and may not be subject to periodic reporting, pursuant to the Securities Exchange Act of 1934, as amended. The Trust currently intends to invest up to 25% of its total assets, measured at the time of investment, in illiquid privately placed or restricted securities. Foreign securities in which the Trust may invest may be U.S. dollar-denominated or non-U.S. dollar-denominated.

The Trust may also invest in securities of other open- or closed-end investment companies, including exchange-traded funds and business development companies, subject to applicable regulatory limits, that invest primarily in securities of the types in which the Trust may invest directly. The Trust classifies its investments in such investment companies as “equity securities” for purposes of its investment policies based upon such investment companies’ stated investment objectives, policies and restrictions.

The Trust will concentrate its investments in companies operating in one or more industries within the technology group of industries.

The Trust may invest up to 20% of its total assets in equity securities issued by companies that are not science or technology companies and in debt securities issued by any issuer, including non-investment grade debt securities. The Trust’s investments in non-investment grade securities and those deemed to be of similar quality are considered speculative with respect to the issuer’s capacity to pay interest and repay principal and are commonly referred to as “junk” or “high yield” securities.

I N V E S T M E N T  O B J E C T I V E S ,  P O L I C I E S  A N D  R I S K S 193

Investment Objectives, Policies and Risks (continued)

Investment Objectives and Policies (continued)

As part of its investment strategy, the Trust intends to employ a strategy of writing (selling) covered call options on a portion of the common stocks in its portfolio, writing (selling) other call and put options on individual common stocks, and, to a lesser extent, writing (selling) call and put index options. This options writing strategy is intended to generate current gains from options premiums and to enhance the Trust’s risk-adjusted returns. A substantial portion of the options written by the Trust may be over-the-counter options.

During temporary defensive periods (i.e., in response to adverse market, economic or political conditions), the Trust may invest up to 100% of its total assets in liquid, short-term investments, including high quality, short-term securities. The Trust may not achieve its investment objectives under these circumstances. The Manager’s determination that it is temporarily unable to follow the Trust’s investment strategy or that it is impractical to do so will generally occur only in situations in which a market disruption event has occurred and where trading in the securities selected through application of the Trust’s investment strategy is extremely limited or absent.

The Trust may invest in structured instruments (such as equity-linked notes) for investment purposes, as an alternative or complement to its options writing strategy or for risk management or leveraging purposes.

The Trust may purchase and sell futures contracts, enter into various interest rate transactions such as swaps, caps, floors or collars, currency transactions such as currency forward contracts, currency futures contracts, currency swaps or options on currency or currency futures and swap contracts (including, but not limited to, credit default swaps) and may purchase and sell exchange-listed and over-the-counter put and call options on securities and swap contracts, financial indices and futures contracts and use other derivative instruments or management techniques for duration management and other risk management purposes, including to attempt to protect against possible changes in the market value of the Trust’s portfolio resulting from trends in the securities markets and changes in interest rates or to protect the Trust’s unrealized gains in the value of its portfolio securities, to facilitate the sale of portfolio securities for investment purposes, to establish a position in the securities markets as a temporary substitute for purchasing particular securities or to enhance income or gain.

The Trust may lend securities with a value of up to 33 1/3% of its total assets (including such loans) to financial institutions that provide cash or securities issued or guaranteed by the U.S. Government as collateral.

The Trust may also engage in short sales of securities. The Trust will not make a short sale if, after giving effect to such sale, the market value of all securities sold short exceeds 25% of the value of its Managed Assets or the Trust’s aggregate short sales of a particular class of securities exceeds 25% of the outstanding securities of that class. The Trust may make short sales “against the box” without respect to such limitations. In this type of short sale, at the time of the sale the Trust owns or has the immediate and unconditional right to acquire at no additional cost the identical security. “Managed Assets” means the total assets of the Trust (including any assets attributable to money borrowed for investment purposes) minus the sum of the Trust’s accrued liabilities (other than money borrowed for investment purposes).

Unless otherwise stated herein, the Trust’s investment policies are non-fundamental policies and may be changed by the Board without prior shareholder approval. The percentage limitations applicable to the Trust’s portfolio described herein apply only at the time of initial investment and the Trust will not be required to sell investments due to subsequent changes in the value of investments that it owns. The Trust’s policy to invest at least 80% of its total assets in equity securities issued by U.S. and non-U.S. science and technology companies in any market capitalization range may be changed by the Board; however, if this policy changes, the Trust will provide shareholders at least 60 days’ written notice before implementation of the change in compliance with rules of the Securities and Exchange Commission.

Leverage: The Trust currently does not intend to borrow money or issue debt securities or preferred shares. Although it has no present intention to do so, the Trust reserves the right to borrow money from banks or other financial institutions, or issue debt securities or preferred shares, in the future if it believes that market conditions would be conducive to the successful implementation of a leveraging strategy through borrowing money or issuing debt securities or preferred shares.

The Trust may enter into reverse repurchase agreements with respect to its portfolio investments subject to certain investment restrictions.

The Trust may enter into “dollar roll” transactions.

The Trust may enter into derivative transactions that have leverage embedded in them.

The Trust may also borrow money as a temporary measure for extraordinary or emergency purposes, including the payment of dividends and the settlement of securities transactions which otherwise might require untimely dispositions of Trust securities.

BlackRock Science and Technology Term Trust (BSTZ)

The Trust’s investment objectives are to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust’s investment objectives may be changed by the Board of Trustees of the Trust (the “Board”) without prior shareholder approval.

BlackRock Advisors, LLC (the “Manager”) may consider a variety of factors when choosing investments for the Trust, but expects to select companies with the potential for rapid and sustainable growth from the development, advancement and use of science and/or technology.

In addition, a variety of countries, including emerging market countries, and industries are likely to be represented in the Trust’s portfolio.

The Trust generally will sell a stock when, in the Manager’s opinion, the stock is fully valued, there is a need to rebalance the portfolio or there is a better opportunity elsewhere.

The Trust may engage in active and frequent trading of portfolio securities to seek to achieve its investment objectives.

Under normal market conditions, the Trust will invest at least 80% of its total assets in equity securities issued by U.S. and non-U.S. science and technology companies in any market capitalization range, selected for their rapid and sustainable growth potential from the development, advancement and use of science and/or technology.

194 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Investment Objectives, Policies and Risks (continued)

Investment Objectives and Policies (continued)

Science and technology companies are companies whose products, processes or services, in the Manager’s view, are being, or are expected to be, significantly benefited by the use or commercial application of scientific or technological developments or discoveries. These companies include companies that, in the Manager’s view, derive a competitive advantage by the application of scientific or technological developments or discoveries to grow their business or increase their competitive advantage, as well as companies that utilize science and/or technology as an agent of change to significantly enhance their business opportunities.

Science, technology and science- or technology-related companies may include companies operating in any industry, including, but not limited to software, internet software & services, IT services, hardware, communications equipment, semiconductors and semiconductor equipment, media, internet retail, consumer finance, life sciences tools & services, biotechnology, pharmaceuticals, energy, defense/aerospace, diversified telecom services and wireless telecom services. It is anticipated that the Trust’s investments will be focused on companies within such industries that the Manager expects will generate a majority of their revenues from the development, advancement, use or sale of new and emerging, or “next generation,” science- or technology-related products, processes or services. There is no assurance, however, that any of the Trust’s assets will be invested in such companies at any time. The Manager determines, in its discretion, whether a company is a science, technology or science- or technology-related company.

The Trust may invest in companies of any market capitalization located anywhere in the world, including companies located in emerging markets. Equity securities in which the Trust may invest include common stocks, preferred stocks, convertible securities, warrants, depositary receipts, exchange-traded funds (“ETFs”) and equity interests in real estate investment trusts (“REITs”) and master limited partnerships. The Trust may invest in shares of companies through initial public offerings (“IPOs”). The Trust may also invest, without limit, in privately placed or restricted securities (including in Rule 144A securities, which are privately placed securities purchased by qualified institutional buyers), illiquid securities and securities in which no secondary market is readily available, including those of private companies. Issuers of these securities may not have a class of securities registered, and may not be subject to periodic reporting, pursuant to the Securities Exchange Act of 1934, as amended. Under normal market conditions, the Trust currently intends to invest up to 25% of its total assets, measured at the time of investment, in illiquid privately placed or restricted securities. The Trust expects certain of such investments to be in “pre-IPO securities,” which are securities of new and early stage companies, often funded by venture capital, whose securities have not been offered to the public and are not publicly traded. Foreign securities in which the Trust may invest may be U.S. dollar-denominated or non-U.S. dollar-denominated.

The Trust may also invest in securities of other open- or closed-end investment companies, including ETFs and business development companies, subject to applicable regulatory limits, that invest primarily in securities of the types in which the Trust may invest directly. The Trust classifies its investments in such investment companies as “equity securities” for purposes of its investment policies based upon such investment companies’ stated investment objectives, policies and restrictions.

The Trust will concentrate its investments in companies operating in one or more industries within the technology group of industries.

The Trust may invest up to 20% of its total assets in equity securities issued by companies that are not science or technology companies and in debt securities issued by any issuer, including non-investment grade debt securities. The Trust’s investments in non-investment grade securities and those deemed to be of similar quality are considered speculative with respect to the issuer’s capacity to pay interest and repay principal and are commonly referred to as “junk” or “high yield” securities.

As part of its investment strategy, the Trust intends to employ a strategy of writing (selling) covered call options on a portion of the common stocks in its portfolio, writing (selling) other call and put options on individual common stocks, and, to a lesser extent, writing (selling) call and put index options. This options writing strategy is intended to generate current gains from options premiums and to enhance the Trust’s risk-adjusted returns. A substantial portion of the options written by the Trust may be over-the-counter options.

During temporary defensive periods (i.e., in response to adverse market, economic or political conditions), the Trust may invest up to 100% of its total assets in liquid, short-term investments, including high quality, short-term securities. The Trust may not achieve its investment objectives under these circumstances. The Manager’s determination that it is temporarily unable to follow the Trust’s investment strategy or that it is impractical to do so will generally occur only in situations in which a market disruption event has occurred and where trading in the securities selected through application of the Trust’s investment strategy is extremely limited or absent.

The Trust may invest in structured instruments (such as equity-linked notes) for investment purposes, as an alternative or complement to its options writing strategy or for risk management or leveraging purposes.

The Trust may purchase and sell futures contracts, enter into various interest rate transactions such as swaps, caps, floors or collars, currency transactions such as currency forward contracts, currency futures contracts, currency swaps or options on currency or currency futures and swap contracts (including, but not limited to, credit default swaps) and may purchase and sell exchange-listed and over-the-counter put and call options on securities and swap contracts, financial indices and futures contracts and use other derivative instruments or management techniques for duration management and other risk management purposes, including to attempt to protect against possible changes in the market value of the Trust’s portfolio resulting from trends in the securities markets and changes in interest rates or to protect the Trust’s unrealized gains in the value of its portfolio securities, to facilitate the sale of portfolio securities for investment purposes, to establish a position in the securities markets as a temporary substitute for purchasing particular securities or to enhance income or gain.

The Trust may lend securities with a value of up to 33 1/3% of its total assets (including such loans) to financial institutions that provide cash or securities issued or guaranteed by the U.S. Government as collateral.

The Trust may also engage in short sales of securities. The Trust will not make a short sale if, after giving effect to such sale, the market value of all securities sold short exceeds 25% of the value of its Managed Assets or the Trust’s aggregate short sales of a particular class of securities exceeds 25% of the outstanding securities of that class. The Trust may make short sales “against the box” without respect to such limitations. In this type of short sale, at the time of the sale the Trust owns or has the immediate and unconditional right to acquire at no additional cost the identical security. “Managed Assets” means the total assets of the Trust (including any assets attributable to money borrowed for investment purposes) minus the sum of the Trust’s accrued liabilities (other than money borrowed for investment purposes).

Unless otherwise stated herein, the Trust’s investment policies are non-fundamental policies and may be changed by the Board without prior shareholder approval. The percentage limitations applicable to the Trust’s portfolio described herein apply only at the time of initial investment and the Trust will not be required to sell investments due to subsequent changes in the value of investments that it owns. The Trust’s policy to invest at least 80% of its total assets in equity securities issued by U.S. and non-U.S. science

I N V E S T M E N T  O B J E C T I V E S ,  P O L I C I E S  A N D  R I S K S 195

Investment Objectives, Policies and Risks (continued)

Investment Objectives and Policies (continued)

and technology companies in any market capitalization range may be changed by the Board; however, if this policy changes, the Trust will provide shareholders at least 60 days’ written notice before implementation of the change in compliance with rules of the Securities and Exchange Commission.

Leverage: The Trust currently does not intend to borrow money or issue debt securities or preferred shares. Although it has no present intention to do so, the Trust reserves the right to borrow money from banks or other financial institutions, or issue debt securities or preferred shares, in the future if it believes that market conditions would be conducive to the successful implementation of a leveraging strategy through borrowing money or issuing debt securities or preferred shares. Any such leveraging will not be fully achieved until the proceeds resulting from the use of leverage have been invested in accordance with the Trust’s investment objectives and policies.

The Trust may enter into reverse repurchase agreements with respect to its portfolio investments subject to certain investment restrictions.

The Trust may enter into “dollar roll” transactions.

The Trust may enter into derivative transactions that have leverage embedded in them.

The Trust may also borrow money as a temporary measure for extraordinary or emergency purposes, including the payment of dividends and the settlement of securities transactions which otherwise might require untimely dispositions of Trust securities.

BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)

The Trust’s investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. The Trust’s investment objective may be changed by the Board of Trustees of the Trust (the “Board”) without prior shareholder approval.

The Trust seeks to achieve its investment objective by investing primarily in equity securities issued by companies that are engaged in the Utilities, Infrastructure or Power Opportunities business segments (as defined below) anywhere in the world and by employing a strategy of writing (selling) covered call and put options.

Under normal market conditions, the Trust will invest at least 80% of its total assets in equity securities issued by companies that are engaged in the Utilities, Infrastructure or Power Opportunities business segments. The Trust considers the “Utilities” business segment to include products, technologies and services connected to the management, ownership operation, construction, development or financing of facilities used to generate, transmit or distribute electricity, water, natural resources or telecommunications, the “Infrastructure” business segment to include companies that own or operate infrastructure assets or that are involved in the development, construction, distribution or financing of infrastructure assets (as described herein), and the “Power Opportunities” business segment to include companies with a significant involvement in, supporting, or necessary to renewable energy technology and development, alternative fuels, energy efficiency, automotive and sustainable mobility and technologies that enable or support the growth and adoption of new power and energy sources. Such companies may include, among others, electrical equipment producers (such as wind turbine manufacturers), producers of industrial and specialty chemicals (such as building insulation producers) and semi-conductor and equipment companies (such as solar panel manufacturers).

The Trust may invest in companies of any market capitalization. Under normal circumstances, the Trust invests a substantial amount of its total assets in foreign issuers, issuers that primarily trade in a market located outside the United States or issuers that do a substantial amount of business outside the United States. Although the Trust expects to invest primarily in companies located in developed countries, it may invest in companies located in emerging markets. Equity securities in which the Trust may invest include common stocks, preferred stocks, convertible securities, warrants, depositary receipts, exchange-traded funds, equity interests in real estate investment trusts, Canadian Royalty Trusts and master limited partnerships (“MLPs”). The Trust will not invest more than 25% of the value of its total assets in MLPs. The Trust may invest directly in equity securities or synthetically through the use of derivatives.

The Trust may invest up to 20% of its total assets in equity securities issued by companies that are not engaged in the Utilities, Infrastructure or Power Opportunities business segments and debt securities issued by any issuer, including up to 10% of its total assets in non-investment grade debt securities. The Trust’s investments in non-investment grade securities and those deemed to be of similar quality are considered speculative with respect to the issuer’s capacity to pay interest and repay principal and are commonly referred to as “junk” or “high yield” securities.

As part of its investment strategy, the Trust intends to employ a strategy of writing (selling) covered call options on a portion of the common stocks in its portfolio, writing (selling) other call and put options on individual common stocks, and, to a lesser extent, writing (selling) call and put index options. This options writing strategy is intended to generate current gains from options premiums and to enhance the Trust’s risk-adjusted returns. A substantial portion of the options written by the Trust may be over-the-counter options.

During temporary defensive periods (i.e., in response to adverse market, economic or political conditions), the Trust may invest up to 100% of its total assets in liquid, short-term investments, including high quality, short-term securities. The Trust may not achieve its investment objective under these circumstances. BlackRock Advisors, LLC’s (the “Manager”) and BlackRock International Limited’s (“BIL” and together with the Manager, the “Advisors”), the Trust’s sub-advisor, determination that they are temporarily unable to follow the Trust’s investment strategy or that it is impractical to do so will generally occur only in situations in which a market disruption event has occurred and where trading in the securities selected through application of the Trust’s investment strategy is extremely limited or absent.

The Trust may purchase and sell futures contracts, enter into various interest rate transactions such as swaps, caps, floors or collars, currency transactions such as currency forward contracts, currency futures contracts, currency swaps or options on currency or currency futures and swap contracts (including, but not limited to, credit default swaps) and may purchase and sell exchange-listed and over-the-counter put and call options on securities and swap contracts, financial indices and futures contracts and use other derivative instruments or management techniques for duration management and other risk management purposes, including to attempt to protect against possible changes in the market value of the Trust’s portfolio resulting from trends in the securities markets and changes in interest rates or to protect the Trust’s unrealized gains in the value of its portfolio securities, to facilitate the sale of portfolio securities for investment purposes, to establish a position in the securities markets as a temporary substitute for purchasing particular securities or to enhance income or gain.

196 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Investment Objectives, Policies and Risks (continued)

Investment Objectives and Policies (continued)

The Trust may lend securities with a value up to 33 1/3% of its total assets (including such loans) to financial institutions that provide cash or securities issued or guaranteed by the U.S. Government as collateral.

The Trust may also engage in short sales of securities. The Trust will not make a short sale if, after giving effect to such sale, the market value of all securities sold short exceeds 15% of the value of its total assets or the Trust’s aggregate short sales of a particular class of securities exceeds 15% of the outstanding securities of that class. The Trust may make short sales “against the box” without respect to such limitations. In this type of short sale, at the time of the sale the Trust owns or has the immediate and unconditional right to acquire at no additional cost the identical security.

Unless otherwise stated herein, the Trust’s investment objective and policies are non-fundamental policies and may be changed by the Board without prior shareholder approval. The Trust’s policy to invest at least 80% of its total assets in equity securities issued by companies that are engaged in the Utilities, Infrastructure and Power Opportunities business segments may be changed by the Board; however, if this policy changes, the Trust will provide shareholders at least 60 days’ written notice before implementation of the change in compliance with rules of the Securities and Exchange Commission.

Leverage: The Trust currently does not intend to borrow money or issue debt securities or preferred shares. Although it has no present intention to do so, the Trust reserves the right to borrow money from banks or other financial institutions, or issue debt securities or preferred shares, in the future if it believes that market conditions would be conducive to the successful implementation of a leveraging strategy through borrowing money or issuing debt securities or preferred shares. Any such leveraging will not be fully achieved until the proceeds resulting from the use of leverage have been invested in accordance with the Trust’s investment objective and policies.

The Trust may enter into reverse repurchase agreements with respect to its portfolio investments subject to certain investment restrictions.

The Trust may enter into derivative transactions that have leverage embedded in them.

The Trust may also borrow money as a temporary measure for extraordinary or emergency purposes, including the payment of dividends and the settlement of securities transactions which otherwise might require untimely dispositions of Trust securities.

Risk Factors

This section contains a discussion of the general risks of investing in each Trust. The net asset value and market price of, and dividends paid on, the common shares will fluctuate with and be affected by, among other things, the risks more fully described below. As with any fund, there can be no guarantee that a Trust will meet its investment objective or that the Trust’s performance will be positive for any period of time. Each risk noted below is applicable to each Trust unless the specific Trust or Trusts are noted in a parenthetical. The order of the below risk factors does not indicate the significance of any particular risk factor.

Non-Diversification Risk (BGR, BIGZ, BMEZ and BCX): The Trust is a non-diversified fund. Because the Trust may invest in securities of a smaller number of issuers, it may be more exposed to the risks associated with and developments affecting an individual issuer than a fund that invests more widely.

Limited Term Risk (BMEZ, BIGZ and BSTZ): In accordance with the Trust’s Agreement and Declaration of Trust, the Trust intends to dissolve as of the first business day following the twelfth anniversary of the effective date of the Trust’s initial registration statement (the “Dissolution Date”); provided that the Board may, by a vote of a majority of the Board and seventy-five percent (75%) of the members of the Board who either (i) have been a member of the Board for a period of at least thirty-six months (or since the commencement of the Trust’s operations, if less than thirty-six months) or (ii) were nominated to serve as a member of the Board by a majority of the Continuing Trustees then members of the Board (a “Board Action Vote”), without shareholder approval, extend the Dissolution Date: (i) once for up to one year, and (ii) once for up to an additional six months, to a date up to and including eighteen months after the initial Dissolution Date (which date shall then become the Dissolution Date). As of a date within twelve months preceding the Dissolution Date (as may be extended as described above), the Board may, by a Board Action Vote, cause the Trust to conduct a tender offer to all common shareholders to purchase 100% of the then outstanding common shares of the Trust at a price equal to the net asset value (“NAV”) per common share on the expiration date of the tender offer (an “Eligible Tender Offer”). The Board has established that the Trust must have at least $200 million of aggregate net assets immediately following the completion of an Eligible Tender Offer to ensure the continued viability of the Trust (the “Dissolution Threshold”). In an Eligible Tender Offer, the Trust will offer to purchase all common shares held by each common shareholder; provided that if the payment for properly tendered common shares would result in the Trust having aggregate net assets below the Dissolution Threshold, the Eligible Tender Offer will be canceled and no common shares will be repurchased pursuant to the Eligible Tender Offer. Instead, the Trust will begin (or continue) liquidating its portfolio and proceed to dissolve on or about the Dissolution Date. If the payment for properly tendered common shares would result in the Trust having aggregate net assets greater than or equal to the Dissolution Threshold, all common shares properly tendered and not withdrawn will be purchased by the Trust pursuant to the terms of the Eligible Tender Offer. Following the completion of an Eligible Tender Offer, the Board may, by a Board Action Vote, eliminate the Dissolution Date without shareholder approval and provide for the Trust’s perpetual existence.

Unless the limited term provision of the Trust’s Agreement and Declaration of Trust is amended by shareholders in accordance with the Agreement and Declaration of Trust, or unless the Trust completes an Eligible Tender Offer and converts to perpetual existence, the Trust will dissolve on or about the first business day following the Dissolution Date. The Trust is not a so called “target date” or “life cycle” fund whose asset allocation becomes more conservative over time as its target date, often associated with retirement, approaches. In addition, the Trust is not a “target term” fund and thus does not seek to return its initial public offering price per common share upon dissolution. As the assets of the Trust will be liquidated in connection with its dissolution, the Trust may be required to sell portfolio securities when it otherwise would not, including at times when market conditions are not favorable, which may cause the Trust to lose money. In addition, as the Trust approaches the Dissolution Date, the Manager may invest the proceeds of sold, matured or called securities in money market mutual funds, cash, cash equivalents, securities issued or guaranteed by the U.S. government or its instrumentalities or agencies, high quality, short-term money market instruments, short-term debt securities, certificates of deposit, bankers’ acceptances and other bank obligations, commercial paper or other liquid debt securities, which may adversely affect the Trust’s investment performance. Rather than reinvesting proceeds received from sales of or payments received in respect of portfolio securities, the Trust may distribute such proceeds in one or more liquidating distributions prior to the final dissolution, which may cause the Trust’s fixed expenses to increase when expressed as a percentage of net assets attributable to common shares, or the Trust may invest the proceeds in lower yielding securities or hold the proceeds in cash or cash equivalents, which may adversely affect the performance of the

I N V E S T M E N T  O B J E C T I V E S ,  P O L I C I E S  A N D  R I S K S 197

Investment Objectives, Policies and Risks (continued)

Risk Factors (continued)

Trust. The final distribution of net assets upon dissolution may be more than, equal to or less than $20.00 per common share. Because the Trust may adopt a plan of liquidation and make liquidating distributions in advance of the Dissolution Date, the total value of the Trust’s assets returned to common shareholders upon dissolution will be impacted by decisions of the Board and the Manager regarding the timing of adopting a plan of liquidation and making liquidating distributions. This may result in common shareholders receiving liquidating distributions with a value more or less than the value that would have been received if the Trust had liquidated all of its assets on the Dissolution Date, or any other potential date for liquidation, and distributed the proceeds thereof to shareholders.

If the Trust conducts an Eligible Tender Offer, the Trust anticipates that funds to pay the aggregate purchase price of shares accepted for purchase pursuant to the tender offer will be first derived from any cash on hand and then from the proceeds from the sale of portfolio investments held by the Trust. The risks related to the disposition of securities in connection with the Trust’s dissolution also would be present in connection with the disposition of securities in connection with an Eligible Tender Offer. It is likely that during the pendency of a tender offer, and possibly for a time thereafter, the Trust will hold a greater than normal percentage of its total assets in cash and cash equivalents, which may impede the Trust’s ability to achieve its investment objectives and decrease returns to shareholders. The tax effect of any such dispositions of portfolio investments will depend on the difference between the price at which the investments are sold and the tax basis of the Trust in the investments.

Any capital gains recognized on such dispositions, as reduced by any capital losses the Trust realizes in the year of such dispositions and by any available capital loss carryforwards, will be distributed to shareholders as capital gain dividends (to the extent of net long-term capital gains over net short-term capital losses) or ordinary dividends (to the extent of net short-term capital gains over net long-term capital losses) during or with respect to such year, and such distributions will generally be taxable to common shareholders. If the Trust’s tax basis for the investments sold is less than the sale proceeds, the Trust will recognize capital gains, which the Trust intends to distribute to common shareholders. In addition, the Trust’s purchase of tendered common shares pursuant to an Eligible Tender Offer will have tax consequences for tendering common shareholders and may have tax consequences for non-tendering common shareholders.

The purchase of common shares by the Trust pursuant to an Eligible Tender Offer will have the effect of increasing the proportionate interest in the Trust of non-tendering common shareholders. All common shareholders remaining after an Eligible Tender Offer will be subject to any increased risks associated with the reduction in the Trust’s assets resulting from payment for the tendered common shares, such as greater volatility due to decreased diversification and proportionately higher expenses. The reduced assets of the Trust as a result of an Eligible Tender Offer may result in less investment flexibility for the Trust and may have an adverse effect on the Trust’s investment performance. Such reduction in the Trust’s assets may also cause common shares of the Trust to become thinly traded or otherwise negatively impact secondary trading of common shares. A reduction in assets, and the corresponding increase in the Trust’s expense ratio, could result in lower returns and put the Trust at a disadvantage relative to its peers and potentially cause the Trust’s common shares to trade at a wider discount, or smaller premium, to NAV than they otherwise would. Furthermore, the portfolio of the Trust following an Eligible Tender Offer could be significantly different and, therefore, common shareholders retaining an investment in the Trust could be subject to greater risk. For example, the Trust may be required to sell its more liquid, higher quality portfolio investments to purchase common shares that are tendered in an Eligible Tender Offer, which would leave a less liquid, lower quality portfolio for remaining shareholders. The prospects of an Eligible Tender Offer may attract arbitrageurs who would purchase the common shares prior to the tender offer for the sole purpose of tendering those shares which could have the effect of exacerbating the risks described herein for shareholders retaining an investment in the Trust following an Eligible Tender Offer.

The Trust is not required to conduct an Eligible Tender Offer. If the Trust conducts an Eligible Tender Offer, there can be no assurance that the payment for tendered common shares would not result in the Trust having aggregate net assets below the Dissolution Threshold, in which case the Eligible Tender Offer will be canceled, no common shares will be repurchased pursuant to the Eligible Tender Offer and the Trust will liquidate on the Dissolution Date (subject to possible extensions). Following the completion of an Eligible Tender Offer in which the payment for tendered common shares would result in the Trust having aggregate net assets greater than or equal to the Dissolution Threshold, the Board may, by a Board Action Vote, eliminate the Dissolution Date without shareholder approval and provide for the Trust’s perpetual existence. Thereafter, the Trust will have a perpetual existence. There is no guarantee that the Board will eliminate the Dissolution Date following the completion of an Eligible Tender Offer so that the Trust will have a perpetual existence. The Manager may have a conflict of interest in recommending to the Board that the Dissolution Date be eliminated and the Trust have a perpetual existence. The Trust is not required to conduct additional tender offers following an Eligible Tender Offer and conversion to perpetual existence. Therefore, remaining common shareholders may not have another opportunity to participate in a tender offer. Shares of closed-end management investment companies frequently trade at a discount from their NAV, and as a result remaining common shareholders may only be able to sell their shares at a discount to NAV.

Although it is anticipated that the Trust will have distributed substantially all of its net assets to shareholders as soon as practicable after the Dissolution Date, securities for which no market exists or securities trading at depressed prices, if any, may be placed in a liquidating trust. Securities placed in a liquidating trust may be held for an indefinite period of time, potentially several years or longer, until they can be sold or pay out all of their cash flows. During such time, the shareholders will continue to be exposed to the risks associated with the Trust and the value of their interest in the liquidating trust will fluctuate with the value of the liquidating trust’s remaining assets. Additionally, the tax treatment of the liquidating trust’s assets may differ from the tax treatment applicable to such assets when held by the Trust. To the extent the costs associated with a liquidating trust exceed the value of the remaining securities, the liquidating trust trustees may determine to dispose of the remaining securities in a manner of their choosing. The Trust cannot predict the amount, if any, of securities that will be required to be placed in a liquidating trust or how long it will take to sell or otherwise dispose of such securities.

Investment and Market Discount Risk: An investment in the Trust’s common shares is subject to investment risk, including the possible loss of the entire amount that you invest. As with any stock, the price of the Trust’s common shares will fluctuate with market conditions and other factors. If shares are sold, the price received may be more or less than the original investment. Common shares are designed for long-term investors and the Trust should not be treated as a trading vehicle. Shares of closed-end management investment companies frequently trade at a discount from their net asset value. This risk is separate and distinct from the risk that the Trust’s net asset value could decrease as a result of its investment activities. At any point in time an investment in the Trust’s common shares may be worth less than the original amount invested, even after taking into account distributions paid by the Trust. During periods in which the Trust may use leverage, the Trust’s investment, market discount and certain other risks will be magnified.

Equity Securities Risk: Stock markets are volatile. The price of equity securities fluctuates based on changes in a company’s financial condition and overall market and economic conditions.

198 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Investment Objectives, Policies and Risks (continued)

Risk Factors (continued)

Common Stock Risk: Common stocks represent equity ownership in a company. Stock markets are volatile. The price of common stock will fluctuate and can decline and reduce the value of a portfolio investing in equities. The value of common stock purchased by the Trust could decline if the financial condition of the companies the Trust invests in declines or if overall market and economic conditions deteriorate. The value of equity securities may also decline due to factors that affect a particular industry or industries, such as labor shortages or an increase in production costs and competitive conditions within an industry. In addition, the value may decline due to general market conditions that are not specifically related to a company or industry, such as real or perceived adverse economic conditions, changes in the general outlook for corporate earnings, changes in inflation, interest or currency rates or generally adverse investor sentiment.

Small and Mid-Capitalization Company Risk: Companies with small or mid-size market capitalizations will normally have more limited product lines, markets and financial resources and will be dependent upon a more limited management group than larger capitalized companies. In addition, it is more difficult to get information on smaller companies, which tend to be less well known, have shorter operating histories, do not have significant ownership by large investors and are followed by relatively few securities analysts.

Preferred Securities Risk: Preferred securities may pay fixed or adjustable rates of return. Preferred securities are subject to issuer-specific and market risks applicable generally to equity securities. In addition, a company’s preferred securities generally pay dividends only after the company makes required payments to holders of its bonds and other debt. For this reason, the value of preferred securities will usually react more strongly than bonds and other debt to actual or perceived changes in the company’s financial condition or prospects. Preferred securities of smaller companies may be more vulnerable to adverse developments than preferred securities of larger companies.

Convertible Securities Risk (BGR, BDJ, BOE, BGY, BME, BMEZ, BIGZ, BCX, BST, BSTZ and BUI): The market value of a convertible security performs like that of a regular debt security; that is, if market interest rates rise, the value of a convertible security usually falls. In addition, convertible securities are subject to the risk that the issuer will not be able to pay interest, principal or dividends when due, and their market value may change based on changes in the issuer’s credit rating or the market’s perception of the issuer’s creditworthiness. Since it derives a portion of its value from the common stock into which it may be converted, a convertible security is also subject to the same types of market and issuer risks that apply to the underlying common stock, including the potential for increased volatility in the price of the convertible security.

Warrants Risk (BGR, BOE, BGY, BME, BMEZ, BIGZ, BCX, BST, BSTZ and BUI): If the price of the underlying stock does not rise above the exercise price before the warrant expires, the warrant generally expires without any value and the Trust will lose any amount it paid for the warrant. Thus, investments in warrants may involve substantially more risk than investments in common stock. Warrants may trade in the same markets as their underlying stock; however, the price of the warrant does not necessarily move with the price of the underlying stock.

Depositary Receipts Risk (BGR, BOE, BGY, BME, BMEZ, BIGZ, BCX, BST, BSTZ and BUI): Depositary receipts are generally subject to the same risks as the foreign securities that they evidence or into which they may be converted. In addition to investment risks associated with the underlying issuer, depositary receipts expose the Trust to additional risks associated with the non-uniform terms that apply to depositary receipt programs, credit exposure to the depository bank and to the sponsors and other parties with whom the depository bank establishes the programs, currency risk and the risk of an illiquid market for depositary receipts. The issuers of unsponsored depositary receipts are not obligated to disclose information that is, in the United States, considered material. Therefore, there may be less information available regarding these issuers and there may not be a correlation between such information and the market value of the depositary receipts. While depositary receipts provide an alternative to directly purchasing underlying foreign securities in their respective markets and currencies, they continue to be subject to many of the risks associated with investing directly in foreign securities, including political, economic, and currency risk.

REIT Investment Risk (BDJ, BOE, BGY, BME, BMEZ, BST, BSTZ and BUI): Investments in REITs involve unique risks. REITs may have limited financial resources, may trade less frequently and in limited volume, may engage in dilutive offerings of securities and may be more volatile than other securities. REIT issuers may also fail to maintain their exemptions from investment company registration or fail to qualify for the “dividends paid deduction” under the Internal Revenue Code of 1986, as amended, which allows REITs to reduce their corporate taxable income for dividends paid to their shareholders.

Master Limited Partnerships Risk (BGR, BCX, BST, BSTZ and BUI): The common units of a master limited partnership (“MLP”) are listed and traded on U.S. securities exchanges and their value fluctuates predominantly based on prevailing market conditions and the success of the MLP. Unlike owners of common stock of a corporation, owners of common units have limited voting rights and have no ability to annually elect directors. In the event of liquidation, common units have preference over subordinated units, but not over debt or preferred units, to the remaining assets of the MLP.

Canadian Royalty Trust Risk (BGR, BCX and BUI): Canadian Royalty Trusts are exposed to many of the same risks as energy and natural resources companies, such as commodity pricing risk, supply and demand risk and depletion and exploration risk.

Initial Public Offerings (“IPOs”) Risk (BOE, BME, BMEZ, BIGZ, BST and BSTZ): The Trust may invest in shares of companies through IPOs. Securities issued in IPOs have no trading history, and information about the companies may be available for limited periods of time. In addition, the prices of securities sold in IPOs may be highly volatile or may decline shortly after the IPO.

Investments in Unseasoned Companies (BDJ, BOE, BGY, BME, BMEZ, BIGZ, BCX and BSTZ): The Trust may invest in the securities of smaller, less seasoned companies. These investments may present greater opportunities for growth, but also involve greater risks than customarily are associated with investments in securities of more established companies. Some of the companies in which the Trust may invest may be start-up companies which may have insubstantial operational or earnings histories or may have limited products, markets, financial resources or management depth. Some may also be emerging companies at the research and development stage with no products or technologies to market or approved for marketing. Securities of emerging companies may lack an active secondary market and may be subject to more abrupt or erratic price movements than securities of larger, more established companies or stock market averages in general. Competitors of certain companies may have substantially greater financial resources than many of the companies in which the Trust may invest. Further, an unseasoned company is more at risk of loss in an adverse market due to its lack of financial resources and ability to sustain itself for an extended period of time in such a market.

I N V E S T M E N T  O B J E C T I V E S ,  P O L I C I E S  A N D  R I S K S 199

Investment Objectives, Policies and Risks (continued)

Risk Factors (continued)

Dividend-Paying Equity Securities Risk (CII, BDJ, BOE, BGY and BME): Dividends on common equity securities that the Trust may hold are not fixed but are declared at the discretion of an issuer’s board of directors. Companies that have historically paid dividends on their securities are not required to continue to pay dividends on such securities. There is no guarantee that the issuers of the common equity securities in which the Trust invests will declare dividends in the future or that, if declared, they will remain at current levels or increase over time. Therefore, there is the possibility that such companies could reduce or eliminate the payment of dividends in the future. Dividend producing equity securities, in particular those whose market price is closely related to their yield, may exhibit greater sensitivity to interest rate changes. The Trust’s investments in dividend producing equity securities may also limit its potential for appreciation during a broad market advance.

The prices of dividend producing equity securities can be highly volatile. Investors should not assume that the Trust’s investments in these securities will necessarily reduce the volatility of the Trust’s NAV or provide “protection,” compared to other types of equity securities, when markets perform poorly.

Investment Style Risk: Under certain market conditions, growth investments have performed better during the later stages of economic expansion and value investments have performed better during periods of economic recovery. Therefore, these investment styles may over time go in and out of favor. At times when the investment style used by the Trust is out of favor, the Trust may underperform other equity funds that use different investment styles.

Risks Associated with the Trust’s Options Strategy: The ability of the Trust to generate current gains from options premiums and to enhance the Trust’s risk-adjusted returns is partially dependent on the successful implementation of its options strategy. There are several risks associated with transactions in options on securities. For example, there are significant differences between the securities and options markets that could result in an imperfect correlation between these markets, causing a given transaction not to achieve its objectives. A decision as to whether, when and how to use options involves the exercise of skill and judgment, and even a well-conceived transaction may be unsuccessful to some degree because of market behavior or unexpected events.

• Risks of Writing Options – As the writer of a covered call option, the Trust forgoes, during the option’s life, the opportunity to profit from increases in the market value of the security covering the call option above the sum of the premium and the strike price of the call, but has retained the risk of loss should the price of the underlying security decline. In other words, as the Trust writes covered calls over more of its portfolio, the Trust’s ability to benefit from capital appreciation becomes more limited.

If the Trust writes call options on individual securities or index call options that include securities, in each case, that are not in the Trust’s portfolio or that are not in the same proportion as securities in the Trust’s portfolio, the Trust will experience loss, which theoretically could be unlimited, if the value of the individual security, index or basket of securities appreciates above the exercise price of the index option written by the Trust.

When the Trust writes put options, it bears the risk of loss if the value of the underlying stock declines below the exercise price minus the put premium. If the option is exercised, the Trust could incur a loss if it is required to purchase the stock underlying the put option at a price greater than the market price of the stock at the time of exercise plus the put premium the Trust received when it wrote the option. While the Trust’s potential gain in writing a put option is limited to the premium received from the purchaser of the put option, the Trust risks a loss equal to the entire exercise price of the option minus the put premium.

• Exchange-Listed Options Risks – There can be no assurance that a liquid market will exist when the Trust seeks to close out an exchange-listed option position. Reasons for the absence of a liquid secondary market on an exchange include the following: (i) there may be insufficient trading interest in certain options; (ii) restrictions may be imposed by an exchange on opening transactions or closing transactions or both; (iii) trading halts, suspensions or other restrictions may be imposed with respect to particular classes or series of options; (iv) unusual or unforeseen circumstances may interrupt normal operations on an exchange; (v) the facilities of an exchange or the Options Clearing Corporation (the “OCC”) may not at all times be adequate to handle current trading volume; or (vi) one or more exchanges could, for economic or other reasons, decide or be compelled at some future date to discontinue the trading of options (or a particular class or series of options).

• Over-the-Counter Options Risk – The Trust may write (sell) unlisted OTC options. OTC options differ from exchange-listed options in that they are two-party contracts, with exercise price, premium and other terms negotiated between buyer and seller, and generally do not have as much market liquidity as exchange-listed options. The OTC options written by the Trust will not be issued, guaranteed or cleared by the OCC. In addition, the Trust’s ability to terminate OTC options may be more limited than with exchange-traded options. Banks, broker-dealers or other financial institutions participating in such transactions may fail to settle a transaction in accordance with the terms of the option as written. In the event of default or insolvency of the counterparty, the Trust may be unable to liquidate an OTC option position.

• Index Options Risk – The Trust may sell index put and call options from time to time. The purchaser of an index put option has the right to any depreciation in the value of the index below the exercise price of the option on or before the expiration date. The purchaser of an index call option has the right to any appreciation in the value of the index over the exercise price of the option on or before the expiration date. Because the exercise of index options is settled in cash, sellers of index call options, such as the Trust, cannot provide in advance for their potential settlement obligations by acquiring and holding the underlying securities. The Trust will lose money if it is required to pay the purchaser of an index option the difference between the cash value of the index on which the option was written and the exercise price and such difference is greater than the premium received by the Trust for writing the option.

• Limitation on Options Writing Risk – The number of call options the Trust can write is limited by the total assets the Trust holds. Furthermore, the Trust’s exchange-listed options transactions will be subject to limitations established by each of the exchanges, boards of trade or other trading facilities, if any, on which such options are traded and cleared.

• Tax Risk – Income on options on individual stocks will generally not be recognized by the Trust for tax purposes until an option is exercised, lapses or is subject to a “closing transaction” (as defined by applicable regulations) pursuant to which the Trust’s obligations with respect to the option are otherwise terminated. If the option lapses without exercise or is otherwise subject to a closing transaction, the premiums received by the Trust from the writing of such options will generally be characterized as short-term capital gain. If an option written by the Trust is exercised, the Trust may recognize taxable gain depending on the exercise price of the option, the option premium, and the tax basis of the security underlying the option. The character of any gain on the sale of the underlying security as short-term or

200 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Investment Objectives, Policies and Risks (continued)

Risk Factors (continued)

long-term capital gain will depend on the holding period of the Trust in the underlying security. In general, distributions received by shareholders of the Trust that are attributable to short-term capital gains recognized by the Trust from its options writing activities will be taxed to such shareholders as ordinary income and will not be eligible for the reduced tax rate applicable to qualified dividend income.

Index options will generally be “marked-to-market” for U.S. federal income tax purposes. As a result, the Trust will generally recognize gain or loss on the last day of each taxable year equal to the difference between the value of the index option on that date and the adjusted basis of the index option. The adjusted basis of the index option will consequently be increased by such gain or decreased by such loss. Any gain or loss with respect to index options will be treated as short-term capital gain or loss to the extent of 40% of such gain or loss and long-term capital gain or loss to the extent of 60% of such gain or loss. Because the mark-to-market rules may cause the Trust to recognize gain in advance of the receipt of cash, the Trust may be required to dispose of investments in order to meet its U.S. federal income tax distribution requirements.

Debt Securities Risk (BGR, BOE, BME, BMEZ, BCX, BST, BSTZ and BUI): Debt securities, such as bonds, involve interest rate risk, such as credit risk, interest rate risk, extension risk, and prepayment risk, each of which are described in further detail below:

• Credit Risk – Credit risk refers to the possibility that the issuer of a debt security (i.e., the borrower) will not be able to make payments of interest and principal when due. Changes in an issuer’s credit rating or the market’s perception of an issuer’s creditworthiness may also affect the value of the Trust’s investment in that issuer. The degree of credit risk depends on both the financial condition of the issuer and the terms of the obligation.

• Interest Rate Risk – The market value of bonds and other fixed-income securities changes in response to interest rate changes and other factors. Interest rate risk is the risk that prices of bonds and other fixed-income securities will increase as interest rates fall and decrease as interest rates rise.

The Trust may be subject to a greater risk of rising interest rates due to the recent period of historically low interest rates. For example, if interest rates increase by 1%, assuming a current portfolio duration of ten years, and all other factors being equal, the value of the Trust’s investments would be expected to decrease by 10%. (Duration is a measure of the price sensitivity of a debt security or portfolio of debt securities to relative changes in interest rates.) The magnitude of these fluctuations in the market price of bonds and other fixed-income securities is generally greater for those securities with longer maturities. Fluctuations in the market price of the Trust’s investments will not affect interest income derived from instruments already owned by the Trust, but will be reflected in the Trust’s net asset value. The Trust may lose money if short-term or long-term interest rates rise sharply in a manner not anticipated by Trust management.

To the extent the Trust invests in debt securities that may be prepaid at the option of the obligor (such as mortgage-backed securities), the sensitivity of such securities to changes in interest rates may increase (to the detriment of the Trust) when interest rates rise. Moreover, because rates on certain floating rate debt securities typically reset only periodically, changes in prevailing interest rates (and particularly sudden and significant changes) can be expected to cause some fluctuations in the net asset value of the Trust to the extent that it invests in floating rate debt securities.

These basic principles of bond prices also apply to U.S. Government securities. A security backed by the “full faith and credit” of the U.S. Government is guaranteed only as to its stated interest rate and face value at maturity, not its current market price. Just like other fixed-income securities, government-guaranteed securities will fluctuate in value when interest rates change.

A general rise in interest rates has the potential to cause investors to move out of fixed-income securities on a large scale, which may increase redemptions from funds that hold large amounts of fixed-income securities. Heavy redemptions could cause the Trust to sell assets at inopportune times or at a loss or depressed value and could hurt the Trust’s performance.

• Extension Risk – When interest rates rise, certain obligations will be paid off by the obligor more slowly than anticipated, causing the value of these obligations to fall.

• Prepayment Risk – When interest rates fall, certain obligations will be paid off by the obligor more quickly than originally anticipated, and the Trust may have to invest the proceeds in securities with lower yields.

High Yield Bonds Risk (BGR, BOE, BME, BMEZ, BCX, BST, BSTZ and BUI): Although junk bonds generally pay higher rates of interest than investment grade bonds, junk bonds are high risk investments that are considered speculative and may cause income and principal losses for the Trust.

U.S. Government Obligations Risk (CII, BME, BMEZ, BCX, BSTZ and BUI): Certain securities in which the Trust may invest, including securities issued by certain U.S. Government agencies and U.S. Government sponsored enterprises, are not guaranteed by the U.S. Government or supported by the full faith and credit of the United States. In addition, circumstances could arise that could prevent the timely payment of interest or principal on U.S. Government obligations, such as reaching the legislative “debt ceiling.” Such non-payment could result in losses to the Trust and substantial negative consequences for the U.S. economy and the global financial system.

Structured Securities Risk (BME, BMEZ, BCX, BST and BSTZ): Because structured securities of the type in which the Trust may invest typically involve no credit enhancement, their credit risk generally will be equivalent to that of the underlying instruments, index or reference obligation and will also be subject to counterparty risk. The Trust may have the right to receive payments only from the structured security, and generally does not have direct rights against the issuer or the entity that sold the assets to be securitized. In addition to the general risks associated with debt securities discussed herein, structured securities carry additional risks, including, but not limited to: the possibility that distributions from collateral securities will not be adequate to make interest or other payments; the quality of the collateral may decline in value or default; and the possibility that the structured securities are subordinate to other classes. The Trust is permitted to invest in a class of structured securities that is either subordinated or unsubordinated to the right of payment of another class. Subordinated structured securities typically have higher yields and present greater risks than unsubordinated structured securities. Structured securities are typically sold in private placement transactions, and there currently is no active trading market for structured securities. Structured securities are based upon the movement of one or more factors, including currency exchange rates, interest rates, reference bonds and stock indices, and changes

I N V E S T M E N T  O B J E C T I V E S ,  P O L I C I E S  A N D  R I S K S 201

Investment Objectives, Policies and Risks (continued)

Risk Factors (continued)

in interest rates and impact of these factors may cause significant price fluctuations. Additionally, changes in the reference instrument or security may cause the interest rate on the structured security to be reduced to zero. Certain issuers of such structured securities may be deemed to be “investment companies” as defined in the Investment Company Act. As a result, the Trust’s investment in such securities may be limited by certain investment restrictions contained in the Investment Company Act.

Derivatives Risk: The Trust’s use of derivatives may increase its costs, reduce the Trust’s returns and/or increase volatility. Derivatives involve significant risks, including:

• Leverage Risk – The Trust’s use of derivatives can magnify the Trust’s gains and losses. Relatively small market movements may result in large changes in the value of a derivatives position and can result in losses that greatly exceed the amount originally invested.

• Market Risk – Some derivatives are more sensitive to interest rate changes and market price fluctuations than other securities. The Trust could also suffer losses related to its derivatives positions as a result of unanticipated market movements, which losses are potentially unlimited. Finally, the Manager may not be able to predict correctly the direction of securities prices, interest rates and other economic factors, which could cause the Trust’s derivatives positions to lose value.

• Counterparty Risk – Derivatives are also subject to counterparty risk, which is the risk that the other party in the transaction will be unable or unwilling to fulfill its contractual obligation, and the related risks of having concentrated exposure to such a counterparty.

• Illiquidity Risk – The possible lack of a liquid secondary market for derivatives and the resulting inability of the Trust to sell or otherwise close a derivatives position could expose the Trust to losses and could make derivatives more difficult for the Trust to value accurately.

• Operational Risk – The use of derivatives includes the risk of potential operational issues, including documentation issues, settlement issues, systems failures, inadequate controls and human error.

• Legal Risk – The risk of insufficient documentation, insufficient capacity or authority of counterparty, or legality or enforceability of a contract.

• Volatility and Correlation Risk – Volatility is defined as the characteristic of a security, an index or a market to fluctuate significantly in price within a short time period. A risk of the Trust’s use of derivatives is that the fluctuations in their values may not correlate with the overall securities markets.

• Valuation Risk – Valuation for derivatives may not be readily available in the market. Valuation may be more difficult in times of market turmoil since many investors and market makers may be reluctant to purchase complex instruments or quote prices for them.

• Hedging Risk – Hedges are sometimes subject to imperfect matching between the derivative and the underlying security, and there can be no assurance that the Trust’s hedging transactions will be effective. The use of hedging may result in certain adverse tax consequences.

• Tax Risk – Certain aspects of the tax treatment of derivative instruments, including swap agreements and commodity-linked derivative instruments, are currently unclear and may be affected by changes in legislation, regulations or other legally binding authority. Such treatment may be less favorable than that given to a direct investment in an underlying asset and may adversely affect the timing, character and amount of income the Trust realizes from its investments.

Foreign Securities Risk: Foreign investments often involve special risks not present in U.S. investments that can increase the chances that the Trust will lose money. These risks include:

• The Trust generally holds its foreign securities and cash in foreign banks and securities depositories, which may be recently organized or new to the foreign custody business and may be subject to only limited or no regulatory oversight.

• Changes in foreign currency exchange rates can affect the value of the Trust’s portfolio.

• The economies of certain foreign markets may not compare favorably with the economy of the United States with respect to such issues as growth of gross national product, reinvestment of capital, resources and balance of payments position.

• The governments of certain countries, or the U.S. Government with respect to certain countries, may prohibit or impose substantial restrictions through capital controls and/or sanctions on foreign investments in the capital markets or certain industries in those countries, which may prohibit or restrict the ability to own or transfer currency, securities, derivatives or other assets.

• Many foreign governments do not supervise and regulate stock exchanges, brokers and the sale of securities to the same extent as does the United States and may not have laws to protect investors that are comparable to U.S. securities laws.

• Settlement and clearance procedures in certain foreign markets may result in delays in payment for or delivery of securities not typically associated with settlement and clearance of U.S. investments.

• The Trust’s claims to recover foreign withholding taxes may not be successful, and if the likelihood of recovery of foreign withholding taxes materially decreases, due to, for example, a change in tax regulation or approach in the foreign country, accruals in the Trust’s net asset value for such refunds may be written down partially or in full, which will adversely affect the Trust’s net asset value.

• The European financial markets have recently experienced volatility and adverse trends due to concerns about economic downturns in, or rising government debt levels of, several European countries as well as acts of war in the region. These events may spread to other countries in Europe and may affect the value and liquidity of certain of the Trust’s investments.

202 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Investment Objectives, Policies and Risks (continued)

Risk Factors (continued)

Foreign Currency Transactions Risk (BGR, BDJ, BME and BCX): The Trust may invest in forward foreign currency exchange contracts. Forward foreign currency exchange contracts do not eliminate movements in the value of non-U.S. currencies and securities but rather allow the Trust to establish a fixed rate of exchange for a future point in time. This strategy can have the effect of reducing returns and minimizing opportunities for gain.

Emerging Markets Risk: Emerging markets are riskier than more developed markets because they tend to develop unevenly and may never fully develop. Investments in emerging markets may be considered speculative. Emerging markets are more likely to experience hyperinflation and currency devaluations, which adversely affect returns to U.S. investors. In addition, many emerging securities markets have far lower trading volumes and less liquidity than developed markets.

Concentration Risk (BGR, BME, BMEZ, BCX, BST and BSTZ): The Trust’s strategy of concentrating a particular industry means that its performance will be closely tied to the performance of a particular market segment. The Trust’s concentration in these companies may present more risks than if it were broadly diversified over numerous industries and sectors of the economy. A downturn in these companies would have a larger impact on the Trust than on a fund that does not concentrate in such companies. At times, the performance of these companies will lag the performance of other industries or the broader market as a whole.

Science and Technology Risk (BST and BSTZ): The Trust’s investments in science and technology companies expose the Trust to special risks. For example, rapid advances in science and technology might cause existing products to become obsolete, and the Trust’s returns could suffer to the extent it holds an affected company’s shares. Companies in a number of science and technology industries are also subject to more government regulations and approval processes than many other industries. This fact may affect a company’s overall profitability and cause its stock price to be more volatile. Earnings disappointments and intense competition for market share can result in sharp price declines. Profitability of science and technology companies can be negatively impacted by aggressive pricing from competitors, research and development costs, and the availability and prices of components. Additionally, science and technology companies are dependent upon consumer and business acceptance as new technologies evolve.

Health Sciences and Healthcare Companies Risk (BME and BMEZ): The Trust’s investments in health sciences companies are subject to a number of risks, including the adverse impact of legislative actions and government regulations. These actions and regulations can affect the approval process for patents, medical devices and drugs, the funding of research and medical care programs, and the operation and licensing of facilities and personnel. The goods and services of health sciences companies are subject to risks of rapid technological change and obsolescence, product liability litigation, and intense price and other competitive pressures.

Energy Sector Risk (BGR): The market value of securities in the energy sector may decline for many reasons, including, among others, changes in energy prices, energy supply and demand, government regulations and energy conservation efforts. Energy companies can be significantly affected by the supply of, and demand for, specific products (e.g., oil and natural gas) and services, exploration and production spending, government subsidization, world events and general economic conditions. In 2020, the energy sector has experienced increased volatility. In particular, significant market volatility occurred and is continuing in the crude oil markets as well as the oil futures markets, which resulted in the market price of the front month futures contract falling fell below zero for a period of time.

Energy and Natural Resources Risk (BCX): The Trust’s investments in energy and natural resources companies are especially affected by variations in the commodities markets (that may be due to market events, regulatory developments or other factors that the Trust cannot control) and these companies may lack the resources and the broad business lines to weather hard times. Energy companies can be significantly affected by the supply of and demand for specific products and services, the supply of and demand for oil and gas, the price of oil and gas, exploration and production spending, government regulation, world events and economic conditions. Natural resources companies can be significantly affected by events relating to international political developments, energy conservation, the success of exploration projects, commodity prices, and tax and government regulations.

Commodities Related Investments Risk (BCX): Exposure to the commodities markets may subject the Trust to greater volatility than investments in traditional securities. The value of commodity-linked derivative investments may be affected by changes in overall market movements, commodity index volatility, changes in inflation, interest rates, or factors affecting a particular industry or commodity, such as drought, floods, weather, embargoes, tariffs and international economic, political and regulatory developments.

Commodities Market Risk (BCX): Stocks of companies engaged in commodities related industries, such as energy or natural resources companies, are especially affected by variations in the commodities markets (that may be due to market events, regulatory developments or other factors that the Trust cannot control) and these companies may lack the resources and the broad business lines to weather hard times.

Risks of Investing in Utilities, Infrastructure and Power Opportunities Issuers (BUI): Investments in issuers in the Utilities, Infrastructure and Power Opportunities business segments are subject to certain risks, including the following, among others:

• Utilities Companies Risk – A variety of factors may adversely affect the business or operations of Utilities issuers, including, but not limited to: high interest costs in connection with capital construction and improvement programs; governmental regulation of rates charged to customers (including the potential that costs incurred by the utility change more rapidly than the rate the utility is permitted to charge its customers); costs associated with compliance with and changes in environmental and other regulations; effects of economic slowdowns and surplus capacity; increased competition from other providers of utility services; inexperience with and potential losses resulting from a developing deregulatory environment; costs associated with reduced availability of certain types of fuel; the effects of energy conservation policies; effects of a national energy policy; technological innovations; potential impact of terrorist activities; the impact of natural or man-made disasters; regulation by various governmental authorities, including the imposition of special tariffs; and changes in tax laws, regulatory policies and accounting standards.

• Infrastructure Companies Risk – Infrastructure issuers may be susceptible to a variety of factors that may adversely affect their business and operations, including, but not limited to: high interest costs in connection with capital construction programs; high leverage; costs associated with environmental and other regulations; surplus capacity costs; and reduced investment in public and private infrastructure projects. A slowdown in new infrastructure projects in developing or developed markets may constrain the abilities of Infrastructure issuers to grow in global markets. Other developments, such as significant changes in population levels or changes in the urbanization and industrialization of developing countries, may reduce demand for products or services provided by Infrastructure issuers.

I N V E S T M E N T  O B J E C T I V E S ,  P O L I C I E S  A N D  R I S K S 203

Investment Objectives, Policies and Risks (continued)

Risk Factors (continued)

• Power Opportunities Companies Risk – A variety of factors may adversely affect the business or operations of Power Opportunities issuers, including, but not limited to: research and development costs related to new technologies; the success or failure of efforts to develop or implement new or existing technologies; government regulation (including environmental regulation); world events and economic conditions, the cyclical nature of the energy sector; intense competition; events relating to domestic and international political developments; energy conservation; environmental costs and liabilities; and the success of exploration projects.

Innovative Securities Risk (BIGZ): There can be no assurance that a company identified as innovative by the Manager will ultimately introduce a new product or service or that such product or service may not be significantly delayed.

Supply and Demand Risk (BGR): A decrease in the production of natural gas, natural gas liquids (“NGLs”), crude oil, coal or other energy commodities or a decrease in the volume of such commodities available for transportation, mining, processing, storage or distribution may adversely impact the financial performance of energy and natural resources companies. Production declines and volume decreases could be caused by various factors, including catastrophic events affecting production, depletion of resources, labor difficulties, environmental proceedings, increased regulations, equipment failures and unexpected maintenance problems, import supply disruption, increased competition from alternative energy sources or commodity prices. Alternatively, a sustained decline in demand for such commodities could also adversely affect the financial performance of energy and natural resources companies. Factors which could lead to a decline in demand include economic recession or other adverse economic conditions, higher fuel taxes or governmental regulations, increases in fuel economy, consumer shifts to the use of alternative fuel sources, changes in commodity prices, or weather.

Depletion and Exploration Risk (BGR): Many energy and natural resources companies are either engaged in the production of natural gas, NGLs, crude oil, refined petroleum products or coal, or are engaged in transporting, storing, distributing and processing these items on behalf of shippers. To maintain or grow their revenues, these companies or their customers need to maintain or expand their reserves through exploration of new sources of supply, through the development of existing sources, through acquisitions, or through long-term contracts to acquire reserves. The financial performance of energy and natural resources companies may be adversely affected if they, or the companies to whom they provide the service, are unable to cost-effectively acquire additional reserves sufficient to replace the natural decline.

Commodity Pricing Risk (BGR): The operations and financial performance of energy and natural resources companies may be directly affected by energy commodity prices, especially those energy and natural resources companies which own the underlying energy commodity. Commodity prices fluctuate for several reasons, including changes in market and economic conditions, the impact of weather on demand, levels of domestic production and imported commodities, energy conservation, domestic and foreign governmental regulation and taxation and the availability of local, intrastate and interstate transportation systems. Volatility of commodity prices, which may lead to a reduction in production or supply, may also negatively impact the performance of energy and natural resources companies which are solely involved in the transportation, processing, storing, distribution or marketing of commodities. Volatility of commodity prices may also make it more difficult for energy and natural resources companies to raise capital to the extent the market perceives that their performance may be directly or indirectly tied to commodity prices.

Leverage Risk: The Trust’s use of leverage may increase or decrease from time to time in its discretion and the Trust may, in the future, determine not to use leverage.

The use of leverage creates an opportunity for increased common share net investment income dividends, but also creates risks for the holders of common shares. The Trust cannot assure you that the use of leverage will result in a higher yield on the common shares. Any leveraging strategy the Trust employs may not be successful.

Leverage involves risks and special considerations for common shareholders, including:

• the likelihood of greater volatility of net asset value, market price and dividend rate of the common shares than a comparable portfolio without leverage;

• the risk that fluctuations in interest rates or dividend rates on any leverage that the Trust must pay will reduce the return to the common shareholders;

• the effect of leverage in a declining market, which is likely to cause a greater decline in the net asset value of the common shares than if the Trust were not leveraged, which may result in a greater decline in the market price of the common shares;

• leverage may increase operating costs, which may reduce total return.

Any decline in the net asset value of the Trust’s investments will be borne entirely by the holders of common shares. Therefore, if the market value of the Trust’s portfolio declines, leverage will result in a greater decrease in net asset value to the holders of common shares than if the Trust were not leveraged. This greater net asset value decrease will also tend to cause a greater decline in the market price for the common shares.

Reverse Repurchase Agreements Risk (BDJ, BME, BMEZ, BIGZ, BCX, BST, BSTZ and BUI): Reverse repurchase agreements involve the sale of securities held by the Trust with an agreement to repurchase the securities at an agreed-upon price, date and interest payment. Reverse repurchase agreements involve the risk that the other party may fail to return the securities in a timely manner or at all. The Trust could lose money if it is unable to recover the securities and the value of the collateral held by the Trust, including the value of the investments made with cash collateral, is less than the value of the securities. These events could also trigger adverse tax consequences for the Trust. In addition, reverse repurchase agreements involve the risk that the interest income earned in the investment of the proceeds will be less than the interest expense.

Dollar Rolls Risk (BME, BMEZ, BIGZ, BST and BSTZ): Dollar rolls involve the risk that the market value of the securities that the Trust is committed to buy may decline below the price of the securities the Trust has sold. These transactions may involve leverage.

When-Issued and Delayed Delivery Securities and Forward Commitments Risk (BDJ, BME, BMEZ, BCX and BSTZ): When-issued and delayed delivery securities and forward commitments involve the risk that the security the Trust buys will lose value prior to its delivery. There also is the risk that the security will not be issued or that the other party to the transaction will not meet its obligation. If this occurs, the Trust may lose both the investment opportunity for the assets it set aside to pay for the security and any gain in the security’s price.

204 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Investment Objectives, Policies and Risks (continued)

Risk Factors (continued)

Short Sales Risk (BDJ, BGY, BME, BMEZ, BCX, BST, BSTZ and BUI): Because making short sales in securities that it does not own exposes the Trust to the risks associated with those securities, such short sales involve speculative exposure risk. The Trust will incur a loss as a result of a short sale if the price of the security increases between the date of the short sale and the date on which the Trust replaces the security sold short.

Repurchase Agreements and Purchase and Sale Contracts Risk (BDJ, BME, BMEZ, BCX and BSTZ): If the other party to a repurchase agreement or purchase and sale contract defaults on its obligation under the agreement, the Trust may suffer delays and incur costs or lose money in exercising its rights under the agreement. If the seller fails to repurchase the security in either situation and the market value of the security declines, the Trust may lose money.

Risks Associated with Private Company Investments (BDJ, BMEZ, BIGZ, BST and BSTZ): Private companies are generally not subject to SEC reporting requirements, are not required to maintain their accounting records in accordance with generally accepted accounting principles, and are not required to maintain effective internal controls over financial reporting. As a result, the Manager may not have timely or accurate information about the business, financial condition and results of operations of the private companies in which the Trust invests. There is risk that the Trust may invest on the basis of incomplete or inaccurate information, which may adversely affect the Trust’s investment performance. Private companies in which the Trust may invest may have limited financial resources, shorter operating histories, more asset concentration risk, narrower product lines and smaller market shares than larger businesses, which tend to render such private companies more vulnerable to competitors’ actions and market conditions, as well as general economic downturns.

These companies generally have less predictable operating results, may from time to time be parties to litigation, may be engaged in rapidly changing businesses with products subject to a substantial risk of obsolescence, and may require substantial additional capital to support their operations, finance expansion or maintain their competitive position. These companies may have difficulty accessing the capital markets to meet future capital needs, which may limit their ability to grow or to repay their outstanding indebtedness upon maturity. In addition, the Trust’s investment also may be structured as pay-in-kind securities with minimal or no cash interest or dividends until the company meets certain growth and liquidity objectives.

Typically, investments in private companies are in restricted securities that are not traded in public markets and subject to substantial holding periods, so that the Trust may not be able to resell some of its holdings for extended periods, which may be several years. There can be no assurance that the Trust will be able to realize the value of private company investments in a timely manner.

• Late-Stage Private Companies Risk (BMEZ and BIGZ) – Investments in late-stage private companies involve greater risks than investments in shares of companies that have traded publicly on an exchange for extended periods of time. These investments may present significant opportunities for capital appreciation but involve a high degree of risk that may result in significant decreases in the value of these investments. The Trust may not be able to sell such investments when the Manager deems it appropriate to do so because they are not publicly traded. As such, these investments are generally considered to be illiquid until a company’s public offering (which may never occur) and are often subject to additional contractual restrictions on resale following any public offering that may prevent the Trust from selling its shares of these companies for a period of time. See “Illiquid Investments Risk.” Market conditions, developments within a company, investor perception or regulatory decisions may adversely affect a late-stage private company and delay or prevent such a company from ultimately offering its securities to the public. If a company does issue shares in an IPO, IPOs are risky and volatile and may cause the value of the Trust’s investment to decrease significantly.

• Pre-IPO Securities Risk (BSTZ) – Investments in pre-IPO securities involve greater risks than investments in shares of companies that have traded publicly on an exchange for extended periods of time. These investments may present significant opportunities for capital appreciation but involve a high degree of risk that may result in significant decreases in the value of these investments. Issuers of pre-IPO securities may not have established products, experienced management or earnings history. The Trust may not be able to sell such investments when the Manager deems it appropriate to do so because they are not publicly traded. As such, these investments are generally considered to be illiquid until a company’s public offering (which may never occur) and are often subject to additional contractual restrictions on resale following any public offering that may prevent the Trust from selling its shares of these companies for a period of time. See “Illiquid Investments Risk.” Market conditions, developments within a company, investor perception or regulatory decisions may adversely affect an issuer of pre-IPO securities and delay or prevent such an issuer from ultimately offering its securities to the public. If a company does issue shares in an IPO, IPOs are risky and volatile and may cause the value of the Trust’s investment to decrease significantly.

Illiquid Investments Risk: The Trust may invest in illiquid or less liquid investments or investments in which no secondary market is readily available or which are otherwise illiquid, including private placement securities. The Trust may not be able to readily dispose of such investments at prices that approximate those at which the Trust could sell such investments if they were more widely traded and, as a result of such illiquidity, the Trust may have to sell other investments or engage in borrowing transactions if necessary to raise cash to meet its obligations. Limited liquidity can also affect the market price of investments, thereby adversely affecting the Trust’s net asset value and ability to make dividend distributions. The financial markets in general, and certain segments of the mortgage-related securities markets in particular, have in recent years experienced periods of extreme secondary market supply and demand imbalance, resulting in a loss of liquidity during which market prices were suddenly and substantially below traditional measures of intrinsic value. During such periods, some investments could be sold only at arbitrary prices and with substantial losses. Periods of such market dislocation may occur again at any time. Privately issued debt securities are often of below investment grade quality, frequently are unrated and present many of the same risks as investing in below investment grade public debt securities.

Investment Companies and ETFs Risk (BME, BMEZ, BIGZ, BCX, BST, BSTZ and BUI): Subject to the limitations set forth in the Investment Company Act and the rules thereunder, the Trust may acquire shares in other investment companies and in ETFs, some of which may be affiliated investment companies. The market value of the shares of other investment companies and ETFs may differ from their net asset value. As an investor in investment companies and ETFs, the Trust would bear its ratable share of that entity’s expenses, including its investment advisory and administration fees, while continuing to pay its own advisory and administration fees and other expenses (to the extent not offset by the Manager through waivers). As a result, shareholders will be absorbing duplicate levels of fees with respect to investments in other investment companies and ETFs (to the extent not offset by the Manager through waivers).

I N V E S T M E N T  O B J E C T I V E S ,  P O L I C I E S  A N D  R I S K S 205

Investment Objectives, Policies and Risks (continued)

Risk Factors (continued)

The securities of other investment companies and ETFs in which the Trust may invest may be leveraged. As a result, the Trust may be indirectly exposed to leverage through an investment in such securities. An investment in securities of other investment companies and ETFs that use leverage may expose the Trust to higher volatility in the market value of such securities and the possibility that the Trust’s long-term returns on such securities (and, indirectly, the long-term returns of shares of the Trust) will be diminished.

As with other investments, investments in other investment companies, including ETFs, are subject to market and selection risk. To the extent the Trust is held by an affiliated fund, the ability of the Trust itself to hold other investment companies may be limited.

Subsidiary Risk (BCX): By investing in the Subsidiary, the Trust is indirectly exposed to the risks associated with the Subsidiary’s investments. The commodity-related instruments held by the Subsidiary are generally similar to those that are permitted to be held by the Trust and are subject to the same risks that apply to similar investments if held directly by the Trust (see “Commodities Related Investments Risk” above). There can be no assurance that the investment objective of the Subsidiary will be achieved. The Subsidiary is not registered under the Investment Company Act, and, unless otherwise noted, is not subject to all the investor protections of the Investment Company Act. However, the Trust wholly owns and controls the Subsidiary, and the Trust and the Subsidiary are both managed by the Manager, making it unlikely that the Subsidiary will take action contrary to the interests of the Trust and its shareholders. The Board has oversight responsibility for the investment activities of the Trust, including its investment in the Subsidiary, and the Trust’s role as sole shareholder of the Subsidiary. The Subsidiary is subject to the same investment restrictions and limitations, and follows the same compliance policies and procedures, as the Trust. Changes in the laws of the United States and/or the Cayman Islands could result in the inability of the Trust and/or the Subsidiary to operate as described and could adversely affect the Trust.

Securities Lending Risk (BDJ, BGY, BME, BMEZ, BIGZ, BCX, BST, BSTZ and BUI): Securities lending involves the risk that the borrower may fail to return the securities in a timely manner or at all. As a result, the Trust may lose money and there may be a delay in recovering the loaned securities. The Trust could also lose money if it does not recover the securities and/or the value of the collateral falls, including the value of investments made with cash collateral. These events could trigger adverse tax consequences for the Trust.

Risk of Investing in the United States (BGR, CII, BDJ, BOE, BME, BMEZ, BIGZ, BCX, BST, BSTZ and BUI): Certain changes in the U.S. economy, such as when the U.S. economy weakens or when its financial markets decline, may have an adverse effect on the securities to which the Trust has exposure.

Market Risk and Selection Risk: Market risk is the risk that one or more markets in which the Trust invests will go down in value, including the possibility that the markets will go down sharply and unpredictably. The value of a security or other asset may decline due to changes in general market conditions, economic trends or events that are not specifically related to the issuer of the security or other asset, or factors that affect a particular issuer or issuers, exchange, country, group of countries, region, market, industry, group of industries, sector or asset class. Local, regional or global events such as war, acts of terrorism, the spread of infectious illness or other public health issues like pandemics or epidemics, recessions, or other events could have a significant impact on the Trust and its investments. Selection risk is the risk that the securities selected by Trust management will underperform the markets, the relevant indices or the securities selected by other funds with similar investment objectives and investment strategies. This means you may lose money.

An outbreak of an infectious coronavirus (COVID-19) that was first detected in December 2019 developed into a global pandemic that has resulted in numerous disruptions in the market and has had significant economic impact leaving general concern and uncertainty. Although vaccines have been developed and approved for use by various governments, the duration of the pandemic and its effects cannot be predicted with certainty. The impact of this coronavirus, and other epidemics and pandemics that may arise in the future, could affect the economies of many nations, individual companies and the market in general ways that cannot necessarily be foreseen at the present time.

Shareholder Activism Risk: Shareholder activism involving closed-end funds has recently been increasing. Shareholder activism can take many forms, including engaging in public campaigns to demand that the Trust consider significant transactions such as a tender offer, merger or liquidation or to attempt to influence the Trust’s corporate governance and/or management, commencing proxy contests to attempt to elect the activists’ representatives or others to the Trust’s Board of Trustees, or to seek other actions such as a termination of the Trust’s investment advisory contract with its current investment manager or commencing litigation. If the Trust becomes the subject of shareholder activism, then management and the Board may be required to divert significant resources and attention to respond to the activist and the Trust may incur substantial costs defending against such activism if management and the Board determine that the activist’s demands are not in the best interest of the Trust. Further, the Trust’s share price could be subject to significant fluctuation or otherwise be adversely affected by the events, risks and uncertainties of any shareholder activism.

206 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Shareholder Update (unaudited)

The following information is presented for BDJ, BME, BST and BUI, in conformance with annual reporting requirements for funds that have filed a shelf offering registration statement pursuant to General Instruction A.2 of Form N-2.

Summary of Expenses

BlackRock Enhanced Equity Dividend Trust (BDJ)

The following table and example are intended to assist shareholders in understanding the various costs and expenses directly or indirectly associated with investing in BDJ’s common shares.

	BDJ
Shareholder Transaction Expenses
Maximum sales load (as a percentage of offering price)(a)		1.00	%
Offering expenses borne by the Trust (as a percentage of offering price)(a)		0.01	%
		$0.02 per share
		for open market
		purchases of
Dividend reinvestment plan fees		common shares	(b)
Estimated Annual Expenses (as a percentage of net assets attributable to common shares) Investment advisory fees(c)(d)		0.80	%
Other expenses		0.06
Acquired fund fees and expenses(e)		0.01
Total annual expenses(e)		0.87
Fee waivers(d)		—
Total annual Trust operating expenses after fee waivers(d)		0.87

^(a)  If the common shares are sold to or through underwriters, the Prospectus Supplement will set forth any applicable sales load and the estimated offering expenses. Trust shareholders will pay all offering expenses involved with an offering.

^(b)  Computershare Trust Company, N.A. (the “Reinvestment Plan Agent”) fees for the handling of the reinvestment of dividends will be paid by BDJ. However, shareholders will pay a $0.02 per share fee incurred in connection with open-market purchases, which will be deducted from the value of the dividend. Shareholders will also be charged a $0.02 per share fee if a shareholder directs the Reinvestment Plan Agent to sell the common shares held in a dividend reinvestment account. Per share fees include any applicable brokerage commissions the Reinvestment Plan Agent is required to pay.

^(c) BDJ currently pays the Manager a monthly fee at an annual contractual investment advisory fee rate of 0.80% of its average weekly value of BDJ’s net assets.

^(d)  BDJ and the Manager have entered into a fee waiver agreement (the “Fee Waiver Agreement”), pursuant to which the Manager has contractually agreed to waive the investment advisory fees with respect to any portion of BDJ’s assets attributable to investments in any equity and fixed-income mutual funds and exchange-traded funds (“ETFs”) managed by the Manager or its affiliates that have a contractual fee, through June 30, 2025. In addition, pursuant to the Fee Waiver Agreement, the Manager has contractually agreed to waive its investment advisory fees by the amount of investment advisory fees BDJ pays to the Manager indirectly through its investment in money market funds managed by the Manager or its affiliates, through June 30, 2025. The Fee Waiver Agreement may be terminated at any time, without the payment of any penalty, only by BDJ (upon the vote of a majority of the Trustees who are not “interested persons” (as defined in the Investment Company Act of 1940, as amended (the “Investment Company Act”), of BDJ (the “Independent Trustees”)) or a majority of the outstanding voting securities of BDJ), upon 90 days’ written notice by BDJ to the Manager.

^(e)  The total annual expenses do not correlate to the ratios to average net assets shown in BDJ’s Financial Highlights for the year ended December 31, 2023, which do not include acquired fund fees and expenses.

The following example illustrates BDJ’s expenses (including the sales load of $10.00 and offering costs of $0.15) that shareholders would pay on a $1,000 investment in common shares, assuming (i) total net annual expenses of 0.87% of net assets attributable to common shares and (ii) a 5% annual return:

	1 Year		3 Years		5 Years		10 Years
Total expenses incurred	$	19	$	38	$	58	$	116

The example should not be considered a representation of future expenses. The example assumes that the estimated “Other expenses” set forth in the Estimated Annual Expenses table are accurate and that all dividends and distributions are reinvested at NAV. Actual expenses may be greater or less than those assumed. BDJ’s actual rate of return may be greater or less than the hypothetical 5% return shown in the example.

S H A R E H O L D E R U P D A T E 207

Shareholder Update (unaudited) (continued)

BlackRock Health Sciences Trust (BME)

The following table and example are intended to assist shareholders in understanding the various costs and expenses directly or indirectly associated with investing in BME’s common shares.

	BME
Shareholder Transaction Expenses
Maximum sales load (as a percentage of offering price)(a)		1.00	%
Offering expenses borne by the Trust (as a percentage of offering price)(a)		0.01	%
		$0.02 per share
		for open market
		purchases of
Dividend reinvestment plan fees		common shares	(b)
Estimated Annual Expenses (as a percentage of net assets attributable to common shares) Investment advisory fees(c)(d)		1.00	%
Other expenses		0.06
Acquired fund fees and expenses(e)		0.01
Total annual expenses(e)		1.07
Fee waivers(d)		—
Total annual Trust operating expenses after fee waivers(d)		1.07

^(a)  If the common shares are sold to or through underwriters, the Prospectus Supplement will set forth any applicable sales load and the estimated offering expenses. Trust shareholders will pay all offering expenses involved with an offering.

^(b)  Computershare Trust Company, N.A.’s (the “Reinvestment Plan Agent”) fees for the handling of the reinvestment of dividends will be paid by BME. However, shareholders will pay a $0.02 per share fee incurred in connection with open-market purchases, which will be deducted from the value of the dividend. Shareholders will also be charged a $0.02 per share fee if a shareholder directs the Reinvestment Plan Agent to sell the common shares held in a dividend reinvestment account. Per share fees include any applicable brokerage commissions the Reinvestment Plan Agent is required to pay.

^(c)  BME currently pays the Manager a contractual investment advisory fee at an annual rate of 1.00% based on BME’s average weekly net assets.

^(d)  BME and the Manager have entered into a fee waiver agreement (the “Fee Waiver Agreement”), pursuant to which the Manager has contractually agreed to waive the investment advisory fees with respect to any portion of BME’s assets attributable to investments in any equity and fixed-income mutual funds and exchange-traded funds managed by the Manager or its affiliates that have a contractual management fee, through June 30, 2025. In addition, pursuant to the Fee Waiver Agreement, the Manager has contractually agreed to waive its investment advisory fees by the amount of investment advisory fees BME pays to the Manager indirectly through its investment in money market funds managed by the Manager or its affiliates, through June 30, 2025. The Fee Waiver Agreement may be terminated at any time, without the payment of any penalty, only by BME (upon the vote of a majority of the Trustees who are not “interested persons” (as defined in the Investment Company Act) of BME or a majority of the outstanding voting securities of BME), upon 90 days’ written notice by BME to the Manager.

^(e)  The total annual expenses do not correlate to the ratios to average net assets shown in BME’s Financial Highlights for the year ended December 31, 2023, which do not include acquired fund fees and expenses.

The following example illustrates BME’s expenses (including the sales load of $10.00 and offering costs of $0.15) that shareholders would pay on a $1,000 investment in common shares, assuming (i) total net annual expenses of 1.07% of net assets attributable to common shares and (ii) a 5% annual return:

	1 Year		3 Years		5 Years		10 Years
Total expenses incurred	$	21	$	44	$	69	$	139

The example should not be considered a representation of future expenses. The example assumes that the estimated “Other expenses” set forth in the Estimated Annual Expenses table are accurate and that all dividends and distributions are reinvested at NAV. Actual expenses may be greater or less than those assumed. BME’s actual rate of return may be greater or less than the hypothetical 5% return shown in the example.

208 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Shareholder Update (unaudited) (continued)

BlackRock Science and Technology Trust (BST)

The following table and example are intended to assist shareholders in understanding the various costs and expenses directly or indirectly associated with investing in BST’s common shares.

	BST
Shareholder Transaction Expenses
Maximum sales load (as a percentage of offering price)(a)		1.00	%
Offering expenses borne by the Trust (as a percentage of offering price)(a)		0.02	%
		$0.02 per share
		for open market
		purchases of
Dividend reinvestment plan fees		common shares	(b)
Dividend reinvestment plan sale transaction fee		$2.50	(b)
Estimated Annual Expenses (as a percentage of net assets attributable to common shares) Investment advisory fees(c)(d)		1.00	%
Other expenses		0.09
Total annual expenses		1.09
Fee waivers(d)		—
Total annual Trust operating expenses after fee waivers(d)		1.09

^(a)  If the common shares are sold to or through underwriters, the Prospectus Supplement will set forth any applicable sales load and the estimated offering expenses. Trust shareholders will pay all offering expenses involved with an offering.

^(b)  Computershare Trust Company, N.A.’s (the “Reinvestment Plan Agent”) fees for the handling of the reinvestment of dividends will be paid by BST. However, shareholders will pay a $0.02 per share fee incurred in connection with open-market purchases, which will be deducted from the value of the dividend. Shareholders will also be charged a $2.50 sales fee and pay a $0.15 per share fee if a shareholder directs the Reinvestment Plan Agent to sell the common shares held in a dividend reinvestment account. Per share fees include any applicable brokerage commissions the Reinvestment Plan Agent is required to pay.

^(c)  BST currently pays the Manager a contractual investment advisory fee at an annual rate of 1.00% based on BST’s average daily managed assets. “Managed Assets” means the total assets of BST (including any assets attributable to money borrowed for investment purposes) minus the sum of BST’s accrued liabilities (other than money borrowed for investment purposes).

^(d)  BST and the Manager have entered into a fee waiver agreement (the “Fee Waiver Agreement”), pursuant to which the Manager has contractually agreed to waive the investment advisory fees with respect to any portion of BST’s assets attributable to investments in any equity and fixed-income mutual funds and exchange-traded funds managed by the Manager or its affiliates that have a contractual management fee, through June 30, 2025. In addition, pursuant to the Fee Waiver Agreement, the Manager has contractually agreed to waive its investment advisory fees by the amount of investment advisory fees BST pays to the Manager indirectly through its investment in money market funds managed by the Manager or its affiliates, through June 30, 2025. The Fee Waiver Agreement may be terminated at any time, without the payment of any penalty, only by BST (upon the vote of a majority of the Trustees who are not “interested persons” (as defined in the Investment Company Act) of BST or a majority of the outstanding voting securities of BST), upon 90 days’ written notice by BST to the Manager.

The following example illustrates BST’s expenses (including the sales load of $10.00 and offering costs of $0.16) that shareholders would pay on a $1,000 investment in common shares, assuming (i) total net annual expenses of 1.09% of net assets attributable to common shares and (ii) a 5% annual return:

	1 Year		3 Years		5 Years		10 Years
Total expenses incurred	$	21	$	44	$	70	$	142

The example should not be considered a representation of future expenses. The example assumes that the estimated “Other expenses” set forth in the Estimated Annual Expenses table are accurate and that all dividends and distributions are reinvested at NAV. Actual expenses may be greater or less than those assumed. BST’s actual rate of return may be greater or less than the hypothetical 5% return shown in the example.

S H A R E H O L D E R U P D A T E 209

Shareholder Update (unaudited) (continued)

BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)

The following table and example are intended to assist shareholders in understanding the various costs and expenses directly or indirectly associated with investing in BUI’s common shares.

	BUI
Shareholder Transaction Expenses
Maximum sales load (as a percentage of offering price)(a)		1.00	%
Offering expenses borne by the Trust (as a percentage of offering price)(a)		0.02	%
		$0.02 per share
		for open market
		purchases of
Dividend reinvestment plan fees		common shares	(b)
Estimated Annual Expenses (as a percentage of net assets attributable to common shares) Investment advisory fees(c)(d)		1.00	%
Other expenses		0.08
Total annual expenses		1.08
Fee waivers(d)		—
Total annual Trust operating expenses after fee waivers(d)		1.08

^(a)  If the common shares are sold to or through underwriters, the Prospectus Supplement will set forth any applicable sales load and the estimated offering expenses. Trust shareholders will pay all offering expenses involved with an offering.

^(b)  Computershare Trust Company, N.A.’s (the “Reinvestment Plan Agent”) fees for the handling of the reinvestment of dividends will be paid by BUI. However, shareholders will pay a $0.02 per share fee incurred in connection with open-market purchases, which will be deducted from the value of the dividend. Shareholders will also be charged a $0.02 per share fee if a shareholder directs the Reinvestment Plan Agent to sell the common shares held in a dividend reinvestment account. Per share fees include any applicable brokerage commissions the Reinvestment Plan Agent is required to pay.

^(c)  BUI currently pays the Manager a contractual investment advisory fee at an annual rate of 1.00% based on BUI’s average daily managed assets. “Managed Assets” means the total assets of BUI (including any assets attributable to money borrowed for investment purposes) minus the sum of BUI’s accrued liabilities (other than money borrowed for investment purposes).

^(d)  BUI and the Manager have entered into a fee waiver agreement (the “Fee Waiver Agreement”), pursuant to which the Manager has contractually agreed to waive the investment advisory fees with respect to any portion of BUI’s assets attributable to investments in any equity and fixed-income mutual funds and exchange-traded funds managed by the Manager or its affiliates that have a contractual management fee, through June 30, 2025. In addition, pursuant to the Fee Waiver Agreement, the Manager has contractually agreed to waive its investment advisory fees by the amount of investment advisory fees BUI pays to the Manager indirectly through its investment in money market funds managed by the Manager or its affiliates, through June 30, 2025. The Fee Waiver Agreement may be terminated at any time, without the payment of any penalty, only by BUI (upon the vote of a majority of the Trustees who are not “interested persons” (as defined in the Investment Company Act) of BUI or a majority of the outstanding voting securities of BUI), upon 90 days’ written notice by BUI to the Manager.

The following example illustrates BUI’s expenses (including the sales load of $10.00 and offering costs of $0.21) that shareholders would pay on a $1,000 investment in common shares, assuming (i) total net annual expenses of 1.08% of net assets attributable to common shares and (ii) a 5% annual return:

	1 Year		3 Years		5 Years		10 Years
Total expenses incurred	$	21	$	44	$	69	$	141

The example should not be considered a representation of future expenses. The example assumes that the estimated “Other expenses” set forth in the Estimated Annual Expenses table are accurate and that all dividends and distributions are reinvested at NAV. Actual expenses may be greater or less than those assumed. BUI’s actual rate of return may be greater or less than the hypothetical 5% return shown in the example.

210 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Shareholder Update (unaudited) (continued)

Share Price Data

The following tables summarize each Trust’s highest and lowest daily closing market prices on the NYSE per common share, the NAV per common share, and the premium to or discount from NAV, on the date of each of the high and low market prices. The trading volume indicates the number of common shares traded on the NYSE during the respective quarters.

	NYSE Market Price Per Common Share					NAV per Common Share on Date of Market Price				Premium/ (Discount) on Date of Market Price
BDJ — During Quarter Ended	High		Low			High		Low		High			Low			Trading Volume
December 31, 2023	$	7.91	$	6.92		$	8.68	$	8.17		(8.87	)%		(15.30	)%		38,503,054
September 30, 2023		8.39		7.47			8.96		8.38		(6.36	)		(10.86	)		35,094,623
June 30, 2023		8.60		8.03			8.76		8.56		(1.83	)		(6.19	)		24,527,314
March 31, 2023		9.36		8.26			9.15		8.23		2.30			0.36			25,059,984
December 31, 2022		9.50		8.14			9.49		8.58		0.11			(5.13	)		29,748,145
September 30, 2022		9.71		8.08			9.42		8.47		3.08			(4.60	)		27,876,699
June 30, 2022		9.96		8.29			10.26		9.26		(2.92	)		(10.48	)		31,606,667
March 31, 2022		10.43		9.15			10.55		9.73		(1.14	)		(5.96	)		40,186,783

As of December 31, 2023, BDJ’s market price, NAV per Common Share, and premium/(discount) to NAV per Common Share were $7.69, $8.82, and (12.81)%, respectively.

	NYSE Market Price Per Common Share				NAV per Common Share on Date of Market Price				Premium/ (Discount) on Date of Market Price
BME — During Quarter Ended	High		Low		High		Low		High			Low			Trading Volume
December 31, 2023	$	40.46	$	35.53	$	42.18	$	39.01		(4.08	)%		(8.92	)%		2,698,691
September 30, 2023		40.90		38.98		43.13		41.02		(5.17	)		(4.97	)		2,017,234
June 30, 2023		42.93		39.55		42.91		41.26		0.05			(4.14	)		1,769,337
March 31, 2023		43.68		39.34		43.03		40.48		1.51			(2.82	)		1,728,269
December 31, 2022		44.88		38.85		42.39		40.17		5.87			(3.29	)		2,275,787
September 30, 2022		44.96		38.27		43.41		39.41		3.57			(2.89	)		2,093,916
June 30, 2022		46.86		39.97		46.49		39.35		0.80			1.58			2,651,572
March 31, 2022		48.20		41.70		47.26		42.50		1.99			(1.88	)		2,486,253

As of December 31, 2023, BME’s market price, NAV per Common Share, and premium/(discount) to NAV per Common Share were $40.46, $42.18, and (4.08)%, respectively.

	NYSE Market Price Per Common Share				NAV per Common Share on Date of Market Price				Premium/ (Discount) on Date of Market Price
BST — During Quarter Ended	High		Low		High		Low		High			Low			Trading Volume
December 31, 2023	$	34.48	$	29.72	$	34.21	$	30.15		0.79	%		(1.43	)%		6,323,509
September 30, 2023		35.25		30.61		34.81		31.31		1.26			(2.24	)		5,818,231
June 30, 2023		34.44		30.25		34.14		30.31		0.88			(0.20	)		5,884,379
March 31, 2023		34.12		28.52		32.41		28.95		5.28			(1.49	)		8,051,284
December 31, 2022		32.45		28.07		31.69		28.47		2.40			(1.40	)		9,877,821
September 30, 2022		38.73		29.38		37.18		31.02		4.17			(5.29	)		9,463,720
June 30, 2022		44.15		31.25		45.87		33.58		(3.75	)		(6.94	)		9,431,070
March 31, 2022		50.99		40.14		52.59		42.32		(3.04	)		(5.15	)		11,617,438

As of December 31, 2023, BST’s market price, NAV per Common Share, and premium/(discount) to NAV per Common Share were $33.66, $34.74, and (3.11)%, respectively.

	NYSE Market Price Per Common Share				NAV per Common Share on Date of Market Price				Premium/ (Discount) on Date of Market Price
BUI — During Quarter Ended	High		Low		High		Low		High			Low			Trading Volume
December 31, 2023	$	21.82	$	18.75	$	22.54	$	19.79		(3.19	)%		(5.26	)%		4,511,140
September 30, 2023		23.34		19.64		23.05		20.42		1.26			(3.82	)		3,117,194
June 30, 2023		23.73		21.56		22.95		22.18		3.40			(2.80	)		2,819,113
March 31, 2023		23.98		20.99		22.97		22.33		4.40			(6.00	)		3,092,154
December 31, 2022		22.24		19.02		23.13		19.61		(3.85	)		(3.01	)		3,657,444
September 30, 2022		24.47		20.06		23.61		20.19		3.64			(0.64	)		3,404,776
June 30, 2022		25.79		20.46		25.13		21.06		2.63			(2.85	)		3,775,619

S H A R E H O L D E R U P D A T E 211

Shareholder Update (unaudited) (continued)

	NYSE Market Price Per Common Share				NAV per Common Share on Date of Market Price				Premium/ (Discount) on Date of Market Price
BUI — During Quarter Ended	High		Low		High		Low		High			Low			Trading Volume
March 31, 2022	$	27.28	$	22.88	$	25.09	$	23.27		8.73	%		(1.68	)%		4,035,794

As of December 31, 2023, BUI’s market price, NAV per Common Share, and premium/(discount) to NAV per Common Share were $21.82, $22.53, and (3.15)%, respectively.

Common shares of each Trust have historically traded at both a premium and discount to NAV.

Shares of closed-end funds frequently trade at a discount to their NAV. Because of this possibility and the recognition that any such discount may not be in the interest of shareholders, the Board might consider from time to time engaging in open-market repurchases, managed distribution plans, or other programs intended to reduce the discount. We cannot guarantee or assure, however, that the Board will decide to engage in any of these actions. Nor is there any guarantee or assurance that such actions, if undertaken, would result in the shares trading at a price equal or close to the NAV.

212 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Shareholder Update (unaudited) (continued)

Financial Highlights

The financial highlights table is intended to help the shareholder to understand BDJ’s financial performance for the periods presented. Certain information reflects financial results for a single common share of BDJ.

	BDJ
	Year Ended 12/31/18			Year Ended 12/31/17			Year Ended 12/31/16			Year Ended 12/31/15			Period from 11/01/14 to 12/31/14			Year Ended 10/31/14
Net asset value, beginning of period	$	9.96		$	9.22		$	8.70		$	9.24		$	9.19		$	8.88
Net investment income(a)		0.18	(b)		0.16			0.17			0.17			0.04			0.16
Net realized and unrealized gain (loss)		(0.84	)		1.14			0.91			(0.15	)		0.10			0.76
Net increase (decrease) from investment operations		(0.66	)		1.30			1.08			0.02			0.14			0.92
Distributions(c)
From net investment income		(0.56	)		(0.17	)		(0.17	)		(0.17	)		(0.03	)		(0.17	)
From net realized gain		—			(0.39	)		—			—			—			—
From return of capital		—			—			(0.39	)		(0.39	)		(0.06	)		(0.44	)
Total distributions		(0.56	)		(0.56	)		(0.56	)		(0.56	)		(0.09	)		(0.61	)
Net asset value, end of period	$	8.74		$	9.96		$	9.22		$	8.70		$	9.24		$	9.19
Market price, end of period	$	7.77		$	9.23		$	8.15		$	7.61		$	8.12		$	8.35
Total Return(d)
Based on net asset value		(6.59	)%		15.06	%		13.90	%		1.10	%		1.69	%(e)		11.40	%
Based on market price		(10.39	)%		20.63	%		15.11	%		0.63	%		(1.65	)%(e)		16.42	%
Ratios to Average Net Assets
Total expenses		0.85	%		0.86	%		0.87	%		0.86	%		0.87	%(f)		0.87	%(g)
Total expenses after fees waived and/or reimbursed		0.85	%		0.86	%		0.85	%		0.85	%		0.84	%(f)		0.86	%(g)
Net investment income		1.85	%(b)		1.73	%		1.91	%		1.85	%		2.30	%(f)		1.81	%
Supplemental Data
Net assets, end of period (000)	$	1,638,237		$	1,868,457		$	1,741,649		$	1,643,508		$	1,747,070		$	1,648,683
Portfolio turnover rate		34	%		42	%		33	%		26	%		0	%(h)		63	%

^(a)  Based on average Common Shares outstanding.

^(b)  Net investment income per share and the ratio of net investment income to average net assets includes $0.01 per share and 0.14%, respectively, resulting from a special dividend.

^(c)  Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

^(d)  Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.

^(e)  Aggregate total return.

^(f)  Annualized.

^(g)  Includes reorganization costs associated with the Trust’s merger. Without these costs, total expenses and total expenses after fees waived and/or reimbursed would have been 0.86% and 0.86%, respectively.

^(h)  Amount is less than 0.5%.

S H A R E H O L D E R U P D A T E 213

Shareholder Update (unaudited) (continued)

Financial Highlights

The financial highlights table is intended to help the shareholder to understand BME’s financial performance for the periods presented. Certain information reflects financial results for a single common share of BME.

	BME
	Year Ended 12/31/18			Year Ended 12/31/17			Year Ended 12/31/16			Year Ended 12/31/15			Period from 11/01/14 to 12/31/14			Year Ended 10/31/14
Net asset value, beginning of period	$	35.69		$	31.30		$	36.19		$	38.61		$	40.22		$	34.92
Net investment income (loss)(a)		0.07			0.02			0.02			(0.06	)		(0.01	)		(0.00	)(b)
Net realized and unrealized gain (loss)		2.51			6.77			(1.91	)		4.34			1.10			9.14
Net increase (decrease) from investment operations		2.58			6.79			(1.89	)		4.28			1.09			9.14
Distributions(c)
From net investment income		(2.40	)		(0.04	)		(0.03	)		(0.63	)		(0.01	)		(0.10	)
From net realized gain		—			(2.11	)		(2.97	)		(6.07	)		(2.69	)		(3.74	)
Return of capital		—			(0.25	)		—			—			—			—
Total distributions		(2.40	)		(2.40	)		(3.00	)		(6.70	)		(2.70	)		(3.84	)
Net asset value, end of period	$	35.87		$	35.69		$	31.30		$	36.19		$	38.61		$	40.22
Market price, end of period	$	36.45		$	36.50		$	31.75		$	39.35		$	42.70		$	41.37
Total Return(d)
Based on net asset value		7.26	%		22.17	%		(5.36	)%		10.70	%		2.38	%(e)		28.00	%
Based on market price		6.57	%		23.17	%		(11.71	)%		8.87	%		10.07	%(e)		36.99	%
Ratios to Average Net Assets(f)
Total expenses		1.11	%		1.12	%		1.15	%(g)		1.13	%		1.16	%(h)		1.11	%
Total expenses after fees waived and/or reimbursed and excluding amortization of offering costs		1.11	%		1.12	%		1.14	%		1.12	%		1.11	%(h)		1.11	%
Net investment income (loss)		0.19	%		0.06	%		0.07	%		(0.14	)%		(0.10	)%(h)		0.01	%
Supplemental Data
Net assets, end of period (000)	$	352,675		$	331,858		$	270,693		$	297,530		$	303,103		$	313,933
Portfolio turnover rate		37	%		38	%		59	%		68	%		6	%		74	%

^(a)  Based on average shares outstanding.

^(b)  Amount is greater than $(0.005) per share.

^(c)  Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

^(d)  Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.

^(e)  Aggregate total return.

^(f)  Excludes expenses incurred indirectly as a result of investments in underlying funds as follows:

	Year Ended			Year Ended			Year Ended			Year Ended			Period from			Year Ended
	12/31/18			12/31/17			12/31/16			12/31/15			11/01/14 to 12/31/14			10/31/14
Investments in underlying funds		0.01	%		0.01	%		—	%		—	%		—	%		—	%

^(g)  Offering costs were not annualized in the calculation of the expense ratios. If these expenses were annualized, the total expenses would have been 1.16%.

^(h)  Annualized.

214 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Shareholder Update (unaudited) (continued)

Financial Highlights

The financial highlights table is intended to help the shareholder to understand BST’s financial performance for the periods presented. Certain information reflects financial results for a single common share of BST.

	BST
		Year Ended 12/31/18			Year Ended 12/31/17			Year Ended 12/31/16			Year Ended 12/31/15			Period from 10/30/2014 to 12/31/2014	(a)
Net asset value, beginning of period	$	27.73		$	20.10		$	19.70		$	19.43		$	19.10	(b)
Net investment income (loss)(c)		(0.13	)		(0.05	)		0.00	(d)		0.03			(0.01	)
Net realized and unrealized gain		0.37			8.96			1.60			1.44			0.48
Net increase (decrease) from investment operations		0.24			8.91			1.60			1.47			0.47
Distributions(e)
From net investment income		(1.68	)		(0.05	)		—			(0.03	)		(0.00	)(f)
From net realized gain		(0.08	)		(0.22	)		—			(0.01	)		—
Return of capital		—			(1.01	)		(1.20	)		(1.16	)		(0.10	)
Total distributions		(1.76	)		(1.28	)		(1.20	)		(1.20	)		(0.10	)
Capital changes with respect to issuance of Common Shares		—			—			—			—			(0.04	)
Net asset value, end of period	$	26.21		$	27.73		$	20.10		$	19.70		$	19.43
Market price, end of period	$	27.48		$	26.69		$	17.94		$	17.31		$	17.59
Total Return(g)
Based on net asset value		0.24	%		45.73	%		9.36	%		8.61	%		2.31	%(h)
Based on market price		9.18	%		57.15	%		11.08	%		5.36	%		(11.55	)%(h)
Ratios to Average Net Assets
Total expenses		1.09	%		1.09	%		1.10	%		1.12	%		1.19	%(i)
Total expenses after fees waived and/or reimbursed		0.89	%		0.89	%		0.90	%		0.92	%		0.97	%(i)
Net investment income (loss)		(0.43	)%		(0.19	)%		0.02	%		0.15	%		(0.24	)%(i)
Supplemental Data
Net assets, end of period (000)	$	587,908		$	620,300		$	452,443		$	443,477		$	437,380
Portfolio turnover rate		53	%		41	%		74	%		91	%		7	%

^(a)  Commencement of investment operations. This information includes the initial investment by BlackRock HoldCo2, Inc.

^(b)  Net asset value, beginning of period, reflects a deduction of $0.8975 per share sales charge from initial offering price of $20.00 per share.

^(c)  Based on average shares outstanding.

^(d)  Amount is less than $0.005 per share.

^(e)  Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

^(f) Amount is greater than $(0.005) per share.

^(g)  Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.

^(h)  Aggregate total return.

⁽ⁱ⁾  Annualized.

S H A R E H O L D E R U P D A T E 215

Shareholder Update (unaudited) (continued)

Financial Highlights

The financial highlights table is intended to help the shareholder to understand BUI’s financial performance for the periods presented. Certain information reflects financial results for a single common share of BUI.

	BUI
	Year Ended 12/31/18			Year Ended 12/31/17			Year Ended 12/31/16			Year Ended 12/31/15			Period from 11/01/14 to 12/31/14			Year Ended 10/30/14
Net asset value, beginning of period	$	21.12		$	19.42		$	19.50		$	22.47		$	22.40		$	20.78
Net investment income(a)		0.49			0.56			0.56			0.47			0.11			0.51
Net realized and unrealized gain (loss)		(1.39	)		2.59			0.81			(1.99	)		0.20			2.68
Net increase (decrease) from investment operations		(0.90	)		3.15			1.37			(1.52	)		0.31			3.19
Distributions(b)
From net investment income		(1.44	)		(0.47	)		(0.49	)		(0.42	)		(0.10	)		(0.51	)
From net realized gain		—			(0.98	)		(0.53	)		(0.54	)		—			(0.37	)
Return of capital		(0.01	)		—			(0.43	)		(0.49	)		(0.14	)		(0.69	)
Total distributions		(1.45	)		(1.45	)		(1.45	)		(1.45	)		(0.24	)		(1.57	)
Net asset value, end of period	$	18.77		$	21.12		$	19.42		$	19.50		$	22.47		$	22.40
Market price, end of period	$	19.76		$	21.62		$	18.41		$	16.78		$	20.74		$	20.02
Total Return(c)
Based on net asset value		(4.40	)%		16.62	%		7.57	%		(6.09	)%		1.50	%(d)		16.94	%
Based on market price		(1.68	)%		25.93	%		18.50	%		(12.45	)%		4.82	%(d)		18.29	%
Ratios to Average Net Assets
Total expenses		1.12	%		1.11	%		1.13	%		1.11	%		1.17	%(e)		1.10	%
Total expenses after fees waived and/or reimbursed		1.09	%		1.09	%		1.13	%		1.11	%		1.11	%(e)		1.10	%
Net investment income		2.46	%		2.70	%		2.83	%		2.24	%		2.83	%(e)		2.36	%
Supplemental Data
Net assets, end of period (000)	$	318,933		$	357,776		$	328,297		$	329,747		$	379,830		$	378,762
Portfolio turnover rate		28	%		31	%		8	%		20	%		2	%		41	%

^(a)  Based on average shares outstanding.

^(b)  Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

^(c)  Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.

^(d)  Aggregate total return.

^(e)  Annualized.

216 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Automatic Dividend Reinvestment Plan

Pursuant to BGR, CII, BDJ, BOE, BGY, BME, BMEZ, BIGZ, BCX, BST, BSTZ and BUI’s Dividend Reinvestment Plan (the “Reinvestment Plan”), Common Shareholders are automatically enrolled to have all distributions of dividends and capital gains and other distributions reinvested by Computershare Trust Company, N.A. (the “Reinvestment Plan Agent”) in the respective Trust’s Common Shares pursuant to the Reinvestment Plan. Shareholders who do not participate in the Reinvestment Plan will receive all distributions in cash paid by check and mailed directly to the shareholders of record (or if the shares are held in street name or other nominee name, then to the nominee) by the Reinvestment Plan Agent, which serves as agent for the shareholders in administering the Reinvestment Plan.

After BGR, CII, BDJ, BOE, BGY, BME, BMEZ, BIGZ, BCX, BST, BSTZ and BUI declare a dividend or determine to make a capital gain or other distribution, the Reinvestment Plan Agent will acquire shares for the participants’ accounts, depending upon the following circumstances, either (i) through receipt of unissued but authorized shares from the Trusts (“newly issued shares”) or (ii) by purchase of outstanding shares on the open market or on the Trust’s primary exchange (“open-market purchases”). If, on the dividend payment date, the net asset value (“NAV”) per share is equal to or less than the market price per share plus estimated brokerage commissions (such condition often referred to as a “market premium”), the Reinvestment Plan Agent will invest the dividend amount in newly issued shares acquired on behalf of the participants. The number of newly issued shares to be credited to each participant’s account will be determined by dividing the dollar amount of the dividend by the NAV on the date the shares are issued. However, if the NAV is less than 95% of the market price on the dividend payment date, the dollar amount of the dividend will be divided by 95% of the market price on the dividend payment date. If, on the dividend payment date, the NAV is greater than the market price per share plus estimated brokerage commissions (such condition often referred to as a “market discount”), the Reinvestment Plan Agent will invest the dividend amount in shares acquired on behalf of the participants in open-market purchases. If the Reinvestment Plan Agent is unable to invest the full dividend amount in open-market purchases, or if the market discount shifts to a market premium during the purchase period, the Reinvestment Plan Agent will invest any un-invested portion in newly issued shares. Investments in newly issued shares made in this manner would be made pursuant to the same process described above and the date of issue for such newly issued shares will substitute for the dividend payment date.

You may elect not to participate in the Reinvestment Plan and to receive all dividends in cash by contacting the Reinvestment Plan Agent, at the address set forth below.

Participation in the Reinvestment Plan is completely voluntary and may be terminated or resumed at any time without penalty by notice if received and processed by the Reinvestment Plan Agent prior to the dividend record date. Additionally, the Reinvestment Plan Agent seeks to process notices received after the record date but prior to the payable date and such notices often will become effective by the payable date. Where late notices are not processed by the applicable payable date, such termination or resumption will be effective with respect to any subsequently declared dividend or other distribution.

The Reinvestment Plan Agent’s fees for the handling of the reinvestment of distributions will be paid by each Trust. However, each participant will pay a pro rata share of brokerage commissions incurred with respect to the Reinvestment Plan Agent’s open-market purchases in connection with the reinvestment of all distributions. The automatic reinvestment of all distributions will not relieve participants of any U.S. federal, state or local income tax that may be payable on such dividends or distributions.

Each Trust reserves the right to amend or terminate the Reinvestment Plan. There is no direct service charge to participants in the Reinvestment Plan; however, each Trust reserves the right to amend the Reinvestment Plan to include a service charge payable by the participants. Participants in BMEZ, BIGZ, BST and BSTZ that request a sale of shares are subject to a $2.50 sales fee and a $0.15 per share sold fee. Per share fees include any applicable brokerage commissions the Reinvestment Plan Agent is required to pay. Participants in BGR, CII, BDJ, BOE, BGY, BME, BCX and BUI that request a sale of shares are subject to a $0.02 per share sold brokerage commission. All correspondence concerning the Reinvestment Plan should be directed to Computershare Trust Company, N.A. through the internet at computershare.com/blackrock, or in writing to Computershare, P.O. Box 43006, Providence, RI 02940-3078, Telephone: (800) 699-1236. Overnight correspondence should be directed to the Reinvestment Plan Agent at Computershare, 150 Royall Street, Suite 101, Canton, MA 02021.

A U T O M A T I C  D I V I D E N D  R E I N V E S T M E N T  P L A N 217

Trustee and Officer Information

Independent Trustees(a)
Name Year of Birth(b)	Position(s) Held (Length of Service)(c)	Principal Occupation(s) During Past 5 Years	Number of BlackRock-Advised Registered Investment Companies (“RICs”) Consisting of Investment Portfolios (“Portfolios”) Overseen	Public Company and Other Investment Company Directorships Held During Past 5 Years
R. Glenn Hubbard 1958	Chair of the Board (Since 2022) Trustee (Since 2007)	Dean, Columbia Business School from 2004 to 2019; Faculty member, Columbia Business School since 1988.	69 RICs consisting of 102 Portfolios	ADP (data and information services) from 2004 to 2020; Metropolitan Life Insurance Company (insurance); TotalEnergies SE (multi-energy)
W. Carl Kester(d) 1951	Vice Chair of the Board (Since 2022) Trustee (Since 2007)	Baker Foundation Professor and George Fisher Baker Jr. Professor of Business Administration, Emeritus, Harvard Business School since 2022; George Fisher Baker Jr. Professor of Business Administration, Harvard Business School from 2008 to 2022; Deputy Dean for Academic Affairs from 2006 to 2010; Chairman of the Finance Unit, from 2005 to 2006; Senior Associate Dean and Chairman of the MBA Program from 1999 to 2005; Member of the faculty of Harvard Business School since 1981.	71 RICs consisting of 104 Portfolios	None
Cynthia L. Egan 1955	Trustee (Since 2016)	Advisor, U.S. Department of the Treasury from 2014 to 2015; President, Retirement Plan Services, for T. Rowe Price Group, Inc. from 2007 to 2012; executive positions within Fidelity Investments from 1989 to 2007.	71 RICs consisting of 104 Portfolios	Unum (insurance); The Hanover Insurance Group (Board Chair); Huntsman Corporation (Lead Independent Director and non- Executive Vice Chair of the Board) (chemical products)
Frank J. Fabozzi(d) 1948	Trustee (Since 2007)	Editor of The Journal of Portfolio Management since 1986; Professor of Finance, EDHEC Business School (France) from 2011 to 2022; Professor of Practice, Johns Hopkins University since 2021; Professor in the Practice of Finance, Yale University School of Management from 1994 to 2011 and currently a Teaching Fellow in Yale’s Executive Programs; Visiting Professor, Rutgers University for the Spring 2019 semester; Visiting Professor, New York University for the 2019 academic year; Adjunct Professor of Finance, Carnegie Mellon University in fall 2020 semester.	71 RICs consisting of 104 Portfolios	None
Lorenzo A. Flores 1964	Trustee (Since 2021)	Vice Chairman, Kioxia, Inc. since 2019; Chief Financial Officer, Xilinx, Inc. from 2016 to 2019; Corporate Controller, Xilinx, Inc. from 2008 to 2016.	69 RICs consisting of 102 Portfolios	None
Stayce D. Harris 1959	Trustee (Since 2021)	Lieutenant General, Inspector General of the United States Air Force from 2017 to 2019; Lieutenant General, Assistant Vice Chief of Staff and Director, Air Staff, United States Air Force from 2016 to 2017; Major General, Commander, 22nd Air Force, AFRC, Dobbins Air Reserve Base, Georgia from 2014 to 2016; Pilot, United Airlines from 1990 to 2020.	69 RICs consisting of 102 Portfolios	KULR Technology Group, Inc. in 2021; The Boeing Company (airplane manufacturer)

218 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Trustee and Officer Information (continued)

Independent Trustees(a) (continued)
Name Year of Birth(b)	Position(s) Held (Length of Service)(c)	Principal Occupation(s) During Past 5 Years	Number of BlackRock-Advised Registered Investment Companies (“RICs”) Consisting of Investment Portfolios (“Portfolios”) Overseen	Public Company and Other Investment Company Directorships Held During Past 5 Years
J. Phillip Holloman 1955	Trustee (Since 2021)	President and Chief Operating Officer, Cintas Corporation from 2008 to 2018.	69 RICs consisting of 102 Portfolios	PulteGroup, Inc. (home construction); Rockwell Automation Inc. (industrial automation); Vestis Corporation (uniforms and facilities services)
Catherine A. Lynch(d) 1961	Trustee (Since 2016)	Chief Executive Officer, Chief Investment Officer and various other positions, National Railroad Retirement Investment Trust from 2003 to 2016; Associate Vice President for Treasury Management, The George Washington University from 1999 to 2003; Assistant Treasurer, Episcopal Church of America from 1995 to 1999.	71 RICs consisting of 104 Portfolios	PennyMac Mortgage Investment Trust

Non-Management Interested Trustee(a)(f)
Name Year of Birth(b)	Position(s) Held (Length of Service)	Principal Occupation(s) During Past 5 Years	Number of BlackRock-Advised Registered Investment Companies (“RICs”) Consisting of Investment Portfolios (“Portfolios”) Overseen	Public Company and Other Investment Company Directorships Held During Past 5 Years
Arthur P. Steinmetz 1958	Trustee (Since 2023)	Consultant, Posit PBC (enterprise data science) since 2020; Director, ScotiaBank (U.S.) from 2020 to 2023; Chairman, Chief Executive Officer and President of OppenheimerFunds, Inc. from 2015, 2014 and 2013, respectively to 2019; Trustee, President and Principal Executive Officer of 104 OppenheimerFunds funds from 2014 to 2019; Portfolio manager of various OppenheimerFunds fixed income mutual funds from 1986 to 2014.	70 RICs consisting of 103 Portfolios	Trustee of 104 OppenheimerFunds funds from 2014 to 2019

T R U S T E E   A N D   O F F I C E R  I N F O R M A T I O N 219

Trustee and Officer Information (continued)

Interested Trustees(a)(e)
Name Year of Birth(b)	Position(s) Held (Length of Service)(c)	Principal Occupation(s) During Past 5 Years	Number of BlackRock-Advised Registered Investment Companies (“RICs”) Consisting of Investment Portfolios (“Portfolios”) Overseen	Public Company and Other Investment Company Directorships Held During Past 5 Years
Robert Fairbairn 1965	Trustee (Since 2018)	Vice Chairman of BlackRock, Inc. since 2019; Member of BlackRock’s Global Executive and Global Operating Committees; Co-Chair of BlackRock’s Human Capital Committee; Senior Managing Director of BlackRock, Inc. from 2010 to 2019; oversaw BlackRock’s Strategic Partner Program and Strategic Product Management Group from 2012 to 2019; Member of the Board of Managers of BlackRock Investments, LLC from 2011 to 2018; Global Head of BlackRock’s Retail and iShares® businesses from 2012 to 2016.	97 RICs consisting of 268 Portfolios	None
John M. Perlowski(d) 1964	Trustee (Since 2015) President and Chief Executive Officer (Since 2010)	Managing Director of BlackRock, Inc. since 2009; Head of BlackRock Global Accounting and Product Services since 2009; Advisory Director of Family Resource Network (charitable foundation) since 2009.	99 RICs consisting of 270 Portfolios	None

^(a) The address of each Trustee is c/o BlackRock, Inc., 50 Hudson Yards, New York, New York 10001.

^(b)  Each Independent Trustee holds office until his or her successor is duly elected and qualifies or until his or her earlier death, resignation, retirement or removal as provided by the Trust’s by-laws or charter or statute, or until December 31 of the year in which he or she turns 75. Trustees who are “interested persons,” as defined in the Investment Company Act serve until their successor is duly elected and qualifies or until their earlier death, resignation, retirement or removal as provided by the Trust’s by-laws or statute, or until December 31 of the year in which they turn 72. The Board may determine to extend the terms of Independent Trustees on a case-by-case basis, as appropriate.

^(c)  Following the combination of Merrill Lynch Investment Managers, L.P. (“MLIM”) and BlackRock, Inc. in September 2006, the various legacy MLIM and legacy BlackRock fund boards were realigned and consolidated into three new fund boards in 2007. Certain Independent Trustees first became members of the boards of other legacy MLIM or legacy BlackRock funds as follows: Frank J. Fabozzi, 1988; R. Glenn Hubbard, 2004; and W. Carl Kester, 1995.

^(d)  Dr. Fabozzi, Ms. Egan, Dr. Kester, Ms. Lynch, Mr. Steinmetz and Mr. Perlowski are also trustees of the BlackRock Credit Strategies Fund and BlackRock Private Investments Fund.

^(e) Mr. Fairbairn and Mr. Perlowski are both “interested persons,” as defined in the 1940 Act, of the Fund based on their positions with BlackRock, Inc. and its affiliates. Mr. Fairbairn and Mr. Perlowski are also board members of the BlackRock Multi-Asset Complex.

^(f)  Mr. Steinmetz is currently classified as a non-management interested Trustee based on his former directorship at another company that is not an affiliate of BlackRock, Inc. Mr. Steinmetz does not currently serve as an officer or employee of BlackRock, Inc. or its affiliates or own any securities of BlackRock, Inc. It is anticipated that Mr. Steinmetz will become an Independent Trustee effective January 19, 2024.

Officers Who Are Not Trustees(a)
Name Year of Birth(b)	Position(s) Held (Length of Service)	Principal Occupation(s) During Past 5 Years
Jonathan Diorio 1980	Vice President (Since 2015)	Managing Director of BlackRock, Inc. since 2015; Director of BlackRock, Inc. from 2011 to 2015.
Trent Walker 1974	Chief Financial Officer (Since 2021)	Managing Director of BlackRock, Inc. since September 2019; Executive Vice President of PIMCO from 2016 to 2019; Senior Vice President of PIMCO from 2008 to 2015; Treasurer from 2013 to 2019 and Assistant Treasurer from 2007 to 2017 of PIMCO Funds, PIMCO Variable Insurance Trust, PIMCO ETF Trust, PIMCO Equity Series, PIMCO Equity Series VIT, PIMCO Managed Accounts Trust, 2 PIMCO-sponsored interval funds and 21 PIMCO-sponsored closed-end funds.
Jay M. Fife 1970	Treasurer (Since 2007)	Managing Director of BlackRock, Inc. since 2007.
Aaron Wasserman 1974	Chief Compliance Officer (Since 2023)	Managing Director of BlackRock, Inc. since 2018; Chief Compliance Officer of the BlackRock-advised funds in the BlackRock Multi-Asset Complex, the BlackRock Fixed-Income Complex and the iShares Complex since 2023; Deputy Chief Compliance Officer for the BlackRock-advised funds in the BlackRock Multi-Asset Complex, the BlackRock Fixed- Income Complex and the iShares Complex from 2014 to 2023.
Janey Ahn 1975	Secretary (Since 2012)	Managing Director of BlackRock, Inc. since 2018; Director of BlackRock, Inc. from 2009 to 2017.

^(a)  The address of each Officer is c/o BlackRock, Inc., 50 Hudson Yards, New York, New York 10001.

^(b)  Officers of the Trust serve at the pleasure of the Board.

220 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Trustee and Officer Information (continued)

Further information about the BME’s, BST’s and BUI’s Trustees and Officers is available in the Trust’s Statement of Additional Information, which can be obtained without charge by calling (800) 882-0052.

Effective July 1, 2023, Aaron Wasserman replaced Charles Park as Chief Compliance Officer of the Trusts.

Effective December 31, 2023, Frank Fabozzi retired as Trustee of the Trusts.

Effective January 19, 2024, Arthur Steinmetz became an Independent Trustee of the Trusts.

Effective June 15, 2023, Rosie Edwards became a portfolio manager of BGY. Ms. Edwards has been employed by BlackRock since 2019 and previously was employed by Berenberg.

Effective January 12, 2023, Misha Lozovik is no longer a portfolio manager of BIGZ.

Effective March 28, 2023, William Broadbent is no longer a portfolio manager of BIGZ.

Effective June 27, 2023, Jeff Lee is no longer a portfolio manager of BME.

Effective June 27, 2023, Jeff Lee is no longer a portfolio manager of BMEZ.

Effective September 14, 2023, Caroline Tall is no longer a portfolio manager of BST.

Effective September 14, 2023, Caroline Tall is no longer a portfolio manager of BSTZ.

Effective June 1, 2023, Lindsay Sinclair became a portfolio manager of BUI. Ms. Sinclair has been employed by BlackRock since 2016.

T R U S T E E   A N D   O F F I C E R  I N F O R M A T I O N 221

Additional Information

Proxy Results

The Annual Meeting of Shareholders was held on July 12, 2023 for shareholders of record on May 15, 2023, to elect trustee nominees for each Trust other than BIGZ and BMEZ. There were no broker non-votes with regard to any of the Trusts.

Shareholders elected the Class I Trustees as follows:

	Lorenzo A. Flores				R. Glenn Hubbard				John M. Perlowski				W. Carl Kester
Trust Name	Votes For		Votes Withheld		Votes For		Votes Withheld		Votes For		Votes Withheld		Votes For		Votes Withheld
BDJ		141,029,718		5,692,272		141,033,404		5,688,586		141,229,386		5,492,604		140,804,103		5,917,887
BGR		21,897,595		1,003,784		21,885,807		1,015,572		21,930,670		970,709		21,929,931		971,448
BOE		48,035,270		5,950,023		49,144,505		4,840,788		49,182,140		4,803,153		49,141,586		4,843,707
BME		10,583,103		420,283		10,551,945		451,441		10,535,294		468,092		10,514,156		489,230
BGY		79,852,648		9,010,840		80,094,143		8,769,345		80,154,505		8,708,983		80,077,439		8,786,049
BCX		64,122,052		4,576,675		64,282,133		4,416,594		64,405,796		4,292,931		64,276,699		4,422,028
BUI		16,025,231		776,397		16,013,846		787,782		16,033,320		768,308		16,003,820		797,808
BST		24,651,506		810,676		24,528,089		934,093		24,577,536		884,646		24,530,482		931,700

For the Trusts listed above, Trustees whose term of office continued after the Annual Meeting of Shareholders because they were not up for election are Cynthia L. Egan, Robert Fairbairn, Stayce D. Harris, J. Phillip Holloman, Catherine A. Lynch, and Frank J. Fabozzi.

Shareholders elected the Class I Trustees as follows:

	Cynthia L. Egan				Lorenzo A. Flores				Stayce D. Harris				Catherine A. Lynch
Trust Name	Votes For		Votes Withheld		Votes For		Votes Withheld		Votes For		Votes Withheld		Votes For		Votes Withheld
BSTZ		60,142,236		4,095,890		59,916,192		4,321,934		60,190,111		4,048,015		60,006,494		4,231,632
CII		33,835,792		1,644,311		33,878,479		1,601,624		33,959,360		1,520,743		34,009,819		1,470,284

For the Trusts listed above, Trustees whose term of office continued after the Annual Meeting of Shareholders because they were not up for election are Robert Fairbairn, J. Phillip Holloman, R. Glenn Hubbard, John M. Perlowski, Frank J. Fabozzi and W. Carl Kester.

The Annual Meeting of Shareholders was held on July 11, 2023 for shareholders of record on May 12, 2023, to elect trustee nominees for BMEZ. There were no broker non-votes with regard to the Trust.

Shareholders elected the Class I Trustees as follows:

Cynthia L. Egan

Lorenzo A. Flores

Stayce D. Harris

Catherine A. Lynch

Trust Name

Votes For

Votes Withheld

Votes For

Votes Withheld

Votes For

Votes Withheld

Votes For

Votes Withheld

BMEZ

91,085,783

5,702,510

91,302,495

5,485,798

91,510,395

5,277,898

90,904,258

5,884,035

For the Trust listed above, Trustees whose term of office continued after the Annual Meeting of Shareholders because they were not up for election are Robert Fairbairn, J. Phillip Holloman, R. Glenn Hubbard, John M. Perlowski, Frank J. Fabozzi and W. Carl Kester.

The Annual Meeting of Shareholders of BIGZ (the “Meeting”) was called for July 10, 2023 for shareholders of record on May 12, 2023 to consider and vote on a proposal to elect four Class I Trustees. The Board of Trustees of BIGZ (the “Board”) nominated four nominees who currently serve as Class I Trustees. A hedge fund managed by Saba Capital Management, L.P. (“Saba”) also nominated four nominees. The Meeting was adjourned to July 25, 2023 and further adjourned to August 7, 2023 to seek additional shareholder participation. A quorum of shareholders required to conduct business at the Meeting was not obtained.

The ballots and proxies received by First Coast Results, Inc., the independent Inspector of Election of the Meeting, reflected votes with respect to the nominees as follows:

Board Nominees/Incumbent Trustees

Cynthia L. Egan

Lorenzo A. Flores

Stayce D. Harris

Trust Name

Votes For

Votes Against

Abstain

Votes For

Votes Against

Abstain

Votes For

Votes Against

Abstain

BIGZ

32,261,222

4,432,605

3,479,799

32,207,921

4,478,253

3,487,452

32,073,881

4,531,170

3,568,575

Catherine A. Lynch

Trust Name

Votes For

Votes Against

Abstain

BIGZ

32,254,080

4,374,506

3,545,040

222 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Additional Information  (continued)

Saba Nominees^(a)

Ravi Bhasin

Ilya Gurevich

Richard Thiemann

Trust Name

Votes For

Votes Against

Abstain

Votes For

Votes Against

Abstain

Votes For

Votes Against

Abstain

BIGZ

0

0

0

0

0

0

0

0

0

Emmanuel Werthenschlag

Trust Name

Votes For

Votes Against

Abstain

BIGZ

0

0

0

^(a)  Saba did not submit for voting any shares held directly or for other shareholders who authorized Saba via proxy to vote on their behalf. A quorum of shareholders required to conduct business at the Meeting was not obtained.

Because a quorum was not obtained to conduct business at the Meeting, each incumbent Class I Trustee listed above will continue to serve on the Board of BIGZ as a “holdover” Trustee until his or her successor has been duly elected and qualified.

The Trustees of BIGZ whose term of office continued after the Meeting because they were not up for election are Frank J. Fabozzi, Robert Fairbairn, J. Phillip Holloman, R. Glenn Hubbard, W. Carl Kester and John M. Perlowski.

Trust Certification

The Trusts are listed for trading on the NYSE and have filed with the NYSE their annual chief executive officer certification regarding compliance with the NYSE’s listing standards. The Trusts filed with the SEC the certification of its chief executive officer and chief financial officer required by Section 302 of the Sarbanes-Oxley Act.

Environmental, Social and Governance (“ESG”) Integration

Although the Trusts do not seek to implement a specific sustainability objective, strategy or process unless otherwise disclosed, Trust management will consider ESG factors as part of the investment process for the Trusts. Trust management views ESG integration as the practice of incorporating financially material ESG data or information into investment processes with the objective of enhancing risk-adjusted returns. These ESG considerations will vary depending on the Trusts’ particular investment strategies and may include consideration of third-party research as well as consideration of proprietary BlackRock research across the ESG risks and opportunities regarding an issuer. The ESG characteristics utilized in the Trusts’ investment process are anticipated to evolve over time and one or more characteristics may not be relevant with respect to all issuers that are eligible for investment. Certain of these considerations may affect the Trusts’ exposure to certain companies or industries. While Trust management views ESG considerations as having the potential to contribute to the Trusts’ long-term performance, there is no guarantee that such results will be achieved.

Dividend Policy

Each Trust’s policy is to make monthly distributions to shareholders. In order to provide shareholders with a more stable level of dividend distributions, each Trust employs a managed distribution plan (the “Plan”), the goal of which is to provide shareholders with consistent and predictable cash flows by setting distribution rates based on expected long-term returns of each Trust.

The distributions paid by each Trust for any particular month may be more or less than the amount of net investment income earned by each Trust during such month. Furthermore, the final tax characterization of distributions is determined after the year-end of a Trust and is reported in each Trust’s annual report to shareholders. Distributions can be characterized as ordinary income, capital gains and/or return of capital. Each Trust’s taxable net investment income and net realized capital gains (“taxable income”) may not be sufficient to support the level of distributions paid. To the extent that distributions exceed the Trust’s current and accumulated earnings and profits, the excess may be treated as a non-taxable return of capital.

A return of capital is a return of a portion of an investor’s original investment. A return of capital is not expected to be taxable, but it reduces a shareholder’s tax basis in his or her shares, thus reducing any loss or increasing any gain on a subsequent disposition by the shareholder of his or her shares. It is possible that a substantial portion of the distributions paid during a calendar year may ultimately be classified as return of capital for U.S. federal income tax purposes when the final determination of the source and character of the distributions is made.

Such distributions, under certain circumstances, may exceed a Trust’s total return performance. When total distributions exceed total return performance for the period, the difference reduces the Trust’s total assets and net asset value (“NAV”) per share and, therefore, could have the effect of increasing the Trust’s expense ratio and reducing the amount of assets the Trust has available for long term investment.

General Information

The Trusts, other than BDJ, BME, BST and BUI, do not make available copies of their Statements of Additional Information because the Trusts’ shares, other than BDJ, BME, BST and BUI, are not continuously offered, which means that the Statement of Additional Information of each Trust, other than BDJ, BME, BST and BUI, has not been updated after completion of the respective Trust’s offerings and the information contained in each Trust’s Statement of Additional Information may have become outdated.

BDJ’s, BME’s, BST’s and BUI’s Statements of Additional Information include additional information about the Board and are available, without charge upon request by calling (800)882-0052.

A D D I T I O N A L  I N F O R M A T I O N 223

Additional Information  (continued)

General Information (continued)

The following information is a summary of certain changes since December 31, 2022. This information may not reflect all of the changes that have occurred since you purchased the relevant Trust.

Except if noted otherwise herein, there were no changes to the Trusts’ charters or by-laws that would delay or prevent a change of control of the Trusts that were not approved by the shareholders. Except if noted otherwise herein, there have been no changes in the persons who are primarily responsible for the day-to-day management of the Trusts’ portfolios.

In accordance with Section 23(c) of the Investment Company Act of 1940, each Trust may from time to time purchase shares of its common stock in the open market or in private transactions.

Quarterly performance, semi-annual and annual reports, current net asset value and other information regarding the Trusts may be found on BlackRock’s website, which can be accessed at blackrock.com. Any reference to BlackRock’s website in this report is intended to allow investors public access to information regarding the Trusts and does not, and is not intended to, incorporate BlackRock’s website in this report.

Electronic Delivery

Shareholders can sign up for e-mail notifications of quarterly statements, annual and semi-annual shareholder reports and, for BDJ, BME, BST and BUI only, prospectuses, by enrolling in the electronic delivery program. Electronic copies of shareholder reports and, for BDJ, BME, BST and BUI only, prospectuses, are available on BlackRock’s website.

To enroll in electronic delivery:

Shareholders Who Hold Accounts with Investment Advisers, Banks or Brokerages:

Please contact your financial adviser. Please note that not all investment advisers, banks or brokerages may offer this service.

Householding

The Trusts will mail only one copy of shareholder documents, including for BDJ, BME, BST and BUI only, prospectuses, annual and semi-annual reports, Rule 30e-3 notices and proxy statements, to shareholders with multiple accounts at the same address. This practice is commonly called “householding” and is intended to reduce expenses and eliminate duplicate mailings of shareholder documents. Mailings of your shareholder documents may be householded indefinitely unless you instruct us otherwise. If you do not want the mailing of these documents to be combined with those for other members of your household, please call the Trusts at (800) 882-0052.

Availability of Quarterly Schedule of Investments

The Trusts file their complete schedules of portfolio holdings with the SEC for the first and third quarters of each fiscal year as an exhibit to their reports on Form N-PORT. The Trusts’ Forms N-PORT are available on the SEC’s website at sec.gov. Additionally, each Trust makes its portfolio holdings for the first and third quarters of each fiscal year available at blackrock.com/fundreports.

Availability of Proxy Voting Policies, Procedures and Voting Records

A description of the policies and procedures that the Trusts use to determine how to vote proxies relating to portfolio securities and information about how the Trusts voted proxies relating to securities held in the Trusts’ portfolios during the most recent 12-month period ended June 30 is available without charge, upon request (1) by calling (800) 882-0052; (2) on the BlackRock website at blackrock.com; and (3) on the SEC’s website at sec.gov.

Availability of Trust Updates

BlackRock will update performance and certain other data for the Trusts on a monthly basis on its website in the “Closed-end Funds” section of blackrock.com as well as certain other material information as necessary from time to time. Investors and others are advised to check the website for updated performance information and the release of other material information about the Trusts. This reference to BlackRock’s website is intended to allow investors public access to information regarding the Trusts and does not, and is not intended to, incorporate BlackRock’s website in this report.

Shelf Offering Program

From time to time, BDJ, BME, BST and BUI may seek to raise additional equity capital through a Shelf Offering. In a Shelf Offering, BDJ, BME, BST and BUI may, subject to market conditions, raise additional equity capital by issuing new Common Shares from time to time in varying amounts at a net price at or above BDJ’s, BME’s, BST’s and BUI’s net asset value (“NAV”) per Common Share (calculated within 48 hours of pricing). While any such Shelf Offering may allow BDJ, BME, BST and BUI to pursue additional investment opportunities without the need to sell existing portfolio investments, it could also entail risks – including that the issuance of additional Common Shares may limit the extent to which the Common Shares are able to trade at a premium to NAV in the secondary market.

BDJ, BME, BST and BUI filed final prospectuses with the SEC in connection with its Shelf Offering on June 2, 2023, April 26, 2022, May 10, 2022 and March 10, 2022, respectively. This report and the prospectuses of BDJ, BME, BST and BUI are not offers to sell BDJ, BME, BST and BUI Common Shares or solicitations of an offer to buy BDJ, BME, BST and BUI Common Shares in any jurisdiction where such offers or sales are not permitted. The prospectuses of BDJ, BME, BST and BUI contains important

224 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Additional Information  (continued)

information about BDJ, BME, BST and BUI, including their investment objectives, risks, charges and expenses. Investors are urged to read the prospectuses of BDJ, BME, BST and BUI carefully and in their entirety before investing. Copies of the final prospectuses for BDJ, BME, BST and BUI can be obtained from BlackRock at blackrock.com.

BlackRock Privacy Principles

BlackRock is committed to maintaining the privacy of its current and former fund investors and individual clients (collectively, “Clients”) and to safeguarding their non-public personal information. The following information is provided to help you understand what personal information BlackRock collects, how we protect that information and why in certain cases we share such information with select parties.

If you are located in a jurisdiction where specific laws, rules or regulations require BlackRock to provide you with additional or different privacy-related rights beyond what is set forth below, then BlackRock will comply with those specific laws, rules or regulations.

BlackRock obtains or verifies personal non-public information from and about you from different sources, including the following: (i) information we receive from you or, if applicable, your financial intermediary, on applications, forms or other documents; (ii) information about your transactions with us, our affiliates, or others; (iii) information we receive from a consumer reporting agency; and (iv) from visits to our websites.

BlackRock does not sell or disclose to non-affiliated third parties any non-public personal information about its Clients, except as permitted by law or as is necessary to respond to regulatory requests or to service Client accounts. These non-affiliated third parties are required to protect the confidentiality and security of this information and to use it only for its intended purpose.

We may share information with our affiliates to service your account or to provide you with information about other BlackRock products or services that may be of interest to you. In addition, BlackRock restricts access to non-public personal information about its Clients to those BlackRock employees with a legitimate business need for the information. BlackRock maintains physical, electronic and procedural safeguards that are designed to protect the non-public personal information of its Clients, including procedures relating to the proper storage and disposal of such information.

Trust and Service Providers

Investment Adviser	(a) For BGR, BOE, BGY, BCX and BUI.
BlackRock Advisors, LLC	(b) For BDJ, BME, BST and BUI.
Wilmington, DE 19809
	Independent Registered Public Accounting Firm
Sub-Adviser	Deloitte & Touche LLP
BlackRock International Limited(a)	Boston, MA 02116
Edinburgh, EH3 8BL
United Kingdom	Legal Counsel
	Willkie Farr & Gallagher LLP
Accounting Agent and Custodian	New York, NY 10019
State Street Bank and Trust Company
Boston, MA 02114	Address of the Trusts
	100 Bellevue Parkway
Transfer Agent	Wilmington, DE 19809
Computershare Trust Company, N.A.
Canton, MA 02021
Distributor
BlackRock Investments, LLC(b)
New York, NY 10001

A D D I T I O N A L  I N F O R M A T I O N 225

Glossary of Terms Used in this Report

Currency Abbreviation
AUD	Australian Dollar
BRL	Brazilian Real
CAD	Canadian Dollar
CHF	Swiss Franc
DKK	Danish Krone
EUR	Euro
GBP	British Pound
HKD	Hong Kong Dollar
JPY	Japanese Yen
KRW	South Korean Won
MXN	Mexican Peso
NOK	Norwegian Krone
SEK	Swedish Krona
SGD	Singapore Dollar
TWD	New Taiwan Dollar
USD	United States Dollar
Portfolio Abbreviation
ADR	American Depositary Receipt
CVR	Contingent Value Right
GDR	Global Depositary Receipt
JSC	Joint Stock Company
LP	Limited Partnership
PJSC	Public Joint Stock Company
REIT	Real Estate Investment Trust
S&P	Standard & Poor’s
SAB	Special Assessment Bonds

226 2 0 2 3  B L A C K R O C K  A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

THIS PAGE INTENTIONALLY LEFT BLANK.

Want to know more?

blackrock.com  |  800-882-0052

This report is intended for current holders. It is not a prospectus. Past performance results shown in this report should not be considered a representation of future performance. Statements and other information herein are as dated and are subject to change.

CEF-BK9-12/23-AR

(b) Not Applicable

Item 2 – Code of Ethics – The registrant (or the “Fund”) has adopted a code of ethics, as of the end of the period covered by this report, applicable to the registrant’s principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. During the period covered by this report, the code of ethics was amended to update certain information and to make other non-material changes. During the period covered by this report, there have been no waivers granted under the code of ethics. The registrant undertakes to provide a copy of the code of ethics to any person upon request, without charge, who calls 1-800-882-0052, option 4.

Item 3 – Audit Committee Financial Expert – The registrant’s board of directors (the “board of directors”), has determined that (i) the registrant has the following audit committee financial experts serving on its audit committee and (ii) each audit committee financial expert is independent:

Frank J. Fabozzi

Lorenzo A. Flores

Catherine A. Lynch

Under applicable securities laws, a person determined to be an audit committee financial expert will not be deemed an “expert” for any purpose, including without limitation for the purposes of Section 11 of the Securities Act of 1933, as a result of being designated or identified as an audit committee financial expert. The designation or identification of a person as an audit committee financial expert does not impose on such person any duties, obligations, or liabilities greater than the duties, obligations, and liabilities imposed on such person as a member of the audit committee and board of directors in the absence of such designation or identification. The designation or identification of a person as an audit committee financial expert does not affect the duties, obligations, or liability of any other member of the audit committee or board of directors.

Item 4 – Principal Accountant Fees and Services

The following table presents fees billed by Deloitte & Touche LLP (“D&T”) in each of the last two fiscal years for the services rendered to the Fund:

	(a) Audit Fees		(b) Audit-Related Fees1		(c) Tax Fees2		(d) All Other Fees
Entity Name	Current  Fiscal Year End	Previous  Fiscal Year End	Current  Fiscal Year End	Previous  Fiscal Year End	Current  Fiscal Year End	Previous  Fiscal Year End	Current  Fiscal Year End	Previous  Fiscal Year End
BlackRock Enhanced International Dividend Trust	$51,510	$49,572	$0	$0	$17,648	$16,200	$407	$431

The following table presents fees billed by D&T that were required to be approved by the registrant’s audit committee (the “Committee”) for services that relate directly to the operations or financial reporting of the Fund and that are rendered on behalf of BlackRock Advisors, LLC ( the “Investment Adviser” or “BlackRock”) and entities controlling, controlled by, or under common control with BlackRock (not including any sub-adviser whose role is primarily portfolio management and is subcontracted with or overseen by another investment adviser) that provide ongoing services to the Fund (“Affiliated Service Providers”):

2

	Current Fiscal Year End	Previous Fiscal Year End
(b) Audit-Related Fees1	$0	$0
(c) Tax Fees2	$0	$0
(d) All Other Fees3	$2,154,000	$2,098,000

¹ The nature of the services includes assurance and related services reasonably related to the performance of the audit or review of financial statements not included in Audit Fees, including accounting consultations, agreed-upon procedure reports, attestation reports, comfort letters, out-of-pocket expenses and internal control reviews not required by regulators.

² The nature of the services includes tax compliance and/or tax preparation, including services relating to the filing or amendment of federal, state or local income tax returns, regulated investment company qualification reviews, taxable income and tax distribution calculations.

³ Non-audit fees of $2,154,000 and $2,098,000 for the current fiscal year and previous fiscal year, respectively, were paid to the Fund’s principal accountant in their entirety by BlackRock, in connection with services provided to the Affiliated Service Providers of the Fund and of certain other funds sponsored and advised by BlackRock or its affiliates for a service organization review and an accounting research tool subscription. These amounts represent aggregate fees paid by BlackRock and were not allocated on a per fund basis.

(e)(1) Audit Committee Pre-Approval Policies and Procedures:

The Committee has adopted policies and procedures with regard to the pre-approval of services. Audit, audit-related and tax compliance services provided to the registrant on an annual basis require specific pre-approval by the Committee. The Committee also must approve other non-audit services provided to the registrant and those non-audit services provided to the Investment Adviser and Affiliated Service Providers that relate directly to the operations and the financial reporting of the registrant. Certain of these non-audit services that the Committee believes are (a) consistent with the SEC’s auditor independence rules and (b) routine and recurring services that will not impair the independence of the independent accountants may be approved by the Committee without consideration on a specific case-by-case basis (“general pre-approval”). The term of any general pre-approval is 12 months from the date of the pre-approval, unless the Committee provides for a different period. Tax or other non-audit services provided to the registrant which have a direct impact on the operations or financial reporting of the registrant will only be deemed pre-approved provided that any individual project does not exceed $10,000 attributable to the registrant or $50,000 per project. For this purpose, multiple projects will be aggregated to determine if they exceed the previously mentioned cost levels.

Any proposed services exceeding the pre-approved cost levels will require specific pre-approval by the Committee, as will any other services not subject to general pre-approval (e.g., unanticipated but permissible services). The Committee is informed of each service approved subject to general pre-approval at the next regularly scheduled in-person board meeting. At this meeting, an analysis of such services is presented to the Committee for ratification. The Committee may delegate to the Committee Chairman the authority to approve the provision of and fees for any specific engagement of permitted non-audit services, including services exceeding pre-approved cost levels.

(e)(2) None of the services described in each of Items 4(b) through (d) were approved by the Committee pursuant to the de minimis exception in paragraph (c)(7)(i)(C) of Rule 2-01 of Regulation S-X.

(f) Not Applicable

(g) The aggregate non-audit fees, defined as the sum of the fees shown under “Audit-Related Fees,”

3

“Tax Fees” and “All Other Fees,” paid to the accountant for services rendered by the accountant to the registrant, the Investment Adviser and the Affiliated Service Providers were:

Entity Name	Current Fiscal Year  End	Previous Fiscal Year End
BlackRock Enhanced International Dividend Trust	$18,055	$16,631

Additionally, the amounts billed by D&T in connection with services provided to the Affiliated Service Providers of the Fund and of other funds sponsored or advised by BlackRock or its affiliates during the current and previous fiscal years for a service organization review and an accounting research tool subscription were:

Current Fiscal Year  End	Previous Fiscal Year  End
$2,154,000	$2,098,000

These amounts represent aggregate fees paid by BlackRock and were not allocated on a per fund basis.

(h) The Committee has considered and determined that the provision of non-audit services that were rendered to the Investment Adviser, and the Affiliated Service Providers that were not pre-approved pursuant to paragraph (c)(7)(ii) of Rule 2-01 of Regulation S-X is compatible with maintaining the principal accountant’s independence.

(i) – Not Applicable

(j) – Not Applicable

Item 5 – Audit Committee of Listed Registrant

(a) The following individuals are members of the registrant’s separately designated standing audit committee established in accordance with Section 3(a)(58)(A) of the Securities Exchange Act of 1934 (15 U.S.C. 78c(a)(58)(A)):

Frank J. Fabozzi

Lorenzo A. Flores

J. Phillip Holloman

Catherine A. Lynch

(b) Not Applicable

Item 6 – Investments

(a) The registrant’s Schedule of Investments is included as part of the Report to Stockholders filed under Item 1(a) of this Form.

4

(b) Not Applicable due to no such divestments during the semi-annual period covered since the previous Form N-CSR filing.

Item 7 – Disclosure of Proxy Voting Policies and Procedures for Closed-End Management Investment Companies – The board of directors has delegated the voting of proxies for the Fund’s portfolio securities to the Investment Adviser pursuant to the Investment Adviser’s proxy voting guidelines. Under these guidelines, the Investment Adviser will vote proxies related to Fund securities in the best interests of the Fund and its stockholders. From time to time, a vote may present a conflict between the interests of the Fund’s stockholders, on the one hand, and those of the Investment Adviser, or any affiliated person of the Fund or the Investment Adviser, on the other. In such event, provided that the Investment Adviser’s Equity Investment Policy Oversight Committee, or a sub-committee thereof (the “Oversight Committee”) is aware of the real or potential conflict or material non-routine matter and if the Oversight Committee does not reasonably believe it is able to follow its general voting guidelines (or if the particular proxy matter is not addressed in the guidelines) and vote impartially, the Oversight Committee may retain an independent fiduciary to advise the Oversight Committee on how to vote or to cast votes on behalf of the Investment Adviser’s clients. If the Investment Adviser determines not to retain an independent fiduciary, or does not desire to follow the advice of such independent fiduciary, the Oversight Committee shall determine how to vote the proxy after consulting with the Investment Adviser’s Portfolio Management Group and/or the Investment Adviser’s Legal and Compliance Department and concluding that the vote cast is in its client’s best interest notwithstanding the conflict. A copy of the Fund’s Proxy Voting Policy and Procedures are attached as Exhibit 99.PROXYPOL, a copy of the Fund’s Global Corporate Governance  & Engagement Principles are attached as Exhibit 99.GLOBAL.CORP.GOV and a copy of the Fund’s Corporate Governance and Proxy Voting Guidelines for U.S. Securities are attached as Exhibit 99.US.CORP.GOV. Information on how the Fund voted proxies relating to portfolio securities during the most recent 12-month period ended June 30 is available without charge, (i) at www.blackrock.com and (ii) on the SEC’s website at http://www.sec.gov.

Item 8 – Portfolio Managers of Closed-End Management Investment Companies

(a)(1) As of the date of filing this Report:

The registrant is managed by a team of investment professionals comprised of Kyle G. McClements, CFA, Managing Director at BlackRock, Christopher Accettella, Director at BlackRock, Olivia Treharne, CFA, Managing Director at BlackRock, Molly Greenen, CFA, Director at BlackRock and Rosie Edwards, Director at BlackRock. Messrs. McClements and Accettella and Mses. Treharne, Greenen and Edwards are the Fund’s portfolio managers and are responsible for the day-to-day management of the Fund’s portfolio and the selection of its investments. Messrs. McClements and Accettella and Mses. Treharne, Greenen and Edwards have been members of the Fund’s portfolio management team since 2005, 2012, 2020, 2022 and 2023 respectively.

 Portfolio Manager     Biography  

5

Kyle G. McClements, CFA	Managing Director of BlackRock since 2009; Director of BlackRock from 2006 to 2008; Vice President of BlackRock in 2005; Vice President of State Street Research & Management from 2004 to 2005.
Christopher Accettella	Director of BlackRock since 2008; Vice President of BlackRock, Inc. from 2005 to 2008.
Olivia Treharne, CFA	Managing Director of BlackRock since 2024; Director of BlackRock from 2019 to 2023; Vice President of Legal & General Investment Management from 2015 to 2019; Associate of Goldman Sachs from 2013 to 2015; Analyst of Goldman Sachs from 2010 to 2013.
Molly Greenen, CFA	Director of BlackRock, Inc. since 2022; Vice President of BlackRock, Inc. from 2018 to 2021; Associate of BlackRock, Inc. from 2016 to 2017; Analyst of BlackRock, Inc. from 2013 to 2015.
Rosie Edwards	Director of BlackRock, Inc. since 2019; Executive Director of Berenberg from 2017 to 2019; Vice President of Berenberg from 2016 to 2017; Vice President of Goldman Sachs from 2012 to 2016; Associate of Goldman Sachs from 2009 to 2012.

(a)(2) As of December 31, 2023:

	(ii) Number of Other Accounts Managed and Assets by Account Type			(iii) Number of Other Accounts and Assets for Which Advisory Fee is Performance-Based
(i) Name of Portfolio Manager	Other Registered Investment Companies	Other Pooled Investment Vehicles	Other Accounts	Other Registered Investment Companies	Other Pooled Investment Vehicles	Other Accounts
Kyle G. McClements, CFA	16	11	1	0	0	0
	$15.45 Billion	$2.55 Billion	$469.5 Million	$0	$0	$0
Christopher Accettella	16	7	0	0	0	0
	$15.45 Billion	$1.94 Billion	$0	$0	$0	$0
Olivia Treharne, CFA	6	11	2	0	0	1
	$3.66 Billion	$3.59 Billion	$1.45 Billion	$0	$0	$1.37 Billion
Molly Greenen, CFA	6	10	2	0	0	1
	$3.66 Billion	$3.59 Billion	$1.45 Billion	$0	$0	$1.37 Billion
Rosie Edwards	1	0	0	0	0	0
	$750.2 Million	$0	$0	$0	$0	$0

(iv) Portfolio Manager Potential Material Conflicts of Interest

BlackRock has built a professional working environment, firm-wide compliance culture and compliance procedures and systems designed to protect against potential incentives that may favor one account over another. BlackRock has adopted policies and procedures that address the allocation of investment opportunities, execution of portfolio transactions, personal trading by employees and other potential conflicts of interest that are designed to ensure that all client accounts are treated equitably over

6

time. Nevertheless, BlackRock furnishes investment management and advisory services to numerous clients in addition to the Fund, and BlackRock may, consistent with applicable law, make investment recommendations to other clients or accounts (including accounts which are hedge funds or have performance or higher fees paid to BlackRock, or in which portfolio managers have a personal interest in the receipt of such fees), which may be the same as or different from those made to the Fund. In addition, BlackRock, Inc., its affiliates and significant shareholders and any officer, director, shareholder or employee may or may not have an interest in the securities whose purchase and sale BlackRock recommends to the Fund. BlackRock, Inc., or any of its affiliates or significant shareholders, or any officer, director, shareholder, employee or any member of their families may take different actions than those recommended to the Fund by BlackRock with respect to the same securities. Moreover, BlackRock may refrain from rendering any advice or services concerning securities of companies of which any of BlackRock, Inc.’s (or its affiliates’ or significant shareholders’) officers, directors or employees are directors or officers, or companies as to which BlackRock, Inc. or any of its affiliates or significant shareholders or the officers, directors and employees of any of them has any substantial economic interest or possesses material non-public information. Certain portfolio managers also may manage accounts whose investment strategies may at times be opposed to the strategy utilized for a fund. It should also be noted that Mses. Treharne and Greenen may be managing hedge fund and/or long only accounts, or may be part of a team managing hedge fund and/or long only accounts, subject to incentive fees. Mses. Treharne and Greenen may therefore be entitled to receive a portion of any incentive fees earned on such accounts.

As a fiduciary, BlackRock owes a duty of loyalty to its clients and must treat each client fairly. When BlackRock purchases or sells securities for more than one account, the trades must be allocated in a manner consistent with its fiduciary duties. BlackRock attempts to allocate investments in a fair and equitable manner among client accounts, with no account receiving preferential treatment. To this end, BlackRock, Inc. has adopted policies that are intended to ensure reasonable efficiency in client transactions and provide BlackRock with sufficient flexibility to allocate investments in a manner that is consistent with the particular investment discipline and client base, as appropriate.

(a)(3) As of December 31, 2023:

Portfolio Manager Compensation Overview

The discussion below describes the portfolio managers’ compensation as of December 31, 2023.

BlackRock’s financial arrangements with its portfolio managers, its competitive compensation and its career path emphasis at all levels reflect the value senior management places on key resources. Compensation may include a variety of components and may vary from year to year based on a number of factors. The principal components of compensation include a base salary, a performance-based discretionary bonus, participation in various benefits programs and one or more of the incentive compensation programs established by BlackRock.

Base Compensation. Generally, portfolio managers receive base compensation based on their position with the firm.

Discretionary Incentive Compensation- Mses. Treharne, Greenen and Edwards

7

Generally, discretionary incentive compensation for Fundamental Equities portfolio managers is based on a formulaic compensation program. BlackRock’s formulaic portfolio manager compensation program is based on team revenue and pre-tax investment performance relative to appropriate competitors or benchmarks over 1-, 3- and 5-year performance periods, as applicable. In most cases, these benchmarks are the same as the benchmark or benchmarks against which the performance of the funds or other accounts managed by the portfolio managers are measured. BlackRock’s Chief Investment Officers determine the benchmarks or rankings against which the performance of funds and other accounts managed by each portfolio management team is compared and the period of time over which performance is evaluated. With respect to these portfolio managers, such benchmarks for the Fund and other accounts are:

Portfolio Manager	Benchmarks
Rosie Edwards	MSCI ACWI ex US
Molly Greenen, CFA   Olivia Treharne, CFA	70% MS_ACWNXUS / 30% LIBOR_3MO; 70% MSACWLDNET / 30% LIBOR_3MO Index; MSCI ACWI HIGH DIVIDEND YIELD - NET USD; MSCI All Country World Index (Net Total Return); MSCI All Country World Net TR Index; MSCI All Country World Net TR Index - in GBP; MSCI World Ex Japan Gross TR Index - in JPY

A smaller element of portfolio manager discretionary compensation may include consideration of: financial results, expense control, profit margins, strategic planning and implementation, quality of client service, market share, corporate reputation, capital allocation, compliance and risk control, leadership, technology and innovation. These factors are considered collectively by BlackRock management and the relevant Chief Investment Officers.

Discretionary Incentive Compensation - Messrs. Accettella and McClements

Discretionary incentive compensation is a function of several components: the performance of BlackRock, Inc., the performance of the portfolio manager’s group within BlackRock, the investment performance, including risk-adjusted returns, of the firm’s assets or strategies under management or supervision by that portfolio manager, and/or the individual’s performance and contribution to the overall performance of these portfolios and BlackRock. Among other things, BlackRock’s Chief Investment Officers make a subjective determination with respect to each portfolio manager’s compensation based on the performance of the Funds, other accounts or strategies managed by each portfolio manager. Performance is generally measured on a pre-tax basis over various time periods including 1-, 3- and 5- year periods, as applicable. The performance of some funds, other accounts or strategies may not be measured against a specific benchmark.

Distribution of Discretionary Incentive Compensation. Discretionary incentive compensation is distributed to portfolio managers in a combination of cash, deferred BlackRock, Inc. stock awards, and/or deferred cash awards that notionally track the return of certain BlackRock investment products.

Portfolio managers receive their annual discretionary incentive compensation in the form of cash. Portfolio managers whose total compensation is above a specified threshold also receive deferred BlackRock, Inc. stock awards annually as part of their discretionary incentive compensation. Paying a portion of

8

discretionary incentive compensation in the form of deferred BlackRock, Inc. stock puts compensation earned by a portfolio manager for a given year “at risk” based on BlackRock’s ability to sustain and improve its performance over future periods. In some cases, additional deferred BlackRock, Inc. stock may be granted to certain key employees as part of a long-term incentive award to aid in retention, align interests with long-term shareholders and motivate performance. Deferred BlackRock, Inc. stock awards are generally granted in the form of BlackRock, Inc. restricted stock units that vest pursuant to the terms of the applicable plan and, once vested, settle in BlackRock, Inc. common stock. The portfolio managers of this Fund have deferred BlackRock, Inc. stock awards.

For certain portfolio managers, a portion of the discretionary incentive compensation is also distributed in the form of deferred cash awards that notionally track the returns of select BlackRock investment products they manage, which provides direct alignment of portfolio manager discretionary incentive compensation with investment product results. Deferred cash awards vest ratably over a number of years and, once vested, settle in the form of cash. Only portfolio managers who manage specified products and whose total compensation is above a specified threshold are eligible to participate in the deferred cash award program.

Other Compensation Benefits. In addition to base salary and discretionary incentive compensation, portfolio managers may be eligible to receive or participate in one or more of the following:

Incentive Savings Plans — BlackRock, Inc. has created a variety of incentive savings plans in which BlackRock, Inc. employees are eligible to participate, including a 401(k) plan, the BlackRock Retirement Savings Plan (RSP), and the BlackRock Employee Stock Purchase Plan (ESPP). The employer contribution components of the RSP include a company match equal to 50% of the first 8% of eligible pay contributed to the plan capped at $5,000 per year, and a company retirement contribution equal to 3-5% of eligible compensation up to the Internal Revenue Service limit ($330,000 for 2023). The RSP offers a range of investment options, including registered investment companies and collective investment funds managed by the firm. BlackRock, Inc. contributions follow the investment direction set by participants for their own contributions or, absent participant investment direction, are invested into a target date fund that corresponds to, or is closest to, the year in which the participant attains age 65. The ESPP allows for investment in BlackRock, Inc. common stock at a 5% discount on the fair market value of the stock on the purchase date. Annual participation in the ESPP is limited to the purchase of 1,000 shares of common stock or a dollar value of $25,000 based on its fair market value on the purchase date. Messrs. McClements and Accettella are eligible to participate in these plans.

United Kingdom-based portfolio managers are also eligible to participate in broad-based plans offered generally to BlackRock employees, including broad-based retirement, health and other employee benefit plans. For example, BlackRock has created a variety of incentive savings plans in which BlackRock employees are eligible to participate, including the BlackRock Retirement Savings Plan (RSP) and the BlackRock Employee Stock Purchase Plan (ESPP). The employer contribution to the RSP is between 10% and 15% of eligible pay capped at £160,000 per annum. The RSP offers a range of investment options, including several collective investment funds managed by the firm. BlackRock contributions follow the investment direction set by participants for their own contributions or, in the absence of an investment election being made, are invested into a target date fund that corresponds to, or is closest to, the year in which the participant attains age 65. The ESPP allows for investment in BlackRock common stock at a 5% discount on the fair market value of the stock on the purchase date. Annual participation in the ESPP is limited to the

9

purchase of 1,000 shares of common stock or a US dollar value of $25,000 based on its fair market value on the purchase date. Mses. Treharne, Greenen and Edwards are eligible to participate in these plans.

(a)(4) Beneficial Ownership of Securities – As of December 31, 2023.

Portfolio Manager	Dollar Range of Equity Securities of the Fund Beneficially Owned
Kyle G. McClements, CFA	$10,001 - $50,000
Christopher Accettella	$10,001 - $50,000
Olivia Treharne, CFA	$10,001 - $50,000
Molly Greenen, CFA	$10,001 - $50,000
Rosie Edwards	None

(c) Not Applicable

Item 9 – Purchases of Equity Securities by Closed-End Management Investment Company and Affiliated Purchasers

Period	(a) Total  Number  of Shares  Purchased1	(b) Average  Price Paid  per Share	(c) Total Number of  Shares Purchased as Part  of Publicly Announced  Plans or Programs1	(d) Maximum Number of  Shares that May Yet Be  Purchased Under the  Plans or Programs1
July 1-31, 2023	233,300	$5.4992	233,300	3,533,742
August 1-31, 2023	245,140	$5.2135	245,140	3,288,602
September 1-30, 2023	182,370	$5.0177	182,370	3,106,232
October 1-31, 2023	191,647	$4.7988	191,647	2,914,585
November 1-30, 2023	251,096	$5.1260	251,096	2,663,489
December 1-31, 2023	0	$-	0	5,013,592
Total:	1,103,553	5.1496	1,103,553	5,013,592

¹ On September 8, 2022, the Fund announced a continuation of its open market share repurchase program. Commencing on December 1, 2022, the Fund may repurchase through November 30, 2023, up to 5% of its common shares outstanding as of the close of business on November 30, 2022, subject to certain conditions. On November 15, 2023, the Fund announced a further continuation of its open market share repurchase program. Commencing on December 1, 2023, the Fund may repurchase through November 30, 2024, up to 5% of its common shares outstanding as of the close of business on November 30, 2023, subject to certain conditions.

Item 10 – Submission of Matters to a Vote of Security Holders – There have been no material changes to these procedures.

Item 11 – Controls and Procedures

10

(a) The registrant’s principal executive and principal financial officers, or persons performing similar functions, have concluded that the registrant’s disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940, as amended (the “1940 Act”)) are effective as of a date within 90 days of the filing of this report based on the evaluation of these controls and procedures required by Rule 30a-3(b) under the 1940 Act and Rule 13a-15(b) under the Securities Exchange Act of 1934, as amended.

(b) There were no changes in the registrant’s internal control over financial reporting (as defined in Rule 30a-3(d) under the 1940 Act) that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, the registrant’s internal control over financial reporting.

Item 12 – Disclosure of Securities Lending Activities for Closed-End Management Investment Companies – Not Applicable

Item 13 – Recovery of Erroneously Awarded Compensation – Not Applicable

Item 14 – Exhibits attached hereto

(a)(2) Section 302 Certifications are attached

(a)(3) Any written solicitation to purchase securities under Rule 23c-1 – Not Applicable

(a)(4) Change in Registrant’s independent public accountant – Not Applicable

(b) Section 906 Certifications are attached

(c) Notices to the registrant’s common shareholders in accordance with the order under Section  6(c) of the 1940 Act granting an exemption from Section 19(b) of the 1940 Act and Rule 19b-1 under the 1940 Act, dated May 9, 2009¹

¹ The Fund has received exemptive relief from the Securities and Exchange Commission permitting it to make periodic distributions of long-term capital gains with respect to its outstanding common stock as frequently as twelve times each year, and as frequently as distributions are specified by or in accordance with the terms of its outstanding preferred stock. This relief is conditioned, in part, on an undertaking by the Fund to make the disclosures to the holders of the Fund’s common shares, in addition to the information required by Section 19(a) of the 1940 Act and Rule 19a-1 thereunder. The Fund is likewise obligated to file with the SEC the information contained in any such notice to shareholders and, in that regard, has attached hereto copies of each such notice made during the period.

11

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BlackRock Enhanced International Dividend Trust

By:	/s/ John M. Perlowski
	John M. Perlowski
	Chief Executive Officer (principal executive officer) of
	BlackRock Enhanced International Dividend Trust

Date: February 23, 2024

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

By:	/s/ John M. Perlowski
	John M. Perlowski
	Chief Executive Officer (principal executive officer) of
	BlackRock Enhanced International Dividend Trust

Date: February 23, 2024

By:	/s/ Trent Walker
	Trent Walker
	Chief Financial Officer (principal financial officer) of
	BlackRock Enhanced International Dividend Trust

Date: February 23, 2024

12